<SEC-DOCUMENT>0001829126-23-004366.txt : 20231219
<SEC-HEADER>0001829126-23-004366.hdr.sgml : 20231219
<ACCEPTANCE-DATETIME>20230622170448
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001829126-23-004366
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		26
FILED AS OF DATE:		20230622
<PUBLIC-REL-DATE>20231218
DATE AS OF CHANGE:		20230622

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEONC TECHNOLOGIES HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001979414
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				921954864
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-06754
		FILM NUMBER:		231034094

	BUSINESS ADDRESS:	
		STREET 1:		8335 SUNSET BOULEVARD
		STREET 2:		SUITE 240
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90069
		BUSINESS PHONE:		310 663 7831

	MAIL ADDRESS:	
		STREET 1:		8335 SUNSET BOULEVARD
		STREET 2:		SUITE 240
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90069
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
submitted confidentially to the Securities and Exchange Commission on June 22, 2023, pursuant to the</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jumpstart
Our Business Startups Act of 2012. This draft registration statement has not been publicly filed</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>with
the Securities and Exchange Commission and all information herein remains strictly confidential.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
No. 333-</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>FORM
S-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
STATEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>NEONC
TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
name of Registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>92-1954864</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
        or other jurisdiction of</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>incorporation
        or organization)</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Primary
        Standard Industrial</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Classification
        Code Number)</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(I.R.S.
    Employer<BR> Identification No.)</B></FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
including zip code, telephone number, including area code, of Registrant&#8217;s Principal Executive Offices)</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8335
Sunset Boulevard, Suite 240<BR> </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Los Angeles, CA 90069<BR> (310)663-7831</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>



<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Name,
address including zip code, telephone number, including area code, of agent for service)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Thomas C. Chen</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8335
Sunset Boulevard, Suite 240</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Los
Angeles, CA 90069</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(310)
663-7831</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Copies
To:</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Thomas
        J. Poletti, Esq.</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Veronica
        Lah, Esq.</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manatt,
        Phelps &amp; Phillips LLP</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>695
        Town Center Drive, 14<SUP>th</SUP> Floor</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Costa
        Mesa, CA 92626</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(714)
        371-2500</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mitchell
        S. Nussbaum, Esq.<BR> Angela M. Dowd, Esq.</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Loeb
        &amp; Loeb LLP<BR> 345 Park Avenue<BR> New York, NY 10154<BR> (212) 407-4000</B></FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate
date of commencement of proposed sale to the public: </B>As soon as practicable after this Registration Statement is declared effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under
the Securities Act, check the following box. &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&nbsp;12b-2 of the Exchange Act (Check one):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</FONT></TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 19%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</FONT></TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 19%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer</FONT></TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</FONT></TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided to Section&nbsp;7(a)(2)(B) of the Securities Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such
date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin: 0pt">&#160;</p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #D81E05"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the Securities
and Exchange Commission declares our registration statement effective. This preliminary prospectus is not an offer to sell these securities
and is not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #D81E05"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>PRELIMINARY
    PROSPECTUS</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 54%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>SUBJECT
    TO COMPLETION, DATED June 22, 2023</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">NEONC
TECHNOLOGIES HOLDINGS, INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is the initial public offering of shares of common stock of NeOnc Technologies Holdings, Inc. Prior to this offering, there has been
no public market for our common stock. The initial public offering price is expected to be between $____ and $____ per share. The actual
number of shares we will offer will be determined based on the actual public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to apply to have our shares of common stock listed on the Nasdaq Capital Market under the symbol &#8220;___&#8221;. The closing
of this offering is contingent upon our listing on the Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined under the federal securities laws and, as such, we have elected to comply with
certain reduced public company reporting requirements for this prospectus and future filings. See &#8220;<I>Prospectus Summary&#8212;
Implications of Being an Emerging Growth Company</I>.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our common stock involves a high degree of risk. See the section entitled &#8220;<I>Risk Factors</I>&#8221; beginning on page 11 to
read about factors you should consider before buying shares of our common stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the Securities and Exchange Commission in the United States nor any other regulatory body has approved or disapproved of these common
shares or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per
    Share</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initial
    public offering price</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    discounts and commissions<SUP>(1)</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds,
    before expenses</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See &#8220;<I>Underwriting</I>&#8221;
    for additional disclosure regarding underwriting discounts and commissions and estimated offering expenses payable to the underwriters.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted the underwriters a 45-day option from the date of this prospectus to purchase up to ______ additional shares of common stock
from us at the initial public offering price less the underwriting discounts and commissions, solely to cover the underwriters&#8217;
option to purchase additional shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters expect to deliver the shares of common stock to purchasers against payment in New York, New York on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2023.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sole
Bookrunning Manager</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Maxim
Group LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Co-Managers</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Brookline
        Capital Markets,</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>a
        division of Arcadia Securities, LLC</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Spartan
    Capital Securities LLC</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin: 0pt">&#160;</p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="toc1"></A>Table
of Contents</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">INDUSTRY
    AND MARKET DATA</FONT></A></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">ii</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">PROSPECTUS
    SUMMARY</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">THE
    OFFERING </FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">RISK
    FACTORS </FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">CAUTIONARY
    STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">77</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">USE
    OF PROCEEDS</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">79</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">DIVIDEND
    POLICY</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">80</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">CAPITALIZATION</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">81</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">DILUTION</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">82</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">MANAGEMENT&#8217;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">84</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">BUSINESS</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">97</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">MANAGEMENT</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">141</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">PRINCIPAL
    SHAREHOLDERS</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">151</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">CERTAIN
    RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">152</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">DESCRIPTION
    OF SECURITIES</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">155</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">SHARES
    ELIGIBLE FOR FUTURE SALE</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">159</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_017"><FONT STYLE="font-size: 10pt">UNDERWRITING</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">161</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">LEGAL
    MATTERS</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">169</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_019"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">169</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_020"><FONT STYLE="font-size: 10pt">WHERE
    YOU CAN FIND ADDITIONAL INFORMATION</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">169</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in
this prospectus or in any free writing prospectuses we have prepared. Neither we nor the underwriters take responsibility for and can
provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only
the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in
this prospectus is current only as of its date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
and including ____, 2023 (the 25<SUP>th</SUP> day after the date of this prospectus), all dealers that buy, sell or trade in our common
shares, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#8217;
obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
investors outside of the United States neither we nor the underwriters have done anything that would permit this offering or possession
or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You
are required to inform yourself about, and to observe any restrictions relating to, this offering and the distribution of this prospectus
outside of the United States. See the section of this prospectus entitled &#8220;<I>Underwriting</I>&#8221; for additional information
on these restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, information in this prospectus concerning economic conditions, our industries and our markets is based on a variety
of sources, including information from third-party industry analysts and publications and our own estimates and research. This information
involves a number of assumptions, estimates and limitations. The industry publications, surveys and forecasts and other public information
generally indicate or suggest that their information has been obtained from sources believed to be reliable. None of the third-party
industry publications used in this prospectus were prepared on our behalf. The industries in which we operate are subject to a high degree
of uncertainty and risk due to a variety of factors, including those described in &#8220;<I>Risk Factors</I>&#8221; in this prospectus.
These and other factors could cause results to differ materially from those expressed in these publications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own or have rights to various trademarks, service marks and trade names that we use in connection with the operation of our businesses.
This prospectus may also contain trademarks, service marks and trade names of third parties, which are the property of their respective
owners. Our use or display of third parties&#8217; trademarks, service marks and trade names or products in this prospectus is not intended
to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks
and trade names referred to in this prospectus may appear without the &reg;, TM or SM symbols, but the omission of such references is
not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of
the applicable owner of these trademarks, service marks and trade names.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_001"></A>INDUSTRY
AND MARKET DATA</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
obtained the industry, market, and competitive position data used throughout this prospectus from our own internal estimates and research,
as well as from independent market research, industry, and general publications and surveys, governmental agencies, and publicly available
information in addition to research, surveys, and studies conducted by third parties. Internal estimates are derived from publicly available
information released by industry analysts and third-party sources, our internal research, and our industry experience, and are based
on assumptions made by us based on such data and our knowledge of our industry and market, which we believe to be reasonable. In some
cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources
of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from
the same sources, unless otherwise expressly stated or the context otherwise requires. In addition, while we believe the industry, market,
and competitive position data included in this prospectus is reliable and based on reasonable assumptions, such data involve risks and
uncertainties and are subject to change based on various factors, including those discussed in the section titled &#8220;<I>Risk Factors</I>.&#8221;
These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties
or by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_002"></A>PROSPECTUS
SUMMARY</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights certain significant aspects of our business and this offering and is a summary of information contained elsewhere
in this prospectus. This summary does not contain all the information that you should consider before deciding to invest in our common
stock. You should read the entire prospectus carefully, including &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and
Analysis of Financial Condition and Results of Operations,&#8221; &#8220;Business&#8221; and our financial statements and related notes
thereto included in this prospectus, before making an investment decision. Unless the context otherwise requires, the terms &#8220;NeOnc&#8221;,
&#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to NeOnc Technologies Holdings, Inc., a Delaware
corporation, and its wholly-owned subsidiary NeOnc Technologies, Inc., and &#8220;this prospectus&#8221; refers to the offering contemplated
this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical
company, we have focused on establishing superior treatments for intracranial malignancies, i.e., aggressive cancers located in
the brain. These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, that have arrived through
metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain-localized malignancies are
particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the
brain. As a result, these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug
delivery methods to be used in combination with novel drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">NeOnc&rsquo;s lead product
candidate is NEO100. NEO100 is administered to patients via intranasal delivery. We have completed human safety testing in a Phase 1 clinical
trial and currently conducting preliminary efficacy testing in a Phase 2a trial with recurrent malignant glioma (Grade IV, IDH1 mutant)
patients. NeOnc is also developing a second product candidate, NEO212, which has completed preclinical testing and an investigational
new drug (IND) application has been filed with the United States Food and Drug Administration (FDA) so that clinical trials can follow
with patients harbouring primary and secondary malignant brain cancer types. Several additional drug candidates are in the pipeline and
are undergoing preclinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
none of our product candidates have been approved for sale in the United States or elsewhere. We have no commercial products nor do we
have a sales or marketing infrastructure. In order to market and sell our products we must conduct clinical trials on patients and obtain
regulatory approvals from appropriate regulatory agencies, like the FDA in the United States, and similar organizations elsewhere in
the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not generated any revenue from product sales and from January&nbsp;1, 2021 to December&nbsp;31, 2022 have only generated revenue
of $20,000. We do not anticipate generating significant revenues for the foreseeable future. We had net loss of $3,046,757 for the year
ended December&nbsp;31, 2022. At December&nbsp;31, 2022, we had an accumulated deficit of $23,788,916.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Opportunity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the market for addressing areas of high unmet medical need in the treatment of CNS diseases will continue to be large for
the foreseeable future and that it will represent a sizable revenue opportunity for us. For example, the World Health Organization (WHO)
has estimated that CNS diseases affect nearly 2 billion people globally, making up approximately 40% of total disease burden (based on
disability adjusted life years), compared with 13% for cancer and 12% for cardiovascular disease. According to Fortune Business Insights,
the CNS treatment market is estimated to grow at 9.4% CAGR to $166.5 billion by 2028 and the global brain tumor drug market to grow at
CAGR of 9.0% to $4.4 billion by 2029.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iHeathcareAnalys
has reported that the malignant Glioblastoma Multiforme (GBM) drug market is expected to grow at 12.7% CAGR to $2.3  billion by 2029.
According to the book, <I>Glioblastoma</I> by Ahmad Faleh Tamimi and Malik Juweid (2017), GBM accounts for up to 54% of gliomas and
16% of all primary brain cancers. We believe that by creating a more effective delivery mechanism for GBM drug therapy, we could
have the ability to significantly impact market demand in this sector.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy is to leverage our considerable industry experience, understanding of the CNS and GBM markets and development expertise to identify,
develop and commercialize product candidates with significant market potential that can fulfill unmet medical needs in the treatment
of brain cancers and CNS diseases. We have assembled a management team along with both scientific and business advisors, including recognized
experts in the fields of neuro-oncology, with significant industry and regulatory experience to lead and execute the development and
commercialization of our NEO platform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to further develop NEO100 and NEO212 as our priority programs. We have generated and plan to continue to generate intellectual property
(IP) that will further protect our products from competition. We will continue to prioritize our product development activities after
taking into account the resources we have available, market dynamics and potential for adding value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property Portfolio and Market Exclusivity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have exclusively licensed a large worldwide patent portfolio from the University of Southern California (USC) consisting of both issued
patents and pending patent applications related to NEO100, NEO212 and other products from the NeOnc patent family for multiple uses,
including oncological and neurological conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key
Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the key elements for our market success include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compelling
    lead product opportunity, with NEO100 currently in Phase 2 trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensed
    large patent portfolio for NEO100 with currently issued patents expiring between 2030-2038; and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
    in additional multiple indications in underserved markets with large patient populations.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
Developments</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On December&nbsp;19, 2022, NeOnc Technologies, Inc. entered into an
engagement agreement with AFH Holdings and Advisory, LLC (&ldquo;AFH&rdquo;). Amir Heshmatpour is the sole member and managing director
of AFH and a member of NeOnc&rsquo;s Board of Directors. AFH was engaged to assist NeOnc Technologies, Inc. in connection with its intent
to effect a public listing. AFH was retained to assist NeOnc Technologies, Inc. with investor presentations and decks, coordinate the
retention of an investment banker for an initial public offering, identify legal and accounting professionals to assist in connection
with such public offering, identify investor relations/public relations firms, advise on private capital markets activities prior to the
initial public offering and coordinate the closing process for the offering. AFH agreed to advance costs of up to $500,000 for such professionals
on behalf of the Company to be repaid out of proceeds from the initial public offering. As of March&nbsp;31, 2023, approximately $101,078
of such advances have taken place. As partial compensation for such services, NeOnc Technologies, Inc. agreed to effect a share exchange
with NeOnc Technologies Holdings, Inc., a special purpose entity substantially beneficially  owned by Amir Heshmatpour and
his affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On April&nbsp;7, 2023,
NeOnc Technologies, Inc. and its shareholders entered into a Share Exchange Agreement (the &ldquo;Share Exchange&rdquo;) with NeOnc
Technologies Holdings, Inc., whereby all of the shareholders of NeOnc Technologies, Inc. exchanged their stock in NeOnc
Technologies, Inc. for a total of 10,500,000 shares of common stock in NeOnc Technologies Holdings, Inc. As a result, all
shareholders of NeOnc Technologies, Inc. became shareholders of NeOnc Technologies Holdings, Inc. and NeOnc Technologies, Inc.
became a wholly-owned subsidiary of NeOnc Technologies Holdings, Inc. At the consummation of this transaction, Amir Heshmatpour,
AFH, and their affiliated entities, individuals, or assignees owned an aggregate of 34.6% of the fully diluted issued and
outstanding common shares of NeOnc Technologies Holdings, Inc. For the year ended December 31, 2022, NeOnc Technologies Holdings,
Inc. had no operations or assets other than cash paid by its shareholders for their shares ($4,500 in the aggregate) and liabilities
of $50,000 pertaining to an amount owing to Mr. Heshmatpour for a professional retainer paid by him on behalf of the company. For
this reason, no separate audited financial statements for the year ended December 31, 2022 are presented herein for NeOnc
Technologies Holdings, Inc. and consolidated financial statements for such year ended with NeOnc Technologies, Inc. are not required
to be filed as the Share Exchange occurred after such year end.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">In addition, NeOnc Technologies, Inc. agreed to retain AFH as its exclusive
advisor on all financing and mergers and acquisitions for a period of two (2) years from the closing of the private securities exchange
offering. Further to the advisory arrangement, AFH shall be paid in cash an aggregate fee in an amount equal to 2% of the post-money valuation
of NeOnc Technologies Holdings, Inc. immediately after the consummation of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Implications
of Being an Emerging Growth Company</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;).
As an emerging growth company, we are eligible to take advantage of specified reduced disclosure and other requirements that are otherwise
applicable generally to public companies and may elect to take advantage of other exemptions from reporting requirements in our future
filings with the Securities Exchange Commission (&#8220;SEC&#8221;). In particular, in this prospectus, these exemptions include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">presenting
    only two years of audited financial statements and only two years of related selected financial data and Management&#8217;s Discussion
    and Analysis of Financial Condition and Results of Operations disclosure in our registration statement of which this prospectus forms
    a part;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    disclosure about our executive compensation arrangements;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemption
    from the requirements to hold non-binding advisory votes on executive compensation (&#8220;Say on Pay&#8221;);</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extended
    transition periods for complying with new or revised accounting standards;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemption
    from the auditor attestation requirement in the assessment of our internal controls over financial reporting pursuant to Section&nbsp;404(b)
    of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;); and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    auditor not being required to comply with the requirement in Public Company Accounting Oversight Board Auditing Standard 3101, <I>The
    Auditor&#8217;s Report on an Audit of Financial Statements When the Auditor Expresses an Unqualified Opinion</I>, to communicate
    critical audit matters in the auditor&#8217;s report.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of this offering or such
earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company if we have more than $1.235
billion in annual revenue, we have more than $700 million in market value of our stock held by non-affiliates (and we have been a public
company for at least 12 months and have filed one annual report on Form&nbsp;10-K) or we issue more than $1 billion of non-convertible
debt securities over a three-year period. We may choose to take advantage of some, but not all, of the available exemptions. We have
taken advantage of certain reduced reporting obligations in this prospectus. Further, pursuant to Section&nbsp;107 of the JOBS Act, as
an emerging growth company, we have elected to use the extended transition period for complying with new or revised accounting standards
until those standards would otherwise apply to private companies. Accordingly, the information contained herein may be different than
the information you receive from other public companies in which you hold stock, and our financial statements may not be comparable to
the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that
are applicable to public companies. See &#8220;<I>Risk Factors&#8212;Risks Related to this offering and Ownership or Our Common Stock</I>&#8221;
which describes that we are an emerging growth company, and we cannot be certain if the reduced disclosure requirements applicable to
emerging growth companies will make our common stock less attractive to investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary
of Risks Related to Our Business</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to numerous risks and uncertainties, including those described in &#8220;<I>Risk Factors</I>&#8221; and elsewhere
in this prospectus. You should carefully consider these risks before making an investment. These risks include, among others, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to our Financial Position and Need for Additional Capital</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have incurred significant losses since our inception and anticipate that we will incur significant and increasing losses for the
    foreseeable future and we may never achieve or maintain profitability.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we complete this offering, we will require additional financing to advance the development of our product candidates. Failure
    to obtain this necessary capital could force us to delay, limit, reduce or terminate our operations.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have never generated any revenue from product sales and may never become profitable. Raising additional capital may cause dilution
    to our shareholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights
    to our technologies or product candidates. The report of our independent registered public accounting firm included a &#8220;going
    concern&#8221; explanatory paragraph.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to Product Discovery, Development and Regulatory Approval</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    development of product candidates based on our technology platform is limited, and we do not know whether we will be able to develop
    any products of commercial value.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    product candidates are in preclinical and clinical stages of development, are not approved for commercial sale and might never receive
    regulatory approval or become commercially viable.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently have two clinical development product candidates (NEO100 and NEO212). The failure of one of these two product candidates
    in clinical development would adversely affect our business. It may require us to discontinue developing other product candidates
    based on the same therapeutic approach.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost
    of product candidate development.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    development involves a lengthy and expensive process with an uncertain outcome and stringent regulations, and delays can occur for
    a variety of reasons.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we experience delays or difficulties in the enrolment of patients in clinical trials, our receipt of necessary regulatory approvals
    could be delayed or prevented.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
    of preclinical studies and early clinical trials may not be predictive of results of future clinical trials.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim,
    topline, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data
    become available and are subject to audit and verification procedures that could result in material changes in the final data.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Serious
    adverse events, undesirable side effects (including emergent drug-drug interactions between NEO100 and any of the other therapeutic
    agents given to the clinical trial subjects) or other unexpected properties of our current or future product candidates may be identified
    during development or after approval, which could halt their development or lead to the discontinuation of our clinical development
    programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation
    of marketing authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such
    product candidate.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    anticipate that many of our product candidates may be used in combination with third-party drugs and/or devices, some of which may
    still be in development, and we have limited or no control over the supply, regulatory status or regulatory approval of such drugs
    and/or devices.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be successful in our efforts to expand our pipeline of product candidates and develop marketable products.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates
    or indications that may be more profitable or for which there is a greater likelihood of success.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we do not achieve our product development goals in the timeframes we announce and expect, the commercialization of our product candidates
    may be delayed and as a result our share price may decline.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming
    and uncertain and may prevent us or any of our existing or potential future collaboration partners from obtaining approvals for the
    commercialization of NEO100 and any other product candidate we develop.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
    approval by the FDA or comparable foreign regulatory authorities is limited to those specific indications and conditions for which
    approval has been granted, and we may be subject to substantial fines, criminal penalties, injunctions, or other enforcement actions
    if we are determined to be promoting the use of any products for unapproved or &#8220;off-label&#8221; uses, resulting in damage
    to our reputation and business.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
    and maintaining marketing approval for our product candidates in one jurisdiction would not mean that we will be successful in obtaining
    marketing approval of that product candidate in other jurisdictions, which could prevent us from marketing our products internationally.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if our product candidates receive regulatory approval, we will be subject to ongoing obligations and continued regulatory review,
    which may result in significant additional expense and limit how we manufacture and market our products.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to Manufacturing</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are subject to multiple manufacturing risks, any of which could substantially increase our costs and limit supply of our product
    candidates.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in product candidate manufacturing or formulation may result in additional costs or delay.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to manufacture product candidates in the volumes that we require on a timely basis, or fail to comply with regulations
    applicable to biopharmaceutical manufacturers, we may face delays in the development and commercialization of, or be unable to meet
    demand for, any product candidates, and may lose potential revenues.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to Commercialization</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we, or our collaboration partners, are unable to successfully commercialize any product candidate for which we receive regulatory
    approval, or experience significant delays in doing so, our business will be materially harmed.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face significant competition from other biopharmaceutical and biotechnology companies, academic institutions, government agencies,
    and other research organizations, which may result in others discovering, developing or commercializing products more quickly or
    marketing them more successfully than us. If their product candidates are shown to be safer or more effective than ours, our commercial
    opportunity may be reduced or eliminated.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to
    market and sell our product candidates, if they are approved, the revenues that we generate may be limited and we may never become
    profitable.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians,
    patients, hospitals, cancer treatment centers, third-party payors and others in the medical community necessary for commercial success.
    The revenues that we generate from their sales may be limited, and we may never become profitable.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the
    actual markets for our product candidates may be smaller than our estimates. If the market opportunities for any product candidates
    we develop are smaller than we believe they are, our potential revenues may be adversely affected, and our business may suffer.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to Our Intellectual Property&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to obtain, maintain and protect our intellectual property rights for our technology and product candidates, or if our
    intellectual property rights are inadequate, our competitive position could be harmed.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to comply with our obligations in the agreements under which we may license intellectual property rights from third parties
    or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights
    that are important to our business.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
    parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would
    be uncertain and could harm our business.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to protect our intellectual property and proprietary rights throughout the world.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing
    our ability to protect NEO100, NEO212 and our other product candidates.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful
    and have a material adverse effect on the success of our business.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we obtain any issued patents covering our technology, such patents could be found invalid or unenforceable if challenged in court
    or before the USPTO or comparable foreign regulatory authority.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
    terms may be inadequate to protect our competitive position on our products for an adequate amount of time, and our product candidates
    for which we intend to seek approval as pharmacological products may face competition sooner than anticipated.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of
    interest and our business may be adversely affected.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to Our Business and Operations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are highly dependent on our key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may
    not be able to successfully implement our business strategy.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience
    adverse consequences resulting from such compromise.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability and
    have to limit the commercialization of any approved products and/or our product candidates.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have identified material weaknesses in our internal control over financial reporting and may identify additional material weaknesses
    in the future.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<DIV STYLE="border: Black 1pt solid; padding: 5pt; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
Information</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeOnc
Technologies, Inc. was incorporated in Delaware in 2008 as NAS-ONC, Inc. In April&nbsp;2023, shareholders of NeOnc Technologies, Inc.
completed a share exchange (the &#8220;Share Exchange&#8221;) with NeOnc Technologies Holdings, Inc. pursuant to which all shareholders
of NeOnc Technologies, Inc. became shareholders of NeOnc Technologies Holdings, Inc. and NeOnc Technologies, Inc. became a wholly-owned
subsidiary of NeOnc Technologies Holdings, Inc. Our executive offices are located at 8335 Sunset Boulevard, Suite 240, Los Angeles, CA
90069 and our telephone number is (310) 633-7831. Our corporate website is www.neonctech.com. Information appearing on our corporate
website is not incorporated as part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
Listing</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to apply to list our common stock on Nasdaq. There is no assurance that our listing application will be approved by Nasdaq. The
approval of our listing on Nasdaq is a condition of closing. If our application to Nasdaq is not approved or we otherwise determine that
we will not be able to secure the listing of the common stock on Nasdaq, we will not complete the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_003"></A>The
Offering</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares
    of Common Stock offered by us</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 70%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___
    shares (or ___ shares if the underwriters exercise the over-allotment option to purchase additional shares in full).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    Stock to be outstanding after this Offering</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___
    shares</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-Allotment</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
        have granted to the underwriters a 45-day option to purchase from us up to an additional ___% of the shares of common stock sold
        in the offering at the initial public offering price, less the underwriting discounts and commissions to cover over-allotments.</FONT></P>
        </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representative
    Warrants</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
    the closing of this offering, we will issue to the representative of the underwriters, warrants to purchase 5.0% of the total number
    of shares of common stock being sold in this offering. The exercise price of the underwriter warrants is equal to 110% of the offering
    price of the shares of common stock offered hereby. The warrants are exercisable commencing six (6) months from the effective date
    of the registration statement for this offering of which this prospectus forms a part and will terminate five (5) years after such
    date. The registration statement of which this prospectus is a part also covers the shares of common stock issuable upon the exercise
    thereof.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
    of Proceeds</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
        estimate that our net proceeds from the sale of our common stock that we are offering will be approximately $___ (or approximately
        $___ if the over-allotment option is exercised in full), assuming an initial public offering price of $____ per share, the midpoint
        of the estimated price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts
        and commissions and estimated offering expenses.</FONT></P>
        </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">The principal
                                            purposes of this offering are to increase our capitalization and financial flexibility and
                                            create a public market for our common stock. As of the date of this prospectus, we cannot
                                            specify with certainty all of the particular uses for the net proceeds to us of this offering.
                                            However, we currently intend to use approximately 35.6% of the net proceeds for clinical
                                            trials, 20.0% of the net proceeds for research and development, 6.3% of the net proceeds
                                            to repay a short term loan provided to us by HCWG LLC, an entity substantially beneficially
                                            owned by our officers and directors, 9.6% of the net proceeds to pay AFH a cash fee in an
                                            amount equal to 2.0% of the post-money valuation of our Company immediately after the consummation
                                            of this offering, 1.3% of the net proceeds to pay accrued salaries, and 27.2% of the net
                                            proceeds for general corporate purposes and working capital. See the section titled &ldquo;<I>Use
                                            of Proceeds</I>&rdquo; for additional information.</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
    Factors</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
    in our common stock involves a high degree of risk. You should carefully read and consider the information set forth under &#8220;Risk
    Factors&#8221; and all other information in this prospectus before investing in our common stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-up
    Agreements</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
    and all of our directors, officers and beneficial owners of 1% or more of our outstanding common stock have agreed with the representative
    not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or securities convertible
    into common stock for a period of six (6) months from the effective date of this prospectus. See &#8220;<I>Underwriting</I>&#8221;
    on page 161.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
        Agent</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VStock
        Transfer LLC.</FONT></P>
        </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
    intend to apply to list our common stock on the Nasdaq Capital Market under the symbol &#8220;___.&#8221; The closing of this offering
    is contingent upon the successful listing of our common stock on the Nasdaq Capital Market.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock that will be outstanding after this offering set forth above is based on ___ shares of common stock
outstanding as of ______, 2023, and excludes the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___
    shares of common stock issuable upon the vesting of stock options to be granted to our directors, director nominees, executive officers
    and advisory board members immediately prior to the effective date of this offering;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___
    shares of common stock issuable upon the vesting of restricted stock units to be granted to our executive officers immediately prior
    to the effective date of this offering;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___
    shares of common stock reserved for future grant or issuance under our 2023 Incentive Stock Plan (the &#8220;2023 Plan&#8221;); and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___
    shares of common stock issuable upon the exercise of the warrants issuable to the Representative of the underwriters upon the closing
    of this offering.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
specifically stated otherwise, all information in this prospectus assumes no exercise of the underwriters&#8217; over-allotment option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary
of Financial Data</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following table sets forth our summary financial data as of the dates and for the periods indicated. We have derived the summary statement
of operations data from our audited annual financial statements for the years ended December&nbsp;31, 2022 and 2021 included elsewhere
in this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
historical results presented below are not necessarily indicative of the results to be expected for any future period and our interim
results are not necessarily indicative of the results that may be expected for a full year. The following summaries of our financial
data for the periods presented should be read in conjunction with the sections of this prospectus entitled &#8220;Risk Factors,&#8221;
&#8220;Capitalization,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;
and our financial statements and the related notes included elsewhere in this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> Statements of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    Ended</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December&nbsp;31,</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenue</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenue</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating
    expenses:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
    and development</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,163,330</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">674,558</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal
    and professional</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">318,205</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">217,951</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,376,069</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,379,174</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    operating expenses</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,857,604</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,271,683</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    from operations</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,837,604</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,271,683</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Other (expense) income:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left"></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Change in fair value of note payable &ndash; Chairman of the Board</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(9,000</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">9,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Interest expense</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(200,153</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(112,919</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    (expense) income</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(209,153</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(103,919</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,046,757</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,375,602</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left; width: 76%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Diluted
    net loss per share</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted average shares outstanding</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Pro forma diluted net
    loss per share<SUP>(1)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Pro forma weighted average shares
    outstanding<SUP>(1)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> Balance Sheet</B></FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <BR> December&nbsp;31,<BR> 2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Actual</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>As Adjusted<SUP>(3)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 76%">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">633,298</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">95,384</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,341,593</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">412,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Promissory note payable, at fair value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Paid-in capital<SUP>(2)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">22,213,505</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(23,788,916</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shareholders&rsquo; equity (deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,575,411</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pro forma gives effect to a 1.222222-for-1
forward split of our outstanding shares of common stock in April&nbsp;2023 and the subsequent issuance of 10,500,000 shares of common
stock to shareholders of NeOnc Technologies, Inc. in April&nbsp;2023 in the Share Exchange.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
    </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">(2)</TD>
    <TD STYLE="text-align: justify">Actual amounts include par value of NeOnc Technologies, Inc. preferred and common stock of $3,030 and $68,621, respectively. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">(3)</TD>
    <TD STYLE="text-align: justify">As adjusted amounts reflect the sale of shares
    in this offering at the assumed initial public offering price of $____ per share, which is the midpoint of the estimated offering price
    range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated
    offering expenses payable by us. A $1.00 increase (decrease) in the assumed initial public offering price of $____ per share, which is
    the midpoint of the estimated offering price range set forth on the cover page of this prospectus, would increase (decrease) the as adjusted
    amount of each of cash, working capital, total assets and total shareholders&rsquo; equity by approximately $___, assuming that the number
    of shares offered by us, as set forth on the cover of this prospectus, remains the same and after deducting estimated underwriting discounts
    and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0 million shares offered by us
    would increase (decrease) the net proceeds to us from this offering by approximately $___, assuming the assumed initial public offering
    price remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by
    us.</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U><A NAME="a_004"></A>Risk
Factors</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information
in this prospectus, before deciding whether to invest in shares of our common stock. If any of the following risks actually occurs, our
business, results of operations and financial condition could be materially adversely affected. In this case, the trading price of our
common stock would likely decline, and you might lose part or all your investment in our common stock.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to our Financial Position and Need for Additional Capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have incurred significant losses since our inception and anticipate that we will incur significant and increasing losses for the foreseeable
future and we may never achieve or maintain profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical stage biopharmaceutical
company, and our operations to date have been focused substantially on organizing and staffing our company, business planning, raising
capital, creating, assessing, and developing our technology, establishing our intellectual property portfolio, identifying potential product
candidates, undertaking preclinical studies, commencing clinical trials and manufacturing. Additionally, as an organization, we have not
yet demonstrated an ability to successfully complete clinical development, obtain regulatory approvals, manufacture a commercial-scale
product, or conduct sales and marketing activities necessary for successful commercialization. We have never generated any revenue from
product sales other than for humanitarian uses of less than $50,000 and have incurred significant operating losses. Our net loss was $3,046,757
and $3,375,602 for the years ended December&nbsp;31, 2022 and 2021, respectively. As of December&nbsp;31, 2022, we had an accumulated
deficit of $23,788,916. We expect to continue to incur significant and increasing operating losses for the foreseeable future. Our prior
losses, combined with expected future losses, have had and will continue to have an adverse effect on our shareholders&rsquo; deficit
and working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that it will be several years, if ever, before we have a commercialized product. The net losses we incur may fluctuate significantly
from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if, and as, we:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
    the Phase 2 registration clinical trial for our lead product candidate, NEO100;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate
    planned and future clinical trials of NEO100 or NEO212 in other cancer indications;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discover
    and develop new product candidates, and conduct research and development activities, preclinical studies and clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture
    preclinical, clinical and commercial supplies of our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">broaden
    and strengthen our internal manufacturing capabilities, including the expansion and upgrade of our in-house manufacturing facility;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    regulatory approvals for any product candidates that successfully complete clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
    expand and protect our intellectual property portfolio;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
    additional research and development, clinical, scientific and management personnel;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">add
    operational, financial and management information systems and personnel;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    a sales, marketing and distribution infrastructure to commercialize any product candidate for which we may obtain regulatory approval
    and we commercialize on our own or in collaboration with others; and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur
    additional legal, accounting and other expenses operating as a public company following the completion of this offering.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue.
This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials,
obtaining regulatory approval for product candidates and manufacturing, marketing and selling products for which we may obtain marketing
approval and satisfying any post-marketing requirements. We are only in the development stages of most of these activities. We may never
succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability. Even
if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to
become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business,
maintain our research and development efforts or even continue our operations. A decline in the value of our company could also cause
you to lose all or part of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we complete this offering, we will require substantial additional financing to advance the development of our product candidates,
which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital could force us to delay, limit, reduce
or terminate our product development programs, potential commercialization efforts or other operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of biopharmaceutical product candidates is capital-intensive. Our operations have consumed substantial amounts of cash since
inception. As of December&nbsp;31, 2022, we had $633,298 in cash. We expect to continue to spend substantial amounts to continue the
preclinical and clinical development of, and seek regulatory approval for, our current and future product candidates. If we are able
to gain marketing approval of any product candidate that we develop, including NEO100 and NEO212, we will require significant additional
amounts of cash in order to launch and commercialize such product either alone or in collaboration with others. Because the design and
outcome of our ongoing, anticipated and any future clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts
necessary to successfully complete the development and commercialization of any product candidate we develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements depend on many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, results and costs of researching and developing NEO100, NEO212 and our other product candidates and programs, and
    of conducting preclinical studies and clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of, and the costs involved in, obtaining marketing approvals for NEO100, NEO212 and future product candidates we develop if
    clinical trials are successful;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of any future collaborations;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of commercialization activities for any approved product, including marketing, sales and distribution costs;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost and timing of establishing, equipping, and operating our current and planned manufacturing activities;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of manufacturing NEO100, NEO212 and future product candidates for clinical trials in preparation for marketing approval and
    commercialization;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost, timing and outcome of seeking FDA and any other regulatory approvals for any future product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation
    or other patent challenge costs and the outcome of such litigation or other patent challenges;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain healthcare coverage and adequate reimbursement for our future products, if any;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, receipt, and amount of sales of, or royalties on, our future products, if any;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    emergence of competing cancer therapies and other adverse market developments;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support
    the development of our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with being a public company;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    need and ability to retain key management and hire scientific, technical, medical and business personnel;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with expanding our facilities or building out our laboratory space; and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effects of the recent disruptions to and volatility in the credit and financial markets in the United States and the overall impact
    of the COVID-19 pandemic.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any committed external source of funds or other support for our development efforts. Until we can generate sufficient product
revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of
public or private equity offerings and debt financings, or other capital sources such as potential collaborations, strategic alliances,
licensing arrangements and other arrangements. Based on our research and development plans, we expect that the net proceeds from this
offering, together with our existing cash balance, will enable us to fund our planned operating expenses and capital expenditure requirements
for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available
capital resources sooner than we expect. In addition, because the design and outcome of our anticipated and any future clinical trials
is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization
of NEO100, NEO212 or any future product candidates. The net proceeds of this offering, together with our existing cash balance, may not
be sufficient to complete development of NEO100, NEO212 or any other product candidate. Accordingly, we will be required to obtain further
funding to achieve our business objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have never generated any revenue from product sales other than for humanitarian uses of less than $50,000 and may never become
profitable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with future partners, to successfully
complete the development of, and obtain the regulatory approvals necessary to commercialize, our development programs. We have no products
approved for commercial sale, have not generated any revenue from product sales, and do not anticipate generating any revenue from product
sales until after we have received marketing approval for the commercial sale of a product candidate, if ever. Our ability to generate
revenue and achieve profitability depends heavily on our success in achieving a number of goals, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completing
    research regarding, and preclinical and clinical development of, product candidates and programs, including NEO100 and NEO212, and
    identifying and developing new product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    marketing approvals for any product candidates for which we complete clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    regulatory approval to use and sell products generated by our existing or future manufacturing processes for NEO100, NEO212 and future
    product candidates, including at our existing manufacturing facility and/or by establishing and maintaining supply and manufacturing
    relationships with third parties;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
    and commercializing product candidates for which we obtain marketing approvals, either directly by establishing a sales force and
    marketing, medical affairs and distribution infrastructure or, alternatively, with a collaborator or distributor;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and maintaining healthcare coverage and adequate reimbursement for our future products, if any;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    market acceptance of product candidates that we develop as viable treatment options;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing
    any competing technological and market developments;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    assessing, acquiring and developing new product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating
    favorable terms in any collaboration, licensing, or other arrangements into which we may enter and performing our obligations in
    such collaborations;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining,
    protecting, and expanding our portfolio of intellectual property rights, including patents, trademarks, trade secrets, and know-how;
    and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attracting,
    hiring, and retaining qualified personnel.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if NEO100, NEO212 or any future product candidates that we develop are approved for commercial sale, we anticipate incurring significant
costs associated with commercializing any such product candidate that we commercialize on our own or in collaboration with others. Our
expenses could increase beyond expectations if we are required by the FDA or comparable foreign regulatory authorities, to change our
manufacturing processes or assays, or to perform clinical, nonclinical, or other types of studies in addition to those that we currently
anticipate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are successful in obtaining regulatory approvals to market NEO100, NEO212 or any future product candidates, our revenue will be dependent,
in part, upon the size of the markets in the territories for which we gain marketing approval, the accepted price for the product, the
ability to get reimbursement at any price, and whether we own the commercial rights for that territory. If the number of our addressable
patients is not as significant as we estimate, the indications approved by regulatory authorities are narrower than we expect, the labels
for our product candidates contain significant safety warnings, regulatory authorities impose burdensome or restrictive distribution
requirements, or the reasonably accepted patient populations for treatment are narrowed by competition, physician choice or treatment
guidelines, we may not generate significant revenue from sales of such products, even if approved. If we are not able to generate revenue
from the sale of any approved products, we could be prevented from or significantly delayed in achieving profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Raising
additional capital may cause dilution to our shareholders, including purchasers of common stock in this offering, restrict our operations
or require us to relinquish rights to our technologies or product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock,
your ownership interest may be diluted. Any future debt financings we undertake, if available, are likely to involve restrictive covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring
dividends. If we raise additional funds through licensing or collaboration arrangements with third parties, we may have to relinquish
valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. We also could be required to seek
collaborators for product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates
or technologies that we otherwise would seek to develop or commercialize ourselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to obtain capital when needed on acceptable terms may force us to delay, limit or terminate our product development and commercialization
of our current or future product candidates, which could have a material and adverse effect on our business, financial condition, results
of operations, stock price and prospects. Securing additional financing could also require a substantial amount of time from our management
and may divert a disproportionate amount of their attention away from daily activities, which may adversely affect our management&#8217;s
ability to oversee the development of NEO100, NEO212 or any future product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
report of our independent registered public accounting firm included a &#8220;going concern&#8221; explanatory paragraph.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
report of our independent registered public accounting firm on our financial statements as of and for the years ended December&nbsp;31,
2022 and 2021 included an explanatory paragraph indicating that there was substantial doubt about our ability to continue as a going
concern. If we are unable to raise additional capital as and when needed, our business, financial condition and results of operations
will be materially and adversely affected, and we may be forced to delay our development efforts, limit our activities and reduce research
and development costs. If we are unable to continue as a going concern, we may have to liquidate our assets, and the values we receive
for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements. The
inclusion of a going concern explanatory paragraph by our independent registered public accounting firm, our lack of cash resources and
our potential inability to continue as a going concern may materially adversely affect our share price and our ability to raise new capital,
enter into licensing and collaboration arrangements or other contractual relationships with third parties and otherwise execute our development
strategy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Product Discovery, Development and Regulatory Approval</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
development of product candidates based on our technology platform is limited, and we do not know whether we will be able to develop
any products of commercial value.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of our business depends primarily upon our ability to identify novel product candidates to successfully develop and commercialize
those product candidates. While we have had promising preclinical and clinical study results for NEO100 and NEO212, to date, it remains
our only product candidate that has moved into clinical trials. We have not yet succeeded and may not succeed in demonstrating efficacy
and safety in commercializing NEO100 or NEO212. We also may be unsuccessful in identifying additional product candidates beyond NEO100
and NEO212, and any of our product candidates may be shown to have harmful side effects or may have other characteristics that may necessitate
additional clinical testing, or make the product candidates unmarketable or unlikely to receive marketing approval. Similarly, adverse
developments with respect to other companies that attempt to use a similar approach to our approach may adversely impact the actual or
perceived value and potential of our discovery platform and resulting product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these events occur, our ability to successfully discover, develop and commercialize any product candidates may be impaired and
the value of our company could decline significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates are in preclinical and clinical stages of development, are not approved for commercial sale and might never receive
regulatory approval or become commercially viable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our product candidates are in research, preclinical or clinical development. We have not completed the development of any product
candidates, we currently generate no revenue, and we may never be able to develop a marketable product. We intend to use the net proceeds
from this offering to fund the Phase 2a portion of our clinical trial of NEO100, Phase 1 of the clinical trial for NEO212, and a Phase
1/2a trial of intranasal NEO100 with chemotherapy (TBD) for a pediatric indication. Other ongoing research on pipeline drugs will use
the remainder of working capital and other general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enrollment
in NEO100 Phase 1 was completed in September&nbsp;2019, and we reported multiple data readouts in 2020 (and expect a final, long-term
readout by the end of 2022). Our Phase 1 clinical trial, an open-label, single-arm study, of our lead product candidate, NEO100, in patients
with recurrent malignant glioma (Grade IV, IDH1 mutation) has been completed. Our Phase 2a trial of NEO100 is currently enrolling patients.
We will need to enroll a total of 30 patients; 5 patients are currently enrolled. We plan to have a total of 12 sites for enrollment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating plan may change due to many unknown factors, and we may need to seek additional funds sooner than planned through equity and
debt financing. We may consider new collaborations or selectively partner with our technology or programs. Even if we have sufficient
funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or have specific strategic
considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of our current and future product candidates will depend on several factors, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    completion of preclinical studies and clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sufficiency
    of our financial and other resources to complete the necessary preclinical studies and clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of INDs/IND amendments for our planned clinical trials or future clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    enrollment and completion of clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    data from our clinical trials that support FDA conclusion of an acceptable risk-benefit profile of our product candidates in the
    intended populations;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
    of regulatory and marketing approvals from applicable regulatory authorities;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    regulatory approval to use our existing or future manufacturing processes for the clinical and commercial manufacture of our product
    candidates at our existing or future manufacturing facilities or at the facilities of one or more third-party manufacturers with
    whom we would need to establish supply arrangements;</FONT></TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of any products we develop and their benefits and uses, if and when approved, by patients, the medical community and third-party
    payors;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectively
    competing with other therapies;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and maintaining healthcare coverage and adequate reimbursement from third-party payors; and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    a continued acceptable safety profile of the products following approval.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to
successfully commercialize our product candidates, which would materially harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
currently have two clinical development product candidates (NEO100 and NEO212). The failure of one of these two product candidates in
clinical development would adversely affect our business. It may require us to discontinue developing other product candidates based
on the same therapeutic approach.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and future success substantially depend on our ability to obtain regulatory approval and license our lead product candidates
successfully. Both NEO100 and NEO212 are in the early stages of clinical development. Our product candidates will require additional
clinical and nonclinical development, regulatory review, and approval in one or more jurisdictions, a substantial investment, access
to sufficient commercial manufacturing capacity, and significant marketing efforts before we can generate revenue from product sales.
In addition, because NEO100 and NEO212 are our most advanced product candidates, and because all of our other future product candidates
will likely be based on similar technology, if either encounters safety or efficacy problems, developmental delays, regulatory issues,
or other problems, our development plans and business for our other product candidates would be significantly harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of
product candidate development.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently advancing our lead product candidates, NEO100, and NEO212, through clinical development and other product candidates through
preclinical development. We are still recruiting for NEO100 Phase 2a and aim to finish that trial in 2 years. After Phase 2a is completed,
Phase 2b or Phase 3 may still have to be performed depending on the results of the studies. Oral NEO212 has been submitted for an IND
for a Phase 1 trial in patients with primary brain cancer and brain metastasis. Twelve patients will be recruited for the Phase 1 trial.
Afterward, a Phase 2a trial will be performed for primary gliomas and metastatic brain cancer. Intranasal NEO212 is still in development
and will be submitted as a Phase 1 trial for brain metastasis. The Company is also working on an intranasal delivery of a chemotherapeutic
agent for midline primary pediatric intracranial tumor. This development is still preliminary but is in development with multi-center
pediatric neuro-oncology consortiums. Any development problems we experience in the future may cause significant delays or unanticipated
costs, and we may not be able to solve any such development problems. Should we encounter development problems, including unfavorable
preclinical or clinical trial results, the FDA or foreign regulatory authorities may place all, or part, of our clinical development
on hold or refuse to approve our product candidates, or may require additional information, tests, or trials, which could significantly
delay product development and significantly increase our development costs. Moreover, even if we are able to provide the requested information
or trials to the FDA, there would be no guarantee that the FDA would accept them or approve our product candidates. We may also experience
delays in developing and obtaining regulatory approval for a sustainable, reproducible and scalable manufacturing process, or developing
or qualifying and validating product release assays, other testing and manufacturing methods, and our equipment and facilities in a timely
manner, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable
basis, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the clinical trial requirements of the FDA and comparable foreign regulatory authorities and the criteria these regulators
use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended
use and market of the potential products. We may need to devote significant time and resources to compliance with these requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
development involves a lengthy and expensive process with an uncertain outcome and stringent regulations, and delays can occur for a
variety of reasons.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to obtain FDA approval to market a new small molecule product, we must demonstrate proof of safety as well as purity and potency
(i.e., efficacy) in humans. To meet these requirements, we will have to conduct adequate and well-controlled clinical trials. Before
we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our
planned INDs in the United States. We cannot be certain of the timely completion or outcome of our clinical trials and cannot predict
if the FDA will accept our proposed clinical programs or if the outcome of our clinical trials will ultimately support the further development
of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs
on the timelines we expect, if at all, we cannot be sure that submission of INDs or similar applications will result in the FDA or other
regulatory authorities allowing clinical trials to begin and we cannot be sure that our planned clinical trials will begin on time or
that our ongoing clinical trials will be completed on schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting
clinical development is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type,
complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which
we are directly conducting preclinical testing and studies may cause us to incur additional operating expenses. We may experience delays
in initiating or completing clinical trials. We also may experience numerous unforeseen events during, or as a result of, any ongoing
or future clinical trials that we could conduct that could delay or prevent our ability to receive marketing approval or commercialize
NEO100 or any future product candidates, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or failures related to the COVID-19 pandemic, which may result in clinical site closures, delays to patient enrollment, patients
    withdrawing prior to receiving treatment (e.g., catheter implantation failure), patients discontinuing their treatment or follow
    up visits or changes to trial protocols;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
    or institutional review boards (IRBs), may not authorize us or our investigators to commence a clinical trial, conduct a clinical
    trial at a prospective trial site, or amend trial protocols, or may require that we modify or amend our clinical trial protocols;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols
    with prospective trial sites and/or contract research organizations (CROs);</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trials of our product candidates may produce negative or inconclusive results, or our studies may fail to reach the necessary level
    of statistical significance, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product
    development programs;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    unsuccessful development of nasal inhalers used to deliver NEO100;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical
    trials may be slower than we anticipate, or participants may drop out of these clinical trials or be lost to follow-up at a higher
    rate than we anticipate, or may elect to participate in alternative clinical trials sponsored by our competitors with product candidates
    that treat the same indications as our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    contractors may fail to comply with regulatory requirements or the clinical trial protocol, or meet their contractual obligations
    to us in a timely manner, or at all, or we may be required to engage in additional clinical trial site monitoring;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    delays;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
    regulators, or IRBs may require that we or our investigators suspend or terminate clinical research for various reasons, including
    noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks, undesirable
    side effects, emergent drug-drug interactions between NEO100 and any of the other therapeutic agents given to the clinical trial
    subjects or other unexpected characteristics of the product candidate, or due to findings of undesirable effects caused by a pharmacologically,
    chemically or mechanistically similar therapeutic or therapeutic candidate;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    could be adopted in marketing approval policies during the development period, rendering our data insufficient to obtain marketing
    approval;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">statutes
    or regulations could be amended, or new ones could be adopted;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    could be adopted in the regulatory review process for submitted product applications;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of clinical trials of our product candidates may be greater than we anticipate, or we may have insufficient funds for a clinical
    trial or product manufacture or to pay the substantial user fees required by the FDA upon the submission of a NDA or equivalent authorizations
    from comparable foreign regulatory authorities;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may
    be insufficient or inadequate;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers
    with which we contract for clinical and commercial supplies;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may decide, or regulators may require us, to conduct or gather, as applicable, additional clinical trials, analyses, reports, data,
    or preclinical trials, or we may abandon product development programs;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may fail to reach an agreement with regulators or IRBs regarding the scope, design, or implementation of our clinical trials, and
    the FDA or comparable foreign regulatory authorities may require changes to our study designs that make further study impractical
    or not financially prudent;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
    may ultimately disagree with the design or our conduct of our preclinical studies or clinical trials, finding that they do not support
    product candidate approval;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may have delays in adding new investigators or clinical trial sites, or we may experience a withdrawal of clinical trial sites;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    that enroll in our studies may misrepresent their eligibility or may otherwise not comply with the clinical trial protocol, resulting
    in the need to drop the patients from the study or clinical trial, increase the needed enrollment size for the clinical trial or
    extend its duration;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    may be regulatory questions or disagreements regarding interpretations of data and results, or new information may emerge regarding
    our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with our trial design, including endpoints, or our interpretation of
    data from preclinical studies and clinical trials or find that a product candidate&#8217;s benefits do not outweigh its safety risks;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may not accept data from studies with clinical trial sites in foreign countries;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with our intended indications;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes
    or our manufacturing facilities for clinical and future commercial supplies;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable
    foreign regulatory authorities to support the submission of a New Drug Application or other comparable submission in foreign jurisdictions
    or to obtain regulatory approval in the United States or elsewhere;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may take longer than we anticipate to make a decision on our product candidates;
    and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not be able to demonstrate that a product candidate provides an advantage over current standards of care or current or future
    competitive therapies in development, including, for example due to a longer-and/or-higher-than-expected response rate determination
    in the active comparator group or a shorter-and/or-lower-than-expected response rate determination in the experimental drug group.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product development costs will also increase if we experience delays in clinical testing or marketing approvals, and we may not have
sufficient funding to complete the testing and approval process for any of our current or future product candidates. We may be required
to obtain additional funds to complete clinical trials and prepare for possible commercialization of our product candidates. We do not
know whether any preclinical tests or clinical trials beyond what we currently have planned will be required, will begin as planned,
will need to be restructured, or will be completed on schedule or at all. Significant delays relating to any preclinical studies or clinical
trials also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our
competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and
may harm our business and results of operations. In addition, many of the factors that cause, or lead to, delays in clinical trials may
ultimately lead to the denial of marketing approval of any of our product candidates. Any delays in our clinical development programs
may harm our business, financial condition and results of operations significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals
could be delayed or prevented.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient
number of eligible patients to participate in these trials as required by the FDA or foreign regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient
population, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, the design of the clinical
trial, competing clinical trials, and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product
candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we
are investigating.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient
number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment or retention in
our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    and efficacy of approved therapies for the disease under investigation;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    eligibility criteria for the trial in question;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    that enrolled subjects will drop out before completion of the trial, including as a result of emergent drug-drug interactions between
    NEO100 and any of the other therapeutic agents given to the clinical trial subjects, contracting COVID-19 or other health conditions
    or being forced to quarantine;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    of excessive catheter implantation failures leading to elimination of particular study sites from the trial in question;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived
    risks and benefits of the product candidate under study;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">efforts
    to facilitate timely enrollment in clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    referral practices of physicians;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to monitor patients adequately during and after treatment;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">proximity
    and availability of clinical trial sites for prospective patients;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdraw
    of consent for any reasons;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    limitations of protocol design; and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">protocol
    amendment by the sponsor and/or as requested by applicable regulatory authorities.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our planned clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic
areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients
who might have opted to enroll in our trials may instead opt to enroll in a competing clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inability to enroll a sufficient number of patients for our anticipated and any future clinical trials would result in significant delays
or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased
development costs for our product candidates, which could have an adverse effect on our business, financial condition, results of operations,
and prospects. In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter patient enrollment
difficulties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Results
of preclinical studies and early clinical trials may not be predictive of results of future clinical trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
our lead product candidate, NEO100, we completed Phase 1 enrollment and reported multiple data readouts in 2021 and 2022. For our Phase
2a clinical trial, expect the final readout by the end of 2024. Clinical development is expensive and can take many years to complete,
and its outcome is inherently uncertain. NEO100 may not perform as we expect in clinical trials, particularly in our open label, randomized,
and controlled Phase 2 registration clinical trial, may ultimately have a different or no impact on malignant gliomas, may have another
mechanism of action than we expect, and may not ultimately prove to be safe and effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of previous clinical trials of NEO100 and NEO212 and results of preclinical studies or early clinical trials of any other product
candidate we may develop, may not be predictive of the results of subsequent and later-stage clinical trials. Many companies in the pharmaceutical
and biotechnology industries have suffered significant setbacks in registration-stage clinical trials after achieving positive results
in earlier development, and we could face similar setbacks. The design of a clinical trial can determine whether its results will support
approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced.
We do not have experience in designing a registration-stage clinical trial and may be unable to design and execute a clinical trial to
support marketing approval. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses.
Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless
failed to obtain marketing approval for the product candidates. Even if we, or future collaborators, believe that the results of clinical
trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may
not grant marketing approval of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product
candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of
the patient populations, changes in and adherence to the clinical trial protocols, variations in conducting clinical trial at different
sites, changes in medical practice, FDA requirements based on agency guidelines or precedence which may be more strict for a Phase 2
clinical trial, the rate of dropout among clinical trial participants and changes in the manufacturing process. Moreover, should there
be an issue with the design of any of our clinical trials, our results may be impacted. We may not discover such a flaw until the clinical
trial is at an advanced stage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Interim,
topline, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data
become available and are subject to audit and verification procedures that could result in material changes in the final data.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publicly disclose interim, topline, or preliminary data from our clinical trials, which is based on a preliminary
analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive
review of the data related to the particular study or trial. We also make assumptions, estimations, calculations, and conclusions as
part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result,
the interim, topline, or preliminary results that we report may differ from future results of the same studies, or different conclusions
or considerations may qualify such results, once additional data have been received and fully evaluated. Interim, topline, and preliminary
data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary
data we previously published. As a result, such data should be viewed with caution until the final data are available. From time to time,
we may also disclose interim data from our clinical trials. Interim, topline, and preliminary data from clinical trials that we may complete
are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient
data become available. Adverse differences between preliminary, interim or topline data and final data could significantly harm our business
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability,
or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose
to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others
may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information
we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or
otherwise regarding a particular product, product candidate, or our business. If the interim, topline, or preliminary data that we report
differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain
approval for, and commercialize NEO100 and any future product candidates may be harmed, which could harm our business, operating results,
prospects, or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Serious
adverse events, undesirable side effects (including emergent drug-drug interactions between NEO100 and any of the other therapeutic agents
given to the clinical trial subjects) or other unexpected properties of our current or future product candidates may be identified during
development or after approval, which could halt their development or lead to the discontinuation of our clinical development programs,
refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing
authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such product candidate.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, NEO100 is the only product candidate we have tested in humans. As we continue our development of NEO100 and initiate clinical trials
of any future product candidates, serious adverse events, undesirable side effects or unexpected characteristics may emerge or be reported,
causing us to abandon these product candidates or limit their development to more narrow uses or subpopulations in which the serious
adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit
perspective. Even if our product candidates initially show promise in early clinical trials, the side effects of therapies are frequently
only detectable after they are tested in large, Phase 2 clinical trials or, in some cases, after they are made available to patients
on a commercial scale after approval. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were
caused by the product candidate or another factor, especially in oncology subjects who may suffer from other medical conditions and be
taking other medications. If serious adverse or unexpected side effects are identified during development and are determined to be attributed
to our product candidates, or the result of drug-drug interactions between our product candidate and any of the concomitant therapies
given to the trial subjects, we, the FDA or comparable foreign regulatory authorities, or IRBs and other reviewing entities, could interrupt,
delay, or halt clinical trials and could result in a more restrictive label, a Risk Evaluation and Mitigation Strategy (REMS) or the
delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory
authorities may also require, or we may voluntarily develop strategies for managing adverse events during clinical development, which
could include restrictions on our enrollment criteria, the use of stopping criteria, adjustments to a study&#8217;s design, or the monitoring
of safety data by a data monitoring committee, among other strategies. Any requests from the FDA or comparable foreign regulatory authority
for additional data or information could also result in substantial delays in the approval of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug-related
side effects could also affect subject recruitment or the ability of enrolled subjects to complete the trial or result in potential product
liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects
caused by such products, a number of potentially significant negative consequences could result, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw approvals of such product;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require additional warnings on the label;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be forced to suspend marketing of that product, or decide to remove the product form the marketplace;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to change the way the product is administered;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be subject to fines, injunctions, or the imposition of criminal or civil penalties;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients; and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product may become less competitive, and our reputation may suffer.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
therapeutic-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result
in potential product liability claims. Any of these events could prevent us from achieving or maintaining market acceptance of the particular
product candidate, if approved, and could significantly harm our business, financial condition, results of operations, stock price and
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
anticipate that many of our product candidates may be used in combination with third-party drugs and/or devices, some of which may still
be in development, and we have limited or no control over the supply, regulatory status or regulatory approval of such drugs and/or devices.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate developing our product candidates for use in combination with other oncology pharmaceutics, including chemotherapies and cellular
and targeted therapies (e.g., immune checkpoint inhibitors. In particular, our development of NEO100 as a solvent (carrier) of other
drugs and biologics to the brain will depend on our ability to access such drugs and devices on commercially reasonable terms for the
clinical trials and their availability for use with the commercialized product, if approved. We cannot be certain that current or potential
future commercial relationships will provide us with a steady supply of such drugs or devices on commercially reasonable terms or at
all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
failure to maintain or enter into new successful commercial relationships, or the expense of purchasing platinum-based and other chemotherapies,
or any other combination products, or any devices in the market, may delay our development timelines, increase our costs and jeopardize
our ability to develop our product candidates as commercially viable therapies. If any of these occur, our business, financial condition,
results of operations, stock price and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the development of product candidates for use in combination with another product or product candidate may present challenges that are
not faced for single agent product candidates. For our product candidates that may be used in combination with platinum-based and other
chemotherapies, or any other combination products or any devices, the FDA may require us to use more complex clinical trial designs in
order to evaluate the contribution of each product and product candidate to any observed effects. It is possible that the results of
these trials could show that there are adverse events tied to the interaction of NEO100 with any of the other therapies, or that any
positive previous trial results are attributable to the combination therapy and not our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
following product approval, the FDA may require that products or devices used in conjunction with each other be cross labeled for combined
use. To the extent that we do not have rights to the other product or device, this may require us to work with a third party to satisfy
such a requirement. The ability to obtain cooperation from the third party may impact our ability to respond to the FDA&#8217;s requests
which could impact our ability to achieve regulatory approval. Moreover, developments related to the other product or device may impact
our clinical trials as well as our commercial prospects should we receive marketing approval. Such developments may include changes to
the safety or efficacy profile of the other product or device, changes to the availability of the approved product or device, and changes
to the standard of care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that any future collaborator or supplier of platinum-based and other chemotherapies, or any other products administered in
combination, or any devices used, with our product candidates does not supply their products on commercially reasonable terms or in a
timely fashion, we would need to identify alternatives for accessing these products. This could cause our clinical trials to be delayed
and limit the commercial opportunities for our product candidates, in which case our business, financial condition, results of operations,
stock price and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be successful in our efforts to expand our pipeline of product candidates and develop marketable products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect initially to develop our lead product candidate, NEO100. We anticipate pursuing clinical development of other product candidates,
alone or in collaboration with our partners. Research programs to identify new product candidates require substantial technical, financial
and human resources. Developing, obtaining marketing approval for, and commercializing additional product candidates will require substantial
additional funding beyond the net proceeds of this offering and will be subject to the risks of failure inherent in medical product development.
We cannot assure you that we will be able to successfully advance any of these additional product candidates through the development
process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain approval from the FDA or comparable foreign regulatory authorities to market additional product candidates for the treatment
of cancer, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace,
or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional
product candidates our commercial opportunity may be limited and our business, financial condition, results of operations, stock price
and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates
or indications that may be more profitable or for which there is a greater likelihood of success.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and managerial resources, we must prioritize our research programs and will need to focus our product candidates
on the potential treatment of certain indications. As a result, we may forego or delay pursuit of opportunities with other product candidates
or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail
to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development
programs and product candidates for specific indications may not yield any commercially-viable products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we may pursue additional in-licenses or acquisitions of development-stage assets or programs, which entails additional risk to us. Identifying,
selecting and acquiring promising product candidates requires substantial technical, financial, and human resources expertise. Efforts
to do so may not result in the actual acquisition or license of a particular product candidate, potentially resulting in a diversion
of our management&#8217;s time and the expenditure of our resources with no resulting benefit. For example, if we are unable to identify
programs that ultimately result in approved products, we may spend material amounts of our capital and other resources evaluating, acquiring
and developing products that ultimately do not provide a return on our investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we do not achieve our product development goals in the timeframes we announce and expect, the commercialization of our product candidates
may be delayed and as a result our share price may decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
development is inherently risky and uncertain. We cannot be certain that we will be able to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete
    IND-enabling preclinical studies or develop manufacturing processes and associated analytical methods that meet current good manufacturing
    practice (cGMP) requirements in time to initiate or to complete our anticipated or future clinical trials in the timeframes we announce;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    sufficient clinical supply of our product candidates to support our anticipated or future clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate
    clinical trials within the timeframes we announce;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enroll
    and maintain a sufficient number of subjects to complete or timely complete any clinical trials; or</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collect
    and analyze the data from any completed clinical trials in the timeframes we announce.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
actual timing of our development milestones could vary significantly compared to our estimates, in some cases for reasons beyond our
control. If we are unable to achieve our goals within the timeframes we announce, the commercialization of our product candidates may
be delayed and, as a result, the stock price of our common stock could fall and you may lose all of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and
uncertain and may prevent us or any of our existing or potential future collaboration partners from obtaining approvals for the commercialization
of NEO100 and any other product candidate we develop.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
current or future product candidate we may develop, and the activities associated with their development and commercialization, including
their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution,
are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and by comparable authorities
in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate
in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction
and it is possible that none of the product candidates we may seek to develop in the future will ever obtain regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securing
marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities
for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy for that indication. Securing marketing
approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities
and clinical trial sites by, the regulatory authorities. If we do not receive approval from the FDA and comparable foreign regulatory
authorities for any of our product candidates, we will not be able to commercialize such product candidates in the United States or in
other jurisdictions. If significant delays in obtaining approval for and commercializing our product candidates occur in any jurisdictions,
our business, financial condition, results of operations, stock price and prospects will be materially harmed. Even if our product candidates
are approved, they may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    subject to limitations on the indicated uses or patient populations for which they may be marketed, distribution restrictions, or
    other conditions of approval;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">contain
    significant safety warnings, including boxed warnings;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">contain
    significant contraindications, and precautions which could reduce the size of the patient population;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    be approved with label statements necessary or desirable for successful commercialization;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">contain
    requirements for costly post-market testing and surveillance, or other requirements, including the submission of a REMS to monitor
    the safety or efficacy of the products; or</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    withdrawn from the market because of a serious safety issue becomes know after approval is granted.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of obtaining marketing approvals, both in the United States and abroad, is expensive, takes many years even if successful, and
can vary substantially in and among jurisdictions based upon a variety of factors, including the type, complexity, and novelty of the
product candidates involved. The number and types of preclinical studies and clinical trials that will be required for regulatory approval
also varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations
applicable to any particular product candidate. Changes in marketing approval policies during the development period, changes in or the
enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays
in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in
the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional
preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing
could delay, limit, or prevent marketing approval of a product candidate. It is possible that our product candidates will never obtain
the appropriate regulatory approvals necessary for us to commence product sales, or any marketing approval we ultimately obtain may be
limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in obtaining approval or if we fail to obtain approval of any current or future product candidates we may develop,
the commercial prospects for those product candidates may be harmed, and our ability to generate revenues will be materially impaired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Regulatory
approval by the FDA or comparable foreign regulatory authorities is limited to those specific indications and conditions for which approval
has been granted, and we may be subject to substantial fines, criminal penalties, injunctions, or other enforcement actions if we are
determined to be promoting the use of any products for unapproved or &#8220;off-label&#8221; uses, resulting in damage to our reputation
and business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
must comply with requirements concerning advertising and promotion for any product candidates for which we obtain marketing approval.
Promotional communications with respect to pharmaceuticals are subject to a variety of legal and regulatory restrictions and continuing
review by the FDA, Department of Justice, Department of Health and Human Services&#8217; Office of Inspector General, state attorneys
general, members of Congress, and the public. When the FDA or comparable foreign regulatory authorities issue regulatory approval for
a product candidate, the regulatory approval is limited to those specific uses and indications for which a product is approved. If we
are not able to obtain FDA approval for desired uses or indications for our product candidates, we may not market or promote them for
those indications and uses, referred to as off-label uses, and our business, financial condition, results of operations, stock price
and prospects will be materially harmed. We also must sufficiently substantiate any claims that we make for any products we develop,
including claims comparing our products to other companies&#8217; products, and must abide by the FDA&#8217;s strict requirements regarding
the content of promotion and advertising.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
regulatory authorities in the United States generally do not restrict or regulate the behavior of physicians in their choice of treatment
within the practice of medicine, physicians may in their independent medical judgment choose to prescribe products for uses that are
not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory
authorities. Regulatory authorities do, however, limit communications by biopharmaceutical companies concerning off-label use. Therefore,
we are prohibited from marketing and promoting the products for indications and uses that are not specifically approved by the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to have impermissibly promoted any products that we may develop, we may become subject to significant liability and government
fines. The FDA and other agencies actively enforce the laws and regulations regarding product promotion, particularly those prohibiting
the promotion of off-label uses, and a company that is found to have improperly promoted a product may be subject to significant sanctions.
The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several
companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions
under which specified promotional conduct is changed or curtailed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the promotion of biopharmaceutical products is subject to additional FDA requirements and restrictions on promotional
statements. If after one or more of our product candidates obtains marketing approval the FDA determines that our promotional activities
violate its regulations and policies pertaining to product promotion, it could request that we modify our promotional materials or subject
us to regulatory or other enforcement actions, including issuance of warning letters or untitled letters, suspension or withdrawal of
an approved product from the market, requests for recalls, payment of civil fines, disgorgement of money, imposition of operating restrictions,
injunctions or criminal prosecution, and other enforcement actions. Similarly, industry codes in foreign jurisdictions may prohibit companies
from engaging in certain promotional activities and regulatory agencies in various countries may enforce violations of such codes with
civil penalties. If we become subject to regulatory and enforcement actions our business, financial condition, results of operations,
stock price and prospects will be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engaging
in the impermissible promotion of our products, in the United States, following approval, for off-label uses can also subject us to false
claims and other litigation under federal and state statutes. These include fraud and abuse and consumer protection laws, which can lead
to civil and criminal penalties and fines, agreements with governmental authorities that materially restrict the manner in which we promote
or distribute therapeutic products and conduct our business. These restrictions could include corporate integrity agreements, suspension
or exclusion from participation in federal and state healthcare programs, and suspension and debarment from government contracts and
refusal of orders under existing government contracts. These False Claims Act (FCA) lawsuits against manufacturers of drugs and small
molecule products have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements,
up to $3.0 billion, pertaining to certain sales practices and promoting off-label uses. In addition, FCA lawsuits may expose manufacturers
to follow-on claims by private payors based on fraudulent marketing practices. This growth in litigation has increased the risk that
a biopharmaceutical company will have to defend a false claim action, pay settlement fines or restitution, as well as criminal and civil
penalties, agree to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid, or other federal
and state healthcare programs. If we do not lawfully promote our approved products, if any, we may become subject to such litigation
and, if we do not successfully defend against such actions, those actions may have a material adverse effect on our business, financial
condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Obtaining
and maintaining marketing approval for our product candidates in one jurisdiction would not mean that we will be successful in obtaining
marketing approval of that product candidate in other jurisdictions, which could prevent us from marketing our products internationally.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
and maintaining marketing approval of our product candidates in one jurisdiction would not guarantee that we will be able to obtain or
maintain marketing approval in any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction may
have a negative effect on the marketing approval process in others. For example, even if the FDA grants marketing approval of a product
candidate, comparable foreign regulatory authorities must also approve the manufacturing, marketing and promotion of the product candidate
in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different
from, and greater than, those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted
in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States,
a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price
that we intend to charge for our products is also subject to approval. In cases where data from foreign clinical trials are intended
to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis
of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed
by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without
the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the
data through an on-site inspection or other appropriate means.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply
prior to marketing in those jurisdictions. Obtaining foreign marketing approvals and compliance with foreign regulatory requirements
could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain
countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals,
our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. If we
obtain approval for any product candidate and ultimately commercialize that product in foreign markets, we would be subject to additional
risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements
and the reduced protection of intellectual property rights in some foreign countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if our product candidates receive regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which
may result in significant additional expense and limit how we manufacture and market our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product candidate for which we obtain marketing approval will be subject to extensive and ongoing requirements of and review by the FDA
or comparable foreign regulatory authorities, including requirements related to the manufacturing processes, post-approval clinical data,
labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising, marketing, and promotional
activities for such product. These requirements further include submissions of safety and other post-marketing information, including
manufacturing deviations and reports, registration and listing requirements, the payment of annual fees, continued compliance with cGMP
requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents, and
GCPs for any clinical trials that we conduct post-approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and comparable foreign regulatory authorities will continue to closely monitor the safety profile of any product even after approval.
If the FDA or comparable foreign regulatory authorities become aware of new safety information after approval of any of our product candidates,
they may withdraw approval, issue public safety alerts, require labeling changes or establishment of a REMS or similar strategy, impose
significant restrictions on a product&#8217;s indicated uses or marketing, or impose ongoing requirements for potentially costly post-approval
studies or post-market surveillance. Any such restrictions could limit sales of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and any of our suppliers or collaborators, including our contract manufacturers, could be subject to periodic unannounced inspections
by the FDA to monitor and ensure compliance with cGMPs and other FDA regulatory requirements. Application holders must further notify
the FDA, and depending on the nature of the change, obtain FDA pre-approval for product and manufacturing changes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, later discovery of previously unknown adverse events or of the product being less effective than previously thought or other
problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements both before and
after approval, may yield various negative results, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on manufacturing, distribution, or marketing of such products;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the labeling, including required additional warnings, such as New Drug Application boxed warnings, contraindications, precautions,
    and restrictions on the approved indication or use;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">modifications
    to promotional pieces;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance
    of corrective information;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to conduct post-marketing studies or other clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    holds or termination of clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to establish or modify a REMS or similar strategy;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    to the way the product candidate is administered;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">liability
    for harm caused to patients or subjects;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reputational
    harm;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product becoming less competitive;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning,
    untitled, or cyber letters;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    of marketing or withdrawal of the products from the market;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authority issuance of safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warnings
    or other safety information about the product candidate;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to approve pending applications or supplements to approved applications that we submit;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recalls
    of products;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    restitution or disgorgement of profits or revenues;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of marketing approvals;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to permit the import or export of our products;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    debarment, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion
    from federal healthcare programs, consent decrees, or corporate integrity agreements; or</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties, including imprisonment.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, or
could substantially increase the costs and expenses of commercializing such product, which in turn could delay or prevent us from generating
significant revenues from its marketing and sale. Any of these events could further have other material and adverse effects on our operations
and business and could adversely impact our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&#8217;s policies or those of comparable foreign regulatory authorities may change and additional government regulations may be enacted
that could prevent, limit or delay regulatory approval of our product candidates, limit the marketability of our product candidates,
or impose additional regulatory obligations on us. Changes in medical practice and standard of care may also impact the marketability
of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are slow or unable to adapt to changes in existing requirements, standards of care, or the adoption of new requirements or policies,
or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and be subject
to regulatory enforcement action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
any of the above actions take place, we could be prevented from or significantly delayed in achieving profitability. Further, the cost
of compliance with post-approval regulations may have a negative effect on our operations and business and could adversely impact our
business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page --> <!-- Field: Split-Segment -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Manufacturing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to multiple manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacture of biopharmaceutical products requires significant expertise and capital investment, including the development of advanced
manufacturing techniques and process controls. The process of manufacturing viral immunotherapies, including our product candidates,
is particularly complex, time-consuming, highly-regulated and costly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers
of small molecules often encounter difficulties in production, particularly in scaling up initial production, with such risks including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">quality
    control, including stability of the product candidate and quality assurance testing;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shortages
    of qualified personnel or key raw materials or components;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    loss during the manufacturing process, including loss caused by contamination, equipment failure or improper installation or operation
    of equipment, or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields,
    product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or in the
    manufacturing facilities in which our products are made, such manufacturing facilities may need to be closed for an extended period
    of time to investigate and remedy the contamination;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor and raw
    material shortages, natural disasters, power failures and numerous other factors; and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    adverse developments affecting manufacturing operations for our products may result in shipment delays, inventory shortages, lot
    failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates. We may also have to take
    inventory write-offs and incur other charges and expenses for product candidate batches that fail to meet specifications, undertake
    costly remediation efforts or seek more costly manufacturing alternatives.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
product candidates are developed through preclinical studies to later-stage clinical trials towards approval and commercialization, it
is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in
an effort to optimize processes and results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in product candidate manufacturing or formulation may result in additional costs or delay.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed product candidate manufacturing agreements with a company in Japan for our core product. We have developed API production
capabilities with a company in Taiwan. We have developed formulation capabilities with a company in San Diego. Moreover, we have obtained
a license for intranasal delivery with a company in Taiwan. We anticipate relying on contract manufacturing organizations (CMOs) to conduct
large-scale manufacture of NEO100 and NEO212 in the future. The inability to identify and contract with suitable CMOs or their failure
to meet their obligations to us could affect our ability to develop or commercialize NEO100 in a timely manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA, state or a comparable foreign regulatory authority does not approve our manufacturing facility for the manufacture of our product
candidates or if it withdraws any such approval in the future, or our current facility is unable to meet our volume requirements, we
may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval
for or market our product candidates, if approved. Any alternative manufacturing facility would require obtaining the necessary equipment
and materials and, if a third-party manufacturer, the necessary manufacturing know-how, which may take substantial time and investment.
We must also receive FDA approval to use any manufacturing facility for commercial supply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
such an instance, we may need to enter into an appropriate third-party relationship. We may fail to establish manufacturing relationships
or alternative arrangements for our product candidates or programs. Any product candidates we develop compete with other products and
product candidates for access to manufacturing facilities. There are a limited number of manufacturers operating under cGMP regulations
capable of manufacturing and filling our viral product for us and willing to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to manufacture and release any product candidates in the volumes that we require on a timely basis, or fail to comply with
stringent regulations applicable to biopharmaceutical manufacturers, we may face delays in the development and commercialization of,
or be unable to meet demand for, any product candidates, and may lose potential revenues.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to self-manufacture our clinical trial and commercial product supplies for the foreseeable future. We currently have only one
manufacturing facility for use in our clinical trials. Our clinical product supply may be limited, interrupted, or of satisfactory quality
or continue to be available at acceptable prices. Any delays in obtaining adequate supplies of our product candidates that meet the necessary
quality standards may delay our development or commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to comply with our specifications, applicable cGMP requirements or other FDA, state or foreign regulatory requirements
of our product candidates for clinical trials and, if approved, commercial supply, and will be subject to FDA and comparable foreign
regulatory authority inspection. These requirements include the qualification and validation of our manufacturing equipment and processes.
We may not be able to develop, retain or acquire the internal expertise and resources necessary for effectively managing our ongoing
manufacturing operations and complying with these requirements. Poor control of production processes can lead to the introduction of
adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of a product candidate that may not
be detectable in final product testing. If we cannot successfully manufacture material that conforms to our specifications and the strict
regulatory requirements of the FDA or other regulatory authorities, we will not be able to secure or maintain regulatory approval for
our manufacturing facility. Any such deviations may also require remedial measures that may be costly and/or time-consuming for us to
implement, particularly in areas relating to operations, quality, regulatory, facilities and information technology. Any such remedial
measures imposed upon us may include the temporary or permanent suspension of a clinical trial or the temporary or permanent closure
of our facility and could materially harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
failure to comply with the applicable regulatory requirements, including periodic regulatory inspections, may result in regulatory enforcement
actions against us or our raw material and component suppliers (including fines and civil and criminal penalties, including imprisonment)
suspension or restrictions of production, injunctions, delay or denial of product approval or supplements to approved products, clinical
holds or termination of clinical trials, warning or untitled letters, regulatory authority communications warning the public about safety
issues with the product candidate, refusal to permit the import or export of the products, product seizure, detention, or recall, operating
restrictions, consent decrees, withdrawal of product approval, environmental or safety incidents and other liabilities. If the safety
of any quantities supplied is compromised due to our failure or our raw material and component suppliers&#8217; failure to adhere to
applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our product
candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
problems or delays we experience in commercial-scale manufacturing of a product candidate or component may result in a delay in product
development timelines and FDA or comparable foreign regulatory authority approval of the product candidate or may impair our ability
to manufacture commercial quantities or such quantities at an acceptable cost and quality, which could result in the delay, prevention,
or impairment of clinical development and commercialization of any product candidates and may materially harm our business, financial
condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Reliance on Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely, and expect to continue to rely, on third parties to supply and quality-test the ingredients for our product candidates and components
for our manufacturing process.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we are responsible for the manufacturing of our product candidates, drug substance and drug product, reliance on raw material and component
suppliers entails risks, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    control for certain aspects of our manufacturing activities;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
    or nonrenewal of the applicable supplier and service agreements in a manner or at a time that is costly or damaging to us;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible breach by our third-party suppliers and service providers of our agreements with them;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    failure of our third-party suppliers and service providers to comply with applicable regulatory requirements;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions
    to the operations of our third-party suppliers and service providers caused by conditions unrelated to our business or operations,
    including the bankruptcy of the manufacturer or service provider; and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible misappropriation of our proprietary information, including our trade secrets and know-how.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
failure or refusal to supply our product candidates or components for our product candidates that we may develop could delay, prevent
or impair our clinical development or commercialization efforts. In addition, we do not have any long-term commitments or guaranteed
prices from our suppliers of raw materials, manufacturing equipment components or devices or combination products. In particular, any
change in our suppliers could require significant effort and expertise because there may be a limited number of qualified replacements.
Further, the terms of any new arrangement could be less favorable and transfer costs relating to technology and processes could be significant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could lead to clinical trial delays or failure to obtain regulatory approval, impact our ability to successfully commercialize
any of our product candidates or otherwise harm our business, financial condition, results of operations, stock price and prospects.
Some of these events could be the basis for FDA or other regulatory authority action, including injunction, recall, seizure or total
or partial suspension of product manufacture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials.
If those third parties do not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing
to comply with regulatory requirements, we may be unable to obtain regulatory approval for our product candidates or any other product
candidates that we may develop in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely, and will rely, on third-party CROs, study sites and others to conduct, supervise, and monitor our preclinical studies and clinical
trials for our product candidates. We expect to continue to rely on third parties, such as CROs, clinical data management organizations,
medical institutions, and clinical investigators, to conduct our preclinical studies and clinical trials. Although we have agreements
governing their activities, we have limited influence over their actual performance and control only certain aspects of their activities.
The failure of these third parties to successfully carry out their contractual duties or meet expected deadlines could substantially
harm our business because we may be delayed in completing or unable to complete the studies required to support future approval of our
product candidates, or we may not obtain marketing approval for or commercialize our product candidates in a timely manner or at all.
Moreover, these agreements might terminate for a variety of reasons, including a failure to perform by the third parties. If we need
to enter into alternative arrangements, our product development activities would be delayed and our business, financial condition, results
of operations, stock price and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
reliance on these third parties for development activities will reduce our control over these activities. Nevertheless, we are responsible
for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards
and our reliance on third parties does not relieve us of our regulatory responsibilities. For example, we will remain responsible for
ensuring that each of our trials is conducted in accordance with the general investigational plan and protocols for the trial. We must
also ensure that our preclinical trials are conducted in accordance with the FDA&#8217;s Good Laboratory Practice (GLP) regulations,
as appropriate. Moreover, the FDA and comparable foreign regulatory authorities require us to comply with standards, commonly referred
to as GCP guidelines, for conducting, recording, and reporting the results of clinical trials to assure that data and reported results
are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. Regulatory authorities
enforce these requirements through periodic inspections of trial sponsors, clinical investigators, and trial sites. If we or any of our
third parties fail to comply with applicable GCPs or other regulatory requirements, we or they may be subject to enforcement or other
legal actions. For example, the data generated in our trials may not have been appropriately collected or documented, and thereby be
deemed unreliable and the FDA or comparable foreign regulatory authorities may conclude the study findings are not adequate and require
us to perform additional studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we will be required to report certain financial interests of our third-party investigators if these relationships exceed certain
financial thresholds or meet other criteria. The FDA or comparable foreign regulatory authorities may question the integrity of the data
from those clinical trials conducted by investigators who may have conflicts of interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our trials
complies with the applicable regulatory requirements. In addition, our clinical trials must be conducted with product candidates that
were produced under cGMP regulations. Failure to comply with these regulations may require us to repeat clinical trials, which would
delay the regulatory approval process. We also are required to register certain clinical trials and post the results of certain completed
clinical trials on one or more government-sponsored databases, e.g., ClinicalTrials.gov, within specified timeframes. Failure to do so
can result in enforcement actions and adverse publicity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
third parties with which we work may also have relationships with other entities, some of which may be our competitors, for whom they
may also be conducting trials or other therapeutic development activities that could harm our competitive position. In addition, such
third parties are not our employees, and except for remedies available to us under our agreements with such third parties we cannot control
whether or not they devote sufficient time and resources to our ongoing clinical, non-clinical, and preclinical programs. If these third
parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our preclinical studies or clinical
trials in accordance with regulatory requirements or our stated protocols, if they need to be replaced or if the quality or accuracy
of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, our
trials may be repeated, extended, delayed, or terminated; we may not be able to obtain, or may be delayed in obtaining, marketing approvals
for our product candidates; we may not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates;
or we or they may be subject to regulatory enforcement actions. As a result, our results of operations and the commercial prospects for
our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. To the extent
we are unable to successfully identify and manage the performance of third-party service providers in the future, our business, financial
condition, results of operations, stock price and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative providers
or to do so on commercially reasonable terms. Switching or adding additional third parties involves additional cost and requires management
time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays could occur,
which could compromise our ability to meet our desired development timelines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will also rely on other third parties to store and distribute our product candidates for the clinical trials that we conduct. Any performance
failure on the part of our distributors could delay clinical development, marketing approval, or commercialization of our product candidates,
which could result in additional losses and deprive us of potential product revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have entered into, and may in the future enter into, certain collaboration agreements and strategic alliances to maximize the potential
of our product candidates, and we may not realize the anticipated benefits of such collaborations or alliances. We expect to continue
to form collaborations in the future with respect to our product candidates, but may be unable to do so or to realize the potential benefits
of such transactions, which may cause us to alter or delay our development and commercialization plans.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may form or seek other strategic alliances, joint ventures, or collaborations, or enter into additional licensing arrangements with third
parties that we believe will complement or augment our development and commercialization efforts with respect to product candidates we
develop. These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption
of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration. We also cannot be certain
that, following a strategic transaction or license, we will achieve the revenue or other anticipated benefits that led us to enter into
the arrangement. Additionally, the success of any collaboration arrangements may depend on the efforts and activities of our collaborators.
Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these arrangements.
Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to
delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration
arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are not able to establish future collaborations on commercially reasonable terms, we may have to alter our development and commercialization
plans for one or more of our other development programs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face significant competition in seeking appropriate additional collaborators. Our ability to reach a definitive agreement for any collaboration
will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of
the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail
the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay
its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake
development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities
on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms,
or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development
and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to
develop our product platform and our business may be materially and adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
future collaborations are not a guarantee of success, and all collaborations are as risky, or more risky, than undertaking the activities
ourselves.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
potential future collaborations we might enter into for NEO100, NEO212 or our other product candidates, may pose a number of risks, including
the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not perform their obligations as expected;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not pursue development and commercialization of product candidates that achieve regulatory approval or may elect not to continue
    or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic
    focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product
    candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    could fail to make timely regulatory submissions for a product candidate;</FONT></TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not comply with all applicable regulatory requirements or may fail to report safety data in accordance with all applicable regulatory
    requirements, which could subject them or us to regulatory enforcement actions;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product
    candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized
    under terms that are more economically attractive than ours;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates
    or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may
    not commit sufficient resources to the marketing and distribution of such product candidate or product;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreements
    with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development,
    might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional
    responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time
    consuming and expensive;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite
    litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;
    and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, all of the risks relating to product development, regulatory approval and commercialization described in this prospectus also
apply to the activities of any of our current or future collaborators.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborations
with biopharmaceutical companies and other third parties often are terminated or allowed to expire by the other party. Any such termination
or expiration could adversely affect us financially and could harm our business reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any collaborations we have entered into or might enter into do not result in the successful development and commercialization of products
or if one of our collaborators subsequently terminates its agreement with us, we may not receive any future research funding or milestone
or royalty payments under such collaboration. If we do not receive the funding we expect under the agreements, our development of our
product candidates could be delayed and we may need additional resources to develop our product candidates and our product platform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if any collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate development or commercialization
of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult
to attract new collaborators and our reputation in the business and financial communities could be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for any collaboration
will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of
the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail
the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay
its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake
development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities
on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms,
or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development
and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to
develop our product platform and our business may be materially and adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Disruptions
at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and
retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a
timely manner, which could negatively impact our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes.
Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies
that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies,
which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December&nbsp;22,
2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical
employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA
to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separately,
the FDA and regulatory authorities outside the United States have and may adopt restrictions or other policy measures in response to
the COVID-19 pandemic that divert resources and delay their attention to any submissions we may make. If a prolonged government shutdown
occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections,
reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely
review and process our regulatory submissions, which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Commercialization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we, or our collaboration partners, are unable to successfully commercialize any product candidate for which we receive regulatory approval,
or experience significant delays in doing so, our business will be materially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we, or our collaboration partners, are successful in obtaining marketing approval from applicable regulatory authorities for NEO100 or
any other product candidate, our ability to generate revenues from any such products will depend on our success in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
    commercial sales of such products, whether alone or in collaboration with others;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receiving
    approved labels with claims that are necessary or desirable for successful marketing, and that do not contain safety or other limitations
    that would impede our ability to market such products;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">creating
    market demand for such products through marketing, sales and promotion activities;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hiring,
    training, and deploying a sales force or contracting with third parties to commercialize such products in the United States;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">creating
    partnerships with, or offering licenses to, third parties to promote and sell such products in foreign markets where we receive marketing
    approval;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    such products in sufficient quantities and at acceptable quality and cost to meet commercial demand at launch and thereafter;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and maintaining agreements with wholesalers, distributors, and group purchasing organizations on commercially reasonable terms;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    patent and trade secret protection and regulatory exclusivity for such products;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    market acceptance of such products by patients, the medical community, and third-party payors;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    coverage and adequate reimbursement from third-party payors for such products;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    patients&#8217; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement from third-party payors;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing
    effectively with other therapies; and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    a continued acceptable safety profile of such products following launch.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent we are not able to do any of the foregoing, our business, financial condition, results of operations, stock price and prospects
will be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face significant competition from other biopharmaceutical and biotechnology companies, academic institutions, government agencies, and
other research organizations, which may result in others discovering, developing or commercializing products more quickly or marketing
them more successfully than us. If their product candidates are shown to be safer or more effective than ours, our commercial opportunity
may be reduced or eliminated.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of cancer immunotherapy products is characterized by rapidly advancing technologies, intense competition
and a strong emphasis on proprietary rights. We face competition with respect to our current product candidates, and will face competition
with respect to any product candidates that we may seek to develop or commercialize in the future, from major biopharmaceutical companies,
specialty biopharmaceutical companies, and biotechnology companies worldwide. There are a number of large biopharmaceutical and biotechnology
companies that currently market and sell products or are pursuing the development of products for the treatment of solid tumors, including
viral immunotherapy and cancer vaccine approaches. Potential competitors also include academic institutions, government agencies, and
other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements
for research, development, manufacturing, and commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
certain of our product candidates may be used in combination with other drugs with different mechanisms of action, if and when marketed
they will still compete with a number of drugs that are currently marketed or in development that also target cancer. To compete effectively
with these drugs, our product candidates will need to demonstrate advantages in clinical efficacy and safety compared to these competitors
when used alone or in combination with other drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective,
have fewer or less severe side effects, are easier to administer or are less expensive alone or in combination with other therapies than
any products that we may develop alone or in combination with other therapies. Our competitors also may obtain FDA or comparable foreign
regulatory authorities&#8217; approval for their products more rapidly than we may obtain approval for ours, which could result in our
competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be
affected in many cases by third-party payors&#8217; coverage and reimbursement decisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the companies with which we are competing or may compete in the future have significantly greater financial resources and expertise
in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing
approved products than we do. Mergers and acquisitions in the biopharmaceutical and biotechnology industries may result in even more
resources being concentrated among a smaller number of our competitors. Early-stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting
and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical
trials, as well as in developing or acquiring technologies complementary to, or necessary for, our programs. If we are unable to successfully
compete with these companies our business, financial condition, results of operations, stock price and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to market
and sell our product candidates, if they are approved, the revenues that we generate may be limited and we may never become profitable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have a commercial infrastructure for the marketing, sale, and distribution of any products that we may develop. If and
when our product candidates receive marketing approval, we intend to commercialize our product candidates on our own or in collaboration
with others and potentially with pharmaceutical or biotechnology partners in other geographies. In order to commercialize our products,
we must build our marketing, sales, and distribution capabilities or make arrangements with third parties to perform these services.
We may not be successful in doing so. Should we decide to move forward in developing our own marketing capabilities, we may incur expenses
prior to product launch or even approval in order to recruit a sales force and develop a marketing and sales infrastructure. If a commercial
launch is delayed as a result of the FDA or comparable foreign regulatory authority requirements or other reasons, we would incur these
expenses prior to being able to realize any revenue from sales of our product candidates. Even if we are able to effectively hire a sales
force and develop a marketing and sales infrastructure, our sales force and marketing teams may not be successful in commercializing
our product candidates. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing
personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also or alternatively decide to collaborate with third-party marketing and sales organizations to commercialize any approved product
candidates, in which event, our ability to generate product revenues may be limited. To the extent we rely on third parties to commercialize
any products for which we obtain regulatory approval, we may receive less revenues than if we commercialized these products ourselves,
which could materially harm our prospects. In addition, we would have less control over the sales efforts of any other third parties
involved in our commercialization efforts, and could be held liable if they failed to comply with applicable legal or regulatory requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no prior experience in the marketing, sale, and distribution of biopharmaceutical products, and there are significant risks involved
in building and managing a commercial infrastructure. The establishment and development of commercial capabilities, including compliance
plans, to market any products we may develop will be expensive and time consuming and could delay any product launch, and we may not
be able to successfully develop this capability. We will have to compete with other biopharmaceutical and biotechnology companies, including
oncology-focused companies, to recruit, hire, train, manage, and retain marketing and sales personnel, which is expensive and time consuming
and could delay any product launch. Developing our sales capabilities may also divert resources and management attention away from product
development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event we are unable to develop a marketing and sales infrastructure, we may not be able to commercialize our product candidates,
which could limit our ability to generate product revenues and materially harm our business, financial condition, results of operations,
stock price and prospects. Factors that may inhibit our efforts to commercialize our product candidates include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to recruit, train, manage, and retain adequate numbers of effective sales and marketing personnel;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability of sales personnel to obtain access to physicians or educate adequate numbers of physicians on the benefits of prescribing
    our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to effectively oversee a geographically dispersed sales and marketing team;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with training personnel, including sales and marketing personnel, on compliance matters and monitoring their actions;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to secure coverage and adequate reimbursement by third-party payors, including government and private health plans;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    unwillingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement from third-party payors;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical indications for which the products are approved and the claims that we may make for the products;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    or warnings, including distribution or use restrictions, contained in the products&#8217; approved labeling;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities or to which we agree as part of
    a mandatory REMS or voluntary risk management plan;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">liability
    for our personnel, including sales or marketing personnel, who fail to comply with applicable law;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies
    with more extensive product lines; and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    costs and expenses associated with creating an independent sales and marketing organization or engaging a contract sales organization.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians,
patients, hospitals, cancer treatment centers, third-party payors and others in the medical community necessary for commercial success.
The revenues that we generate from their sales may be limited, and we may never become profitable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never commercialized a product candidate for any indication. Even if our product candidates are approved by the appropriate regulatory
authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors, and others in the medical
community. If any product candidates for which we obtain regulatory approval does not gain an adequate level of market acceptance, we
could be prevented from or significantly delayed in achieving profitability. Market acceptance of our product candidates by the medical
community, patients, and third-party payors will depend on a number of factors, some of which are beyond our control. For example, physicians
are often reluctant to switch their patients and patients may be reluctant to switch from existing therapies even when new and potentially
more effective or safer treatments enter the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and
may not be successful. If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we could
be prevented from or significantly delayed in achieving profitability. The degree of market acceptance of any product for which we receive
marketing approval will depend on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    efficacy of our product, including in combination with other cancer therapies;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    commercial success of any cancer therapies with which our product may be co-administered;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence and severity of adverse events associated with our product or those products with which it is co-administered;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical indications for which our product is approved and the approved claims that we may make with respect to the product;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    or warnings contained in the FDA-approved labeling of the product or the labeling approved by comparable foreign regulatory authorities,
    including potential limitations or warnings for our product that may be more restrictive than other competitive products;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the standard of care for the targeted indications for our product, which could reduce the marketing impact of any claims that
    we could make following FDA approval or approval by comparable foreign regulatory authorities, if obtained;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relative convenience and ease of administration of our product and any products with which it is co-administered;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of treatment compared with the economic and clinical benefit of alternative treatments or therapies;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of coverage and adequate reimbursement by third-party payors, such as private insurance companies and government healthcare
    programs, including Medicare and Medicaid;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to have our product placed on approved formularies;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients&#8217;
    willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement from third-party payors;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    price concessions required by third-party payors to obtain coverage and adequate reimbursement;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent and strength of our marketing and distribution of our product;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    safety, efficacy, and other potential advantages over, and availability of, alternative treatments already used or that may later
    be approved;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">distribution
    and use restrictions imposed by the FDA or comparable foreign regulatory authorities with respect to our product or to which we agree
    as part of a REMS or voluntary risk management plan;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of market introduction of our product, as well as competitive products;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to offer our product for sale at competitive prices;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent and strength of our raw material supplier and service provider support;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    actions of companies that market any products with which our product is co-administered;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval of other new products;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    publicity about our product or any products with which it is co-administered, or favorable publicity about competitive products;
    and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    product liability claims.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual
markets for our product candidates may be smaller than our estimates. If the market opportunities for any product candidates we develop
are smaller than we believe they are, our potential revenues may be adversely affected, and our business may suffer.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
potential market opportunities for our product candidates are difficult to estimate and will depend in large part on the drugs with which
our product candidates are co-administered and the success of competing therapies and therapeutic approaches. Our estimates of the potential
market opportunities are predicated on many assumptions, which may include industry knowledge and publications, third-party research
reports, and other surveys. Although we believe that our internal assumptions are reasonable, these assumptions involve the exercise
of significant judgment on the part of our management, are inherently uncertain, and their reasonableness has not been assessed by an
independent source. These estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of these
diseases. The number of patients in the United States, Europe, and elsewhere may turn out to be lower than expected, and patients may
not be amenable to treatment with our product. If any of the assumptions proves to be inaccurate, the actual markets for our product
candidates could be smaller than our estimates of the potential market opportunities. Additionally, because of the potential that any
product candidates we develop could cure a target disease, we may not receive recurring revenues from patients and may deplete the patient
population prevalence through curative therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to obtain, maintain and protect our intellectual property rights for our technology and product candidates, or if our intellectual
property rights are inadequate, our competitive position could be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the
United States and other countries with respect to our technology, including NEO100, NEO212 and our other product candidates. We also
rely in part on trade secret, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third
parties, all of which offer only limited protection. We seek to protect our proprietary position by filing and prosecuting patent applications
in the United States and abroad related to our technology and product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent positions of biotechnology and pharmaceutical companies generally are uncertain, involve complex legal and factual questions and
have in recent years been the subject of much litigation or patent challenges in the United States Patent and Trademark Office or in
corresponding patent offices. As a result, the issuance, scope, validity, enforceability and commercial value of our licensed patents
and any patents we may own are highly uncertain. The steps we have taken to protect our proprietary rights may not be adequate to preclude
misappropriation of our proprietary information or infringement of our intellectual property rights, both inside and outside of the United
States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the examination process may require us to narrow the claims for our pending patent applications, which may significantly limit the scope
of patent protection that may be obtained if these applications issue. Our pending and future patent applications may not result in patents
being issued that protect our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive
product candidates. In addition, the scope of a patent may also be reinterpreted after issuance. The rights that may be granted under
our issued patents may not provide us with the proprietary protection or competitive advantages we are seeking. Even if our patent applications
issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing
with us or otherwise provide us with any competitive advantage. If we are unable to obtain and maintain patent protection for our technology
or for NEO100, NEO212 or our other product candidates, or if the scope of the patent protection obtained is not sufficient, our competitors
could develop and commercialize products similar or superior to ours in a non-infringing manner, and our ability to successfully commercialize
NEO100, NEO212 or our other product candidates and future technologies may be adversely affected. It is also possible that we will fail
to identify any patentable aspects of inventions made in the course of our development and commercialization activities before it is
too late to obtain patent protection on them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain,
enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. Although we enter into
non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and
development output, such as our employees, collaborators, and other third parties, any of these parties may breach the agreements and
disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. It is also possible
that we will fail to identify patentable aspects of our research and development efforts in time to obtain any patent protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
pending applications cannot be enforced against third parties practicing the inventions claimed in such applications unless and until
a patent issues from such applications with a claim that covers infringing third-party activity. Because the issuance of a patent is
not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we license from third parties or own in
the future may be challenged in the courts or patent offices in the United States and abroad, including through opposition proceedings,
derivation proceedings, post-grant review, <I>inter partes </I>review, post-grant review, derivation proceedings, interference proceedings
or litigation. Such proceedings may result in the loss of patent protection, the narrowing of claims in such patents or the invalidity
or unenforceability of such patents, which could limit our ability to stop others from using or commercializing similar or identical
products, or limit the duration of the patent protection for our technology. Protecting against the unauthorized use of our patented
inventions, trademarks and other intellectual property rights is expensive, time consuming, difficult and in some cases may not be possible.
In some cases, it may be difficult or impossible to detect third-party infringement or misappropriation of our intellectual property
rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult. If we are unable to obtain,
maintain, and protect our intellectual property our competitive advantage could be harmed, and it could result in a material adverse
effect on our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with our obligations in the agreements under which we may license intellectual property rights from third parties or
otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are
important to our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may need to obtain licenses from others to advance our research and development activities or allow the commercialization of our current
or future product candidates. We expect any such license agreements will impose various development, diligence, commercialization, and
other obligations on us. In spite of our efforts, our licensors might conclude that we have materially breached our obligations under
such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and
commercialize products and technology covered by the intellectual property under any such license agreements. If such in-licenses were
to be terminated, or if the underlying patents were to fail to provide the intended exclusivity, competitors or other third parties would
have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development
and commercialization our product candidates. Any of the foregoing could have a material adverse effect on our competitive position,
business, financial conditions, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
disputes may arise regarding intellectual property subject to a licensing agreement, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope of rights granted
    under the license agreement and other interpretation-related issues and our respective compliance therewith;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which our
    product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing
    agreement;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sublicensing of patent
    and other rights under our collaborative development relationships;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our diligence obligations
    under the license agreement and what activities satisfy those diligence obligations;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inventorship and ownership
    of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners;
    and</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the priority of invention
    of patented technology.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the agreements under which we may license intellectual property or technology from third parties are likely to be complex,
and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation
disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology,
or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material
adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property
that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms,
we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect
on our business, financial conditions, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could
be adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to seeking patent protection, we also rely on other proprietary rights, including protection of trade secrets, know-how and
confidential and other proprietary information. To maintain the confidentiality of our trade secrets and proprietary information, we
enter into confidentiality agreements with our employees, consultants, collaborators, contractors, and other third parties who have access
to our trade secrets. Our agreements with employees and consultants also provide that any inventions conceived by the individual employee
or consultant in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements
in all circumstances, and individuals with whom we have these agreements may not comply with their terms. The assignment of intellectual
property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against
third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property
or that of our licensor. In addition, we cannot be certain that our trade secrets and other confidential proprietary information will
not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent
information and techniques. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements,
even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the
extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes
may arise between us and those third parties as to the rights in related inventions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adequate
remedies may not exist in the event of unauthorized use or disclosure of our confidential information including a breach of our confidentiality
agreements. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time consuming,
and the outcome is unpredictable. In addition, some courts in and outside of the United States are less willing or unwilling to protect
trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party,
we would have no right to prevent them from using that technology or information to compete with us. The disclosure of our trade secrets
or the independent development of our trade secrets by a competitor or other third party would impair our competitive position and may
materially harm our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Third
parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would
be uncertain and could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends on our ability and the ability of any future collaborators to develop, manufacture, market and sell NEO100,
NEO212 and our other product candidates, and to use our related proprietary technologies without infringing, misappropriating or otherwise
violating the intellectual property and proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized
by extensive litigation regarding patents and other intellectual property rights. We may become party to, or threatened with, adversarial
proceedings or litigation regarding intellectual property rights with respect to our current and any other future product candidates,
including interference proceedings, post-grant review, <I>inter partes</I> review and derivation proceedings before the USPTO (or similar
proceedings in foreign jurisdictions). Third parties may assert infringement or other intellectual property claims against us based on
existing patents or patents that may be granted in the future. Numerous U.S. and foreign-issued patents and pending patent applications,
which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical
industries expand and more patents are issued, the risk increases that we may be subject to claims of infringement of the patent rights
of third parties. If we are found to infringe a third party&#8217;s intellectual property rights, and we are unsuccessful in demonstrating
that such intellectual property rights are invalid or unenforceable, we could be required to obtain a license from such third party to
continue developing, manufacturing and commercializing NEO100, NEO212 and our other product candidates. However, we may not be able to
obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive,
thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make
substantial licensing and royalty payments. We also could be forced, including by court order, to cease developing, manufacturing, and
commercializing NEO100, NEO212 or our other product candidates. In addition, in any such proceeding or litigation, we could be found
liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed
a patent or other intellectual property right. Any of the foregoing could have a material adverse effect on our business, financial condition,
results of operations, stock price and prospects. Any claims by third parties that we have misappropriated their confidential information
or trade secrets could have a similar material adverse effect on our business. Defense of these claims, regardless of their merit, would
involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties
making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have
substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by
disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse
effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial
condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
we plan to develop our product candidates in combination with products developed by companies that may be covered by patents or licenses
held by those entities to which we do not have a license or a sublicense. In the event that a labeling instruction is required in product
packaging recommending that combination, we could be accused of, or held liable for, infringement of the third-party patents covering
the product candidate or product recommended for administration with NEO100, NEO212 or our other product candidates. In such a case,
we could be required to obtain a license from the other company or institution to use the required or desired package labeling, which
may not be available on commercially reasonable terms, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to protect our intellectual property and proprietary rights throughout the world.</I></B></FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting and defending patents on our technology throughout the world would be prohibitively expensive, and our intellectual property
rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws and practices
of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States.
Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States,
or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may
use our technologies in jurisdictions where we have not obtained patent protection to develop and/or manufacture their own products,
and may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as
that in the United States. These products may compete with our products and our patent claims or other intellectual property rights may
not be effective or sufficient to prevent them from so competing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the granting or enforcement of patents,
trade secrets and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult
for us to obtain patent rights or stop the infringement of our patents or marketing of competing products in violation of our intellectual
property and proprietary rights generally in those countries. Proceedings to enforce our intellectual property and proprietary rights
in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could
put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke
third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded,
if any, may not be commercially meaningful. Accordingly, our efforts to protect and enforce our intellectual property and proprietary
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property we develop or license.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the laws of certain foreign countries may not protect our rights to the same extent as the laws of the United States, and those
foreign laws may also be subject to change. For example, methods of treatment and manufacturing processes may not be patentable in certain
jurisdictions, and the requirements for patentability may differ in certain countries. Furthermore, competitors may challenge the scope,
validity and enforceability of our patents, requiring us to engage in complex, lengthy and costly litigation or proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. Many countries
limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have
limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with
respect to any patents relevant to our business, our competitive position may be impaired, and our business and results of operations
may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Obtaining
and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
similar provisions during the patent application process and to maintain patents after they are issued. For example, periodic maintenance
fees, renewal fees, annuity fees and various other government fees on issued patents and patent applications often must be paid to the
USPTO and foreign patent agencies over the lifetime of our licensed patents or any patents we own. In certain circumstances, we may rely
on future licensing partners to take the necessary action to comply with these requirements with respect to licensed intellectual property.
Although an unintentional lapse may be curable, depending on the jurisdiction, for a period of time by payment of a late fee or by other
means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the
patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events
that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official
actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to
obtain and maintain the patents and patent applications covering our products or procedures, we may not be able to stop a competitor
from marketing products that are the same as or similar to NEO100, NEO212 or our other product candidates, which could have a material
adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our
ability to protect NEO100, NEO212 and our other product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.
Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly,
time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States
or other jurisdictions in which we have or seek patent protection could increase the uncertainties and costs surrounding the prosecution
of patent applications and the enforcement or defense of issued patents. Patent reform legislation in the United States and other countries,
including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, signed into law in the United States on September&nbsp;16, 2011,
could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of
our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect
the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors
to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution
and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review,
<I>inter partes</I> review, and derivation proceedings. After March&nbsp;2013, under the Leahy-Smith Act, the United States transitioned
to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent
application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention.
However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent
applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business,
financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain
circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S.
courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable
ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful
and have a material adverse effect on the success of our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our licensed patents or any patent we own, or misappropriate or otherwise violate our intellectual property rights. Litigation
may be necessary in the future to enforce or defend our intellectual property rights, to protect our trade secrets, or to determine the
validity and scope of our own intellectual property rights or the proprietary rights of others. If we were to initiate legal proceedings
against a third party to enforce a patent covering our product candidates, the defendant could counterclaim that the patent covering
our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity
and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory
requirements, including lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability assertion
could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a
misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.
Our licensed patents and any patents we own in the future may become involved in priority or other intellectual property related disputes.
Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine
the priority of inventions with respect to our patents or patent applications. Also, third parties may initiate legal proceedings against
us to challenge the validity or scope of our owned or licensed intellectual property rights. These proceedings can be expensive and time
consuming. Many of our current and potential competitors have the ability to dedicate substantially greater resources to conduct intellectual
property related litigations or proceedings than we can. We may not have sufficient financial or other resources to conduct such litigation
or proceedings adequately. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating
our intellectual property. Litigation and other intellectual property related proceedings could result in substantial costs and diversion
of management resources, which could harm our business and financial results. In addition, in an infringement proceeding, a court may
decide that a patent owned by or licensed to us is invalid or unenforceable, or may refuse to stop the other party from using the technology
at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or other intellectual
property related proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation in the United States, there
is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also
be public announcements of the results of hearings, motions or other interim proceedings or developments in any such proceedings. If
securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares
of our common stock, and could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials,
continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help
us bring our product candidates to market. Any of the foregoing may have a material adverse effect our business, financial condition,
results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims by third parties asserting that we, our employees or any future collaborators have misappropriated their intellectual
property, or claiming ownership of what we regard as our own intellectual property.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our employees, including our senior management team, were previously employed at, or consulted for, universities or other biotechnology
or pharmaceutical companies, including our competitors or potential competitors. Some of these people, including each member of our senior
management team, executed proprietary rights, non-disclosure and non-competition agreements, or similar agreements, in connection with
such previous employment or consulting agreements, that assigned ownership of intellectual property relating to work performed under
such agreements to the contracting third party. Although we try to ensure that our employees, as well as those of our licensor and contractors,
do not use, claim as theirs, or misappropriate the intellectual property, proprietary information or know-how of others in their work
for us, we may be subject to claims that we or these employees have used, claimed as theirs, misappropriated or disclosed intellectual
property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation
may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may
lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third
party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license
may not be available on commercially reasonable terms, or at all. Even if we are successful in defending against such claims, litigation
could result in substantial costs and be a distraction to management. Any of the foregoing may have a material adverse effect on our
business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed confidential information of
third parties or are in breach of non-competition or non-solicitation agreements with our competitors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could be subject to claims that we or our employees, including senior management, have inadvertently or otherwise used or disclosed alleged
trade secrets or other confidential information of former employers or competitors or others. Although we try to ensure that our employees
and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for
us, we may be subject to claims that we caused an employee to breach the terms of their non-competition or non-solicitation agreement,
or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information
of a former employer or competitor or other party. Litigation may be necessary to defend against these claims. Even if we are successful
in defending against these claims, litigation could result in substantial costs and could be a distraction to management. If our defenses
to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features
that are essential to NEO100, NEO212 and our other product candidates, if such technologies or features are found to incorporate or be
derived from the trade secrets or other proprietary information of the former employers, competitors or other parties. An inability to
incorporate such technologies or features would have a material adverse effect on our business, and may prevent us from successfully
commercializing NEO100, NEO212 and our other product candidates. In addition, we may lose valuable intellectual property rights or personnel
as a result of such claims. Moreover, any such litigation or the threat thereof may adversely affect our ability to hire employees or
consultants. A loss of key personnel or their work product could hamper or prevent our ability to develop and commercialize NEO100, NEO212
and our other product candidates, which could have an adverse effect on our business, financial condition, results of operations, stock
price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we obtain any issued patents covering our technology, such patents could be found invalid or unenforceable if challenged in court or
before the USPTO or comparable foreign regulatory authority.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering any of our technology,
the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in
the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace, and there are numerous grounds upon
which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be, among other things,
an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds
for an unenforceability assertion could be, among other things, an allegation that someone connected with prosecution of the patent withheld
relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims
before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination,
<I>inter partes</I> review, post-grant review, interference proceedings, derivation proceedings and equivalent proceedings in foreign
jurisdictions, such as opposition proceedings. Such proceedings could result in revocation, cancellation or amendment to our patents
in such a way that they no longer cover and protect NEO100, NEO212 and our other product candidates. The outcome following legal assertions
of invalidity and unenforceability is unpredictable. For example, with respect to the validity of our licensed patents or any patents
we obtain in the future, we cannot be certain that there is no invalidating prior art of which we, our patent counsel or our licensing
partner&#8217;s patent counsel(s), and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal
assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on NEO100, NEO212
and our other product candidates. Such a loss of patent protection could have a material adverse impact on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Patent
terms may be inadequate to protect our competitive position on our products for an adequate amount of time, and our product candidates
for which we intend to seek approval as pharmacological products may face competition sooner than anticipated.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection
it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open
to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing
and regulatory review of new product candidates, such as NEO100 and our other product candidates, patents protecting such candidates
might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not
provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years
beyond the normal expiration of the patent for the patent term lost during the FDA regulatory review process. The length of the patent
term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term
of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended.
Similar provisions are available in Europe and other non-U.S. jurisdictions to extend the term of a patent that covers an approved drug.
In the future, if and when our pharmaceutical products receive FDA approval, we expect to apply for patent term extensions on patents
that we believe are eligible for such extension. We also intend to seek patent term extensions in other jurisdictions where these are
available. However, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether
such extensions should be granted, and even if granted, the length of such extensions.. If this occurs, our competitors may be able to
take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their
products earlier than might otherwise be the case, which could have a material adverse effect on our business, financial condition, results
of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Some
intellectual property which we have licensed may have been discovered through government funded programs and thus may be subject to federal
regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for United States industry. Compliance
with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements,
and limit our ability to contract with non-U.S. manufacturers.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intellectual property rights we licensed from USC has been generated through the use of United States government funding and is therefore
be subject to certain federal regulations. As a result, the United States government may have certain rights to intellectual property
embodied in our future products and product candidates pursuant to the Bayh-Dole Act of 1980. These United States government rights in
certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license
to use inventions for any governmental purpose. In addition, the United States government has the right to require us to grant exclusive,
partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps
have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii)
government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;).
The United States government also has the right to take title to these inventions if we fail to disclose the invention to the government
and fail to file an application to register the intellectual property within specified time limits. In addition, the United States government
may acquire title to these inventions in any country in which a patent application is not filed within specified time limits. Intellectual
property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require
us to expend substantial resources. In addition, the United States government requires that any products embodying the subject invention
or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference
requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made
to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that
under the circumstances domestic manufacture is not commercially feasible. This preference for United States manufacturers may limit
our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. Any exercise by the government
of any of the foregoing rights could harm our competitive position, business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, we could lose
rights that are important to our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
license agreement with USC, under which we license all of our current patent rights and a significant portion of our technology for our
product candidates, imposes royalty and other financial obligations on us and other substantial performance obligations. We also may
enter into additional licensing and funding arrangements with third parties that may impose diligence, development and commercialization
timelines and milestone payment, royalty, insurance and other obligations on us. If we fail to comply with our obligations under current
or future license and collaboration agreements, our counterparties may have the right to terminate these agreements, in which event we
might not be able to develop, manufacture or market any product or product candidate that is covered by these agreements or may face
other penalties under the agreements. Such an occurrence could diminish the value of our products or product candidates. Termination
of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated
agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual
property or technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, it is possible that USC may conclude that we have materially breached the USC licensing agreement and might therefore terminate
the agreement, thereby removing our ability to market products covered by our license agreement with USC. If the USC licensing agreement
is terminated, or if the underlying patents fail to provide the intended market exclusivity, competitors would have the freedom to seek
regulatory approval of, and to market, products similar or identical to ours. Moreover, if our license agreement with USC is terminated,
USC may be able to prevent us from utilizing the technology covered by the licensed patents and patent applications. If we breach the
agreement (including by failing to meet our payment obligations) and do not adequately cure such breach, the rights in the technology
licensed to us under the USC license agreement will revert to USC at no cost to USC. This could have a material adverse effect on our
competitive business position, our financial condition, our results of operations and our business prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the agreement under which we currently license intellectual property is complex, and certain provisions in such agreements
may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow
what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be
our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business,
financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent
or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully
develop and commercialize the affected products or product candidates, which could have a material adverse effect on our business, financial
conditions, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
and our business may be adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive or determined
to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop
using these names, which we need for name recognition by potential partners or customers in our markets of interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although
we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO
and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications
and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks
may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not
be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties,
such as distributors. Although these license agreements may provide guidelines for how our trademarks and trade names may be used, a
breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill
associated with our trademarks and trade names.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we
have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review
of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent
administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend
significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws,
not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining
a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior
trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability
to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement
claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks
or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable,
or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we
could ultimately be forced to cease use of such trademarks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Government Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with federal and state healthcare laws, including fraud and abuse laws, we could face substantial penalties and our
business, financial condition, results of operations, stock price and prospects will be materially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and future arrangements with healthcare providers, third-party payors, customers, and others may expose us to broadly applicable
healthcare fraud and abuse, and other healthcare laws, which may constrain the business or financial arrangements and relationships through
which we research, as well as sell, market and distribute any products for which we obtain marketing approval. The applicable federal,
state and foreign healthcare laws and regulations that may affect our ability to operate include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal Anti-Kickback
    Statute, which prohibits, among other things, individuals and entities from knowingly and willfully soliciting, receiving, offering
    or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in
    kind, to induce, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of,
    any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such
    as the Medicare and Medicaid programs.</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal civil and criminal
    false claims laws, including, without limitation, the civil FCA, and the federal Civil Monetary Penalties Law, which prohibit individuals
    or entities from, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment of
    federal funds, and knowingly making, or causing to be made, a false record or statement material to a false or fraudulent claim to
    avoid, decrease or conceal an obligation to pay money to the federal government.</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Health Insurance Portability
    and Accountability Act of 1996 (HIPAA), which prohibits, among other things, knowingly and willfully executing, or attempting to
    execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations,
    or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless
    of the payor (e.g., public or private), willfully obstructing a criminal investigation of a healthcare offense, and knowingly and
    willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious
    or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare
    matters.</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S. Federal Food,
    Drug and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, small molecule products and
    medical devices.</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal physician payment
    transparency requirements, sometimes referred to as the Physician Payments Sunshine Act, created under the ACA and its implementing
    regulations, which require certain manufacturers of drugs, devices, small molecule products and medical supplies for which payment
    is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually
    to the Centers for Medicare &amp; Medicaid Services (CMS) information related to payments or other transfers of value made to physicians
    (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician
    assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by such physicians
    and their immediate family members.</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analogous state and foreign
    anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services
    reimbursed by non-governmental third-party payors, including private insurers, or that apply regardless of payor; state laws that
    require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant
    compliance guidance promulgated by the federal government; state and local laws that require drug manufacturers to report information
    related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws
    that require the reporting of information related to drug pricing; and state and local laws requiring the registration of pharmaceutical
    sales representatives.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our operations are found to be in violation of any federal or state healthcare law, or any other governmental laws or regulations
that apply to us, we may be subject to penalties, including significant civil, criminal, and administrative penalties, damages, monetary
fines, disgorgement, imprisonment, suspension and debarment from government contracts, and refusal of orders under existing government
contracts, exclusion from participation in U.S. federal or state health care programs, additional reporting requirements and/or oversight
if we become subject to corporate integrity agreements or similar agreement to resolve allegations of non-compliance, contractual damages,
reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could
materially adversely affect our ability to operate our business and our financial results. If any of the physicians or other healthcare
providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, it may be subject to
significant criminal, civil or administrative sanctions, including but not limited to, exclusions from participation in U.S. federal
or state healthcare programs, which could also materially affect our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot
be entirely eliminated. Moreover, achieving and sustaining compliance with such laws may prove costly. Any action against us for violation
of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s
attention from the operation of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
the government or third-party payors fail to provide adequate coverage, reimbursement and payment rates for our product candidates, or
if health maintenance organizations or long-term care facilities choose to use therapies that are less expensive or considered a better
value, our revenue and prospects for profitability will be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
both domestic and foreign markets, sales of our products will depend in part upon the availability of coverage and adequate reimbursement
from third-party payors or placement on approved product formularies. Such third-party payors include government health programs such
as Medicare and Medicaid, managed care providers, private health insurers, and other organizations. Coverage decisions may depend upon
clinical and economic standards that disfavor new therapeutic products when more established or lower cost therapeutic alternatives are
already available or subsequently become available, even if our products are alone in a class. Third-party payors establish reimbursement
levels. Therefore, even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or
maintain a market share sufficient to realize a sufficient return on our or their investments. If reimbursement is not available, or
is available only to limited levels, our product candidates may be competitively disadvantaged, and we may not be able to successfully
commercialize our product candidates. Alternatively, securing favorable reimbursement terms may require us to compromise pricing and
prevent us from realizing an adequate margin over cost. Our failure to obtain or maintain timely or adequate pricing or formulary placement
of our products, or failure to obtain such formulary placement at favorable pricing may negatively impact our revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is significant uncertainty related to third-party payor coverage and reimbursement of newly approved small molecule products. Marketing
approvals, pricing, and reimbursement for new therapeutic products vary widely from country to country. Current and future legislation
may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals.
Some countries require approval of the sale price of a therapeutic before it can be marketed. In many countries, the pricing review period
begins after marketing or product licensing approval is granted. In some foreign markets, prescription biopharmaceutical pricing remains
subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for
a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for
lengthy time periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country.
Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates
obtain marketing approval. Our ability to commercialize our product candidates will depend in part on the extent to which coverage and
reimbursement for these products and related treatments will be available from third-party payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
significant trend within the healthcare industry is cost containment, both in the United States and elsewhere. Third-party payors, whether
foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs,
including use of formularies. Exclusion of a product from a formulary or other restrictions can significantly impact drug usage in the
patient population and beyond. Consequently, pharmaceutical companies compete to gain access to formularies for their products, typically
on the basis of unique product features, such as greater efficacy, better patient ease of use, or fewer side effects, as well as the
overall cost of the therapy. Certain third-party payors are requiring that companies provide them with predetermined discounts from list
prices, are using preferred drug lists to leverage greater discounts in competitive classes, are disregarding therapeutic differentiators
within classes, are challenging the prices charged for therapeutics, and are negotiating price concessions based on performance goals.
In addition, third-party payors are increasingly requiring higher levels of evidence of the benefits and clinical outcomes of new technologies,
seeking performance-based discounts, and challenging the prices charged. We cannot be sure that coverage will be available for any product
candidate that we commercialize and, if available, that the reimbursement rates will be adequate. If payors subject our product candidates
to maximum payment amounts, or impose limitations that make it difficult to obtain reimbursement, providers may choose to use therapies
which are less expensive when compared to our product candidates. Additionally, if payors require high copayments, beneficiaries may
seek alternative therapies. We may need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of any products
to the satisfaction of hospitals, other target customers and their third-party payors. Such studies might require us to commit a significant
amount of management time and financial and other resources. Our products might not ultimately be considered cost-effective. Adequate
third-party coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate
return on investment in product development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore,
coverage and reimbursement for products can differ significantly from payor to payor. Further, we believe that future coverage and reimbursement
will likely be subject to increased restrictions both in the United States and in international markets. Third-party coverage and reimbursement
for our products or product candidates for which we receive regulatory approval may not be available or adequate in either the United
States or international markets, which could have a negative effect on our business, financial condition, results of operations, stock
price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may also be delays in obtaining coverage and reimbursement for newly approved therapeutics, and coverage may be more limited than the
indications for which the product is approved by the FDA or comparable foreign regulatory authorities. Such delays have made it increasingly
common for manufacturers to provide newly approved drugs to patients experiencing coverage delays or disruption at no cost for a limited
period in order to ensure that patients are able to access the drug. Moreover, eligibility for reimbursement does not imply that any
therapeutic will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and
distribution. Interim reimbursement levels for new therapeutics, if applicable, may also not be sufficient to cover our costs and may
only be temporary. Reimbursement rates may vary, by way of example, according to the use of the product and the clinical setting in which
it is used. Reimbursement rates may also be based on reimbursement levels already set for lower cost products or may be incorporated
into existing payments for other services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
inability to promptly obtain coverage and adequate reimbursement from third-party payors for any of our product candidates for which
we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize
products and our overall financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to new legislation, regulatory proposals and third-party payor initiatives that may increase our costs of compliance, and
adversely affect our ability to market our products, obtain collaborators, and raise capital.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval
activities and affect our ability to profitably sell any products for which we obtain marketing approval. We expect that current laws,
as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional
downward pressure on the price that we may receive for any approved products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, the ACA was passed in March&nbsp;2010 and substantially changed the way healthcare is financed by both governmental and private
insurers, and continues to significantly impact the United States pharmaceutical industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been executive, judicial and congressional challenges to certain aspects of the ACA. For example, legislation enacted in 2017, informally
titled the Tax Cuts and Jobs Act of 2017 (the Tax Act), includes a provision repealing, effective January&nbsp;1, 2019, the tax-based
shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part
of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On June&nbsp;17, 2021 the U.S. Supreme Court dismissed
a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221;
was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on
January&nbsp;28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining
health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and
reconsider their existing policies and rules that limit access to healthcare, including among others, re-examining Medicaid demonstration
projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health
insurance coverage through Medicaid or the ACA. In addition, on August&nbsp;16, 2022, President Biden signed the Inflation Reduction
Act of 2022 (the IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage
in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning
in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program.
It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges
and the healthcare reform measures of the Biden administration will impact the ACA and our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted in the United States since the ACA. For example, through the process created by the
Budget Control Act of 2011, there are automatic reductions of Medicare payments to providers up to 2% per fiscal year, which went into
effect in April&nbsp;2013 and, following passage of the Bipartisan Budget Act of 2018 (BBA) and the Infrastructure Investment and Jobs
Act, will remain in effect until 2031 unless additional Congressional action is taken. However, COVID-19 relief support legislation suspended
the 2% Medicare sequester from May&nbsp;1, 2020 through March&nbsp;31, 2022. Under current legislation the actual reduction in Medicare
payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there have been a number of other legislative and regulatory proposals aimed at changing the biopharmaceutical industry. For
instance, the Drug Quality and Security Act of 2013 imposes obligations on manufacturers of biopharmaceutical products related to product
tracking and tracing. Further, manufacturers have product investigation, quarantine, disposition, and notification responsibilities related
to counterfeit, diverted, stolen, and intentionally adulterated products that would result in serious adverse health consequences of
death to humans, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such
that they would be reasonably likely to result in serious health consequences or death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with the federal track and trace requirements may increase our operational expenses and impose significant administrative burdens. As
a result of these and other new proposals, we may determine to change our </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">current
manner of operation, provide additional benefits or change our contract arrangements, any of which could have a material adverse effect
on our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription
drugs. Such scrutiny has resulted in presidential executive orders, congressional inquiries and proposed and enacted federal and state
legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and
manufacturer patient programs, and reform government program reimbursement methodologies for products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal
budget proposals, executive orders and policy initiatives. For example, on July&nbsp;24, 2020 and September&nbsp;13, 2020, the Trump
administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s
proposals. The FDA concurrently released a final rule and guidance in September&nbsp;2020, implementing a portion of the importation
executive order providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November&nbsp;20,
2020, the U.S. Department of Health and Human Services (HHS) finalized a regulation removing safe harbor protection for price reductions
from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price
reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as
a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The implementation of the rule
has been delayed until 2032. On March&nbsp;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates
the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator
multiple source drugs, beginning January&nbsp;1, 2024. In July&nbsp;2021, the Biden administration released an executive order, &#8220;Promoting
Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive
order, on September&nbsp;9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug
pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative
actions HHS can take to advance these principles. In addition, the IRA directs the Secretary of HHS to establish a Drug Price Negotiation
Program (the Program) to lower prices for certain single-source prescription drugs and biologics covered under Medicare Parts B and D,
based on criteria established under the IRA. Under the Program, the Secretary of HHS will publish a list of &#8220;selected drugs,&#8221;
and will then negotiate maximum fair prices (MFP) with their manufacturers. Beginning in 2026, the first year of the Program, the number
will be limited to 10 Part D drugs and biologics. By 2029, and in subsequent years thereafter, the number will increase to 20 drugs and
biologics covered under Part D and Part B. Agreements between HHS and manufacturers will remain in place until a drug or biologic is
no longer considered a &#8220;selected drug&#8221; for negotiation purposes. Manufacturers who do not comply with the negotiated prices
set under the Program will be subject to an excise tax based on a percentage of total sales of a &#8220;selected drug&#8221; up to 95%
and the potential of civil monetary penalties. Further, the IRA imposes rebates under Medicare Part B and Medicare Part D to penalize
price increases that outpace inflation. In addition, the Biden administration released an additional executive order on October&nbsp;14,
2022, directing HHS to submit a report within ninety (90) days on how the Center for Medicare and Medicaid Innovation can be further
leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
new laws or regulations, including those that may result in additional reductions in Medicare and other healthcare funding, could have
a material adverse effect on customers for our products, if approved, and, accordingly, on our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the ACA, as well as other federal and state healthcare reform measures that may be adopted in the future, may result in more
rigorous coverage criteria, increased regulatory burdens and operating costs, decreased net revenue from our biopharmaceutical products,
decreased potential returns from our development efforts, and additional downward pressure on the price that we receive for any approved
product. It is also possible that additional governmental action is taken in response to the COVID-19 pandemic. Any reduction in reimbursement
from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation
of cost containment measures or other healthcare reforms may prevent us from commercializing our products and being able to generate
revenue, and we could be prevented from or significantly delayed in achieving profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as import and export control laws, customs
laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal
penalties, and other consequences, which could adversely affect our business, financial condition, results of operations, stock price
and prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act (FCPA) and other anti-corruption laws
that apply in countries where we do business. The FCPA and these other anti-corruption laws generally prohibit us and our employees and
intermediaries from authorizing, promising, offering, providing, soliciting, or receiving, directly or indirectly, corrupt or improper
payments or anything else of value to or from recipients in the public or private sector. We can be held liable for the corrupt or other
illegal activities of our personnel or intermediaries, even if we do not explicitly authorize or have prior knowledge of such activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to other laws and regulations governing our international operations, including applicable import and export control
regulations, economic sanctions on countries and persons, anti-money laundering laws, customs requirements and currency exchange regulations,
collectively referred to as the trade control laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
can provide no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws or
other legal requirements, including trade control laws. If we are not in compliance with applicable anti-corruption laws or trade control
laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses,
which could have an adverse impact on our business, financial condition, results of operations, stock price and prospects. In addition,
we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject
or the manner in which existing laws might be administered or interpreted. An investigation of any potential violations of anti-corruption
laws or trade control laws by U.S. or other authorities could also have an adverse impact on our reputation, our business, financial
condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations
related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations
or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss
of customers or sales; and other adverse business consequences.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, we process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit,
and share (collectively, processing) personal data and other sensitive information, including proprietary and confidential business data,
trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, sensitive third-party
data, and patient information. Our data processing activities may subject us to numerous data privacy and security obligations, such
as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other
obligations that govern the processing of personal data by us and on our behalf.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to or affected by evolving federal, state and foreign data protection laws and regulations, such as laws and regulations
that address privacy and data security. In the United States, federal, state, and local governments have enacted numerous data privacy
and security laws, including data breach notification laws, personal data privacy laws, and consumer protection laws (e.g. Section&nbsp;5
of the Federal Trade Commission Act). For example, HIPAA as amended by the Health Information Technology for Economic and Clinical Health
Act (HITECH), imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information.
We may obtain health information or other personal information from third parties, including research institutions from which we obtain
clinical trial data, that are subject to privacy and security requirements under HIPAA. While we do not believe that we are currently
acting as a covered entity or business associate under HIPAA and thus are not directly regulated under HIPAA, any person may be prosecuted
under HIPAA&#8217;s criminal provisions if it knowingly receives individually identifiable health information from a HIPAA-covered healthcare
provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health
information under aiding-and-abetting or conspiracy principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
states have also adopted data privacy and security laws and regulations, which govern the privacy, processing and protection of health-related
and other personal information. Such laws and regulations will be subject to interpretation by various courts and other governmental
authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example,
the California Consumer Privacy Act of 2018 (CCPA) imposes obligations on covered businesses. These obligations include, but are not
limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal
data. The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation). Although the CCPA exempts some data processed
in the context of clinical trials, the CCPA may increase compliance costs and potential liability with respect to other personal data
we may maintain about California residents. In addition, it is anticipated that the California Privacy Rights Act of 2020 (CPRA), which
became effective January&nbsp;1, 2023, will expand the CCPA. The CPRA establishes a new California Privacy Protection Agency to implement
and enforce the CPRA, which could increase the risk of enforcement. Other states have enacted data privacy laws. For example, Virginia
passed the Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act, both of which become effective in 2023. In addition,
data privacy and security laws have been proposed at the federal, state, and local levels in recent years, which could further complicate
compliance efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example,
the European Union&#8217;s General Data Protection Regulation (EU GDPR), the United Kingdom&#8217;s GDPR (UK GDPR), and the Swiss Federal
Act on Data Protection impose strict requirements for processing personal data. For example, under the EU GDPR, government regulators
may impose temporary or definitive bans on data processing, as well as fines of up to 20 million euros or 4% of annual global revenue,
whichever is greater. Further, individuals or consumer protection organizations authorized at law to represent their interests may initiate
litigation related to processing of individuals&#8217; personal data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with U.S. and foreign data protection laws and regulations could require us to take on more onerous obligations in our contracts, in
addition to direct compliance obligations under those laws. We may be directly or contractually subject to data privacy and security
obligations, including industry standards adopted by industry groups and may become subject to new data privacy and security obligations
in the future. For example, certain privacy laws, such as the EU GDPR and the CCPA, require companies to impose specific contractual
restrictions on their service providers. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information,
as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the United States or other countries.
Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries.
In particular, Europe has significantly restricted the transfer of personal data to the United States and other countries whose privacy
laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border
data transfer laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
there are currently various mechanisms that may be used to transfer personal data from Europe to the United States in compliance with
law, such as the EU and UK&#8217;s standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance
that we can satisfy or rely on these measures to lawfully transfer personal data to the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
there is no lawful manner for us to transfer personal data from Europe or other jurisdictions to the United States, or if the requirements
for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation
of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant
expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners,
vendors and other third parties, which could limit our ability to conduct clinical trial activities in Europe or elsewhere, and injunctions
against our processing or transferring of personal data necessary to operate our business. Some European regulators have prevented companies
from transferring personal data out of Europe for allegedly violating the GDPR and EU&#8217;s cross-border data transfer limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
related to data privacy and security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective
future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent
or conflict among jurisdictions. Preparing for and complying with these obligations requires significant resources and may necessitate
changes to our information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.
Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have
failed) to do so. We may also be bound by contractual obligations related to data privacy and security, and our efforts to comply with
such obligations may not be successful. Additionally, we publish privacy policies, self-certifications, and other documentation regarding
our collection, use and disclosure of personal information and/or other confidential information. Although we endeavor to comply with
our published policies, certifications, and documentation, we may at times fail to do so or may be perceived to have failed to do so.
Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations. Such failures
can subject us to potential international, local, state and federal action if they are found to be deceptive, unfair, or misrepresentative
of our actual practices, which could negatively impact our business operations and compliance posture. For example, any failure by a
third-party processor to comply with applicable law, regulations, or contractual obligations could result in adverse effects, including
inability to or interruption in our ability to operate our business and proceedings against us by governmental entities or others. If
we fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant
consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties,
audits, inspections, and similar); litigation (including class-related claims); additional reporting requirements and/or oversight; bans
on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. Any of these events could
have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers;
interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process personal data or
to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend
any claim or inquiry; adverse publicity; or revision or restructuring of our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Violations
of or liabilities under environmental, health and safety laws and regulations could subject us to fines, penalties or other costs that
could have a material adverse effect on the success of our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous federal, state and local environmental, health and safety laws and regulations, including those governing laboratory
procedures, the handling, use, storage, treatment and disposal of hazardous materials and wastes and the cleanup of contaminated sites.
Our operations involve the controlled production, storage, use and disposal of hazardous and flammable materials, including chemicals..
We would incur substantial costs as a result of violations of or liabilities under environmental requirements in connection with our
operations or property, including fines, penalties and other sanctions, investigation and cleanup costs and third-party claims. Although
we generally contract with third parties for the disposal of hazardous materials and wastes from our operations, we cannot eliminate
the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous
materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant
costs associated with civil or criminal fines and penalties, as well as our curtailment of the use of these materials or even shutting
down our facilities and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. While we maintain
insurance covering our manufacturing facility only, and not our other facilities, for environmental liability or toxic tort claims that
may be asserted against us in connection with our storage or disposal of our products or hazardous materials, such insurance coverage
may not be sufficient to cover extraordinary or unanticipated events at our manufacturing facility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Business and Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are highly dependent on our key personnel, including our Chief Executive Officer and Chairman. If we are not successful in attracting,
motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate
and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management and particularly
on the services of our personnel including Dr. Thomas C. Chen, our Chief Executive Officer and Chairman. We believe that his drug discovery
and development experience and overall biopharmaceutical company management experience, would be difficult to replace. Any of our executive
officers could leave our employment at any time, as all of our employees are &#8220;at-will&#8221; employees. We currently do not have
&#8220;key person&#8221; insurance on any of our employees. The loss of the services of our key personnel and any of our other executive
officers, key employees, and scientific and medical advisors, and our inability to find suitable replacements, could result in delays
in our research and development objectives and harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recruiting
and retaining qualified employees, consultants and advisors for our business, including scientific and technical personnel, also will
be critical to our success. We conduct our operations at our facilities in Southern California, a region that is home to many other biopharmaceutical
companies and many academic and research institutions. Competition for skilled personnel is intense and the turnover rate can be high.
We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology
companies and academic institutions for skilled individuals. In addition, failure to succeed in preclinical studies, clinical trials
or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit,
or the loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development
and commercialization objectives and have a material adverse effect on our business, financial condition, results of operations, stock
price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock option grants that
vest over time. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock
price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Although
we have employee agreements with our key employees, these agreements provide for at-will employment, which means that any of our employees
could leave our employment at any time, with or without notice. We do not maintain &#8220;key person&#8221; insurance policies on the
lives of all of these individuals or the lives of any of our other employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management team has limited public company experience.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management team has limited public company experience. Our entire management team, as well as other Company personnel, will need to devote
substantial time to compliance, and may not effectively or efficiently manage our transition into a public company. If we are unable
to effectively comply with the regulations applicable to public companies or if we are unable to produce accurate and timely financial
statements, which may result in misstatements that may be material in our financial statements or possible restatement of financial results,
our stock price may be materially adversely affected. Any such failures could also result in litigation or regulatory actions by the
SEC or other regulatory authorities, loss of investor confidence, delisting of our securities, harm to our reputation and diversion of
financial and management resources from the operation of our business, any of which could materially adversely affect our business, financial
condition, results of operations, and growth prospects. Additionally, the failure of a key employee to perform in his or her current
position could result in our inability to continue to grow our business or to implement our business strategy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will need to continue to expand the size of our organization, and we may experience difficulties in managing this growth, which could
disrupt our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&nbsp;31, 2022, we had five full-time and part-time employees, all of whom areengaged in research and development and manufacturing.
As our development and commercialization plans and strategies develop, and as we transition into operating as a public company, we expect
to need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant added
responsibilities on members of management, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying, recruiting,
    integrating, maintaining and motivating additional employees;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing our internal development
    efforts effectively, including the clinical, FDA and comparable foreign regulatory review process for our product candidates, while
    complying with our contractual obligations to contractors and other third parties; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">improving our operational,
    financial and management controls, reporting systems and procedures.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future financial performance and our ability to commercialize NEO100, NEO212 and any other product candidates we develop will depend,
in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount
of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors
and consultants to provide certain services. The services include substantially all aspects of clinical trial management and manufacturing.
We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on
a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced
activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may
be extended, delayed or terminated, and we may not be able to obtain marketing approval of NEO100and our other product candidates or
otherwise advance our business. We cannot assure you that we will be able to manage our existing consultants or find other competent
outside contractors and consultants on economically reasonable terms, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to effectively expand our organization by hiring qualified new employees and expanding our groups of consultants and
contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize NEO100, NEO212 and
our other product candidates and, accordingly, may not achieve our research, development and commercialization goals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our shareholders, cause
us to incur debt or assume contingent liabilities, and subject us to other risks.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property
rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased operating expenses
    and cash requirements;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the assumption of additional
    indebtedness or contingent liabilities;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the issuance of our equity
    securities;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assimilation of operations,
    intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the diversion of our management&#8217;s
    attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">retention of key employees,
    the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks and uncertainties
    associated with the other party to such a transaction, including the prospects of that party, their regulatory compliance status,
    and their existing products or product candidates and marketing approvals; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to generate
    revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset
    the associated acquisition and maintenance costs.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses
and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable
acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be
important to the development of our business. Any of the foregoing may materially harm our business, financial condition, results of
operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Unfavorable
market and economic conditions may have serious adverse consequences on our business, financial condition, results of operations, stock
price and prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A
severe or prolonged economic downturn could result in a variety of risks to our business, including a reduced ability to raise additional
capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in
supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic
climate and financial market conditions could adversely impact our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Public
health crises such as pandemics, including the ongoing COVID-19 pandemic, or similar future outbreaks could materially and adversely
affect our preclinical studies and clinical trials, business, financial condition and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March&nbsp;2020, the World Health Organization declared COVID-19 a global pandemic and the United States declared a national emergency
with respect to COVID-19. In response to the COVID-19 pandemic, a number of governmental orders and other public health guidance measures
have been implemented across much of the United States, including in the locations of our office, clinical trial sites and third parties
on whom we rely. As the COVID-19 pandemic started to spread in the first half of 2020, our clinical trial sites reported it had the most
impact on patient care as facilities were generally ill prepared to conduct business as usual; adequate clinical evaluations, physical
exams and tests were either absent or drastically reduced. Our clinical trial sites further reported that their institutions better adjusted
to pandemic conditions beginning in the second half of 2020. Additionally, we have experienced disruption to our manufacturing supply
chain which has delayed receipt of ordered materials and delayed our manufacturing timeline; while we now have received all ordered materials,
we do not have insight into whether, or to what extent, there may be future delays.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
further negative impact on our clinical development timelines could materially and adversely affect our business, financial condition
and results of operations. Further, we have implemented a work-from-home policy allowing employees who can work from home to do so, while
those needing to work in laboratory and manufacturing facilities work in shifts to reduce the number of people gathered together at one
time. Business travel has been suspended, and online and teleconference technology is used to meet virtually rather than in person. We
have taken measures to secure our research and development project activities, while work in laboratories has been organized to reduce
risk of COVID-19 transmission. Our increased reliance on personnel working from home may negatively impact productivity, or disrupt,
delay or otherwise adversely impact our business. For example, with our personnel working from home, some of our research activities
that require our personnel to be in our laboratories could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the COVID-19 pandemic, or similar pandemics, and related governmental orders and other public health guidance measures, we
have and may in the future experience disruptions that could materially and adversely impact our preclinical studies, clinical trials,
business, financial condition and results of operations. Potential disruptions might include but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays or difficulties
    in enrolling patients in our clinical trials;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays or difficulties
    in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical
    site investigators and clinical site staff;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased rates of patients
    withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being
    forced to quarantine;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption of key clinical
    trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing
    and analyses, due to limitations on travel imposed or recommended by federal, state or local governments, employers and others or
    interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical study endpoints;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion of healthcare
    resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and
    hospital staff supporting the conduct of our clinical trials;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays or disruptions in
    preclinical experiments and studies due to restrictions of on-site staff and unforeseen circumstances at CROs and vendors;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption or delays
    in the operations of the FDA and comparable foreign regulatory agencies;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption of, or delays
    in receiving, supplies of our product candidates from third-party providers due to staffing shortages, production slowdowns or stoppages
    and disruptions in delivery systems;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations on employee
    or other resources that would otherwise be focused on the conduct of our clinical trials and preclinical work, including because
    of sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased
    reliance on working from home, school closures or mass transit disruptions;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in regulations
    as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted,
    which may result in unexpected costs, or to discontinue the clinical trials altogether; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in necessary interactions
    with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced
    furlough of government or contractor personnel.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extent to which the ongoing COVID-19 global pandemic may affect our preclinical activities, clinical trials, business, financial condition
and results of operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, such as
the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and actions to contain the outbreak
or treat its impact, such as social distancing and quarantines or lock-downs or vaccine rollout in the United States, business closures
or business disruptions and the effectiveness of actions taken in the United States to contain and treat the disease. Future developments
in these and other areas present material uncertainty and risk with respect to our clinical trials, business, financial condition and
results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience
adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines
and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and
other adverse consequences.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we may process, collect, store, and transmit proprietary, confidential, and sensitive data, including
de-identified personal data (such as health-related data), intellectual property, proprietary business information and trade secrets
(collectively, sensitive information). We may rely upon third-party service providers and technologies to operate critical business systems
to process sensitive information in a variety of contexts, including, without limitation, third-party providers of information technology
infrastructure, cloud-based infrastructure, encryption and authentication technology, employee email, content delivery to customers,
and other functions. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties
may not have adequate information security measures in place. We may share or receive sensitive information with or from third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyber-attacks,
malicious internet-based activity, and online and offline fraud are prevalent and continue to increase. These threats are becoming increasingly
difficult to detect. These threats come from a variety of sources, including traditional computer &#8220;hackers,&#8221; &#8220;hacktivists,&#8221;
threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors
now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical
reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the
third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could
materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services. We and
the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to social-engineering
attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced
persistent threat intrusions), denial-of-service attacks (such as credential stuffing), personnel misconduct or error, ransomware attacks,
supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology
assets, adware, telecommunications failures, earthquakes, fires, floods, and other similar threats. Ransomware attacks, including by
organized criminal threat actors, nation-states, and nation-state-supported actors, are becoming increasingly prevalent and severe and
can lead to significant interruptions in our operations, disruption of clinical trials, loss of data (including data related to clinical
trials), and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware
attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such
payments. Similarly, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure
in our supply chain or our third-party partners&#8217; supply chains have not been compromised or that they do not contain exploitable
defects or bugs that could result in a breach of or disruption to our information technology systems or the third-party information technology
systems that support us and our services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remote
work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize
network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public
locations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities,
as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the previously identified or similar threats could cause a security incident or other interruption. A security incident or other interruption
could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure
of, or access to our sensitive information. A security incident or other interruption could disrupt our ability (and that of third parties
upon whom we rely) to provide our products. For example, the loss of clinical trial data from completed or ongoing or planned clinical
trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against
security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures,
industry-standard or reasonable security measures to protect our information technology systems and sensitive information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we have established physical, electronic and organizational security measures to safeguard and secure our systems against security incidents,
and rely on commercially-available systems, software, tools, and monitoring to provide security for our information technology systems
and the processing, transmission and storage of digital information, there can be no assurance that these measures will be effective.
We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change
frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Despite our efforts
to identify and address vulnerabilities, if any, in our information technology systems, our efforts may not be successful. Further, we
may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable
data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly,
and the disclosure or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom
we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences.
These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections);
additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation
(including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions
in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences
may cause customers to stop using our products, deter new customers from using our products, and negatively impact our ability to grow
and operate our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in
our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.
We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out
of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or
that such coverage will pay future claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability and have
to limit the commercialization of any approved products and/or our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of our product candidates in clinical trials, and the sale of any product for which we obtain regulatory approval, exposes us to
the risk of product liability claims. We face inherent risk of product liability related to the testing of our product candidates in
human clinical trials, including liability relating to the actions and negligence of our investigators, and will face an even greater
risk if we commercially sell any product candidates that we may develop. For example, we may be sued if any product candidate we develop
allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product
liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the
product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts.
Product liability claims might be brought against us by consumers, healthcare providers or others using, administering or selling our
products. If we cannot successfully defend ourselves against these claims, we will incur substantial liabilities or be required to limit
commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless
of merit or eventual outcome, liability claims may result in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss of revenue from decreased
    demand for our products and/or product candidates;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment of our business
    reputation or financial stability;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs of related litigation;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial monetary awards
    to patients or other claimants;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion of management
    attention;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal of clinical
    trial participants and potential termination of clinical trial sites or entire clinical programs;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability to commercialize
    our product candidates;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant negative media
    attention;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreases in our stock
    price;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation of investigations
    and enforcement actions by regulators; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product recalls, withdrawals
    or labeling, marketing or promotional restrictions, including withdrawal of marketing approval.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe we have sufficient insurance coverage in place for our business operations. However, our insurance coverage may not reimburse
us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly
expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect
us against losses due to liability. We intend to expand our insurance coverage to include clinical trials and the sale of commercial
products if we obtain FDA or comparable foreign regulatory approval for our product candidates in development, but we may be unable to
obtain commercially reasonable product liability insurance for any products approved for marketing, or at all. Failure to obtain and
retain sufficient product liability insurance at an acceptable cost could prevent or inhibit the commercialization of products we develop.
On occasion, large judgments have been awarded in class action lawsuits based on therapeutics that had unanticipated side effects. A
successful product liability claim or series of claims brought against us could cause our stock price to fall and, if judgments exceed
our insurance coverage, could decrease our cash, and materially harm our business, financial condition, results of operations, stock
price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
employees, independent contractors, consultants, commercial partners, principal investigators, contract manufacturing organizations (CMOs),
or contract research organizations (CROs) may engage in misconduct or other improper activities, including noncompliance with regulatory
standards and requirements and insider trading, which could have a material adverse effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees, independent contractors, consultants, commercial
partners or principal investigators could include intentional, reckless, negligent, or unintentional failures to comply with FDA regulations,
comply with applicable fraud and abuse laws, provide accurate information to the FDA, properly calculate pricing information required
by federal programs, report financial information or data accurately or disclose unauthorized activities to us. This misconduct could
also involve the improper use or misrepresentation of information obtained in the course of clinical trials, which could result in regulatory
sanctions and serious harm to our reputation. It is not always possible to identify and deter this type of misconduct, and the precautions
we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting
us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations.
Moreover, it is possible for a whistleblower to pursue a FCA case against us even if the government considers the claim unmeritorious
and/or declines to intervene, which could require us to incur costs defending against such a claim. In addition, we are subject to the
risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted
against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on
our business, financial condition, results of operations, stock price and prospects, including the imposition of significant civil, criminal
and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in U.S. federal healthcare
programs, integrity oversight and reporting obligations to resolve allegations of non-compliance, imprisonment, contractual damages,
reputational harm, diminished profits and future earnings, and curtailment of our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have generated significant net operating loss (NOL) carryforwards and research and development tax credits, and our ability to utilize
our net operating loss carryforwards and research and development tax credits to reduce future tax payments may be limited or restricted.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #0E101A">We
have generated significant NOL carryforwards and research and development tax credits (R&amp;D credits) due to our incurrence of losses
and our conduct of research activities since inception. As of December&nbsp;31, 2022, we had federal and state NOL carryforwards of $13.3
million and $</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F497D">13.3</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #0E101A">million,
respectively. We do not anticipate generating revenue from sales of products for the foreseeable future, if ever, and we may never achieve
profitability. Our U.S. federal NOL carryforwards developed in taxable years beginning before January&nbsp;1, 2018, can be carried forward
to each of the 20 taxable years following the year of the loss. These NOL carryforwards could expire unused and be unavailable to offset
future income tax liabilities. Under current law, U.S. federal NOLs incurred in tax years beginning after December&nbsp;31, 2017, totaling
$</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F497D">6.2</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #0E101A">million,
may be carried forward indefinitely, but the utilization of U.S. federal NOLs generated in tax years beginning after December&nbsp;31,
2020, is limited. As of December&nbsp;31, 2022, we also had federal</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F497D">and
state</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #0E101A">R&amp;D credit carryforwards of
$</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F497D">0.2 and $0.1 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #0E101A">million</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F497D">,
respectively</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #0E101A">. Our U.S. federal R&amp;D
credit carryforwards can be carried forward for 20 taxable years. If not utilized in that period, these R&amp;D credit carryforwards
could expire unused and be unavailable to offset future income tax liabilities. Under current law, the California state R&amp;D credits
carry forward indefinitely until utilized. These R&amp;D credit carryforwards could expire unused and be unavailable to offset future
income tax liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under Sections&nbsp;382 and
383 of the Code, and corresponding provisions of state law, if a corporation undergoes an &ldquo;ownership change,&rdquo; the corporation&rsquo;s
ability to use its pre-change NOL carryforwards and R&amp;D credits to offset its post-change income and taxes, respectively, may be limited.
For purposes of these rules, an &ldquo;ownership change&rdquo; generally occurs if one or more shareholders or groups of shareholders
who own at least 5% of our stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within
a rolling three-year period. The application of these rules could limit the amount of NOLs or R&amp;D credit carryforwards that we can
utilize annually to offset future taxable income or tax liabilities. In addition, at the state level, there may be periods during which
the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
NOL and R&amp;D credit carryforwards are subject to review and possible adjustment by U.S. and state tax authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Common Stock and this Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our listing application for our common stock is not approved by Nasdaq, we will not be able to consummate this offering.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to apply to list our common stock on the Nasdaq Capital Market under the symbol &#8220;_____.&#8221; Our initial public offering
is conditioned upon the approval of our listing by Nasdaq, which approval may not be granted. If our listing is not approved by Nasdaq,
we will not be able to complete this initial public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>An
active trading market for our common stock may not develop, and you may not be able to resell your shares at or above the initial public
offering price.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we intend to apply to list our common stock on The Nasdaq Capital Market, an active trading market for our shares may never develop or
be sustained following this offering. The initial public offering price of our common stock was determined through negotiations between
us and the underwriters. This initial public offering price may not be indicative of the market price of our common stock after this
offering. In the absence of an active trading market for our common stock, investors may not be able to sell their common stock at or
above the initial public offering price or at the time that they would like to sell. An inactive trading market may also impair our ability
to raise capital to continue to fund operations by selling shares and may impair our ability to enter into collaborations or acquire
other companies or technologies using our shares as consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers
of our common stock in this offering.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
stock price is likely to be volatile. The stock market in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology
stocks in particular, have experienced extreme price and volume fluctuations that have been often unrelated or disproportionate to the
operating performance of the issuer. In particular, the trading prices for pharmaceutical, biopharmaceutical and biotechnology companies
have been highly volatile, and we note recent instances of extreme stock price run-ups followed by rapid price declines and stock price
volatility seemingly unrelated to company performance following a number of recent initial public offerings, particularly among companies
with relatively smaller public floats. As a result of this volatility, you may not be able to sell your common stock at or above the
initial public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as a relatively small-capitalization company with limited public float, we may experience greater stock price volatility, extreme
price run-ups, lower trading volume and less liquidity than companies with larger market capitalization. In particular, our common shares
may be subject to rapid and substantial price volatility, low volumes of trades and large spreads in bid and ask prices. In addition,
if the trading volumes of our common shares are low, persons buying or selling in relatively small quantities may easily influence prices
of our common shares. This low volume of trades could also cause the price of our common shares to fluctuate greatly, with large percentage
changes in price occurring in any trading day session. Holders of our common shares may also not be able to readily liquidate their investment
or may be forced to sell at depressed prices due to low volume trading. A decline in the market price of our common shares also could
adversely affect our ability to issue additional shares of common shares or other securities and our ability to obtain additional financing
in the future. No assurance can be given that an active market in our common shares will develop or be sustained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price for our common stock may be influenced by many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">results from, and any delays
    in, our clinical trials for NEO100 and NEO212, our preclinical studies and any other future clinical development programs, including
    any delays related to the COVID-19 pandemic;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated changes
    in estimates as to financial results, development timelines or recommendations by securities analysts;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commencement or termination
    of collaboration, licensing or similar arrangements for our development programs;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by our competitors
    of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure or discontinuation
    of any of our development programs;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to commercialize
    NEO100, NEO212 and our other product candidates, if approved, inside and outside of the United States, either independently or working
    with third parties;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our partners&#8217; and
    collaborators&#8217; ability to successfully commercialize their licensed product candidates;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments or setbacks
    related to drugs that are co-administered with any of our product candidates, such as cellular and targeted therapies;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory or legal developments
    in the United States and other countries;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments or disputes
    concerning patent applications, issued patents or other proprietary rights;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the recruitment or departure
    of key personnel;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the level of expenses related
    to the development of NEO100, NEO212 and any other product candidate we may develop;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the competitive
    landscape in our industry, including results of clinical trials of existing and potential future products that compete with NEO100,
    NEO212 and our other product candidates;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to adequately
    support future growth;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations in our financial
    results or those of companies that are perceived to be similar to us;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">future accounting pronouncements
    or changes in our accounting policies;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements or expectations
    of additional financing efforts by us;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our common stock
    by us, our insiders or other shareholders;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expiration of market stand-off
    or lock-up agreements;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommendations and changes
    in estimates or recommendations by securities analysts, if any, that cover our stock;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the structure
    of healthcare payment systems;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">market conditions in the
    pharmaceutical and biotechnology sectors;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic, political,
    and market conditions and overall fluctuations in the financial markets in the United States and abroad, including the COVID-19 pandemic;
    and</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">investors&#8217; general
    perception of us and our business.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
and other market and industry factors may cause the market price and demand for our common stock to fluctuate rapidly and substantially,
including any stock price run-up, regardless of our actual or expected operating performance and financial condition or prospects, which
may limit, prevent or make it difficult for prospective investors to assess the rapidly changing value of our common stock or to sell
their shares at or above the price paid for the shares and may otherwise negatively affect the liquidity of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will suffer immediate and substantial dilution with respect to the common stock you purchase in this offering. Based on an assumed initial
public offering price of $____ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and
assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, purchasers of
common stock in this offering will experience immediate dilution of $____ per share, representing the difference between our pro forma
as adjusted net tangible book value per share after giving effect to this offering and the assumed initial public offering price, and,
following the completion of this offering, investors purchasing common stock in this offering will have contributed ___% of the total
amount invested by shareholders since inception but will only own ____% of the shares of common stock outstanding. See &#8220;<I>Dilution</I>&#8221;
for a more detailed description of the dilution to new investors in the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have broad discretion in how we use the proceeds of this offering and may not use these proceeds effectively, which could affect our
results of operations and cause our stock price to decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will have considerable
discretion in the application of the net proceeds of this offering. Because of the number and variability of factors that will determine
our use of the net proceeds, their ultimate use may vary substantially from their currently intended use. Management might not apply our
net proceeds in ways that ultimately increase the value of your investment. While we expect to use the net proceeds from this offering
as set forth in &ldquo;<I>Use of Proceeds</I>,&rdquo; we are not obligated to do so. As a result, investors will be relying upon management&rsquo;s
judgment with only limited information about our specific intentions for the use of the balance of the net proceeds of this offering.
We may use the net proceeds for purposes that do not yield a significant return or any return at all for our shareholders. In addition,
pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should not rely on an
investment in our common stock to provide dividend income. We currently anticipate that we will retain future earnings for the development,
operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return
to shareholders will therefore be limited to the appreciation of their stock, which may never occur, as the only way to realize any return
on their investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our executive officers, directors, and shareholders
and their affiliates who beneficially own more than 5% of our common stock will continue to exercise significant influence over our company
after this offering, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon the number of shares
of our common stock outstanding as of December&nbsp;31, 2022, the existing holdings of our executive officers, directors, and shareholders
and their affiliates who beneficially own more than 5% of our common stock are expected to represent beneficial ownership, in the aggregate,
of approximately ____% of our outstanding common stock (assuming no exercise of the underwriters&rsquo; option to purchase additional
shares and no purchases by such holders in this offering). As a result, these shareholders, if they act together, will be able to exercise
significant influence over our management and affairs and the outcome of matters submitted to our shareholders for approval, including
the election of directors and any sale, merger, consolidation, or sale of all or substantially all of our assets. These shareholders acquired
their shares of common stock at prices per share that were substantially less than the per share price of the shares of common stock being
sold in this offering, these shareholders may have interests with respect to their common stock that are different from those of investors
in this offering, and the concentration of voting power among these shareholders may have an adverse effect on the price of our common
stock. In addition, this concentration of ownership might adversely affect the market price of our common stock by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delaying, deferring or
    preventing a change of control of our company;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impeding a merger, consolidation,
    takeover or other business combination involving our company; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discouraging a potential
    acquirer from making a tender offer or otherwise attempting to obtain control of our company.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &ldquo;<I>Principal Shareholders</I>&rdquo;
in this prospectus for more information regarding the ownership of our outstanding common stock by our executive officers, directors,
principal shareholders and their respective affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Conflicts of interest may arise because
some members of our board of directors are representatives of our principal shareholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our principal shareholders
or their affiliates are investment funds or other investment vehicles that could invest in companies that directly or indirectly compete
with us. As a result of these relationships, conflicts may arise between the interests of the principal shareholders or their affiliates
and the interests of other shareholders, and members of our board of directors that are representatives of such principal shareholders
may not be disinterested in such conflicts. We expect that all decisions made by our executive officers and directors will be made in
accordance with their duties and obligations to deal fairly and in good faith and to act in the best interests of us and our shareholders,
as well as in compliance with our Code of Conduct, which will be adopted in connection with this offering and includes a &ldquo;conflicts
of interest&rdquo; section applicable to all employees, executive officers and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Sales of a substantial number of shares
of our common stock by our existing shareholders in the public market could cause our stock price to fall.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our existing shareholders
sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the lock-up and other legal
restrictions on resale discussed in this prospectus lapse, the trading price of our common stock could decline. Based on shares of common
stock outstanding as of December&nbsp;31, 2022 upon the closing of this offering, we will have an outstanding total of ______ shares of
common stock (assuming no exercise of the over-allotment option to purchase additional shares). Of these shares, only the shares of common
stock sold in this offering by us, including any upon exercise of the underwriters&rsquo; option to purchase additional shares, will generally
be freely tradable without restriction in the public market immediately following this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our directors, officers and beneficial owners of over one percent of our outstanding common stock have agreed that, until 180 days
after the date of this prospectus, subject to certain exceptions, we and they will not, without the prior written consent of the Representatives,
offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of any of our shares of
common stock, any options or warrants to purchase any of our shares of common stock or any securities convertible into or exchangeable
for or that represent the right to receive shares of our common stock; the Representatives may release any of the securities subject
to these lock-up agreements at any time, subject to applicable notice requirements. After the lock-up agreements expire, up to an additional
________shares of common stock will be eligible for sale in the public market, of which ______ shares are held by directors, executive
officers and other affiliates and will be subject to volume limitations under Rule&nbsp;144 under the Securities Act. In addition, shares
of common stock that are either subject to outstanding options or reserved for future issuance under our employee benefit plans will
become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the lock-up agreements,
and Rule&nbsp;144 and Rule&nbsp;701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived
that they will be sold, in the public market, the trading price of our common stock could decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result
in additional dilution of the percentage ownership of our shareholders and could cause our stock price to fall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that we will need significant additional capital in the future to continue our planned operations, including conducting clinical
trials, commercialization efforts, expanded research and development activities, and costs associated with operating a public company.
To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and
in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may
be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing shareholders, and new investors
could gain rights, preferences and privileges senior to the holders of our common stock, including shares of common stock sold in this
offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price
of our stock could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will rely, in part, on the research and reports that industry or financial analysts publish about
us or our business. We may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage
of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering
our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to
cover our stock, we could lose visibility in the market for our stock, which, in turn, could cause our stock price to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
failure to meet Nasdaq&#8217;s continued listing requirements could result in a delisting of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
after listing, we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the
minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative
effect on the price of our common stock and would </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">impair your ability
to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action
taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market
price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement
or prevent future non-compliance with the listing requirements of Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
could be subject to securities class action litigation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, securities class action litigation has often been brought against public companies following declines in the market prices
of their securities. This risk is especially relevant for biopharmaceutical companies, which have experienced significant stock price
volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention
and our resources, which could harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are an emerging growth company and a smaller reporting company, and the reduced reporting requirements applicable to emerging growth
companies and smaller reporting companies may make our common stock less attractive to investors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &ldquo;emerging growth company&rdquo; as defined in the JOBS
Act. For as long as we continue to be an emerging growth company, we may take advantage of certain exemptions from various public company
reporting requirements, including being permitted to provide only two years of audited financial statements, in addition to any required
unaudited interim financial statements with correspondingly reduced &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations&rdquo; disclosure in this prospectus, not being required to have our internal control over financial reporting
audited by our independent registered public accounting firm under Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in this prospectus and our periodic reports and proxy statements, and exemptions from the requirements
of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously
approved. We may take advantage of these exemptions until the last day of the fiscal year ending after the fifth anniversary of this offering
or until we are no longer an emerging growth company, whichever is earlier. We will cease to be an emerging growth company prior to the
end of such five-year period if certain earlier events occur, including if we become a &ldquo;large accelerated filer&rdquo; as defined
in Rule&nbsp;12b-2 under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), our annual gross revenues exceed
$1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards
apply to private companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we
(i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided
in the JOBS Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company
even after we are no longer an emerging growth company, which would allow us to take advantage of many of the same exemptions available
to emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of
the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation. We will be able to take advantage of these
scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured
on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed
fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business
day of our second fiscal quarter. Investors may find our common stock less attractive because we may rely on these exemptions. If some
investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock
price may be more volatile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Provisions in our amended and restated certificate
of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of us, which may be beneficial to our
shareholders, more difficult and may prevent attempts by our shareholders to replace or remove our current management.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions in our amended
and restated certificate of incorporation and our amended and restated bylaws that will become effective immediately prior to the completion
of this offering and provisions of Delaware law may discourage, delay or prevent a merger, acquisition or other change in control of us
that shareholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These
provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing
the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management
team, these provisions may frustrate or prevent any attempts by our shareholders to replace or remove our current management by making
it more difficult for shareholders to replace members of our board of directors. Among other things, these provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish a classified
    board of directors such that not all members of the board are elected at one time;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">allow the authorized number
    of our directors to be changed only by resolution of our board of directors;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit the manner in which
    shareholders can remove directors from the board;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish advance notice
    requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require that stockholder
    actions must be effected at a duly called stockholder meeting and prohibit actions by our shareholders by written consent;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prohibit our shareholders
    from calling a special meeting of our shareholders;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize our board of
    directors to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called
    &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing
    acquisitions that have not been approved by our board of directors; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require the approval of
    the holders of at least 66 2/3% of the votes that all our shareholders would be entitled to cast to amend or repeal certain provisions
    of our charter or bylaws.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law,
which prohibits a person who owns 15% or more of our outstanding voting stock from merging or combining with us for a period of three
years after the date of the transaction in which the person acquired 15% or more of our outstanding voting stock, unless the merger or
combination is approved in a prescribed manner. These provisions could discourage potential acquisition proposals and could delay or
prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common
stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit
the price that investors are willing to pay for our stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our amended and restated bylaws will provide
that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive
forums for substantially all disputes between us and our shareholders, which could limit our shareholders&rsquo; ability to obtain a favorable
judicial forum for disputes with us or our directors, officers or employees.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated bylaws that will become effective immediately prior to the completion of this offering will provide that the Court
of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory
or common law:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any derivative action or
    proceeding brought on our behalf;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any action asserting a
    breach of fiduciary duty;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any action asserting a
    claim against us arising under the Delaware General Corporation Law, our certificate of incorporation or our bylaws; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any action asserting a
    claim against us that is governed by the internal affairs doctrine.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the
federal courts have exclusive jurisdiction. Furthermore, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal
and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such
claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different
courts, among other considerations, our certificate of incorporation further provides that the federal district courts of the United
States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the
Delaware courts have determined that such choice of forum provisions are facially valid and several state trial courts have enforced
such provisions and required that suits asserting Securities Act claims be filed in federal court, there is no guarantee that courts
of appeal will affirm the enforceability of such provisions and a stockholder may nevertheless seek to bring a claim in a venue other
than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability
of the exclusive forum provisions of our certificate of incorporation. This may require significant additional costs associated with
resolving such action in other jurisdictions and the provisions may be enforced by a court in those other jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a court were to find the exclusive forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action,
we may incur further significant additional costs associated with litigating Securities Act claims in state court, or both state and
federal court, which could harm our business, financial condition, results of operations, and prospects. Further, this exclusive forum
provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or
our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will incur significantly increased costs as a result of operating as a public company, and our management will be required to devote
substantial time to new compliance initiatives and corporate governance practices.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we will incur significant legal, accounting, and other expenses that we did not incur as a private company. We will
be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual,
quarterly, and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as
rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on
public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate
governance practices. Further, in July&nbsp;2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the Dodd-Frank Act)
was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require
the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Emerging growth companies
and smaller reporting companies are exempted from certain of these requirements, but we may be required to implement these requirements
sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the
current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations,
which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and
to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from
other business concerns, they could have a material adverse effect on our business, financial condition, and results of operations. The
increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business
or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and
more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain
the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these
requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve
on our board of directors, our board committees or as executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to maintain proper and effective internal controls over financial reporting our ability to produce accurate and timely financial
statements could be impaired.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to maintain internal controls over financial reporting. Commencing with our fiscal year ending the year after this offering
is completed, we must perform system and process design evaluation and testing of the effectiveness of our internal controls over financial
reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Form&nbsp;10-K
filing for that year, as required by Section&nbsp;404 of the Sarbanes-Oxley Act. This will require that we incur substantial additional
professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts.
Prior to this offering, we have never been required to test our internal controls within a specified period and, as a result, we may
experience difficulty in meeting these reporting requirements in a timely manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to comply with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable
to maintain proper and effective internal controls over financial reporting, we may not be able to produce timely and accurate financial
statements. If that were to happen, our investors could lose confidence in our reported financial information, the market price of our
stock could decline and we could be subject to sanctions or investigations by the SEC, Nasdaq or other regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of
simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or
arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by
the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly,
because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have identified material weaknesses in our intern</I></B>al <B><I>control over financial reporting and may identify additional material
weaknesses in the future. Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. If we fail to
establish and maintain effective internal controls over financial reporting, our operating results and our ability to operate
our business could be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a private company, NeOnc has not been required to document and test its internal controls over financial reporting, nor has management
been required to certify the effectiveness of its internal controls, and our auditors have not been required to opine on the effectiveness
of its internal control over financial reporting. Similarly, NeOnc has not been subject to the SEC&#8217;s internal control reporting
requirements. Upon the completion of this offering, we will become subject to the periodic reporting requirements of the Exchange Act.
We must design our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit
under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time
periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and
procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the
control system are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the audit of NeOnc Technologies, Inc.&#8217;s financial statements as of and for the years ended December&nbsp;31,
2022 and 2021, NeOnc Technologies, Inc. and its independent registered public accounting firm identified material weaknesses in its internal
control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial
reporting such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not
be prevented or detected on a timely basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The material weaknesses that
NeOnc Technologies, Inc. and its independent registered public accounting firm identified in NeOnc Technologies, Inc.&rsquo;s financial
statements as of and for the years ended December&nbsp;31, 2022 and 2021 occurred because NeOnc Technologies, Inc. was a private company
that had not previously been audited and had maintained a complement of resources with various levels of accounting knowledge, experience,
and expertise that are not commensurate with our prospective financial reporting needs. These material weaknesses relate to the fact that
we do not maintain a comprehensive policies and procedures manual designed to establish internal controls over financial reporting to
reduce the risk of publishing materially misstated financial statements, as well as defined responsibilities and segregated incompatible
duties to reduce the risk of unauthorized transactions. Collectively, this could result in difficulties in meeting our internal reporting
needs and our external reporting requirements and assessing the appropriate accounting treatment for various events and/or transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have initiated various
remediation efforts, including the hiring of additional financial personnel/consultants with the appropriate public company and technical
accounting expertise. We cannot reasonably estimate the cost of such
remediation plan at this time. We can give no assurance that such efforts will remediate these material weaknesses internal control over
financial reporting or that additional material weaknesses in its internal control over financial reporting will not be identified in
the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may discover additional weaknesses in our system of internal financial
and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control
over financial reporting will not prevent or detect all errors and all fraud. Because of the inherent limitations in all control systems,
no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues
and instances of fraud will be detected.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of
simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or
arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by
the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly,
because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
to build our finance infrastructure and improve our accounting systems and controls could impair our ability to comply with the financial
reporting and internal controls requirements for publicly traded companies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we will operate in an increasingly demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley
Act, the regulations of the Nasdaq Capital Market, the rules and regulations of the Securities and Exchange Commission, expanded disclosure
requirements, accelerated reporting requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley
Act include establishing corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures.
Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud.
Commencing with our fiscal year ending the year after this offering is completed, we must perform system and process evaluation and testing
of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial
reporting in our Form&nbsp;10-K filing for that year, as required by Section&nbsp;404 of the Sarbanes-Oxley Act. Prior to this offering,
we have never been required to test our internal controls within a specified period and, as a result, we may experience difficulty in
meeting these reporting requirements in a timely manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that the process of building our accounting and financial functions and infrastructure will require significant additional
professional fees, internal costs and management efforts. For example, we expect that we will need to implement new systems to enhance
and streamline the management of our financial, accounting, human resources and other functions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
such systems will likely require us to complete many processes and procedures for the effective use of the systems, which may result
in substantial costs. Any disruptions or difficulties in implementing or using these systems could adversely affect our controls and
harm our business. Moreover, such disruption or difficulties could result in unanticipated costs and diversion of management attention.
In addition, we may discover additional weaknesses in our system of internal financial and accounting controls and procedures that could
result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect
all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance
that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of
controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances
of fraud will be detected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to comply with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable
to implement proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If we cannot
provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence
in our reported financial information and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our
reported results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our reported financial position
or results of operations. Financial accounting standards in the United States are constantly under review and new pronouncements and
varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future. As
a result, we may be required to make changes in our accounting policies. Those changes could affect our financial condition and results
of operations or the way in which such financial condition and results of operations are reported. We intend to invest resources to comply
with evolving standards, and this investment may result in increased general and administrative expenses and a diversion of management
time and attention from business activities to compliance activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_005"></A>CAUTIONARY
STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus includes forward-looking statements within the meaning of the federal securities laws. We have based these forward-looking
statements largely on our current expectations and projections about future events and financial trends affecting the operating results
and financial condition of our business. Forward-looking statements should not be read as a guarantee of future performance or results
and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking
statements are based on information available at the time those statements are made and/or management&#8217;s good faith belief as of
that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to
differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences
include, but are not limited to, statements about:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">estimates
    of our expenses, future revenues, capital requirements and our needs for additional financing;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to continue as a going concern;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    projected financial position and estimated cash burn rate;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates of the size of our market opportunities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to effectively manage our growth;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success, cost and timing of our clinical trial;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    dependence on third parties in the conduct of our clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential that results of pre-clinical and clinical trials indicate our current product candidates or any future product candidates
    we may seek to develop are unsafe or ineffective;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain the necessary regulatory approvals to market and commercialize our product candidates;;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain intellectual property protection for our current product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce
    or protect our intellectual property rights;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    acceptance of our product candidates, the size and growth of the potential markets for our current product candidates and any future
    product candidates we may seek to develop, and our ability to serve those markets;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of competing therapies and products that are or become available;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    successful development of our commercialization capabilities, including sales and marketing capabilities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expected use of proceeds from this offering;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential lack of liquidity and trading of our securities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    potential ability to obtain additional financing;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain the listing of our common stock on the Nasdaq Capital Market;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    disruption in, or breach in security of, our information technology systems and resultant interruptions in service and any related
    impact on our reputation;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    attraction and retention of qualified employees and key personnel;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of our internal controls and disclosure controls;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in laws and government regulation affecting our business;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of adverse economic conditions;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sufficiency of our cash and cash equivalents to meet our liquidity needs and service our indebtedness; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">outcomes
    of legal or administrative proceedings.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in this prospectus, the words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221;
&#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; and similar expressions,
as they relate to our Company, our business and our management, are intended to identify forward-looking statements. In light of these
risks and uncertainties, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could
differ materially from those anticipated or implied in the forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements speak only as of the date of this prospectus. You should not put undue reliance on any forward-looking statements. We assume
no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting
forward-looking information, except to the extent required by applicable laws. If we update one or more forward-looking statements, no
inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus and the documents that we reference in this prospectus and have filed with the Securities and Exchange Commission
as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels
of activity, performance and events and circumstances may be materially different from what we expect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_006"></A>USE
OF PROCEEDS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the net proceeds from our issuance and sale of shares of our common stock in this offering will be approximately $___,
assuming an initial public offering price of $____ per share, which is the midpoint of the estimated offering price range set forth on
the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable
by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal purposes of
this offering are to increase our capitalization and financial flexibility, increase our visibility in the marketplace and create a public
market for our common stock. As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net
proceeds to us of this offering. However, we currently intend to use approximately 35.6% of the net proceeds for clinical trials, 20.0%
of the net proceeds for research and development, 6.3% of the net proceeds to repay a short term loan provided to us by HCWG LLC, an entity
substantially beneficially owned by our officers and directors, 9.6% of the net proceeds to pay AFH a cash fee in an amount equal to 2.0%
of the post-money valuation of our Company immediately after the consummation of this offering, 1.3% of the net proceeds to pay accrued
salaries, and 27.2% of the net proceeds for general corporate purposes and working capital. For more information, see &ldquo;<I>Certain
Relationships and Related Party Transactions &ndash; Letter of Intent &ndash; AFH Holdings and Advisory, LLC</I>&rdquo; and &ldquo;<I>Certain
Relationships and Related Party Transactions &ndash; Short-term loans</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we have not allocated a specific amount of the remaining net proceeds from this offering to any particular purpose, we may use such remaining
net proceeds for the acquisitions of additional businesses or technologies. We do not have any understandings or agreements for any acquisitions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds we actually expend for the acquisition of additional businesses may vary significantly depending on a number of factors,
including our ability to locate such companies and enter into a binding acquisition agreement on favorable terms and the negotiated purchase
price. In addition, the net proceeds we actually expend for general corporate purposes may vary significantly depending on a number of
factors, including future revenue growth and our cash flows. As a result, we will retain broad discretion over the allocation of the
remaining net proceeds from this offering. Pending use of the net proceeds from this offering, we intend to invest the net proceeds in
short-term, investment-grade securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
$1.00 increase or decrease in the assumed initial public offering price of $____ per share, which is the midpoint of the estimated offering
price range set forth on the cover page of this prospectus, would increase or decrease our net proceeds from this offering by approximately
$___, assuming that the number of shares of our common stock offered by us, as set forth on the cover page of this prospectus, remains
the same and after deducting estimated underwriting discounts and commissions payable by us. An increase or decrease of 1.0 million shares
in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease our net proceeds
from this offering by approximately $___, assuming no change in the assumed initial public offering price per share and after deducting
estimated underwriting discounts and commissions payable by us. We do not expect that a change in the offering price or the number of
shares by these amounts would have a material effect on our intended uses of the net proceeds from this offering, although it may impact
the amount of time prior to which we may need to seek additional capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing represents our current intentions to use and allocate the net proceeds of this offering based upon our present plans and business
conditions. We will have broad discretion over how to use the net proceeds to us from this offering. We intend to invest the net proceeds
to us from the offering that are not used as described above in investment-grade, interest-bearing instruments. See &#8220;<I>Risk Factors&#8212;Risks
Related to this Offering and Our Common Stock &#8212; Our management has broad discretion in the use of the net proceeds from this offering
and may not use the net proceeds effectively.&#8221;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_007"></A>DIVIDEND
POLICY</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation
and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination to
pay dividends will be made at the discretion of our board of directors or any authorized committee thereof after considering our financial
condition, results of operations, capital requirements, business prospects and other factors our board of directors or such committee
deems relevant, and subject to the restrictions contained in our current or future financing instruments. <FONT STYLE="background-color: white">See
also &#8220;</FONT><I>Risk Factors&#8212; Risks Related to this Offering and Our Common Stock <FONT STYLE="background-color: white">&#8212;
We have never paid dividends on our capital stock and we do not intend to pay dividends for the foreseeable future. Consequently, any
gains from an investment in our common stock will likely depend on whether the price of our common stock increases.&#8221;</FONT></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_008"></A>CAPITALIZATION</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
our cash and capitalization as of December&nbsp;31, 2022 (i) on an actual basis, (ii) on a pro forma basis giving effect to (a) a 1.222222-for-1
forward split of the outstanding shares of common stock in April&nbsp;2023 and (b) the subsequent issuance of 10,500,000 shares of our
common stock to shareholders of NeOnc Technologies, Inc. in April&nbsp;2023 in the Share Exchange and (iii) on a pro forma as adjusted
basis, giving effect to our receipt of estimated net proceeds from the sale of shares of common stock that we are offering at an assumed
initial public offering price of $____ per share, which is the midpoint of the estimated offering price range set forth on the cover page
of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses. You should read
this table together with the section titled &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of
Operations</I>&rdquo; and our consolidated financial statements and related notes included elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As of<BR>
December&nbsp;31,<BR>
2022</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Pro Forma<BR>
As</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Actual</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Pro Forma</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Adjusted</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 64%"><FONT STYLE="font-size: 10pt">Cash and cash equivalents</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">633,298</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: black 2.25pt double; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Indebtedness, including current portion</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">50,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Preferred Stock, $0.001 par value, 10,000,000 shares authorized, no
shares issued and outstanding actual,  pro forma, and pro forma as adjusted

</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Common Stock, $0.001 par value, 100,000,000 shares authorized, 4,500,000 shares issued and outstanding actual, 16,000,000 pro forma, and ____ shares issued and outstanding pro forma as adjusted</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">4,500</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Paid-in capital</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">22,209,005</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Accumulated deficit</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(23,788,916</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Total shareholders&rsquo; equity (deficit)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(1,575,411</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Total capitalization</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(1,525,411</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total number of shares of our common stock reflected in the discussion and table above excludes the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">___ shares of common stock issuable upon the vesting of stock options to be granted to our directors, director nominees, executive officers and advisory board members immediately prior to the effective date of this offering;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___
    shares of common stock issuable upon the vesting of restricted stock units to be granted to our executive officers immediately prior
    to the effective date of this offering;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___
    shares of common stock reserved for future grant or issuance under our 2023 Plan; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___
    shares of common stock issuable upon the exercise of the warrants issuable to the Representative of the underwriters upon the closing
    of this offering.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in; text-align: justify">Each $1.00 increase or decrease
in the assumed initial public offering price of $____ per share, which is the midpoint of the estimated offering price range set forth
on the cover page of this prospectus, would increase or decrease, as applicable, our cash, and total shareholders&rsquo; equity and total
capitalization by approximately $___, assuming that the number of shares of our common stock offered by us, as set forth on the cover
page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions payable by us. Each increase
or decrease of 1.0 million shares in the number of shares offered by us would increase or decrease the amount of our cash, total shareholders&rsquo;
equity and total capitalization by approximately $___, assuming an initial public offering price of $____ per share, which is the midpoint
of the estimated offering price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts
and commissions payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_009"></A>DILUTION</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our common stock, your interest will be diluted to the extent of the difference between the public offering price per share
of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. <FONT STYLE="background-color: white">Dilution
in net tangible book value per share to new investors is the amount by which the offering price paid by the purchasers of the shares
sold in this offering exceeds the pro forma as adjusted net tangible book value per </FONT>share of common stock <FONT STYLE="background-color: white">after
this offering. Net tangible book value per share is determined at any date by subtracting our total liabilities from the total book value
of our tangible assets and dividing the difference by the number of shares of </FONT>our common stock <FONT STYLE="background-color: white">deemed
to be outstanding at that date.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our historical net tangible
book value (deficit) as of December&nbsp;31, 2022 was $(___), or $(___) per share of common stock. After giving effect to a 1.222222-for-1
forward split of the outstanding shares of common stock in April&nbsp;2023 and the subsequent issuance of 10,500,000 shares of common
stock to shareholders of NeOnc Technologies, Inc. in April&nbsp;2023 in the Share Exchange, our pro forma historical net tangible book
value as of December&nbsp;31, 2022 was $___, or $___ per share of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After giving effect to our
sale of _____ shares of our common stock in this offering at an assumed initial public offering price of $___ per share, which is the
midpoint of the estimated offering price range set forth on the cover page of this prospectus, after deducting estimated underwriting
discounts and commissions payable by us, our pro forma as adjusted net tangible book value as of December&nbsp;31, 2022, would have been
$___, or $___ per share. This represents an immediate increase in pro forma adjusted net tangible book value of $___per share to our existing
shareholders and an immediate dilution of $___per share to new investors purchasing shares of common stock in this offering. The following
table illustrates this dilution on a per share basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed
    initial public offering price per share</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 76%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical
    net tangible book value (deficit) per share as of December&nbsp;31, 2022</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(___</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    per share attributable to the pro forma adjustments described above</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
    forma net tangible book value (deficit) per share as of December&nbsp;31, 2022</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in pro forma net tangible book value per share attributable to new investors purchasing shares in this offering</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
    forma as adjusted net tangible book value (deficit) per share after this offering</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution
    in pro forma as adjusted net tangible book value per share to new investors in this offering</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total number of shares of our common stock reflected in the discussion and table above excludes the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___
    shares of common stock issuable upon the vesting of stock options to be granted to our directors, director nominees, executive officers
    and advisory board members immediately prior to the effective date of this offering;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___
    shares of common stock issuable upon the vesting of restricted stock units to be granted to our executive officers immediately prior
    to the effective date of this offering;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___
    shares of common stock reserved for future grant or issuance under our 2023 Plan; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___
    shares of common stock issuable upon the exercise of the warrants issuable to the Representative of the underwriters upon the closing
    of this offering</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
$1.00 increase or decrease in the assumed initial public offering price of $____ per share, which is the midpoint of the estimated offering
price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, our pro forma as adjusted net
tangible book value by approximately $____, or approximately $____per share, and would increase or decrease, as applicable, dilution
per share to new investors in this offering by $____, assuming that the number of shares of our common stock offered by us, as set forth
on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions payable by
us. An increase or decrease of 1,000,000 shares in the number of shares offered by us would increase or decrease, as applicable, our
pro forma as adjusted net tangible book value by approximately $___, or approximately $____ per share. An increase of 1,000,000 shares
in the number of shares offered by us would decrease dilution per share to new investors in this offering by approximately $____ and
a decrease of 1,000,000 shares in the number of shares offered by us would increase dilution per share to new investors in this offering
by approximately $____ per share, assuming an initial public offering price of $____ per share, which is the midpoint of the estimated
offering price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions
payable by us. The pro forma as adjusted information discussed above is illustrative only and will be adjusted based on the actual public
offering price and other terms of this offering determined at pricing. If the underwriters exercise their option to purchase additional
shares in full, the pro forma as adjusted net tangible book value per share would be $____ per share, and the dilution per share to new
investors in this offering would be $____ per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
on a pro forma as adjusted basis as described above, as of December&nbsp;31, 2022, the differences between the existing shareholders and
new investors with respect to the number of shares of common stock purchased from us, the total consideration paid to us and the average
price per share paid or to be paid to us at an assumed initial public offering price of $____ per share, which is the midpoint of the
estimated offering price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and commissions
and estimated offering expenses payable by us:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="padding-bottom: 1pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Total
    Consideration</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Average<BR>
    Price</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Shares
    Purchased</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-left: 0.125in; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Number</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-left: 0.125in; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percent<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Amount</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Percent</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Per
    Share</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Existing shareholders</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 1%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,000,000</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 1%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 9%; text-align: right"></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">New
    investors</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: right"></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Totals</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100.0</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100.0</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the underwriters exercise their option to purchase additional shares in full, the percentage of shares of our common stock held by
    existing shareholders would be ____% and the percentage of shares of our common stock held by new investors would be ____%.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_010"></A>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial
statements and related notes thereto included elsewhere in this prospectus. In addition to historical information, this discussion and
analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially
from these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to
these differences below and elsewhere in this prospectus, including those set forth in the sections of this prospectus entitled &#8220;Risk
Factors&#8221; and &#8220;Cautionary Statement Concerning Forward-Looking Statements&#8221;.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical
company, we have focused on establishing superior treatments for intracranial malignancies, i.e., aggressive cancers located in the brain.
These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, that have arrived through metastatic
spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain-localized malignancies are particularly
difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result,
these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug delivery methods to
be used in combination with novel drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeOnc&#8217;s
lead product candidate is NEO100. NEO100 is administered to patients via intranasal delivery. We have completed human safety testing
in a Phase 1 clinical trial and are currently conducting preliminary efficacy testing in a Phase 2a trial with recurrent malignant glioma
(Grade IV, IDH1 mutant) patients. NeOnc is also developing a second product candidate, NEO212, which has completed preclinical testing
and an investigational new drug (IND) application has been filed with the United States Food and Drug Administration (FDA) so that clinical
trials can follow with patients harboring primary and secondary malignant brain cancer types. Several additional drug candidates are
in the pipeline and are undergoing preclinical development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, our operations have focused on organizing and staffing our company, business planning, raising capital, acquiring and developing
our technology, establishing our intellectual property portfolio, identifying potential product candidates and undertaking preclinical
and clinical studies and manufacturing. We do not have any products approved for sale and have not generated any revenue from product
sales other than for humanitarian usage. From inception through December&nbsp;31, 2022, we had raised an aggregate of approximately $13.1
million of gross proceeds through the sale and issuance of preferred stock and common stock, not including grants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, we have incurred significant operating losses. Our net loss was $3,046,757 and $3,375,602 for the years ended December&nbsp;31,
2022 and 2021, respectively. As of December&nbsp;31, 2022, we had an accumulated deficit of $23,788,916. We expect to continue to incur
significant and increasing expenses and operating losses for the foreseeable future, as we advance our current and future product candidates
through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and
future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business
personnel and operate as a public company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval
for our product candidates. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party
commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support
product sales, marketing, manufacturing, and distribution activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can
generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private
equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing
arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable
terms, or at all. Our failure to raise capital or enter into such agreements as, and when needed, could have a material adverse effect
on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
report of our independent registered public accounting firm on our financial statements as of and for the year ended December&nbsp;31,
2022 included an explanatory paragraph indicating that there was substantial doubt about our ability to continue as a going concern.
See Note 1 to our annual financial statements appearing at the end of this prospectus for additional information on our assessment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&nbsp;31, 2022, we had a cash balance of $633,298. We believe that our existing cash, together with the anticipated net proceeds
from this offering, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Components
of Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Revenue</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognized $20,000 of revenue for the year ended December&nbsp;31, 2022 related to a fee received from a patient for a &#8220;right to
try&#8221; humanitarian program. Such revenues occur occasionally but are not part of our core business. There was no revenue recorded
from any sources during the year ended December&nbsp;31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have deferred payments received for the license of our products to third parties &#8211; See collaboration agreement accounting policy
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Operating
Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating expenses consist of (i) research and development expenses and (ii) legal and professional expenses and (iii) general and administrative
expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs incurred for our research and development activities, including our product candidate
discovery efforts and preclinical and clinical studies under our research programs, which include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related
    expenses, including salaries, benefits and stock-based compensation expense for our research and development personnel;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of funding research performed by third parties that conduct research and development and preclinical and clinical activities on our
    behalf;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of manufacturing drug product and drug supply related to our current or future product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of conducting preclinical studies and clinical trials of our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consulting
    and professional fees related to research and development activities, including equity-based compensation to non-employees;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of maintaining our laboratory, including purchasing laboratory supplies and non-capital equipment used in our preclinical studies;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    related to compliance with clinical regulatory requirements; and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">facility
    costs and other allocated expenses, which include expenses for rent and maintenance of facilities, insurance, depreciation and other
    supplies.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Costs for certain activities are recognized based on an evaluation of the progress to
completion of specific tasks using data such as information provided to us by our vendors and analyzing the progress of our preclinical
and clinical studies or other services performed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful development of our product candidates is highly uncertain. We cannot reasonably estimate or know the nature, timing, and estimated
costs of the efforts that will be necessary to complete development of our current or future product candidates. We are also unable to
predict when, if ever, material net cash inflows will commence from the sale of our product candidates, if they are approved. This is
due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, rate of progress, and expenses of our ongoing research activities as well as any preclinical studies and clinical trials and
    other research and development activities;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    an appropriate safety profile;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    enrollment in and completion of clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    our product candidates show safety and efficacy in our clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
    of marketing approvals from applicable regulatory authorities;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    commercial manufacturing capabilities or making arrangements with third-party manufacturers;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercializing
    product candidates, if and when approved, whether alone or in collaboration with others; and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continued
    acceptable safety profile of the products following any regulatory approval.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in the outcome of any of these variables with respect to the development of our current and future product candidates would significantly
change the costs and timing associated with the development of those product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities are central to our business model. Product candidates in later stages of clinical development generally have
higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage
clinical trials. We expect research and development costs to increase significantly for the foreseeable future as we commence clinical
trials and continue the development of our current and future product candidates. However, we do not believe that it is possible at this
time to accurately project expenses through commercialization. There are numerous factors associated with the successful commercialization
of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined
with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control
will impact our clinical development programs and plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Legal
and Professional Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
and professional expenses consist of costs related to corporate and intellectual property legal costs and accounting and auditing fees.
We also anticipate increased expenses associated with being a public company, including costs for audit, legal, regulatory and tax-related
services related to compliance with the rules and regulations of the Securities and Exchange Commission, or the SEC, and listing standards
applicable to companies listed on a national securities exchange, director and officer insurance premiums, and investor relations costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses include salaries and other compensation-related costs, including stock-based compensation, for personnel
in executive, finance and accounting, business development, operations and administrative roles. Other significant costs include insurance
costs, travel costs, facility and office-related costs not included in research and development expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our general and administrative expenses will increase in the future as our business expands to support expected growth
in research and development activities, including our future clinical programs. These increases will likely include increased costs related
to the hiring of additional personnel and fees to outside service providers, among other expenses. In addition, if we obtain regulatory
approval for any of our product candidates and do not enter into a third-party commercialization collaboration, we expect to incur significant
expenses related to building a sales and marketing team to support product sales, marketing and distribution activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comparison
of the Years Ended December&nbsp;31, 2022 and 2021</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our results of operations for the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December&nbsp;31.</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 64%">Revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">20,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">20,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,163,330</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">674,558</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">488,772</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Legal and professional</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">318,205</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">217,951</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,254</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,376,069</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,379,174</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,003,105</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,857,604</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,271,683</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(414,079</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,837,604</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,271,683</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">434,079</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Other (expense) income:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Change in fair value of note payable - Chairman of the Board</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Interest expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(200,153</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(112,919</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(87,234</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total other expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(209,153</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(103,919</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(105,234</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,046,757</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,375,602</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">328,845</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Revenue</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
was a one-time fee received for a &#8220;right to try&#8221; humanatian program during 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the components of our research and development expenses for the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    ended December&nbsp;31,</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Clinical
    trial expense</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">650,621</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">288,449</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">362,172</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
    and laboratory</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">512,709</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">386,109</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">126,600</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    research and development expense</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,163,330</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">674,558</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">488,772</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses were $1,163,330 and $674,558 for the years ended December&nbsp;31, 2022 and 2021, respectively. A portion of
these expenses are from the University of Southern California (USC) where Dr. Chen is a member of the faculty and amounted to approximately
$442,000 and $372,000 for the years ended December&nbsp;31, 2022 and 2021, respectively. The increase of $488,772 was primarily due to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    manufacture of capsules in preparation for the NEO212 oral clinical trial of $150,800</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
    in expenses for the preparation of the NEO212 and related expenses for the preparation of IND.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Legal
and Professional Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
and professional expense were $318,205 and $217,951 for the years ended December&nbsp;31, 2022 and 2021, respectively. The increase of
$100,254 was primarily due to conducting our audits of the financial statements and preparation thereof and increased legal expense related
to filing new patents and maintenance of current patent portfolio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expense were $1,376,069 and $2,379,174 for the years ended December&nbsp;31, 2022 and 2021, respectively. The decrease
of $1,003,105 was primarily due to the decrease in stock based compensation expense of $927,424 from 2021 to 2022, because options were
not issued in 2022, and a decrease of $150,000 of accrued compensation to officers and consultants (there were no such costs approved
by the Board of Directors in 2022).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Interest
Expense and change in fair value of the note payable</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interest expense in 2021
relates primarily to the fair value of a stock option granted to Dr. Chen in 2021 in connection with the issuance of a promissory note.
Interest expense in 2022 primarily relates to charges associated with the settlement of advances made by Dr. Chen. At December&nbsp;31,
2022, we have a $50,000 promissory note outstanding. The note was recorded at fair value and was repaid in 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Sources
of Liquidity/ Going Concern</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have funded our operations through the sale and issuance of preferred and common stock. From inception through December&nbsp;31,
2022, we raised an aggregate of $13,116,815 in gross proceeds from the sales of our stock. As of December&nbsp;31, 2022, we had cash
on hand in the amount of $633,298.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement
of liabilities and commitments in the normal course of business. Since our inception, we have not generated any revenue from product
sales or any other sources, except humanitarian use, and we have incurred significant operating losses. We have not yet commercialized
any products and we do not expect to generate revenue from sales of any product candidates for a number of years, if ever. As reflected
in the accompanying financial statements, we have incurred recurring net losses since our inception. During the year ended December&nbsp;31,
2022, we incurred a net loss of $3,046,757 and used cash in operations of $881,736 and had a shareholders&#8217; deficit of $1,575,411
as of December&nbsp;31, 2022. During the year ended December&nbsp;31, 2021, we incurred a net loss of $3,375,602 and used cash in operations
of $396,693 and had a shareholders&#8217; deficit of $ 2,616,346 as of December&nbsp;31, 2021. These factors raise substantial doubt
about our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to raise additional
funds and implement our strategies, such as executing additional licensing contracts. The financial statements do not include any adjustments
that might be necessary if we are unable to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability to continue as a going concern is dependent on us raising additional capital and attaining and maintaining profitable operations
in the future to meet our obligations and repay our liabilities arising from normal business operations when they come due. Since inception,
we have funded our operations primarily through equity and debt financings and licensing income and we expect to continue to rely on
these sources of capital in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to
us. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing,
or cause substantial dilution for our shareholders, in the case of equity financing, or grant unfavorable terms in licensing agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Funding
Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our expenses to increase in connection with our ongoing activities, particularly as we continue our research and development,
initiate and conduct preclinical studies and clinical trials, and seek marketing approval for our current and any of our future product
candidates. In addition, if we obtain marketing approval for any of our current or our future product candidates, we expect to incur
significant commercialization expenses related to product sales, marketing, manufacturing and distribution, which costs we may seek to
offset through entry into collaboration agreements with third parties. Furthermore, upon the completion of this offering, we expect to
incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding
in connection with our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we would be forced
to delay, reduce or eliminate our research and development programs or future commercialization efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our existing cash, together with the anticipated net proceeds from this offering, will enable us to fund our operating expenses
and capital expenditure requirements for at least 12 months. We have based this estimate on assumptions that may prove to be wrong, and
we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on a number of
factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of conducting preclinical studies and clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of manufacturing;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, results and costs of discovery, preclinical development, laboratory testing, and clinical trials for product candidates
    we may develop, if any;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing, and outcome of regulatory review of our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain collaborations on favorable terms, if at all;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    achievement of milestones or occurrence of other developments that trigger payments under any license or collaboration agreements
    we might have at such time;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of future commercialization activities, including product sales, marketing, manufacturing and distribution, for
    any of our product candidates for which we receive marketing approval;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive
    marketing approval;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights,
    and defending intellectual property-related claims;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    headcount growth and associated costs as we expand our business operations and research and development activities; and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of operating as a public company.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds of this offering, together with our existing cash, will be sufficient to progress our Phase 2 registration trial of development
of NEO100, but will not be sufficient to progress trials in other indications or the development of any other product candidate. Accordingly,
we will be required to obtain further funding to achieve our business objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through public or private equity
offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interests may
be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect your rights as
a common stockholder. Additional debt financing, if available, may involve agreements that include restrictive covenants that limit our
ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely
impact our ability to conduct our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we raise funds through potential collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our technologies, future revenue streams, research programs or product candidates, or to grant licenses on terms that
may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate
our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise
prefer to develop and market ourselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
from the National Institute of Health</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March&nbsp;2020, we were awarded a grant of $336,000 from the NIH for developing a clinically relevant radiosensitizer (NEO212) for temozolomide-resistant
gliomas. The project period for the grant was from April&nbsp;1, 2020 to March&nbsp;31, 2021, which was subsequently extended to March&nbsp;31,
2022. We received the balance of the $336,000 grant, approximately $156,000, during the year ended December&nbsp;31, 2021, respectively,
from the NIH. We contracted with USC to perform a portion of the work related to this grant totaling $180,000. As of December&nbsp;31,
2021, all work required for the grant was complete and all NIH funding had been received.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
related to this NIH grant totaled approximately $98,000 during the year ended December&nbsp;31, 2021, and was classified as a reduction
of research and development costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accrued
compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred $0 and $150,000 for the years ended December&nbsp;31, 2022 and 2021 for compensation to the Chairman and a consultant,
both of whom are shareholders. This compensation is recorded in the statement of operations as part of general and administrative expenses.
Accrued compensation payable to the Chairman and the consultant was $412,500 and $462,000 as of December&nbsp;31, 2022 and 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Short-term
loan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February&nbsp;2022, we entered into a $75,000 loan agreement bearing interest at 2.5% per annum with a maturity date of August&nbsp;2022
from Martin Schmieg, a former executive officer of NeOnc Technologies, Inc. The loan was fully paid off in December&nbsp;2022. Interest
expense paid related to this loan for the year ended December&nbsp;31, 2022 was approximately $1,500.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advances
from Chairman</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have periodically received cash advances from the Chairman or have had certain costs incurred by the University of Southern California
(&#8220;USC&#8221;) on our behalf paid for by the Chairman. These advances were non-interest bearing and had no stated maturity. At December&nbsp;31,
2021, the balance outstanding was $897,891. During the year ended December&nbsp;31, 2022, we repaid in cash $700,000 of such advances
to the Chairman and $197,891 was converted to 395,782 shares of common stock on December&nbsp;31, 2022. The fair value of the common
stock issued of $395,782 exceeded the remaining balance due the Chairman. Such excess fair value of $197,891 was recorded as interest
expense in the statement of operations for the year ended December&nbsp;31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholder
advances</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="color: #333333">Periodically
certain of our shareholders have advanced</FONT> the Company funds to support operations under informal loan arrangements (the &ldquo;Shareholder
Advances&rdquo;). These Shareholder Advances bear no interest and have no specified maturity date. There were Shareholder Advances outstanding
totaling $0 and $10,000 as of December&nbsp;31, 2022 and 2021, respectively. During the year ended December&nbsp;31, 2022, we repaid all
outstanding Shareholder Advances of $10,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
payable &#8211; Chairman of the Board</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August&nbsp;18, 2021, we entered into a loan agreement with the Chairman with a principal amount of $250,000 (the &#8220;Chairman Note&#8221;).
The Chairman Note bore no interest and was payable when we received funding in excess of $1,000,000. We received funding in excess of
$1,000,000 during the year ended December&nbsp;31, 2022, at which time the Chairman Note was repaid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
Flows</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our cash flows for the periods indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    ended December&nbsp;31,</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash provided by (used in):</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating
    activities</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(881,736</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(396,693</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(485,043</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Financing
    activities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,490,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">250,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,240,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    increase in cash</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">608,264</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(146,693</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">754,957</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Operating
Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December&nbsp;31, 2022, net cash used in operating activities was $881,736, consisting primarily of our net loss of
$3,046,757 less the non-cash charge for share based compensation expense of $1,291,909 and an offset by an increase in accounts
payable of $804,147. During the year ended December&nbsp;31, 2021, net cash used in operating activities was $396,693, consisting
primarily of our net loss of $3,375,602 less the non-cash charge for share based compensation of $2,219,333, an increase in accounts
payable of $423,172, and an increase in accrued compensation of $150,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financing
Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December&nbsp;31, 2022, cash provided by financing activities was $1,490,000 consisting primarily of net proceeds of $2,400,000
from the sale of our common stock, $125,000 from related parties, offset by the repayment of advances made by Dr. Chen of $700,000 and
the net repayment of loans from related parties, including Dr. Chen&#8217;s promissory note, of $250,000. At December&nbsp;31, 2022,
the debt outstanding consisted of a $50,000 convertible promissory note from a stockholder due August&nbsp;2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December&nbsp;31, 2021, cash provided by financing activities was $250,000, consisting primarily of a note from our Chairman.
This was fully repaid in 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual
Obligations and Commitments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into agreements in the normal course of business for sponsored research, preclinical studies, contract manufacturing, and other
services and products for operating purposes, which are generally cancellable upon written notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>USC
License</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March&nbsp;9, 2009,
Nas-Onc, Inc. (k/n/a NeOnc Technologies, Inc.) entered into an exclusive, worldwide license agreement with USC, pursuant to which
USC granted us a license to use certain patents and patent applications for the treatment and therapies of disease symptoms in
mammals (the &ldquo;USC Agreement&rdquo;). The license is exclusive except for the rights granted to the US government pursuant to
the Bayh-Dole Act and the right of USC and other non-profit academic research institutions to practice and improve the licensed
patents for educational and research purposes. Pursuant to the USC Agreement, we (1) paid USC an upfront royalty payment of $20,000,
(2) granted USC common stock (as amended and described below), (3) will pay USC an earned royalty of 2% of Net Sales (as that term
is defined in the USC Agreement), and (4) have paid and will continue to pay annual maintenance royalties of: $5,000 due
January&nbsp;1, 2011, $5,000 due January&nbsp;1, 2012, $10,000 due January&nbsp;1, 2013, and $20,000 due January&nbsp;1 thereafter.
Annual maintenance royalties paid to USC are creditable toward earned royalties. We are also responsible for paying all reasonable
patent expenses incurred by USC for filing prosecution and maintaining the licensed patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of suspected
patent infringement, the parties may agree to jointly institute suit, wherein the parties will share equally all costs and any recovery,
with control of such lawsuit being by agreement between us and USC. Absent an agreement to jointly institute a suit, USC has the sole
right to institute suit, at its option, where USC will bear the cost of such litigation and retain all recovery. In the event that USC
does not institute the lawsuit, the Company may bring suit, at its option, and bear all such costs. Any recovery obtain by us must be
shared with USC, after litigation costs reimbursement, as royalties on Net Sales for the remaining recovery. These rights and obligations
were changed pursuant to the Amendment discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The USC Agreement is sublicensable
subject to the same terms, except that (1) sublicensees may not grant sublicenses, (2) the earned royalty may be increased as to sublicensees,
(3) the sublicense reverts to USC in the event the USC Agreement is terminated as to us and, (4) additional issue and maintenance fees
are owed to USC for each sublicense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may challenge the
licensed patents upon 90 days notice and payment of all royalties due. If we are unsuccessful in its challenge, the earned royalty
will thereafter be increased by a factor of three.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Term of the USC
Agreement extends until the last to expire of the licensed patents. The USC Agreement may be terminated by either party upon 30 days
notice or upon material breach, wherein the breaching party is permitted 30 days to remedy such breach. USC may terminate
immediately if (1) we attempt to sublicense, transfer or assign its rights contrary to the terms of the agreement, (2) we do not
maintain the required insurance coverage, or (3) we are determined to be insolvent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The parties amended the USC
Agreement on April&nbsp;5, 2023 (&ldquo;Amendment&rdquo;). The Amendment added NeOnc Technologies Holdings, Inc., our parent company,
as a licensee. The Amendment adds additional patents to the prior license grant and requires us to record before the USPTO various assignments
of the licensed patents to USC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As referenced above,
pursuant to the USC Agreement, we issued to USC 800,000 shares of common stock in exchange for the license and as subsequently
agreed by the Amendment, we issued additional shares of our common stock such that USC&rsquo;s ownership of our Company, when
combined with the shares currently held by USC, equals three and one-half percent (3.5%) of our fully diluted capitalization. For
more information, see &ldquo;<I>Business &ndash; Exclusive Patent License Agreement between USC and our Company</I>.&rdquo; In
addition, the Amendment provides for an 4% earned royalty on Net Sales on licensed products protected by the newly added patents on
a country by-country basis. In the event that a licensed product is protected by patents from both the USC Agreement and the
Amendment, the higher royalty will apply. The Amendment also recognizes a Royalty Credit, in the event that we must obtain
additional licenses from third parties in order to sell the licensed products. The Amendment also grants us control the prosecution
of any patent application and maintenance of any patent included within Licensed Patents. We continue to be responsible for all
costs associated with the prosecution and maintenance of the licensed patents. The Amendment also changed the parties enforcement
obligations. Specifically, we shall have the first right, following consultation with USC, at our sole expense, to file suit against
any alleged infringer or in defense of any Third Party claim. Any recovery or settlement in excess of litigation costs paid to us
will be shared with USC as if it were Sublicense Revenue as defined in the USC Agreement. USC must consent to any settlement that is
detrimental to USC or USC&rsquo;s intellectual property rights. If we elect not to file suit against an alleged infringer, then upon
such election, we will be deemed to have assigned to USC all rights, causes of action, and damages resulting from the alleged
infringement. USC then has the sole right to institute suit, at its option. The parties further amended the USC Agreement on
May 30, 2023 (&ldquo;Second Amendment&rdquo;). The Second Amendment revised the license agreement to permit Sublicensees to
sublicense the patents pursuant to specific terms.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Controls
and Procedures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
company&#8217;s internal control over financial reporting is a process designed by, or under the supervision of, that company&#8217;s
principal executive and principal financial officers, or persons performing similar functions, and effected by that company&#8217;s board
of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements in accordance with GAAP. Because of its inherent limitations, internal control over financial reporting
may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness in future periods are subject to the risk
that controls may become inadequate because of changes in conditions or that the degree of compliance with policies or procedures may
deteriorate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have concluded that there were material weaknesses in internal control over financial reporting. Historically, we were a private company
that had not previously been audited and had maintained a complement of resources with various levels of accounting knowledge, experience,
and expertise that are not commensurate with our prospective financial reporting needs. These material weaknesses relate to the fact
that we do not maintain a comprehensive policies and procedures manual designed to establish internal controls over financial reporting
to reduce the risk of publishing materially misstated financial statements, as well as define responsibilities and segregate incompatible
duties to reduce the risk of unauthorized transactions. Collectively, this could result in difficulties in meeting our internal reporting
needs and our external reporting requirements and assessing the appropriate accounting treatment for various events and/or circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have initiated various remediation efforts, including the hiring of additional financial personnel/&#8203;consultants with the appropriate
public company and technical accounting expertise and other actions that are more fully described below. As such remediation efforts
are still ongoing, we have concluded that the material weaknesses have not been fully remediated. Our remediation efforts to date have
included the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have assessed our current accounting personnel, financial reporting, and information system environments and capabilities. Based on our
preliminary findings, we have found these resources and systems lacking and have concluded that these resources and systems will need
to be supplemented and/or upgraded. We have hired a Chief Financial Officer and implemented accounting procedures and controls, such
as a two-signature policy for all disbursements and vendor invoice/contract review processes. We have also instituted procedures to store
and maintain vendor invoices, contracts and agreements for efficient retrieval, and analysis of financial reporting requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
engaged external consultants with public company and technical accounting experience to facilitate accurate and timely accounting closes
and to accurately prepare and review the financial statements of NeOnc Technologies Holdings, Inc. and related footnote disclosures.
We plan to retain these financial consultants until such a time that our internal resources have been upgraded and the required financial
controls have been fully implemented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
actions that have been taken are subject to continued review, implementation, and testing by management, as well as audit committee oversight.
While we have implemented a variety of steps to remediate these weaknesses, we cannot assure you that we will be able to fully remediate
them, which could impair our ability to accurately and timely meet our public company reporting requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the assessment that our internal controls over financial reporting are not effective and that material weaknesses exist, we believe that
we have employed supplementary procedures to ensure that the financial statements contained in this filing fairly present our financial
position, results of operations, and cash flows for the reporting periods covered herein in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies and Significant Judgments and Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notes
payable</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company has elected to account for the $250,000 (original principal amount) note payable to the Chairman of the Board (Chairman) and
the $50,000 (original principal amount) note payable to a shareholder using the fair value option in accordance with the guidance contained
in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 825-10-25. The fair
value option provides an option to elect fair value as an alternative measurement for selected financial assets, financial liabilities,
unrecognized firm commitments, and written loan commitments. See Note 3 for additional information. Our Company accounted for the fair
value of the stock options issued in connection with the note payable to the Chairman as additional interest expense on the grant date,
using the same methodology to determine the fair value of the stock option as discussed in the share-based compensation policy footnote
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fair
value measurements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
ASC Topic 820, &#8220;<I>Fair Value Measurements and Disclosures</I>&#8221; (&#8220;ASC 820&#8221;), defines fair value, the methods
used to measure fair value and the expanded disclosures about fair value measurements. Fair value is the price received to sell an asset
or paid to transfer a liability in an orderly transaction between the buyer and the seller at the measurement date. In determining fair
value, the valuation techniques consistent with the market approach, income approach and cost approach shall be used to measure fair
value. ASC 820 establishes a fair value hierarchy for inputs, representing the assumptions the buyer and seller use in pricing the asset
or liability. These inputs are further defined as observable and unobservable inputs. Observable inputs are those that the buyer and
seller would use in pricing the asset or liability based on market data obtained from sources independent of our Company. Unobservable
inputs reflect our Company&#8217;s assumptions about the inputs the buyer and seller would use to price the asset or liability developed
based on the best information available in the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of our Company&#8217;s accounts receivable, accounts payable, shareholder advances, and advances from the Chairman approximate
fair value because of the short-term nature of these financial instruments. Our Company&#8217;s note payable to Chairman is reported
at fair value (see Note 3). The promissory note payable is reported at face value as the fair value difference is not material (see Note
4).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value hierarchy is categorized into three levels based on the inputs as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 &#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that our Company has
    the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices
    that are readily and regularly available in an active market, the valuation of these securities does not entail a significant degree
    of judgment.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 &#8212; Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets
    that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv)
    inputs that are derived principally from or corroborated by the market through correlation or other means.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 &#8212; Valuations based on unobservable inputs and significant to the overall fair value measurement.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Determination
of the Fair Value of Equity-Based Awards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate the fair value of stock option awards granted using the Black-Scholes option-pricing model, which uses as inputs the fair value
of our common stock and subjective assumptions we make, including expected stock price volatility, the expected term of the award, the
risk-free interest rate, and expected dividends. Due to the lack of a public market for the trading of our common stock and a lack of
company-specific historical and implied volatility data, we base the estimate of expected stock price volatility on the historical volatility
of a representative group of publicly traded companies for which historical information is available. The historical volatility is generally
calculated based on a period of time commensurate with the expected term assumption. We use the simplified method to calculate the expected
term for options granted to employees and directors. We utilize this method as we do not have sufficient historical exercise data to
provide a reasonable basis upon which to estimate the expected term. For options granted to non-employees, we utilize the contractual
term. The risk-free interest rate is based on a U.S. treasury instrument whose term is consistent with the expected term of the stock
options. The expected dividend yield is assumed to be zero, as we have never paid dividends and do not have current plans to pay any
dividends on our common stock. We determine the fair value of common stock awards based on the fair value of our common stock on the
date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
there has been no public market for our common stock, the estimated fair value of our common stock has been approved by our board of
directors, with input from management, as of the date of each award grant, considering our most recently available sale of our common
stock to independent investors and our board of directors&#8217; assessment of additional objective and subjective factors deemed relevant
that may have changed from the date of the most recent determination through the date of the grant. The additional objective and subjective
factors considered by our board of directors in determining the fair value of our common stock included the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prices of our common stock and preferred stock sold to outside investors in arm&#8217;s length transactions, if any, and the rights,
    preferences and privileges of our preferred stock as compared to those of our common stock, including the liquidation preferences
    of our preferred stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    progress of our research and development efforts, including the status of preclinical studies and planned clinical trials for our
    product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    lack of liquidity of our equity as a private company;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    stage of development and business strategy and the material risks related to our business and industry;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    valuation of publicly traded companies in the biotechnology industry, as well as recently completed mergers and acquisitions of peer
    companies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    external market conditions affecting the biotechnology industry, and trends within the biotechnology industry;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    likelihood of achieving a liquidity event, such as an IPO or a sale of our company in light of prevailing market conditions; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    analysis of IPOs and the market performance of similar companies in the biotechnology industry.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assumptions underlying our board of directors&#8217; valuation determinations represented our board&#8217;s best estimates, which involved
inherent uncertainties and the application of our board&#8217;s judgment. As a result, if factors or expected outcomes had changed or
our board of directors had used significantly different assumptions or estimates, our equity-based compensation expense could have been
materially different. Following the completion of this offering, our board of directors will determine the fair value of our common stock
based on the quoted market prices of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December&nbsp;31, 2022 and 2021, we did not have, and we do not currently have, any off-balance sheet arrangements (as
defined under SEC rules).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quantitative
and Qualitative Disclosures about Market Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not currently exposed to significant market risk related to changes in foreign currency exchange rates. However, we have contracted
with and may continue to contract with foreign vendors that are located in Europe. Our operations may be subject to fluctuations in foreign
currency exchange rates in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation
generally affects us by increasing our cost of labor. We do not believe that inflation had a material effect on our business, financial
condition or results of operations during the years ended December&nbsp;31, 2022 or 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_011"></A>BUSINESS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: justify; width: 78%"><P STYLE="text-indent: 0.5in; margin-top: 0; margin-bottom: 0">Our Company was originally
formed in Delaware in 2008 under the name NAS-ONC, Inc. and was renamed to NeOnc Technologies, Inc. in 2009. In 2015, the Delaware entity
was merged with and into NeOnc Technologies California, Inc., a California corporation, and the surviving California corporation was renamed
to NeOnc Technologies, Inc. Our Company is devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical
company, we have focused on establishing superior treatments for intracranial malignancies, i.e., aggressive cancers located in the brain.
These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, that have arrived through metastatic
spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain-localized malignancies are particularly
difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result,
these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug delivery methods to
be used in combination with novel drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; margin-top: 0; margin-bottom: 0">NeOnc&rsquo;s lead product candidate is NEO100. NEO100 is to be administered
to patients via intranasal delivery. We have completed human safety testing in a Phase 1 clinical trial and currently conducting preliminary
efficacy testing in a Phase 2a trial with recurrent malignant glioma (Grade IV, IDH1 mutant) patients. NeOnc is also developing a second
product candidate, NEO212, which has completed preclinical testing and an investigational new drug (IND) application has been filed with
the United States Food and Drug Administration (FDA) so that clinical trials can follow with patients harboring primary and secondary
malignant brain cancer types. Several additional drug candidates are in the pipeline and are undergoing preclinical development.</P></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_001.jpg" ALT="" STYLE="height: 435px; width: 375px"></FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Pipeline of NeOnc Drug Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_002.jpg" ALT="" STYLE="height: 482px; width: 750px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page --> <!-- Field: Split-Segment -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lead
Product: NEO100</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO100
is our most advanced product candidate. Its chemical structure (on the right) is based on perillyl alcohol (POH). This naturally occurring
monoterpenoid can be found as a constituent of essential oils from various botanicals, including peppermint, spearmint, lavender, bergamot,
lemongrass, sage, thyme, cherries, and others. POH has been used in cosmetics, fragrances, and some cleaning products and as an ingredient
in baked goods, frozen dairy, gelatine, puddings, beverages, and candies. Over the past three decades, POH has also been investigated
for its potential anticancer activity. Still, clinical trials with an oral POH formulation administered to cancer patients failed to
realize therapeutic expectations, and oral dosing was not well tolerated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the direction of NeOnc, a novel manufacturing and delivery pathway was developed that we believe avoids the drawbacks of oral POH and
capitalizes on its recognized anticancer properties. Using derivatization of POH with a crystalline intermediate enabled the production
of ultra-pure, pharmaceutical-grade NEO100. NEO100 received fast-track status and orphan-drug status from the FDA. We are currently expanding
our clinical trial sites and enrolling the remaining Phase 2a patients. A data read out for any patient enrolled in the clinical trial
is expected beginning six months from the enrollment of such patient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_003.jpg" ALT="" STYLE="height: 440px; width: 550px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Therapeutic
applications of NEO100 that are under development by NeOnc</U>: </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal
    delivery that we believe bypasses the blood-brain barrier (BBB), that we expect will permit delivery of drugs to the brain via cranial
    nerves I and V, thereby we expect will permit delivery of most pharmaceutics to the brain.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    high concentrations, NEO100 we are testing the use as a therapeutic for treating brain cancers.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    low concentrations, NEO100 may act as a solvent for traditional large-molecule pharmaceutics, thereby we expect will permit to bypass
    the BBB and effectively enter the brain.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intra-arterial
    delivery of NEO100 may create a temporary opening in the BBB, that we expect will permit traditional large-molecule pharmaceutics
    to pass through and enter the brain.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO100
    may be covalently conjugated with other pharmaceutics to create novel fusion compounds that we believe may permit superior BBB penetration
    ability and, higher activity against brain cancer.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Intranasal
NEO100 for the treatment of malignant glioma</U>: </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA granted NEO100 Orphan Drug Designation (ODD) for treating malignant glioma. Orphan drug designation qualifies sponsors for incentives
including: tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after
approval. Upon approval, the exclusivity granted to orphan drugs provides seven years without generic competition for the approved orphan
designation but does not prevent generic competition for other approved uses of the medicine. This means the FDA may not approve other
applications to market the same drug for the same indication for seven years (except in limited circumstances, such as showing clinical
superiority to the product with orphan drug exclusivity).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
clinical testing of NEO100, a combined Phase 1/2a trial was initiated, with the first patient enrolled in April&nbsp;2017. Phase 1 was
to establish the safety of NEO100. NEO100 is administered intranasally 4-times a day to patients with recurrent glioblastoma. These advanced
malignant tumors were treated with standard therapy, but the disease returned and was deemed untreatable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of 12 such patients were enrolled in Phase 1, which was completed in 2020. The results demonstrated that intranasal NEO100, even
at the highest dose given, was well tolerated, and there were no serious adverse events in any of the patients; i.e., there were only
minor side effects, such as a runny nose or nasal discomfort.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
from Phase 1 also suggested that intranasal NEO100 may have exerted therapeutic activity in some of these patients, although statistical
analysis was limited by the small number of 12 patients. Nonetheless, the initial analysis suggested that the efficacy of intranasal
NEO100 for heavily pre-treated, recurrent glioblastoma patients was promising. Most patients survived for more than a year, and 4 (33%)
survived for well over 24 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Phase 1 clinical trial furthermore revealed a predictive marker for best response, based on the status of the isocitrate dehydrogenase
(IDH1) gene. We found that patients harboring an IDH1 mutation in their tumor cells responded to treatment more favorably. Among the
12 patients, 5 presented with IDH1 mutant status. Among these five, four patients (80%) survived far longer than the seven patients without
IDH 1 mutation. As of February&nbsp;12, 2021, three of them were still alive four years after the recurrence of their original tumor
and initiation of NEO100 treatment. This outcome compares very favorably to historical results from other studies, where these patients
fare worse and generally succumb to the disease within less than a year</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
advantage of intranasal NEO100 is that intranasal delivery via a nebulizer device does not require surgeries, infusions, or other invasive
procedures that would require medical visits. Rather, intranasal delivery can be done conveniently at home (or while traveling) by the
patients themselves. Compared to the well-known toxicities of many chemotherapeutic agents, NEO100 was well tolerated at the doses tested
in the limited Phase 1 trial, and none of the typical side effects of other cancer pharmaceutics (nausea, debilitating fatigue, anemia,
infections, diarrhea, hair loss, etc.) were observed. It, therefore, would not be expected to lead to deterioration of quality of life
for patients (<FONT STYLE="color: Red">Sch&ouml;nthal AH et al., <I>Neuro-Oncol. Adv.</I> 3:1, 2021</FONT>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_004.jpg" ALT="" STYLE="height: 372px; width: 700px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pipeline
Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO212</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-indent: 0.5in; text-align: justify; width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO212
    (chemical structure shown on the right) was designed as a hybrid compound where NEO100 was covalently conjugated to temozolomide
    (TMZ), an alkylating agent that represents the current standard of chemotherapeutic care for patients with glioblastoma. Based on
    the recognition that amphipathic NEO100 very effectively permeates biological barriers and cellular membranes, we expected that this
    novel covalent molecule would penetrate the blood-brain barrier, enabling a double punch against malignant lesions in the brain.
    Indeed, our preclinical characterization of NEO212 in various mouse tumor models suggests that this multifunctional agent may be
    effective against a variety of cancer types. NEO212 showed activity against primary and secondary brain cancers as well as cancer
    types that were chemoresistant to other commonly used anticancer interventions.</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_005.jpg" ALT="" STYLE="height: 102px; width: 250px"></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO212
offers the intriguing feature that its anticancer activity is greater than the sum of its parts. That is: merely applying its individual
constituents, NEO100 and TMZ, as a mix of two independent compounds (akin to the conventional combination therapy mode) cannot mimic
the significantly greater cancer therapeutic impact of the conjugated hybrid molecule. We believe the toxicological studies in rodents
and dogs suggest that NEO212 was well tolerated. When administered at the same dosages as those that showed strong anticancer activity
in mouse cancer models, there were no detectable side effects in mice, rats, or dogs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effective anticancer activity of NEO212, which was tested in diverse mouse tumor models and published in over a dozen peer-reviewed reports,
along with its low toxicity profile, boded well for our IND application that was approved by the FDA. FDA approval sets the stage for
Phase 1/2a clinical trials, primarily focusing on patients with intracranial malignancies. We are designing clinical trials that evaluate
two different modes of NEO212 delivery: oral and intranasal. Oral NEO212 during Phase 1 will be administered to patients with brain malignancies
that include primary and secondary brain cancers (so-called &#8220;all comers&#8221;). Phase 2a will focus on newly-diagnosed, primary
glioblastoma. Intranasal NEO212 will be used in a Phase 1/2a trial in patients with metastatic brain cancer, i.e., where brain lesions
originated from cells that were disseminated by tumors from outside the brain, such as lung cancer, breast cancer, or melanoma. All these
patients represent a cohort in dire need of better therapies, and NEO212 holds the potential to improve their prognosis and survival
significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA granted NEO212 Orphan Drug Designation (ODD) for three different indications: (i) glioma, (ii) brain metastases from breast cancer,
and (iii) nasopharyngeal carcinoma. As stated above, if a product that has ODD subsequently receives the first FDA approval for the disease
for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA
may not approve any other applications to market the same drug for the same indication for seven years (except in limited circumstances,
such as a showing of clinical superiority to the product with orphan drug exclusivity).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
NeOnc Products Beyond NEO100 and NEO212</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO214:
    Perillyl alcohol conjugated to rolipram, an inhibitor of phosphodiesterase type 4.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO216:
    Perillyl alcohol conjugated to valproic acid, an inhibitor of histone deacetylases.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO218:
    Perillyl alcohol conjugated to 3-bromo-pyruvate, an inhibitor of cancer cell metabolism.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO400:
    Perillyl alcohol conjugated to linoleic acid, a polyunsaturated omega-6 fatty acid.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO412:
    Triple conjugation of perillyl alcohol, linoleic acid, and temozolomide.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-indent: 0.5in; text-align: justify; width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>NEO214</U>:
    </I>Covalent conjugation of perillyl alcohol (POH) to rolipram resulted in NEO214 (shown on the right). The biological activity of
    rolipram is based on its ability to selectively inhibit phosphodiesterase type 4 (PDE4) enzymes, which are known to degrade cyclic
    adenosine monophosphate (cAMP), a second messenger important in many biological processes. Studies have investigated rolipram for
    its potential usefulness as an antidepressant for autoimmune diseases, spinal cord injury, and neurological diseases, among others.
    In its novel form as a component of NEO214, PDE4-inhibitory activity is maintained. Similar to the pleiotropic cellular impact of
    its individual constituents, NEO214 has revealed several pharmacologic actions, including the ability to aggravate endoplasmic reticulum
    (ER) stress and inhibit autophagy, which represent two key cellular processes that are targets for cancer therapy. Increased ER stress
    has been found to upregulate DR5 (death receptor 5) in glioblastoma cells, and secretion of TRAIL ligands in astrocytes, leading
    to apoptosis via microenvironmental immunotherapy. In comparison to POH or rolipram as individual agents, NEO214 exerts substantially
    stronger potency, which cannot be achieved even with a mixture of POH and rolipram as individual agents; i.e., we believe the biological
    impact of the conjugated molecule, NEO214, will be greater than the sum of its parts (<FONT STYLE="color: Red">Sch&ouml;nthal AH
    et al., <I>Int. J. Mol. Sci. </I>19:277, 2018; Cho HY et al., <I>Mol. Cancer Ther.</I> 18:517, 2019; Ou M. et al., <I>Autophagy,
    </I>2023, submitted</FONT>).</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_006.jpg" ALT="" STYLE="height: 97px; width: 250px"></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-indent: 0.5in; text-align: justify; width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>NEO216</U>:
    </I>Covalent conjugation of perillyl alcohol (POH) to valproic acid (VPA) resulted in NEO216 (shown on the right). VPA acts as an
    inhibitor of histone deacetylase enzymes and voltage-gated sodium channels and affects the neurotransmitter gamma-butyric acid (GABA)
    levels. It is used clinically to treat seizures, epilepsy, bipolar disorder, and migraines. Preliminary results from preclinical
    trials indicate that it might help treat cancer. Our preclinical studies with its novel, conjugated format, i.e., NEO216, demonstrated
    its ability to inhibit migration of medulloblastoma cells, preventing craniospinal metastasis.</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_007.jpg" ALT="" STYLE="height: 112px; width: 250px"></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-indent: 0.5in; text-align: justify; width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>NEO218</U>:
    </I>Covalent conjugation of perillyl alcohol (POH) to 3-bromo-pyruvate (3BP) resulted in NEO218. 3BP is an alkylating agent that
    inhibits cancer cell metabolism. Specifically, it pyruvylates key metabolic proteins, which results in the inhibition of their enzymatic
    activities. Among its critical targets is glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a pivotal enzyme of energy-producing
    glycolysis. Consequently, NEO218 causes depletion of intracellular ATP energy pools, leading to necrotic tumor cell death. The anticancer
    potency of NEO218 could also be verified in an <I>in vivo</I> model of tumor-bearing mice. Treatment of these animals with only three
    doses of NEO218 resulted in stunted tumor development (<FONT STYLE="color: Red">Chen TC et al., <I>Cancer Lett.</I> 400:161, 2017</FONT>).</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_008.jpg" ALT="" STYLE="height: 130px; width: 250px"></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>NEO400</U>:
</I>Covalent conjugation of perillyl alcohol (POH) to linoleic acid (LA) resulted in NEO400. LA is an essential fatty acid from the polyunsaturated
omega-6 fatty acids family. It represents an essential component of the human diet and is required for prostaglandins and cell membrane
biosynthesis. Research sponsored by NeOnc showed that NEO400 may repair skin damage caused by ultraviolet radiation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>NEO412</U>:
</I>This compound was generated by covalently conjugating both perillyl alcohol (POH) and linoleic acid (LA) to temozolomide (TMZ). Our
studies in mouse melanoma models showed anticancer activity after topical application to mouse skin. NEO412, has potential as a transdermal
cancer therapeutic. Our mouse studies showed encouraging therapeutic activity against drug-resistant melanoma (<FONT STYLE="color: Red">Swenson
S et al., Oncotarget 9:37026, 2018</FONT>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Three
Drug Delivery Pathways Enabled by NEO100</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancerous
tissue in the brain is protected from systemically circulating anticancer drugs by the blood-brain barrier (BBB), which prevents the
brain entry of most pharmaceutical agents. We used NEO100 to establish three different methods of overcoming the obstacle placed by the
BBB:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Intranasal
    delivery</U>: </I> As part of a direct nose-to-brain route, this pathway allows direct brain access without interference from the
    BBB.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Monotherapy
    with NEO100</U>: </I> At higher dosages, intranasal delivery of NEO100 is in clinical testing for patients with glioblastoma.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Combination
    therapy with NEO100</U>: </I> At lower dosages, intranasal NEO100 may be used as a carrier for the co-delivery of established therapeutics
    to the brain.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Conjugated
    delivery</U>: </I> Stable conjugation of NEO100 to other therapeutic agents (such as temozolomide, creating NEO212) showed increased
    ability of the fused compound to penetrate the BBB and enter the brain.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Permeable
    delivery</U>: </I> Intra-arterial delivery of NEO100 creates temporary (up to 4 hours) openings in the BBB, that we believe may enable
    drugs (Adriamycin&reg;, Velcade&reg;, etc.) and therapeutic antibodies (Herceptin&reg;, Opdivo&reg;, etc.) to enter the brain and
    reach the tumor bed.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 78%"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe these three delivery areas (details below) hold the key to a significant shift in physicians&#8217; ability to treat brain diseases
on a previously unobtainable level. They represent pathways for potentially reliable delivery of pharma-therapeutics to the brain, potentially
mitigate problems and side effects from current methodologies, and potentially provide more effective treatment protocols to existing
pharma manufacturers for their drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO100&#8217;s
unique properties may dramatically impact pharma-therapeutic treatments for a wide variety of disease models that have been difficult
to treat and are increasing in numbers. Examples are attention-deficit/hyperactivity, Alzheimer&#8217;s disease, amyotrophic lateral
sclerosis, autism, Bell&#8217;s palsy, bipolar disorder, catalepsy, cerebral palsy, chronic pain, Creutzfeldt-Jacob disease, encephalitis,
focal epilepsy, general dementia, generalized anxiety, generalized epilepsy, glioblastoma, gliomas, Huntington&#8217;s disease, Korsakoff
syndrome, Lewy body dementia, major depressive disorder, migraines, mixed dementia, multiple sclerosis, myelopathy, Parkinson&#8217;s
disease, post-traumatic stress disorder, seizure disorder, and Tourette syndrome.</FONT></P>

</TD><TD STYLE="width: 2%; text-align: left">&nbsp;</TD><TD STYLE="text-align: right; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_009.jpg" ALT="" STYLE="height: 328px; width: 300px"></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Intranasal
Delivery of NEO100</U>: Administration of NEO100 into the nose is accomplished by a nebulizer that aerosolizes NEO100 into fine particles
that reach the olfactory mucosa and its embedded nerve endings in the nasal cavity. Uptake by these and other nerve cells enables direct
nose-to-brain transport of NEO100 so it can reach the tumor sites without interference from the BBB. This direct mode of brain-targeted
drug administration is thought to deliver higher levels of the drug to the brain tumor site as compared to oral delivery of a given drug,
also because this route of transport avoids drug breakdown in the liver. It also lowers total drug exposure to the rest of the body;
therefore, fewer side effects are expected. We believe the value of this principle was shown in the Phase 1 clinical trial with glioblastoma
patients above-mentioned (<FONT STYLE="color: Red">Sch&ouml;nthal AH et al., <I>Neuro-Oncol. Adv.</I> 3:1, 2021</FONT>). And the actual
presence of NEO100 (perillyl alcohol), along with its major metabolite, perillic acid, has been confirmed in brain tumor tissue (<FONT STYLE="color: Red">Sch&ouml;nthal
AH et al., <I>J. Neurosurg. Case Lessons</I> 4:case22215, 2022</FONT>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Ongoing
activities for intranasal delivery of NEO100</U>: </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Phase 2a component of our clinical trial is ongoing in patients with recurrent Grade IV glioma (further details are provided below).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    similar trial of intranasal NEO100 for patients with malignant meningioma is in the planning stages. Meningiomas are slow-growing
    tumors originating in the meninges, the membranous layers surrounding the brain and spinal cord.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal
    NEO100, mixed with levodopa (L-DOPA), is in the planning stages for a clinical trial in patients with Parkinson&#8217;s disease (PD).
    NeOnc&#8217;s laboratory experiments showed that intranasal NEO100 mixed with levodopa was able to reverse PD symptoms in mice. A
    Phase 1 clinical trial is planned to study the impact on human patients.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Stable
Conjugation of NEO100 to Other Therapeutic Agents</U>: Many drugs work quite well for diseases in the rest of the body but are not effective
in the brain due to the BBB obstacle. We saw promising pre-clinical results that stable conjugation of several such drugs to NEO100 increased
their ability to reach lesions located in the brain. Our product candidate, NEO212, represents the best-studied example of this concept.
Temozolomide (TMZ) is widely used to treat malignant glioma&#8212;even though it enters the brain sub-optimally, its modest therapeutic
impact is an expression of this limitation. However, when conjugated to NEO100, creating NEO212, the molecule crosses the BBB more effectively,
and in preclinical mouse models, various types of brain malignancies have shown therapeutic activity. NEO212&#8217;s IND application
was approved by the FDA in May&nbsp;2023. (Further details on NEO212 are provided below.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-indent: 0.5in; text-align: justify; width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Intra-arterial
    Injection of NEO100</U>: Our preclinical studies in mouse models with brain cancer demonstrated that intra-arterial delivery of NEO100
    safely opens the BBB up to four hours, which allows other therapeutic agents to enter the brain from the bloodstream or a catheter
    in those models. The mechanism appears to be via a transient opening of the tight junctions between the brain endothelial cells.
    Catheters can be used to deliver NEO100 to specific parts of the brain, particularly to the sites where the tumor bed is located,
    so that co-delivered pharmaceutics can immediately access the malignant tissue. In this manner, NEO100 and any other co-delivered
    therapeutic agent can unfold their instant attack against the tumor. Combined, we believe this highly targeted intervention will
    increase drug efficacy while minimizing possible side effects that might arise with systemic delivery in the rest of the body. For
    example, well-known side effects of the brain cancer agent temozolomide (TMZ) are bone marrow suppression and resulting infections.
    We believe these side effects may be avoided if the bone marrow can be spared from whole-body exposure to TMZ, as is a consequence
    of the typical oral ingestion of TMZ. This catheter-based approach is based on the co-delivery of another agent (as a mix). It is
    distinct from the above described stable conjugation of NEO100 to another compound, such as TMZ, which creates a single fusion molecule
    (as in NEO212).</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_010.jpg" ALT="" STYLE="height: 253px; width: 300px"></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Markets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 78%"><P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
        products address high growth global markets. The global central nervous system (CNS) treatment market is expected to grow at
        9.4% CAGR to reach $166.5 billion by 2028, and the global brain tumor drug market is expected to grow at CAGR of 9.0% reach $4.4
        billion by 2029, according to Fortune Business Insights.</FONT></P>
        <P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major
        market growth drivers include increased disease incidence, R&amp;D activity, and more favorable regulatory standards. There is
        also increasing FDA approval activity for novel therapy and combination therapy. Radiation therapy still accounts for 38% of
        the brain cancer treatment market, while drug treatment remains second mostly due to current inefficiencies of drug delivery,
        according to Grandview Research.</FONT></P></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_011.jpg" ALT="" STYLE="height: 350px; width: 407px"></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_012.jpg" ALT="" STYLE="height: 350px; width: 186px"></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 78%"><P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
        also address the malignant glioblastoma multiforme (GBM) treatment market. The GBM drug market is expected to grow at 12.7% CAGR
        to $2.3 billion by 2029, according to iHealthcare Analyst, with the market being driven by rising geriatric population, growing
        incidence cases, and a strong pipeline of new products.</FONT></P>
        <P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GBM
        accounts for up to 54% of gliomas and 16% of all primary brain cancers, according to research published in the journal, <I>Glioblastoma</I>.
        By creating a more effective delivery mechanism for GBM drug therapy, we believe we can significantly impact market demand in
        this sector.</FONT></P>
        <P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
        on our 3-year treatment model (per chart, below), we estimate that the near-term addressable market in U.S. alone for the NEO100
        treatment of only IDH1, GMB and Non-GMB Gliomas totals more than $1.5 billion. For our POH platform technology for metastatic
        brain tumor, Alzheimer&#8217;s, Parkinson&#8217;s and Epilepsy (combined), we estimated our near-term addressable market is more
        than $3.0 billion based on similar 3-year treatment models.</FONT></P> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify"><P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
        goal is to disrupt the cancer therapeutic landscape by developing novel therapeutic approaches leveraging dual approaches of
        novel drug delivery methods in combination with novel drug candidates that result in superior therapeutic impact with low side
        effects.</FONT></P>
        <P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
        following five clinical applications of our drugs are at different stages of preclinical or clinical development:</FONT></P></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD ROWSPAN="13" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_013.jpg" ALT="" STYLE="height: 609px; width: 450px"></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal delivery of
    NEO100 to patients with IDH mutant malignant glioma (Phase 2a clinical trial has started).</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal delivery of
    NEO212 to patients with brain metastasis (IND approved).</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal delivery of
    NEO100 alone, and in combination with doxorubicin for pediatric brain tumors (IND is in the process of being prepared).</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal co-delivery
    of NEO100 with levodopa for Parkinson&rsquo;s disease (preclinical stage).</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intra-arterial delivery
    of NEO100 to open the patient&rsquo;s blood-brain barrier, allowing brain entry of BBB-impermeable pharmaceuticals or biologics (preclinical
    stage).</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oral NEO212 for primary
    brain cancer, including glioblastoma (IND approved).</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>





<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Details:
<B>1. </B>Intranasal delivery of NEO100 to patients with IDH mutant malignant glioma (Phase 2a clinical trial has started)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO100
is our most advanced product candidate. Its chemical structure (<B>Figure 1</B>) is based on the natural compound perillyl alcohol (POH).
We have developed a novel manufacturing and delivery pathway that avoided the drawbacks of oral POH and capitalized on its recognized
anticancer properties. The FDA granted NEO100 Orphan Drug Designation (ODD) for treating malignant glioma.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_014.jpg" ALT="" STYLE="height: 175px; width: 305px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
1: Chemical structure of NEO100</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeOnc
sponsored a Phase 1 clinical trial, where NEO100 was administered to patients with recurrent glioblastoma. All enrolled patients had
already undergone standard therapy for this disease, consisting of radiation treatment combined with chemotherapy. Still, this standard
therapy had stopped working, and patients were no longer benefiting from it. At this stage of the re-emerging glioblastoma disease, there
is no clear clinical recommendation for specific further Treatment because effective treatments do not exist for this patient group.
Rather, the prognosis is dismal, and the average median survival is only 6-9 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
enrollment in our study, patients received intranasal NEO100 four times daily, using a nebulizer and nasal mask. After initial instructions
by a nurse, patients can self-administer this treatment at the convenience of their home. Four cohorts of 3 patients each received the
following dosages: 96 mg/dose (384 mg/day), 144 mg/dose (576 mg/day), 192 mg/dose (768 mg/day), and 288 mg/dose (1152 mg/day). Completion
of 28 consecutive days of treatment was recorded as one cycle. Adverse events were documented, and radiographic response <I>via</I> RANO
criteria was evaluated every two months. Progression-free and overall survival were determined after 6 and 12 months, respectively (PFS-6,
OS-12).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trial was completed in 2020, and after peer review, the results obtained from these 12 patients were published in 2021 (<FONT STYLE="color: Red">Sch&ouml;nthal
AH et al., <I>Neuro-Oncology Advances</I> 3(1):1-12, 2021</FONT>). Data analysis showed that intranasal NEO100 was well tolerated at
all four dose levels, and even at the highest dose levels, no severe adverse events were noted. Minor side effects included a runny nose
or nasal discomfort. PFS-6 was 33%, OS-12 was 55%, and the average median survival was 15 months (<B>Figure 2</B>, left panel). Four
patients (33%) survived &gt;24 months. Thus, compared to historical controls and what is commonly observed in clinical practice, average
patient survival in our clinical trial with these 12 patients was improved. As important, there were none of the typically harsh side
effects of many conventional chemotherapies, such as nausea, debilitating fatigue, anemia, infections, diarrhea, hair loss, etc.). Treatment
with intranasal NEO100, therefore, does not lead to deterioration of quality of life for patients. <I>Id</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
2: Survival of all 12 patients (left) and survival in relation to IDH status (right).</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_015.jpg" ALT="" STYLE="height: 205px; width: 650px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">from:
<FONT STYLE="color: Red">Sch&ouml;nthal AH et al., <I>Neuro-Oncology Advances</I> 3(1):1-12, 2021</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Detailed
further analysis of our Phase 1 study revealed that patients who appeared to benefit the most from intranasal NEO100 were those whose
tumor harbored a mutation in the gene for isocitrate dehydrogenase 1 (IDH1) (<B>Figure 2</B>, right panel). In the five patients with
this mutation, 4 (80%) survived a minimum of 24 months while being treated with intranasal NEO100. In contrast, seven patients without
this mutation succumbed to disease earlier&#8212;although their average median survival of 11 months was still longer than what would
have been expected based on historical experience in the clinic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the positive experience and highly encouraging results from our Phase 1 clinical study, a Phase 2a continuation of intranasal NEO100
was started in 2021 for high-grade glioma patients with IDH1 mutations. As with Phase 1, the trial is being conducted as a multicenter
study. A total of 12 institutions will be recruited to enroll 31 patients for our Phase 2a trial, of which five have been recruited.
The mechanism by which these IDHI mutant patients have a specific survival advantage in response to NEO100 is the subject of our current
laboratory investigations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Details:
<B>2.</B> Intranasal delivery of NEO212 to patients with brain metastasis (IND submission scheduled for late 2023)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO212
is a hybrid compound where NEO100 is covalently conjugated to temozolomide (TMZ) via a carbamate bridge (<B>Figure 3</B>). While TMZ
has been widely used as the standard of care for the treatment of glioblastoma, it does, in fact, not penetrate the BBB very effectively;
unsurprisingly, its clinical efficacy is relatively modest. Also, its activity is even further reduced when applied to tumors that are
positive for O6-methylguanine methyltransferase (MGMT). This DNA repair protein protects tumor cells from killing by TMZ. Our extensive
preclinical studies have established that NEO212 is potently able to overcome these drawbacks and exert its activity even against tumor
cells that are positive for MGMT. The FDA granted NEO212 Orphan Drug Designation (ODD) for three different indications: (i) glioma, (ii)
brain metastases from breast cancer, and (iii) nasopharyngeal carcinoma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
3: Chemical structure of NEO212: NEO100 conjugated to temozolomide.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_016.jpg" ALT="" STYLE="height: 175px; width: 367px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO212
was initially designed as a therapeutic molecule with enhanced capability of crossing the blood-brain barrier to address the urgent clinical
need for better treatments of intracranial malignancies, such as glioblastoma and brain-metastatic lesions from peripheral cancers. In
mouse models we showed that NEO212 enters the brain more effectively than TMZ. We believe additional beneficial features of this compound
that can be summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO212
    exerts greater anticancer activity than the sum of its parts; i.e., a mere combination of the individual components, TMZ plus POH
    at equimolar ratios, is unable to mimic the superior anticancer activity of the conjugated compound, both <I>in vitro</I> and in
    mouse tumor models <I>in vivo</I> (<FONT STYLE="color: Red">Chen TC et al., <I>Molecular Cancer Therapeutics </I>13:1181, 2014; Chen
    TC et al., <I>Cancer Letters</I> 358:144, 2015; Chen TC et al., <I>Journal of Biomedical Sciences</I> 22:71, 2015; Cho HY et al.,
    <I>Molecular Cancer Therapeutics </I>13:2004, 2014; Jhaveri N et al., <I>Cancer Letters</I> 371:240, 2016; Marin-Ramos NI et al.,
    <I>Oncoscience </I>5:148, 2018; Marin-Ramos NI et al., <I>Molecular Cancer Therapeutics </I>17:625, 2018</FONT>).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    mouse tumor models, NEO212 displayed intracranial therapeutic activity not only against glioblastoma (<FONT STYLE="color: Red">Cho
    HY et al., <I>Molecular Cancer Therapeutics </I>13:2004, 2014; Jhaveri N et al., <I>Cancer Letters</I> 371:240, 2016; Marin-Ramos
    NI et al., <I>Oncoscience </I>5:148, 2018; Marin-Ramos NI et al., <I>Molecular Cancer Therapeutics </I>17:625, 2018; Minea RO et
    al., <I>PLoS One</I> 15(9):e0238238, 2020</FONT>) but also against brain-metastatic breast cancer xenografts (<FONT STYLE="color: Red">Chen
    TC et al., <I>Molecular Cancer Therapeutics </I>13:1181, 2014</FONT>) (<B>Figure 4</B>).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Besides
    intracranial tumors, NEO212 was also effective against peripheral cancers, including subcutaneous melanoma (<FONT STYLE="color: Red">Chen
    TC et al., <I>Cancer Letters</I> 358:144, 2015</FONT>), nasopharyngeal carcinoma (<FONT STYLE="color: Red">Chen TC et al., <I>Journal
    of Biomedical Sciences </I>22:71, 2015; Xie L et al., <I>Oncotarget</I> 7:1651, 2016</FONT>) ovarian carcinoma (<FONT STYLE="color: Red">Song
    X et al., <I>Journal of Experimental and Clinical Cancer Research</I> 38:239, 2019</FONT>), lung cancer (<FONT STYLE="color: Red">Song
    X et al., <I>Cell Death &amp; Disease</I> 9:202, 2018; Song X et al., <I>Scientific Reports</I> 6:22762, 2016; Chang M et al., <I>Journal
    of Experimental and Clinical Cancer Research </I>37:250, 2018</FONT>), cutaneous T-cell lymphoma (<FONT STYLE="color: Red">Silva-Hirschberg
    C et al., <I>Therapeutic Advances in Medical Oncology</I> 11:1758835919891567, 2019</FONT>), and cytosine arabinoside-resistant leukemia
    (<FONT STYLE="color: Red">Sch&ouml;nthal AH et al., <I>Cancers </I>13(14):3385, 2021</FONT>).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    striking anticancer activity of NEO212 was also documented with the use of primary patient samples, including glioblastoma stem cells
    (<FONT STYLE="color: Red">Jhaveri N et al., <I>Cancer Letters</I> 371:240, 2016; Marin-Ramos NI et al., <I>Oncoscience</I> 5:148,
    2018</FONT>) as well as xenografts of a variety of TMZ-resistant glioma and melanoma lines, where drug resistance was based on different
    molecular mechanisms (<FONT STYLE="color: Red">Chen TC et al., <I>Cancer Letters</I> 358:144, 2015; Cho HY et al., <I>Molecular Cancer
    Therapeutics </I>13:2004, 2014</FONT>).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    all tested in <I>vivo</I> models, NEO212 exerted therapeutic activity in the range of 5-50 mg/kg (once per day, repeat dosing). This
    dose range was well tolerated by mice, rats, and dogs and did not result in detectable signs of toxicity. Thus, despite exerting
    potent cancer therapeutic activity, NEO212 was very well tolerated and displayed a reassuringly wide therapeutic window.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
4: Representative result showing survival of mice with brain-metastatic breast cancer.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_017.jpg" ALT="" STYLE="height: 231px; width: 450px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">source:
<FONT STYLE="color: Red">Chen TC et al., <I>Molecular Cancer Therapeutics </I>13:1181, 2014</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The strong anticancer activity of NEO212, which was consistently recapitulated
in a variety of preclinical tumor models, along with its low toxicity profile, boded well for our IND application to the FDA which was
approved in May&nbsp;2023. FDA approval sets the stage for Phase 1/2a clinical trials, primarily focusing on patients with intracranial
malignancies (metastatic and malignant primary brain cancer types). Although NEO212 also shows potent activity against peripheral cancer
types (melanoma, lung cancer, breast cancer, and others), our first clinical trial will focus on patients with aggressive brain cancer
types because the clinical need is the greatest here; no effective therapies exist. Because NEO212 was designed for superior blood-brain
barrier penetration, we expect it to reveal its most valuable impact in patients with brain malignancies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Details:
<B>3.</B> Intranasal co-delivery of NEO100 with levodopa for Parkinson&#8217;s disease (preclinical stage)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
preclinical research in mouse brain tumor models discovered that intranasal delivery of NEO100 supported nose-to-brain transport of NEO100
itself and enabled co-delivered pharmaceutics to be carried along this axis and enter the brain as well. For example, intranasal co-delivery
of NEO100 with bortezomib (an anticancer drug marketed under the trade name Velcade) enabled bortezomib to enter the mouse&#8217;s brain
resulting in activity against brain cancer. Without NEO100, bortezomib could not enter the brain (<FONT STYLE="color: Red">Wang
W et al., <I>Journal of Neurosurgery</I> 132(3):959, 2019</FONT>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Having
shown preclinical results of NEO100&#8217;s ability to act as a vehicle to carry other pharmaceutics into the brain, we considered its
application to neurological diseases, such as Parkinson&#8217;s disease (PD) or Alzheimer&#8217;s disease (AD), which are increasing
in numbers as the U.S. population is aging. PD Patients are treated with levodopa (L-Dopa) pills, which must be dosed precisely. These
pills have common side effects, such as hypotension, nausea, confusion, and dyskinesia. Therefore, intranasal delivery with direct nose-to-brain
transport would be highly desirable because it is expected to achieve better brain-directed delivery without exposing the entire body
to the drug, minimizing the undesirable side effects. As well, smaller doses can be given. In our work, we used mice with PD-type lesions
in their brains and co-administered NEO100 together with L-Dopa by intranasal delivery. As we predicted, intranasal co-delivery of NEO100
and L-Dopa suppresses PD symptoms in these mice. Intranasal delivery of L-Dopa without the added NEO100 did not achieve this beneficial
effect (<B>Figure 5</B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
5: Mixture of NEO100 with L-Dopa (red underline), when given intranasally, restores healthy brain function of PD in mice as effectively
as subcutaneous injection of apomorphine (blue underline).</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_018.jpg" ALT="" STYLE="height: 615px; width: 550px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From:
<FONT STYLE="color: Red">Wang W et al., <I>manuscript in preparation.</I></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
health benefits of this approach in the mice were analyzed by determining the physical activity of the mice, in particular their ability
to rotate to one side. Untreated PD mice are sick and unable to perform rotations, which is a symptom of the disease. But mice receiving
intranasal NEO100 combined with L-Dopa are again physically active and perform rotations (bar graphs of mice in <B>Figure 5</B> with
the label underlined in red). The figure also shows that mice injected with apomorphine recover from PD (label underlined in blue). However,
compared to the ease of intranasal delivery, injections are invasive and do not support brain-targeted delivery due to the resulting
systemic distribution of the injectate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Details
to <B>4.</B> Intra-arterial delivery of NEO100 to open the patient&#8217;s blood-brain barrier will allow brain entry of BBB-impermeable
pharmaceuticals or biologics (preclinical stage)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
intranasal applications of NEO100 exploit direct nose-to-brain access routes and thereby circumvent the obstacle placed by the blood-brain
barrier (BBB), an intra-arterial path of administering NEO100 has provided evidence that it also can directly confront the BBB and &#8220;open&#8221;
it, diminishing its barrier function to enable mostly unrestricted permeation of otherwise BBB-impermeable compounds. We established
this procedure, characterized it in preclinical mouse tumor models, and demonstrated that it has clear advantages over the currently
established clinical method of opening the BBB with mannitol (<FONT STYLE="color: Red">Wang W et al., <I>Neuro-Oncology</I> 23(1):63,
2021</FONT>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
used mouse models of brain-metastatic breast cancer positive for human epidermal growth factor receptor 2 (HER2). In humans, HER2+ breast
cancer is usually treated with trastuzumab (Herceptin), a humanized monoclonal antibody, and this treatment often shows success. However,
HER2+ breast cancer has a propensity to metastasize to the brain, and trastuzumab does not work well because it cannot effectively penetrate
the BBB. Our work has established that intra-arterial NEO100 safely and reversibly opens the BBB of mice for a few hours, allowing a
brain influx of therapeutic agents that are circulating in the bloodstream. In the case of mice with HER2+ metastases in their brains,
a single application of BBB opening with NEO100 enabled brain influx of trastuzumab that had been given by intravenous injection, and
this approach resulted in the cure of several of the animals (<B>Figure 6</B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
6: BBB opening by intra-arterial (IA) NEO100 achieves cure of several brain-metastatic mice treated with intravenous (IV) trastuzumab.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_019.jpg" ALT="" STYLE="height: 362px; width: 500px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">from:
<FONT STYLE="color: Red">Wang W et al., <I>Neuro-Oncology</I> 23(10):1656, 2021</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
cancer therapy breakthroughs introduced immune checkpoint-inhibitory antibodies as novel tools to treat cancer. However, as with other
antibody-based therapies, these biologics&#8217; applications are limited due to the BBB, which prevents their brain entry and minimizes
their usefulness against brain-localized malignancies, i.e., brain metastases and primary malignant brain tumors such as glioblastoma.
Therefore, we applied our BBB opening method with intra-arterial NEO100 to a glioblastoma mouse model, where mice received a one-time
dose of a checkpoint-inhibitory antibody within the mixture of intra-arterially applied NEO100. The result was striking and showed that
all six mice treated in this fashion were cured of their brain cancer (blue line in <B>Figure 7</B>). In contrast, all other mice died
within 4-7 weeks, including those treated with checkpoint-inhibitory antibodies in the absence of NEO100.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
7: BBB opening by intra-arterial (IA) NEO100 achieves cure for all glioblastoma mice treated with checkpoint-inhibitory antibodies.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_020.jpg" ALT="" STYLE="height: 338px; width: 550px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From:
<FONT STYLE="color: Red">Wang W et al., <I>Journal of Neurosurger</I>y, Feb 3:1-9, 2023 [online ahead of print]<I>.</I></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
recent breakthroughs in cancer therapy include the production of CAR T cells, where T lymphocytes are being modified to harbor a chimeric
antigen receptor (CAR). While such cells have yielded impressive therapeutic advances, their activity&#8212;similar to the case of therapeutic
antibodies&#8212;is limited by their poor entry into the brain; as a result, they do not work well for brain-localized diseases. Therefore,
we applied our BBB opening method with intra-arterial NEO100 to a mouse model with intracranial lymphoma (lymphoma in the brain), where
mice received a one-time dose of intravenous lymphoma-targeted CAR T cells, along with BBB opening by intra-arterial NEO100. The result
was striking and showed that all six mice treated in this fashion were cured of their brain lymphoma (blue line in <B>Figure 8</B>).
In comparison, most mice that received CAR T cells without BBB opening with intra-arterial NEO100 died within the first three weeks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
8: BBB opening by intra-arterial (IA) NEO100 achieves cure of all brain-lymphoma mice treated with lymphoma-directed CAR T cells.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_021.jpg" ALT="" STYLE="height: 299px; width: 550px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From:
<FONT STYLE="color: Red">Wang W et al., <I>manuscript in preparation.</I></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Details
to <B>5.</B> Oral NEO212 for advanced cancer types, including leukemia (preclinical stage)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO212
was initially designed as a therapeutic molecule with enhanced capability of crossing the blood-brain barrier to address the urgent clinical
need for better treatments of intracranial malignancies, such as glioblastoma and brain-metastatic lesions from peripheral cancers. And
indeed, its therapeutic impact against brain-localized cancers could be convincingly and consistently documented in our mouse tumor models.
At the same time, however, we also noted NEO212&#8217;s effective potency, along with low toxicity, against cancer types outside the
brain, such as lung cancer, melanoma, ovarian cancer, leukemia, and others (<FONT STYLE="color: Red">Chen TC et al., <I>Cancer Letters
</I>358:144, 2015; Chen TC et al., <I>Journal of Biomedical Sciences</I> 22:71, 2015; Xie L et al., <I>Oncotarget</I> 7:1651, 2016; Song
X et al., <I>Journal of Experimental and Clinical Cancer Research</I> 38:239, 2019; Song X et al., <I>Cell Death &amp; Disease</I> 9:202,
2018; Song X et al., <I>Scientific Reports</I> 6:22762, 2016; Chang M et al., <I>Journal of Experimental and Clinical Cancer Research
</I>37:250, 2018; Silva-Hirschberg C et al., <I>Therapeutic Advances in Medical Oncology</I> 11:1758835919891567, 2019; Sch&ouml;nthal
AH et al., <I>Cancers </I>13(14):3385, 2021</FONT>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
the most striking examples of NEO212&#8217;s therapeutic impact on peripheral cancer types, as established in mouse tumor models, is
its effect on leukemia, particularly drug-resistant acute myeloid leukemia (AML), which in daily clinical practice remains very difficult
to treat and often is fatal. First-line treatment of AML usually includes intravenous cytarabine. Still, often the tumor becomes resistant
to this drug, which precludes further cytarabine treatment and generally requires subsequent hematopoietic stem cell transplantation.
In our experiments, treatment of mice harboring cytarabine-resistant AML with NEO212 proved quite effective and very well tolerated.
Oral NEO212 was administered once daily for five days, followed by 7-14 days of a treatment holiday; this cycle was repeated twice more
for three cycles in total (green arrows in <B>Figure 9</B>); there were no further treatments after week 8. All mice in this treatment
group survived beyond 200 days, which can be considered a curative outcome (<B>Figure 9</B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
9: Treatment of mice harboring cytarabine-resistant AML with NEO212 results in the cure of all treated animals.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_022.jpg" ALT="" STYLE="height: 212px; width: 550px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">from:
<FONT STYLE="color: Red">Sch&ouml;nthal AH et al., <I>Cancers</I> 13(14):3385, 2021.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the therapeutic activity of NEO212 against a variety of tumor types studied in mouse tumor models, the initial Phase 1 clinical safety
study will be conducted with patients harboring brain cancers, including primary brain cancers such as recurrent glioblastoma and secondary
brain cancers (metastatic) derived from lung, breast, and melanoma. NeOnc is in the process of submitting the IND application for this
trial, and the trial will start as soon as the FDA has granted IND. Phase 1 is expected to last up to two years, followed by Phase 2,
which is also expected to last about two years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extending
the above, we are also designing a Phase 1/2a trial of oral NEO212 that will specifically focus on patients with newly-diagnosed glioblastoma.
With current standard of care, these patients have an average life expectancy of only 15 months after initial diagnosis. Based on the
encouraging results from our extensive preclinical studies, we expect that NEO212 will be able to provide superior benefit and significantly
improve upon the poor prognosis of this patient cohort. Phase 1 of our trial is designed to establish a well-tolerated dosing regimen
for oral NEO212 (in combination with radiotherapy), and Phase 2a will investigate its therapeutic efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competitive
Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the key elements that will support our market success include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compelling
    lead product opportunity, with NEO100 currently in Phase 2 trials.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensed
    large patent portfolio for NEO100 with currently issued patents expiring between 2030-2038.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
    in additional multiple indications in underserved markets with large patient population.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
    peer-reviewed published research articles on NEO100 prove its viability as both a delivery vehicle for chemotherapeutics as well
    as ability to effect GBM treatment.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also believe that our NEO100 outperforms the current standard of care for recurrent high-grade gliomas across key treatment factors,
including no surgery or radiation is required, bone marrow is unaffected, normal wound healing occurs, no significant systemic side-effects,
and treatment is relatively easy to-administer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>NEO100
vs. Current Standard of Care for Recurrent High-Grade Gliomas</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_023.jpg" ALT="" STYLE="height: 302px; width: 750px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Peer-Reviewed
Published Research</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_024.jpg" ALT="" STYLE="height: 460px; width: 750px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Future
Growth Drivers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate a number of our goals and plans will support our long-term growth, with some supported by additional high-growth global markets:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercial
    launch of NEO100 following FDA market approval.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    trials &amp; FDA approval of other POH compounds in our product pipeline.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advance
    NEO100 pediatric indication.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently
    developing several additional proprietary chemotherapy agents that have demonstrated positive effects in laboratory tests on various
    types of cancers, i.e., NEO212 oral and intranasal delivery for primary and metastatic brain cancer.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatments
    for other CNS diseases and disorders based on our POH technology, such as Alzheimer&#8217;s, Parkinson&#8217;s and Epilepsy.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_025.jpg" ALT="" STYLE="height: 350px; width: 675px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manufacturing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate manufacturing facilities for the production of NEO100 nor do we plan to develop our own manufacturing operations
in the foreseeable future. We currently depend on third party contract manufacturers for all of our required raw materials, active pharmaceutical
ingredient and finished products for our preclinical and clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers
of our products are required to comply with applicable FDA manufacturing requirements contained in the FDA&#8217;s current good manufacturing
practice standards (&#8220;cGMP&#8221;) regulations. cGMP regulations require among other things, quality control and quality assurance
as well as the corresponding maintenance of records and documentation. Pharmaceutical product manufacturers and other entities involved
in the manufacture and distribution of approved pharmaceutical products are required to register their establishments with the FDA and
certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with
cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality
control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer,
or holder of an approved NDA/NDA, including withdrawal of the product from the market. In addition, changes to the manufacturing process
generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new
indications and additional labeling claims, are also subject to further FDA review and approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
Property</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has exclusively licensed a large worldwide patent portfolio from USC consisting of both issued patents and pending patent applications
related to NEO100, NEO212 and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
In the United States, the Company has exclusive rights to 28 issued patents and 14 pending patent applications. Internationally, the
Company has 65 patents issued and 28 patents applications pending.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The patent families of our product candidates are briefly described
in the table below. All patents are exclusively licensed to us from USC. Patent Term Extension (PTE) may be available on certain patents
after product approval.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid; text-align: left; width: 12%; padding-left: 5.5pt; font-size: 10pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Product
    Candidate</B></FONT></TD>
    <TD STYLE="text-align: center; width: 30%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.5pt; font-size: 10pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Title
    [description]</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 12%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>US
    Application #</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 12%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>US
    Patent</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 12%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.55pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Expiration
    Date</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 22%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Foreign
    Counterparts</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO100</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">Pharmaceutical Compositions Comprising Monoterpenes</P>

    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">[Ultra Pure]</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">13/040,059</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">13/939,834</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">14/817,286</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">14/843,097</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">15/040,002</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">15/220,135</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">16/575,587</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">17/749,293</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">8,507,734</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">9,133,085</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">9,480,659</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">9,498,448</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">9,700,524</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">10,457,618</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">10,899,691</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">pending</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">8/29/2031</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">6/5/2031</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3/3/2031</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3/3/2031</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3/3/2031</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3/3/2031</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3/3/2031</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">pending</P>
    </TD>
    <TD STYLE="border-right: black 1pt solid; text-align: left; border-bottom: black 1pt solid; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Canada, China, China, EU (France, Germany, United Kingdom, Ireland, and Italy)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">NEO212</P>
    </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">Pharmaceutical Compositions Comprising POH Derivatives</P>

    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">[POH conjugated to temozolomide (TMZ)]</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">13/566,731</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">14/455,371</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">13/818,972</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">15/408,866</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">8,916,545</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">9,580,372</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">9,499,461</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">10,092,562</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">8/26/2031</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">8/26/2031</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">8/26/2031</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">8/26/2031</P>
    </TD>
    <TD STYLE="border-right: black 1pt solid; text-align: left; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil, China, EU (Germany, Spain, France, United Kingdom Switzerland, Ireland, Italy, Netherlands, Sweden), Japan, Hong Kong</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO 214</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">Pharmaceutical Compositions Comprising POH Derivatives</P>

    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">[POH conjugated to rolipram]</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">16/123,729</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">16/388,535</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">17/306,167</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">11,077,104</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">11,013,804</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">pending</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">8/26/2031</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">8/26/2031</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">pending</P>
    </TD>
    <TD STYLE="border-right: black 1pt solid; text-align: left; border-bottom: black 1pt solid; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Japan, EU (Spain, France, United Kingdom, Ireland, Italy, Netherlands, Sweden)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO 216</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">Pharmaceutical Compositions Comprising Poh Derivatives and
    Methods of Use</P>

    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">[POH conjugated to valproic acid]</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">16/606,520</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">18/150,933</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">11,559,508</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">pending</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">11/24/2038</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">pending</P>
    </TD>
    <TD STYLE="border-right: black 1pt solid; text-align: left; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">China, EU</P>

    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">(pending in both)</P>
    </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO 218</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">A Perillyl Alcohol-3-Bromopyruvate Conjugate and Methods
    of Treating Cancer</P>

    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">[POH conjugated to 3- Bromopyruvate]</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">16/465,081</FONT></TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,858,305</FONT></TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.55pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">11/29/2037</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; text-align: left; border-bottom: black 1pt solid; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">China, EU, Japan (pending in all)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO 400</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">Pharmaceutical Compositions Comprising POH Derivatives</P>

    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">[POH conjugated with linoleic acid (LA)]</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">17/251,452</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">17/313,258</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">17/573,693</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">pending</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">pending</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">pending</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">pending</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">pending</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">pending</P>
    </TD>
    <TD STYLE="border-right: black 1pt solid; text-align: left; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">China, EU</P>

    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">(pending in both)</P>
    </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO 412</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">Pharmaceutical Compositions Comprising Perillyl Alcohol Derivatives</P>

    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">[Triple conjugation of perillyl alcohol, linoleic acid, and
    temozolomide]</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">15/041,743</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">16/126,586</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">9,522,918</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">10,696,680</P>
    </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2/11/2036</P>

    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2/11/2036</P>
    </TD>
    <TD STYLE="border-right: black 1pt solid; text-align: left; border-bottom: black 1pt solid; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Australia, China, EU (Germany, France, United Kingdom, Ireland), Japan</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the
United States and other countries with respect to our technology, including NEO100, NEO212 and our other product candidates. We also
rely in part on trade secret, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third
parties, all of which offer only limited protection. We seek to protect our proprietary position by filing and prosecuting patent applications
in the United States and abroad related to our technology and product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions
and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial
value of our licensed patents and any patents we own are highly uncertain. The steps we and our licensor have taken to protect our proprietary
rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights,
both inside and outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the examination process may require us to narrow the claims for our licensed pending patent applications, which may limit the scope of
patent protection that may be obtained if these applications issue. Our pending licensed and future patent applications may not result
in patents being issued that protect our product candidates, in whole or in part, or which effectively prevent others from commercializing
competitive product candidates. The scope of a patent may also be reinterpreted after issuance. The rights that may be granted under
our issued patents may not provide us with the proprietary protection or competitive advantages we are seeking. Even if patent applications
issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing
with us or otherwise provide us with any competitive advantage. If we are unable to obtain and maintain patent protection for our technology
or for NEO100 or our other product candidates, or if the scope of the patent protection obtained is not sufficient, our competitors could
develop and commercialize products similar or superior to ours in a non-infringing manner, and our ability to successfully commercialize
NEO100 or our other product candidates and future technologies may be adversely affected. It is also possible that we will fail to identify
patentable aspects of inventions made in the course of our development and commercialization activities before it is too late to obtain
patent protection on them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain,
enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. Although we enter into
non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and
development output, such as our employees, collaborators, and other third parties, any of these parties may breach the agreements and
disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. It is also possible
that we will fail to identify patentable aspects of our research and development efforts in time to obtain patent protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
licensed pending applications cannot be enforced against third parties practicing the inventions claimed in such applications unless
and until a patent issues from such applications with a claim that covers infringing third-party activity. Because the issuance of a
patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we license from third parties
or own in the future may be challenged in the courts or patent offices in the United States and abroad, including through opposition
proceedings, derivation proceedings, post-grant review, <I>inter partes </I>review, interference proceedings or litigation. Such proceedings
may result in the loss of patent protection, the narrowing of claims in such patents or the invalidity or unenforceability of such patents,
which could limit our ability to stop others from using or commercializing similar or identical products, or limit the duration of the
patent protection for our technology. Protecting against the unauthorized use of our patented inventions, trademarks and other intellectual
property rights is expensive, time consuming, difficult and in some cases may not be possible. In some cases, it may be difficult or
impossible to detect third-party infringement or misappropriation of our intellectual property rights, even in relation to issued patent
claims, and proving any such infringement may be even more difficult. If we are unable to obtain, maintain, and protect our intellectual
property our competitive advantage could be harmed, and it could result in a material adverse effect on our business, financial condition,
results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exclusive Patent License Agreement between
USC and our Company</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March&nbsp;9, 2009, Nas-Onc,
Inc. (k/n/a NeOnc Technologies, Inc). entered into an exclusive, worldwide license agreement with USC, pursuant to which USC granted us
a license to use certain patents and patent applications for the treatment and therapies of disease symptoms in mammals(the &ldquo;USC
Agreement&rdquo;). The license is exclusive except for the rights granted to the US government pursuant to the Bayh-Dole Act and the right
of USC and other non-profit academic research institutions to practice and improve the licensed patents for educational and research purposes.
Pursuant to the USC Agreement, we (1) paid USC an upfront royalty payment of $20,000, (2) granted USC common stock (as amended and described
below), (3) will pay USC an earned royalty of 2% of Net Sales (as that term is defined in the USC Agreement), and (4) has paid and will
continue to to pay annual maintenance royalties of: $5,000 due January&nbsp;1, 2011, $5,000 due January&nbsp;1, 2012, $10,000 due January&nbsp;1,
2013, and $20,000 due January&nbsp;1 thereafter. Annual maintenance royalties paid to USC are creditable toward earned royalties. We are
also responsible for paying all reasonable patent expenses incurred by USC for filing prosecution and maintaining the licensed patents.
In the event of suspected patent infringement, the parties may agree to jointly institute suit, wherein the parties will share equally
all costs and any recovery, with control of such lawsuit being by agreement between us and USC. Absent an agreement to jointly institute
a suit, USC has the sole right to institute suit, at its option, where USC will bear the cost of such litigation and retain all recovery.
In the event that USC does not institute the lawsuit, we may bring suit, at its option, and bear all such costs. Any recovery obtain by
us must be shared with USC, after litigation costs reimbursement, as royalties on Net Sales for the remaining recovery. These rights and
obligations were changed pursuant to the Amendment discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The USC Agreement is sublicensable
subject to the same terms, except that (1) sublicensees may not grant sublicenses, (2) the earned royalty may be increased as to sublicensees,
(3) the sublicense reverts to USC in the event the USC Agreement is terminated as to us and, (4) additional issue and maintenance fees
are owed to USC for each sublicense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may challenge
the licensed patents upon 90 days notice and payment of all royalties due. If the Company is unsuccessful in its challenge, the earned
royalty will thereafter be increased by a factor of three.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term of the USC Agreement
extends until the last to expire of the licensed patents. The USC Agreement may be terminated by either party upon 30 days notice or upon
material breach, wherein the breaching party is permitted 30 days to remedy such breach. USC may terminate immediately if (1) we attempt
to sublicense, transfer or assign its rights contrary to the terms of the agreement, (2) we do not maintain the required insurance coverage,
or (3) we are determined to be insolvent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The parties amended the USC
Agreement on April&nbsp;5, 2023 (&ldquo;Amendment&rdquo;). The Amendment added NeOnc Technologies Holdings, Inc.as a licensee. The Amendment
adds additional patents to the prior license grant and requires us to record before the USPTO various assignments of the licensed patents
to USC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As mentioned above,
pursuant to the USC Agreement, we issued to USC 800,000 shares of common stock in exchange for the license and as agreed by the
Amendment, the Company issued additional shares of our common stock such that USC&rsquo;s ownership of our Company, when combined
with the shares currently held by USC, equals three and one-half percent (3.5%) of our fully diluted capitalization. In addition,
the Amendment provides for an 4% earned royalty on Net Sales on licensed products protected by the newly added patents on a country
by-country basis. In the event that a licensed product is protected by patents from both the USC Agreement and the Amendment, the
higher royalty will apply. The Amendment also recognizes a Royalty Credit, in the event that we must obtain additional licenses from
third parties in order to sell the licensed products. The Amendment also grants us sole control the prosecution of any patent
application and maintenance of any patent included within Licensed Patents. We continue to be responsible for all costs associated
with the prosecution and maintenance of the licensed patents. The Amendment also changed the parties enforcement obligations.
Specifically, we shall have the first right, following consultation with USC, at our sole expense, to file suit against any alleged
infringer or in defense of any Third Party claim. Any recovery or settlement in excess of litigation costs paid to us will be shared
with USC as if it were Sublicense Revenue as defined in the USC Agreement. USC must consent to any settlement that is detrimental to
USC or USC&rsquo;s intellectual property rights. If we elect not to file suit against an alleged infringer, then upon such election,
we will be deemed to have assigned to USC all rights, causes of action, and damages resulting from the alleged infringement. USC
then has the sole right to institute suit, at its option. The parties further amended the USC Agreement on May 30, 2023
(&ldquo;Second Amendment&rdquo;). The Second Amendment revised the license agreement to permit Sublicensees to sublicense the
patents pursuant to specific terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>



<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Government
Regulation and Product Approval</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates small molecule products under the Federal Food, Drug, and Cosmetic Act, or the FDCA, the PHSA, and
regulations and guidance documents implementing these laws. The FDCA, PHSA and their corresponding regulations govern, among other things,
the testing, manufacturing, safety, purity, potency, labeling, packaging, storage, record keeping, distribution, reporting, advertising
and other promotional practices involving biological products. Consent from the FDA is required before conducting human clinical testing
of small molecule products. FDA licensure also must be obtained before marketing of biological products. The process of obtaining regulatory
approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure
of substantial time and financial resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S.
Small Molecule Products Development Process</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
drug product must be approved by the FDA before it may be legally marketed in the United States. The process required by the FDA before
a drug product candidate may be marketed in the United States generally involves the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of preclinical
    laboratory tests and in vivo studies in accordance with the FDA&#8217;s Good Laboratory Practice (GLP) regulations and applicable
    requirements for the humane use of laboratory animals or other applicable regulations;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission to the FDA of
    an investigational new drug (IND) application, which allows human clinical trials to begin unless FDA objects within 30 calendar
    days;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval by an independent
    institutional review board (IRB), reviewing each clinical site before each clinical trial may be initiated;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance of adequate
    and well-controlled human clinical trials according to the FDA&#8217;s Good Clinical Practice (GCP) regulations, and any additional
    requirements for the protection of human research subjects and their health information, to establish the safety, purity and potency
    of the proposed product candidate for its intended use;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation and submission
    to the FDA of a small molecule products license application, or NDA, for marketing approval that includes substantial evidence of
    safety, purity and potency from results of nonclinical testing and clinical trials;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Review of the product by
    an FDA advisory committee, if applicable;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfactory completion
    of an FDA inspection of the manufacturing facility or facilities where the product candidate is produced to assess compliance with
    current Good Manufacturing Practice (cGMP) requirements and to assure that the facilities, methods and controls are adequate to preserve
    the product candidate&#8217;s identity, safety, strength, quality, potency and purity;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential FDA audit of
    the nonclinical and clinical trial sites that generated the data in support of the NDA; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of user fees and
    FDA review and approval, or licensure, of the NDA.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
testing and approval process of product candidates requires substantial time, effort, and financial resources. Satisfaction of the FDA&#8217;s
pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type,
complexity, and novelty of the product or disease. Before testing any product candidate in humans, the product candidate must undergo
preclinical testing. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry,
toxicity and formulation, as well as in vivo studies to assess the potential safety and activity of the product candidate and to establish
a rationale for therapeutic use. The conduct of the preclinical tests must comply with federal regulations and requirements including
GLPs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, companies usually must complete some long-term preclinical testing, such as animal tests of reproductive adverse
events and carcinogenicity, and must also develop additional information about the chemistry and physical characteristics of the drug
and finalize a process for manufacturing the drug in commercial quantities in accordance with cGMP requirements. The manufacturing process
must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop
methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be
selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration
over its shelf life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any
available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue
even after the IND is submitted. The IND automatically becomes effective 30 calendar days after receipt by the FDA, unless before that
time the FDA raises concerns or questions related to a proposed clinical trial, including concerns that human research subjects will
be exposed to unreasonable health risks, and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA
must resolve any outstanding concerns before the clinical trial can begin. The FDA also may impose partial or full clinical holds on
a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical
hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be
sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that
partially or fully suspend or terminate such studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Human
Clinical Trials Under an IND</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational product to healthy volunteers or patients under the supervision of qualified
investigators which generally are physicians not employed by, or under, the control of the trial sponsor. Clinical trials must be conducted
under written study protocols detailing, among other things, the objectives of the trial, subject selection and exclusion, the trial
procedures, the parameters to be used in monitoring safety, the effectiveness criteria to be evaluated, and a statistical analysis plan.
Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
clinical trials must be conducted in accordance with federal regulations and GCP requirements, which include the requirements that all
research subjects provide their informed consent in writing for their participation in any clinical trial, as well as review and approval
by an IRB at each study site participating in the clinical trial or a central IRB. An IRB is charged with protecting the welfare and
rights of trial participants and considers items such as whether the risks to individuals participating in the clinical trials are minimized
and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must
be signed by each clinical trial subject, or their legal representative, reviews and approves the study protocol, and must monitor the
clinical trial until completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials typically are conducted in three sequential phases that may overlap or be combined:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase 1.</I> The product
    candidate initially is introduced into a small number of healthy human subjects and tested for safety, dosage tolerance, absorption,
    metabolism, distribution, excretion and, if possible, to gain an early understanding of its effectiveness. In the case of some product
    candidates for severe or life-threatening diseases, especially when the product candidate may be too inherently toxic to ethically
    administer to healthy volunteers, the initial human testing is often conducted in patients.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase 2</I>. The product
    candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate
    the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing
    schedule.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase 3</I>. Phase 3
    clinical trials are commonly referred to as &#8220;pivotal&#8221; or &#8220;registrational&#8221; studies, which typically denotes
    a study which presents the data that the FDA or other relevant regulatory agency will use to determine whether or not to approve
    a product. In Phase 3 studies, the product candidate is administered to an expanded patient population, generally at multiple geographically
    dispersed clinical trial sites in adequate and well-controlled clinical trials to generate sufficient data to statistically confirm
    the potency and safety of the product for approval. These clinical trials are intended to establish the overall risk/benefit ratio
    of the product candidate and provide an adequate basis for product labeling.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial approval. These clinical trials are
used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term
safety follow-up.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical
data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the
FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
IND safety reports must be promptly submitted to the FDA and the investigators for: serious and unexpected adverse events; any findings
from other studies, in vivo laboratory tests or in vitro testing that suggest a significant risk for human subjects; or any clinically
important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The
sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting.
The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days
after the sponsor&#8217;s initial receipt of the information. Relevant additional information obtained by the sponsor that pertains to
a previously submitted IND safety report must be submitted as a follow-up IND safety report. Such report should be submitted within 15
calendar days after the sponsor receives the information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
about certain clinical trials, including a description of the study and, in some cases, study results, must be submitted within specific
timeframes to the National Institutes of Health, or NIH, for public dissemination on their clinicaltrials.gov website. Manufacturers
or distributors of investigational products for the diagnosis, monitoring, or treatment of one or more serious or life-threatening diseases
or conditions where no other comparable or satisfactory therapeutic options exist must also have a publicly available policy on evaluating
and responding to requests for expanded access, sometimes called &#8220;compassionate use,&#8221; requests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor that regularly
reviews accumulated data and advises the study sponsor regarding the continuing safety of the trial. This group may also review interim
data to assess the continuing validity and scientific merit of the clinical trial. This group receives special access to unblinded data
during the clinical trial and may advise the sponsor to halt the clinical trial if it determined there is an unacceptable safety risk
for subjects or on other grounds, such as no demonstration of efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes
that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical
trial patients. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to
comply with the IRB&#8217;s requirements or if the trial poses an unexpected serious harm to subjects. The FDA or an IRB may also impose
conditions on the conduct of a clinical trial. Clinical trial sponsors may also choose to discontinue clinical trials as a result of
risks to subjects, a lack of favorable results, or changing business priorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Compliance
with cGMP Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers
of pharmaceutical products must comply with applicable cGMP regulations, including quality control and quality assurance and maintenance
of records and documentation. Manufacturers and others involved in the manufacture and distribution of such products also must register
their establishments with the FDA and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon
their initial participation in the manufacturing process. Establishments may be subject to periodic, unannounced inspections by government
authorities to ensure compliance with cGMP requirements and other laws. Discovery of problems may result in a government entity placing
restrictions on a product, manufacturer or holder of an approved NDA, and may extend to requiring withdrawal of the product from the
market. The FDA will not approve a NDA unless it determines that the manufacturing processes and facilities are in compliance with cGMP
requirements and adequate to assure consistent production of the product within required specification.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, companies usually complete additional preclinical studies and must also develop additional information about the
physical characteristics of the product candidate as well as finalize a process for manufacturing the product candidate in commercial
quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents or of causing other
adverse events with the use of small molecule products, the PHSA emphasizes the importance of manufacturing control for products whose
attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product
candidate and, among other requirements, the sponsor must develop methods for testing the identity, strength, quality, potency and purity
of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate
that the product candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
relation to the clinical trials that may be conducted in other countries with a view to obtaining a marketing authorization, there are
equivalent cGMP requirements and other regulatory rules that are implemented nationally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S.
FDA Review and Approval Process</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of the required clinical and preclinical testing, the results of the preclinical tests and clinical trials together
with detailed information relating to the product&#8217;s CMC, including negative or ambiguous results as well as positive findings,
and proposed labeling, among other things, are submitted to the FDA for NDA (new drug application) approval to market the product for
one or more indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Prescription Drug User Fee Act (PDUFA), as amended, each NDA must be accompanied by a significant user fee. The FDA adjusts the PDUFA
user fees on an annual basis. The PDUFA also imposes an annual program fee for approved therapeutic products. Fee waivers or reductions
are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business.
Additionally, no user fees are assessed on NDAs for product candidates designated as orphan drugs, unless the product candidate also
includes a non-orphan indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the Pediatric Research Equity Act (PREA), an NDA for a new active ingredient, indication, dosage form, dosage regimen,
or route of administration, must contain data that are adequate to assess the safety and effectiveness of the product for the claimed
indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which
the product is safe and effective. Also, applications for product candidates intended for the treatment of adult cancer which are directed
at molecular targets that the FDA determines to be substantially relevant to the growth or progression of pediatric cancer, in place
of the PREA investigations, sponsors must submit, with the application, reports from molecularly targeted pediatric cancer investigations
designed to yield clinically meaningful pediatric study data, using appropriate formulations, to inform potential pediatric labeling.
The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until
after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Orphan products are
also exempt from the PREA requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA reviews a NDA within 60 days of submission to determine if it is substantially complete before the agency accepts it for filing.
The FDA may refuse to file any NDA that it deems incomplete or not properly reviewable at the time of submission and may request additional
information. In that event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject
to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth, substantive review
of the NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA reviews the NDA to determine, among other things, whether the proposed product candidate is safe and potent, or effective, for its
intended use, has an acceptable purity profile and whether the product candidate is being manufactured in accordance with cGMP to assure
and preserve the product candidate&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for
novel therapeutic products or therapeutic products that present difficult questions of safety or efficacy to an advisory committee, typically
a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should
be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations
carefully when making decisions. During the product approval process, the FDA also will determine whether a risk evaluation and mitigation
strategy, (REMS) is necessary to assure the safe use of the product candidate. REMS use risk minimization strategies beyond the professional
labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will
consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected
duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. A REMS could
include medication guides, physician communication plans and elements to assure safe use, such as restricted distribution methods, patient
registries and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS;
the FDA will not approve the NDA without a REMS, if required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving a NDA, the FDA will inspect the facilities at which the product candidate is manufactured. The FDA will not approve the product
candidate unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate
to assure consistent production of the product candidate within required specifications. Additionally, before approving a NDA, the FDA
typically will inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements
and GCP requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the basis of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may
issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific
prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and
may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies
have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product candidate receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications
for use may otherwise be limited. Further, the FDA may require that certain contraindications, warnings or precautions be included in
the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of
a REMS, or otherwise limit the scope of any approval. The FDA may also require post-marketing clinical trials, sometimes referred to
as Phase 4 clinical trials, designed to further assess a product&#8217;s safety and effectiveness, and testing and surveillance programs
to monitor the safety of approved products that have been commercialized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
five years, the FDA agrees to specified performance goals in the review of NDAs under the PDUFA. One such current goal is to review standard
NDAs in ten months after the FDA accepts the NDA for filing, and priority NDAs in six months, whereupon a review decision is to be made.
The FDA does not always meet its PDUFA goal dates for standard and priority NDAs and its review goals are subject to change from time
to time. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the NDA sponsor otherwise
provides additional information or clarification regarding information already provided in the submission within the last three months
before the PDUFA goal date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Post-Approval
Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
approval, there also are continuing annual program user fee requirements for approved products, excluding, under certain circumstances,
orphan products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rigorous
and extensive FDA regulation of pharmaceutical products continues after approval, particularly with respect to cGMP requirements. Manufacturers
are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance
of records and documentation. To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance
of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately
suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages
and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread
of communicable diseases in the United States and between states.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
post-approval requirements applicable to pharmacological products include reporting of cGMP deviations that may affect the identity,
potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated
safety and efficacy information and complying with electronic record and signature requirements. After a NDA is approved, the product
also may be subject to official lot release. If the product is subject to official release by the FDA, the manufacturer submits samples
of each lot of product to the FDA, together with a release protocol, showing a summary of the history of manufacture of the lot and the
results of all tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing
the lots for distribution. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity,
potency and effectiveness of pharmacological products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, manufacturers and other entities involved in the manufacture and distribution of approved pharmaceutics are required to register
their establishments with the FDA and certain state agencies, list their products, and are subject to periodic announced and unannounced
inspections by the FDA and these state agencies for compliance with current cGMP and other requirements, which impose certain procedural
and documentation requirements upon us and third-party manufacturers. Manufacturers must continue to expend time, money, and effort in
the areas of production and quality-control to maintain compliance with current cGMPs. Regulatory authorities may withdraw product approvals
or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing,
or if previously unrecognized problems are subsequently discovered. In addition, changes to the manufacturing process or facility generally
require prior FDA approval or notification before being implemented, and other types of changes to the approved product, such as adding
new indications and additional labeling claims, are also subject to further FDA review and approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the Drug Quality and Security Act imposes obligations on manufacturers of pharmaceutical products related to product tracking and tracing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
event reporting and submission of periodic reports, including annual reports and deviation reports, are required following FDA approval
of a NDA. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency,
or with manufacturing processes, or failure to comply with regulatory requirements, may result in significant regulatory actions. Such
actions may include refusal to approve pending applications, license suspension or revocation, imposition of a partial or full clinical
hold or termination of clinical trials, warning letters, untitled letters, cyber letters, modification of promotional materials or labeling,
provision of corrective information, imposition of post-market requirements including the need for additional testing, imposition of
distribution or other restrictions under a REMS, product recalls, product seizures or detentions, refusal to allow imports or exports,
total or partial suspension of production or distribution, FDA debarment, injunctions, fines, consent decrees, corporate integrity agreements,
suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from participation
in federal and state healthcare programs, restitution, disgorgement, or civil or criminal penalties, including fines and imprisonment,
and result in adverse publicity, among other adverse consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
sponsor also must comply with the FDA&#8217;s advertising and promotion requirements, such as the prohibition on promoting products for
uses or in-patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;).
The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that
is found to have improperly promoted off-label uses may be subject to significant liability. Violations relating to the promotion of
off-label uses may lead to investigations alleging violations of federal and state healthcare fraud and abuse and other laws, as well
as state consumer protection laws. Companies, however, may generally share truthful and non-misleading information that is otherwise
consistent with a product&#8217;s FDA approved labeling. Discovery of previously unknown problems or the failure to comply with the applicable
regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well
as possible civil or criminal sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval,
may subject an applicant or manufacturer to administrative or judicial civil or criminal actions and adverse publicity. These actions
could include refusal to approve pending applications or supplemental applications, withdrawal of an approval, clinical hold, suspension
or termination of a clinical trial by an IRB, warning or untitled letters, product recalls, product seizures, total or partial suspension
of production or distribution, injunctions, fines or other monetary penalties, refusals of government contracts, mandated corrective
advertising or communications with healthcare providers, debarment, restitution, disgorgement of profits or other civil or criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broadly
equivalent requirements and controls typically apply in other countries to the submission of marketing authorization applications and,
post-approval, to the holding of such marketing authorizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Healthcare Laws and Regulations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business activities, including but not limited to, research, sales, promotion, distribution, medical education, and other activities
following product approval will be subject to regulation by numerous federal and state regulatory and law enforcement authorities in
the United States in addition to the FDA, including potentially the Department of Justice, the Department of Health and Human Services
(HHS) and its various divisions, including the Centers for Medicare &amp; Medicaid Services (CMS) and the Health Resources and Services
Administration, the Department of Veterans Affairs, the Department of Defense, and state and local governments. Healthcare providers
and third-party payors play a primary role in the recommendation and use of pharmaceutical products that are granted marketing approval.
Arrangements with third-party payors, existing or potential customers and referral sources, including healthcare providers, are subject
to broadly applicable fraud and abuse laws and regulations, and these laws and regulations may constrain the business or financial arrangements
and relationships through which manufacturers conduct clinical research, market, sell and distribute the products for which they obtain
marketing approval. Such restrictions under applicable federal and state healthcare laws and regulations include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and wilfully soliciting,
    receiving, offering or paying remuneration, directly or indirectly, in cash or kind, in exchange for, or to induce, either the referral
    of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal
    healthcare programs such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between
    pharmaceutical manufacturers, on the one hand, and prescribers, purchasers, formulary managers and other individuals and entities
    on the other. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively,
    the ACA) amended the intent requirement of the federal Anti-Kickback Statute such that a person or entity no longer needs to have
    actual knowledge of this statute or specific intent to violate it in order to commit a violation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal civil and criminal false claims, including the civil FCA, and Civil Monetary Penalties Laws which prohibit, among other things,
    individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other
    third-party payors that are false or fraudulent, or making a false statement to avoid, decrease, or conceal an obligation to pay
    money to the federal government. Certain marketing practices, including off-label promotion, also may implicate the FCA. In addition,
    the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute
    constitutes a false or fraudulent claim for purposes of the FCA;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal Physician Payments
    Sunshine Act, which requires certain manufacturers of drugs, devices, therapeutic products and medical supplies for which payment
    is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually
    to the Centers for Medicare &amp; Medicaid Services, or the CMS, information related to payments and other transfers of value made
    to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals
    (such as physician assistants and nurse practitioners), and teaching hospitals, and ownership and investment interests held by physicians
    and other healthcare providers and their immediate family members;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Insurance Portability
    and Accountability Act of 1996 (HIPAA) prohibits knowingly and willfully executing, or attempting to execute, a scheme to defraud
    or to obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under
    the custody or control of, a healthcare benefit program, regardless of whether the payor is public or private, in connection with
    the delivery or payment for health care benefits, knowingly and willfully embezzling or stealing from a health care benefit program,
    willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing, or covering
    up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment
    for, healthcare benefits, items, or services relating to healthcare matters. Additionally, the ACA amended the intent requirement
    of certain of these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute,
    or the specific intent to violate it, to have committed a violation; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State and foreign law equivalents
    of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by
    any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical
    industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise
    restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers
    to report information related to payments and other transfers of value to physicians and other healthcare providers and drug pricing
    and/or marketing expenditures; and state and local laws requiring the registration of pharmaceutical sales representatives and state
    laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant
    ways and may not have the same effect, thus complicating compliance efforts.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business.
HIPAA, as amended by the Health Information Technology for Clinical Health Act of 2009 (HITECH), and its respective implementing regulations
imposes certain requirements, including mandatory contractual terms, on covered entities, business associates and their covered subcontractors
relating to the privacy, security, and transmission of certain individually identifiable health information known as protected health
information. Among other things, HITECH, through its implementing regulations, makes HIPAA&#8217;s security standards and certain privacy
standards directly applicable to business associates, defined as a person or organization, other than a member of a covered entity&#8217;s
workforce, that creates, receives, maintains, or transmits protected health information on behalf of a covered entity for a function
or activity regulated by HIPAA. HITECH also strengthened the civil and criminal penalties that may be imposed against covered entities,
business associates, subcontractors, and individuals, and gave state attorneys general new authority to file civil actions for damages
or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing
federal civil actions. In addition, other federal and state laws may govern the privacy and security of health and other information
in certain circumstances, many of which differ from each other in significant ways and may not be pre-empted by HIPAA, thus complicating
compliance efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may
include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation
of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU, the data privacy laws are generally perceived to be stricter than those which apply in the United States and include specific
requirements for the transfer of personal data outside the EU to the United States to ensure that EU standards of data privacy will be
applied to such data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violation
of the laws described above or any other governmental laws and regulations may result in significant penalties, including administrative,
civil and criminal penalties, damages, fines, the curtailment or restructuring of operations, the exclusion from participation in federal
and state healthcare programs, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, imprisonment,
and additional reporting requirements and oversight if a person becomes subject to a corporate integrity agreement or similar agreement
to resolve allegations of non-compliance with these laws. Furthermore, efforts to ensure that business activities and business arrangements
comply with applicable healthcare laws and regulations can be costly for manufacturers of branded prescription products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Coverage
and Reimbursement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United
States, sales of any product candidates for which regulatory approval for commercial sale is obtained will depend in part on the availability
of coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities and health programs
in the United States such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. These third-party
payors are increasingly reducing reimbursements for medical products and services. The process for determining whether a payor will provide
coverage for a drug product may be separate from the process for setting the reimbursement rate that the payor will pay for the drug
product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all
of FDA-approved drugs for a particular indication. Additionally, the containment of healthcare costs has become a priority of federal
and state governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign
governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement
and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more
restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further,
coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process
is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products
to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the
first instance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services,
in addition to their safety and efficacy. New metrics frequently are used as the basis for reimbursement rates, such as average sales
price, average manufacturer price and actual acquisition cost. In order to obtain coverage and reimbursement for any product that might
be approved for sale, it may be necessary to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity
and cost-effectiveness of the products, in addition to the costs required to obtain regulatory approvals. If third-party payors do not
consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit
under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketability of any product candidates for which we or our collaborators receive regulatory approval for commercial sale may suffer
if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in
the United States has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and
third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more
products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may
be implemented in the future. The cost containment measures that healthcare payors and providers are instituting and any healthcare reform
could significantly reduce our revenues from the sale of any approved product candidates. We cannot provide any assurances that we will
be able to obtain and maintain third-party coverage or adequate reimbursement for our product candidates in whole or in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only
after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness
of a particular product candidate to currently available therapies. EU member states may approve a specific price for a product or it
may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other
member states allow companies to fix their own prices for products, but monitor and control company profits. The downward pressure on
health care costs has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition,
in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country.
Any country that has price controls or reimbursement limitations may not allow favorable reimbursement and pricing arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Health
Reform</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change
the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United
States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare
costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these
efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing,
coverage, and reimbursement of pharmaceutical products, especially under government-funded health care programs, and increased governmental
control of drug pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
way of example, in March&nbsp;2010, the ACA was signed into law, intended to broaden access to health insurance, reduce or constrain
the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health
insurance industries, impose taxes and fees on the healthcare industry and impose additional health policy reforms. Among the provisions
of the ACA of importance to our business are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page --> <!-- Field: Split-Segment -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An annual, non-deductible
    fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these
    entities according to their market share in certain government healthcare programs;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the
    average manufacturer price for branded and generic drugs, respectively;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled,
    infused, instilled, implanted or injected;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extension of a manufacturer&#8217;s
    Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expansion of eligibility
    criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income
    at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Medicare Part D coverage
    gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable
    brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs
    to be covered under Medicare Part D;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expansion of the entities
    eligible for discounts under the Public Health Service pharmaceutical pricing program; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Patient-Centered Outcomes
    Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding
    for such research.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, on June&nbsp;17, 2021 the U.S.
Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual
mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme
Court ruling, on January&nbsp;28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes
of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies
to review and reconsider their existing policies and rules that limit access to healthcare, including among others, re-examining Medicaid
demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining
access to health insurance coverage through Medicaid or the ACA. In addition, in August&nbsp;2022, President Biden signed the Inflation
Reduction Act of 2022 (the IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing coverage in
ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning
in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted in the United States since the ACA. For example, through the process created by the
Budget Control Act of 2011, there are automatic reductions of Medicare payments to providers up to 2% per fiscal year, which went into
effect in April&nbsp;2013 and, following passage of the BBA and the Infrastructure Investment and Jobs Act, will remain in effect until
2031 unless additional Congressional action is taken. However, COVID-19 relief support legislation suspended the 2% Medicare sequester
from May&nbsp;1, 2020 through March&nbsp;31, 2022. Under current legislation the actual reduction in Medicare payments will vary from
1% in 2022 to up to 4% in the final fiscal year of this sequester.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription
drugs and biologics, also has resulted in executive orders, congressional inquiries and proposed and enacted federal and state legislation
designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer
patient programs, and reform government program reimbursement methodologies for products. At the federal level, President Trump used
several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders, and policy initiatives.
For example, on July&nbsp;24, 2020 and September&nbsp;13, 2020, the Trump administration announced several executive orders related to
prescription drug pricing that attempt to implement several of the administration&#8217;s proposals. The FDA concurrently released a
final rule and guidance in September&nbsp;2020 implementing a portion of the importation executive order providing pathways for states
to build and submit importation plans for drugs from Canada. Further, on November&nbsp;20, 2020, the HHS finalized a regulation removing
safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through
pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions
reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and
manufacturers. The implementation of the rule has been delayed until 2032. Additionally, on March&nbsp;11, 2021, President Biden signed
the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s
average manufacturer price, for single source and innovator multiple source drugs, beginning January&nbsp;1, 2024. In July&nbsp;2021,
the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions
aimed at prescription drugs. In response to Biden&#8217;s executive order, on September&nbsp;9, 2021, HHS released a Comprehensive Plan
for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies
that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA
directs the Secretary of HHS to establish a Drug Price Negotiation Program (the Program) to lower prices for certain single-source prescription
drugs and biologics covered under Medicare Parts B and D, based on criteria established under the IRA. Under the Program, the Secretary
of HHS will publish a list of &#8220;selected drugs,&#8221; and will then negotiate maximum fair prices (MFP) with their manufacturers.
Beginning in 2026, the first year of the Program, the number will be limited to 10 Part D drugs and biologics. By 2029, and in subsequent
years thereafter, the number will increase to 20 drugs and biologics covered under Part D and Part B. Agreements between HHS and manufacturers
will remain in place until a drug or biologic is no longer considered a &#8220;selected drug&#8221; for negotiation purposes. Manufacturers
who do not comply with the negotiated prices set under the Program will be subject to an excise tax based on a percentage of total sales
of a &#8220;selected drug&#8221; up to 95% and the potential of civil monetary penalties. Further, the IRA imposes rebates under Medicare
Part B and Medicare Part D to penalize price increases that outpace inflation. In addition, the Biden administration released an additional
executive order on October&nbsp;14, 2022, directing HHS to submit a report within ninety (90) days on how the Center for Medicare and
Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the state level, individual states in the United States have increasingly passed legislation and implemented regulations designed to
control pharmaceutical and therapeutic product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. Some third-party payors also require pre-approval of coverage for new or innovative devices
or therapies before they will reimburse healthcare providers that use such therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that these initiatives, as well as other healthcare reform measures that may be adopted in the future, as well as the trend toward
managed healthcare and increasing influence of managed care organizations, may result in more rigorous coverage criteria and lower reimbursement,
and in additional downward pressure on the price that we receive for any approved product. It is also possible that additional governmental
action is taken in response to the COVID-19 pandemic. Any reduction in reimbursement from Medicare or other government-funded programs
may result in a similar reduction in payments from private payors. The implementation of current and future cost containment measures
or other healthcare reforms may adversely affect our operations and prevent us from being able to generate revenue, attain profitability
or commercialize our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Data
Privacy and Security</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we collect, process and store confidential and sensitive information, including personal information,
intellectual property, trade secrets, and proprietary information owned or controlled by ourselves or other third parties. We, and third
parties upon whom we rely, use sophisticated information technology, software and services to process, store, use, generate, transfer
and disclose information, as well as other sensitive information controlled by ourselves or other third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also be subject to federal, state, and foreign data privacy and security laws and regulations. In the United States, numerous federal
and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and
state consumer protection laws and regulations (e.g., Section&nbsp;5 of the FTC Act), govern the collection, use, disclosure, and protection
of health-related and other personal information could apply to our operations or the operations of our partners, vendors, or other third
parties on whom we rely. The legislative and regulatory framework related to the collection, use, retention, safeguarding, disclosure,
sharing, transfer, security and other processing of personal data worldwide is rapidly evolving. The number and scope of data protection
laws and regulations is changing, subject to differing applications and interpretations, and may be inconsistent among jurisdictions,
or in conflict with other rules, laws or other data processing obligations. Efforts to ensure that our current and future business arrangements,
including our relationship with our CROs or other vendors who process data on our behalf, comply with applicable data privacy and data
security laws and regulations will involve substantial costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, HIPAA, as amended by HITECH, and its implementing regulations, impose requirements relating to the privacy, security and transmission
of individually identifiable health information on certain health care providers, health plans and health care clearinghouses, known
as covered entities, as well as their business associates and covered subcontractors that perform certain services that involve creating,
receiving, maintaining or transmitting individually identifiable health information for or on behalf of such covered entities. Entities
that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information, a complaint about privacy
practices or an audit by HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional
reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations
of HIPAA non-compliance. Further, entities that knowingly obtain, use, or disclose individually identifiable health information maintained
by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA may be subject to civil and criminal penalties. Even
when HIPAA does not apply, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep
consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&nbsp;5
of the FTC Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity
and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security
and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Likewise,
we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection
in the United States, the EU and other jurisdictions, such as the California Consumer Privacy Act of 2018 (CCPA), which has been characterized
as the first &#8220;GDPR-like&#8221; privacy statute to be enacted in the United States. Although the CCPA exempts certain data processed
in the context of clinical trials, the CCPA, to the extent applicable to our business and operations, may increase our compliance costs
and potential liability with respect to the personal information we maintain about California residents. The CCPA among other effects,
creates individual privacy rights for California consumers (as defined in the law), places increased privacy and security obligations
on entities handling certain personal data of consumers or households, requires covered companies to provide disclosures to consumers
regarding data collection, use and sharing practices, requires covered companies to allow users to opt-out of certain sales or transfers
of personal information, and provides consumers with a private right of action for certain data breaches. The CCPA became effective on
January&nbsp;1, 2020, and the California Attorney General&#8217;s authority to begin bringing enforcement actions began July&nbsp;1,
2020. As currently written, the CCPA may impact our business activities and exemplifies the vulnerability of our business to the evolving
regulatory environment related to personal data and protected health information. Further, the California Privacy Rights Act (CPRA) was
recently voted into law by California residents. The CPRA significantly amends the CCPA, and imposes additional data protection obligations
on covered companies doing business in California, including additional consumer rights processes and opt outs for certain uses of sensitive
data. It also creates a new California data protection agency specifically tasked to enforce the law, which would likely result in increased
regulatory scrutiny of California businesses in the areas of data protection and security. The substantive requirements for businesses
subject to the CPRA went into effect on January&nbsp;1, 2023, and become enforceable on July&nbsp;1, 2023. A similar law, the Consumer
Data Protection Act (CDPA), was recently passed in Virginia and went into effect on January&nbsp;1, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also are or will become subject to privacy laws in the jurisdictions in which we are established or in which we sell or market our products
or run clinical trials. For example, in the EU, we are subject to Regulation (EU) 2016/679, the GDPR, in relation to our collection,
control, processing, and other use of personal data (i.e. data relating to an identified or identifiable living individual). We process
personal data in relation to participants in our clinical trials in the European Economic Area (EEA), including the health and medical
information of these participants. The GDPR is directly applicable in each EU and EEA Member State, however, it provides that EU and
EEA Member States may introduce further conditions, including limitations which could limit our ability to collect, use and share personal
data (including health and medical information), or could cause our compliance costs to increase, ultimately having an adverse impact
on our business. As noted above, the GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain
a record of their data processing and implement policies as part of its mandated privacy governance framework. It also requires data
controllers to be transparent and disclose to data subjects (in a concise, intelligible and easily accessible form) how their personal
information is to be used, imposes limitations on retention of personal data; defines for the first time pseudonymized (i.e., key-coded)
data; introduces mandatory data breach notification requirements; and sets higher standards for data controllers to demonstrate that
they have obtained valid consent for certain data processing activities. We are also subject to EEA rules with respect to cross-border
transfers of personal data out of the EEA. As noted above, recent legal developments in the EU have created complexity and uncertainty
regarding transfers of personal data from the EEA to the United States, e.g. on July&nbsp;16, 2020, the Court of Justice of the European
Union (CJEU), invalidated the EU-U.S. Privacy Shield Framework, or the Privacy Shield, under which personal data could be transferred
from the EEA to U.S. entities who had self-certified under the Privacy Shield scheme. While the CJEU upheld the adequacy of the standard
contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism,
and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all
circumstances. Use of the standard contractual clauses must now be assessed on a case-by-case basis taking into account the legal regime
applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or
contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. On June&nbsp;4,
2021, the European Commission adopted new standard contractual clauses under the GDPR for data transfers from entities that are subject
to the GDPR to transfer personal data outside of the EEA. The new standard contractual clauses impose additional obligations, including
the obligation to conduct a transfer impact assessment and, depending on a party&#8217;s role in the transfer, to implement additional
security measures and to update internal privacy practices. If we elect to rely on the standard contractual clauses for data transfers,
we may be required to incur significant time and resources to update our contractual arrangements and to comply with new obligations.
Additionally, on September&nbsp;8, 2020, the Swiss Data Protection Authority (the Federal Data Protection and Information Commissioner)
concluded that the Swiss-U.S. Privacy Shield does not provide an adequate level of protection for personal data transfer from Switzerland
to the U.S. pursuant to the Swiss Federal Act on Data Protection. As supervisory authorities issue further guidance on personal data
export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action,
we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer
personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services,
the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the supervision of local data protection authorities in those EU jurisdictions where we are established or otherwise subject
to the GDPR. Fines for certain breaches of the GDPR are significant: up to the greater of &#8364;20.0 million or 4% of total global annual
turnover. Further, following the withdrawal of the United Kingdom from the EU on January&nbsp;31, 2020, pursuant to the transitional
arrangements agreed between the United Kingdom and the EU, we will have to comply with the GDPR and separately the GDPR as implemented
in the United Kingdom, each regime having the ability to fine up to the greater of &#8364;20 million / &pound;17 million or 4% of global
turnover. Following December&nbsp;31, 2020, and the expiry of the post-Brexit transitional arrangements between the United Kingdom and
EU, although it is likely that the data protection obligations of the GDPR will continue to apply to UK-related processing of personal
data in substantially unvaried form and fashion, for at least the short term thereafter, the relationship between the United Kingdom
and the EU in relation to certain aspects of data protection law remains unclear. For example, it is not yet clear whether the United
Kingdom will be the subject of a so-called adequacy decision of the European Commission, and it is therefore unclear how data transfers
between EU/EEA Member States and the United Kingdom will be treated. Any changes relating to the UK and EU position regarding aspects
of data protection law may lead to additional compliance costs and could increase our overall risk. In addition to the foregoing, a breach
of the GDPR or other applicable privacy and data protection laws and regulations could result in regulatory investigations, reputational
damage, orders to cease/change our use of data, enforcement notices, an inability to process personal data or to operate in certain jurisdictions,
or potential civil claims including class action type litigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we use third-party service providers and subprocessors to help us operate our business and engage in processing on our behalf. If we,
our service providers, partners, or other relevant third-parties have experienced, or in the future experience, any security incident(s)
that result in any data loss, deletion or destruction, unauthorized access to, loss of, unauthorized acquisition or disclosure of, or
inadvertent exposure or disclosure of sensitive information, or compromise related to the security, confidentiality, integrity of our
(or their) information technology, software, services, communications or data, it may result in a material adverse impact, including
without limitation, regulatory investigations or enforcement actions, litigation, or an inability to process data in some jurisdictions.
Furthermore, applicable data protection laws, privacy policies and data protection obligations may require us to notify relevant stakeholders
of security breaches, including affected individuals, customers, and regulators. Such disclosures are costly, and the disclosure or the
failure to comply with such requirements, could result in a material adverse impact, including without limitation, regulatory investigations
or enforcement actions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information on the potential impact of the GDPR, and associated EEA data protection laws, on our business, see the section titled
&#8220;<I>Risk Factors&#8212;Failure to comply with health and data protection laws and regulations could lead to government enforcement
actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our
operating results and business</I>.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Additional
Regulation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational
Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act, affect our business. These and
other laws govern the use, handling and disposal of various biologic, chemical and radioactive substances used in, and wastes generated
by, operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could
be liable for damages and governmental fines. Equivalent laws have been adopted in other countries that impose similar obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S.
Foreign Corrupt Practices Act</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Foreign Corrupt Practices Act (FCPA) prohibits U.S. corporations and individuals from engaging in certain activities to obtain or
retain business abroad or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the
payment of anything of value, directly or indirectly, to any foreign government official, government staff member, official or employee
of a public international organization, or a political party or political candidate for the purpose of influencing any act or decision
of the foreign entity in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity.
The scope of the FCPA includes interactions with healthcare professionals of foreign state-owned or affiliated hospitals, universities,
or research institutions. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting
provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation,
including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international
operations. Activities that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines,
imprisonment, disgorgement, oversight, and suspension and debarment from government contracts, and refusal of orders under existing government
contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equivalent
laws have been adopted in other foreign countries that impose similar or arguably broader obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&nbsp;31, 2022, we had five full-time employees. None of our employees is subject to a collective bargaining agreement or
represented by a trade or labor union. We consider our relationship with our employees to be good.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Properties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently own or lease any properties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">We are currently involved in, and may in the future
be involved in additional actual and/or threatened legal proceedings, claims, investigations and government inquiries arising in the ordinary
course of our business, including legal proceedings, claims, investigations and government inquiries involving intellectual property,
data privacy and data protection, privacy and other torts, illegal or objectionable content, consumer protection, securities, employment,
contractual rights, civil rights infringement, false or misleading advertising, or other legal claims relating to our business. We are
involved in the following matter:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">On July 1, 2022, NeOnc Technologies, Inc. and Fox Infused, LLC, a Delaware
limited liability company (&ldquo;Fox Infused&rdquo;), entered into an Intellectual Property License and Supply Agreement (the &ldquo;Agreement&rdquo;)
whereby NeOnc agreed to supply certain products to Fox Infused and license certain of the Company&rsquo;s patents. The Company terminated
the Agreement with Fox Infused on April 25, 2023. On June 6, 2023, Fox Infused filed a complaint against NeOnc in the Central District
of California alleging that the termination was improper. Fox Infused also filed an ex parte application for a temporary restraining order
and an order to show cause on a preliminary injunction against the Company seeking to have the court stop the termination of the contract.
The Company denies liability and intends to vigorously defend itself.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">On November 8, 2013, NeOnc Technologies, Inc. entered into a Collaboration
and License Agreement with Orient EuroPharma Co., Ltd. (&ldquo;OEP&rdquo;). On June 14, 2023, the Company sent OEP a letter terminating
the Collaboration and License Agreement pursuant to Section 12. On June 20, 2023, we received a letter from OEP&lsquo;s counsel disputing our ability to terminate the license and alleging that
our termination letter breached the party&rsquo;s agreement.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_012"></A>MANAGEMENT</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors,
Executive Officers, Key Employees and Director Nominees</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our directors, executive officers, key employees and director nominees are listed below as of the date of this prospectus.
The executive officers are full-time employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors
    and Executive Officers:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Thomas C. Chen</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
    Walters</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Operating Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keithly
    Garnett<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amir
    Heshmatpour</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Vice Chairman and Secretary</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Alan Chiang</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
    Nominees:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasim
    Shomali</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    Nominee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Sikirat Iyabo Tinubu-Karch</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    Nominee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    Nanula</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    Nominee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Victoria
    Medvec, PhD.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    Nominee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keithly Garnett will resign
    as a director on or prior to the effective date of the public offering.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of our directors holds office until the next annual meeting of
our shareholders or until his/her successor has been elected and qualified, or until his/her death, resignation, or removal. Our executive
officers are appointed by our board of directors and hold office until their death, resignation, or removal from office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
Experience</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a brief overview of the education and business experience of each of our directors, executive officers and director nominees
during at least the past five years, including their principal occupations or employment during the period, the name and principal business
of the organization by which they were employed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
and Executive Officers:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dr.
Thomas C. Chen</I> has served as NeOnc Technologies Holdings, Inc.&#8217;s Chief Executive Officer since April&nbsp;2023 and Chairman
since May&nbsp;2023. Dr. Chen has served as NeOnc Technologies, Inc.&#8217;s Chief Executive Officer, Chairman and Chief Medical Officer
of the Board since inception. Dr. Chen has served as NeOnc Technologies Holdings, Inc.&#8217;s Dr. Chen is a respected Neurosurgeon and
Professor at the University of Southern California (USC). He has been the Director of Surgical Neuro-Oncology and Professor of Neurosurgery
&amp; Pathology. He has published or been associated with 148+ articles and peer-reviewed clinical studies. He maintains a clinical practice
in both surgical neuro-oncology and spine surgery. As well as heads a research laboratory focused on glioma biology. He graduated summa
cum laude from the University of Illinois at Urbana-Champaign with Bronze Tablet honors and Phi Beta Kappa. He graduated from University
of California San Francisco with MD degree, and was in the top 10% of his class, awarded Alpha Omega Alpha. He earned his Ph.D. in pathobiology
from University of Southern California where he wrote his thesis on the role of immunotherapy in malignant brain tumors. We believe that
Dr. Chen&#8217;s extensive knowledge of NeOnc&#8217;s business and his extensive corporate and leadership experience as the founder of
NeOnc and its Chief Executive Officer qualifies him to serve on our Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Patrick
Walters</I> has served as NeOnc Technologies Holdings, Inc.&#8217;s President and Chief Operating Officer since April&nbsp;2023.
Mr. Walters has served as NeOnc Technologies, Inc.&#8217;s Chief Financial Officer from inception to January&nbsp;2023. Mr. Walters has
served as NeOnc Technologies, Inc.&#8217;s Chief Operating Officer and Director from January&nbsp;2023 to April&nbsp;2023. For over 30
years, Mr. Walters has held senior management positions in corporate finance, financial reporting, planning analysis, operations, business
development, and strategic planning. He started his career at Deloitte &amp; Co., earning his CPA license. He has spent 16 years as a
senior financial executive at Sony Pictures as the SVP of Worldwide Finance for Theatrical Films. He also spent five years managing a
Forbes 400 family office as the managing director. His vast industry experience includes Biotech, Retail, Service, Entertainment, Publishing,
Start-up, Banking, Venture Capital, and a Family Office. Mr. Walters is in the process of reactivating his CPA license. Mr. Walters holds
a Bachelor of Arts degree in Economics Accounting from California State University, Northridge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Keithly
Garnett</I> has served as NeOnc Technologies Holdings, Inc.&#8217;s Chief Financial Officer since April&nbsp;2023 and director since
January&nbsp;2023. Mr. Keithly Garnett has spent over 17 years with Ernst &amp; Young LLP (known as EY) in their Transaction Advisory
Services practice. During that time, he specialized in business valuation modelling and strategy. His services were provided in support
of audit related work for financial reporting, tax planning and management planning. His client list included companies such as Amgen,
Edwards Life Sciences, Medtronic, etc. In any given year, he led over 50 transaction analyses and/or review for publicly traded companies,
in connection with their SEC financial reporting requirements. Over the past five years, he has worked as the chief financial officer
of a single member family office based in Malibu. Since 2018, he has been involved with the Shuttle Pharmaceutical Holdings public offering,
which was successfully listed on the Nasdaq in 2022. Mr. Garnett holds a master&#8217;s in business administration with a concentration
in Corporate Financial Management, and a Bachelor of Science degree in Business Management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Amir
Heshmatpour</I> has served on NeOnc Technologies Holdings, Inc.&#8217;s board of directors since January&nbsp;2023. Mr. Heshmatpour,
through his family office, has been involved in multiple biotech transactions from private to public. Since 2018, through a special purpose
vehicle (SPV), Shuttle Pharmaceuticals Holdings Inc. restructured the board of directors, management, and recapitalized an IPO of a Georgetown
phase 2 oncology asset. The SPV was created in 2018 and eventually was successfully listed on NASDAQ in 2022. Since then, he has been
involved in NeOnc Technologies Inc., where he has provided strategic advisory services that resulted in a share exchange with NeOnc Technologies
Holdings, Inc. Mr. Heshmatpour has a certification from the UCLA Anderson School of Business in corporate governance. He is also involved
in the UCLA Anderson School of Business Management, Price Center, as a director. We believe that Mr. Heshmatpour&#8217;s extensive corporate
and leadership experience qualifies him to serve on our Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Ming-Fu
(Alan) Chiang, MD, PhD, EMBA, FICS</I> has served on NeOnc Technologies Inc.&#8217;s board of directors since 2016 and on NeOnc Technologies
Holdings, Inc.&#8217;s board of directors since April&nbsp;2023. Dr. Chiang has also been the CEO of NeuCen Biomedical, Inc. since 2014
and CEO of Orion Biotech Inc. since 2015. Dr. Chiang is an active neurosurgeon and the former Vice-Director of the Department of Surgery
and former Chairman of Neurosurgery at Mackay Memorial Hospital in Taipei, Taiwan. He is active in clinical neurosurgical practice at
Chung-Shan Hospital and Taiwan Adventist Hospital in Taipei, Taiwan. Dr. Chiang&#8217;s Ph.D. in neuro-oncology was taken at Free University
of Berlin, Germany, and his EMBA (Executive Management Business &amp; Administration) from National Taiwan University. We believe that
Dr. Chiang&#8217;s extensive knowledge of NeOnc&#8217;s business and his corporate and leadership education and experience qualifies
him to serve on our Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
Nominees:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nasim
Shomali</I>. Nasim Shomali, MBA, is a seasoned business strategy consultant who, as Sustainability Strategy Senior Manager at Accenture,
partners with senior executives from Fortune 500 companies to help them tackle operational challenges and drive innovation and growth.
Ms. Shomali is responsible for managing and growing Accenture&#8217;s US divisions&#8217; Software, Platform, and Technology industries
sustainability book of business, and also serves as one of Accenture&#8217;s leading data center experts, driving operational efficiencies
and future state design for her global hyperscale clients. Ms. Shomali&#8217;s education credentials are equally diverse: prior to earning
her MBA at UCLA, she took dual degrees in Bio-engineering and mathematics at University of Washington and completed the prestigious World
Business Council for Sustainable Development Executive Leadership Program in partnership with Yale School of Business. We believe that
Ms. Nasim Shomali&#8217;s extensive corporate and leadership experience qualify her to serve on our Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dr.
Sikirat Iyabo Tinubu-Karch</I>. Dr. Iyabo Tinubu-Karch, MD, MHA is a highly respected geriatric medicine specialist in Seattle, Washington
with over thirty years of experience in the field. Dr. Iyabo Tinubu-Karch received her MD from St. Georges School of Medicine, and completed
a residency at Lenox Hill Hospital. Thereafter, Dr. Iyabo Tinubu-Karch completed a MD fellowship in critical care medicine at the University
of Washington and later earned her Master of Health Administration from the same university. Dr. Iyabo Tinubu-Karch&#8217;s current practice
is through her 6M Geriatrics &amp; Hospital Medicine entity (of which she is CEO), which is affiliated with Swedish Edmonds Campus. Dr.
Iyabo Tinubu-Karch is also a member of the board of directors of Rippl Care and Sidra Medicine, where she serves on the audit committee.
We believe that Dr. Iyabo Tinubu-Karch&#8217;s extensive corporate and leadership experience qualify her to serve on our Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Richard
Nanula</I>. Richard D. Nanula, MBA is a widely renowned and vastly experienced senior executive with deep knowledge of corporate governance
and navigating the capital markets. A Harvard Business School graduate, Mr. Nanula was the long-time EVP &amp; CFO at the Walt Disney
Company, and later the President and COO of Starwood Hotels before turning his career focus to the biosciences. As EVP of Finance and
Strategy at Amgen, Mr. Nanula not only scrupulously restructured the company to bring down capital costs and concentrate equity, but
also architected what was the largest acquisition in the history of the biotech industry at the time. Mr. Nanula has since served as
an advisory board member and CEO of PureForm Global, Inc., a tech-focused biosciences company, and is currently the Executive Chairman
at Lucy Scientific Discovery, a drug manufacturer with heavy emphasis on research and development. We believe that Mr. Richard Nanula&#8217;s
extensive corporate and leadership experience qualify her to serve on our Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Victoria
Medvec, PhD</I>. Dr. Victoria Medvec is the Adeline Barry Davee Professor of Management and Organizations at the Kellogg School of
Management at Northwestern University. In addition, Dr. Medvec is a co-founder and the Executive Director of the Center for
Executive Women at the Kellogg School and is the CEO of Medvec and Associates, a consulting firm focused on high stakes negotiations
and strategic decisions. A Cornell University Ph.D., Dr. Medvec is a renowned expert in the areas of negotiations, executive
decision making, influence, and corporate governance and her research is published in top academic journals in addition to authoring
the best-selling book, Negotiate Without Fear. Dr. Medvec has served on both public and private company Boards across many
industries, including banking, human resources and benefits administration. She also is a Ringleader in Ringleader Ventures, a
unique venture fund matching start up technologies with corporate needs. We believe that Dr. Victoria Medvec&#8217;s extensive
corporate and leadership experience qualify her to serve on our Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Family
Relationships</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our executive officers or directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Involvement
in Certain Legal Proceedings</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the best of our knowledge, none of our directors or executive officers were involved in any legal proceedings described in Item&nbsp;401(f)
of Regulation S-K in the past ten years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CORPORATE
GOVERNANCE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Composition
of our Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current Board of Directors consists of Dr. Thomas C. Chen, Amir Heshmatpour, Keithly Garnett and Dr. Alan Chiang.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nasim Shomali, Dr. Iyabo Tinubu-Karch,
Richard Nanula, and Dr. Victoria Medvec will become directors on the effective date of this offering and Mr. Garnett will resign on or
prior to the effective date of the public offering. Our board of directors may establish the authorized number of directors from time
to time by resolution. In accordance with our amended and restated certificate of incorporation, our board of directors will be divided
into three classes with staggered three-year terms. At each annual meeting of shareholders, the successors to directors whose terms then
expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors
are divided among the three classes as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">the Class I directors are ________ and ________, and their terms will expire at the annual meeting of shareholders to be held in 202__;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">the Class II directors are ________ and ________, and their terms will expire at the annual meeting of shareholders to be held in 202__; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">the Class III directors are ________ and ________, and their terms will expire at the annual meeting of shareholders to be held in 202__.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that any additional directorships resulting from an increase in the number of directors will be distributed among the three classes
so that, as nearly as possible, each class will consist of one third of the directors. The division of our board of directors into three
classes with staggered three-year terms may delay or prevent a change of our management or a change in control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the listing requirements and rules of the Nasdaq Stock Market LLC (Nasdaq Listing Rules), a majority of our directors must be independent
directors. Nasim Shomali, Dr. Sikirat Iyabo Tinubu-Karch, Richard Nanula, and Victoria Medvec, PhD. are considered independent based
on the listing standards of Nasdaq. In order to promote open discussion among independent directors, our Board intends to adopt a policy
of regularly conducting executive sessions of independent directors at scheduled meetings led by the lead independent director and at
such other times requested by other independent directors. Executive sessions shall not include Dr. Chen or Mr. Heshmatpour.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Committees
of our Board of Directors</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has established an audit committee, a compensation committee and a nominating and corporate governance committee,
each of which will operate pursuant to a charter to be adopted by our Board of Directors and will be effective upon the effectiveness
of the registration statement of which this prospectus is a part. The Board of Directors may also establish other committees from time
to time to assist our Company and the board of directors. Upon the effectiveness of the registration statement of which this prospectus
is a part, the composition and functioning of all of our committees will comply with all applicable requirements of the Sarbanes-Oxley
Act of 2002, the Nasdaq Capital Market and SEC rules and regulations, if applicable. Upon our listing on the Nasdaq Capital Market, our
committees&#8217; charters will be available on our website at www.NeOnctech.com. The reference to our website address does not constitute
incorporation by reference of the information contained at or available through our website, and you should not consider it to be part
of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
Committee</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee will consist of Nasim Shomali, Dr. Sikirat Iyabo Tinubu-Karch, Richard Nanula, and Victoria Medvec, PhD. Our Board of
Directors has determined that each of Nasim Shomali, Dr. Sikirat Iyabo Tinubu-Karch, Richard Nanula, and Victoria Medvec, PhD, satisfies
the independence requirements under Nasdaq listing standards and Rule&nbsp;10A-3(b)(1) of the Exchange Act. The chair of our audit committee
will be Mr. Richard Nanula, who our Board of Directors has determined is an &#8220;audit committee financial expert&#8221; within the
meaning of SEC regulations. Each member of our audit committee can read and understand fundamental financial statements in accordance
with applicable requirements. In arriving at these determinations, our Board of Directors has examined each audit committee member&#8217;s
scope of experience and the nature of their employment in the corporate finance sector.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal duties and responsibilities of our audit committee will include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing,
    approving the compensation of, and assessing the independence of our independent registered public accounting firm;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-approving
    auditing and permissible non-audit services, and the terms of such services, to be provided by our independent registered public
    accounting firm;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the overall audit plan with our independent registered public accounting firm and members of management responsible for preparing
    our financial statements;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements
    and related disclosures as well as critical accounting policies and practices used by us;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">coordinating
    the oversight and reviewing the adequacy of our internal control over financial reporting;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    policies and procedures for the receipt and retention of accounting-related complaints and concerns;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending,
    based upon the audit committee&#8217;s review and discussions with management and our independent registered public accounting firm,
    whether our audited financial statements shall be included in our Annual Report on Form&nbsp;10-K;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring
    the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to our financial
    statements and accounting matters;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    the audit committee report required by SEC rules to be included in our annual proxy statement;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    all related person transactions for potential conflict of interest situations and approving all such transactions; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    quarterly earnings releases.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
Committee</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee will consist of Nasim Shomali, Dr. Sikirat Iyabo Tinubu-Karch, Richard Nanula, and Victoria Medvec, PhD. The chair
of our compensation committee will be Nasim Shomali. Our Board of Directors has determined that each of Nasim Shomali, Dr. Sikirat Iyabo
Tinubu-Karch, Richard Nanula, and Victoria Medvec, PhD is independent under Nasdaq listing standards, a &#8220;non-employee director&#8221;
as defined in Rule&nbsp;16b-3 promulgated under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal duties and responsibilities of our compensation committee will include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
    the performance of our Chief Executive Officer in light of such corporate goals and objectives and based on such evaluation: (i)
    recommending to the board of directors the cash compensation of our Chief Executive Officer, and (ii) reviewing and approving grants
    and awards to our Chief Executive Officer under equity-based plans;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and recommending to the board of directors the cash compensation of our other executive officers;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and establishing our overall management compensation, philosophy, and policy;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    and administering our compensation and similar plans;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation of compensation
    matters and evaluating and assessing potential and current compensation advisors in accordance with the independence standards identified
    in the applicable Nasdaq rules;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">retaining
    and approving the compensation of any compensation advisors;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving our policies and procedures for the grant of equity-based awards;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and recommending to the board of directors the compensation of our directors; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    the compensation committee report required by SEC rules, if and when required, to be included in our annual proxy statement.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominating
and Corporate Governance Committee</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and corporate governance committee will consist of Nasim Shomali, Dr. Sikirat Iyabo Tinubu-Karch, Richard Nanula, and Victoria
Medvec, PhD. The chair of our nominating and corporate governance committee will be Victoria Medvec, PhD. Our Board of Directors has
determined that each of Nasim Shomali, Dr. Sikirat Iyabo Tinubu-Karch, Richard Nanula, and Victoria Medvec, PhD is independent under
Nasdaq listing standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominating and corporate governance committee&#8217;s responsibilities include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    and recommending to the board of directors&#8217; criteria for board and committee membership;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    procedures for identifying and evaluating board of director candidates, including nominees recommended by shareholders;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the composition of the board of directors to ensure that it is composed of members containing the appropriate skills and expertise
    to advise us;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying
    individuals qualified to become members of the board of directors;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    to the board of directors the persons to be nominated for election as directors and to each of the board&#8217;s committees;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and recommending to the board of directors&#8217; appropriate corporate governance guidelines; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    the evaluation of our board of directors.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
Governance</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the effectiveness of the registration statement of which this prospectus is a part, we will adopt a written code of business conduct
and ethics that applies to our directors, officers, and employees, including our principal executive officer, principal financial officer,
principal accounting officer, or controller, or persons performing similar functions. Following the effectiveness of the registration
statement of which this prospectus is a part, a current copy of this code will be posted on the Corporate Governance section of our website,
which is located at www.NeOncco.com. The information on our website is deemed not to be incorporated in this prospectus or to be a part
of this prospectus. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for
any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form&nbsp;8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Scientific
Advisory Board</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have assembled a scientific advisory board with expertise in oncology and clinical trials. The members of our scientific advisory board
have made significant scientific contributions in their individual fields. Members of our scientific advisory board provide strategic
advice to us in fields pertinent to gynecologic oncology and perform other such services as may be mutually determined by us and the
scientific advisory board member. Our scientific advisory board meets on an as-needed basis, based on our need for advice in their fields
of expertise from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
provide compensation for their time and on a per meeting basis to members of our scientific advisory board. We also reimburse each member
of our scientific advisory board for all reasonable and necessary travel expenses in connection with the performance of his services.
We have also granted Dr. Holloway an option to purchase shares of our common stock. Our scientific advisory board includes: Dr. Patrick
Y. Wen, MD, Axel H. Sch&ouml;nthal, PhD, Dr. Iyabo Tinubu-Karch, Dr. David M. Peereboom, Dr. Daniel Levin and Dr. Thomas Chen.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Leadership Structure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors and management believe that the choice of whether
the Chair of our Board of Directors should be an executive of the Company, or a non-executive or independent director, depends upon a
number of factors, taking into account the candidates for the position and the best interests of the Company and its shareholders. Dr.
Chen serves as the Board Chair. Dr. Chen&rsquo;s operating and leadership experience as an officer and director of our company since its
inception made him a compelling choice for Board Chair. Dr. Chiang will serve as lead independent director of our Board of Directors.
As lead independent director, Dr. Chiang will preside over executive sessions of the independent directors and serves as a liaison between
the independent directors and our management team.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
Oversight</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board oversees a company-wide approach to risk management. Our Board will determine the appropriate risk level for us generally, assess
the specific risks faced by us and review the steps taken by management to manage those risks. While our Board has ultimate oversight
responsibility for the risk management process, its committees will oversee risk in certain specified areas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically,
our compensation committee will be responsible for overseeing the management of risks relating to our executive compensation plans and
arrangements, and the incentives created by the compensation awards it administers. Our audit committee will oversee management of enterprise
risks and financial risks, as well as potential conflicts of interest. Our Board is responsible for overseeing the management of risks
associated with the independence of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation
Committee Interlocks and Insider Participation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our officers currently serves, or has served during the last completed fiscal year, on the compensation committee or board of directors
of any other entity that has one or more officers serving as a member of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
and Officer Indemnification Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to enter into separate indemnification agreements with our directors and executive officers, in addition to the indemnification
provided for in our certificate of incorporation and bylaws. These agreements, among other things, require us to indemnify our directors
and executive officers for certain expenses, including attorneys&#8217; fees, judgments, penalties, fines and settlement amounts incurred
by a director or executive officer in any action or proceeding arising out of their services as one of our directors or executive officers
or as a director or executive officer of any other company or enterprise to which the person provides services at our request. The indemnification
agreements and our certificate of incorporation and bylaws require us to indemnify our directors and officers to the fullest extent permitted
by Delaware law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXECUTIVE
COMPENSATION</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides certain information regarding compensation awarded to, earned by or paid to persons serving as our principal
executive officer and our principal financial officer during the year ended December&nbsp;31, 2022 and 2021*.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Compensation Table</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Name
    and Principal Position</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Fiscal<BR>
    Year</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Salary<BR>
    Paid<BR> ($)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Bonus<BR>
    ($)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock<BR>
    Awards<BR> ($)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Option<BR>
    Awards<BR> ($)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Non-Equity<BR>
    Incentive<BR> Plan<BR> Compensation<BR> ($)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Non-<BR>
    Qualified<BR> Deferred<BR> Compensation<BR> Earnings<BR> ($)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Other<BR>
    Compensation<BR> ($)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total<BR>
    ($)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Dr.
    Thomas C. Chen &ndash; <BR>
    Chief Executive Officer</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2022</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2021</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,262,724</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><SUP>(1)</SUP>&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,262,724</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Patrick
    Walters &ndash; <BR>
    President and Chief Operating Officer<SUP>(2)</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2022</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">50,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">50,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2021</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">688,758</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><SUP>(1)</SUP>&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">688,758</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Keithly
    Garnett &ndash;<BR>
    Chief Financial Officer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2022</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2021</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT></TD>
    <TD STYLE="padding-left: -0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such Options were converted
    to shares of common stock of NeOnc Technologies Holdings, Inc. immediately prior to the Share Exchange.</FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Walters served as our
    Chief Financial Officer until April&nbsp;7, 2023.</FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Nothing was paid
    out in 2021 as executive compensation.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-Employee
Director Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not pay any compensation, make any equity awards or non-equity awards to, or pay any other compensation to any of the non-employee
members of our board of directors in 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023
Incentive Stock Plan</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a 2023 Incentive Stock Plan (the &#8220;2023 Plan&#8221;). An aggregate of 4,000,000 shares of our common stock
is reserved for issuance and available for awards under the 2023 Plan, including incentive stock options granted under the 2023 Plan.
The 2023 Plan administrator may grant awards to any employee, director, consultant or other person providing services to us or our affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Plan is currently administered by the Board. The 2023 Plan administrator has the authority to determine, within the limits of the
express provisions of the 2023 Plan, the individuals to whom awards will be granted, the nature, amount and terms of such awards and
the objectives and conditions for earning such awards. The Board may at any time amend or terminate the 2023 Plan, provided that no such
action may be taken that adversely affects any rights or obligations with respect to any awards previously made under the 2023 Plan without
the consent of the recipient. No awards may be made under the 2023 Plan after the tenth anniversary of its effective date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
under the 2023 Plan may include incentive stock options, nonqualified stock options, restricted shares of common stock and restricted
stock units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock
Options</I>. The 2023 Plan administrator may grant to a participant options to purchase our common stock that qualify as incentive
stock options for purposes of Section&nbsp;422 of the Internal Revenue Code (&#8220;incentive stock options&#8221;), options that do
not qualify as incentive stock options (&#8220;non-qualified stock options&#8221;) or a combination thereof. The terms and
conditions of stock option grants, including the quantity, price, vesting periods, and other conditions on exercise will be
determined by the 2023 Plan administrator. The exercise price for stock options will be determined by the 2023 Plan administrator in
its discretion, but non-qualified stock options and incentive stock options may not be less than 100% of the fair market value of
one share of our Company&#8217;s common stock on the date when the stock option is granted. Additionally, in the case of incentive
stock options granted to a holder of more than 10% of the total combined voting power of all classes of our stock on the date of
grant, the exercise price may not be less than 110% of the fair market value of one share of common stock on the date the stock
option is granted. Stock options must be exercised within a period fixed by the 2023 Plan administrator that may not exceed ten
years from the date of grant, except that in the case of incentive stock options granted to a holder of more than 10% of the total
combined voting power of all classes of our stock on the date of grant, the exercise period may not exceed five years. At the 2023
Plan administrator&#8217;s discretion, payment for shares of common stock on the exercise of stock options may be made in cash,
shares of our common stock held by the participant or in any other form of consideration acceptable to the 2023 Plan administrator
(including one or more forms of &ldquo;cashless&#8221; or &#8220;net&#8221; exercise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Restricted
Shares and Restricted Units</I>. The 2023 Plan administrator may award to a participant shares of common stock subject to specified restrictions
(&#8220;restricted shares&#8221;). Restricted shares are subject to forfeiture if the participant does not meet certain conditions such
as continued employment over a specified forfeiture period and/or the attainment of specified performance targets over the forfeiture
period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_013"></A>PRINCIPAL
SHAREHOLDERS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information with respect to the beneficial ownership of our shares as of _____, 2023 by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    named executive officer;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our directors and director nominees;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    directors, director nominees and executive officers as a group; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person or entity known by us to own beneficially more than 5% of our common stock.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the rules and regulations of the SEC, and the information is not necessarily indicative of beneficial ownership for any
other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities
named in the table below have sole voting and sole investment power with respect to all shares that they beneficially own, subject to
applicable community property laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable
percentage ownership before the offering is based on 16,000,000 shares of common stock outstanding. In computing the number of shares
beneficially owned by a person and the percentage ownership of such person, we deemed to be outstanding all shares subject to options
held by the person that are currently exercisable, or exercisable or would vest based on service-based vesting conditions within 60 days
of ____________, 2023. However, except as described above, we did not deem such shares outstanding for the purpose of computing the percentage
ownership of any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, the address for each beneficial owner listed in the table below is c/o NeOnc Technologies Holdings, Inc., 8335 Sunset
Boulevard, Suite 240, Los Angeles, CA 90069:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name
    and Address of Beneficial Owner</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of<BR> shares<BR> beneficially<BR> owned</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percentage<BR>
    of shares<BR> beneficially<BR> owned <BR> before <BR> Offering</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percentage
    <BR> of shares <BR> beneficially <BR> owned after <BR> Offering</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Directors,
    Director Nominees and Executive Officers:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr.
    Thomas C. Chen</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,839,321</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(1)</SUP>&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.75</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Patrick
    Walters</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">587,905</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Keithly
    Garnett</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amir
    Heshmatpour</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,950,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(2)</SUP>&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">30.94</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr.
    Alan Chiang</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nasim
    Shomali</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr.
    Sikirat Iyabo Tinubu-Karch</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Richard
    Nanula</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Victoria
    Medvec, PhD.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
    executive officers, directors and director nominees as a group (9 persons)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,964,726</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">49.78</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    5% of greater shareholders:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Neucen
    Biomedical Co. LTD<SUP>(3)</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">888,148</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.55</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents shares of our
    common stock held of record by TR Chen Third Family Limited Partnership over which Mr. Chen and Mr. Chen&#8217;s spouse, Rosa Chen,
    exercise sole voting and investment control. The address of TR Chen Third Family Limited Partnership is c/o NeOnc Technologies Holding,
    Inc., 8335 Sunset Blvd., Suite 240, Los Angeles CA 90069.</FONT></TD> </TR>
  </TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 3,712,500
    shares of our common stock held of record by AFH Holding and Advisory, LLC, of which Mr. Heshmatpour is the sole member and over
    which he has sole voting and investment control; (ii) 550,000 shares of our common stock held of record by KIG LLC of which Mr. Heshmatpour&#8217;s
    spouse, Kathy Heshmatpour, exercises sole voting and investment control; (iii) 275,000 shares held by Angelina Heshmatpour, the minor
    daughter of Mr. Heshmatpour, (iv) 275,000 shares held by Amir Heshmatpour, and (v) 137,500 shares held by Amir &amp; Kathy Heshmatpour
    Family Fund. The address of AFH Holding and Advisory, LLC is c/o NeOnc Technologies Holding, Inc., 8335 Sunset Blvd., Suite 240,
    Los Angeles CA 90069.</FONT></TD> </TR>
  </TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The address of Neucen Biomedical
    Co. LTD is 5-1F, No. 88, Sec. 2, Chong-Qing N. Rd., Taipei 10345, Taiwan. Dr. Alan Chiang and affiliates own 17% of the ownership
    interest of Neucen Biomedial Co. LTD. Dr. Thomas C. Chen owns approximately 5% of the ownership interest of Neucen Biomedical Co.
    LTD.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_014"></A>CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as disclosed below, and except for the compensation arrangements and regular salary and bonus payments made to our directors and
officers in the ordinary course of business as described in &#8220;<I>Executive Compensation</I>,&#8221; there have been no transactions
since January&nbsp;1, 2021, or any currently proposed transaction or series of similar transactions to which the Company was or is to
be a party, in which the amount involved exceeds $120,000 and in which any current or former director or officer of the Company, any
5% or greater shareholder of the Company or any member of the immediate family of any such persons had or will have a direct or indirect
material interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Letter
of Intent &#8211; AFH Holdings and Advisory, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December&nbsp;19,
2022, NeOnc Technologies, Inc. entered into an engagement agreement with AFH Holdings and Advisory, LLC (&ldquo;AFH&rdquo;). Amir
Heshmatpour is the sole member and managing director of AFH and a member of NeOnc&rsquo;s Board of Directors. AFH was engaged to
assist NeOnc Technologies, Inc. in connection with its intent to effect a public listing. AFH was retained to assist NeOnc
Technologies, Inc. with investor presentations and decks, coordinate the retention of an investment banker for an initial public
offering, identify legal and accounting professionals to assist in connection with such public offering, identify investor
relations/public relations firms, advise on private capital markets activities prior to the initial public offering and coordinate
the closing process for the offering. AFH agreed to advance costs of up to $500,000 for such professionals on behalf of the Company
to be repaid out of proceeds from the initial public offering. As of March&nbsp;31, 2023, approximately $101,078 of such advances
have taken place. As partial compensation for such services, NeOnc Technologies, Inc. agreed to effect a share exchange with NeOnc
Technologies Holdings, Inc., a special purpose entity substantially beneficially owned by Amir Heshmatpour
and his affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April&nbsp;7, 2023, NeOnc
Technologies, Inc. entered into a Share Exchange Agreement (the &ldquo;Share Exchange&rdquo;) with NeOnc Technologies Holdings, Inc.,
whereby all of the shareholders of NeOnc Technologies, Inc. exchanged their stock in NeOnc Technologies, Inc. for a total of 10,500,000
shares of common stock in NeOnc Technologies Holdings, Inc. As a result, all shareholders of NeOnc Technologies, Inc. became shareholders
of NeOnc Technologies Holdings, Inc. and NeOnc Technologies, Inc. became a wholly-owned subsidiary of NeOnc Technologies Holdings, Inc.
At the consummation of this transaction, Amir Heshmatpour, AFH, and their affiliated entities, individuals, or assignees owned an aggregate
of 34.6% of the fully diluted issued and outstanding common shares of NeOnc Technologies Holdings, Inc. For the year ended December 31,
2022, NeOnc Technologies Holdings, Inc. had no operations or assets other than cash paid by its shareholders for their shares ($4,500 in
the aggregate) and liabilities of $50,000 pertaining to an amount owing to Mr. Heshmatpour for an a professional retainer paid by him
on behalf of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, NeOnc Technologies, Inc. agreed to retain AFH as an exclusive
advisor on all financing and mergers and acquisitions for a period of two (2) years from the closing of the private securities exchange
offering. Further to the advisory arrangement, AFH shall be paid in cash an aggregate fee in an amount equal to 2% of the post-money valuation
of NeOnc Technologies Holdings, Inc. immediately after the consummation of this offering.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholder
advances</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Periodically certain of our shareholders have advanced us funds to
support operations under informal loan arrangements (the &ldquo;Shareholder Advances&rdquo;). These Shareholder Advances bear no interest
and have no specified maturity date. There were Shareholder Advances outstanding totaling $0 and $10,000 as of December&nbsp;31, 2022
and 2021, respectively. During the year ended December&nbsp;31, 2022, we repaid all outstanding Shareholder Advances of $10,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
payable &#8211; Chairman of the Board</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August&nbsp;18, 2021, we entered into a loan agreement with the
Chairman with a principal amount of $250,000 (the &ldquo;Chairman Note&rdquo;). The Chairman Note bore no interest and was payable when
the Company received funding in excess of $1,000,000. We received funding in excess of $1,000,000 during the year ended December&nbsp;31,
2022, at which time the Chairman Note was repaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advances
from Chairman</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have periodically received cash advances from the Chairman or has
had certain costs incurred USC on our behalf paid for by the Chairman. These advances were non-interest bearing and had no stated maturity.
At December&nbsp;31, 2021, the balance outstanding was $897,891. During the year ended December&nbsp;31, 2022, we repaid in cash $700,000
of such advances to the Chairman and $197,891 was converted to 395,782 shares of common stock on December&nbsp;31, 2022. The fair value
of the common stock issued of $395,782 exceeded the remaining balance due the Chairman. Such excess fair value of $197,891 was recorded
as interest expense in the statement of operations for the year ended December&nbsp;31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transactions
with USC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March&nbsp;9, 2009, we
entered into an exclusive license agreement with USC, pursuant to which USC granted a license to use certain patented technology related
to the use of monoterpenes as a solvent, specifically perillyl alcohol. This technology is the basis of the current products under development
by the Company. We granted USC 800,000 shares of common stock in exchange for the license. Additionally, pursuant to the USC Agreement,
we (1) paid USC an upfront royalty payment of $20,000, (2) granted USC common stock, (3) will pay USC an earned royalty of 2% of Net
Sales (as that term is defined in the USC Agreement), and (4) has paid and will continue to pay annual maintenance royalties of: $5,000
due January&nbsp;1, 2011, $5,000 due January&nbsp;1, 2012, $10,000 due January&nbsp;1, 2013, and $20,000 due January&nbsp;1 thereafter.
We have not paid any royalties through December&nbsp;31, 2022, since no products are being sold using such technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also utilize laboratory services from USC. The Company has incurred
approximately $442,000 and $372,000 of research and development-related costs from USC for the years ended December&nbsp;31, 2022 and
2021, respectively. We incurred approximately $20,100 and $12,000 of patent maintenance and legal-related expenses for the years ended
December&nbsp;31, 2022 and 2021, respectively. At December&nbsp;31, 2022 and 2021, we owe USC approximately $75,633 and $51,000, respectively.
From time to time, we have been unable to reimburse USC for such costs. Therefore, USC deducted certain amounts due to the Chairman for
compensation for his services as faculty at USC to satisfy the amounts due from the Company to USC. Such amounts deducted from the Chairman&rsquo;s
USC faculty compensation are recorded as Advances from the Chairman on December&nbsp;31, 2022 and 2021. Additionally, included in accounts
payable at December&nbsp;31, 2022 and 2021 are approximately $800,651 and $365,000, respectively, due to the Chairman related to such
deductions.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accrued
compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred $0 and $150,000 for the years ended December&nbsp;31,
2022 and 2021 for compensation to the Chairman and a consultant, both of whom are shareholders. This compensation is recorded in the statement
of operations as part of general and administrative expenses. The amount accrued for the Chairman and the consultant were $412,500 and
$462,000 as of December&nbsp;31, 2022 and 2021, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Short-term
loans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February&nbsp;2022, we
entered into a $75,000 loan agreement bearing interest at 2.5% per annum with a maturity date of August&nbsp;2022 from a Martin Schmieg,
a former executive officer of NeOnc Technologies, Inc. The loan was paid off in December&nbsp;2022. Interest expense paid related to this
loan for the year ended December&nbsp;31, 2022 was approximately $1,500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive officers and directors beneficially own substantially
all of the membership interests of HCWG LLC, an entity which has loaned us approximately $2.8 million to cover operating expenses after
December&nbsp;31, 2022. This short term loan does not bear interest, matures after twelve months after the date of issuance and is repayable
with a 1x return in full from the proceeds of this offering.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>



<!-- Field: Page; Sequence: 157; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock-Based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December&nbsp;31, 2021 NeOnc Technologies, Inc.
issued stock options for 7,250,000 shares of common stock to directors and advisors and, in connection with the Chairman Note, 250,000
options to the Dr. Thomas Chen at an exercise price of $0.66 per share. On December&nbsp;31, 2022, all of the option holders converted
the then aggregate outstanding options to acquire 18,705,451 shares into 9,150,051 shares of common stock pursuant to the cashless exercise
provision of the 2013 Option Plan. A portion of the outstanding options (those with an exercise price of $1.25 per share) were repriced
to an exercise price of $1.00 immediately before the cashless exercise. This modification of the stock option resulted in a charge to
share-based compensation of $182,243, which is recorded within general and administrative expenses on the statement of consolidated operations
during the year ended December&nbsp;31, 2022. The remaining outstanding stock options to acquire 166,060 shares of common stock were cancelled
during 2023 per cancellation agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Collaboration
and License Agreement between NeOnc and Orient EuroPharma Co., Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November&nbsp;8, 2013, we entered into a Collaboration and License
Agreement with Orient EuroPharma Co., Ltd. (&ldquo;OEP&rdquo;), which is partially owned by Alan Chiang, a director of the Company pursuant
to which NeOnc licensed OEP the right to commercialize NEO100. We terminated this Collaboration and License Agreement on June&nbsp;14,
2023.</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreement by and between NeOnc Technologies and Neucen Biomedical Co., Ltd</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December&nbsp;5, 2015,
we previously entered into a License Agreement with Neucen Biomedical Co. Ltd. (&ldquo;Neucen&rdquo;), which is owned by Alan Chiang and
Thomas Chen, pursuant to which NeOnc licensed to Neucen the right to commercialize NEO212. We terminated this License Agreement on May&nbsp;30,
2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 158; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_015"></A>DESCRIPTION
OF SECURITIES</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description summarizes the most important terms of our capital stock and certain provisions of our amended and restated certificate
of incorporation and amended and restated bylaws that will become effective immediately prior to the completion of this offering. This
summary does not purport to be complete and is qualified in its entirety by the provisions of our amended and restated certificate of
incorporation and amended and restated bylaws, copies of which have been filed as exhibits to the Registration Statement of which this
prospectus is a part, and by the applicable provisions of Delaware law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently
and upon filing of our amended and restated certificate of incorporation, our authorized capital stock consists of 110,000,000 shares
of capital stock, of which (i) 100,000,000 shares are common stock with a par value $0.0001 per share and (ii) 10,000,000 shares are
preferred stock with a par value of&#8201;$0.0001 per share. All of our authorized shares of preferred stock will be undesignated. As
of ___________, 2023, there were 16,000,000 shares of common stock and no shares of preferred stock  issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of common stock are entitled to one vote per share on all matters
to be voted upon by the shareholders, including the election of directors. Such holders are not entitled to vote cumulatively for the
election of directors. Our amended and restated certificate of incorporation that will become effective immediately prior to the completion
of this offering establishes a classified board of directors that is divided into three classes with staggered three-year terms. Only
the directors in one class will be subject to election by a plurality of the votes cast at each annual meeting of our shareholders, with
the directors in the other classes continuing for the remainder of their respective three-year terms. The affirmative vote of holders
of at least 66 2/3% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be required
to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended
and restated bylaws, the classified structure of our board of directors, the size of our board of directors, removal of directors, director
liability, vacancies on our board of directors, special meetings, shareholder notices, actions by written consent, and exclusive jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividends</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to preferences that may be applicable to any outstanding preferred
stock, our common shareholders are entitled to receive ratably such dividends, if any, as may be declared from time to time by the board
of directors out of funds legally available for that purpose. We have never declared or paid any cash dividends on our capital stock.
We currently expect to retain future earnings, if any, to finance the growth and development of our business and do not anticipate paying
any cash dividends in the foreseeable future. See the section titled &ldquo;<I>Dividend Policy</I>&rdquo; for further information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liquidation
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of our liquidation, dissolution or winding up, our common
shareholders are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights
of preferred stock, if any, then outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>No
Preemptive or Similar Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common shareholders have no preemptive or conversion rights or
other subscription rights. There are no redemption or sinking fund provisions applicable to the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon filing of our amended and restated certificate of incorporation
that will become effective immediately prior to the completion of this offering, our board of directors is authorized, without action
by the shareholders, to designate and issue up to 10,000,000 shares of preferred stock in one or more series and to designate the powers,
preferences and rights of each series, which may be greater than the rights of the common stock. It is not possible to state the actual
effect of the issuance of any shares of preferred stock upon the rights of holders of the common stock until the board of directors determines
the specific rights of the holders of such preferred stock. However, the effects might include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairing dividend rights
    of the common stock;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diluting the voting power
    of the common stock;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairing the liquidation
    rights of the common stock; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delaying or preventing a change in control of us without further action by the shareholders</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
Promissory Note</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022, NeOnc
Technologies, Inc. issued a $50,000 convertible note to a shareholder due August&nbsp;30, 2023 (&ldquo;Note&rdquo;). The Note bears
interest at 2% per annum and is convertible. The Note and all accrued interest thereon is convertible, at the option of the
noteholder, into the class and series of equity securities (&ldquo;Conversion Stock&rdquo;) that is sold by us in its next issuance
of equity securities in a Financing Transaction (as defined below), consummated after the issuance date of the note. A Financing
Transaction is a sale, other than in an initial public offering, of equity securities by us to investors for cash. The Financing
Transaction does not include the issuance of stock, options, or warrants to service providers in connection with the rendition of
such services or to third parties in connection with the contribution of non-cash assets tous. The number of shares of Conversion
Stock to be issued to the noteholder upon such conversion shall be equal to the quotient obtained by dividing (i) the entire
principal amount of the Note plus accrued interest by (ii) the Financing Transaction conversion price, which shall be equal to 75%
of the price paid for one share of Conversion Stock by the investors in the Financing Transaction. The entire principal amount of
and accrued interest of the Note shall automatically be converted, without further action on the part of the noteholder or us, into
the class and series of stock issued by us, at the closing of an initial public offering. The number of shares of stock to be issued
to the holder upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal amount of the Note
plus accrued interest by (ii) the initial public offering conversion price, which shall be equal to 75% of the price paid for one
share of Conversion Stock by the investors in the initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Takeover
Provisions<FONT STYLE="font-weight: normal"> </FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
of Incorporation and Bylaws</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because our shareholders do not have cumulative voting rights, our
shareholders holding a majority of the outstanding shares of common stock outstanding will be able to elect all of our directors. Our
amended and restated certificate of incorporation and our amended and restated bylaws, each to be effective immediately prior to the closing
of this offering, will provide for shareholder actions at a duly called meeting of shareholders. A special meeting of shareholders may
be called by a majority of our board of directors, the chair of our board of directors, or our chief executive officer or president. Our
amended and restated bylaws will establish an advance notice procedure for shareholder proposals to be brought before an annual meeting
of our shareholders, including proposed nominations of persons for election to our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described above in &#8220;<I>Management&#8212;Corporate Governance,&#8221;</I> in accordance with our amended and restated certificate
of incorporation to be filed in connection with this offering, our board of directors will be divided into three classes with staggered
three-year terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing provisions will make it more difficult for our existing
shareholders to replace our Board of Directors as well as for another party to obtain control of us by replacing our Board of Directors.
Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for
existing shareholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock
makes it possible for our Board of Directors to issue preferred stock with voting or other rights or preferences that could impede the
success of any attempt to change our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions are intended to enhance the likelihood of continued stability in the composition of our Board of Directors and its policies
and to discourage certain types of transactions that may involve an actual or threatened acquisition of us. These provisions are also
designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy
fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the
effect of deterring hostile takeovers or delaying changes in our control or management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;203
of the Delaware General Corporation Law</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to Section&nbsp;203
of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested
shareholder for a period of three years after the date that such shareholder became an interested shareholder, with the following exceptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the shareholder becoming an interested shareholder;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">upon closing of the transaction that resulted in the shareholder becoming an interested shareholder, the interested shareholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested shareholder) those shares owned by (i) persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">on or after such date, the
    business combination is approved by the board of directors and authorized at an annual or special meeting of the shareholders, and
    not by written consent, by the affirmative vote of at least 66 2&#8725;3% of the outstanding voting stock that is not owned by the
    interested shareholder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, Section&nbsp;203 defines
business combination to include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">any merger or consolidation involving the corporation and the interested shareholder;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested shareholder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested shareholder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested shareholder; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">the receipt by the interested shareholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, Section&nbsp;203
defines an &ldquo;interested shareholder&rdquo; as an entity or person who, together with the person&rsquo;s affiliates and associates,
beneficially owns, or within three years prior to the time of determination of interested shareholder status did own, 15% or more of the
outstanding voting stock of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exclusive forum for adjudication of disputes provision which limits
the forum to the Delaware Court of Chancery for certain shareholder litigation matters actions against the Company, which may limit an
investor&rsquo;s ability to obtain a favorable judicial forum for disputes with the Company or its directors, officers, employees or shareholders.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated bylaws,
that will become effective immediately prior to the completion of this offering, dictate that, unless we consent in writing to the selection
of an alternative forum, the Delaware Court of Chancery (or, if the Delaware Court of Chancery does not have jurisdiction, the federal
district court for the State of Delaware) is, to the fullest extent permitted by law, the sole and exclusive forum for certain actions
including derivative action or proceeding brought on our behalf; an action asserting a breach of fiduciary duty owed by an officer, director,
employee or to the shareholders of the Company; any claim arising under Delaware corporate law, our certificate of incorporation or our
bylaws; and any action asserting a claim governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring
any interest in shares of capital stock of the Company shall be deemed to have notice of and consented to the provisions of our amended
and restated bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, this provision of
our amended and restated bylaws will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other
claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims,
Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created
by the Exchange Act or the rules and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, unless we consent
in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive
forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, or the rules and regulations promulgated
thereunder. We note, however, that Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts
over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. There is
uncertainty as to whether a court would enforce this provision and that investors cannot waive compliance with the federal securities
laws and the rules and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Delaware corporation is
allowed to mandate in its corporate governance documents a chosen forum for the resolution of state law-based shareholder actions, derivative
suits and other intra-corporate disputes. With respect to such state law claims, the Company&rsquo;s management believes limiting state
law based claims to Delaware will provide the most appropriate outcomes as the risk of another forum misapplying Delaware law is avoided,
Delaware courts have a well-developed body of case law and limiting the forum will preclude costly and duplicative litigation and avoids
the risk of inconsistent outcomes. Additionally, Delaware Chancery Courts can typically resolve disputes on an accelerated schedule when
compared to other forums.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The choice of forum provisions contained in our amended and restated
bylaws may limit a shareholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company
or any of its directors, officers, other employees or shareholders, which may discourage lawsuits with respect to such claims.
Alternatively, the enforceability of similar choice of forum provisions in other issuers&rsquo; bylaws and certificates of incorporation
has been challenged in legal proceedings, and it is possible that in connection with any applicable action brought against the Company,
a court could find the choice of forum provisions contained in our Bylaws to be inapplicable or unenforceable in such action. As a result,
we could incur additional costs associated with resolving such actions in other jurisdictions, which could harm our business, operating
results and financial condition.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer
Agent and Registrar</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have appointed VStock Transfer LLC, 18 Lafayette Pl Woodmere, NY 11598, telephone: (212) 828-8436, as the transfer agent for our common
stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
Symbol and Market</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, we intend to apply to have our shares of common stock listed on the Nasdaq Capital Market under the symbol
&#8220;___&#8221;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 162; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_016"></A>SHARES
ELIGIBLE FOR FUTURE SALE</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
the closing of this offering, there has been no public market for our common stock. Future sales of substantial amounts of our common
stock, including shares issued on the exercise of outstanding options, in the public market after this offering, or the possibility of
these sales or issuances occurring, could adversely affect the prevailing market price for our common stock or impair our ability to
raise equity capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our shares outstanding as of ______, 2023, upon the closing of this offering, a total of ______shares of common stock will be outstanding.
Of these shares, all of the common stock sold in this offering by us will be freely tradable in the public market without restriction
or further registration under the Securities Act, unless these shares are held by &#8220;affiliates,&#8221; as that term is defined in
Rule&nbsp;144 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remaining shares of common stock will be, and shares of common stock subject to stock options will be on issuance, &#8220;restricted
securities,&#8221; as that term is defined in Rule&nbsp;144 under the Securities Act. These restricted securities are eligible for public
sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rules&nbsp;144
or 701 under the Securities Act, which are summarized below. Restricted securities may also be sold outside of the United States to non-U.S.
persons in accordance with Rule&nbsp;904 of Regulation S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the lock-up agreements described below and the provisions of Rule&nbsp;144 or Regulation S under the Securities Act, as well as our
insider trading policy, these restricted securities will be available for sale in the public market after the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule&nbsp;144</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under Rule&nbsp;144
as currently in effect, once we have been subject to public company reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of
the Exchange Act for at least 90 days, an eligible shareholder is entitled to sell such shares without complying with the manner of sale,
volume limitation, or notice provisions of Rule&nbsp;144, subject to compliance with the public information requirements of Rule&nbsp;144.
To be an eligible shareholder under Rule&nbsp;144, such shareholder must not be deemed to have been one of our affiliates for purposes
of the Securities Act at any time during the 90 days preceding a sale and must have beneficially owned the shares proposed to be sold
for at least six months, including the holding period of any prior owner other than our affiliates. If such a person has beneficially
owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates,
then such person is entitled to sell such shares without complying with any of the requirements of Rule&nbsp;144, subject to the expiration
of the lock-up agreements described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under Rule&nbsp;144, as currently in effect, our affiliates
or persons selling shares on behalf of our affiliates are entitled to sell shares on expiration of the lock-up agreements described below.
Beginning 90 days after the date of this prospectus, within any three-month period, such shareholders may sell a number of shares that
does not exceed the greater of:</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1% of the number of shares
    of common stock then outstanding, which will equal approximately _____ shares immediately after this offering; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the average weekly trading
    volume of our common stock on the Nasdaq Capital Market during the four calendar weeks preceding the filing of a notice on Form&nbsp;144
    with respect to such sale.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
under Rule&nbsp;144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale
provisions and notice requirements and to the availability of current public information about us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 163; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule&nbsp;701</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rule&nbsp;701 generally allows a shareholder who was issued shares
under a written compensatory plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding
90 days, to sell these shares in reliance on Rule&nbsp;144, but without being required to comply with the public information, holding
period, volume limitation, or notice provisions of Rule&nbsp;144. Rule&nbsp;701 also permits affiliates of our company to sell their Rule&nbsp;701
shares under Rule&nbsp;144 without complying with the holding period requirements of Rule&nbsp;144. All holders of Rule&nbsp;701 shares,
however, are required by that rule to wait until 90 days after the date of this prospectus before selling those shares under Rule&nbsp;701,
subject to the expiration of the lock-up agreements described below.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
S-8 Registration Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to file one or more registration statements on Form S-8 under the Securities Act with the SEC to register the offer and sale of
shares of our common stock that are issuable under our 2023 Plan. This registration statement will become effective immediately on filing.
Shares covered by this registration statement will then be eligible for sale in the public markets, subject to vesting restrictions,
any applicable lock-up agreements described below, and Rule&nbsp;144 limitations applicable to affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-up
Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We, our executive officers and directors, and beneficial owners of
over one percent of our outstanding common stock have agreed, subject to certain exceptions, not to offer, sell, assign, transfer, pledge,
contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or similar
agreement or arrangement that transfers, in whole or in part, the economic risk of ownership of, directly or indirectly, engage in any
short selling of any common stock or securities convertible into or exchangeable or exercisable for any common stock, whether currently
owned or subsequently acquired, without the prior written consent of the representative, for a period of 180 days from the date of this
prospectus. These agreements are described in &ldquo;<I>Underwriting&mdash;Lock-Up Agreements.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 164; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_017"></A>UNDERWRITING</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering our common stock described in this prospectus through the underwriters named below. Maxim Group LLC, or Maxim or the representative,
is acting as representative of the underwriters. We have entered into an underwriting agreement with the representative. Subject to the
terms and conditions of the underwriting agreement, the underwriters have agreed to purchase, and we have agreed to sell to the underwriters,
the number of common stock listed next to its name in the following table.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underwriter</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of<BR> Shares</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Maxim
    Group LLC </FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Brookline
    Capital Markets, a division of Arcadia Securities, LLC</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Spartan
    Capital Securities LLC</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters are offering the shares of our common stock subject to their acceptance of the shares of our common stock from us and subject
to prior sale. The underwriting agreement provides that the obligations of the underwriters to pay for and accept delivery of the shares
of our common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other
conditions. The underwriters are obligated to take and pay for all of the shares of our common stock if any such shares of our common
stock are taken.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the underwriters or securities dealers may distribute prospectuses electronically.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-allotment
Option</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted to the underwriters an option exercisable not later than 45 days after the date of this prospectus to purchase up to a number
of additional shares of our common stock equal up to 15% of the shares of common stock at the public offering price per share set forth
on the cover page hereto less the underwriting discounts and commissions. The underwriters may exercise the option solely to cover overallotments,
if any, made in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriting
Discounts and Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
sold by the underwriters to the public will initially be offered at the initial offering price set forth on the cover of this prospectus.
Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share from the initial public offering price. The representative may offer the shares through one or more of their affiliates or selling
agents. If all the shares are not sold at the initial public offering price, the representative may change the offering price and the
other selling terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to pay the underwriters a cash fee equal to eight percent (8.0%) of the aggregate gross proceeds from the sale of the common
stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the underwriting discount and commission to be paid to the underwriters by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per
    Share<BR> (1)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total<BR>
    with Full<BR> Exercise of<BR> Overallotment</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Public
    offering price</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underwriting
    discount to be paid to the underwriters by us</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    to us (before expenses)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 165; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to pay the representative&#8217;s out-of-pocket accountable expenses, including the representative&#8217;s legal fees, up
to a maximum amount of $150,000 if this offering is completed. We have paid $50,000 to the representative as an advance to be applied
towards out-of-pocket expenses, or the Advance. Any portion of the Advance shall be returned back to us to the extent not actually incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the total expenses of the offering payable by us, not including the underwriting discount, will be approximately $___.
We expect the net proceeds from this offering to be approximately $__ million after deducting $_____in underwriting commissions and $_____in
our other estimated offering expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act. If we are unable
to provide this indemnification, we have agreed to contribute to payments the underwriter may be required to make in respect of those
liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and our directors and officers and any other holders of one percent
(1.0%) or more of our outstanding common stock as of the effective date of the registration statement which this prospectus forms a part
of (and all holders of securities exercisable for or convertible into one percent (1.0%) or more of our common stock) have entered into
customary &ldquo;lock-up&rdquo; agreements in favor of Maxim pursuant to which such persons and entities have agreed, for a period of
six (6) months after the effective date of the registration statement related to this offering, that they shall neither offer, issue,
sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any our securities without Maxim&rsquo;s prior
written consent, including the issuance of shares of common stock upon the exercise of currently outstanding options approved by Maxim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriter&#8217;s
Warrant</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also agreed to issue to Maxim (or its permitted assignees) a warrant to purchase a number of our shares of common stock equal to
an aggregate of 5% of the total number of securities sold in this offering (the &#8220;Underwriter&#8217;s Warrant&#8221;). The
Underwriter&#8217;s Warrant will have an exercise price equal to 110% of the public offering price of the share of common stock sold
in this offering and may be exercised on a cashless basis. The Underwriter&#8217;s Warrant is non-exercisable for six months from the
commencement of sales of this offering, and will expire five years after the commencement of sales of this offering. The Underwriter&#8217;s
Warrant is not redeemable by us. We have agreed to register the shares of common stock underlying the Underwriter&#8217;s Warrant. The
Underwriter&#8217;s Warrant also provides for one demand and unlimited &#8220;piggyback&#8221; registration rights at our expense (and
an additional demand registration at Maxim&#8217;s expense) with respect to the underlying shares of common stock during the five year
period from the commencement of sales of this offering. The Underwriter&#8217;s Warrant and the shares of common stock underlying the
Underwriter&#8217;s Warrant, have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to FINRA
Rule&nbsp;5110(e)(1). The underwriters (or permitted assignees under the Rule) may not sell, transfer, assign, pledge or hypothecate
the Underwriter&#8217;s Warrant or the securities underlying the Underwriter&#8217;s Warrant, nor will they engage in any hedging, short
sale, derivative, put or call transaction that would result in the effective economic disposition of the Underwriter&#8217;s Warrant
or the underlying securities for a period of 180 days from the commencement of sales of this offering, except to any FINRA member participating
in the offering, their officers or partners, registered persons or affiliates. The Underwriter&#8217;s Warrant will provide for adjustment
in the number and price of such Underwriter&#8217;s Warrant (and the shares of common stock underlying such Underwriter&#8217;s Warrant)
to prevent dilution in the event of a forward or reverse stock split, stock dividend or similar recapitalization. The Underwriter&#8217;s
Warrants shall further provide for anti-dilution protection (adjustment in the number and price of such warrants and the shares underlying
such warrants) resulting from corporate events (which would include dividends, reorganizations, mergers, etc.).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 166; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->162<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed to grant Maxim, upon the closing of this offering, for
a period of twelve (12) months from such closing, a right of first refusal to act as lead managing underwriter and lead book runner, lead
placement agent, or lead sales agent with minimum economics of 70%, for any and all future public or private equity, equity-linked or
debt (excluding commercial bank debt) offerings for which we retain the service of an underwriter, agent, advisor, finder or other similar
person or entity in connection with such offering during such twelve (12) months period of our Company, or any successor to or any subsidiary
of our Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriter and its affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings in
the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions
for these transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
Public Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has not been a public market for our securities in the U.S. and the public offering price for our common stock
will be determined through negotiations between us and the underwriter. Among the factors to be considered in these negotiations will
be prevailing market conditions, our financial information, market valuations of other companies that we and the underwriter believe
to be comparable to us, estimates of our business potential, the present state of our development and other factors deemed relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
offer no assurances that the initial public offering price will correspond to the price at which our common stock will trade in the public
market subsequent to this offering or that an active trading market for our common stock will develop and continue after this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
Exchange</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to apply to list our common stock on the Nasdaq Capital Market, under the symbol &#8220;____&#8221; There can be no assurance
that we will be successful in listing our common stock on the Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available on websites or through other online services maintained by the underwriter of this
offering, or by their affiliates. Other than the prospectus in electronic format, the information on any underwriter&#8217;s website
and any information contained in any other website maintained by an underwriter is not part of this prospectus or the registration statement
of which this prospectus forms a part, has not been approved and/or endorsed by us or any underwriter in its capacity as underwriter,
and should not be relied upon by investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price
Stabilization, Short Positions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the underwriter may engage in activities that stabilize, maintain or otherwise affect the price of our
common stock during and after this offering, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stabilizing transactions;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">short sales;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases to cover positions
    created by short sales;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition of penalty bids;
    and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">syndicate covering transactions.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 167; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->163<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stabilizing
transactions consist of bids or purchases made for the purpose of preventing or retarding a decline in the market price of our common
stock while this offering is in progress. Stabilization transactions permit bids to purchase the underlying security so long as the stabilizing
bids do not exceed a specified maximum. These transactions may also include making short sales of our common stock, which involve the
sale by the underwriter of a greater number of common stock than they are required to purchase in this offering and purchasing common
stock on the open market to cover short positions created by short sales. Short sales may be &#8220;covered short sales,&#8221; which
are short positions in an amount not greater than the underwriter&#8217;s option to purchase additional shares referred to above, or
may be &#8220;naked short sales,&#8221; which are short positions in excess of that amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriter may close out any covered short position by either exercising their option, in whole or in part, or by purchasing shares
in the open market. In making this determination, the underwriter will consider, among other things, the price of shares available for
purchase in the open market as compared to the price at which they may purchase shares through the over-allotment option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naked
short sales are short sales made in excess of the over-allotment option. The underwriter must close out any naked short position by purchasing
shares in the open market. A naked short position is more likely to be created if the underwriter is concerned that there may be downward
pressure on the price of the common stock in the open market that could adversely affect investors who purchased in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriter also may impose a penalty bid. This occurs when a particular underwriter repays to the underwriter a portion of the underwriting
discount received by it because Maxim has repurchased shares sold by or for the account of that underwriter in stabilizing or short covering
transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
stabilizing transactions, short sales, purchases to cover positions created by short sales, the imposition of penalty bids and syndicate
covering transactions may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a
decline in the market price of our common stock. As a result of these activities, the price of our common stock may be higher than the
price that otherwise might exist in the open market. The underwriter may carry out these transactions on the Nasdaq Capital Market, in
the over-the-counter market or otherwise. Neither we nor the underwriter make any representation or prediction as to the effect that
the transactions described above may have on the price of the shares. Neither we, nor the underwriter make any representation that the
underwriter will engage in these stabilization transactions or that any transaction, once commenced, will not be discontinued without
notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Determination
of Offering Price</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there was no public market for our common stock. The initial public offering price will be determined by negotiation
between us and Maxim. The principal factors to be considered in determining the initial public offering price include, but not limited
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the information set forth
    in this prospectus and otherwise available to Maxim;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our history and prospects
    and the history and prospects for the industry in which we compete;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our past and present financial
    performance;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our prospects for future
    earnings and the present state of our development;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the general condition of
    the securities market at the time of this offering;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the recent market prices
    of, and demand for, publicly traded shares of generally comparable companies; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other factors deemed relevant
    by the underwriter and us.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated public offering price range set forth on the cover page of this preliminary prospectus is subject to change as a result of
market conditions and other factors. Neither we nor the underwriter can assure investors that an active trading market will develop for
our common stock or that the common stock will trade in the public market at or above the initial public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 168; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->164<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Affiliations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriter and its respective affiliates are full service financial institutions engaged in various activities, which may include securities
trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging,
financing and brokerage activities. The underwriter and its affiliates may from time to time in the future engage with us and perform
services for us or in the ordinary course of their business for which they will receive customary fees and expenses. In the ordinary
course of their various business activities, the underwriter and its respective affiliates may make or hold a broad array of investments
and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for
their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or
instruments of us. The underwriter and its respective affiliates may also make investment recommendations and/or publish or express independent
research views in respect of these securities or instruments and may at any time hold, or recommend to clients that they acquire, long
and/or short positions in these securities and instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offer
Restrictions Outside the United States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
action has been taken in any jurisdiction (except in the United States) that would permit a public offering of the common stock the possession,
circulation or distribution of this prospectus or any other material relating to us or the common stock in any jurisdiction where action
for that purpose is required. Accordingly, the common stock may not be offered or sold, directly or indirectly, and neither this prospectus
nor any other material or advertisements in connection with the common stock may be distributed or published, in or from any country
or jurisdiction except in compliance with any applicable laws, rules and regulations of any such country or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selling
Restrictions</B> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Canada</I></B>.
The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument 45-106 <I>Prospectus Exemptions</I> or subsection&nbsp;73.3(1) of the Securities Act (Ontario), and
are permitted clients, as defined in National Instrument 31 103 <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>.
Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements
of applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised
by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser
should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars
of these rights or consult with a legal advisor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to section&nbsp;3A.3 of National Instrument 33 105 <I>Underwriting Conflicts</I> (NI 33 105), the underwriters are not required to comply
with the disclosure requirements of NI 33-105 regarding underwriters conflicts of interest in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>European
Economic Area. </I></B>In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive
(each, a &#8220;Relevant Member State&#8221;) an offer to the public of any securities may not be made in that Relevant Member State,
except that an offer to the public in that Relevant Member State of any securities may be made at any time under the following exemptions
under the Prospectus Directive, if they have been implemented in that Relevant Member State:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    any legal entity which is a qualified investor as defined in the Prospectus Directive;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural
    or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive,
    subject to obtaining the prior consent of the representatives for any such offer; or</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 169; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->165<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall
    result in a requirement for the publication by us or any underwriters of a prospectus pursuant to Article 3 of the Prospectus Directive.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to any securities in any Relevant Member
State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to
be offered so as to enable an investor to decide to purchase any securities, as the same may be varied in that Member State by any measure
implementing the Prospectus Directive in that Member State, the expression &#8220;Prospectus Directive&#8221; means Directive 2003/71/EC
(and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes
any relevant implementing measure in the Relevant Member State, and the expression &#8220;2010 PD Amending Directive&#8221; means Directive
2010/73/EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>United
Kingdom.</I></B> Each underwriter has represented and agreed that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement
    to engage in investment activity (within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000 (the FSMA))
    received by it in connection with the issue or sale of the securities in circumstances in which Section&nbsp;21(1) of the FSMA does
    not apply to us; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the securities
    in, from or otherwise involving the United Kingdom.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Switzerland.
</I></B>The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (the <I>SIX</I>) or
on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure
standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing
prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility
in Switzerland. Neither this document nor any other offering or marketing material relating to the securities or the offering may be
publicly distributed or otherwise made publicly available in Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
this document nor any other offering or marketing material relating to the offering, or the securities have been or will be filed with
or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will
not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of securities has not been and will not be
authorized under the Swiss Federal Act on Collective Investment Schemes (<I>CISA</I>). Accordingly, no public distribution, offering
or advertising, as defined in CISA, its implementing ordinances and notices, and no distribution to any non-qualified investor, as defined
in CISA, its implementing ordinances and notices, shall be undertaken in or from Switzerland, and the investor protection afforded to
acquirers of interests in collective investment schemes under CISA does not extend to acquirers of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Australia.
</I></B>No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian
Securities and Investments Commission (<I>ASIC</I>), in relation to the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001
(the <I>Corporations Act</I>) and does not purport to include the information required for a prospectus, product disclosure statement
or other disclosure document under the Corporations Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
offer in Australia of the securities may only be made to persons (the <I>Exempt Investors</I>) who are &#8220;sophisticated investors&#8221;
(within the meaning of section&nbsp;708(8) of the Corporations Act), &#8220;professional investors&#8221; (within the meaning of section&nbsp;708(11)
of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section&nbsp;708 of the Corporations Act so that
it is lawful to offer the securities without disclosure to investors under Chapter 6D of the Corporations Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 170; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->166<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page --> <!-- Field: Split-Segment -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the
date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act
would not be required pursuant to an exemption under section&nbsp;708 of the Corporations Act or otherwise or where the offer is pursuant
to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring securities must observe such Australian
on-sale restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains general information only and does not take account of the investment objectives, financial situation or particular
needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment
decision, investors need to consider whether the information in this prospectus is appropriate to their needs, objectives and circumstances,
and, if necessary, seek expert advice on those matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notice
to Prospective Investors in the Cayman Islands.</I></B> No invitation, whether directly or indirectly, may be made to the public in the
Cayman Islands to subscribe for our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Taiwan</I></B>.
The securities have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities
laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes
an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory
Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise intermediate
the offering and sale of the securities in Taiwan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notice
to Prospective Investors in Hong Kong</I></B>. The contents of this prospectus have not been reviewed by any regulatory authority in
Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of this prospectus,
you should obtain independent professional advice. Please note that (i) our securities may not be offered or sold in Hong Kong, by means
of this prospectus or any document other than to &#8220;professional investors&#8221; within the meaning of Part I of Schedule&nbsp;1
of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) (SFO) and any rules made thereunder, or in other circumstances which
do not result in the document being a &#8220;prospectus&#8221; within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong)
(CO) or which do not constitute an offer or invitation to the public for the purpose of the CO or the SFO, and (ii) no advertisement,
invitation or document relating to our securities may be issued or may be in the possession of any person for the purpose of issue (in
each case whether in Hong Kong or elsewhere) which is directed at, or the contents of which are likely to be accessed or read by, the
public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to the securities which
are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; within the meaning
of the SFO and any rules made thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notice
to Prospective Investors in the People&#8217;s Republic of China</I></B>. This prospectus may not be circulated or distributed in the
PRC and the shares may not be offered or sold, and will not offer or sell to any person for re-offering or resale directly or indirectly
to any resident of the PRC except pursuant to applicable laws, rules and regulations of the PRC. For the purpose of this paragraph only,
the PRC does not include Taiwan and the special administrative regions of Hong Kong and Macau.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notice
to prospective investors in Japan.</I></B> The shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of
the Financial Instruments and Exchange Act. Accordingly, none of the shares nor any interest therein may be offered or sold, directly
or indirectly, in Japan or to, or for the benefit of, any &#8220;resident&#8221; of Japan (which term as used herein means any person
resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale,
directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration
requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations
and ministerial guidelines of Japan in effect at the relevant time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 171; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->167<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notice
to prospective investors in Israel.</I></B> In the State of Israel this prospectus supplement shall not be regarded as an offer to the
public to purchase shares of common stock under the Israeli Securities Law, 5728&#8212;1968, which requires a prospectus to be published
and authorized by the Israel Securities Authority, if it complies with certain provisions of Section&nbsp;15 of the Israeli Securities
Law, 5728&#8211;1968, including, inter alia, if: (i) the offer is made, distributed or directed to not more than 35 investors, subject
to certain conditions, or the Addressed Investors, or (ii) the offer is made, distributed or directed to certain qualified investors
defined in the First Addendum of the Israeli Securities Law, 5728&#8212;1968, subject to certain conditions, or the Qualified Investors.
The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities
in addition to the 35 Addressed Investors. The company has not and will not take any action that would require it to publish a prospectus
in accordance with and subject to the Israeli Securities Law, 5728&#8212;1968. We have not and will not distribute this prospectus supplement
or make, distribute or direct an offer to subscribe for our common stock to any person within the State of Israel, other than to Qualified
Investors and up to 35 Addressed Investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualified
Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities
Law, 5728&#8212;1968. In particular, we may request, as a condition to be offered common stock, that Qualified Investors will each represent,
warrant and certify to us and/or to anyone acting on our behalf: (i) that it is an investor falling within one of the categories listed
in the First Addendum to the Israeli Securities Law, 5728&#8212;1968; (ii) which of the categories listed in the First Addendum to the
Israeli Securities Law, 5728&#8212;1968 regarding Qualified Investors is applicable to it; (iii) that it will abide by all provisions
set forth in the Israeli Securities Law, 5728&#8212;1968 and the regulations promulgated thereunder in connection with the offer to be
issued common stock; (iv) that the shares of common stock that it will be issued are, subject to exemptions available under the Israeli
Securities Law, 5728&#8212;1968: (a) for its own account; (b) for investment purposes only; and (c) not issued with a view to resale
within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728&#8212;1968; and (v) that
it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in
respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#8217;s name,
address and passport number or Israeli identification number.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 172; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->168<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_018"></A>LEGAL
MATTERS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the shares of common stock offered by this prospectus will be passed upon for us by Manatt, Phelps &amp; Phillips, LLP, Costa
Mesa, California. Certain legal matters in connection with this offering will be passed upon for the underwriters by Loeb &amp; Loeb
LLP, New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_019"></A>EXPERTS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">The
financial statements of NeOnc Technologies, Inc. as of and for the years ended December&nbsp;31, 2022 and 2021, appearing in this prospectus
have been audited by Marcum LLP, independent registered public accounting firm, as set forth in their report thereon, appearing elsewhere
in this prospectus, and are included in reliance on the report of such firm given upon their authority as experts in auditing and accounting.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_020"></A>WHERE
YOU CAN FIND ADDITIONAL INFORMATION</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered
by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all the information set
forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and
regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement,
including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents
of any contract or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration
statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract
or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC maintains an internet website that contains
reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is http://www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the completion of this offering, we will be subject to the information reporting requirements of the Exchange Act, and we will file reports,
proxy statements and other information with the SEC. These reports, proxy statements and other information will be available at http://www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also maintain a website at www.NeOncco.com. Information contained in, or accessible through, our website is not a part of this prospectus,
and the inclusion of our website address in this prospectus is only as an inactive textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 173; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->169<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC
TECHNOLOGIES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL
STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DECEMBER&nbsp;31,
2022 AND 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 174 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin: 0pt">&#160;</p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC
TECHNOLOGIES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Page</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 90%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A HREF="#b_001">Report
    of Independent Registered Public Accounting Firm (PCAOB ID#688)</A></B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-2</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Financial
    Statements</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_003">Balance
    Sheets as of December&nbsp;31, 2022 and 2021</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-3</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_004">Statements
    of Operations for the years ended December&nbsp;31, 2022 and 2021</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-4</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_005">Statements
    of Changes in Shareholders&rsquo; Deficit for the years ended December&nbsp;31, 2022 and 2021</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-5</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_006">Statements
    of Cash Flows for the years ended December&nbsp;31, 2022 and 2021</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-6</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_007">Notes
    to Financial Statements</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-7 &ndash; F-18</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 175; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><A NAME="b_001"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors of<BR> NeOnc Technologies, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
on the Financial Statements</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheets of NeOnc Technologies, Inc. (the &#8220;Company&#8221;) as of December&nbsp;31, 2022 and
2021, the related statements of operations, changes in shareholders&#8217; deficit and cash flows for each of the two years in the period
ended December&nbsp;31, 2022, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion,
the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2022
and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December&nbsp;31, 2022,
in conformity with accounting principles generally accepted in the United States of America<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going
Concern</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described
in Note 1, the Company has a significant working capital deficiency, has incurred significant losses and needs to raise additional funds
to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company&#8217;s ability to continue
as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
for Opinion</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the
United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were
we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an
understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the
Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Marcum LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia,
PA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May&nbsp;1,
2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>



<!-- Field: Page; Sequence: 176; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="b_003"></A><FONT STYLE="font-size: 10pt"><B>NEONC
TECHNOLOGIES, INC.</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Balance
Sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December&nbsp;31,</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assets</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    Assets</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.25in; width: 76%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">633,298</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,034</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid
    expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">95,384</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,457</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Current Assets</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">728,682</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,491</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Assets</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">728,682</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,491</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liabilities
    and Shareholders&rsquo; Deficit</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    Liabilities</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,341,593</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">537,446</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    compensation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">412,500</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">462,500</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    revenue</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">500,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">500,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Promissory
    note payable, at fair value</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">50,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholder
    advance</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Note
    payable - Chairman of the Board, at fair value</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">241,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Advances
    from Chairman of the Board</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">897,891</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Current Liabilities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,304,093</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,648,837</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commitments
    and contingencies</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholders&rsquo;
    Deficit:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preferred
    stock, $0.001 par value, 3,030,303 shares authorized; 3,030,303 Series A shares issued and outstanding as of December 31, 2022 and
    2021</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,030</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,030</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    stock, $0.001 par value, 100,000,000 shares authorized; 68,620,340 and 59,674,906 shares issued and outstanding as of December 31,
    2022 and 2021, respectively</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">68,621</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">56,675</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
    paid in capital</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">22,141,854</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,066,108</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(23,788,916</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(20,742,159</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Shareholders&rsquo; Deficit</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,575,411</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,616,346</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Liabilites and Shareholders&rsquo; Deficit</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">728,682</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,491</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the financial statements.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 177; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="b_004"></A><FONT STYLE="font-size: 10pt"><B>NEONC
TECHNOLOGIES, INC.</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statements
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">For
    the<BR>
    years ended<BR> December&nbsp;31,</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenues</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in; width: 76%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenue</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating
    Expenses:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
    and development</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,163,330</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">674,558</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal
    and professional</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">318,205</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">217,951</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,376,069</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,379,174</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Operating Expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,857,604</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,271,683</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    From Operations</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,837,604</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,271,683</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    (Expense) Income:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in fair value of note payable - Chairman of the Board</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    expense</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(200,153</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(112,919</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Other Expense</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(209,153</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(103,919</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    Loss</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,046,757</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,375,602</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 178; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="b_005"></A><FONT STYLE="font-size: 10pt"><B>NEONC
TECHNOLOGIES, INC.</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statements
of Changes in Shareholders&#8217; Deficit</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Additional</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Total</B></FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common
    Stock</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Preferred
    Stock</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Paid In
    </B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Accumulated</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Shareholders&rsquo;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Capital</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deficit</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deficit</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 30%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance
    - December 31, 2020</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">56,674,506</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">56,675</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,030,303</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,030</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15,733,856</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(17,366,557</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,572,996</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expense
    related to options granted to related party debtholder in conjunction with debt issuance</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">112,919</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">112,919</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share
    based compensation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,219,333</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,219,333</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,375,602</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,375,602</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance
    - December 31, 2021</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">56,674,506</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">56,675</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,030,303</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,030</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,066,108</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(20,742,159</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,616,346</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sale
    of common stock</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,400,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,400</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,397,600</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,400,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share
    based compensation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,291,909</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,291,909</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares
    issued upon cashless exercise of stock options</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,150,051</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,150</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9,150</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Charge
    associated with settlement of shareholder advances through the issuance of shares of common stock</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">395,783</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">396</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">395,387</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">395,783</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,046,757</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,046,757</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance
    - December 31, 2022</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">68,620,340</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">68,621</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,030,303</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,030</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">22,141,854</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(23,788,916</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,575,411</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the financial statements. </FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 179; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="b_006"></A><FONT STYLE="font-size: 10pt"><B>NEONC
TECHNOLOGIES, INC.</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statements
of Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the year ended<BR> December&nbsp;31,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    flows from operating activities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,046,757</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,375,602</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adjustments
    to reconcile net loss to net cash used in operating activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in fair value of note payable - Chairman of the Board</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    on conversion of advances from Chairman of the Board to common stock</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">197,891</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expense
    related to options granted to related party debtholder in conjuction with debt issuance</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">112,919</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share
    based compensation expense</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,291,909</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,219,333</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes
    in operating assets and liabilities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Grant
    receivable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">47,748</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid
    expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(87,926</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(263</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    receivable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">35,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    compensation</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(50,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">150,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">804,147</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">423,172</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(881,736</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(396,693</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    flows from financing activities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from note payable - Chairman of the Board</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">250,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from note payable - related parties</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Repayment
    of notes payable - related parties</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(335,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from sale of common stock</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,400,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Repayment
    of advances from the Chairman of the Board</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(700,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,490,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">250,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    increase (decrease) in cash</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">608,264</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(146,693</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    - beginning of year</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,034</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">171,727</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    - end of year</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">633,298</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,034</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Supplemental
    cash flow disclosures:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    paid</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,261</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Supplemental
    disclosure of non-cash financing activities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable settled by the Chairman of the Board, reclassified</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">176,404</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Conversion
    of advances from Chairman of the Board to common stock</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">197,891</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the financial statements.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 180; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="b_007"></A><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Note
1 &#8211; Description of Business and Liquidity</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEONC
Technologies, Inc. (&#8220;NeOnc&#8221; or the &#8220;Company&#8221;) was incorporated on April&nbsp;13, 2005, as a California corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeOnc
is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous
system diseases. The Company&#8217;s lead product, NEO100, commenced Phase 2a clinical trials in July of 2019 (which is still ongoing
as of December&nbsp;31, 2022), treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and
Drug Administration (&#8220;FDA&#8221;). The Company licensed the underlying technology from the University of Southern California. (&#8220;USC&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other
things, the realization of assets and satisfaction of liabilities in the normal course of business. At December&nbsp;31, 2022, the Company
had cash totaling $633,298. For the year ended December&nbsp;31, 2022, the Company has incurred a net loss of $3,046,757 and has an accumulated
deficit of $23,788,916 at December&nbsp;31, 2022. The Company has financed its working capital requirements to date primarily through
the issuance of common stock, preferred stock and shareholder loans. As of December&nbsp;31, 2022, the Company had not raised sufficient
funds to finance the operating requirements for at least the next 12 months from the issuance date of these financial statements. The
Company has engaged with an investment bank to assist with additional financing activities. However, there can be no assurance that financing
can be completed on terms acceptable to the Company. These factors raise substantial doubt regarding the Company&#8217;s ability to continue
as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December&nbsp;2022, the Company signed a Letter of Intent (&#8220;LOI&#8221;) with an investment advisory firm (&#8220;Firm&#8221;) to
create a newly formed corporation called NeOnc Technologies Holding Company, Inc. (&#8220;Newco&#8221;) to facilitate future fundraising
transactions (see Note 3). On April&nbsp;7, 2023, the shareholders of the Company exchanged their shares for shares of Newco. (see Note
10). The Firm will assist the Company in a fundraising transaction, which may include bridge financing before an Initial Public Offering
(IPO) or private financing. The Firm will also act as an investment advisor in future financing transactions and be able to appoint a
majority of the Board of Directors of Newco. Except for the completed exchange transaction described above, there is no assurance of
consummation of any of the transactions contemplated by the LOI. There can be no assurance that a fundraising transaction can be completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
risks and uncertainties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to biopharmaceutical companies, including, but not limited to, new technological innovations, dependence
on key personnel, protection of proprietary technology, compliance with government regulations, product liability, and the uncertainty
of market acceptance of products and the potential need to obtain additional financing. The Company is dependent on third-party suppliers
and, in some cases, single-source suppliers. The Company&#8217;s products require approval or clearance from the FDA prior to commencing
commercial sales in the United States. Approvals or clearances are also required in foreign jurisdictions where the Company may license
or sell its products. There can be no assurance that the Company&#8217;s products will receive all required approvals or clearances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that the Company&#8217;s products, if approved, will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost with appropriate performance characteristics or that
such products will be successfully marketed, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December&nbsp;2019, a novel strain of coronavirus (&#8220;COVID-19&#8221;) was reported in Wuhan, China. The World Health Organization
declared COVID-19 a &#8220;Public Health Emergency of International Concern&#8221; on January&nbsp;30, 2020, and a global pandemic on
March&nbsp;11, 2020. In March&nbsp;2020, individual states mandated &#8220;stay-at-home orders,&#8221; restricted access to hospitals,
prohibited elective surgeries, and instituted other restrictions in connection with the COVID-19 outbreak. The extent of the impact of
COVID-19 on the Company&#8217;s operational and financial performance will depend on future developments, including access to products,
potential disruption in global freight networks, domestic and foreign government actions and changes in demand based on the duration
and severity of the COVID-19 outbreak.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 181; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
2 &#8211; Basis of Presentation and Summary of Significant Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#8220;GAAP&#8221;), including all pronouncements of the U.S. Securities and Exchange Commission applicable to annual financial
statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing the Company&#8217;s financial statements in conformity with GAAP, management is required to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial
statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those
estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, from time to time during the period covered by these financial statements, may have had bank account balances in excess of federally
insured limits. The Company has not experienced losses in such accounts. <FONT STYLE="color: #333333">For the statements of cash flows,
the Company considers all short-term investments purchased with a maturity of three months or less to be cash equivalents.</FONT> Cash
and cash equivalents include all cash balances on hand and highly liquid investments having original maturities of three months or less
when purchased. At December&nbsp;31, 2022 and 2021, the Company did not have any cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deferred
revenue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
revenue arises from amounts received in advance of the culmination of the earnings process and is recognized as revenue in future periods
as performance obligations are satisfied. Deferred revenue expected to be recognized within the next twelve months is classified as a
current liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
payable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected to account for the $250,000 (original principal amount) note payable to the Chairman of the Board (Chairman) and
the $50,000 (original principal amount) note payable to a shareholder using the fair value option in accordance with the guidance contained
in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 825-10-25. The fair
value option provides an option to elect fair value as an alternative measurement for selected financial assets, financial liabilities,
unrecognized firm commitments, and written loan commitments. See Note 3 for additional information. The Company accounted for the fair
value of the stock options issued in connection with the note payable to the Chairman as additional interest expense on the grant date,
using the same methodology to determine the fair value of the stock option as discussed in the share-based compensation policy footnote
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
value measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
ASC Topic 820, &#8220;<I>Fair Value Measurements and Disclosures</I>&#8221; (&#8220;ASC 820&#8221;), defines fair value, the methods
used to measure fair value and the expanded disclosures about fair value measurements. Fair value is the price received to sell an asset
or paid to transfer a liability in an orderly transaction between the buyer and the seller at the measurement date. In determining fair
value, the valuation techniques consistent with the market approach, income approach and cost approach shall be used to measure fair
value. ASC 820 establishes a fair value hierarchy for inputs, representing the assumptions the buyer and seller use in pricing the asset
or liability. These inputs are further defined as observable and unobservable inputs. Observable inputs are those that the buyer and
seller would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable
inputs reflect the Company&#8217;s assumptions about the inputs the buyer and seller would use to price the asset or liability developed
based on the best information available in the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 182; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the Company&#8217;s accounts receivable, accounts payable, shareholder advances, and advances from the Chairman approximate
fair value because of the short-term nature of these financial instruments. The Company&#8217;s note payable to Chairman is reported
at fair value (see Note 3). The promissory note payable is reported at face value as the fair value difference is not material (see Note
4).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value hierarchy is categorized into three levels based on the inputs as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 &#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has
    the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices
    that are readily and regularly available in an active market, the valuation of these securities does not entail a significant degree
    of judgment.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 &#8212; Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets
    that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv)
    inputs that are derived principally from or corroborated by the market through correlation or other means.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 &#8212; Valuations based on unobservable inputs and significant to the overall fair value measurement.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licenses
of intellectual property (&#8220;IP&#8221;)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates intellectual property licensing agreements in accordance with ASC 808, <I>Collaborative Arrangements.</I> If the license
to the Company&#8217;s IP is determined to be distinct from the other performance obligations identified in the arrangement, the Company
recognizes revenues from consideration allocated to the license when the license is transferred to the customer, and the customer can
use and benefit from the licenses. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature
of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point
in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the
measure of progress each reporting period and, if necessary, adjusts the measurement of performance and related revenue recognition.
Determining the revenue recognition of IP licenses requires significant judgment and is discussed in further detail for each of the Company&#8217;s
license and collaboration agreements in Note 5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the inception of each arrangement that includes development or regulatory milestone payments, the Company evaluates the probability of
reaching the milestones. The Company estimates the amount to be included in the transaction price using the most likely amount method.
If it is probable that a significant revenue reversal will not occur in the future, the associated milestone value is included in the
transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s, such as regulatory approvals,
are not considered probable of being achieved until those approvals are received. Therefore, revenue recognized is constrained as management
cannot assert that a revenue reversal would not be possible. The transaction price is then allocated to each performance obligation on
a residual basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end
of each subsequent reporting period, the Company re-evaluates the probability of achieving such development milestones and any related
constraints. The Company adjusts its estimate of the overall transaction price if necessary. Any such adjustments are recorded on a cumulative
catch-up basis, which would affect revenues and earnings in the adjustment period. To date, the Company has not recognized any milestone
revenue resulting from any of its agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
performance obligations are not required of the Company or following the completion of the performance obligation period, such amounts
are recognized as revenue upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other
than sales-based milestones and royalties are classified as license and collaboration revenue. Sales-based milestones and royalties will
be recognized as royalty revenue at the later of when the related sales occur or when the performance obligation to which some or all
of the royalty has been allocated has been satisfied (or partially satisfied).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized point-in-time revenue of $20,000 and $0 for the years ended December&nbsp;31, 2022 and 2021, respectively, for the
sale/license of technology where the Company has no further performance obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 183; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and
development activities, including third-party contractors performing research, conducting clinical trials, and manufacturing drug supplies
and materials. The Company recognizes the proceeds from the National Institute of Health (&#8220;NIH&#8221;) grant as a reduction of
research and development expenses when the costs related to the grant are incurred. Grant receivables consist of unbilled amounts due
from the NIH for costs incurred under the grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share-based
compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has granted stock options and common shares to employees, non-employee consultants and non-employee members of our Board of Directors.
The Company measures the compensation cost associated with all share-based payments based on the grant date fair values. The Company
recognizes share-based compensation expense over the requisite service period of each award, which generally equals the vesting period,
using the straight-line method for awards that contain only service conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option is estimated on the date of grant using an option pricing model. The Company uses the Black-Scholes option
pricing model to estimate the fair value of its stock options. The determination of the fair value of share-based payment awards utilizing
the Black-Scholes model is affected by the Company&#8217;s stock price and a number of assumptions, including expected volatility, expected
term, risk-free interest rate and expected dividends. For grants of stock options, the Company uses a blend of historical and implied
volatility for similar companies in order to estimate the expected volatility assumption required in the Black-Scholes model. The Company&#8217;s
use of a blended volatility estimate in computing the expected volatility assumption for stock options is based on its belief that while
the implied volatility is representative of expected future volatility, the historical volatility over the expected term of the award
is also an indicator of expected future volatility. The expected term of stock options granted is estimated using historical experience.
The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the Company&#8217;s
stock options. The dividend yield assumption is based on the Company&#8217;s history and expectation of no dividend payouts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
costs associated with grants of common shares are measured at fair value at the date of grant, which has historically been the most recent
price paid by investors to purchase shares of the Company&#8217;s common stock prior to such grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
costs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
patent-related costs incurred in filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the
recovery of the expenditure. Amounts incurred are classified as legal and professional expenses in the accompanying statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes federal, state, and foreign current tax liabilities or assets based on its estimate of taxes payable to or refundable
by tax authorities in the current fiscal year. The Company also recognizes federal and state deferred tax liabilities or assets based
on the Company&#8217;s estimate of future tax effects attributable to temporary differences and carryforwards. Deferred tax assets and
liabilities are measured using enacted tax rates expected to apply to taxable income in the years those temporary differences are expected
to be recovered or settled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets are reduced by valuation allowances if, based on the consideration of all available evidence, it is more likely than not that
some portion of the deferred tax asset will not be realized. The Company evaluates deferred income taxes quarterly to determine if valuation
allowances are required by considering available evidence. If the Company is unable to generate sufficient future taxable income in certain
tax jurisdictions, or if there is a material change in the actual effective tax rates or time period within which the underlying temporary
differences become taxable or deductible, the Company could be required to increase its valuation allowance against its deferred tax
assets which could result in an increase in the Company&#8217;s effective tax rate and an adverse impact on operating results. The Company
will continue to evaluate the necessity of the valuation allowance based on the remaining deferred tax assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the accounting guidance related to financial statement recognition, measurement and disclosure of uncertain tax positions.
The Company recognizes the impact of an uncertain income tax position on an income tax return at the largest amount that is more likely
than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it is
less than 50% likely to be sustained. Uncertain tax positions are recognized in the first subsequent financial reporting period in which
that threshold is met or from changes in circumstances such as the expiration of applicable statutes of limitations. The Company will
recognize interest and penalties related to tax positions in income tax expense. As consideration for the</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 184; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
3 &#8211; <FONT STYLE="background-color: white">Related party transactions</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter
of Intent &#8211; AFH Holdings and Advisory, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">On
December&nbsp;19, 2022, the Company entered into an engagement agreement with AFH Holdings and Advisory, LLC (&ldquo;AFH&rdquo;).
AFH was engaged to assist the Company in connection with its intent to affect a public listing. AFH was retained to assist the
Company with investor presentations and decks, coordinate the retention of an investment banker for an initial public offering,
identify legal and accounting professionals to assist in connection with such public offering, identify investor relations/public
relations firms, advise on private capital markets activities prior to the initial public offering and coordinate the closing
process for the offering. AFH agreed to advance costs of up to $500,000 for such professionals on behalf of the company to be repaid
out of proceeds from the initial public offering. As of December&nbsp;31, 2022, no such advances have taken place. As compensation
for such services, the Company agreed to affect a share exchange with a special purpose entity substantially owned by <FONT STYLE="background-color: white">AFH</FONT>, whereby such holders retained approximately 34.4% of the shares of the
combined entity after the share exchange. In addition, the Company agreed to retain AFH as an exclusive advisor to the Company on
all financing and mergers and acquisitions for a period of two (2) years from the closing of the private securities offering.
Further to the advisory arrangement, AFH shall be paid an aggregate fee in an amount equal to 2% of the post-money valuation of the
Company immediately after the effective time of the public offering. The share exchange occurred on April&nbsp;7, 2023 (see Note
10).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
advances</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #333333">Periodically
certain shareholders of the Company have advanced</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Company funds to support operations under informal loan arrangements (the &#8220;Shareholder Advances&#8221;). These Shareholder Advances
bear no interest and have no specified maturity date. There were Shareholder Advances outstanding totaling $0 and $10,000 as of December&nbsp;31,
2022 and 2021, respectively. During the year ended December&nbsp;31, 2022, the Company repaid all outstanding Shareholder Advances of
$10,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
payable &#8211; Chairman of the Board</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August&nbsp;18, 2021, the Company entered into a loan agreement with the Chairman with a principal amount of $250,000 (the &#8220;Chairman
Note&#8221;). The Chairman Note bore no interest and was payable when the Company received funding in excess of $1,000,000. The Company
received funding in excess of $1,000,000 during the year ended December&nbsp;31, 2022, at which time the Chairman Note was repaid. The
Company has elected to account for the Chairman Note under the fair value option (See Note 2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Chairman Note is classified within Level 3 of the fair value hierarchy. In order to calculate the fair value of the
Chairman Note, the Company utilized the following inputs:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>December&nbsp;31,<BR>
    2021</B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>August&nbsp;18,<BR>
    2021<BR> (initial measurement)</B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underlying
    principal amount of note payable</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">250,000</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">250,000</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    flow discount rate</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.89</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.21</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Term
    (years)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.37</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.73</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discount rate was based on a 3-month CCC debt yield based upon a comparative credit rating for the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chairman Note was repaid on May&nbsp;12, 2022. The changes in the fair value of the Chairman Note from the inception through December&nbsp;31,
2022 are summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    promissory note at inception, August 18, 2021</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">250,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in fair value</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    promissory note, December 31, 2021</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">241,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in fair value</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Repayment</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(250,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    promissory note, December 31, 2022</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 185; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of the Chairman Note, the Chairman received a stock option grant from the Company to purchase 250,000 shares
of common stock at an exercise price of $0.66 per share. The stock option vested immediately and was valued using the Black-Scholes option-pricing
model utilizing the following assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    volatility</FONT></TD>
    <TD STYLE="width: 1%; color: windowtext"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; color: windowtext; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">82.0</FONT></TD>
    <TD STYLE="width: 1%; color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate</FONT></TD>
    <TD STYLE="color: windowtext"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="color: windowtext; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.2</FONT></TD>
    <TD STYLE="color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    dividend yield</FONT></TD>
    <TD STYLE="color: windowtext"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="color: windowtext; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD>
    <TD STYLE="color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    life of options in years</FONT></TD>
    <TD STYLE="color: windowtext"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="color: windowtext; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1</FONT></TD>
    <TD STYLE="color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per
    share fair value of common stock</FONT></TD>
    <TD STYLE="color: windowtext"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="color: windowtext; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.47</FONT></TD>
    <TD STYLE="color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total fair value of the stock option grant was $112,919, recognized as interest expense for the year ending December&nbsp;31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances
from Chairman</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has periodically received cash advances from the Chairman or has had certain costs incurred by the University of Southern California
(&#8220;USC&#8221;) on behalf of the Company paid for by the Chairman. These advances were non-interest bearing and had no stated maturity.
At December&nbsp;31, 2021, the balance outstanding was $897,891. During the year ended December&nbsp;31, 2022, the Company repaid in
cash $700,000 of such advances to the Chairman and $197,891 was converted to 395,782 shares of common stock on December&nbsp;31, 2022.
The fair value of the common stock issued of $395,782 exceeded the remaining balance due the Chairman. Such excess fair value of $197,891
was recorded as interest expense in the statement of operations for the year ended December&nbsp;31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
with USC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March&nbsp;9, 2009, the Company entered into an exclusive license agreement with USC, pursuant to which USC granted a license to use
certain patented technology related to the use of monoterpenes as a solvent, specifically <I>perillyl alcohol</I>. This technology is
the basis of the current products under development by the Company. The Company granted USC 800,000 shares of common stock in exchange
for the license. Additionally, the Company is required to pay an annual patent maintenance cost of $20,000 and a 2% royalty on all net
sales, as defined. The Company has not paid any royalties through December&nbsp;31, 2022, since no products are being
sold using such technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also utilizes laboratory services from USC. The Company has incurred approximately $442,000 and $372,000 of research and development-related
costs from USC for the years ended December&nbsp;31, 2022 and 2021, respectively. The Company incurred approximately $20,100 and $12,000
of patent maintenance and legal-related expenses for the years ended December&nbsp;31, 2022 and 2021, respectively. At December&nbsp;31,
2022 and 2021, the Company owes USC approximately $75,633 and $51,000, respectively. From time to time, the Company has been unable to
reimburse USC for such costs. Therefore, USC deducted certain amounts due to the Chairman for compensation for his services as faculty
at USC to satisfy the amounts due from the Company to USC. Such amounts deducted from the Chairman&#8217;s USC faculty compensation are
recorded as Advances from the Chairman on December&nbsp;31, 2022 and 2021. Additionally, included in accounts payable at December&nbsp;31,
2022 and 2021 are approximately $800,651 and $365,000, respectively, due to the Chairman related to such deductions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
compensation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred $0 and $150,000 for the years ended December&nbsp;31, 2022 and 2021 for compensation to the Chairman and a consultant,
both of whom are shareholders. This compensation is recorded in the statement of operations as part of general and administrative
expenses. The amount accrued for the Chairman and the consultant were $412,500 and $462,000 as of December&nbsp;31, 2022 and 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
loan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February&nbsp;2022, the Company entered into a $75,000 loan agreement bearing interest at 2.5% per annum with a maturity date of August&nbsp;2022
from a related party. The loan was paid off in December&nbsp;2022. Interest expense paid related to this loan for the year ended December&nbsp;31,
2022 was approximately $1,500.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 186; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4 &#8211; <FONT STYLE="font-variant: small-caps">Convertible
promissory note offering</FONT></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2022, the Company issued $50,000 of convertible notes to a shareholder due August&nbsp;30, 2023 (&#8220;Note&#8221;). The Note bears
interest at 2% per annum.  This Note and all accrued interest thereon is convertible, at the option of the noteholder, into
the class and series of equity securities (&#8220;Conversion Stock&#8221;) that is sold by the Company in its next issuance of equity
securities in a Financing Transaction (as defined below), consummated after the issuance date of the note. A Financing Transaction is
a sale, other than in an initial public offering (&#8220;IPO&#8221;), of equity securities by the Company to investors for cash. The
Financing Transaction does not include the issuance of stock, options, or warrants to service providers in connection with the rendition
of such services or to third parties in connection with the contribution of non-cash assets to the Company. The number of shares of Conversion
Stock to be issued to the noteholder upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal
amount of this Note plus accrued interest by (ii) the Financing Transaction Conversion Price (as defined below). The Financing Transaction
Conversion Price shall be equal to seventy-five percent (75%) of the price paid for one share of Conversion Stock by the investors in
the Financing Transaction. The entire principal amount of and accrued interest on this Note shall automatically be converted, without
further action on the part of the noteholder or the Company, into the class and series of stock issued by the Company, at the closing
of an IPO. The number of shares of stock to be issued to the holder upon such conversion shall be equal to the quotient obtained by dividing
(i) the entire principal amount of this Note plus accrued interest by (ii) the IPO Conversion Price (as defined in the Note).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #333333">The
Company has elected to account for the Note under the fair value option (See Note 2). The fair value of the Note (</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">classified
within Level 3 of the fair value hierarchy) <FONT STYLE="color: #333333">approximated the face amount of $50,000 at both the issuance
date of March&nbsp;28, 2022 and at December&nbsp;31, 2022. As such, no adjustment was made to the carrying value of the Note.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
5 &#8211; Common and preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total number of shares of common stock available for issue is 100,000,000 shares at $0.001 par value per share and the total number of
preferred stock available to issue is 3,030,303 shares at $0.001 par value per share. The Company issued 2,400,000 shares of common stock
for proceeds totaling $2,400,000 as part of a series of private placements during 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
shareholders are entitled to one vote for each share of common stock held at the record date of the vote. Each holder of outstanding
shares of Series A Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of common stock
into which the shares of such Series A Preferred Stock held by such holder are convertible as of the record date for determining shareholders
entitled to vote on such matter. The holders of Series A Preferred Stock shall vote together with the common shareholders as a single
class. When the holders of Series A Preferred Stock hold 5% (on a fully diluted basis) of the outstanding common shares, such holders
shall be entitled to vote for one director of the Company and all remaining directors shall be elected by common shareholders. For so
long as any shares of Series A Preferred Stock remain outstanding, the vote or written consent of the holders of the majority of the
outstanding shares of Series A Preferred Stock is necessary for the Company to conduct certain corporate actions. These include, but
are not limited to, the sale of the Company, certain amendments to the certificate of incorporation or bylaws that adversely affect the
power, preferences, or rights of the Series A preferred shareholders, or authorizing the issuance of any dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, the holders of Series A Preferred Stock
then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its shareholders before
any payment shall be made to the holders of common stock. The amount per share equals 1.0 times the Series A Original Issue Price ($0.33
per share as of December&nbsp;31, 2022, as defined), plus any dividends declared but unpaid thereon. If upon any such liquidation, dissolution,
or winding up of the Company, the proceeds available for distribution shall be insufficient to pay the preferred shareholders the full
amount to which they are entitled, the holders share ratably in the distribution of available proceeds. The liquidation preference of
such preferred shares at December&nbsp;31, 2022 and 2021 is $1,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no stated dividends on the common or Series A Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #333333">Each
share of Series A Preferred Stock is convertible, at the option of the holder, at any time and from time to time into shares of common
stock at a conversion rate which is computed by dividing the Series A Original Issue Price by the Series A Conversion Price. Series A
Original Issue Price initially means $0.33 per share and Series A Conversion Price initially means $0.33 per share, as defined. The conversion
price may be adjusted for certain dilutive events such as down-round provision, stock splits and combinations, certain dividends and
distributions, or any merger or reorganization. Conversion to common stock shall be mandatory upon closing an initial public offering
resulting in net proceeds of at least $20,000,000. A down round occurs when shares are offered at less than the </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
A Original Issue Price ($0.33 per share). If a down round occurred, the holders of the Series A preferred stock would be entitled to
an adjustment in the number of preferred shares. As of December&nbsp;31, 2021, no down round has occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 187; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
6 &#8211; Collaboration and license agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreement - Orient Europharma Co., Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November&nbsp;8, 2013, the Company entered into a collaboration agreement (&#8220;Agreement&#8221;) with Orient EuroPharma Co., Ltd.
(&#8220;OEP&#8221;), pursuant to which the parties will develop certain licensed products defined in the Agreement. NeOnc will license
OEP the right to commercialize the Company&#8217;s drug NEO100, a highly purified form of perillyl alcohol (&#8220;Licensed Product&#8221;),
<FONT STYLE="color: #202124; background-color: white">in the territories specified in the license agreement (&#8220;Territory&#8221;).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Agreement, OEP will bear the cost of, and be responsible for, among other things, developing pre-clinical materials,
conducting the clinical studies and other developmental activities for the Licensed Products, and bear the cost of and be responsible
for, among other things, preparing and filing applications for regulatory approval in the Territory and for commercializing Licensed
Products in the Territory, and will use commercially reasonable efforts to commercialize Licensed Products and obtain pricing approval
for Licensed Products in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Agreement, OEP agreed to compensate the Company as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimbursement
    of the costs related to an <FONT STYLE="color: #202124; background-color: white">Investigational New Drug Application</FONT> filing
    with the FDA, which was received in 2014 and 2015;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$200,000
    paid upon signing the agreement in 2013; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specified
    development milestone payments of up to $1,900,000. The Company received a milestone payment of $300,000 during the year ended December&nbsp;31,
    2020 upon completion of the first phase of clinical trials. The Company has received no other development milestone payments through
    December&nbsp;31, 2021.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has determined that the arrangement is within the scope of ASC 808, <I>Collaborative Arrangements,</I> as both NeOnc and OEP
are active participants in the activity, and they are both exposed to significant risks and rewards dependent on the commercial success
of the activity. The Company has determined two performance obligations under the arrangement &#8211; product development and the license
of the completed product. The Company has deferred recognition of revenue on the $200,000 paid upon signing the agreement and the $300,000
milestone payment received in 2020 as the product development obligation had not yet been completed as of December&nbsp;31, 2022. Deferred
revenue as of December&nbsp;31, 2022 and 2021 of $500,000 is recorded on the accompanying balance sheet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OEP
is also obligated to pay potential milestone payments to the Company totaling up to $6,000,000 for the achievement of certain sales milestones.
In addition, during the Royalty Term (as defined in the underlying Agreement), OEP is obligated to pay the Company tiered royalties between
1-5% of net sales of Licensed Products in the Territory. However, under certain conditions, royalties will not be paid if (i) no patent
covering the Licensed Products is issued to NeOnc in counties defined within the collaboration agreement, and (ii) a generic version
of the Licensed Products has launched in such country, and (iii) the gross profit margin for the Licensed Products in such country is
less than 50%. No consideration has been received as of December&nbsp;31, 2022 for the license of the completed product, as it is still
under development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
party may terminate the Agreement for material breach upon a party&#8217;s insolvency, bankruptcy, or safety reasons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
after completion of Phase II clinical trials, the Company enters into one or more agreements to license any of the patent rights or Licensed
Products to a party other than OEP, then the Company will reimburse specified amounts based upon amounts paid by OEP to the Company,
not to exceed $3,000,000 to be paid as various milestones are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 188; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>License
Agreement &#8211; Neucen Biomedical Co.., Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December&nbsp;5, 2015,  the Company entered into a license agreement with Neucen Biomedical Co., Ltd. (&#8220;NB&#8221;),
a shareholder of NeOnc Technologies, Inc., in which NeOnc will license to NB the right to commercialize the Company&#8217;s drug NEO212,
a conjugate of perillyl alcohol and <FONT STYLE="color: #202124; background-color: white">temozolomide (&#8220;NB Licensed Product&#8221;)
in the territories specified in the license agreement (&#8220;NB Territory&#8221;).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Agreement, NB will bear the cost of, and be responsible for, among other things, developing pre-clinical materials,
conducting the clinical studies and other developmental activities for the NB Licensed Products, and bear the cost of, and be responsible
for, among other things, preparing and filing applications for regulatory approval in the NB Territory and for commercializing NB Licensed
Products in the NB Territory, and obtain pricing approval for NB Licensed Products in the NB Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NB
must pay the Company tiered royalties of 1-5% on net sales of NB Licensed Products in the NB Territory. The Company received no sales
milestones or royalties through December&nbsp;31, 2022, as no commercialized products are using such technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
7 &#8211; Grant from the National Institute of Health</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March&nbsp;2020, the Company was awarded a grant of $336,000 from the NIH for developing a clinically relevant radiosensitizer for temozolomide-resistant
gliomas. The project period for the grant was from April&nbsp;1, 2020 to March&nbsp;31, 2021, which was subsequently extended to March&nbsp;31,
2022. The Company received approximately $156,000 during the year ended December&nbsp;31, 2021, respectively, from the NIH. The Company
contracted with USC to perform a portion of the work related to this grant totaling $180,000. As of December&nbsp;31, 2021, all work
required for the grant was complete and all NIH funding had been received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
related to this NIH grant totaled approximately $98,000 during the year ended December&nbsp;31, 2021, and was classified as a reduction
of research and development costs in the accompanying Statement of Operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
8 &#8211; Stock-Based Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Company&#8217;s 2013 Stock Incentive Plan (the &#8220;2013 Option Plan&#8221;), up to 20,000,000 shares of the Company&#8217;s common
stock may be issued pursuant to awards granted in the form of incentive stock options, non-statutory stock options, rights to purchase
common stock, stock appreciation rights, restricted stock, restricted stock, performance shares, and performance units to employees,
directors and consultants of the Company and its affiliates. The 2013 Option Plan requires the exercise price of stock options to be
not less than the fair value of the Company&#8217;s common stock on the date of grant or 110% of fair value in the case of incentive
options granted to a ten-percent shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December&nbsp;31, 2021, the Company issued stock options for 7,250,000 shares of common stock to directors and advisors
and 250,000 to the Chairman (See Note 3) at an exercise price of $0.66 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December&nbsp;31, 2022, all of the option holders converted the then aggregate outstanding options to acquire 18,705,451 shares into
9,150,051 shares of common stock pursuant to the cashless exercise provision of the 2013 Option Plan. A portion of the outstanding options
(those with an exercise price of $1.25 per share) were repriced to an exercise price of $1.00 immediately before the cashless exercise.
This modification of the stock option resulted in a charge to share-based compensation of $182,243, which is recorded within general
and administrative expenses on the statement of consolidated operations during the year ended December&nbsp;31, 2022. The remaining outstanding
stock options to acquire 166,060 shares of common stock were canceled during 2023 per cancellation agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 189; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December&nbsp;31, 2022, the Company has 1,128,489 options remaining available to be issued under the 2013 Option Plan. The following
table summarizes stock-based activities, including the 250,000 options issued to the Chairman as part of the Chairman Note (see Note
3):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>Shares<BR>
    Underlying<BR> Options</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>Weighted<BR>
    Average<BR> Exercise<BR> Price</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; font-style: italic; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>Weighted<BR>
    Average<BR> Contractual<BR> Term to<BR> expiration<BR> (years)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Outstanding
    at December 31, 2020</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">11,371,511</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">0.60</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">5.82</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Granted</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">7,500,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">0.66</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">9.17</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Outstanding
    at December 31, 2021</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">18,871,511</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">0.63</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">6.55</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Exercised</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">(18,705,451</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">)</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">0.63</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">6.55</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Outstanding
    at December 31, 2022</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">166,060</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">0</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Exercisable
    Options at December 31, 2022</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">166,060</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">$</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">0.36</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">0</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Exercisable
    Options at December 31, 2021</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">16,454,844</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">$</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">0.63</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">6.55</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock option awards is estimated using the Black-Scholes option-pricing model. The estimated fair value of each stock option
is then expensed over the vesting period, approximately three years. The determination of fair value using the Black-Scholes model is
affected by the Company&#8217;s share price and assumptions regarding a number of complex and subjective variables, including expected
price volatility and the risk-free interest rate. Stock options granted in 2022 and 2021 were 0 and 7,500,000, respectively. Stock options
granted during the year ended December&nbsp;31, 2021 were valued using the Black-Scholes option-pricing model with the following weighted
average assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; font-style: italic; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 88%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Expected
    volatility</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">82.16</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Risk
    free interest rate</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">1.50</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Expected
    dividend yield</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">0.00</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Expected
    life of options in years</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">6.4</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of stock options granted during 2021 was approximately $0.46. The weighted average fair value
of stock options vested in 2022 and 2021 was approximately $0.92 and $0.92, respectively. Share-based compensation expense related to
vesting stock options was $1,958,151 and $2,219,333 for the years ended December&nbsp;31, 2022 and 2021, respectively, and is recorded
in the accompanying statements of operations within general and administrative expenses. The intrinsic value of stock options outstanding
and exercisable at December&nbsp;31, 2022 was approximately $111,000. At December&nbsp;31, 2022, there was no unrecognized compensation
cost related to non-vested options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 190; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
9 &#8211; Income Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no significant current income taxes due because of the losses generated in each period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and those used for income tax purposes. The Company&#8217;s deferred tax assets relate primarily to its net operating loss carryforwards
and other balance sheet basis differences. In accordance with ASC 740, the Company recorded a valuation allowance to fully offset the
gross deferred tax asset because it is not &#8220;more likely than not&#8221; that the Company will realize future benefits associated
with these deferred tax assets at December&nbsp;31, 2022 and 2021. The valuation allowance increased by approximately 851,000 and $948,000
for the years ended December&nbsp;31, 2022 and 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
components of the Company&#8217;s deferred tax assets at December&nbsp;31, 2022 and 2021 as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December&nbsp;31,</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December&nbsp;31,</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    tax assets:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    operating losses</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,732,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,578,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share
    based compensaton</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,405,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,044,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    expense</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">87,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    wages</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">116,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">130,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    research and development costs</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">293,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    revenue and costs</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">140,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">140,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    deferred tax assets</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,773,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,924,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Valuation
    allowance</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,773,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,924,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    tax asset, net of valuation allowance</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
difference between income taxes at the statutory federal income tax rate and income taxes reported in the Statements of Operations is
attributable to a full valuation allowance recorded in all periods since inception.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provision for income taxes for the taxable periods ended December&nbsp;31, 2022 and 2021 differs from the statutory federal income tax
rate for the years ended December&nbsp;31, 2022 and 2021 as follows: 2022 to be reviewed</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tax
    benefit at the Federal statutory rate</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21.0</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21.0</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">State
    tax, net of Federal benefit</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Permanent
    differences</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.4</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.4</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in the valuation allowance</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(27.6</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(28.4</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective
    income tax rate</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December&nbsp;31, 2022, the Company had Federal net operating loss carryforwards of approximately $13,300,000, which will begin to expire
in 2035. Of the total Federal net operating losses, the amounts incurred after 2017 of approximately $6,200,000 will carry forward indefinitely.
Sections&nbsp;382 and 383 of the Internal Revenue Code, and similar state regulations, contain provisions that may limit the NOL carryforwards
available to be used to offset income in any given year upon the occurrence of certain events, including changes in the ownership interests
of significant shareholders. In the event of a cumulative change in ownership in excess of 50% over a three-year period, the amount of
the NOL carryforwards that the Company may utilize in any year may be limited. Although the Company has not undertaken a formal analysis,
it is likely that such an ownership change occurred prior to 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&#8217;s financial
statements as of December&nbsp;31, 2022 or 2021. The Company does not expect any significant changes in its unrecognized tax benefits
within twelve months of the reporting date. No tax audits were commenced or were in process for the taxable periods that ended December&nbsp;31,
2022 and 2021. No tax related interest or penalties were incurred during the years ended December&nbsp;31, 2022 and 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 191; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
10 &#8211; Subsequent Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events through May&nbsp;1, 2023, the date the financial statements were available to be issued and determined
that there have been no events that have occurred that would require adjustments to our disclosures in the financial statements except
for the transactions described below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>License
Agreement</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April&nbsp;5, 2023, NeOnc amended the exclusive license agreement with USC dated March&nbsp;9, 2009 (see Note 3) (&#8220;Amended Agreement&#8221;)
to include all of the worldwide patents developed by the Company related to the biotechnology under development by the Company. The Amended
Agreement also had NeOnc Technologies Holding Company, Inc. (&#8220;Newco&#8221;) as a licensee. In addition, the Amended Agreement contained
the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; background-color: white; color: #222222; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company will issue to USC, within fifteen (15) days of the Amended Agreement, shares of common stock of the Company which (when combined
    with shares previously held by USC) represents three and one-half percent (3.5%) of the fully diluted capitalization of Newco after
    completion of the transactions contemplated in the LOI. (see Note 1)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; background-color: white; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222222">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
    Company will pay USC nonrefundable earned royalties of 4% on Net Sales of Licensed Products covered by the licensed patents in all
    countries in which the manufacture, use, sale, offer for sale, or import of such Licensed Products, as such capitalized terms are
    defined in the Amended Agreement. To date, no sales have been made using the Licensed Products, and no royalties are due to USC.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; background-color: white; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222222">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
    Company will assume responsibility for patent-related costs.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Share
Exchange</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April&nbsp;7, 2023, the Company entered into
Share Exchange Agreements with Newco, whereby all of the shareholders of the Company exchanged their stock in the Company for a total
of 10,500,000 shares of common stock in Newco. At the consummation of this transaction, AFH, and its affiliated entities,
individuals, or assignees owned an aggregate of 34.6% of the fully diluted issued and outstanding common shares of Newco.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Options
Cancelled</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January&nbsp;2023, the remaining 166,060 options to acquire shares of common stock were canceled pursuant to cancellation agreements
with the option holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Legal
Proceedings</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April&nbsp;2023, upon the termination of a licensing agreement by the Company with a third party, the Company received correspondence
from the third party threatening litigation for breach of contract. Due to the preliminary nature of this matter, management currently
cannot reasonably estimate any related potential loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 192; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">NEONC
TECHNOLOGIES HOLDINGS, INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">PRELIMINARY
PROSPECTUS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sole
Bookrunning Manager</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Maxim
Group LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Co-Managers</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Brookline
        Capital Markets,</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>a
        division of Arcadia Securities, LLC</B></FONT></P></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Spartan
    Capital Securities LLC</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2023</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in this prospectus. No dealer, salesperson or other person is authorized to give information
that is not contained in this prospectus. This prospectus is not an offer to sell nor is it seeking an offer to buy these securities
in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is correct only as of the
date of this prospectus, regardless of the time of the delivery of this prospectus or any sale of these securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 (25 days after the commencement of this
prospectus), all dealers that effect transactions in these securities, whether or not participating in this prospectus, may be required
to deliver a prospectus. This is in addition to the dealers&#8217; obligation to deliver a prospectus when acting as underwriters and
with respect to their unsold allotments or subscription.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 193 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin: 0pt">&#160;</p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
II</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION
NOT REQUIRED IN PROSPECTUS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM&nbsp;13.
OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the costs and expenses payable by us (the Registrant), other than underwriting discounts and commissions,
in connection with the issuance and distribution of the securities being registered hereunder. All of the amounts shown are estimates,
except for the SEC Registration Fee and FINRA filing fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amounts<BR>
    to be Paid</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">SEC
    registration fee</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">FINRA
    filing fee</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nasdaq
    filing fee</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Printing
    fees and expenses</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal
    fees and expenses</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounting
    fees and expenses</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Transfer
    agent and registrar fees</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Miscellaneous
    fees and expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be completed by amendment.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM&nbsp;14.
INDEMNIFICATION OF OFFICERS AND DIRECTORS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;102
of the DGCL permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its shareholders
for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to
act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a
stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our amended and restated certificate
of incorporation provides that no director of the registrant shall be personally liable to it or its shareholders for monetary damages
for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that
the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;145
of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person
serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities
against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred
by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any
threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner
he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had
no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation,
no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable
to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the
adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity
for such expenses which the Court of Chancery or such other court shall deem proper.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 194; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            bylaws authorize the indemnification of our officers and directors, consistent with Section&nbsp;145
                                            of the DGCL, as amended. Reference is made to Section&nbsp;102(b)(7) of the DGCL, which enables
                                            a corporation in its original certificate of incorporation or an amendment thereto to eliminate
                                            or limit the personal liability of a director for violations of the director&#8217;s fiduciary
                                            duty, except (i) for any breach of the director&#8217;s duty of loyalty to the corporation
                                            or its shareholders, (ii) for acts or omissions not in good faith or which involve intentional
                                            misconduct or a knowing violation of law, (iii) pursuant to Section&nbsp;174 of the DGCL,
                                            which provides for liability of directors for unlawful payments of dividends of unlawful
                                            stock purchase or redemptions or (iv) for any transaction from which a director derived an
                                            improper personal benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into indemnification agreements with each of our directors and officers. These indemnification agreements require us, among
other things, to indemnify our directors and officers for some expenses, including attorneys&#8217; fees, judgments, fines and settlement
amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers,
or any of our subsidiaries or any other company or enterprise to which the person provides services</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out
of claims based on acts or omissions in their capacities as directors or officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
any underwriting agreement we enter into in connection with the sale of common stock being registered hereby, the underwriters will agree
to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities
Act, against certain liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM&nbsp;15.
RECENT SALES OF UNREGISTERED SECURITIES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is information regarding shares of capital stock issued by us within the past three years. Also included is the consideration
received by us for such shares and information relating to the section of the Securities Act, or rule of the SEC, under which exemption
from registration was claimed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December&nbsp;31, 2021 NeOnc Technologies, Inc. issued stock options for 7,250,000 shares of common stock to directors
and advisors and, in connection with the Chairman Note, 250,000 options to the Chairman at an exercise price of $0.66 per share. On December&nbsp;31,
2022, all of the option holders converted the then aggregate outstanding options to acquire 18,705,451 shares into 9,150,051 shares of
common stock pursuant to the cashless exercise provision of the 2013 Option Plan. A portion of the outstanding options (those with an
exercise price of $1.25 per share) were repriced to an exercise price of $1.00 immediately before the cashless exercise. This modification
of the stock option resulted in a charge to share-based compensation of $182,243, which is recorded within general and administrative
expenses on the statement of consolidated operations during the year ended December&nbsp;31, 2022. The remaining outstanding stock options
to acquire 166,060 shares of common stock were cancelled during 2023 per cancellation agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
January&nbsp;2022 and December&nbsp;2022, 2.4 million shares of our NeOnc Technologies, Inc.&#8217;a common stock were issued for $1
per share in private placements, amounting to net proceeds of $2.4 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February&nbsp;2022, NeOnc Technologies, Inc. issued a $50,000 convertible note to a shareholder due August&nbsp;30, 2023 (&#8220;Note&#8221;).
The Note bears interest at 2% per annum and is convertible. This Note and all accrued interest thereon is convertible, at the option
of the noteholder, into the class and series of equity securities (&#8220;Conversion Stock&#8221;) that is sold by the Company in its
next issuance of equity securities in a Financing Transaction (as defined below), consummated after the issuance date of the note. A
Financing Transaction is a sale, other than in an initial public offering (&#8220;IPO&#8221;), of equity securities by the Company to
investors for cash. The Financing Transaction does not include the issuance of stock, options, or warrants to service providers in connection
with the rendition of such services or to third parties in connection with the contribution of non-cash assets to the Company. The number
of shares of Conversion Stock to be issued to the noteholder upon such conversion shall be equal to the quotient obtained by dividing
(i) the entire principal amount of this Note plus accrued interest by (ii) the Financing Transaction Conversion Price (as defined below).
The Financing Transaction Conversion Price shall be equal to seventy-five percent (75%) of the price paid for one share of Conversion
Stock by the investors in the Financing Transaction. The entire principal amount of and accrued interest on this Note shall automatically
be converted, without further action on the part of the noteholder or the Company, into the class and series of stock issued by the Company,
at the closing of an IPO. The number of shares of stock to be issued to the holder upon such conversion shall be equal to the quotient
obtained by dividing (i) the entire principal amount of this Note plus accrued interest by (ii) the IPO Conversion Price (as defined
in the Note).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 195; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            January&nbsp;2023, NeOnc Technologies Holdings, Inc. issued 4,500,000 shares of its common
                                            stock to seven  accredited investors at a per share price of $0.001. In April&nbsp;2023,
                                            NeOnc Technologies Holdings, Inc. effected a 1.222222-for-1 forward split of the outstanding
                                            shares of its common stock, resulting in 5,500,000 shares of common stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April&nbsp;2023, following effectiveness of the forward split, NeOnc Technologies Holdings, Inc. issued 10,500,000 shares of its common
stock to sixty-seven (67)  accredited investors in exchange for shares of stock in NeOnc Technologies, Inc. held by such investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. Unless otherwise
specified above, we believe these transactions were exempt from registration under the Securities Act in reliance on Section&nbsp;4(2)
of the Securities Act (and Regulation D or Regulation S promulgated thereunder) or Rule&nbsp;701 promulgated under Section&nbsp;3(b)
of the Securities Act as transactions by an issuer not involving any public offering or under benefit plans and contracts relating to
compensation as provided under Rule&nbsp;701. The recipients of the securities in each of these transactions represented their intentions
to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate
legends were placed on the share certificates issued in these transactions. All recipients had adequate access, through their relationships
with us, to information about us. The sales of these securities were made without any general solicitation or advertising.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 196; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;16.
Exhibits and Financial Statement Schedules.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
the Exhibit Index on the page immediately preceding the signature page for a list of exhibits filed as part of this registration statement
on Form S-1, which Exhibit Index is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Financial Statement Schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial statement schedules are omitted because the information required to be set forth therein is not applicable or is shown in the
consolidated financial statements or the notes thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;17.
Undertakings.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            undersigned registrant hereby undertakes:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            file, during any period in which offers or sales are being made, a post-effective amendment
                                            to this registration statement:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            reflect in the prospectus any facts or events arising after the effective date of the registration
                                            statement (or the most recent post-effective amendment thereof) which, individually or in
                                            the aggregate, represent a fundamental change in the information set forth in the registration
                                            statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
                                            offered (if the total dollar value of securities offered would not exceed that which was
                                            registered) and any deviation from the low or high end of the estimated maximum offering
                                            range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&nbsp;424(b)
                                            if, in the aggregate, the changes in volume and price represent no more than 20 percent change
                                            in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration
                                            Fee&#8221; table in the effective registration statement; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            include any material information with respect to the plan of distribution not previously
                                            disclosed in the registration statement or any material change to such information in the
                                            registration statement;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provided,
however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included
in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant
pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration
statement, or is contained in a form of prospectus filed pursuant to Rule&nbsp;424(b) that is part of the registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
                                            for the purpose of determining any liability under the Securities Act of 1933, each such
                                            post-effective amendment shall be deemed to be a new registration statement relating to the
                                            securities offered therein, and the offering of such securities at that time shall be deemed
                                            to be the initial bona fide offering thereof.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            remove from registration by means of a post-effective amendment any of the securities being
                                            registered which remain unsold at the termination of the offering.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 197; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
                                            for the purpose of determining liability under the Securities Act of 1933 to any purchaser
                                            each prospectus filed pursuant to Rule&nbsp;424(b) as part of a registration statement relating
                                            to an offering, other than registration statements relying on Rule&nbsp;430B or other than
                                            prospectuses filed in reliance on Rule&nbsp;430A (&sect; 230.430A of this chapter), shall
                                            be deemed to be part of and included in the registration statement as of the date it is first
                                            used after effectiveness. Provided, however, that no statement made in a registration statement
                                            or prospectus that is part of the registration statement or made in a document incorporated
                                            or deemed incorporated by reference into the registration statement or prospectus that is
                                            part of the registration statement will, as to a purchaser with a time of contract of sale
                                            prior to such first use, supersede or modify any statement that was made in the registration
                                            statement or prospectus that was part of the registration statement or made in any such document
                                            immediately prior to such date of first use.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
                                            for the purpose of determining liability of the registrant under the Securities Act of 1933
                                            to any purchaser in the initial distribution of the securities: the undersigned registrant
                                            undertakes that in a primary offering of securities of the undersigned registrant pursuant
                                            to this registration statement, regardless of the underwriting method used to sell the securities
                                            to the purchaser, if the securities are offered or sold to such purchaser by means of any
                                            of the following communications, the undersigned registrant will be a seller to the purchaser
                                            and will be considered to offer or sell such securities to such purchaser:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            preliminary prospectus or prospectus of the undersigned registrant relating to the offering
                                            required to be filed pursuant to Rule&nbsp;424;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            free writing prospectus relating to the offering prepared by or on behalf of the undersigned
                                            registrant or used or referred to by the undersigned registrant;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            portion of any other free writing prospectus relating to the offering containing material
                                            information about the undersigned registrant or its securities provided by or on behalf of
                                            the undersigned registrant; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            other communication that is an offer in the offering made by the undersigned registrant to
                                            the purchaser.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            undersigned registrant hereby undertakes that, for purposes of determining any liability
                                            under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant
                                            to section&nbsp;13(a) or section&nbsp;15(d) of the Securities Exchange Act of 1934 (and,
                                            where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant
                                            to section&nbsp;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference
                                            in the registration statement shall be deemed to be a new registration statement relating
                                            to the securities offered therein, and the offering of such securities at that time shall
                                            be deemed to be the initial bona fide offering thereof.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
                                            as indemnification for liabilities arising under the Securities Act of 1933 may be permitted
                                            to directors, officers and controlling persons of the registrant pursuant to the foregoing
                                            provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
                                            and Exchange Commission such indemnification is against public policy as expressed in the
                                            Act and is, therefore, unenforceable. In the event that a claim for indemnification against
                                            such liabilities (other than the payment by the registrant of expenses incurred or paid by
                                            a director, officer or controlling person of the registrant in the successful defense of
                                            any action, suit or proceeding) is asserted by such director, officer or controlling person
                                            in connection with the securities being registered, the registrant will, unless in the opinion
                                            of its counsel the matter has been settled by controlling precedent, submit to a court of
                                            appropriate jurisdiction the question whether such indemnification by it is against public
                                            policy as expressed in the Act and will be governed by the final adjudication of such issue.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            undersigned registrant hereby undertakes that:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            purposes of determining any liability under the Securities Act of 1933, the information omitted
                                            from the form of prospectus filed as part of this registration statement in reliance upon
                                            Rule&nbsp;430A and contained in a form of prospectus filed by the registrant pursuant to
                                            Rule&nbsp;424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part
                                            of this registration statement as of the time it was declared effective.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the purpose of determining any liability under the Securities Act of 1933, each post-effective
                                            amendment that contains a form of prospectus shall be deemed to be a new registration statement
                                            relating to the securities offered therein, and the offering of such securities at that time
                                            shall be deemed to be the initial bona fide offering thereof.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 198; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT
INDEX</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
    Number</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; vertical-align: bottom; width: 90%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriting Agreement</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
    of Incorporation of NeOnc Technologies Holdings, Inc., as currently in effect</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
    of Amendment of NeOnc Technologies Holdings, Inc., as currently in effect</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Amended and Restated Certifiate of Incorporation </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws
    of NeOnc Technologies Holdings, Inc., as currently in effect</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Amended and Restated Bylaws</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Common Stock Certificate</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory
    Note, dated February&nbsp;17, 2022, by NeOnc Technologies, Inc. to R &amp; J Brownstone</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of the Representative&#8217;s Warrant (Included in Exhibit 1.1)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Manatt, Phelps &amp; Phillips, LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*<FONT STYLE="background-color: white"><B>#</B></FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeOnc
    Technologies Holdings, Inc. 2023 Equity Incentive Plan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*<FONT STYLE="background-color: white"><B>#</B></FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Indemnity Agreement between NeOnc Technologies Holdings, Inc. and each of its directors and executive officers</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive
    Patent License Agreement between the University of Southern California and NAS-ONC, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Amendment to Exclusive License Agreement between the University of Southern California and NeOnc Technologies, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
    Amendment to Exclusive License Agreement between the University of Southern California and NeOnc Technologies, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">10.6*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">Engagement Agreement dated December 19, 2022, between NeOnc Technologies, Inc. and AFH Holdings and Advisory, LLC</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">10.7*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">Share Exchange Agreement dated April 7, 2023 between NeOnc Technologies, Inc. and NeOnc Technologies Holdings, Inc</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">10.8*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">Loan Agreement dated April 21, 2023 by and between HCWG LLC and NeOnc Technologies</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List
    of Subsidiaries of NeOnc Technologies Holdings, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Manatt, Phelps &amp; Phillips LLP (included in Exhibit 5.1)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Marcum LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#poa">Power of Attorney</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Nasim Shomali, director nominee</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Dr. Iyabo Tinubu-Karch, director nominee</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Richard Nanula, director nominee</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Victoria Medvec, PhD., director nominee</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC
    Filing Fee Table</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>*</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To be filed by amendment.</B></FONT></TD> </TR>
  </TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>#</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indicates management
    contract or compensatory plan.</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 199; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">SIGNATURES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pursuant
to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in Los Angeles, California, on ______, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC
    TECHNOLOGIES HOLDINGS, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Dr. Thomas C. Chen</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Thomas C. Chen</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="poa"></A>POWER
OF ATTORNEY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNOW
ALL MEN BY THESE PRESENTS, that each person whose individual signature appears below hereby authorizes and appoints Dr. Thomas C. Chen
with full power of substitution and resubstitution and full power to act, as his true and lawful attorney-in-fact and agent to act in
his name, place and stead, and to execute in the name and on behalf of each person, individually and in each capacity stated below, and
to file any and all amendments to this registration statement, any related registration statement filed pursuant to Rule&nbsp;462(b)
under the Securities Act of 1933, as amended, and any or all pre- or post-effective amendments thereto, and to file the same, with all
exhibits thereto, and all other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said
attorney-in-fact and agent, and full power and authority to do and perform each and every act and thing requisite and necessary to be
done in and about the premises, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming
that said attorney-in-fact and agent, or any substitute, may lawfully do or cause to be done by virtue hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
required under the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities
and on the dates indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Dr. Thomas C. Chen</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Executive Officer and Chairman</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____,
    2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Thomas C. Chen</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(<I>Principal
    Executive Officer</I>)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Keithly Garnett</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Financial Officer and Director</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____,
    2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keithly
    Garnett</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(<I>Principal
    Accounting Officer</I>)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Amir Heshmatpour</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Vice Chairman and Secretary</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____,
    2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amir
    Heshmatpour</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Dr. Alan Chiang</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____,
    2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Alan Chiang</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 200; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" =F!F # 2(  A$! Q$!_\0
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M"=7$/_EY^"/(X]0UR/\ YE743_VS?_XBIO[8US&/^$3U'_OA_P#XBO5J*?\
MK#_TXC]\B>:M_/\ @CR5]3UYO^96U$?]LW_^(IIU'7BN/^$6U'_OV_\ \17K
ME%'^L/\ TXC]\@YZW\_X(\8FDUZ7_F6M1'_;%_\ XFJ;VNO.<GP_J/\ WX?_
M .)KW.BE_K O^?$?_ I%JOB%M4_!'A0L==#9_P"$?U'_ +\/_P#$UH6\NMP
M9\,:BW_;)Q_[)7LM%/\ UB_Z<1^^0W7Q,MZGX(\G_M77=N!X4U'_ +X?_P"(
MJL]WKSY_XIC41_VR?_XBO8:*?^L7_3B/WR,U*LOM_@CQDRZ\?^9:U'_OR_\
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M_A3#X+UTG/\ 96H_^ ;_ .%?2M%'^L;_ .?,?OD'M*_\_P""/FG_ (0G7?\
MH%ZC_P" ;_X4H\%Z\/\ F%ZC_P" ;_X5]*T4?ZQO_GS'[Y![2O\ S_@CYL'@
M[7A_S"M1_P# -_\ "I5\)Z\O_,(U$_\ ;H_^%?1U%'^L7_3B/WR*]MB/^?GX
M(^<O^$5UW_H$:C_X"/\ X4X>%M='_,'U'_P$?_"OHNBE_K%_TXC]\A^WQ/\
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MX4YSOR1;MV3?Y("JOBK37\2G0!YWVP$C.SY,A=W7/I6Y7ED'_);3_P!='_\
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M<%5P=:5*HMG:^MGZ70#Z**I7NK:=II O;ZVMR1D++(%)'L#7+"$IOEBKORU
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M ZF-PV/RJ6O&_$_AB?P1-:ZEI>H3;7?8&/RNK8SCC@@X/Y5ZKHM^=4T2ROF
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MC)Q^M=-3$UIX7"8N;M4YW&_5QNM^_5#.)\"^#],\1Z;<W%\UP'BFV+Y;@#&
M?0^M>KV5G%I]C!9P ^5!&(TW')P!CFN&^$Q']BWZYY%P"1_P$5Z#7!Q#B:T\
M=4I3DW&+T71:+83,SQ#JO]B:!>:@%#-"GR ]"Q.!^I%>;^$/"*^*TN-8UJYG
MD5I"J@-\SD=23Z=L5VGQ!A:;P3?A<Y38^/8.N:I_#&ZBF\)K"A'F03.KCOR<
M@_K^E:X.I/"Y34Q%#2;FHM]4K7^5V FF> 8]#\36VI:=>R+:H&$L,G+'*D
MCJ,X//I7&^,H;NX^)$]O8%A<S".)-IQ]Z, \^F"<U[$\\,<L<3RHLDA(1&8
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M#OBS3]3M/[0U-3IUL"/)69FW#:0!C'0<=>F*[VBBL,9C)XNI[2:2?DDO/IU
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MHPF95\+&4(6<9;II-?<P//[#PIXKNM4M+O6M;!B@E67RHW8[MISC  49]:]
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M_/\ C_X#(KV.(_Y]_BCW6BO"Q>ZX?^9BU'_O^_\ \53_ +5KG_0QZC_W_?\
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M7_/^/W2*5'$/:G^*_P SVNBO#)+S7(_^9BU'_O\ O_\ %56?5]<3_F/ZB?\
MMX?_ .*H7#U_^7\?ND5]6Q7_ #[_ !7^9[Y17SX=?UT'']MZC_X$O_C4L>LZ
MY)UU[41_V\O_ /%4?ZN_]/X_=(3P^)7_ "[_ !7^9[]17@CZKK:#(\0:B?\
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M<E;^3\4?3-%?.,7BGQ)*1C4=1'_;X]:MM?\ B.XQG6M13/\ T\N?ZT?ZN_\
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MP@*V#5U%YIHQZEF)<@5HVRXJE#@5HP8J9'131<B7!K0BZ"J*'IBK<1K,)FE
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M>] &;<1&)L]JB!S6K(BR*<CFLV2,QDYZ4&D7<;10.1FC% PHHHH ***2@!:
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MOZBN28EW+$_,>IK6,3AK5;C<44ZDK0Y HHHI@%%%% !1110 4444 %(:6B@
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M#C/'K4#39;@TK%)W+0ER::['/6JC2X/)Q33*P//X46'?H62YI,%AP:HR3N)
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M)_$EU,<(=GTK"$+I'IU:ZC)HZ^6>.(;G< 5FW&O6T&=I#&N2GOKFX_UDA-0
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M>*LPMQ38](U*0X6SF./]FK46DZDIP;&;_OFE9@G'N6K>7(Q6K:#)Q5&WTG4
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M3N*P9HI<447 3%&*6E)HN E%%% !1110 $TTL!UIV*:4!H 3>M.!!'%)L%*
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M\FGXI:2&,Z44[%&*>@#:*=BC%&@#:*=BC%&@#:*=11H VBG44: -HIU&!1H
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MWYR8^]1YJ?WJQ/LM]_SQD_*C[-?_ //&3\J?,A>Q9M^:G]ZCS4_O5B?9[_\
MYXO^5'V>_P#^>+_E1=![&1M^>G]X4GG)ZBL?[)?_ //%Z/LE_P#\\7I<R'["
M1L^>G]X4>>GJ*QOLE_\ \\7_ "H^QWW_ #Q>CF0>P9L><G]X4OG)_>%8OV/4
M/^>3_E1]CU#_ )Y/^5/F0>PD;7GI_>%'GI_>%8WV._\ ^>3_ )4AL]0Q_J7_
M "HYD'L)&UYZ?WA1YZ?WA6']CU#_ )X/0+34<_ZAZ+H/82-WST_O"CST_O5A
M_8]1_P">+_E2_8=1/6)_RHN@]A(VOM"?WZ/M"?WZQ?L%_P#\\GH^P7__ #R>
MES![!FU]H3^_1]HC_O5B_8+_ /YY/^5'V"__ .>3T<P>P9M?:(_[PH^T)_>%
M8WV"^_YXO1]@OO\ GB]'.'L&;/VB/^]2?:$_O5C?8+[_ )XO1]@O_P#GD]+G
M0>P9L_:$_O4?:4_O"L;[!?\ _/)Z/L%__P \7I\Z#V#-C[4G]X4?:D_O"L?[
M!?\ _/%Z/L%]_P \7I<Z#V#-C[4G]X4?:D_O"L?[!?\ _/%Z/[/O_P#GB]/F
M#V#-C[4G]X4OVF/^\*QO[/O_ /GB]']GZ@?^6#T<P>PD;/VF/^\*/M4?]X5C
M_P!F:B?^634X:5J!_P"6+4<P>P9J_:H_[PI/M47]ZLIM*U ?\L6IO]FW_P#S
MQ:CF'[!FQ]JC[,*!<I_>%8_]G7X&?)>HS;7J]8G_ "HYA>P9O"X0_P 0I?.7
M^\*Y\0WO_/*3\J<(+WO#)^5','L&;IF7^\*3ST_O"L,PW@_Y8R?E0(;TG_4O
M^5','L&;OGKZYH\Y367!97['Y86_&K:Z;J9'^I_6CF#V$NB+1D':D\RH/[,U
M4?\ ++-']G:I_P \?UHYD'L)]BQO!IP(QUJK_9NJ_P#/']:=_9^JCCR?UI\Z
M#ZO4[#Y)=@R#6;<7)+;@>E6Y-*U9_P#EC^M5VT#5&_Y8_K4\R+CAYKH55U"X
M602(>11-?W$S;W;)%61X=U0?\L1^='_".:F?^6/ZTN8OV,OY2G]LE/? '6I$
MU&>-2$8A3U%6/^$<U/\ YX_K1_PCFI_\\?UI7#V,OY2F+Z4' X%.^W3#D-5K
M_A'-3_YXC\Z/^$<U/_GC^M/F#V,OY2F;^=CRU/6]E ZU8_X1O4_^>/ZTH\.Z
MH.D/ZT<P>PE_*5OM\OK2_P!H3C^*K'_".:G_ ,\1^='_  CFI_\ /']:+A["
M7\I6^WR_WJ/M\O\ >JS_ ,(YJ?\ SQ'YT?\ ".:G_P \1^=%P]A+^4K"^F[-
MB@W\I/+59_X1S4_^>/ZT?\(YJ?\ SQ_6E</82_E*WV^7^]1]OF[-5G_A'-3_
M .>(_.C_ (1S4_\ GC^M.X>PE_*5SJ$_3=2?;YO6K/\ PCFI_P#/']:/^$=U
M3_GB/SHN'L)?RE;[?+_>H^WR_P!ZK/\ PCFI_P#/$?G1_P (YJ?_ #Q'YT7#
MV$OY2K]OE_O4&_F_OU:_X1S4_P#G@/SH_P"$<U/_ )XC\Z+H/82_E*GVZ;^_
M2B^F_OU:_P"$<U/_ )XC\Z/^$<U/_GB/SHN@]C+^4K?;IO[](;Z;^]5K_A'-
M3_YXC\Z/^$<U/_GC^M%T'L)?RE7[=/\ WJ!?S_WJM?\ ".:G_P \?UH_X1S4
M_P#GC^M%P]C+^4K?VA/_ 'J3[=,?XJM?\(YJ?_/']:/^$=U/_GC^M%T'L9?R
ME7[=+_>I?[1F_O59_P"$<U/_ )X_K2?\(WJ7_/']:+H/82_E*W]H3_WJ/[0G
M_O59_P"$;U/_ )XC\Z/^$;U/_GC^M%T'L)?RE?\ M&;UI/M\_P#>JS_PC>I?
M\\1^='_"-:G_ ,\?UHN@]A+^4K?;YO[U']H3>M6?^$:U/_GC^M'_  C>I_\
M/']:.8/82_E*W]H3>M)]NG_O5:_X1O4_^>/ZT?\ "-ZG_P \?UHY@]A+^4J_
M;I_[U+]OG_O59_X1O4_^>(_.E_X1S5/^>(_.CF#V$OY2K]OG_O4GVZ?^]5O_
M (1O4_\ GB/SI/\ A&]3_P">(_.BX>PE_*51?S_WJ7[?/ZU9_P"$;U/_ )XC
M\Z7_ (1O4_\ GC^M*X>PE_*5?M\_K1]OG]:M?\(YJ?\ SQ'YT?\ ".:G_P \
M1^=/F#V$OY2K]OG_ +U'V^?^]5K_ (1S4_\ GB/SH_X1S4_^>/ZT<P>PE_*5
MA?3_ -ZC[?/ZU9_X1S4_^>/ZT?\ ".:G_P \?UI7#V$OY2H;Z?\ O4GVZ?\
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M\<!?SHYE8GZK4ZQ*!U*8 9IHU&8]ZT/^$1U/_9_.D_X1'5!T4?G0I(?U6?\
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MI3_M-_2E_M1O:KG_  B&H^JT?\(?J'=EHYT'U.?\I2_M-Z3^TWJ]_P (??\
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M:/.UG_GZA_[]K_\ $U8HH_M;$?W?_ 4']AX3^]_X$_\ (K>=K'_/U#_WPO\
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M1_PD=_\ WA631@T<S#V%/L:W_"1ZA_>6D_X2/4/[RUE;3[48I\S#V%/L:O\
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M3\J;_9]L3_J4_*CVH*G)]3B!(2,X-(9L<8-=T;"W XB3\J0:?:_\\4S]*?M
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M9Y/^^32_8K__ )X/_P!\UW&3GK3@QH=1C]CYG"_8KX\>0_Y4O]G7_P#SP?\
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MO"O3[G,_V!J'HO\ WU1_86H^@_.NH74;8_\ +5?SJ59XVY#C%%V4E![,Y/\
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M?K=,]AO[*+4;":SF+".9=K%#@X]JQ-,\#Z-I=XEU&DTTL9W(9G!"GUP *O\
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M^$[9S@\XJ,9IT8_?DGTHN3)(>[EB<FFYI""3GM11<:09YHI*,T#%HS29HHN
MN:,TE+3N =:.***0!24M% #2V#BG;@JY8TC84%R.@KF-3U*:28HIPH]*N%/F
M.>M7C31O3:C;Q Y<9]*H2Z_$N=JYKG&<N<EB?K3:ZXX<\B>9SO[IMOXA<\*N
M!4)UR<GBLFBK]DC!XZLS5_MRZ]:/[=NO45E?C1^-/V2)^N5C6&NW(ZBID\0R
M#JM8F:*'20+&UD=-'K\3#YTQ5R#4+:;^, ^E<;3@2/NG!K-TCJAF51;G=#8_
MW30%*FN6T_4Y8I5C8D_6NJ1M\:L>]<M16/5H8CVJ'4AZT$TWO6:.BPZC-)10
M,7-&:2B@!<T9Q110 9S0:**+@-R: 33L4H'!HN%QK_<)7KBH[$G[$QZ?O#4K
M8"'Z5'98-DV/^>AH3(=B7)P*:6IQ%-Q1<I!DTH/%&**5QADT9-%%,!<TE%%
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M0V@]:YG4!_I/_ 153!JZGQ,\[!5&L/!>1U.ES11VS!Y$4[R<%@.PJ[]IM_\
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M-)SZ4_%%,=AF*7%.Q1BBX6&XHQ3L48HN%AN!1M%/VTG2E=A9";?:FMQ3P2W
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M!8;BC%.Q1B@5AF*,4[%&* L-Q2XI0.:?MHN"1%BC%2;:7 '6BX^4CVT;:<6
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MW TM(H;BDVT_-&V@+#-M&VI,4F*06& <T$4\#F@B@+$16E48IY% % K"BG4
M4N*"T,[TM+BDQ0(::!2XYI0M K!C(II6I *0TAM%=H\C%0F J?:K$CA6J,2-
M(<**TIJ4WRI'/6E3@N:;!=BC#5&[9/R(:OV^FM-@D'-7UTETY4?G7ITLK<M6
M?,XKB6E"7)35_,Y\"13DQG%#7(Z%<&M^33W"_,?PJA-I^WG;FMIY5IN<U+B;
M6THZ&7MW\BGQK@XQ4XMQG@;?:G K'VYKSZE!T7JCWJ&/HUX\T'J$-L"<N*N)
M%&G057$I-.$RKU-9G0IEU" *<90H.36<UV#]TU'O9CG-0W8Z(JY;EEWGVJI)
M&#T%2 YIVT&HYC;D3*?E'-21K@CBK'E@TH0"CF$J6HS;[TW8>U38HVTKE\I7
M)P:<M2[!36CXHN+E8W%. IN,4H;UI /I* PIXYH*6HPTE2-'GFF8HN#0HH:E
M I'I(.A"U,VU(>M&*HS:N1;33@M2!:7%%PY2/92A:?BEQ2N/E&;!1BI,4F*!
MV&XHVT[%*!0.PT"EQ3L4&@=AN*2E) [TQI!02]"?&2WX4TX%([[68?2H2Y-5
M5^-G+@))82GZ?YDC2@5"9O:D:D"EN@J;7-W)B%B>:,$U9BM'?'%7H[!5'S52
MB'*V920.YP%-6X--)Y<BM-45>BT[!(]*KE0<A4:".WMW9!E@*Y9I/-F9CZUU
MMRZI;R#OBN-!Q(?K4S,*]XM(O0QGUK:TQ0)E!]:Q('K3M9MCAO2N=[FU&UCU
MSPXD)10U=-?PV_V4XQTKS'1M=6(+STK9NO$@>$C=VKMA526IXV(P<W5TV,3Q
M*J(SA<5P,B%9B5(QFNDUG4?M#G!S7-2MN:L)5&IJ4>AZ4L/&5#V51:,L6EN\
M\H4]*Z_3M!\Q1\E8FA(ID!/6O6/#]M&Z*2!TK:\JNLSEJ2C@Z7)15D<?<^'=
MD?W*Y;4-/,#$$<5[AJ5I"(3@#I7F'B*%59\5E5IV1678F51VD</(BG((ID5L
MAD'%2SG#&DMF_> GUK")WR2YCL=!TP2[<K7<0>'0T6=G:N9\.7**4Z5Z-::A
M$+8@D=*[*:CNSQ,;4JJ=T>?ZYHR1*WRXK@KV$1NPKU/Q#=1N'P17F6HL&F;%
M85N7H>M@I2E2]XQ)E[U2D;#'FM&4"J$JC>:5-V9%9$0EJ5)0:I.V&XIT;UTI
M71R*HT[&DLHJU&^5%9BMFKL3?**AJYU4YEU#4P-5XS5E:EH[(:B@T8IP%+BI
MV-;#=M)MJ3%(PQ2N%B,TE*2*9NIDL=24W<*0O2N*Z)!UIQ('>JX?FE+9I!S$
MAD Z4QGIAIPC9N@IV;)<F-)I ,]JMQV3OU&!5R*Q1>35* K7,Q8&?HI-7(+$
M#EJO[%3A12D@#DU22*Y1B(J<!:<V>^ *B:X5?N\U7>=W-.]AJFNI99T7O4#W
M)/"U"03UHVU#F4H(1F=CDFDQZT[%&VIYAV$R*3K3L48HN.PVC%.Q2XI!8CVT
M;:EVT;:8<I"8<^E,,1[&K%(11<3BBL0R^]"MS4Y7UIICS1<GE8!@:<!3!&13
M@2.O2F->8[;28S1O!/%!.!R>*!C2,=Z,&JTUT$X'-5OM<F<@XJ7+L9.I%,T2
M,#K2 C-9K7L@Z\TL-Z&;# CWJD[D>VC>Q?!R^*D1-QS[U51RQW+T%:=K'N4<
M<FOH<GHJ4>9F%:5W8E@@W\!:O1Z<[=JU-+L-VWY:ZFVT?<H.VO8J8A0..IB(
MT]#@Y-/9!]VJ,T.W/&*]'O-(V*?EKE-3LMF3C&*TIU8U"Z=95$<N\55I(\&M
M.5<50G^\:)Q5@G&QGRK526,\FKLG6JTG2N6<4UJ<LMS'N#M?%-1B> #5BXC!
M;-$2*N#7SV(@E-F7,TR2&-V[5J6]N%P6(-5(7YXJ[&V,$FN=I'52DV:<)P %
M%6D]ZS4N0HJ7SV:LVST:4>YHF15[BH7N3VJL,FG 9J'(ZE%",S/U--V'/6G[
M>:<16;=V5RD)CW5&T97G-6@*BE. :=V)Q5C/N[CREVC[QK.+2,>34LC&6Y-2
MB&FZLNYY\ESO0@1">IJ0Q<592+':I/*R*R<V]S2-+0S'15Y*YHMI+BRG%S;R
M;"#G%7VA!ZU!+M08QQ51J-.Z,JF'4E:6QZ!HOBPWUH S_OE&&YJKKTMOJ5I)
M#.RYZJ?0UP-O<36DK-;G!;K1++=7,FZ60C\:]B.-@Z5IGR]7)JKQ"G2E9('4
MP.8R.G0CO2"2D9-O?-,(KRI\KDW'8^BASQBE)W9+YU(9_8TQ5R>M3+ #4:&B
MYGL1>9O/ -2+"6YS5E+8=<5.D.!TJ7)=#2-)O<I?9R!SBH7CQ6JT?%5WB!H4
MBI4=-#*>+O4!^5L5I318S5"1<'-=-.=]&<-6GRDD1JW&X%4$:IU>M))!3E8U
M4?&*G245GK)P*L1N*Q:T.Z$R\3\A-4W#2-G/&:E:3C'K4MM:M,0%%<[;N=#]
MXK&$@=,TGDD^E=%'HLCIDBJ]QI<D(SCI1RRM<7+%NR9AM;$#.15.9<*:UIE(
MXJA(O/-$6958):(L:9<C8$P01ZUUVEW>"#G%</!(L4F>U;MK= X*&OK<KQ4:
MM/DGNCC<=+,],T_4PH'S5IOK *?>KS>WU)HQR:LG5B1@-71]5YI-LXYX6,I;
M'0:EJ.X-S7(WD_F.31/?M)G+5GRS ]ZZZ45!:'73IJE$BE;)/-5)/3-22'/>
MJDKE#R>M3)I:LSG(BF^6LN[F7&W!S5Z:8;361,VZ2O*QE:T6HG/-D8Y<D5,B
MD"HT'-657->+?0<%<DB2K\*&JT*5?A3I6<F=U&)8C2K:#"BH8UJPHX%8R/2I
MJPN*79FEQ3A4FMB/93#'4^*3%-,'%%<Q'M2$$=:L$4TCUIW)<2$$=Z?N]*4Q
M@TS:1TH%9H=GVIV*:"._6GCF@:$VT%:6BD,;LI0N*<!FG8HN%AH7-+MI<8HI
M7*L,VTA%/-,9@*8FA57-!PM1F7'2F,Y:E<FZ)#* *C+ENE1D4W<>@%-)LS<^
MX/AVV?Q>M:VFZ>#@G%9D,>926ZUTVF1Y(QTKZ' 8=1IJ<D? <09E.=65&+LD
M:MCIQ;&%XK871BRYQ5[1K8-MXKK8[%/)S@5T5,3:7+$\.GA54L>9WNFE <+T
MK#N+?;D$&O2=7M40-Q7#:@N&-=5*;DM3GJP]G.QS-U NTE>#65,2BDD9K>N%
MZUE7,0.145Z49+5'7A<34HRYH,R1=LQ('&*8;AB>35><^3<>U1EP7S7S=2+4
MK'WU&NITU)&E$^>:LI(.F*H0O\M3QOR*PDCOIS+RFI5J!#5A:S9V1'BEI0*7
M%3<U2&THI<4H%%QV$P*1AD4_%&* L1;*0QU+BC%.XN4@\L]C1RO6K&VF,HHW
M$XVV$1_6E*@FF&,CI299>M/1"N^HYCLJ%Y@3T-2@A^#3Q9A^5-(4KVT*RG=3
MP,TCPM$2*2,FJ2(1(!2'K2[J;GFD6*!2XIN\"FF3- KHDHQ47F8I#*32N',B
M7@=Z-XJ#.:0L:-1<Q.9 *89<CI46:%#/T%-)LES8%\TTG/2K45G(YZ<5<BL$
M4\TU 5FS/GSYIQZ"A(7?H*T8+5907;UQ5R.)(QP*TJ)<[.7+U_LM/T,R+3V.
M"U7$MHXQTS5OD_2HV95ZFA6.U1$ XX&*7ZFH6N /NBH&E=ZELT42RTZKTYJ%
MKAFZ<5#BE Q4N121',"ZL,]:YVXB,4A!]:Z7J*H:A:>8FX#D4F<^(I\T;HR8
M7P:OQ25ED[&P1S5F&4C -1)')2G9V-6.X9#P:F-W(PP7-48PS'@5=CL)I!D*
M:SLV=BG;5E>9R<\U47F2M&?3YH^H-474Q/DTTK&<GS:FIIUQ]GE&>E=]I&NB
M%5^:O+A-[U=@OI4QAC5QJ.)G5HPK*S/5KWQ"'CQNKA-9O_/D8 YK,?497'+&
MJ;S%B<FB=5R5BZ&&A1U1#,<@U%$V#22R8J%9.:A+04IKF.CT[4F@(^; %=''
MXD*Q@;ZX%)>.M3+.0.M5SM#<*<_B.EU#6#.#ALYKGII-Q)J,SYJ"26HU;U-+
MQC&T1DKCUJA,^2?6II'R:A\J20_*.*WI4Y2=HHX:L[F>^[)HC<\5=&FRNWS9
MQ4ZZ1QGFO4AAJO+L<'))RNBK')5Z&3*BH6T]UZ4+NC.TCI6,Z%1;HZ*<G'<T
MXGJRDE9<<H/4XJPLH'>N2<))G?3JHT@].WBL\3X[T?:,]ZAQ9NJR-#S!4;2Y
MJH)">]/W>E*S'[2XYGJ/>:D6-G/ JQ'I\C]13460[LIY)IU7OL!!Q3AIQ)ZT
M^4+% *2>E3I S=!6A'8JG7FK2*J# %4DD/1%"&PRV7Z5:6!$Z+4W.>>E->14
MIW125Q0*1F5>IJM)<$\+4!+,<DTFRU$L/<8^[5=Y&?J:2C%2V780+3L4E&:D
M8['K1BFYHW4F.XIHI,YHH$+24M)3L H%+244K#%HI** $HI<44"$Q2XXHHS0
M @%! Q12TP("HSZ54DE+N4SQ5FX;;&1WJ&VM6D88&2:AN^B,)[V1 T9IIBKH
M(]%E=0<'\JKW.FR0=5.*EIHA1C+9F%)#Q51XRF36Q*F#@BJ<R @4XR,JM(9I
M\K*2C'K75:> 66N1A&VX'UKI[&7:PP:^JR6?[N2.5W/0-'C!VUW-A A09(KS
MO2;P*%YKKK350B=:O%4Y-W1XV*A)RT-'48DV-R*X+657YA73WVJ!E/-<7J]X
M&W<UOA826YT82$EN<U<8#'ZUG3_>JY.^2:I2FO0GL>A-E&3K5>7I4\IYJM+R
M*Y).R.21GS9W4BL *+B3'%5\D\U\]B97J,QM>1<27!XJS'(6QS5",5;AKE;.
MNBK&A'S5Z,=*H15?3M6,CU*1.HI^*:M/K-G6@[T&BC-(H*K7>5@8BK2C-1S1
M[HR*&3)7B8$8_?9J[&,FJRJ5E(/K5VW0EJB1Q4ET+EK9M.0 .*UDT%RF<'GV
MK6\/V"R!,@9->@6^BHT .T=*TA2N8XG&JB['CEUI;0$Y'%8ES;G)KUG7]+6-
M6P!7FVI1^3,P[5,Z;BS2E7A7@8+0$&E$1-66.X]*DB0D]*7,)4TWH5XX&(.Z
MFO!CM6H8C@<5"\1]*GF9HZ*L99CP:EA;!P:FDCJNZE2,5=[F/+RLU;9/,7@5
MM6FD/.,[:I:'$)648S7J.A:6DB+P*(4[LTK8E4:=S@IM =5)VD5AW=HT#$,*
M]PO]&1("<#I7FWB&S6,MQ5U*5C##XU5G8X:9.#65<_*#6W=#"UB7C 4J.X8I
M6165JD1\U7!I\9YKKE'0\Z,R\LF.]6(GS5)!FKL$;''%9R1UTY-LOHN[8/6N
MQT"P6382.O%<>BM&RL>@KNO#MTBE,D<5A;4[*DFH.QW-EH*- #M[5B:[I*PH
MV%KJ['5HTMP"17/^(=121&P171)+E/&PU6M[34\NU"#RYF':LBX3Y3BMG4Y@
M]PV*Q;ER(B17%]H]^HURZF=.C*AQ6QH5M->6<AC)W(16>S P'/7'%=YX T9S
MI<LKKGS6!7\*];+)-53Y[-:TL/2]I!G/&>6!MDR%?>E$N>0U>EWOAF"[@*RQ
M!N/3%<;?^#WMBQAE*K_=KZJ-6,M$<&'SN$H)U=&8A)8=:B8$<YITME=VY(W9
MQ[5 R7###'%-N2.O^U,))7YACRA>IJC>3AEW ]*L_9B3ECGZU4U&,)"0*XL3
M-*#?4Y5FM.I/V<.IGO.7XJ'J32#C!IZ\UX%2;D['=%\R'(O-6HUS44:U;B2L
M7H=5*)/"E7HDQ4,*=*O1IQ64F>E2@.5:F4<4T"I .*S9V104M+BBD6%%+24A
MA2$4M% A,"DVTZEIA8B,8-,*$=ZL$4W&:!.)"&QU%.!![T\H,<U&8_2F39HD
M%**KEF6F^>:0<Z1:)'K3&<"JYD)II)- G4)6DSTJ(L314D<#N>!3Y6S-ML@;
M/:I(D+&KT6G$L"YX]*NI#&G 0<=Z:@);F:EF[G!&*M1V2)RPI;C4(+8$$[F[
M"LN7699/]6@3WJN91(JM/1%YQ#]H;D*1CBM73WV,,&N/>>[D;S"^X^XJU::M
M+ P$BFO=PF/I*G&#9\'FF38F5:=6"NF[GK6CWH3;EJZE-67RL9KR;2]720*0
MV,UMG5"B9WY%=;ITZFL#P7*=!\DE9G1ZK?K(K<UQ=_+R:FFU+S$SGK61<7&[
M/-=$(<J.=N4Y794G>LZ=^<U:F;-4)N:<VC>",+4<+SZFJ:MBK>J$%1CUJB.*
M^?Q-KGU^62?L%<O1O\M3Q-\PJ@C5;A/(KB:T/;ISNT:L;590U0C:KD;5DT>E
M3D6@:7-1!J=NJ+'0F/S2U&&I=U%AW)*6F!J4&BPTQ]&*;FEI%"TA%+13 ;BD
MP.].H- K$10=J;YCQ-P>*FII7)HL2T023%SR*C4X/6K+("*@:/'2J1E)-"&2
MFECBF["33_+-&Y.I'DFCI4HC-.^SN>@ZT*(K$&X4*":O1:<2,M5E+%5[52B*
MUS)*XIZ0/)T4UK"QC!R14Z((_N@4[(I1,R+3V/WN*NQVT<?\-63D]:3<JCFC
M1%<HT# P!0<#J<5#)= 9"]:KM*S]31S(M1+5CS"?]ZIGD5!S5.WEV0,.^ZHW
M=G/-.I\;./+H_P"RTWY?YD\ER3PM5SN8\L:0+3NE9W9WI"8Q2YQ112&)GVI<
MTE% " 4,-PP:6EI(+&?<:=%-T^5O:J(M##+AFS6V< 'UK,D8M.<TI'+4IP3O
M8V-'L1,P)KO].\/K)"#MY^E<EX==0RYKU;1KB 0KDBMJ4%U/*QU:<':)R>IZ
M (T)*UY[KMEY9;:N.:]IUN:%HS@BO*]=*M*P&.M*K!+5&V!J3J1M(XG+*V#4
M\<V.U+=0X8D53W%#6&Z-FW39H-<<=*A:X/I5;S,]ZBD<C&#3412K.UR:61B,
M@5"DK.Q 0DCTJ6)7N&6&,C<>YKK-%\/"%<R;68]?>NW#825;7H>5F&8PPB3E
MNSE$N,-M(P:>\V& %=S>^!HK]/.A9XI>P5<@_6N7O?"&NZ?N+PI(O8J<FE6P
MDH2L@PV;4JT4KV9FO*RTQ9FE. .:&L=1<[6M95QW*\5?L;$Q-B4#=[44,%4J
M.UCMAB(U)6BQEM8F9_F.*UH=.V#:O/X5:M+,/(-M=)9:5O XKZ>A@Z.'BG;W
M@E-1W.973V Y7-,> H.8Z[S^Q/D^[6;>:5L4_+75"HF[$1J1;.->'/M5.6T&
M2<_I6_/;[&((K/FC^8U56C":U1<H6U,22VV\BJYD*G K5GC.#67.A4\"OG\=
MA5'6*)4K LQ[C%6%&>AJAO\ 6IXIRO%>6UT9I"IW+Z*3Q6E:6A/+U2M%WX8U
MJQR'I4V.B$RU'$B]%%3#(]JAC;%2@Y//2DSH3N.P#VIK.%J*:?9\J\U79V;K
M4MFL8=RUY@S3O.C'>J&XCBFG)YJ6V5R1+LDX*\54D<L:3=QBFY%*X[);"K[T
MI-,9L=*C>54&68"BP.:1+NI<U0:_A4\Y-(NHQ$XSBC0S]M'N7V([4F:KK<)(
M/E8&@R$=:+,?M$3DBDW5#YE+O%/E#G)PW%+FH0U/#4K%*1)FEIH-.%!2$SSB
MGA<]Z-O&:3.*16VX%0.])CWI"2:09IBN.!]>*4XQP:",T*@'>DH^8QF6]*<,
M$<G%2%AC %0$$M3$]!_'K2\8ZU&P/:F'(I"O89<X,@%=)H.GK*5)7K7,3']X
MIKLO#=TB[,D41BKW.+$U)*+Y3M;30 \ ..WI6)KFCB)&&/TKK[/5(DMP,CI7
M/^(;^.1&PPKIE"/*>+AJE;VUF]#RR_@\N5AZ5EN.M;&IRAYG/O6+(X4'-<-M
M3WZEK%.60H^<5L6$XDC!W8-8<S;^O&*U=#T^>YMY94SCHM>UE522J<J>AY5:
MM&E[TMCIK/4?*PN>:V8M7PN-W-<0C20S&.52'%6EG([U]14C!M(B*A5CS'57
M&KDKC=6+=W1EZFJ'GY[U&\QQ1'ECLC:,8P6@LC\U6D>FO+4#R\<TI.Z,I3(Y
M6YJI+(0#Z5)+(,'FLZ>?=\HKSL364$8MD,QWOG-*O.*: >E3(F.*\"<U*39,
M5J.C'-784Z5#$G-78H^16;.NC'4L1)BKJ+Q5>-#BK:C@5FSU*41XXIX.::!3
MP*S9T(3M31G/-2XI#@4QM !2,,GJ*0EL'&*C9B.V*5A.2V*%S!Y<I<=*=;R$
M'I5J3###=*IO&8SE>E1*-C!KE=T=UX=OU0)STKT*UUR-8 IQT]:\-L]1:W8<
MX K3/B]85V\DUO3FT>;C,/&J[L[O7]324-@UYEJLX>=L<TEWXH:XS@$"LO[6
MLSY/4TJLF]2\,HTX<I+&N3R*U;"R:=P .*HPA3CFNM\/1H77I6$5=G8W[.',
M6+7P\77[I/X57U#0/*4_+C'M7J.D6,+19.*I:]90HC8QTKJ6'NN8\EYI-5.5
M(\3NX#$Q4CI69+GTKJ=:B19B:YN0@O@5S-<LK'J2]Z*D^IJ:!<")ANZYKU+0
M]66-5.17D$1,>"O%;%IK$D0 )-73J69C6PZJPLSU[4-:62 C<.E><>(+Q7W<
MYJC-K[LF-QK"O;]IF.3Q6DZET<^&PJHRO8KWCH(\[N?2N<N92[].*O7DQ<E1
MFLS#;NF:JA3ZF.-Q";L !QQ4L2$TZ*TEDZ#%7(+-XFR]=L,/4F>7+&4E+EN2
M6UOD@M6S;HB@#:#5&'\JO1$#O6=3#SCN=U#%4K_$698A+ 57A@<TMC?M:OM)
MZ5')=+ G'WCVK.RTC%O6N&H[,]>+4EKJ=M#XB(CP7_6J%]K33@@-Q7-@NO<T
MUI6]ZEU)-6'&G3CK8GGFW,235*5P0<]*:\AJM,Q('H3S2C&[(JU;)LM:=92:
MI?QVT RN<L?05[]X9TZ&#3X844;4&#GUKS#PO%:V<*R0$,7Y+=Z[P>)+/1[,
MW%Q,%4#A1_$:]ZE05&CS=3X?'XR6,K>Q2T.VGM8Q;EFQM ^F*X/7+S3HBP^U
M19] V:X/Q#\1-7UIVCMY6M;;H G)8>]<JR22GS99'8GKDU@LP=)W1V1X?]K%
M*;L=?=7UF7;#H?QK-DN(')P5/TK%2)?[I/XTK6[+\R9!K6.<INTXE2X7LKPF
M7)=KGY367J<9$#?-FIUE(X/!JEJ4S!0#_%6U7$0J4VXL\ZE@:U#$*,D9H&5&
M:E YIF.E2KR:\U]SZ*FK(FC'2KT*<53C'(K0A^[6<M3OH)%J),5<056BJTE8
MR/3I(E XIPZ4@IV*@Z$)2T8HQ0,*;3L48H ;0*=BC%(!*6C%%,8M)FBDI !I
M,4M%&HB%ESUJ%HQGK5IA4+4&<DAD: M@G%2&("F$="*LP+Y[@5<2=!UO9B3E
MN!6@D:HN M/50JA0.E+BJ(8T#)]ZS=5U+['#M0 NW&/2M)OD!?\ NC)^E<9?
MS&YO';/RYXHD[(SJSY5H('>5RS'.:LQQ9( %0PJ,5JZ?#YDZBN=N[%3C?5EN
MRTB2<#Y>*O/X?=5SL_2NS\.Z6LJKD"NEN]$C6V)P.E;0HJ2N<-;'N$^1'A\]
MM+9R,X;&/X<<5>M=0,L&UC\U;?B.Q1-PP,UQ89H)R,\9XKT,!B94Y\LGH>3G
M> ABJ7MJ4?>6_F;C3X&"V *ISWR+P#DU0>X><X7-6X-(DF7<P)KT,1FL5I$\
MC \/U:UI57RHJ2Z@,X J!KO<.@K6ET)PN=AJD;%4)#C!KS'FL[ZGNKAW#R5H
M_><Y>LSL .@-5S@]#S6Q-:C<>*@6Q&_.*YY8A3U9T1P'LER0V*]O TF.HK3C
ML]JY#'\JU=,TGS  %KH4\.'RP0AK*4F]CMITZ=/XCC5C93S4ZNJ]ZV[W1S I
M.#6)+"5)XK)RDMSKC%6O$E$H[4[S!BLXR,C8-*9_0UI%ID^UL7_-IPDK/$U/
M6;WJFAJJ: DIX>J:R9J:-LFIL;1G<L@TZHU-2CFAHV6HE*#2XH J1A24ZDH&
M)BD[TZC% AI Q43#FIC3&%&HI(A*4O\ #CO3Z:1@4[LBPQ6VL,UJVL6X;CT[
M5DMRX%;T(VPH!UQ6B,F*1GMQ2J,>].Q2XQS1<$1D!>34!F!;@XI+N7LM55.!
M4W-HQ+,MP%7CDU5=F?O3>IYIU)E)#0OKS2XI:*0Q(ONM]:=BDB&5;ZT[%75^
M-G'ES_V2GZ?YC:*4CFC%0=@E%+S1@T )12X-&#0 E%+BBA#$P-N>YXK&8G[2
M?K6R%&#GUK%ND,-P:F1S5NC-6QNS;N,'BNNL?$'EQ@;A^=>>I-GO5A)F X-2
MIRB8SI4ZNYW-]X@$D9&^N4NKHS2EB:I-.WK4+S\5,I2D:04*2M$;=-UK*D;+
M8%6IYMW%5U3<:N*LCEK2YGH, )I&C+8JVL7%2+ #3YB%2;*R0LJ@JQ5AWK<T
M/Q/)IMY''>H9("<%AU%9K(X[<5$4#C;W-;T<54I[,YL7@*6(CRS1]#: MMJ%
MLD]NZNC#.1R*NW^G1K&25!SVKQ7P-XOG\,ZM';S,7LIFVL#SM)Z&O:[G4HIH
M RL"".H[UZ="JZVJW/E<?@XX5<JT[,X/Q''%:6TK;5& <<5Y]:;I',C#DFNP
M\=7>^U54/5\&N7@4(@Q7T%)14$DM3T,AHOV?M&[F_I4&YU.*[O2;0,%^6N%T
MB8!EYKOM)NE&WFN?$P:5[ZGH8SF>QOKIR^5TK!U6R"*V!71B]7RNHK U6Z4J
MW-<E+GYCEH.?-J<!JL&QB16%,,5T&JR!V(S7/3M@XKVHWY=3W%?DU*4RYK,N
M$'2M24UG7 ZUSUXJ43FGH8SG;+CM0'.0:6Y&UB:A#?=KY>M#EFS'FL=#:N0B
M\UHQ-GG-8]L_RK6E"U8-'13F:<;9%233K''CN:KQ-Q4;N7?!Z5$CT*.NH\$G
MDT.X49)P*BDD$<3/(< 5C7%X\S84_+639T2KJ*-"74(T.!R:A.H.3P.*H(,M
MCK5A82W2H<C%5)RV+(OU/WLYJ43!AE3FJPLV/09IODR1'Y0:%(KFFMR2YNQ$
MG!YK,::24DDFGSJQ?+4)'GD57,<\W*4B(*32;#5Q8L]J?Y'M4\P>R;*:,T?*
MFK:7)=<,>:8\0 S59P4.151D)W@7_-.*<LIJJDBE0<TOFCM6RU)]M8NK)VJ9
M7K.27)JS&])HVA6N7U-2 U6C.<<U909'6H9UPG<>3\M,[T_%)BAEMZCE3(H9
M0*?NVK3"0.6HA3<@JU84HWD(<5$S*GWF%,9GE^[P#2"S!Y=LFO5HY7W9\AC>
M*(OW:"^8TW,?8F@7"8^]1)9C' JN;9AQCBNIY7"QY5/B+%1>]RT)1@$'-+),
MH7-9TF^#IR*&N!Y>3UKSL3A/9ZGT.79Y]87)):D\[94/QBKNGW_D $-6/Y<L
M@W<X]*4$KQ7F\W8]CF;^);G<P>(B(L;Q^=9VH:V9@0&S7,"5AW-*9>.M#G*U
MB(4X1=RQ-*6))-9\_P X %$DQ[FH!*\CB.)"SMP *(0<G9$UJT4FY;"/ \TJ
M01*6D<X '6O7?#7ADV6C0QE?F/S'(]:P_!?AK;<)=W@!F'3/:O8M/M4>,%@
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M:ZRPT+S%^Y69H,*LRY^M>HZ'91.@X'2II1YD<V+Q7LOA.(NO#Y6/A*YB_L#
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M:N:02+1L?WS52SYOK[_KK_4UV5?X5;Y?^E(\?#;X7Y_^DLNT445X9]"%%%%
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MSK^M7=P[?K0"/3FE<JQ6BU!7.&!0_P"U5G*N,JP;Z5%+;QS?>P/I5?[*\)S
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M=1NJ/-&:86)<T9J/=1NH"Q)FC-1[J-U 6),TA-,W49H"P_-&:9FC-*PFA^:
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M1N1@C(]*9NHSQP:2NG=#2NC(U#1(YLR0X5O2L5K::W^65"#VKL,X^M12+O\
MO8/UKT\/F4J>DMCGG03U.660=^*D$R_WLUK3V4,A_P!6*KM80QG*K7I1SB-M
MC+V310,Y)P*ADD8L0>E7WC]%Q59X,GGK6%;-KJT49RT,Z16+>U5+B(QN&QP:
MV##D4V6U\V,KW'2O*K5)57=F<+W,^!OE%7HFY%9QC:!RK BK44G2N*2/1I2M
MN=9HEZ(9 ":]%T[752+!;M7CD,^T@@XK0CUF6-<;JN%6P8K"QKZGHVLZVLB'
M#=J\UUJ[\V0XIMUK$LBD;C6+-*\C$DU?/S21C"G&@K%.3+.?2FKPPSTJ0J>>
M:<$RO%="]UIGDU(J=1G9Z<?]&/\ O5#8_P#'W>_]=/ZFI-/;$!'^U5.&[CM;
MNZWACN<XVCW--TYU:=:$%=NWYHWC5A1AA:E1V2OK_P!NLUZ*H?VO!_<D_(?X
MT?VM;_W)/R'^->9_9V+_ .?;_KYGI_VM@?\ GZOZ^1?HJA_:\']R7\A_C1_:
M]O\ W)/R'^-']FXO_GV_Z^8?VM@?^?J_KY%^BJ']KP?W)/R'^-']K6_]R3\A
M_C1_9V+_ .?;_KYA_:V!_P"?J_KY%^BJ']KP?W)?R'^-']KV_P#<D_(?XT?V
M;B_^?;_KYA_:V!_Y^K^OD7Z*H?VO!_<D_(?XT?VM;_W)/R'^-']G8O\ Y]O^
MOF']K8'_ )^K^OD7Z*H?VO!_<E_(?XT?VO;_ -R3\A_C1_9N+_Y]O^OF']K8
M'_GZOZ^1?HJA_:\']R3\A_C1_:UO_<D_(?XT?V=B_P#GV_Z^8?VM@?\ GZOZ
M^1?HJA_:\']R7\A_C1_:]O\ W)/R'^-']FXO_GV_Z^8?VM@?^?J_KY%^BJ']
MKP?W)/R'^-']K6_]R3\A_C1_9V+_ .?;_KYA_:V!_P"?J_KY%^BJ']KP?W)?
MR'^-']KV_P#<D_(?XT?V;B_^?;_KYA_:V!_Y^K^OD7Z*H?VO!_<D_(?XT?VM
M;_W)/R'^-']G8O\ Y]O^OF']K8'_ )^K^OD7Z*H?VO!_<E_(?XT?VO;_ -R3
M\A_C1_9N+_Y]O^OF']K8'_GZOZ^1?HJA_:\']R3\A_C1_:UO_<D_(?XT?V=B
M_P#GV_Z^8?VM@?\ GZOZ^1?HJA_:\']R7\A_C1_:]O\ W)/R'^-']FXO_GV_
MZ^8?VM@?^?J_KY%^BJ']KP?W)/R'^-']K6_]R3\A_C1_9V+_ .?;_KYA_:V!
M_P"?J_KY%^BJ']KP?W)?R'^-']KV_P#<D_(?XT?V;B_^?;_KYA_:V!_Y^K^O
MD7Z*H?VO!_<D_(?XT?VM;_W)/R'^-']G8O\ Y]O^OF']K8'_ )^K^OD7Z*H?
MVO!_<E_(?XT?VO;_ -R3\A_C1_9N+_Y]O^OF']K8'_GZOZ^1?HJA_:\']R3\
MA_C1_:UO_<D_(?XT?V=B_P#GV_Z^8?VM@?\ GZOZ^1?HJA_:\']R7\A_C1_:
M]O\ W)/R'^-']FXO_GV_Z^8?VM@?^?J_KY%^BJ']KP?W)/R'^-']K6_]R3\A
M_C1_9V+_ .?;_KYA_:V!_P"?J_KY%^BJ']KP?W)?R'^-']KV_P#<D_(?XT?V
M;B_^?;_KYA_:V!_Y^K^OD7ZQ[!=T)_WOZ"K/]KP?W)/R'^-1:8,V[?[Y_D*[
ML/AJU"A4]I%J[C^IQ5<50Q.+I*C)2LI7M\BXJ#'2GJ@IZJ,4X 5GJ>C& @6G
M 445)?*A'3*U6.0<5:SQ4$HP<T!8AE3<F5ZBI[:XW18)Y6H0W)QWJL6:.Y4#
MHQYJT2T;5E#Y\GF-]WM6GN[#H*KVRB*%5%2Y IF3'AJ4RXJ,G%1R.$&32%&-
MPDG8=ZA,Q8\FH&D+$XZ4T-4,W4"8O3"U,S1F@NP_=1NJ.B@!^:,TW-&:+!8=
MFC--S29H"P_)HR:9NHS0(=NI0QIN11D4 /R:,FF9HS18=F/S1DTW-)NH%8?D
MT9-,W4;J 'YHS3,T9IV"Q)FDS3=U(328V)<1+<P&-JX^^LGLYV#J=F?E^E=E
MGTJO<017*%)1N![^E=V$Q4J4CFK4E-''*Y[FIEDP>M6;W1Y+=BT1WQG\ZSV#
MQMA@17T5/$QG'<\^4)0>QH)-[U,LU9BR8XS4@F [UTJJDM6-39H^=QUJ"6XX
MXJOY^1T)J&5\C@&L:N+A%?$6Y,;<7)VL!W%9ZH7.35HJ6/S"F!2KYQQ7S^(Q
M+JR.6;<F1!/:I1$KKC'-3B,$9 J6.+##CFN5L(TR.VAVN%)X-;=K988,3D52
M6 L..M;EDG[I5/6I;N=<*>A<ABQC'2K:Q@#FDA4*M->89P*EF\:8YL"H7-(S
MDTS.:DWC3 &G"DXI1Q2L:)6'"C--S1N%(JX\&EW5'FC- $F:3)IF:-U K#\T
M9-,W4;J L/R:,FF;O>DWT#LR7)HR:CWTN\4KH5B3-&:CW?6C=3&/W4;JCS1F
MC0!^31DTS<:-U K#\T9-,W4;J L/R:,FF;J-U 6'YI<TS-&: '9I=V*CS032
M'8E#4N_ J'=1GB@"8/Q44@##--SQ43R%6YZ4"<1%R&Q5J%%SDU3+@\BIK63S
M7*>G--$-,V(G4+Q4F\&J:@J0!4H; JK&+6I.7J,OC)-,9L#)-4I9BQ('2E(N
M,"26<NV!4.ZF9].M)FI-%&Q)NI,TS-&Z@H?FC-,W4F: 'YHIF:=NIV![6%SC
MFJMW9I<)D</5C/-(< Y'6KI594I:'/B\)#$4O9/J89\ZW?;(OR^M7;>[5<8-
M7' D7#J#566UC(X7%>U0S.*TF?(8SAJK%_NG=%^._ 'WJ)=34#EJR#;!.<G\
MZBD7TKIJ9C1W1YT,@Q+>JL6+S4_E^4USUU,\[G/2KTL98\U 8<=J\VOC74?N
MH]G!Y0L,N:6K,\)VJ1(_:K7D\U(D//2N2]]6>HJ?+L,ACYJ_"G2F1Q5<B05#
M9U4Z=D31*!BKB"JZKR*LID8K)G7"!,H/I4@#>E1I,4XP#4QNQC[HK%N5R[,0
MJ<4WI36F9C3=WK5H>I+NHW5%NHW4R[$FZC=4>:,T 2[J-U19HS0*Q-OQ43RC
M%,8DBJDCG=B@+#Y7 8-6G:W0**!UK$+$@YJ_I W!F;H.E78RF;0DI"^:CHHL
M963'%\53F9BW7BIY2%&35!Y"S<=*3-H00\FDSS3,FC-3J:6),TF33<TF:8^4
M?FC-,W4;J35PY1^:4&H]U*&%-: .S33S29HS2;%N,85$R@U,:81339+@BJ\8
M-0M"*O%13"@--.VYDZ2*/DBCR1^-7/+]J#$#SW%5SD^R2*$MFERNQEPW8UGR
M:5-$3Y?-=#LW#D8/M0%]ZEQ1:B<UY%PGWE/Y4H@F;J"*Z%DR?F -0NF:CD0<
MS[&*;8@'<:B:+VK6>+VJ%H1Z5M&"2.:KS2>QE^54B0^U7?(]J<L/M57.?V&M
MS5L!F$G_ &JMXJG8DB _[U6=]347OL[< O\ 9:>O3_,=THS3/,&>M+GTJ+'7
M;S'YI<U'DT9HL/0DS1FHPZG^(4N:+!H/W4;JC(([&C-*P68_-&:;D>M&:+#Y
M6/W4V0Y0BFYI">*:0K%4G#5%/SM_WA3W/SU%,>%_WA56):T.FML"W3Z5)G-5
M[=C]G3Z4]F..E!C8D!QG-4[F4DX!J:23;&36<9"S9S0S2,20''6EW5$6SWHW
M#%2:V)=U&ZH=PHW 4#M?0FW4A:H\YH)P:6HN4DW4!JBR/6E!IA;N2;J7=46Y
M1W%&<]*+!>*)=]+NJ'FD\P"BQ+FB?=33+A2.]0>:/>D,RFFB7)$OG$KAER*I
M76G0739QM/M5CS0>W%*6XX!K6%:5+X3.:C+<PI=&FC<^4014)L)QW7\ZWR2>
MN:@D('45V0S":1SRI0,4VTPZE?SIK0GO6F^W!JNX4]31+,*DM#-QBMC.:*F>
M5[5?*)V84GE"N:4G)W9BX)LJ+'STJ9(N>E6%B%2I&,U%RU!#(XN:N1IBA(_:
MIU6H9U0A$EB%3J*A4A>IJ52.QJ6="CV)0:,TP9/8T9]1BD6HL?FC-,R/449'
MK18?*QQ/%13-\M/+#UJ*8@CK18.5D(.#3& -Q&?>@GC@4TG]]']::1$D=,IP
MH^E+FHU/RCGM2Y'K56,;#RW'-4IYMS8J6>4*N,U19LMFDT7&+'[J-U19I<GT
MI&VJ'[J7=49XI-P]:5BM"3<*7=461ZTN1ZT6#0DW4;JCS[TA<#O3L1R^9+NH
MW5"9!ZTGFKZT6%MU)LT9J+S5I0^>@-'*'.B3-&:9\Q_A-&'/1&-*P<T1^:,T
M@27_ )YM^5'ER_W&_*E9A>'<7-&::5E'\#?E0%D_YYM^5%FPO#N.S1NQ3</W
M1ORII)'4$4^4?/$EW4;JAW@=31O'K3L+VB)MU&ZH=X]:7</6BP^9,DW4F[DY
MIF:"<X!' I<C>P]&*<^Q%5KBVBE(\R-,>U3G&>M,)![@UI&52&S(E33*,EC;
M9^1!^=026L0Z1&M)AGL*B>,^]:_6ZRW9A*A;8RVA"]!BH&B]JU'2H?*SVK-U
MI2>IE*BS.\GVJ-HL'I6IY0J&2,9Z55T0J'<K1I5J*+=*!0B8(XJY:1[KA:EC
M5&Q:AM!GI6A!$%-/2,#M4\:@5+-%%C)7"1\=:I9);-27+_/@&H@>.*ALZ808
M_-&:9\P[&C/KQ2U-K6) <4NZHLY/'/TI<XHU%=(>3FDS3,@]Z:9%'4T[$\R)
M<T9J-7#?=YIXCF;[L3GZ"G8ES0N31FGK:7+?\L7'X5(-,NF_@(^M'*+VJ(=U
M&XU971KH_P 0%2C1;CNZ_G3Y!>VB42WM3<Y[BM(:%*W5Q3AH _BDHLB76CW,
MS=CN*-WN*U/[!C_YZ4G]A1_WZ7(@56/<R]WN:-WN:U1H"?\ /0T?V!&/^6E.
MP_;0,O)]12Y;VK3_ +"3M+2'0FQ\L@_.GRH7M8F;NS1S5TZ)<=G7\Z8=(NUY
MR#]*.4KVL2IDT9-3-I]VO_+)C^%1FUNE^] X'KBERC]HAN:,XI&5UZJ147FC
M.*FQ7.B;=2[JAW@]Z7<*+#NB7=1NS46:-Q'8T6'>Y)FC-,W4;A18I)#\U!<9
MZU)N'K44Q&.M%A-,A!.*M:9_Q\/]*I;L=#FK6F-_I+\]A3BM3&=[&T/O"EZF
MH\_,*7=P:IHSBFR*XEPN :IAN*)G)D/-1[AZU+1T1@R7=2;J9GVINX>O-*Q3
MB2[J3-1Y]Z<&4_Q"BPE'N.S1FF;A0#FG8-"3-&:92&11_%187,B3-&:B\U?6
MCS%/0T6$YI$A-,:@98\*33C'(?\ EFWY46)=1,@=<BJ[I5XP3'I$Q_"F-:SX
MSY+_ )4]B'RLS6BIABJ^;6X/_+!_RIOV6?\ YXO^5.[,VHHI>1[4Y8:NK:S_
M //%_P J<+2?_GB_Y4:DKD*R18J=%Q4HMYAUB8?A3O(F'_+)ORJ6W<UBXC5X
MJ934>QP>4(_"G9(_A-!KSHDR*,BH3)CK2><@ZL!2L4I1)]U)NJ'S5/0@T[<O
MJ*+!S1)-U+NJ+<O]X4OTHL.Y)NI=U1;@.,T;AZT6'9#]U&ZF9'K2$T6"R)-U
M5)/OFI]P'>JTC#?18+(;G@UHZ0?W3_6LS/7/%:.D$>4_(ZU1E*)J;J U,) [
MTA;"DT&2BKD5S-_"*J;L"DDDWR'%,W9-1J=,$D2;J7=46:7-,II,EW4A;-,S
M2;@>].P<J74?FC-1[Q1O%%B6TNI)FES4)E4=Z!*#T-%A<Z)LTF:CWTY0[#*H
MQ^@HL)S0[-(32B*8_P#+)_RI?(G/_+)_RHL',AAI*D\BX_YX/^5 MK@_\L'_
M "H2$YQ(Z*E^RW6?^/=_RH^R7/\ SP?\J=D+VD2*C%2_9+G_ )X/^5'V6Z'_
M "[R?E19![2#W(#3&6K)M;G_ )]Y/RIIMK@?\L7_ "HT)<X%-HZC,57&@F'6
M)_RJ,HW]TTKVV)]UE;RJ415-M(Z@T;@*>X**-'0[:UFL&:9L-YA'7M6B=.L#
M_'^M86F74<4!C=@#NS6HKAQE6!K:I%\S9QX%)X>'O="Q_9%JW*M36T1#]V3%
M198'J:7S&SC>?SK-6.SV;[C&T.<$E9,CM43:7=+T&:MB=U_B-/%Y*.C4:!:H
M9AL+I>L7Z5"\4J?>1JVQ?2=^:>+Y3UC4_A1H'O\ 8YS>/>G!A71&:V?@P*/P
MIA@L7ZQ@4N4?M)+=& 7ST- ;WK<_LZQ;H/UJ-M$@8Y1\'ZT<I2K]S(S01QUK
M5.A'M-4;:!+VGHY6/VL>YAOP]1RG[N?[PK8;P[/G/G9K,O;"YMR-Z$J#UIV)
M=1-&W"?W"8]*D&<<U!:K+-%&J(<8ZU:&G76,[OPIV,N=%.Z<@8JCGU%:LVE7
M,ASO J+^P[DG_6"E8VC4BEN4,T \5HC09SUFQ^%._P"$>D)YGI<H.K'N9>_W
M%.#@^AK83P_$.7DW5,NCV2=1^M/E)]LEL8!84Y$D<?(A-=$L%E#_  #\:>+F
MVC^Y&/RHY1>VD]D8"V-R_2,_E4R:1=/U.T>E;#:H%^Z@J%M1=CP,462"]670
MK1Z"W\<@J==$MQ]YLGZTTW4K?Q5&T\G=C1>(N2;ZEG^R[->I_6@6EDO'%4R^
MX\DTG0__ %Z/0:IOJR^([)?X5I=UF/X$_*LF6ZBA^\X%4Y-;MTZ$&J4)/H93
MG2CO(Z/?:_W$_*@R6W_/-?RKE?\ A(8^RTG_  D,?]RJ]G+L9>WH?S'4&6V_
MYYK^5-,EH>L:?E7,GQ!'_<H7Q#$>J4>SGV#V]'^8Z$M9'(\M/RJ)HK(_P)^5
M8O\ ;EN>H%3IJ5K(/O@4>SDNA49TI;,O-:V##E5J(Z?8-TP*8DD<G*,#4I0]
M:EM]314XO80:19L>&%._L. _=<"D"8Z4\<=S^=3H4J(S^P,_<DYI#H<Z_=;-
M3AF'1CGZU(MQ(O\ $:+HKV<EL43I=VAX3=^%,:RNDY:(C\*UDO90>#4JZ@_\
M2@_A1H+]XNASKAEX96%()!T(-=*;R)_OPJ?PIC?8Y?O0J*-!^TFMT<\"H[TN
MX>HK=-EI[]5Q^-(=)LGZ<?C3L5[9]3#W ]Q4,C#':N@.B6YZ/^M1MH$#?\M/
MUI6#VYSA/'6F9_?Q_6NC/AV+H)*H7^B26H$L;[@I'%%A2JQ9?4G ^E.++BG1
MZ9=2*I,FT$5(-)D4X:?/X4[&7.F9MVXP,54#<_>%;[:+$^"\F:4:+9 ?-S^-
M%BU6L<\9 .]-\T>C&ND6PT^,\(/SJ=6M(Q@1I^5+E8.K)[(YM(97^ZC&K"V-
MV>D1_*MPWT2=(U_*F'4O1,4:"O4?0RDTBYD^\0*G70).-TE6WU&0],#\*B-Y
M,>K470?O6*F@Q+]XG\ZD&C6B\D_K5<W$AZL?SIA=CU8_G1=#]E+JR\-/LDZX
M-*(;!.0JYK/R?4TF31=#]CYFB6M!_"GY4OFVH_@7\JS2<#+<"J=SJ=O!P2":
MJ*<MC.:C#=F]]HMQTC!_"C[9"/\ ED!^%<A/X@ &(UQ6=)K%U(?OD"ME29RS
MQ-*/4[[[?#_<'Y4OV^'^X/RKSLZC<_\ /0T?VG=#_EH:?L69?7*9Z)]NB/\
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M\^,=6%.S"Z'T"HC<PC_EHOYTW[7 /XQ^=%F',NY9S1FJ;:A"OJ?I4)U:(?\
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M1+<]X&_*ERL/;0+5+57SYN\#_P#?-)]K?O!)_P!\FDXL:JQ9;HJL+L]X)/\
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M +ZKFL+1A:+1"TNYTXGM?^?H_P#?5.$MO_S^#_OJN6P*/EI6B%I=SJO-M_\
MG\'_ 'U2^=;+UNA_WU7*<4?+ZT606EW.K-[9@8^T#_OJFF_LQ_RV/_?5<M\H
M]*3>*+(5GU9TYU*S_P">C'\:/[4LQ_$WYUS&X>E&[VHL@MYG3'6;->FXTG]O
M6@_@:N:W ]!1D^E.R#E.D_X2&V'1&IA\0PG_ )9M7/<T4<J#E1T/_"01?\\B
M?J*3_A((O^>/Z5@4<T60<B-UM?C/2$?B*C.O+VMU_P"^:QLFC)HL@Y$;!U['
M2W3_ +YI#K\@^["@_P" UD<^M%&@O9HUQXAN/^>2?E33XAN>R+^595%.Z#V:
M-,Z_>'H0*3^W+WLXK+.<\4?-1H.R1JC7KP=2#2_V_=_[/Y5D_-1S1H%D:_\
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M60<J-?\ X2&Y_P">:?E2CQ!-WB3\JQ\&CFBR'RFU_P )"^.84_*D_P"$A/\
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MF3?:$]:/M">M0?8V_N-2?8V_N-1[!A_;]/LRS]H3UH^T)ZU6^RD?P-2?9_\
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M/TJMY2^]*(E]Z/9"_M[^Z3_:8_2D^TIZ5#Y*^A_.CRE]Z?LA?V]_=)OM2>E
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M]VCV*#^W*Q0^V2?W:47<I_AJ]_9DG]RD_LR7^[^M'L4']N5BG]JE]*0W<O\
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M@49HS18 P*-HHS1FBP!M%)BES29HL!1\-PF32V(_YZFM1HI$[55\*<:0^/\
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M7*AAR :@ELUD!*\'VI#4NYG]:,4KQM$2#313*%Q1BC-% !BC%%% !BC%&:*
M#%&*** #%&*,T4 +BC%)DT9I +BC%)FC)H ,48HHH ,48HS0* #%&**,T &*
M,4NX4A.: #%&*,&C-, Q1THW"C<#VI &:,T<48IV *!UI.<X_E05.<'(H5@
MCGBJM\NZ$YJUST/'I44MI=W@\N"(D'JWI429<$V]#FF7+$"K^GZ29QYUT?+B
M'.3QD5H+::5HW[[4)_.EZB-#Q^-<_KVO2:DY2 >5"/NQKP *QG421Z-+#SEJ
M]$+XA\0BXB33+-!'9Q]-O&3ZGWKF2#W/%2N23C\ZC88&.U<TG=GHPBHJQ S,
M,CJM=[X-\363V0TC5,!?^63'^$UP#MC@=*C&2^>GN*:E;8FK3C-69[U) 53>
MIW1]G'>H<5YUX7\;W&ENL%\6FM1P%;G%=W9:[H^KG_19_*8_PR&NJ%2Z/%K8
M.47=%K;Q25,T,J#[NY>Q%1$[?O*:U3.)Q:W$I:3.><X%*!GI3N(*3%*0:3GU
MIW !FEZ4"E'/447 3M24]L 4W(I7 **-WM2Y]J+L!M%.SFDHN 48HQ2<TP'#
M@4E%%( Q1BC-&:>H"&C-+10 WBEXI:2@ _"C\*6B@ XH_"BB@!,48I:* $Q1
M2T4 )S12T4 )BBEHH ****0!^%(:6B@!*":6B@! :7-%% !FC^5%%,!K1(_4
M"J\EB"-R?E5JC)!ZT7!-HR6B:,_,*;BM6>+S4XK,=3&VT]JELT3N)BC%+WI*
M8PQ1BC-% !BC%%% !BC%&:* (O"G_('?_KL:W*Q/"G_('?\ Z[&MLU,=D*K\
M;#.!UJM=Q#;N'6K%1W7$%:)&:W,P=*6D'2BD:BT444 %%%)0 M%%% !1124
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M1K$9YNY&^IK553FE@CV78<XY-(<KU!KS"R\?:K9D$M&X]&!-:L?Q+DE8&ZM
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MD9RKLOT-6JK,)8*E(]U6QEE'[AU<>NX4'3;M.JI_WT*\>BU?48E_=WLR_P#
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MB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "CK110 JY%4KR/#;O6KE17/,!I-#3U,ZDI1TI*#0****8!1124 +111
M0!%X4_Y [_\ 78UN5B^%XVCTIU;KYIK:Y!]JB.R%6TJ, ,U1O)OFV5-=3A5P
MIK.)W'<>M6**ZB]*6DZTM!04444 %%%% !1110 4444 %%% .#0 44N:3-(
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MW%HHI,4+40M%)BEI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4E+10 5!>G$0JP*IWS9P/2D..Y2':EI124S0**** "BBDH 6BBB@"K8?\
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M5EXJD0T5RE,*5:5.<4K1@"GH0XE/;BG!B> *G6/=3A#M-%R&D18XP>],9><
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M )2T4E "T444 %%%)0 M%%%  %IV0.*89 ,+4UM;7-]+Y-NA.3Z5+8TFR)W
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M&1<TG-2[#1L]J0FB'FD-3&.FF.F*Q"1334Q2F%*"6B%LXJ/D58*U&4IHBUB
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M]WVJ%G+2&0DDGK]:?%G'2N.4KL^@ITU&-D3!B?O<FG $TB#FIU2H-DBK8_\
M'N<_WJE8#TJ#3B7MB?\ :JR5JI;LSH-JG$BQZ4TK4VVDVU)H]=R$#FG8 IY&
M!3#3):&/STJ6"$MCBEBA+MTK4@M]H'%*YI"%]QT,(6IRG2G*,4^IN;Q0P+3M
MM/ %.Q04TB';2A<5+@4$4AI#1TI"*"<"DS0##I2@TA--'6D!+3LXIBTXGB@8
M$TTF@FDIB$--S2DTPT"'9%,:B@T"8PTTTXTTT"&DU&QYIYZ4P]:8AF:0TIIA
M-4D(*832EJC8XH)8UFQ3#R:1CDU+#&6-!+'1)FKT2D#I2108 XJPJT%I#<4<
M]*DVDTNP^E R,KE:C(Q5C!Z8J-T-*Q2&8IL@RM.Z"FO]V@92<\XQ2PP[WS0P
M^>KMLF,'%0S6!(B;!2.QS5O"[.:KF,LW%0SI0P$D@FI@V14+HR=:C$A!H+3+
M8'O07[57\WB@/DT6+4R>A>M(O(IZBI+6HXK4;#%2]JB<T%[$9/-)FF,W--WT
M[(5R0FD+9J/=DTTG%%D),)#Q5<G)I[O3%YIBDR:/K4^[BH%XIY;%(0K-3,TC
M-3,T!<DW9I":;32>:9+%8@U$33S49'%%S-H3.:8]+GFFL::8F-J-QQ3\TTFF
M0T0LM0.N*M-43KFF9M%8BF$5,PJ,B@AD3"HB*G(IC+3(:(#4;#VJ<BHS3,Y+
M0IR)59TZU>DJLXR::,G$ID<TWN 1Q4SK@U&W:F92B6M,G-GJD$ZGF-@17MID
M\^"VG/\ RVC#$^]>%JOS!AVKVGP_,+_PA;29R\,FT_3%;TV>?F%-.G<T+9_*
MNHWS]TUWT9W1H1SD5YRS$].QKO-(F\ZP1CV%=$M5J>9A6]2WV)]*6C&,TM8G
M;(3VKD?$DA>]4>@Q76_Q5P^LR>9J,G^S6D$<V(>B,R<[;9JR\9.:TKPX@Q6<
M.E;'''8.E%!HI%!1BBE%  ,9YZ&I(+=[JY2"-<Y-1,P7!-:%G.-(TVXU63K@
M^7]:F;LBZ<>:21B>/]4M]EMI%H=Z6X^=QW8]1^%<.!D#CI4T\AN[N:X8DF5R
MYSZGFD5<&N&4K[GT^'I*$+(0 ],8%2JE."Y[5*JUG<Z8Q&JM3*M*JU(J4C3E
MN,"U($-/5<4^D6HD:K3L8IP&33MO%!:3&CI3@N: *<*5QV #%+C-%.%,97D7
M%0Y.:M.,U788-(+$D9JP*J*V#4Z-0.Y*<TE*#FD- [C7J$U/VJ)AS2L,93UI
MH'-/ XJ;%!FE'-&*4"G8+ABC%%(33 ,48Q1F@4@%_"E S0*4&F*XW%(:DHV@
MBG8EMC N:D"T!:=0 C#'2D'2G8IK%5&2:3(<K",0>O%5IYUC4\U!=7BKG!K&
MN+PNQ&:I&<I$MY>$Y -9Q+.<FGD;^33@.U49-WW$1,<XJ8#%(*<!F@+"@5*@
MSVI%7-3I'Q2"Q-"@)&:L^2M01C;5I#FF );@]JG2SSVJ>!>E78PM S/%B#VH
M-D%[5KC;Z4U@IH&C*%L!VIIM<]JU-@-'E"@9D&UP.E,^SX[5LM$!BFF %A@4
M 9R6H92",5-' $&W&:U%MQL'%'D#/2@1F"W&>E2"W '2M-;<8I_DBD29/DY'
M2F^5E@,5KFW%,%N.M,13\KCI1Y7M5_RA1Y0]*!%#RJ3RJO\ E"D,0HN(H>52
M>6:O>7[4W91<"KY5'DU<V4;:+AJ5/*]J0Q^U7-GM2%*+BL4O+I#'Q5SRZ/+H
MNQ&>8ZC9*TFAJ)H>*+BL9S)BHRE7VBJ%HN*JY+139:C9?E/KVJVR'TIAC]:"
M''L4>5&!WZFNO\%W;2-+9RMN7'R9[5S+Q59TNZ;3[^.8= >:N+U,*]-3AJ=O
M-&8I6B/!!Y%;7AN\V7#0,<*PZ^E9MZZW"PWL?W95P?PJ.SD\B[C<'O7:M8GS
M[CR5#T$$=,TG>FP.LL(<=Q4G8"L9([X["5@>*/\ CW0UT&*P?$X_T5/K3@]3
M.M\!RE'7)]!12] WTK='F,RY?]<349ITAS,::>M!J%%%%, H7DGVI*$.W-'0
M!2IDE2-!EB0,4WQE*Z7\=@@'E0  $&MC0(HOMQN9\>7$"237'7<TEW?S32/G
M+'%<]23L>G@*:=Y,JK$O''7FITC H3[HP.E3*M<AZZN(JX-3**:%J0"@M(R=
M#^:P8GKYAK0(J7PYI072V$P._P P]#VK5.EP>C?G5R6ISTYJ,5%F&:::W#I4
M'HWYTTZ3;^C_ /?538OVL3"(S2I&6-;?]DV_H_\ WU3TT^%/N@_G19A[6)5M
MK8!<U<"X'2IEBV# I=AI<K-(UZ:( I/:G[#4@4BEPU+E9:Q-,BQBC-2%":;Y
M5'*P>)@ YH-*(R*78:.5C6*I^9"PIIX%3F+-)Y-'*Q/%4RO2@\U-Y ]Z/(Q2
MY&'UJF,!H)J3RJ/*I\C#ZU3(\TAJ7RJ/)HY6'UJ!7)IN:L^0/>D^SCWHY6+Z
MS KYI":L_9Q[TGV<>]'*P^LP*K&F$U=-LI]?SI/LB>_YT<K%]8@43TJ,UH_8
MT]_SI/L,9['\Z.5B^L0,PFF&M7[!$>S?G2?V=#Z-^=587MX&.YJ-FR*VSID!
M[-^=-_LFW]'_ .^J+"]O$Q$C+FM.WM\5;33H4Z!OQ-3K%MZ4-,%6@0A".*D6
M+(S3]AIPWKTQ^5*S+^L0'Q0;NU6#9$#.*A2>9/N[?RJ0WUR1C*_]\T[,%B($
M<ML5'2JCICBK;W$SC#%?RJ$JQZT6']9@4VB[U ^>E:)CS3#;*>H-%F'UF!F"
M/+\5?B3:HIXM54Y&?SJ780,5+@RXXNFNXAY0"D7Y>U.VMBC8:GV;-?KU+S&N
MF^JDL6*N[6IK0[NN:7LV/Z_2\RAM-/5*M?9E]Z40 >M'LV/Z_2\_N(EX%/!I
M_E?6E\KZTO92-8YE17?[AA/%02$U:\KZTTVX;KFCV4@>9T?/[B@QJ(M6B;1#
M_>_.F_88_P#:_.G[-B_M*CY_<9^<&D=CBM'[!'_M?G0;"(CG=^='LV+^TJ/G
M]QCL].C:M,Z7 ?[_ .=*-,A'0/\ G1[-B>8T7W^XIJ:1C6@+&,?WOSI#81G^
M]^='LY#_ +1H^?W&:33"<5J_V?%_M?G2'3H3_>_.CV;#^T:/G]QE[Z86YK5_
MLV'_ &OSH_LR'/\ %^='LV#S&CY_<998XJ,N<XK8_LV$_P![\Z3^RH/1_P Z
M/9LAX^CY_<9 ]:1A6Q_9<'H_YT?V7!Z/^=/V;%]>I>9B$4TBMS^RH/1_SH.D
MVY[/_P!]4^1B^O4O,Y\FFD5T!T>V]'_[ZI/[&MO1_P#OJCD9+QM+S.;<5&5K
MISHEJ>H?_OJD_L*T])/^^J?(R7BZ?F<L1367-=5_8%GZ2?\ ?5)_8%GZ2?\
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M%/\ */K1Y9]:/;1#ZG4\B&3M]:E\:9LM!M+/D;@'/X\TOEG(/I3]9+Z\(A?
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MX5HT4 9W]@:-_P! BP_\!D_PH_L#1O\ H$6'_@,G^%:-% &=_8&C?] BP_\
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M6C10!G?\(_HO_0(L/_ 9/\*/^$?T7_H$6'_@,G^%:-% &=_PC^B_] BP_P#
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M&3_"C_A']%_Z!%A_X#)_A6C10!G?\(_HO_0(L/\ P&3_  H_X1_1?^@18?\
M@,G^%:-% &=_PC^B_P#0(L/_  &3_"C_ (1_1?\ H$6'_@,G^%:-% &=_P (
M_HO_ $"+#_P&3_"C_A']%_Z!%A_X#)_A6C10!G?\(_HO_0(L/_ 9/\*/^$?T
M7_H$6'_@,G^%:-% &=_PC^B_] BP_P# 9/\ "C_A']%_Z!%A_P" R?X5HT4
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M $!]/_\  9/\*/\ A'M$_P"@/I__ (#)_A6E10!F_P#"/:)_T!]/_P# 9/\
M"C_A'M$_Z ^G_P#@,G^%:5% &;_PCVB?] ?3_P#P&3_"C_A'M$_Z ^G_ /@,
MG^%:5% &;_PCVB?] ?3_ /P&3_"C_A'M$_Z ^G_^ R?X5I44 9O_  CVB?\
M0'T__P !D_PH_P"$>T3_ * ^G_\ @,G^%:5% &;_ ,(]HG_0'T__ ,!D_P *
M/^$>T3_H#Z?_ . R?X5I44 9O_"/:)_T!]/_ / 9/\*/^$>T3_H#Z?\ ^ R?
MX5I44 9O_"/:)_T!]/\ _ 9/\*/^$>T3_H#Z?_X#)_A6E10!F_\ "/:)_P!
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M!F_\([HG_0&T_P#\!4_PH_X1W1/^@-I__@*G^%:5% &;_P ([HG_ $!M/_\
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MPH_X1W0_^@-IW_@*G^%:=% &9_PCNA_] ;3_ /P%3_"E_P"$=T3_ * VG_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;Q<+GOQ3?^$VUS_GX7\JU]C(XOKU+S/7J*\A_P"$VUS_ )^%_*C_ (3;7/\
MGX7\J/8R#Z]2\SUZBO(?^$VUS_GX7\J/^$VUS_GX7\J/8R#Z]2\SUZBO(?\
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M\:</&NL'_EX'Z_XTO:(/J57R/6Z*\E_X3/6O^?@?D?\ &@^,]:'_ "\#]?\
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MVE]Y=C>K2MFLM+F,=6_2K"7L ZOC\#2="I_*_N+AB*7\R^\NDXIZ/5$WUO\
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M9RQ5'^9?>C;7YJCG<(M97_"3:2.EW_Y#?_"J5YXCL)1B.XS_ , ;_"AT:O\
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MU7-XG]_/X&E]7J_RO[CICB<.O^7B^]%B:;)JN\HQ5:2X#=#4#R,1Q5?5ZO\
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MRR[![.78N453_M2S_P">W_CI_P */[4L_P#GM_XZ?\*.678/9R[%O^(4V?\
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M%3_"M*.1)8UDC=71AD,IR"*=4_6:_P#/+[W_ )AR1[&7_P (WH7_ $!=._\
M 5/\*7_A&]"_Z NG?^ J?X5IT4?6:_\ /+[W_F')'L9G_"-Z%_T!=._\!4_P
MI/\ A&]"_P"@+IW_ ("I_A6I11]9K_SR^]_YAR1[&7_PC>A?] 73O_ 5/\*7
M_A&]"_Z NG?^ J?X5IT4?6:_\\OO?^8<D>QF?\(WH7_0%T[_ ,!4_P *3_A&
M]"_Z NG?^ J?X5J44?6:_P#/+[W_ )AR1[&7_P (WH7_ $!=._\  5/\*7_A
M&]"_Z NG?^ J?X5IT4?6:_\ /+[W_F')'L9G_"-Z%_T!=._\!4_PI/\ A&]"
M_P"@+IW_ ("I_A6I11]9K_SR^]_YAR1[&7_PC>A?] 73O_ 5/\*7_A&]"_Z
MNG?^ J?X5IT4?6:_\\OO?^8<D>QF?\(WH7_0%T[_ ,!4_P *3_A&]"_Z NG?
M^ J?X5J44?6:_P#/+[W_ )AR1[&7_P (WH7_ $!=._\  5/\*7_A&]"_Z NG
M?^ J?X5IT4?6:_\ /+[W_F')'L9G_"-Z%_T!=._\!4_PI/\ A&]"_P"@+IW_
M ("I_A6I11]9K_SR^]_YAR1[&7_PC>A?] 73O_ 5/\*7_A&]"_Z NG?^ J?X
M5IT4?6:_\\OO?^8<D>QF?\(WH7_0%T[_ ,!4_P *3_A&]"_Z NG?^ J?X5J4
M4?6:_P#/+[W_ )AR1[&7_P (WH7_ $!=._\  5/\*7_A&]"_Z NG?^ J?X5I
MT4?6:_\ /+[W_F')'L9G_"-Z%_T!=._\!4_PI/\ A&]"_P"@+IW_ ("I_A6I
M11]9K_SR^]_YAR1[&7_PC>A?] 73O_ 5/\*7_A&]"_Z NG?^ J?X5IT4?6:_
M\\OO?^8<D>QF?\(WH7_0%T[_ ,!4_P *3_A&]"_Z NG?^ J?X5J44?6:_P#/
M+[W_ )AR1[&7_P (WH7_ $!=._\  5/\*7_A&]"_Z NG?^ J?X5IT4?6:_\
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M>6];%O=AHQDU:,*RN)<OR:I-)BI;J8%LYK.EFH,$M FFS5.67BDDEJI+)G-
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M:9-/AJK239K#E/4H2(+J6LUY.:?>3'<:I1G?(!0SM<^AN:/:^?<*<=Z]1TV
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M_+^E/MO&GBZTLEL9-%EEN478LKV\F\^A([FM3P)X6U"VU&?7M94K=2AMB/\
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M#BK^)1_PO_TH]W+OX;"BBBOE3T HHHI %%%%, HHHI %%%%, HHHI %%%%,
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M445R@%%%%, HHHI %%%%, IKML1FP3@$X49)IU% 'E_@W2=1U+QK=:YJEE/
M$+2)YT97+MP ,CG S],"O4***[<PQTL;551KE2222V20!1117" 4444P"BBB
MD 4444P"BBBD 5S'Q"_Y$;4?^V7_ *-2NGKF/B%_R(VH_P#;+_T:E=V6_P"^
MT?\ %'\T9U?@EZ'D$1S!'Z!13\!AD<'T--A_U,?^Z*?7Z?>S9\P]R2UO+JRE
M$EO*5 Z@=ZZ%;[2_$,'V?48OL\Q&!(HXS[US5)SV.#Z^E9R@I&E.K*F[HS]=
MTB;1KLQMF2#/RRKT-94K#9QS77PZBWDFWNT\Z$\>_P"%-E\*66IVY;1I=DN,
MF!S\U<=3#N.Q[N&S)3=IZ'%PG][CO6W8.?,P.W6LJXMY[*Y>WG4I)&<,".15
MVUDY1ONYZ>]<]NY[,:J:]T[33GX%;L,^ !FN7T^;Y!6O%+Q3CH<E1ZW-E9_>
MK"/GO6.DM7(IL+UIO42:99=L-5::09ZTR6< =:HRW/'!K.;.JBB2:3!ZU%]H
MP.M4Y)R347FGO6#1Z$(EB68DU&LA)JNTF:17Q2L;HN>9Q3/,-5O,)IP;BAE6
M)_--(7J'<<TN<BA 3(QSQ5N%R#S5&-L&IQ(?6K):-59@!UJ)YN3S5$S$#K3/
M-)-(S<"T\QIIEXZU 6)J,O4C2N22OFJS>U.+U&6HL:K086(I-U-=JCWXIE,D
M8U&::7S2;B.*:)N-8_-BE' YIC>M5Y;C:,9IH;6EQMS+R0#5>)LOS43R[GS5
MB"(NPP.M,A25M28GTIIC)K8M])=T#%:22U6(X(IM&7M+O0RTA)IXMVK1CB7-
M/9% I6'S,SE@Q0815MMHIC8IV)WU*PB IDD8Q4[$"H';)IF;1!Y8[TR1 !5A
MJK3].M4C&13G)'0TQ9=J\]:63KS4+=:LP<1[N2F[%0I*Q;!%2N?DQ4<2$M3,
MVS2M #C-7U;:>*H0#8!5V+YC2>@XHU+4YQFM6)<#-9=LO2M6,YCQ4,V:LB9>
M3Q5J)3Z5#"F<5>ACIQ1S39/$@-2F/ Z4D:X-3/PM:QA=7,'(SIP>U4CUYJW<
M'+9!P*I.PR:Q;ULS>GJ(S#%0L:5G&.M0L_O4VEV-XQ&L:C8XZT,5SP>:8S]C
M3]2KV FF$T%JC8\4XZ@V.+4PFFDTTM3)N#&F$TA:F%JHEL<6J(M0S<5'OHL0
MY"LU1EJ1VJ,-BFB') [8'-4Y%WL:GD?FHCCK3N8R=S.D5@^.U1D8SS5Z4J.3
M5>558+CD^@JB&I%-VPIJ(%BN3PM7$M99YUCC0LQZ "MN#08+;$UZVYQR$%/E
M;,:E6,5N<];6=Q>/B.-@G]X]*V88+?3DP@#R]V/:KL]P&7;&H11T K/?GFMH
MTSSZN*;T1#-(TA)9L_6JD@'K5B2JS^U78Y[MZLA:H6J9LU"U)E[GLWCE6F\9
M7\2(2W[OG_MFM9MKI-G8IYMUAI3T4UT'C.]\GQ1>QQH-_P FYL?["US#NY;E
MMP;KGM2A2OJ77QK5XKH3S7>\;(T\M>V.*K?[W)]:7A1P>*;UKIC%(\R4I3>H
M;1Z4N,CTH"NW0&GB&3NK?E1<GE8T#BC%.V2+_"WY4TAA][(HN'*Q,T<TF#CK
M0#ZTQ6%HHI>U(! 2K CJ#D5U]M\0]1M[:.'[);R;%"[F)R:Y"BDXJ6Y<*DX?
M"[':?\+)U'_GPM?^^FH_X63J/_/A:_\ ?35Q=%3[.'8T^M5OYCM?^%DZA_SX
M6OYM2?\ "R=1_P"?"U_-JXRBCV<>P?6JW\QHZUK,^N7_ -KN$1&"[0J= *P;
MU#@$"KM13KNB-6ET1ES-RNS)2:>UOK2\MT5Y+:42J&Z94@C//3BNK_X69XC_
M .?'3O\ OA__ (NN6^Z2#2CI6%?"8?$6=:FI6VO_ ,.CKIXFI35HLZC_ (69
MXC_Y\=._[X?_ .+I/^%F>(_^?'3O^^'_ /BZYBDK#^RL!_SYC^/^9?UVMW.H
M_P"%F>(_^?'3O^^'_P#BZ/\ A9GB/_GQT[_OA_\ XNN8I*/[*P'_ #YC^/\
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M_BZX&*3>" <XH=OFK+ZG@_\ GQ'[G_F=JHW^T_P_R.^_X6OKG_/IIW_?M_\
MXND/Q8UL=;73O^_<G_Q=<$"2:E6!G8<4?4\'_P ^(_<_\QJA?[3_  _R.Y7X
MKZZW2TTX_P#;*3_XNIT^)?B2092PT\_]LW_^+KE+33\@9%::1&(X J7A,&O^
M7$?N?_R1K'"7^V_P_P C=7XA^*6Z:=IW_?+?_%T'XA^*5ZZ=IP_X"W_QRLD,
M5%,<[JGZK@_^?$?N?_R1LL G]M_A_D:__"Q?$_\ T#]._P"^6_\ BZ</B'XI
M/33]._[Y;_XY6'@4H;%2\/@_^?$?N?\ \D:?V='^>7X?Y&X/B#XJ/_,.T[\F
M_P#CE+_PG_BO_H&Z=^3?_'*Q%?YJE#T?5\)_SXC]S_\ DA?V='^>7X?Y&K_P
ML#Q5_P! [3O^^6_^.4A^(7BD?\P[3O\ OEO_ (Y69D4T\TOJ^$_Y\1^Y_P#R
M12RV'\\OP_R-4?$+Q23_ ,@[3O\ OEO_ (Y3O^$^\5XS_9NG?DW_ ,<K*08;
M-*I&2Q/%"P^$_P"?$?N?_P D.6602^.7WK_(LW'Q1\06CA)K/3E8]MCG^3TP
M?%?73TM-._[]O_\ %UQFN*W]I$G.T]*TM!TK[=(,C(K-TL+>RH0^Y_\ R1T0
MRBDU>527WK_(Z(_%771UM-._[]O_ /%TT_%C6QUM=._[]2?_ !=6[GP@J6N_
MR^V:X74K0VLS1D=*)4<-'>A#[G_\D$,IP]2_)4E]Z_R.L'Q=UDR+&+;3MS'
M'E2?_%ULKXT\9.H9=*TT@C(Z_P#QRO()%9YT1/O%L#ZUZ+:WLEO9Q _+M4 D
MU<,-AI[4(_<__DC">5Q3LIR_#_(V'\;^,$^]I>G#\_\ XY41\?>*QUTW3?R;
M_P".5C2WXR1YH;/O4'VH'^,?G6OU&AUP\?N?_P D']EQ_GE^'^1O'XA>*1P=
M/T[_ +Y;_P".5&WQ(\2I]ZPTX?\  &_^+K'W%\'((JK,V=P%#PF$6]"/W/\
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MY_X _P#\73QX_P#%9'_(-T__ +Y;_P".55"+&, "HWDP*GZMA/\ GQ'[G_\
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MXJ_Z!VG?]\M_\<H_X6#XJ_Z!VG?]\M_\<K+CC>9@%4Y-;5CX<GGPTW"4WEF
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M,5QMQ:O:RF.08]*I99@'_P N8_C_ )G/4Q=>/4T?^%A>*?\ H':=_P!\M_\
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M<D;B>U86N:2KQF>$8/4BM%.YR5**2NCE0.*0GBE7*Y!I.U:(Y HHHH ****
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MT(.#45Q$)%Z<U+WHQFD(R2-K$&C%7+JW!&5ZU4S@8[T]C5.XE%%% !24M)0
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M@G:A)]*(D37NGG]ZFR\D4=CBJ_M5F_8-?3$=-QJ C@&MT>5+<2BBBK$%%%%
M!1110 444AH 48Q@]*H7,!5LCH:O4$!U(- T[&3GF@U+<0F)LU"#D4&@M%%)
M0 M%%% !1124 +1U-%(#@T 6[*]:QGR<F(]5]:DUG2P"FH62[K:09;;_  GW
MJDWS"M/1-0%OOLKCFWD]>U95(<R.O"8CV,[]#)AVNC <>U#J%7K5G6=.?2;H
M,.8)/F1^U933F3H:\^4.5GTE&LIJX,WS<4H=@,YIJJ1UHD&U:AH[85$3QW/U
MJ7S<C.:R?,*FG"Z[9J6="9HL^.])YM5%GW=ZD# T6+3+:2$M5A7Q5%7QWJ17
M]ZEJQ29=$F:4-53?QUIZM2L6F7$;+ >M<]J;9U3'. .*VE?'-9FK19V2J.<\
MUVX&2A4U/(SFC*=#G1;L9A&02>:[/2-9\A 0VWV%>=6\V['-:*WAC  -?0PE
M%JS/B)P=[H[K5/$/G0G=@BO+]:NVO;\JOW5-:MQ>AH#D\US9;=>2'/>JA&"5
MK;'L9-%RKN4MS0MR H%:]B1YR@UC1'!&:U+>4 @CJ*UB^B/M:=[:'H^@+&=F
M:[A(X3;]NE>6Z1J?E[>:ZE-=_=8W5Q8BA)R//KX>I)W&Z['& _M7F^HK^_8]
MJZW5M5$BM\U<9=S%V)KJPU-PCJ=N&IN$-3)E4%F]J;$<-BEF/S'WJ)6 :FW9
M@]S3@;D5U>B7(7'-<=$_2M*TNFB.0:V6JL;Q]Y6/8-.U.-8ASVJ+5-11T.&%
M<!;ZYY:<MBH[O7-ZX#5YTL&W4YCSG@VIW&:[<!G;!K@M3E&XBMO4+XL&)-<C
M>7&^0C-3F%:*AR(ZIVA&Q&[\XS41;-1KEFK1M+)I3TKY\YN8JQPM*1\IK=T_
M16F*Y3BM73-#R 2*Z&"U6W3@#BDWH%RG8:4L&"5'%;,;1HN,56:5L8%0EVSU
MK-)BE(OEU-,8C'6JPDXIKRG'6JL9<VI,9-O>HFD!-5V<FFY-"B#F3,_O4+/F
MHV8YIC-Q5<IDZ@K/5>23FG,XQ5=W&::1+F->2H6DXHD85 TH4U5B>:X2-^-1
MEATSS3'E$9^8]:ELK"YU*;RK:)G/<J.E-1NS*I4C%$');&.>P]:W=&\*W6I$
M37/^C6PY)DXW?2MS3]#LM'027 \^Y].H7ZU8N;Z2Z^4. HZ(O:NB%(\S$8[E
M7NDT;V.F0^1IUNNX<-*PY_"J;RR2L69B3[TS'J<'TI<\5TQ@D>15KRJ/43@<
MXYH(R,YI#3D0RN$7ESVK1M&*5Q887G<)&I))Q7::1HT5G&'F :0C(INC:4EM
M")I5&\]JU\USSD=U&EW%Z4W..E+FDK.[.JR0=>II.IP/SH/3FC!*X' 'ZT6&
MV&"3P,_2@$'OSZ5'+-'#&6E<1*O4DXS6)=>+M'M25^UQNWH&YJE3;V,W42W-
M[K[4F:P[3Q9I%P=KW2*3T!/-;*R)(@=6# ],4Y0DD$9Q;']:*!G/S<'THK-7
M9HUIH* "032*-YQW'-.Z@COVK/U'4X[&W93_ *TC@5I&)G.=HG.>(9%EU)BI
MK*49/-.ED-Q*TK?>-1,=@+L<"MXQO[IYUG4E:)+E0<4C.!TQ63<ZK@E8%W>I
M%47:[F))8J*Z(85[L]C"Y'6K:RT.BWG^[FG!E/I7+F&X(_US_G4:S7MLV5DW
M?6M'A[HZ:O#LXJ\9'6X6HS@&L6RUO>XCNL*WKVK9WJ0".0>AKGE0<-SQ<1@Z
MM!^^APY%)3L8%)4'( P00:S[J'8VX=*OYILB"0<TF-.S,G-+2RQE'/UI.U,T
M%HH%+2 2BBDI@+1UHH'6@ QBC-*332*$^X"''7O5JRU&XL)0\9RO\2'HPJK@
MTJ D\#--I-#3:=T;6H:-IWB6U-W8%8+U1\UN>,_2N$G@GLKAH;F-HY0<88=:
MZ..>2";S8B4D'>MH3:=X@LQ:ZBJQ7 ^Y.> 3]:Y*M#FU1ZV$S%PTF<$LG.#P
M?>G&7!X.:NZ]X>O-#;,J%K=ONRCH?QK'$N %Z8KD<.4]^E7C4C=%X2T-)FJ8
MEIK3&I:-XS+328[U"\W-5VG]ZB,O-38U]H7(GR]:MLV,5B6[Y85KP/A118I5
M#2\SBG(]5A)Q3Q(!2M8OG+H?/2I%<52644X2<TFAJ1;+#UIA<57,GO32_O4V
M*YB9FS2!J@+TTOBBQ2D3.U-#8ZU%YGO44MQ@4T@;+#2)W/%9=RR&8[&.*;)-
MD]:KCYI.M.Q#D7;)=TO?K766;A(*P+"' SBM,S>6F,TQ-DES/O8C-10G:P))
MQ58REFJS"N:3&K$^<L2.AIXSBD"T\4AMB <T[C%)03B@+C>AJ0'BJ\C=,4*]
M!+)<XIP88J+.:1CBJ1E(<2.:8#S30WK13Z$2>A*""*KSX*FI%^]4<P !-7"+
M9SVNS)N4#=!S5C3[>Q@0R7LS$?W8^34$C%Y"B#G/6KEII/F'<V2U>M0P2LI/
MJ;0PT5[S([RZMG(^P1R #O(,5#'>W*$$H#6Z-$;:3MJG<6+0YRM>C'!4FCLA
M"-M!MOKL(=5D1U/<XXKH[2:.90T3JX/]TYKBI[88)/2H;2_N=,FWQ$[,\BN+
M$9?&*O PK4KH]3MV ..]66E^3.?PK%TC4H]0M5EB;+8^8>]77F^<5Y,HR@[2
M/*J1Y'J+<N&1O4"O-Y5SJ<V>I;FO0Y6RH/IUK@]3B,&KNV/ED.17I9=)<YVX
M%JQH6-L)9 ,5V>F:,)(Q\HKF-$93(":],T8Q[$Z5Z6+J-/0Z<75<5H8MYH02
M+[HKC-5LO(9CBO7=2:+RCC%><:^5)>L\+6E+<SP=>4MSAYOO52F7>I J[<\,
M<52+;22:ZILZI[V,XC;.I]#S6Q)J<:M@(YSZ"LN)3<7N .*UX[((F6&37%7P
MZGJ?,9ECG3G[. )<QRCKM/H:5FR.#5.>WPV5.*;&[ [6/TKSZV$Y5<YL/C7)
M\LNI8:4+Q4:1RSOB*-G;T49J:TLIM3NUMX5)8FNZM]-AT*U VAKAAS[5RQIG
M95Q,81NC"TG0!"!=:BVSN(_XORK8GU!G410H$B P/4U6EEDF<NYW-3.OU[UU
M0@D?/U\7.HQ#EB<L<4#CK0:0ULK'*VV.+<8J,XH-(J-(P5!EC4M@E<9M+R!%
M&2?2N@TS1 BB:?!)Z"K.DZ,MO&)IA\QYP:U'(QQP*RG([:-+JRJR[> ,*.U5
M)B3FKDE4I>]9'7RI%*6J$M7I>]49>M(T11EJE+5V6J4M($5)*KO5B2J[T%'T
M)JW_ "$YO^ _^@BJ)%7M6_Y"4WX?R%4C5+8RE\3$IM.IM,D**#0*8Q#10U(*
M0"G@9-5-3NEM+5BW4CBK8P,F0X YKC]=U#[9.8E/RK5Q1SUJEE9&07W.S'^(
MYHW<8IN**V//>HM%%%,04444 %%%% !1110 E'2EI*0#9%$B<BLZ6,QDUJ<5
M#-"'0X'-.XXNQG#D9HQ0RE&P:*#0,4444 %%%% !3<4ZDI6&*HQ0^"<C[WK2
MCI32.,B@1NZ?<1:M8-IEX1\O,;'M7/WVE2Z==&-Q\O\ >]J52Z,)%8A@<BNA
M,T>NZ:+:1@+I1P?6L*]-.UCT<)BG#W9/0YI=NW(.1ZU'*,T^]MY["3R9D*@'
MCWJ)9-U<<HV/<IS=KE29,9JDQ*L:U9DS5&6&I:1VTZRDM"*.0BK"38JBQVG%
M-$N.]%C539J+/S5A)*R$FYZU:CEXZU/*W+R+4S1$@IXDJ@) >M/,P(P*F2UL
MBXS- 2T.RR(RD9R.*HK/L&2X'UI/M\'1G.?:M(TZB=XHJ45-69'):3Q$M&N1
M48G=>'4YJ<W]O_?8U(MQ'*GR[?Q%=T<357QH\6KD<9N\)6*Q$D^ J''<U1F@
M:VO#N/WN:V5E8#"X%4M3A9BLN<[1M_"M\/CN:HU(WPN6K#:K5C4D!Z5=MVY'
M-944@QBK"3[:]:$G>_0]*,UU-V.X*,,'%6AJ$@7&^L%+C(S4@FS6_M(R.A3T
MU-&6[9LY;-49)=QJ,R>]0/**4I$RJ$<LHW_C4#/M?.*;DEV)IOF<'->/7QG)
M*R9@Y+J7XKA?2K N5!QFL-IMK# /YT\WR)U0D_6NB&84^74:J>9NO<[5ZYJI
M-J 0<UDRZGD?+6=/<M*>6Q6=7,;*T&.=9(N7NJ"0D &LW)=L^M1'YCZUI6-H
M92N17C5*CJ.\CDG4YWJ2V%@TK#BNQTS3HXXP6 S4.F6B0K\P%:;2 <+6 I3L
M60RQ+A>*C\YB>35<R$T@:GRD>T+:D'DTUV4<U!YN!432%SC-59&;J$S2^E)D
MM4:KW)I3(J#K18AU!V>>:4GBJ4MTH/!J$7P&>:9G*HV7)7"BJ;W('>JUQ>;@
M<&LV2YQU-%P2N:<ET.>:KFY'KS68UT">M-\UF/R<GT%&O0IPMJ7I+E1P3\WI
M4/FM(P55+,W  K1T?PQ>:HWFM_H\ Y9V'/ZUUVGV>G:"I-K"KSXYD<;L_0'I
M6L:;>YQ5\53IQ\S,TCPJ%C6ZU-@H/(C/6MYKV*& 6]E"(HEZ$##'\:JRRM("
M[993V)Z4TBNJ%**/&KXR4]$(2S'+$DT9Z< 8]*2BM3B=WJQ3R<]Z.M%%,05N
M>'+ 33^<PZ5AUV'A@_Z ?[V:AHUHV;LS;[Y[#C%)1GGFBN=[GIJ+@KL*3(]:
M6G X&#@_A5:)"YT^@PC/O5>]NH[.T>:<[509%664=22/:N*^(-[)!IL4"'_7
M,0?I54HN3)F[1N<EKWB6[UJY(BD*P(2, ]:R$M-YW, 3ZU);VY(  QMZ^]:M
ME9M(PXKTZ-!6..=2QDFS[XP?6MK0?$EYHTZ13,SP,<<\X%7FTABG2LF[@6W5
MOD);MFFZ,7<B%2[T/7;>:*XA2:!MT;C.:D+*N2YVCWK@O"OB,V^E&%AEXSM4
M'TJ:\UBYO'.YMJ^U>=**4K'6ZDH1O(W]1UV*V!2+YF[$5RMS<S74A>1LGM3"
MN3N))^M-)JDE?0Y)U7,-V%)(YK%O;Q[BX:",X4=_6KVH3_9[5G'7%96F1%Y?
MFY-=U"BOB9[^2X"-3][)&IIND"50V.3UK=70LI]S]*TM!M5=4X%=M'IL?DYP
M.E54Q;@^5'T%3$^S]T\FO=),()48'I6-)&%SE:].UNR1588%>>:E'Y<QQ752
MG[2.ITX>KSP,&]A5U/&/2IM%U62%_LUP=PZ+3IEW"LF=&682+P14UH)JQR8[
M"QKQM)'>+@J.:3KFJ.E3_:=.CDS\PR#5XG('O7ES5F? UZ?LZDH]FQ.*4+F@
MC%*#BH,F5KQ RY K/[5KLN]"*RG4K(13+BQ*7-%)04%%%4X;9+B:?<6&UN,?
MC4RE&$7.6R-*<.=V+E)4?]G0_P!Y_P Q_A1_9T/]Y_S'^%<_U[#]W]W_  3;
MZL^Y)3LU#_9T/]Y_S'^%']G0_P!Y_P Q_A0\=AWU?W?\$/JS[DV132 >Y'TJ
M/^SH?[S_ )C_  H_LZ'^\_YC_"E]=PW=_=_P0^K/N2$9;)ZTA'?O3/[.A_O/
M^8_PH_LZ'^\_YC_"G]>P_=_=_P $/JS[FS8:VT<9M+]!<6C#&UN2/I6)K/A,
M.&O-(S)$>3&.2M._LZ'^\_YC_"C^SH?[S_F/\*RGB<++J[^G_!.JA.K1:L]#
MD26C<HX*L.H-1M*"">@'>NR_LZ'^\_YC_"C^SH?[S_F/\*Q]IAOYW]W_  3T
M%CY+[/XG!M-T*G(- DR<9KO/[.A_O/\ F/\ "C^SH?[S_F/\*/:8;^9_=_P2
MEF,NL?Q_X!Q]LWS"M:.0;16U_9T/]Y_S'^%']G0_WG_,?X4>TPW\[^[_ ((_
M[2E_+^/_  #-26G^9S5_^SH?[S_F/\*/[.A_O/\ F/\ "AU,,_M/[O\ @E_V
MH_Y/Q_X!2$M.$M6_[.A_O/\ F/\ "C^SH?[S_F/\*GFPW\[^[_@C6;/^3\?^
M 53+2>;5O^SH?[S_ )C_  H_LZ'^\_YC_"CFPW\[_P# ?^"5_:[_ )/Q_P"
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M[&$QK8BY/9V&*M+?,D7E0QK''_=Q57#=B*/QK=4X+9'%/%U9;R'%W)Y8X]*
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M'X&G GH>:<2*;FB[ ,4O%)10 [-(U)10 4444P"BBB@ HHHH **** "BBB@
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MY'_7S#F1;HJI_:,/]U_R'^-']HP_W7_(?XT?4L1_(_Z^8<R+=%5/[1A_NO\
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MJCW4RM@2, /0TGVR<=)'_.LHN*>QG5IU+<KD_O9>%G)2_8Y/>J'VVX_YZO\
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MLTW^V;__ )^&_.E_MF__ .?AOSH]L']@KN+_ ,(EJ'^S1_PB6H?[-)_;-_\
M\_#?G1_;.H?\_#?G1[8/[!7</^$2U#_9H_X1+4/]FC^V;_\ Y^&_.C^V;_\
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M/[:U#_GX;\Z/;!_8*[@/"6H'NM._X0^_/\2TTZUJ!_Y>&_.F_P!LZA_S\O\
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M,O?[XI/^$-O?[XJI_:E__P _DW_?5)_:E_\ \_DW_?5+VX_["AW+G_"&WO\
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MW.1=2_BU/_M.^Q_Q\R?G1[8/[#I]&7/^$*NNGFK^=)_PA5YVE7\ZI_VI??\
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M?]:/^$,D[S_K69_:5[_S\/\ G3AJ-Z?^7A_SH]HP_L6B:7_"&/\ \_'ZT?\
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MQ14O]GZE_P ^C_F*/[/U(_\ +H_YBE=#YD14N%I_]FZF?^71_P Q1_9>I?\
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MNY@ZM&EF%25=7CKTOV(_!FO7.O:7))=JOG0R;"ZC 88SG'K7*?$R&--8M)5
M$DD.'QWP>#_GTKT+3=+M='L1:V,02,9.">6;U)KRCQHVJ2:\\FIP>22NV%5.
MY=@]#WZ\_7M48OFCAU&>K[FN6<E3'RJ4O=CKI_P/Q\CG:***\@^I*NH_\>$O
MX?S%6K6PL9+.!G@&XQJ2?4XJKJ/_ !X2_A_,5>M/^/*WX_Y9K_*O9PKMA/\
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M\Q:5A=S>IKI?#)_XDNO_ /7M_P"RO7,UTWAG_D":_P#]>W_LKUQX[^"_6/\
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MUB>J]LS)X2BRJ?#DV>'6F_\ ".W']]:M_P#"16XZH]'_  DMO_<>G[=F;P=
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MQ1)_RT0?A7>>"]9CO?#OB>7:0(+0,W_?$G^%>1;<=*]#^'P(\(^->G_'@/\
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M.*-E2<T8-(.4CV4;*?@T<T!89Y=&RI!FEP:8<J(MN*,5(13<4@L- HVTX"G
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MQ3:D(--*T$M$38[U3D&U\K5N7CK5.1^:;5T85&6()<=ZTX-2>$85R/I7/^>
M<G-1/>D?=S6?L9,(XI01O7.I/<RK$TA )ZFMBQO#;VZ6^<*.E>?/<R/*&STJ
M]%K$@(\S.!Z5Z^7RCA]6?,YVJV,:4=D=C+< ,3NR:S;R=<9)%8TNLJZ_+NS[
MU2>[DE[\5WUL;&3NF>-1RNM)ZJQ8GF\QBHYH1, 5#" &W-5L$,>*\:I5<F[G
MUF#PZI4U%;DT(XJQ&G-,A0U:1,5S.]SUJ<=! M+BG!:=L-#31LD,Q1CBI-OT
MI#P*D=B/%&*<!GM01BG80W%&*<.M.V<9I#L1XHQ3CQ2;J+"T$Q1BG?A0.30
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MI8C(I-M2[:7;3N+E(@*,5(5I,4!89BEQ3L48H"PS%&*?MHVTPL,Q1BG[:-M
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M16"J.:LI&J# %4H)#1GQ6'K5N.V2/M4^*C>95XSS39:0_&!Q3&(7DFH&N6/
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M';T^E>%+<^^A>42S@]6I"ZKU-0R3X7 -5F);J32D[&ZBK$\EUCA:KL[/U-(
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M)EF+EBJ"E4C9CP*>!38WCD'RMSZ4]1^E<U[GIJPN*,8IPI3TI%C:#TI:0]*
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M4X3Y?I3XM/DGY;)^M>QA\H;^(XZM6/0B8(>=PIOE>9T85??1V5,[:IR6KQ'
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M7D]*R-2U-[V3<QK :<H^#0USGH:^7DI;,]"$X0V1+.^0:-.7?<%O[M5"YD;
MK2LT6%?]HU<(F?/>5S44U,*K1GBK*<U;.R,R0"C%.45(%![5#-;E5ZB/)JW)
M%4/EX--">Q7>/(JK)%FM(Q\5$\6>U4F<\X7,EH:K/#S6P\%0-![52D<LJ1E-
M#430G%:K0>U1M!QTJE(YY46M3,\O IH+*,9J\\/RGBJ3QG)H<4R>=Q$,CCO4
ML2[@&;O55D.!6C;Q_NUXH5-(SE7E>Q,B?,,5?C7Y*@BCYJ^B?)TIO8TI*[N1
M1*<U:1:BC4YJTBU@V>M16@]5XI<4X"C%)G0AN*,4[%.Q2'<Z?QX/^*TU#_MG
M_P"BUKF\5T_CH?\ %97_ /VS_P#1:USA%7/XF<.#?^SP]%^1#BC%2XXI,5!U
MID6*,5)@YI,47'<9BC%.Q1@T7"XVBG8-&#1<+C<48I^#1@T7"XS%&*?@T8-%
MPN,Q1BGX-!!HN%QN* *7!I0#2N*XFVDVU)BDVT7'<CQ2;:EV4;<47)(=M*%J
M7;2@4T.Y&%IZKQ3L4[( I7$1,F:C\NIF-,-.]A[:C E/$8(ZT@X-5K^\%I#Z
MLU:4J3F]#'%XF.&I.I(?-<0V_P!YJJ-J\(Z0MCUK-7,K%W^;/K5Q+;<G3BO:
MHY>[79\17XBK\UZ6GXEJ'489?;ZU8E8&/(Z5FM9 +D+S0DCQ'RY#\IZ5G7RZ
M25XG7@N))RFH5EOU)^2*C3Y[E![THDP,#IZT6O\ Q^Q@^]>19IM,^ODXN*<>
MIT,7 "^U3567(P:>)-IYH,N4CO%Z53*U:N) YJN>12;-H[%=EJI*M7W7BJ\B
M4(RFC(G3.:HR+P<5L2Q\=*I2P^E:TW;4X:J9F[I%'#D?2HC+*3S(Q_&KCQ'%
M0&*MO;5.YQ2YDRNVYCR3^-)M'XU8\LTGE4I2E+J0]=R)0P.15R*<XP34&PTQ
MD(Z<5A."9U4JKB:!FQT-,:?%4 K_ -XT]$.>>:S5,W>(9:1R[9-78ADBJ<(K
M0A7D5K9)6,XMSE=EZ(9Q5M!S56(<"K:CBLI:-(]!-:)&!J4C27KQD\+TID<6
M_ Q4EXN-1D9AQQ6OHULEY<JF!6;WL*,5=N1GK8OM^[56:!H\AJ]IM/"<,ED'
MPN<5P'BC25M93MQP<54Z?(KWN9PQ%*M)PANCE;"8P7JA1P3BM"6X:XD*] "1
M62ZE9P5/0UJHZ[5X&:]S*:',N=F4YM7B:-A;>;(!BNWTK1UD49%<GH[*)1FO
M2]!9-HSBO9Q5245[IQ8J3BM"M-H($><5RNKZ8(PQ Y%>J7$D7DGI7":^R$/@
M]JRPU6I)ZF&&JRDSSRYCY(;M5>.4HVUAQVJ]?#YS65+GKGI73BZ,9Q:9Z3DX
M2T-18PPS3O)'6HK27?"&].*MIC'/>OC:U/V=1H[X.ZN0[!Z4&,5.11MK$JQ
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MBQ1BI<4;: 9'BC%2;:,4!<Z7QD,^++W_ +9_^@+6 171>,-W_"5WN!Q\G/\
MP!:P2!GCDU=3XV<>%?[B'HOR(B*:14VVFE*@Z;D.*,5(5I"M [C,4;:?BC%
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MH)AQ5MEQ5>49HB[L39ES#.:S;E 1C%;,L=9\\=:TZK@]#BQ-*-56DC(;S$&
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MU;$J=ZIS19%6F<]1&%+$#GBJ+QX/2MR6'K5-X.:U5ELCAG3L9!C/H*01C/\
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M/E0J/4UH6VDGK*X/M4UE()+:-L=5!K03I5V5C)S>PD-K%"H"H!CN*G(]*0,
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MCH:;FES0@%/-(P5A\ZYHS1Q3"QK^-#_Q5U]_VS_]%K7&ZZ?]!3_KH/Y&NO\
M&W_(WWW_ &S_ /1:UQVM_P#'DG_70?R-=N&_WJ/K_F>9B?\ D5O_  K]"U11
M17SY] %%%% %S2?^0S8_]?$?_H0KWA]H1M^-N.<],5X/I/\ R&;'_KXC_P#0
MA7M.O_\ (N:I_P!>DO\ Z :]7+W:$W_6Q\WGD>:M2CW_ ,T8$OQ%TF/4?LZQ
MS20!MIN%QCZ@=2/\XKI+^RMM7TV2VF"O#,G!QG&>C#W[UX+7NGA[?_PCFF[\
M[OLT><_[HK3"8B5=RC/8PS/ T\'&$Z+:=_RUN>6>%H'MO&]I;R??BF=&^H#
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MY5ZM:CSUX36S_34^9PF+='!5:3W6WST?ZFGXWU#^S_"]R <27&(%_P"!=?\
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M:@)HW>XJE]L##*L#3/.8@TN49=\Q?7-(95]:H+(?Q[YIK3*IR6R?04["+K2
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M,]=OXC$]Z8XV&"L*A,_B.?UK J:V*@Z?LJ2LB\)EU55_K&)E>1Z]X$U6._\
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M#!6)0F?Q'-;.IA+\RB_Z^9RQP^:64'427?K^1+X/T.TU[4Y[:[>152 NOED
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MJ6S942L(JD6*IO+]*<JXH&J:0Q5J=1BFCBG@U+-HQ1(" *=NJ/=@8XI X_O
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M#4"GFI,UFXLZ5%DN:,TP4F:+,=F29HS4>:,TFF%B3<*,BH\T9IH+'0>.R?\
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MZ _V1;$?W!5<BJ:(I;!G-+2"ESBIL:A1BC-&:+, Q2&ES1UHV 3)HI<48HN
M4M)29H$*:%."*6F]Z$P,O6[5YHMRYS7,,A7A\Y%=Z=KKAA5&YTJUGS@8;O71
M3JJ)YN)PLIO0X[@"D(!Z&N@G\/D#Y&S5"31[J/D*#75&NCS*F#JQV1G 8ZFB
MK!L[A>L1J%H9!_ U4JESG=.JMT-HP:<$/=6HPQ_A:GSBY*G8;FEQGO2[&_N-
M3E@E<X6,BES:W*2J6LD,[]<5<TM"U\HP<9I\&CSS,-PP#70V&F1VA#'EJRK5
M4U8[,'A9J5VB\ 0HSVHH.2Q-%<!] E96"BBB@8E%+24 %&:**  \T8HSBC-
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M=W):V\PPR#!JC+HMLYXXKHCB%U//J9=+[)R7?KFC\*Z1O#T9/ROBD_X1Y?\
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MU2%[6?8WS<..D+&FFYFQ\ML3^-8!UN\]0*:=9O/[U4J5@YYLW&N;[/RV!/\
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M3^Z*7%%%P$V+_=%&Q?[HI>:*+@)L3^Z*-B?W12XHHN GEI_=%'EH>H%+2T7
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M=^?\:EU4:+!U.J-,%V^ZC-^%.$%PW2%_RK&G^(UX.+>SC@_W15&3XA^(2/\
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MYE&3&P%.Z#V<NQ'BC%!##J*-U5=$\K0449S1D4M!!24ZC%,!**#UHH ****
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ME'H144F1G'>E/%,R"BBCI0 4444 %%%% !1110 4444 %%%% !1110 4444
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M_ME_Z+6N8[UO#X4<=7^)+U#%+113,PHHHH **** "BC%)0 M%)D44 +1124
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MY)H'$D4A5AZ&G8(ZTQU&?:JN9R5]SL=(\80R1"VU4;B.!)Z5T!B2: 3VKB6
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M)$\1PZE?KWI 01[ULFCAE%QW&YI<YI2OI28(ZBJTL3I8****0!1110 4444
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M27%X-_!JH]QDGFJDC<YS41<FDV7&"6Y8>8>M5)F!--<U [4P<;%:X56K+FB
MSQ6I)5.09S5&$DS*D3VJF\>6Z5KRQU3>,]<4S-Q,YXJA:,BM(H:8\0Q5)F,H
MF6V130QJ\UOFH&@VFJN9.+(=QI=_K3_*J*12*9DUT';A07%5\FFEC1H)W18W
MBDW\X!"D]ZK[C32W(]J#-HU=/U:YTJ82VTS@^YX_*O1=!\;6FKQ);:J4AG'
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MY^\16<I6.BE3<V-NKN.!/(MB,_Q-64?F;/6FIG)SWI_2L&[GH0BDK'M'Q/\
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M4FRU$B&:LQ-46!4J"D4D6 :=FF*<U)@8H+2$ZT9Q1C%(12N787-. XJ,5)D
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M$]JU)H6@E,;#E3S[UUTY<RU/#Q%!TY71U_A^^$]J(F/*ULMC/'2N$TF[-K>
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MC_K)L@>U-D4RNL:C+,<"H/$3 2Q0(XVH@!'OCFL)O0[,-#FE<YYR68D]>]-
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &% ET# 2(  A$! Q$!_\0
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M9QG^]QCK5.DJ-%[17W(/:5.[.D_X3[Q-_P!!/_R!'_\ $T?\)]XF_P"@G_Y
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M)_\ D"/_ .)H_P"$^\3?]!/_ ,@1_P#Q-<W11]7I?RK[@]K/NSI/^$^\3?\
M03_\@1__ !-7M5\;>(;:\CCAU#:IMK>0CR8S\S1(S'E>Y)-<;6EKG_(0B_Z\
M[7_T1'4NA2YE[JZ]/0:J3L]6:7_"?>)O^@G_ .0(_P#XFC_A/O$W_03_ /($
M?_Q-9EMH6IWFF2ZC;6;RVD1*NZD$@C&>,Y/7KBLZFJ-%MI16GH+VE1*]V=)_
MPGWB;_H)_P#D"/\ ^)H_X3[Q-_T$_P#R!'_\37-U<N-+O+6%Y9H@B)Y>X[U/
MWUW+QGN.?YT.C16\5]R!5*CV;-C_ (3[Q-_T$_\ R!'_ /$T?\)]XF_Z"?\
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M'H.>E+V5"]K+\!\]2U[LVO\ A/O$W_03_P#($?\ \31_PGWB;_H)_P#D"/\
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M 20 ,D] *F%"D[^ZMWT'*I/NSH_^$^\3?]!/_P @1_\ Q-'_  GWB;_H)_\
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M<#..I(]:F-&BH7E%?<4ZD^:R;-;_ (3[Q-_T$_\ R!'_ /$T?\)]XF_Z"?\
MY C_ /B:Q)-/NXH9I98&1()!%)OX*N02 0>>QJM5*C1>T5]R)=2HMVSI/^$^
M\3?]!/\ \@1__$T?\)]XF_Z"?_D"/_XFN;JYIFDWVL7)M["W:>4*6(! P/4D
M\4.C12NXK[D"J5'HFS8_X3[Q-_T$_P#R!'_\35[2O&WB*YO)(YM0W*+:>0#R
M8Q\RQ.RGA>Q -<?)&\4C1R*4="596&"".H-:&A_\A"7_ *\[K_T1)4SH4N5M
M17W#C4GS6;9I?\)]XF_Z"?\ Y C_ /B:/^$^\3?]!/\ \@1__$US=:-MH6IW
MFF2ZC;6;RVL1*NZD$@C&>,Y/7J!5.C1BKN*_ 2J5&[)LT_\ A/O$W_03_P#(
M$?\ \31_PGWB;_H)_P#D"/\ ^)K!NK2>SE$5PFQRBN!D'Y6 (/'L14--4*+V
MBON#VD^[.D_X3[Q-_P!!/_R!'_\ $T?\)]XF_P"@G_Y C_\ B:YNKS:-J*:2
MNJM:.+%FVB7C&>G3KC/&>E)T:*WBON0*I4>S9K?\)]XF_P"@G_Y C_\ B:]$
M\!:O?:UH<]SJ$_G2K<M&&V*N%VJ<8 '<FO%Z]:^%W_(M7/\ U^-_Z E<F.I4
MXT;QBEJC?#3DZEFSB?'W_([:A_VS_P#1:UE:)>QZ=K=E>3*6CAE5V"]< ]JU
M?'W_ ".VH?\ ;/\ ]%K7-UUT4G1BGV_0PJ?&_4ZO2I=*TS59KDZ\S%CN1X$D
M0D;P<,QC)R1G( P>A;FK<'B#38%FM(YXULYY[SS%\C/[ME'EXRN0-PZ#T&:X
MFBE+#QENQJJT[I'8ZIK=C/HBVT-ZC('MC#;"$J80JG>"=H!^8D]35Q?$6F!K
M\Q7Z11S3W;R(T#%I]ZXB(.WC&3U(QSZUP5%)X:#5AJM).YW*:[I=G%I30ZA)
M,]M=1.=ZDF*/9MD"C8 H]@6SUSFF3:]I\EAJ'F7<<]U-),9 =Z)< J!&<"(Y
M*]@2N",]\UQ-%'U:&]_ZO<%6D@K2TS_D'ZS_ ->:_P#H^&LVM+3/^0?K/_7F
MO_H^&MI_#]WYHSCN9M:F@7-K8ZLEY=D[;=6D1!G+R ?* <''..3QQ6713E'F
M30D[.YVMC?65_K]M>6TABD_LZ5)UF'F%&2-@&;Y0'RH!X'X5IVVMVQ\_4!?P
M(!/:+=7)MB1.=CB3:NW(R,C.!^&:\WHKGEA8RZFJK-?UY6.MDUG2FLVC#$(;
M,1"$(<Y^T[]O3'W/PJVFLV']OS7<FN$1*,6WD1-%LCW@B,MY9(P!T QVSR:X
M>BJ^KQ[B]JSNK;Q+90K%;I?)%:0ZNT_E>2W,&X,I7"]CDXX-4XM8TU-%$'VE
M/*-N5:T\IMQN/,SYN<8^[CG.<<8KD:*%AH('5D_Z]?\ ,ZCQ1K=KJ]L0DR22
M17LQAVP[,0-@KV'?)YY]:Y>BBM*=-4X\J)G-S=V:6A_\A"7_ *\[K_T1)6;6
MEH?_ "$)?^O.Z_\ 1$E9M-?$_E^HGL@I\+!)XV8X 8$_G3**LEJZL=[+XGTX
MW%S$MTAM;F>[,N8"2R,B^7R5R,L.WIS5/5-;L9]$6VAO49 ]L8;80E3"%4[P
M3M /S$GJ:XZBN:.&A%IKH;2K2::?7]3L-1U>PNH+Q+;4$@2:]FDG0P%FN$+
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MB.G8 'IG%<7167U:"6G:QHZTG>YVUQK&B236?F3(UM!?%A;P(^SRBS'<R,H
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M #X?^1I?_BJU;S_C[?\ #^505Y<9U$E:3^\['&-]D4?^$-\(_P#/A_Y&E_\
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MA'_GP_\ (TO_ ,55ZBCVE3^9_>'+#^5%'_A#?"/_ #X?^1I?_BJ/^$-\(_\
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MJC_A#?"/_/A_Y&E_^*J]11[2I_,_O#EA_*BC_P (;X1_Y\/_ "-+_P#%4?\
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M#T(I:KVE3^=_>3R1_E11_P"$-\(_\^'_ )&E_P#BJ/\ A#?"/_/A_P"1I?\
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M\]D_)O\ "HZ* )/+7_GLGY-_A1Y:_P#/9/R;_"HZ* )/+7_GLGY-_A1Y:_\
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M70@Y&147V6WW[_(BW[_,W;!G?C;N^N.,^G%)WZ K'-:'XON=6F@2?2)+5)V
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ME0QA0#FY 4AN=PB4\??49(I6=OKFJZ393:3>ZG/")91+*EP9"KY7:RG[;AD
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MT 1T5)YB_P#/%/S;_&CS%_YXI^;?XT 1T5)YB_\ /%/S;_&CS%_YXI^;?XT
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MS;_&GQ.I<_ND'RMW/H?>A@045)YB_P#/%/S;_&CS%_YXI^;?XT 1T5)YB_\
M/%/S;_&CS%_YXI^;?XT 1T5)YB_\\4_-O\:/,7_GBGYM_C0!'14GF+_SQ3\V
M_P :/,7_ )XI^;?XT 1T5)YB_P#/%/S;_&CS%_YXI^;?XT !_P"/=/\ >;^0
MJ.IRZ^0I\I/O'C)]![TSS%_YXI^;?XT(".BI/,7_ )XI^;?XT>8O_/%/S;_&
M@".BI/,7_GBGYM_C1YB_\\4_-O\ &@".BI/,7_GBGYM_C1YB_P#/%/S;_&@
MF^^/]U?Y"HZGE=0X_=(?E7N?0>],\Q?^>*?FW^-" CHJ3S%_YXI^;?XT>8O_
M #Q3\V_QH CHJ3S%_P">*?FW^-'F+_SQ3\V_QH CJ2'[Y_W6_D:/,7_GBGYM
M_C3XG4N?W2#Y6[GT/O0P(**D\Q?^>*?FW^-'F+_SQ3\V_P : (Z*D\Q?^>*?
MFW^-'F+_ ,\4_-O\: (Z*D\Q?^>*?FW^-'F+_P \4_-O\: (ZTM/_P"/=O\
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M[#4-3C!DEAAMX((\!!;%E9&V;\F0 9W=\#!QA=2N=;2RDN+2_P!9:**VM_*
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MT 1T5)YB_P#/%/S;_&CS%_YXI^;?XT 1T5)YB_\ /%/S;_&CS%_YXI^;?XT
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M?XT(".BI/,7_ )XI^;?XT>8O_/%/S;_&@".BI/,7_GBGYM_C1YB_\\4_-O\
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M7^0J.D@"BBBF 4444 %20_?/^ZW\C4=20_?/^ZW\C28$=%%%, HHHH ****
M"M+3_P#CW;_>_H*S:TM/_P"/=O\ >_H*B>PX[E2\_P"/M_P_E4%6KMU%RX,:
MGIR2?3ZU#YB_\\4_-O\ &FM@>Y'14GF+_P \4_-O\:/,7_GBGYM_C3$1T5)Y
MB_\ /%/S;_&CS%_YXI^;?XT 1T5)YB_\\4_-O\:/,7_GBGYM_C0!'4D?W)?]
MW^HH\Q?^>*?FW^-/1UV2?ND^[ZGU'O0P(**D\Q?^>*?FW^-'F+_SQ3\V_P :
M (Z*D\Q?^>*?FW^-'F+_ ,\4_-O\: (Z*D\Q?^>*?FW^-'F+_P \4_-O\: (
MZ*D\Q?\ GBGYM_C1YB_\\4_-O\: (Z*D\Q?^>*?FW^-'F+_SQ3\V_P : "'[
MY_W6_D:CJ>)U+G]T@^5NY]#[TSS%_P">*?FW^- $=%2>8O\ SQ3\V_QH\Q?^
M>*?FW^- $=%2>8O_ #Q3\V_QH\Q?^>*?FW^- $=%2>8O_/%/S;_&CS%_YXI^
M;?XT 1T5)YB_\\4_-O\ &CS%_P">*?FW^- $=%2>8O\ SQ3\V_QH\Q?^>*?F
MW^- $=23??'^ZO\ (4>8O_/%/S;_ !I\KJ''[I#\J]SZ#WH @HJ3S%_YXI^;
M?XT>8O\ SQ3\V_QH CHJ3S%_YXI^;?XT>8O_ #Q3\V_QH CHJ3S%_P">*?FW
M^-'F+_SQ3\V_QH CJ2'[Y_W6_D:/,7_GBGYM_C3XG4N?W2#Y6[GT/O0P(**D
M\Q?^>*?FW^-'F+_SQ3\V_P : (Z*D\Q?^>*?FW^-'F+_ ,\4_-O\: (ZBEMT
MFDC9^0F?E]:L^8O_ #Q3\V_QH\Q?^>*?FW^-*24E9H<9.+NF1T5)YB_\\4_-
MO\:/,7_GBGYM_C3$1T5)YB_\\4_-O\:/,7_GBGYM_C0 '_CW3_>;^0J.IRZ^
M0I\I/O'C)]![TSS%_P">*?FW^-" CHJ3S%_YXI^;?XT>8O\ SQ3\V_QH CHJ
M3S%_YXI^;?XT>8O_ #Q3\V_QH CHJ3S%_P">*?FW^-'F+_SQ3\V_QH )OOC_
M '5_D*CJ>5U#C]TA^5>Y]![TSS%_YXI^;?XT(".BI/,7_GBGYM_C1YB_\\4_
M-O\ &@".BI/,7_GBGYM_C1YB_P#/%/S;_&@".I(?OG_=;^1H\Q?^>*?FW^-/
MB=2Y_=(/E;N?0^]# @HJ3S%_YXI^;?XT>8O_ #Q3\V_QH CHJ3S%_P">*?FW
M^-'F+_SQ3\V_QH CHJ3S%_YXI^;?XT>8O_/%/S;_ !H CK2T_P#X]V_WOZ"J
M/F+_ ,\4_-O\:OV)#0,0H7YN@SZ"IGL5'<IWG_'V_P"'\J@J>\_X^W_#^505
M4=B7N%%4-8UG3] TY]0U.X%O:HRJTA4L 6.!T!/4U6NO%.D69VR3S.YN#;!(
M+:69FD">9@*BDGY><CBBX&Q16/+XIT>'4ET^2YD6<ND9/V>38CN,JC/MVJQR
M,*2#R..:)/%6BPZC/837GDSP1/*YFB=(]B8W$2, K8W#."<4706-BBL-_%^A
MQP6$[7<@AOMGD2?9I2OS,%7<=N$R2 -V*W*8!4D?W)?]W^HJ.I(_N2_[O]12
M8$=%%%, HHHH **** "BHK:YANX?-@?>FYDS@CE6*GK[@U+0 4444 20_?/^
MZW\C4=20_?/^ZW\C4=( HHHI@%%5K6_M[TN+=G8(2"QB95R&92 2,'!4]/;U
M%6: "BBF":)IV@$J&9%#M&&&X*<@$CT.#^1H ?14-S=0V<2R3L55G6,84MEF
M( &!ZDBGQ2K-"DJ!PKJ& ="C8/J" 0?8\T /HHHH *DF^^/]U?Y"HZE6W^T/
M(QFD7;M4!=O]Q3W'O42ERV*C&]R*BI398_Y>)O\ QW_"F&U(_P"6\OY+_A2Y
MWV_(?(N_YC:*:8&'_+>3\E_PIAC<?\MY/R7_  I\S[?D+E7?\R6BJY$@_P"6
MS_DO^%,+2C_EL_Y+_A3O+M^06CW_ #+=20_?/^ZW\C68TLP_Y;-^0_PIOVFX
M0Y$QZ8^Z/\*=I/I^0O=[_F:-%91N[@?\M3_WR/\ "F&^N1_RT_\ '1_A3Y9]
MOQ0O=[_F;%%8G]H7/_/3_P =%']H7/\ ST_\=%)\RW7Y#2B^OYFW16)_:%S_
M ,]/_'12_;[G_GI_XZ*S=2VZ_(T5*_7\S:J.X_X]I?\ </\ *LG[?<_\]/\
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M%'F+_P \4_-O\:?*ZAQ^Z0_*O<^@]Z (**D\Q?\ GBGYM_C1YB_\\4_-O\:
M(Z*D\Q?^>*?FW^-'F+_SQ3\V_P : (Z*D\Q?^>*?FW^-'F+_ ,\4_-O\: (Z
MDA^^?]UOY&CS%_YXI^;?XT^)U+G]T@^5NY]#[T,""BI/,7_GBGYM_C1YB_\
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M?Y"HZ2 ****8!1110 5)#]\_[K?R-1U)#]\_[K?R-)@1T444P"BBB@ HHHH
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MDXYQ6AX9?7+N9)M3O;GRH[=2(S;A%E9FD&6+PH^X*$Z!!GG&#0G<1U%6H/\
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MRO8F=)[2-(U<P02,VS.&+/&S*>?X2M&H:&[IVI6^JV:W5J)_)8_*9K>2$GW
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *) RL# 2(  A$! Q$!_\0
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M[);?\\(_^^14U% $/V2V_P">$?\ WR*/LEM_SPC_ .^14U% $/V2V_YX1_\
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MV2V_YX1_]\BC[);?\\(_^^14U% $/V2V_P">$?\ WR*/LEM_SPC_ .^14U%
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M\BC[);?\\(_^^14U% $/V2V_YX1_]\BC[);?\\(_^^14U% $/V2V_P">$?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE=7_ .0I
M-^'\A755RNK_ /(4F_#^0H Z.R_X\8/^N:_RJ>H++_CQ@_ZYK_*IZ "BBB@
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MPD'T^SCS?7%PQ94<#+!<$9 !!SUYZ"O0/AWXU3QWX8&I_9Q;W$<I@GB#9 <
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MAG\2KGQG=ZAI6JZ<MCJEC\SJF0I ;:1@\J0< CGK7HU !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3U!9?\>,'_7-?Y5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!<7<%
MJ%\U\%SA5 )9CZ #DU/5*-1_;5PV!D6\0S_P*2@:7<KW,%]J5N=R_9HP5=(@
M09&92&&XX('(' S]:CMM::-_)U",QR*NYF"XVC_:7G _V@2O!Y%;-13VT-TJ
MK-&'"L&4]U/J#U!I6+4ELUH2(ZR('1@RD9!!R#2UGZ, +.4   74_ _ZZM6A
M31$E9V"BBL+QE=3V?A*_N+:5XID5-KH<$?.HZTF[*Y5*#J34%U=C=HKSSP'X
MEO'OGTG6)Y))9D6:VDE;)(*@[<^XY'XUH:3J-Y+\2M6LI+J5K6.'*1%CM4_)
MT'XFH51-)]SKJ8&=.4XM_"K^J\CLZ*\O5]:UKQMJNFP:]<V44+.ZX8D !@,
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M\/Y"NJKE=7_Y"DWX?R% '1V7_'C!_P!<U_E4]067_'C!_P!<U_E4] !1110
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M>[%K8WZR3D$A#&R$X]-P&:VJ::>QC.G.F[333\PHHHID!1110 4444 %%%%
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M[\+_ (4?\(QH/_0'L?\ OPO^%:M%'*NP>WJ_S/[W_F97_",:#_T!['_OPO\
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MWE89!J2H4$I\QV3QDI8:.'[/_A@HHHJSC"BBB@ HHHH **** "BBB@ HHHH
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M$'\P*EJ%!*3D=E7&2J8>%!_9_I!1115G&%%%% !1110 4444 %%%% !1110
M4444 %%%% !7*ZO_ ,A2;\/Y"NJKE=7_ .0I-^'\A0!T=E_QXP?]<U_E4]06
M7_'C!_US7^53T %%%% !16)/KLLU[+8Z-8F_GA.V:4R"."%O[K/@DM[*"?7%
M(#XM(S]GT5?;SY3C_P <J>9=#;V$K>\TO5V-RBL3_BK/^>.B_P#?Z7_XFC_B
MK/\ GCHO_?Z7_P")HYO)C]A_>C]__ -NBL3_ (JS_GCHO_?Z7_XFC_BK/^>.
MB_\ ?Z7_ .)HYO)A[#^]'[_^ ;=%8G_%6?\ /'1?^_TO_P 31_Q5G_/'1?\
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M ,!XO\*/[*U/_H.S?^ \7^%%WV#V<?YU^/\ D:5%9O\ 96I_]!V;_P !XO\
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M_P!!V;_P'B_PH_LK4_\ H.S?^ \7^%%WV#V<?YU^/^1I45F_V5J?_0=F_P#
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MC&?O#ITQ6C-XB\7>&O%'A"?5-<CU&Q\12+%+9K;+&MNS[,;&&20"XY/7'OP
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M:,@/'*A1USR"5/.#6A7G7AVWN;C5[5H)I8Y% N+E2_\ "25V-GF1L@Y)X7&
M!TKT6G%W1%:FH2L@K,U[0K#Q+HMUI.IQ&2UN% 8 X((.00>Q! -:=9NN:]IO
MAO2I=4U>Y^S6414/)L9\%C@<*">I':J,3D/#_P -+S0M3M)W\::[=V%FV8;&
M27$>,8"MSA@/3 _"N0T>STWX@_&M?$^DVMT=&LH4DGN)8RB3W2 JF ?0%?\
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M7&X]2<=J23+<HK=W\KLYY)D\0Z[:WFF)B&U(,MYR/,!'^J'KV)SP,>O3JZ
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M"US@E;:YM[A\=E29&8_D#6W3)8HYX7AE0/&ZE65AD$'@@TI*ZL72FH34GT+
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MYMM0AB\MXY"S,"%R?[V,9Y]JZW_A(['_ )XZE_X++G_XW1_PD=C_ ,\=2_\
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MX++G_P"-T<R[A[&I_+_7WFM163_PD=C_ ,\=2_\ !9<__&Z/^$CL?^>.I?\
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M@CPU;27,]I%JZQF0G$FUV))RH&/O'FO7/[=L_P#GG?\ _@OG_P#B*/[=L_\
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MA%T[SEIH_P 58U:***HP"N5U?_D*3?A_(5U5<KJ__(4F_#^0H Z.R_X\8/\
MKFO\JGJ"R_X\8/\ KFO\JGH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HJA<:O;6VL6>ER"3[1=J[1X7Y<*"3D_A5^E<IQE%)M;A1113)"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLO\ CQ@_ZYK_ "J>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6VU*)>[/83 #_P =K3M[F"[@6>WF26)NCHV0:::>Q,J4XJ\D2T444R HHHH
M**** "N5U?\ Y"DWX?R%=57*ZO\ \A2;\/Y"@#H[+_CQ@_ZYK_*IZ@LO^/&#
M_KFO\JGH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D]8_Y*-X
M<_ZY3_\ H#5UE<GK'_)1O#G_ %RG_P#0&KK*B.[]3JQ/P4O\/ZL****LY0HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?0H4U">?6YP'E>5XK;<
M,^5$K%>/0L023[@=JWJQ?"?_ "+=O_OR_P#HQJVJF.QMB'^\:[:?<%%%%48A
M1110 45F:OKEMHWD+-%<337!*PPV\1=W(&2!_P#7K)N_%&J6L*W<OA^6WL1(
M@EFN)U#*K,%SL&3W]:ER2-(TIRU1U-%%%49A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5@SVXTOQ#:S6R[(-0=HKB,?=\P*
M75P/4A6!]>*WJRM8_P"/S1O^OT_^B):4C6B_>:Z-/\F7Z***9D%%%% !1110
M 5RNK_\ (4F_#^0KJJY75_\ D*3?A_(4 ='9?\>,'_7-?Y5/4%E_QXP?]<U_
ME4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <GK'_ "4;PY_U
MRG_] :NLKD]8_P"2C>'/^N4__H#5UE1'=^IU8GX*7^']6%%%%6<H4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% &7X3_Y%NW_ -^7_P!&-6U6+X3_
M .1;M_\ ?E_]&-6U4Q^%&V(_BR]6>1>(?B-K]KJE[I\*6]KY$S1AQ'N; . ?
MFR.>O2L32?%^LMXCT^>\U.XEB%PN]&<[-I.#\HXZ$U;^)]D;;Q>\^WY;J%)
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MMH--U&6W$H_=HL:@8+$D\\]:X3P/,)_C;#<PZU_:\<VDN#>QV"VB2$,,J%4
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MT:.FQT5E_ND9%.HH :B+&H5%"J.@ P*/+0R"38N\#&['./K3J* &"*-0P$:
M/]X =?K088B@0Q(47D+M&!3Z* &-#$Y8M&AW<-E1S]:4QH8_+**4QC;CC\J=
M10 Q8HU*E8U!48&!T% BC5658T ;[P"CGZT^B@!BPQ+MVQ(-OW<*./I2B-%+
M%44%OO$#K]:=10 U8HT38J*$_N@<4D<4<0Q&BH/11BGT4 ,6&)'+K$BL>K!0
M":IZUI%KKVCW.F7@/DSIC<IPR$<JP/8@@$>XJ_10!%;Q-%!"LLGG3(@5I64
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M+^WK'^[>?^ ,W_Q%']O6/]V\_P# &;_XBKM%&H<U/^7\?^ 4O[>L?[MY_P"
M,W_Q%']O6/\ =O/_  !F_P#B*NT4:AS4_P"7\?\ @%+^WK'^[>?^ ,W_ ,11
M_;UC_=O/_ &;_P"(J[11J'-3_E_'_@%+^WK'^[>?^ ,W_P 11_;UC_=O/_ &
M;_XBKM%&H<U/^7\?^ 4O[>L?[MY_X S?_$4?V]8_W;S_ , 9O_B*NT4:AS4_
MY?Q_X!2_MZQ_NWG_ ( S?_$4?V]8_P!V\_\  &;_ .(J[11J'-3_ )?Q_P"
M4O[>L?[MY_X S?\ Q%']O6/]V\_\ 9O_ (BKM%&H<U/^7\?^ 4O[>L?[MY_X
M S?_ !%']O6/]V\_\ 9O_B*NT4:AS4_Y?Q_X!2_MZQ_NWG_@#-_\11_;UC_=
MO/\ P!F_^(J[11J'-3_E_'_@%+^WK'^[>?\ @#-_\11_;UC_ ';S_P  9O\
MXBKM%&H<U/\ E_'_ (!2_MZQ_NWG_@#-_P#$4?V]8_W;S_P!F_\ B*NU#=75
MO96[7%U,D,*8W/(V ,G Y^IHU[C3@W91?W_\ @_MZQ_NWG_@#-_\11_;UC_=
MO/\ P!F_^(JZ#D9'2BC45Z?\OX_\ I?V]8_W;S_P!F_^(H_MZQ_NWG_@#-_\
M15VBC4.:G_+^/_ *7]O6/]V\_P# &;_XBC^WK'^[>?\ @#-_\15VBC4.:G_+
M^/\ P"E_;UC_ ';S_P  9O\ XBC^WK'^[>?^ ,W_ ,15VBC4.:G_ "_C_P
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M/]V\_P# &;_XBC^WK'^[>?\ @#-_\15VBC4.:G_+^/\ P"E_;UC_ ';S_P
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M_7*?_P! :NLKD]8_Y*-X<_ZY3_\ H#5UE1'=^IU8GX*7^']6%%%%6<H4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S/Q _P"1(U#_
M +9_^C%KIJYGX@?\B1J'_;/_ -&+43^%G3@_]XI^J_,Z2/\ U2?[HIU-C_U2
M?[HIU6<[W"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5RNK_ /(4F_#^0KJJY75_^0I-
M^'\A0!T=E_QXP?\ 7-?Y5/4%E_QXP?\ 7-?Y5/0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% ')ZQ_R4;PY_P!<I_\ T!JZRN3UC_DHWAS_ *Y3
M_P#H#5UE1'=^IU8GX*7^']6%%%%6<H4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ;RQS0R*'CDC8,KJ>A!'!%%D'M9?TE_D9_\ 9=Y_T&[S_OU#_P#$4?V7>?\
M0;O/^_4/_P 16I4<L\,./-ECCSTW,!FBR#VLOZ2_R,_^R[S_ *#=Y_WZA_\
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MS(/85.WY?YFU6+9Z/<6/B34[N.2)M.U%$DEA;[R3J A8<8(9 N?0H.NXX/\
MA);?_GPU;_P E_PH_P"$EM_^?#5O_ "7_"CF0>PJ=OR_S*"?#[0$=5"7IM$<
M2+8-?3&U4@[AB'=LQGG;C'M6\=-M3JZ:H4/VM+=K<-N.-A8,1CIU450_X26W
M_P"?#5O_   E_P */^$EM_\ GPU;_P  )?\ "CF0>PJ=OR_S%G\+Z5<V6K6<
ML+F'59?-NP)"-S;57@]N$7I4FK>'=/UE[>6X$\5Q;Y$5Q;3O#*@/5=R$'!P,
M@\<5%_PDMO\ \^&K?^ $O^%'_"2V_P#SX:M_X 2_X4<R#V%3M^7^80^%-(M]
M.AL8X'\J*Z6\W-*S.\RL&#NY)9CD#J3TQTJ*]\':3?ZG-?R"[BDN HN4@NY(
MH[C P/,16 ;CCD<C@\5+_P )+;_\^&K?^ $O^%'_  DMO_SX:M_X 2_X4<R#
MV%3M^7^8V?PCH]QHMCI302QP6 46CPS/'+!@8!5U(8<<=:/^$2TM]&GTNY^V
M7=O.XD=KJ[EED##&TJ[,64@@$8(Q3O\ A);?_GPU;_P E_PH_P"$EM_^?#5O
M_ "7_"CF0>PJ=OR_S&Z;X2TS2]334HS=SWRQ-#]HNKJ29RC%25RY/&5&!]?4
MUH7&EVMUJ5EJ$J$W%EYGDL&( W@!N._ JC_PDMO_ ,^&K?\ @!+_ (4?\)+;
M_P#/AJW_ ( 2_P"%',@]A4[?E_F7M3TRUU>R^R7B%X?,23 8CYD8.O(]U%1Z
MOHMCKELD%[&Y\MQ)%)%(T<D3CHR.I#*>2.#T)%5?^$EM_P#GPU;_ , )?\*/
M^$EM_P#GPU;_ , )?\*.9!["IV_+_,2U\)Z1:V%_:&&6Y34%*7<EU.\TDRX(
MP78DX )P <#/%1'P;I+Z,NESM>W$*2B:*2:]E>6%P  8Y"VY, =B.I]34W_"
M2V__ #X:M_X 2_X4?\)+;_\ /AJW_@!+_A1S(/85.WY?YC$\)Z<NF7.GS2W]
MU#<NCR&ZO99FRK!E +,<#(Z"M*#3;:WU.[U"-"+B[6-9FW$@A,[>.WWC5#_A
M);?_ )\-6_\  "7_  H_X26W_P"?#5O_   E_P *.9!["IV_+_,NZ7I=IH]E
M]DLD*0^9)+@L6^9W+MR?=C1;Z5:6VH7U]'&?/OMGGDL2&V+M7CMQ5+_A);?_
M )\-6_\  "7_  H_X26W_P"?#5O_   E_P *.9!["IV_+_,B?P;HKZ/!I?DS
M);VTIFMFCN'22W8DG]VX(90,D  XQQTIX\*60TU[+[9JQ#RB8S'4IS,& QP^
M[<!C^'I[4[_A);?_ )\-6_\  "7_  H_X26W_P"?#5O_   E_P *.9!["IV_
M+_,Q=?\ !D1\+76GZ;;S7<]W>6TMPUU<&2254E0MN>0Y("*<#/T'-;.E^%-,
MTG43?Q->3W7EF))+R[DN#&A()5-[':#@9QUQ2_\ "2V__/AJW_@!+_A1_P )
M+;_\^&K?^ $O^%',@]A4[?E_F5F\#:&UT93'=>0TWGM9?:Y/LQDSNR8=VS[W
M.,8SVK8M],M;;4;R_B0BXO @F8L2#L!"\=N":H?\)+;_ //AJW_@!+_A1_PD
MMO\ \^&K?^ $O^%',@]A4[?E_F,;PEIW]FVUC!+?VL5N[O&;6\DB;+L6;)4C
M(R>AS2-X.T5M$&E-;RM )OM E-P_G>=G/F>;G?OSWSGMTXJ3_A);?_GPU;_P
M E_PH_X26W_Y\-6_\ )?\*.9!["IV_+_ #*5YX6DB\/W^FZ7>W337X$,MQ?W
MLL[1QGABFXMR%+8' SC)KH;2UBL;*"TMUVPP1K%&OHJC 'Y"LO\ X26W_P"?
M#5O_   E_P */^$EM_\ GPU;_P  )?\ "CF0>PJ=OR_S-JBL7_A);?\ Y\-6
M_P# "7_"C_A);?\ Y\-6_P# "7_"CF0>PJ=OR_S-JBL7_A);?_GPU;_P E_P
MH_X26W_Y\-6_\ )?\*.9!["IV_+_ #-JBL7_ (26W_Y\-6_\ )?\*/\ A);?
M_GPU;_P E_PHYD'L*G;\O\S:HK%_X26W_P"?#5O_   E_P *9+KEW>1M%I>F
M78G/ EO(3#''[G=RV/0#\J.9!["IU5ON_P QV@$&UO".GV^Y_P#1K5JU4TVP
M33=/BM48OMR6=NKL3EF/U))JW36B)JR4IMK8****9F%%%% !1110 4444 %<
MKJ__ "%)OP_D*ZJN5U?_ )"DWX?R% '1V7_'C!_US7^53U!9?\>,'_7-?Y5/
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ')ZQ_P E&\.?]<I_
M_0&KK*Y/6/\ DHWAS_KE/_Z U=941W?J=6)^"E_A_5A1115G*%%%% !1110
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MXT?VWI/_ $%++_P(3_&BZ#V4_P"5_<_\B_15#^V])_Z"EE_X$)_C1_;>D_\
M04LO_ A/\:+H/93_ )7]S_R+]%4/[;TG_H*67_@0G^-']MZ3_P!!2R_\"$_Q
MHN@]E/\ E?W/_(OT50_MO2?^@I9?^!"?XT?VWI/_ $%++_P(3_&BZ#V4_P"5
M_<_\B_15#^V])_Z"EE_X$)_C1_;>D_\ 04LO_ A/\:+H/93_ )7]S_R,S4O"
MEOJ/BBPUAMH\@'S4[R,/N'\#_(5T54/[;TG_ *"EE_X$)_C1_;>D_P#04LO_
M  (3_&DN5;&D_;345)/166C_ ,B_15#^V])_Z"EE_P"!"?XT?VWI/_04LO\
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M18.9]R+[+;_\\(O^^!1]EM_^>$7_ 'P*EHHL',^Y%]EM_P#GA%_WP*/LMO\
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M_A'=$_Z VG_^ J?X4?\ ".Z)_P! ;3__  %3_"M*BGRKL9^VJ?S/[W_F9O\
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MT!M/_P# 5/\ "M*BCE78/;5/YG][_P S-_X1W1/^@-I__@*G^%'_  CNB?\
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M!E8="#T->:?!_0-"N?A?ITKZ?9W,EUYC73RQ+(7?>PPV1V  Q5#4_$U]\/\
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MR/7_ !7X<TFY2;3H[@WVGLF=HC; 91GH%.T?G6'8^+/B#J'PSN_%Z>)+>/\
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MAW4,SN3]XDD]:Y_6?$]Y+XNU'2+>;6[.TTV.)<Z1IJW+22.N[YBR.%4#:
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ME>B4 %%%% !1110 4444 %9FO?\ (-C_ .ORU_\ 1\=:=9FO?\@V/_K\M?\
MT?'2EL:4OXB+M%%%,S"BBB@ HHHH **** "BBB@ HHHH *Y75_\ D*3?A_(5
MU5<KJ_\ R%)OP_D* .CLO^/&#_KFO\JGJ"R_X\8/^N:_RJ>@ HHHH S/"?\
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M& !["G44));!.K.:2DVT@HHHID&5X<^]J_\ V$9/_05K;K$\.?>U?_L(R?\
MH*UMU,=C:O\ Q'\OR044451B8<_R>-[-G^[)82HA_P!H.A(_+^55I]1U!#J<
M^G16,=I8.WF1R*0\[!0S'(("=>"0<]:U=7T][^W0P2B&[@<2V\I&0K@8P1W4
M@D$>AKG;R;29YI)-5L7MM3VCS+:2X,45R1T^;(20?7G'!%0]#IA:5M+]/Z_K
M0N>&;=[33[R:WU'^T9I<2K#)+@QDC(#9+;2>_;T%3:H\MKJ.CZI-&N=WV26(
M'=L,I4 J>^&4#Z$U#;#P_P"'_MEW;7]NDMS\VUYPXSEF 51R>6/ R>:GL([S
M6;RWU&^B,%M;KFWA92"\A&#(RGD#!(4'GDDT+:P2^)S>WW=-B&72(H[\Q17,
M\\4=PMX=/78,.SYW;C@[0V6VYZC\*Z6DI:I*QA*;E:X5R%[X!L]5\?Q^*-3F
M2[C@M?L]O8R0 HAYRQ))W'EN,=QZ5U]%,DXRY^'UI'XVL?%&F3IIQM;=X);2
M"W4).IW=<$8/S>AZ"O+OAS\.3XO\"JS^(=2LM/FO)!>6$+9CGVL,'G[IX&>#
MT''%?0E% '$>(?AM;:G>:?J.C:I=:%J=A MK#<6H# PCHC*<9Q]?KGBN<\4>
M"K'P9\'?$\5O<7%W=W:+-=W=PV7FDWKS[#D_F>37K5% 'D_A;X71747AK6-1
MU_4KZRM+:&YM-.G;*0R%%;ANZ@]!CH ,XZ[]Y\.Y6\=3>)M-\0WNG?:S$;VU
MB0%9]F,#.> 0!G@]3ZUW-% 'G6M?"B.]UG4+_1O$.H:*FJ?\A&WML%)_4CD;
M2<MSSU/J<Z4O@*6QT/2M+\+Z_>Z&FG!P&1%F$V_EC(K8#'.2#VR<5V=% 'FL
MGP?LV\'3:&NK3_:+F_6_NKUX@3)(.P0$!1^-:GBGP-JGB*ZO/L_BV^L-/O81
M#<V/D)+&RXP=N[[F1UQWKMJ* ,[0-$M/#FA6>CV._P"S6D?EH9&RQ[DD^I))
MK&\/V-QI'B?Q#82V\CV.H3?VC;S;"8\NH22-CT#;EW8[AO8UU5% ''6W@W5=
M(1;/0O%-Q9:4A/EVDMI'<&($YVH[<A?0'=CZ<5<U'PM=/JTFK:-K4NF7\\21
M73&!9HYPN=K,AQAADC((XXQ72T4 8;:!-/=:'=7>I27%QIDLDK2/$JF8O&R8
MPN H&[C@]/QJ;P]H:Z!97%LMP9A->3W6XKMQYLA?;U/3.,UK44 <E>^%-7/B
M6_UC2?$2Z>;Z.*.6)K%9O]6" 02P_O'M5W3O"&GV=CJ4%S)/J$^J@B_NKE@9
M)P5V[>  J@$@*  ,UT%% '-Z/X>UC29X(3XFGN=+MU"16TMK'YA4# #R]6QZ
MX!..M95Q\/)Y])U#0U\0W$6AW7FM'9K;INB9V+\R=64,2=O![$XZ]S10!SFH
M^&;B?7[76=-U5[&[CMQ:S P+*LT(;=C!(VG.>1Z]*N:-H2Z1_:N+@R_VA>R7
M9RF-F\ ;>O.,=:UZ* .&N?#UQ;:5X8\)6XEN+:VFBGN[IHMJ>5 P< GH&9P@
M"YZ;CT%=S110 4444 %%%% !1110 5F:]_R#8_\ K\M?_1\=:=9FO?\ (-C_
M .ORU_\ 1\=*6QI2_B(NT444S,**** "BBB@ HHHH **** "BBB@ KE=7_Y"
MDWX?R%=57*ZO_P A2;\/Y"@#H[+_ (\8/^N:_P JGJ"R_P"/&#_KFO\ *IZ
M"BBB@#)\-RI;V\VD/E9[*1E"MU:,L2CCVP0/J#6Y67?Z5;:@R2/YD5Q'GR[B
M%RDB9Z@$=O8Y%,73[Y5Q_;M\?K'!_P#&ZE76AO/DJ/FO9O?<UZ*R?L-]_P!!
MN\_[]0__ !NC[#??]!N\_P"_4/\ \;IW?8CDC_-^#-:BLG[#??\ 0;O/^_4/
M_P ;H^PWW_0;O/\ OU#_ /&Z+OL')'^;\&:U%9/V&^_Z#=Y_WZA_^-T?8;[_
M *#=Y_WZA_\ C=%WV#DC_-^#-:BLG[#??]!N\_[]0_\ QNC[#??]!N\_[]0_
M_&Z+OL')'^;\&:U%9/V&^_Z#=Y_WZA_^-T?8;[_H-WG_ 'ZA_P#C=%WV#DC_
M #?@S6HK)^PWW_0;O/\ OU#_ /&Z/L-]_P!!N\_[]0__ !NB[[!R1_F_!FM1
M63]AOO\ H-WG_?J'_P"-T?8;[_H-WG_?J'_XW1=]@Y(_S?@S6HK)^PWW_0;O
M/^_4/_QNC[#??]!N\_[]0_\ QNB[[!R1_F_!FM163]AOO^@W>?\ ?J'_ .-T
M?8;[_H-WG_?J'_XW1=]@Y(_S?@S6HK)^PWW_ $&[S_OU#_\ &Z/L-]_T&[S_
M +]0_P#QNB[[!R1_F_!FM163]AOO^@W>?]^H?_C='V&^_P"@W>?]^H?_ (W1
M=]@Y(_S?@S6HK)^PWW_0;O/^_4/_ ,;H^PWW_0;O/^_4/_QNB[[!R1_F_!FM
M163]AOO^@W>?]^H?_C=,ETJZG79+K>H;#U"")"?^!*@(_ T7?8.2'\WX,BFD
M74/%5NL)+)IL;M*XZ>8X "?4#)/ID>M;%06=E;V%LMO:Q+'&"3@=R>I)ZD^Y
MJ>A(*DE)I1V6@4444S,**** "BBB@ HHHH **** ,G0V$&HZO9N<3&Z^T*I_
MBC=5P1[9!'X5N5EW^E6^H-'*S2PW$6?*N(6VNF>HSW!]#D4Q;"^"@?VY>GW,
M<'_QNI5UH;S<)^]>S^9KT5D_8;[_ *#=Y_WZA_\ C='V&^_Z#=Y_WZA_^-T[
MOL1R1_F_!FM3)8HYHS'+&LB'JKC(/X5F?8;[_H-WG_?J'_XW1]AOO^@W>?\
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MK_*IZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KE=7_P"0I-^'\A755RNK_P#(4F_#^0H
MZ&S<)$+=_EEB&UE/H.A^AJSD>M9/B/[T'XUAT =ED>M&1ZUQM% '99'K1D>M
M<;10!V61ZT9'K7&T4 =ED>M&1ZUQM% '99'K1D>M<;10!V61ZT9'K7&T4 =E
MD>M&1ZUQM% '99'K1D>M<;10!V61ZT9'K7&T4 =ED>M&1ZUQM% '99'K1D>M
M<;10!V61ZT9'K7&T4 =ED>M&1ZUQM% '99'K1D>M<;10!V61ZT9'K7&T4 =E
MD>M&1ZUQM% '99'K1D>M<;10!V61ZT9'K7&T4 =ED>M&1ZUQM% '99'K1D>M
M<;10!V61ZT9'K7&T4 =ED>M&1ZUQM% '99'K1D>M<;10!V61ZT9'K7&T4 =E
MD>M&1ZUQM% '99'K1D>M<;10!V61ZT9'K7&T4 =ED>M&1ZUQM% '99'K1D>M
M<;10!V61ZT9'K7&T4 =ED>M&1ZUQM% '99'K1D>M<;10!V61ZT9'K7&T4 =E
MD>M&1ZUQM% '99'K1D>M<;10!V61ZT9'K7&T4 =ED>M&1ZUQM% '99'K1D>M
M<;10!V61ZT9'K7&T4 =ED>M&1ZUQM% '99'K1D>M<;10!V61ZT9'K7&T4 =E
MD>M&1ZUQM% '99'K1D>M<;10!V61ZT9'K7&T4 =ED>M&1ZUQM% '99'K1D>M
M<;10!V61ZT9'K7&T4 =ED>M&1ZUQM% '8,ZHI9V"J.I)K&N-*N-0G:ZC 5)/
7NAN#@<9_'&:S;;_CZA_WQ7;CH* /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6["L8# 2(  A$! Q$!_\0
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M10 M)11VH *.U%+0 E+1FDH 6D%%% "T49I* "BBB@ HHI>U !2444 %%%%
M!12BDH !2TE% "T4E% "T4E% "TE%% !1110 4444 +1244 %%+BDH ****
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M&* $I:"*!3L(,44M)BBPPHI:*!"4F*7%%(8E)2T4#$S1FBB@ S1110 4444
M%%%+0 4 4N*4"@0@%. I0*<!0,;MI0M/Q2@4 -Q2XIV*7;0 S%+BG@4N*!D>
M/:C'M4FVC% $>*3'M4NV@B@1%BD(J3%(10!$11MIY%(10!&13:D(II% #*2G
MXIIH 2BEHQ0 E%+BDH *6DHH *44E% !1110 M!HHH 2BBB@ HHI>U ""BBE
MH 2BE-)0 M)110 444M "44M% "4444  I:2C- "T4E% "TE%% !2TE% "TE
M%+0 E%+24 %%%% !1110 M)110 4444 +1244 !HHHH **7%&<T )12TE !1
M110 4444 +124N: $-%%% !1110 4444 %%%% "T4E% "T9I** %I#UHHH *
M**.U !1VHI: $H[444 %%%% !1110 4444 +BC%)10(*7M129H ****!A111
M0 4444 %%%% !1110 4444 %+FDHH 7%)110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%&:!"TE&:,T %%%% PHHHH ****  4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4X=:;3Q28T/%2+3%J5164F6D.%/
M6D48IZ]:PDRT.%2+30,U(!BLVRB1#[583!JNE3I0I T6$J=.:A3M4Z\5M&1F
MT2J!4@-1K4@-;19C)#E'%.I :4=:T3,VAI%,Q4C<TPGBM$9M##41J1C43&J(
M:&-UJ%Q4C4PFJ((&'6H2*G>H&- R%Q5=ZG;GK4$E(M%=ZBJ5Z9Q2L:)B44[B
MCBG8+B8HQ3J*+"N,Q1BG4$46'<C(HI]-I6'<2C%%+VI6'<;BDQ3J,4K#N-QF
MDVTZE HL%Q@6EQ3\48HY0N,H'6GXHVT6%<*44 4N*I(EL*7-)S2@50KBBDI:
M,4""BBBF(**!1UI,$+4BK2*M3*M2V:QB(J^U/5?:GJE2!<5A*1K%$>RE"9J0
MID4X*,8KGE+4TL,V>E*%]:E4<4[:,5'..Q#MI"O-3;:;MYJE,+$3*332G%3E
M:"N:N,Q-%;;4;+S5HKBF%:WC(EHP-?7%BA_Z:C^1HJ3Q&,6"?]=1_(T5C5^(
MN&QHFFFGFF&NLYAM-:GTTT ,II%28II%(0PBDQ3Z;3L%QM%+10*X4F*=118+
MC:,4[%&*+#N-Q1BG8HHL%QM&*=BC%.P7&TM&*,4A7"BC%&*=@N&*3%.HHL%Q
MM%+BC%*P7"C%+1B@0F*,4N**8PQ24M%%@"DI:6BP#:*4T4 )12T4 %%%%( I
M*6BF E+110 F.:*6BD,2DI<4F* "BBBD,2BBBD,*2EI*!A2444AB4E.I"*0!
M2444#"BBB@04444#"CM110 4=J** "BBB@ HHHH **** "BBB@ I:2BD 4HH
MQ2TQ!12T4[""BEQ118 Q1BBBF(,48HHH ,48HHHL,2BEHQ2L VBEHQ188VBE
MI#2L 9I*** "BBB@8M**2G 9I **<!0!3P* $ IV*4"G!: $Q2@4X"G 4#&X
MI<4[%+MH ;MHQ3\&E H C I<4_%&* (]M)BI<4W;0 S%(13]M)MH CQ32*EQ
M2$4"(B*:14I%,(H C(IA%2D4TBF!%13B*:10 4E%% !112]J $HHHH ****
M"EHS24 %%%% !1VHHH *6DHH 6DHHH ,44M)WH *6BDH *6BB@!**6DH ***
M6@!**6DH **** "BBB@ HHHH *6DHH 6BDHH 6DHH[4 %%%+0 E%%% !1110
M 4444 +FCBDHH 6DHHH **** "BBB@ HH-% !1110 444M "44&B@ HHHH *
M*6DH **6DQ0 448HH *.U%** $HI:0T %%%% !0*** "BE-)0 4444 %%%%
M"TE%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHHH **** %I*6DH **** "BBB@ HI12&@ HHHH **** "BBB@ HHHH ****
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M110 444M "44M)0 4444 %%%% !1110 4444 %%%% !12T4"$HI:*!B4444
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M3L4$4["$Q12XXHQ3L*XF*,4M+18+C:,4[C%)BE8!I%)3L4N*!C11B@#FG46
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M&%%%% !1110 4444 +124M !24M)0 4444 %%%% !112YH 2BBB@ HI>U)0
M44N*,4 )12XI* "BBB@ I:2B@!<48HS1F@08HQ1FC- !2&BB@84449H 444"
MB@!*!10* %I*6DH **** "BBEH 2BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHS2T""DHHH **7-)0,**** "BBB@ HHHH *6DI
M: "DS2TE !1110 4M)2T"#%%)10 M)110,**7-)0 4444 %%%% !1110 444
M4 %%%% @HHHH&%%%% !1110 4444 %%%% !1110 4444 %%'%% !11BE"DT6
M%<2CFG!*7;BG85QFTTH6GXI<4["N-"TNWFEHIV%<!4@-1XQ3U.:30*1*M2+F
MHT%3+BERFBF2+4J\5"#4@J7$KF)!S3LU&#S3B>:7*/F'@TA)!IN:7/%)P'S"
MAJ0M32>*9DT*(-DI;BDW =ZB9B*;G-4HD-DN^F%ZC+XJ,O6B1$F2,_O4+/36
M:HRW-58S;%9LU&:<:;3L2-P<T=Z>!1MH'<%J0"E5:=MJD0V IPHQ2U1(9I<\
M4W-(0:8AP-!.33>:,4@%)H-)2]:: ;FF$5+BF'K28T, YI=O%+C% I6&*!2X
MH%+3$)BEI:3%,!<48HHS0(*<HIO6GKTH!CP*>!30.*>!Q5(D,4"EQ@4H'M3
M0BC'%.(Q0* &XXIIXIY%-(H$,).:D4@BFXI12:*BR50!3QUJ+-2*>*PDC>+)
M*>K5$IJ0=:YIQ-TQYYIR8 J,=:5>M<<Z9JF2J>:?FH<X-/S6#IEW'$FDS2%J
M3-"IA<4GBHB<&GFF&M53"XUB3322!0QIA-=$(DMF)XH_Y!L?_78?R:BD\3G.
MG1_]=A_(T425F"-.D-+017H'$--)3SBFGB@0VFFG4A]ZJPAF,TA6GTTT"&XH
MQ2T$4R1* *!2K3$% %*,9H YH 2@#/6E(I<4 )2XI<44"$Q1C-+2X% #<4F*
M=G!I">: $Q28IW-+C- #0N:7%*.*4T -[4 44N.* $-)BEH(H ;BBEH(I#&T
MO:C%)0%Q#2T44#&D4E.-'&*0QA%&,TI%)@TAW"C% I>!0 VEI.]+2&%)2TE
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M0F@!#333C3<4 ,---/(IAH ::B85(:8:8$9%1FI6J(B@0TTE*13: %I*4TE
M!1110 4444 +1244"%HI**!A1110 4444 +1244 +2444  I:2ES0 E%%% !
M2TE% !112]J $HS110 9HHHH 6BDHH **** "BBEH 2BEI.] "T44&@ HI*!
M0 M%%)0 4444 %%%% !1110 4444 +12"B@!:2BEH **#24 %%%% !1110 4
M4N:* $I:*2@ HHHH **** "BBB@!:2BE% "44M% "44M!H 2BBB@ HHHH **
M*,4A!1BEIP%-!<;BG8I<4H%580W%&*<11BBPKC,48I^*"*5AW(R*2I,4TK18
M=QM%*:2I&%%%% !1113 *6DI: #-%)10 M)110 4444 %%%% !110* "BEHH
M 2BBB@!:*2EH *2BB@ HHHH 6DHHH ****0!1113 **** "BBC% @HI<&EVT
M!<;1BI HI<"G8+C M+MI^**=B6QN*7%+BBG85Q*6C%%,5Q*6C% IB"C%+BE
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MC6I!2&/6GCBHQ3P:!C\\4HIO:E%(84F:=C%)C%( HHHH **3-+0 4=**3.:
M'#I1244 %%%% !1BE%!H 2D-!II- "&HR>:>:8>M,!#4;4]JC:@!C4PT]JC-
M AK5S/C'Q!=^'[.VFM(X7:60J?-4D8QGC!%=,:X/XG?\@RQ_Z['_ -!J9.R'
M'<Q?^%EZS_S[6'_?M_\ XJE'Q+UC/-K88_W'_P#BJY73;5;W5+2T9BJSS)&6
M'4!F S^M>@2?#&U*$1ZE,K=BT8(_F*R3F]BWRK<BL?B:I<+?Z?M4]7@?./\
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M"G"K)8M%'>E%-$,!2T4M,0E.I*6F 48HHH *,4HI,T (10*=VI* #%)BEI*
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MKYYKWO0,MX<TMB<DVD1)_P" "JI:Z$U--3A/BB,7&F?[DG\UK"\"?\CGI_\
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M U[3X-_Y%'3_ /</_H1KQ:O:?!O_ "*.G_[A_P#0C6-+<N>QQWQ#UNXDU/\
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MCT_"M"V^)]RB 7.FQ2MZQRE!^1!K/VBZE<K-SQ9X2L;[3[F^@B6"\B1I-R#
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M1FF4M AV:6F@4\4T)DJ]*E6HT-2"M$9L>*<!30:?FJ(%%+FD%(:8#Z;11VH
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MFDTA--)H #24$TE !1110 4444 %%%% !1110 4444 %%%% !1110 44IHH
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M "GI2"@FB@!2<TE%% !01Q2&E!Q0  \49H)S2C% !FDR:#UI: $I#3LTWM0
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M-(5IX'%&*+!<CQ32M2D4T]*30TRI(M1BK#CFH&&*Q:-HL#24HYI*DH6BDHH
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MI@)THQS2FE H 2C)H[T4 +24X4A'- "&D!IV*,8H 2D(IU!H 8::*>1Q3:
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M+185JD#9JNIJ0&J1FT3@XJ0-4 -2!JI",CQ0<Z9%_P!=A_Z"U%-\3G.FQ_\
M78?R-%>=BOXAZ.&_AFMBE'6DZTX#BO0.$7% IP&12[:8"4F*7I10 F,T8I:*
M $ZT'I2]*3-*P#*2@]:,4 .%%)F@4 !HH- - A#28IW>@B@!AHI<44 &:*3%
M ZT &:*7O28H 44IIH%.%  *0TM% #:#2GBD'- "4"E/%)0,***":!!24HZ4
ME( I:0&EH& IV*04N:12%HQ24M(M!2]J!106 -%+BD/6I*0'BDZTO6DQB@8A
M%)3Z3%(9'U-+3L4TTK#N---(I])2L.XW%)3\4F*+!<;2T8I:5@&TM&*,46&)
MCFEQ1BDH"XWO2TX"EP*5AW&48IV,4F*+"N-Q334A%-(HL%QAI*>13<4[$-B4
MAIQI*JQ+8VDQ3L<TA%.QFQM***<!Q3)$%/%, IXIB'8I5&:2G 8IB "E')H%
M*!3)#%.Q24<T &.:7I113 ,4@%+VH/2@ Q2#WH!H[T *:!2T4 %)BEIM  2*
M;@&E-)G%(88I#R*7-)2 8>M'UI2*,4#$Q1C%+BC% 7&XS1MIV*7%%AW&$4F*
M?BDQ2L%QI%)BG48I6"XS%&*7&**+#N)28-+12'<812TN*3% [B&FXIQZTF*F
MP[C<4F*?BDQ18:8VFXIY%)BI:*3(R*;BI"*::EHI,2BCO14E!124M( HHI<4
M )13L48IV"XF*,4N*7%.P7&XHQ3J3%%@N-Q13J,46 ;13L4F*0"44M)2&%%%
M% !1113 ****!!UJ15Q356I *I(EL7% HI:LS;"@TM--,1)&:F'%11CFI<C-
M6B6/!IPXJ+.*=NXJDR"7/>FEJ;NI*8,7WIIY%.[4AX%2QHK-G=333F^]32*A
MFB(V&:CJ<BHB*RDC6+&T445!84444Q!11BEQ0%Q.M+BE I<4TA7$ I0M*!3L
M4TA.0F!1BG8HQ56)N(!2TN*,55A7$I,4[%&*5@N-Q24_%-HL%Q.E%+B@"E8+
M@!3J2BJL3<6B@4&F &GH*8.:F4<4T2V/4<U*.E1KP:>"*T1FR6/&14XJ"+&:
ML=:H0A%,9O2G'CK4#'FA@3*2!3^U1*<BI!TH C89H[4TM@XHS0 $U&_-/S33
MUI 14&E;@TTFD,::04IIM2QA2GI0!3PM!5A@YHVFGA:=BBX6(BM)BIRO%,*T
MKCL1@8IXIP4&E*T[@T,S36IQ%1N:+BL-SS2YI@/-**FX[#\T9I,44Q#@:7%-
MI<TQ"YIIHH(H 0GBHSUIY%,(YJ64AII!3C1BI+&TM+BC% A*6@"EI@&*4"@4
MH!S1808I<4X"G8JDB6R/;3@M/VYIZIQ3L*Y&%I=@J7:*-N:=A7(\4N*?MHVT
MQ7&XI:6B@!M+12XH ::;3C3:+#"DI:7;18!N,TNVG 48I6%<9C!I<4I I#0,
M0T@H-"\T@'5(*93Q5"']J*2E%,0M(<GZ4M)0 8Q2&@FDSQ0,3=33S2YIC&DQ
MC33":<3334L8@IPI!3@* % HQ12BF(,4HI<4N*!I"8HQ3@#3J12B1@5(HI.]
M2JO%""P!:-M.[4H%4+E&XHQ3C33F@7*(:;BG4TT!RC#3,U)3"*0K##3#4A%-
M(H!##24\TF#2L5<;13MA)IPB-%A7& 4H!J98L5(L5-(39 %HQBK7E@"FF/-.
MPKD(%2*.*#'@U(HXJ&[&D421KQ4F*1!Q4JC'6I<BU$ M."T]4)J41TKCL1"/
M%.\NI@AI2O/%%PL0%>*3;@58V4GE\U5Q6*Y6HV3FK3C%1,*:8FBN5J(I5DK4
M9'-4F0T5BN*814SJ:C(XJDS-H;BD-+1BF2-H-&.:#0-"'FDZ4[%&V@&-IPI,
M<TH'%(!Z]*5>#35%/Q5"%-(!FE[4HXH :1BF'FI#S3<"D(9BDQFG$4=:!W&$
M8IN*DIN,TK#$I#2T4#N,I<4&BD.XVD(IV*"* N1FDQ3\4F*DJXT4\"DQS3J:
M$QRT\&F+3U%4B&2 YI_2HAQ3QDU0C*\3'_B6Q_\ 78?R-%)XD_Y!T?\ UU'\
MC17FXK^(>AAOX9L@<TX=:;3A7HG".&:4FC-'6@ Q28I<4E,!3244AH 7---*
M 2>E2_9IF'$9_'BIE)+=C46]D5N:45-]CN/^>?ZBC['<?\\_U%3[2'=%>SGV
M(>U':I_L=Q_SS_44?8Y_^>?ZBCVD.Z#V<^Q#VI,8YJ?['<?\\_U%'V2XQ_J_
MU%'M(=T+V<^Q!0#4WV.X_P">?ZBE^QW'_//]11[2'=![.?8AXIO>K'V.?_GG
M^HI/L4X/^K_44>TAW0>SGV(,\T8[U/\ 8KC_ )Y_J*7['<8^Y^HH]I#N@]G/
ML5NM&*L?8I_^>?ZBC[%<9_U?ZBCVD.Z#V<^Q7I<&IS97&?\ 5_J*/L=Q_P \
M_P#QX4>UAW0>SGV*_>BK'V.X_P">?_CPH^QW'_//_P >%'M(=T'LY]BN::3@
MU9-E<_\ //\ \>%(;&XQ_J__ !X4>TAW0>SGV*Q.:45-]@N?^>?_ (\*/L-S
M_P \O_'A2]I#N@]G/L09HJQ]AN?^>?\ X\*#8W/_ #S_ /'A3]I#NA^SGV*P
MH!JS]AN<?ZO_ ,>% L;G_GG_ ./"E[2'="]G/L5AUIQJ;[!<Y_U?_CP_QIWV
M&Y_YY_\ CPH]I#NA^SGV(*6IOL-Q_P \_P!12_8KC_GG_P"/"CVD.XU"78AI
M14WV.X_YY_\ CPI19SC_ )9_J*7M(=RU"78AH-6/LDW]S]12?8Y_[GZBE[2'
M<KEEV(!2&K/V2<?P?J*#:3?\\_U%'/#N4HR[%8]*%'K5C['/_<_44?9)_P#G
MG^HI<\>X^5]BOFEQ4YLY_P"Y^HI/L=Q_<_44N>/<.5]BN::15O['/C[GZBD-
ME/\ W/U%'/'N/E?8JXIO>K?V*X_YY_J*3[#/_P \_P!11SQ[A9]BMCBDQ5K[
M%<?\\_\ QX4?8;C_ )Y_^/"ESQ[CL^Q4Q15K[#<?\\__ !X4&QN/^>?_ (\*
M7/'N%F5<4G-6OL%S_P \_P#QX4?8+C_GG_X\*.>/<=F5:3O5K[!<_P#//_QX
M4"PN?^>?_CPHYX]PLRM@TH%6?L-S_P \_P#QX4?8;G_GG_X\*.>/<+,JF@U:
M^P7/_//_ ,>%-^P7/_/+_P >'^-'/'N%F5:*M?V?<_\ /+_QX?XT?8+G_GE_
MX\/\:.>/<5GV*>#015O^S[G_ )Y?^/#_ !H.GW6/]5_X\/\ &GSQ[DN,NQ2Q
M2$5=_LZZ_P">7_CP_P ::=-N_P#GE_X\/\:?/'N0XR[%+%(:N'3+S_GE_P"/
M#_&C^S+O_GC_ ./#_&GSQ[DN$NQ3QS3ZM#3+O_GE_P"/#_&G?V;=?\\O_'A_
MC3YX=R>278I@4\"K7]G77_/+_P >'^-*-/NO^>7_ (\/\:/:0[AR2[%8+2XY
MJU_9]S_SS_\ 'A_C1]@N<_ZO_P >%/VD.XO9R[%4BE[5:^P7/_//_P >%'V&
MY_YY_P#CPI^TAW%[.78K"EJQ]AN/^>?_ (\*7[#<?\\__'A1[2'</9S[%8C-
M&VK/V&X_YY_^/"C[#<_\\_\ QX4>TAW0>SGV*^.*2K/V*Y_YY_\ CPI#8W/_
M #S_ /'A1[2'="]G/L5N]+BK'V"Y_P">?_CPH^PW/_//_P >%'M(=T'LY]BO
M15C[#<?\\_\ QX4?8;G_ )Y_^/"CVD.Z'[.?8KTF*M?8;C_GG_X\*0V%S_SS
M_P#'A1[2'<7LY]BH:2K1T^Z_YY_^/#_&D_LZY_YY_P#CP_QI>TAW'[.?8K"D
M-6O[/NO^>7_CP_QI/[/NO^>7_CP_QH]I#N/V<NQ5I,XJU_9UW_SR_P#'A_C0
M=.NO^>7_ (\/\:/:0[A[.78K45:&G77_ #R_\>'^-+_9]S_SR_\ 'A_C1[2'
M<.278J@4N*L_V?=?\\O_ !X?XT?V?=9_U7_CP_QH]I#N')/L5328JQ);31#+
MQL!Z]JAJDT]B6FMQF*.*>128H$,XH(IQ&#2&@=QA%)BGD4A%(=QI%--/Q2!2
MQP 23T I#&8I*N#3;MAD0G\2!1_95Y_SQ_\ 'A_C6?/'N7R2[%3&:3%7?[+O
M/^>/_CP_QH_LN\_YX_\ CP_QHYX]Q\LNQ1Q25>_LJ\_YX_\ CP_QI#I5[_SQ
M_P#'A_C2<X]Q\LNQ0Q32*OG2;[_GA_X^O^-']DWW_/#_ ,?7_&I<H]RDI=C.
M(HK0.D7Q_P"6'_CZ_P"--_L>^_YX?^/K_C4WCW*L^QGTM:']CWW_ #P_\?7_
M !H_L>^_YX?^/K_C2YEW'9]BCBEJ[_9%_P#\\/\ Q]?\:7^R+[_GA_X^O^-.
M\>X6?8HTM7?[(OO^>'_CZ_XTO]D7W_/#_P ?7_&GS1[BL^Q1HJ]_9-]_SP_\
M?7_&C^R;[_GA_P"/K_C1S1[BY9=BCBBKW]DWW_/#_P ?7_&C^R+[_GA_X^O^
M-'-'N%GV*.*3%7O[(OO^>'_CZ_XTO]D7W_/'_P ?7_&CFCW'9]BABC%7_P"R
M+W_GC_X^O^-']D7O_/'_ ,?7_&B\>X>]V,X@TE:7]D7O_/'_ ,?7_&FG1[[_
M )X?^/K_ (TFX]QZ]C/HJ_\ V-?_ //#_P ?7_&D_L>__P">'_CZ_P"-3==Q
MV91HJ]_8]_\ \\/_ !]?\:/['O\ _GA_X^O^-',NX[,HT]15T:/??\\/_'U_
MQIW]DWH_Y8?^/K_C5)Q[DM/L4P*6KHTJ]_YX_P#CZ_XT?V5>_P#/'_QY?\:M
M2CW,W&3Z%(4M7/[*O?\ GC_X\O\ C1_95[_SQ_\ 'U_QI\\>X<C[%+O1WJ[_
M &5>_P#/'_QY?\:3^RKW/^I_\?7_ !HYX]PY9=BNF<U*!SS4R:9>#K#_ ./#
M_&I#IUW_ ,\?_'A_C5*<>Y#A+L5&INZK9TV\_P">/_CP_P :;_9=[G_4_P#C
MP_QI>TCW%[.78A!IXJ<:;=_\\?\ QX?XTX:==?\ /+_QX?XU?M(]Q>SEV(.M
M-:K8T^Y_YY?^/#_&FG3[K_GE_P"/#_&AU(=P4)=C.;[U,ZU>;2[TG_4_^/#_
M !I/[+O?^>/_ (\/\:ASCW-%"78I$U&PXK0_LJ]_YX_^/C_&D.DWI_Y8?^/+
M_C4N4>Y24NQF=Z2M$Z/?=H/_ !]?\:;_ &-?_P#/#_Q]?\:SYEW+L^Q1%*!5
M[^Q[_P#YX?\ CZ_XTO\ 9%]_SP_\?7_&CF7<+/L4:7%7?['OO^>'_CZ_XTHT
MB^_YX?\ CZ_XU2E'N)I]BD!3L5<&DWO_ #P_\?7_ !IW]E7O_/'_ ,>7_&JY
MH]R7&78I 4M7?[*O?^>/_CP_QH_LJ\_YX_\ CP_QI\\>Y/++L4J*N_V5>?\
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M&JX;.X/_ "S_ %%,:QN3TB_\>'^-)U(=T'LY]BO&W-3'-"V%T/\ EE_X\/\
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M/<.1]BF%Q2D5:^Q7'_//]11]AN/^>?\ X\*%4CW&X/L4F6H76M$V%P?^6?\
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M[%4TP@FKWV&;^Y^HIWV*7^Y^HH]I#N2X2[&?L)I/+.:T/L<W:/\ 44GV*?\
MYY_J*?M(=T0Z<NQ1\K%.$8JY]BN,?ZO_ ,>%(+*X_P">?ZBGSP[HGDGV*>T
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M.Z(=.?8KTF*L_8+G_GE_X\*/L%S_ ,\__'A1[2'="5.?8K"C-6?L%U_SR_\
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M4>PIRJ%4*!@ 8 H->:VV[L]!))608'I1@>E%%(88'I1@>E%% !@>E&!Z444
M&!Z48'I110 8'I1@>E%+0 F!Z48'I2YHH$)@>E&!Z4M% Q,#THP/2BB@ P/2
MC ]*** # ]*,#THHH 3CTHP/2BB@ P/2C ]*** # ]*7 ]*2B@ P/2EP/2BB
M@ P/2C ]*** # ]*,#THHH ,#THP/2BEH&)CVHP/2EI* #CTHP/2BEH ,#TI
M,#TI:* $P/2C ]*6B@!,#THP/2EHI )@>E&!Z444 &!Z48'I110,,#THP/2B
MB@0F!Z48'I2T4## ]*3 ]*6B@!,#THP/2EHH$)@>E&!Z4M)0 8'I28'I2T4
M)@>E&!2T4"$P/2C ]*6BF F!Z4N!Z448H ,#THP/2EHH 3 ]*7 ]*** # ]*
M,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]***
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M/2BB@08%&!Z4M% !@>E&!Z444 &!Z4F!Z4M% "8'I1@>E+24 &!Z4F!Z4M%
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MH **6B@0E+113 **7%)0 4444 %%%+0 E%+10 E%+10 E%%% !1110 4444
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M*** "BC-% !1110 4444 %4M5_Y!LOX?S%7:I:K_ ,@V7\/YBDP1YQ2@4I%
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M[LIMB2/<;7QEH-[X<G\06]\6TJ#=YEP8)%QC&<*5W'KV%8?_  N+P'_T'?\
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M/S8U;C$B<,,>I4_^.TKA8^@JY+2?B9X/US5(--T[5_.NYR1'']FF7<0">K(
M. >]=;7R7\*?^2GZ'_UU?_T6U-L$?6E%%%,0E%%+0 E%%% !1110 4E+24 %
M%%%  :2EI* "BBB@ I#2TE !2TE+0 4444 %%%% !5/5O^0;+^'\Q5RJ>K?\
M@V7\/YBDPZGG.<TM %%>L>6)2TN*,4 !I,4[%!XH 0"O1-)_Y!L7X_S->=UZ
M)I/_ "#8OQ_F:Y,5T.K#=2Z:2EHKE.H2EHHH *2EI* "BBDH ***,4 %+110
M E+2XI: $Q12TN* &XI<4M% @HHQ2XH 2DIV*2@!*,4M% "8HI:#0 E)2TE
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MZK]GNXP&:/[/*^ 1D<JI'3WJE#\6_ L\@1->0$]WMY4'YE *\2^-/_)3;_\
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M4$]3Z55\.>+M#\61W$FB7WVI;<JLI\ITVDYQ]Y1GH>E<S\:O^28:A_UUA_\
M1BURO[.W_(/U_P#ZZP_R>B^H'M9KD]8^)/A#0=1DT_4=9CBNH_OQI%))M/H2
MBD ^W6N0^+OCCQ#I%W;^'=$L;B&6^3Y;Q!N>7/&R(#H?4]>> .#7A'B'0K_P
M[JS:?J8"W@C2210V[:6&[!/<\\^]#8'V<CK)&KH<JP!!]0:=4%E_QX6__7)?
MY"I\4P(KFY@L[>2XNIXX((QN>25PJJ/4D\"N0E^+/@:&?R7U^(OG&4AE=?\
MOH*1^M>=_M!:Q=K>Z7HR2LEH83<2(#P[;BHS],''UI_A+X):+KOA&PU2ZU:]
M-Q=PB4?9R@C3/\.""21T/(Y!I7 ]CTCQ!H^O1&32M2M;Q1]X0R E?J.H_&LW
MQ!X]\,^%K]+'6=2^RW,D0F5/(D?*$D Y52.JG\JPOA[\+HO VJ:A>M?"]DG0
M10/Y6PQIG+ \GDD+^5>8_M ?\CY8_P#8,C_]&RT ?1%E>6^HV%O?6LGF6US$
MLT3X(W(P!!P>1P1UK+\1>+=#\*1V\FMWWV5;@LL1\IWW$8S]U3CJ.M-\%?\
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MQ5_Q[1_C_,5T.*Y_Q3_Q[Q?C_,54/B0I?"SD,&D'-.I#Q7HG$(:=VH49I<4
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M\-O!'_"$>'#;3R++?7+^;<NOW0<8"CU ]?4FO/OV@M"PVE:_&G7-I,?S9/\
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MC%%>O=\GCE%4 ?\ CQ_&AZ#/6OV?-"RVJZ_(G3%I"?R9_P#V3]:]!^*>O?\
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M\5]#T;PO!HFNR2VSVI81SB(NCH6+<[02",D=.F*.HNAN_'[_ )$2Q_["<?\
MZ*EH^ /_ "(E]_V$Y/\ T5%7$?%SXCZ9XMM+/2M&\V2UAF\^2>1"@9MI50H/
M/1FSD#M7IOP;T.YT/P!#]K1HY;V=KORV&"JL%5?S"@_C1U#H>.?&G_DIM_\
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M=%S/I[BZ3']T</\ ^.DG\*YOX#>(8_\ A'-5TNYE"K8R?:5+=HV'S?@"I/\
MP*O8+FWBN[6:VG0/#,C1NI[J1@C\J^2$NKOP-KOB'2SOWR03Z<Y'&58\-^(
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M;X'TSP/9W-MID]W*EQ()'-RZL00,<;5%)XQ\"Z1XWM+>#5//C:W<M'-;LJN
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M-X3GO9+DW6JH))#)Y231A!DYVCY,X[=<^]>G(BQHJ(H55   Z 4ZBE8+G/\
MC#P?I_C;2(M-U*:ZBABG$ZM;,JMN"LN/F4C&&/:F>#O!>G>"-.GLM-GNI8IY
M?.8W+JQ!P!QM4<<5T=% QKHLB,CJ&5@00>A%>8P? ;PG!>QW(NM5<1R"3RGF
MC*'!SM/R9QVZY]Z]0HH *\[UOX->'M?U^YUB_OM5:XN9/,=5EC"=@%'R9P
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M%WIEV&-O=1-%)M." 1C(]QU%<GX3^%FB^#=9.IZ9?:F\IB:)DGEC*,IP<$!
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MHHI )12T4 %%%% !12TM PHQ2T4 %%%+2&%%%+B@!*,444 )BBEHIB&T4M%
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M444 %%%%, HI:* "BC%+0 E%+10 "EI*6@04E+24 %%+10 E)2TE PI*6B@
MHHHI %%%% !24M%,!**6BD 444M, I:2EH$+24M% "4M%% #312TE PHHHH
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M %%+10 4444 +1110 4444 )2&E-%,0E%%%,04444 %%%% @I*** "BBEQ0
ME%+10 "BBEH !1110 444"@!<4444 %%%% !1110 4444#"BBB@ HHHH ***
M* "BBB@ HHHI )12T4P$HI:* $HHHH *2EHH 2BBBD 4E+24#"BE%% "4444
M %)2TE PHHHI %%%% !1113 6BBB@052U;_D&R_A_,5=JEJW_(-E_#^8H8'
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M** "BBB@ I<TE%,!:=3:=0(6DI:#0 E%%% Q***2@ HHHI#"DI:2@84HI**
M%HI*6@!:***!!2444 +2TVE%,0M%%)0(,TM)WHH *2EI* "J6K?\@V7\/YBK
MM4M6_P"0;+^'\Q0]@1YU(*A)Q5AQFJS@@UZK/,3&,>:C-2'I3&K-FB(FIE/-
M-(J&:(NZ1_R$X?\ @7_H)KU4=*\JTC_D)P_\"_\ 037JHZ5RUOB.FE\(4M)2
MUD:!1110 M%(*6@04M)10,=12"EH&+124N:0PHI,T4 %%%% Q:***!!1110
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M%PL:7@_Q=I_C71#JNFPW,4 E:';<JJMD $_=8C'/K6_7EGP _P"2</\ ]?\
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M4#"BBB@ HHHQ0 4444 %)BEH-,0E)2TE "44M)0 AHHHH 2BEI* "G"FTX4
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MBBBF E&*6BD 4AI:*8"4444 %%%% A**6DI#"BBB@!**6DH **** $HI324
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M?_1%='?_  HO]>TZ6#Q'XQO=4E$96U+P".*%SQYAC5OG8#(!)[FM7Q'\._\
MA(/AYIGA3^U?L_V%(%^U?9]^_P I-GW-PQGKU./>F!V-B!_9]LN!CRE&/P%>
M,:5K8^&%QX]T%MJ16JG4M+5NA$F%5?< M&/P:O;((_)@CBSG8H7..N!7"^.?
MA=9>-]>TO4YKS[,;7"7$8AW_ &F(,&"9W#;_ !<\_>Z<4V"(O ?A]O#WPB*3
M*1>7EK+>7);[Q=U)&?<+M'U%9_P6LH-2^$)L;E-]O<2W$4B^JMP1^1KTN\M1
M=Z?<6@;RQ+$T88#.W(QG%87@/PC_ ,(3X8CT;[=]MV2O)YWE>7G<<XQN/\Z
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M %%%% !1110 4444 %%%% !2T44#"BBB@!:6DHH&+24M)2 *6DI:8!24M!H
M;24XTAH 2DI:2@0444E "T4E% "T4E% "T4E%(!PI1313J8!0:6DI %%%+0
M4444P"BBBD 4&BB@8AI*6C% "4E+10 E%+24 %+110 4X4VG4Q!0:*0T  I3
M2"EH&)2T44@"BBEH&)BDIU&* &T4M)2 0T4M(:!A1110 4444Q!2BDI10(6D
MI:2F(2BBB@0E+110 52U;_D&R_A_,5=JEJW_ "#9?P_F*3V&CSPFFL<T9I*]
M=GDD;CM5=^#5DU Z\U$C2+(324XC%)63-47-*'_$RA_'^1KU,=!7EFE$_P!I
M0_C_ "->J#H*Y:_Q'32^$,T48HQ61J9?B35WT#PY?ZLEHUV;2(RF%6VE@.O.
M#C R>G:LC27\/?$CPM9:K=Z7972S)\T<JK*T#C[R;L @@]^..>]=4\:21M'(
MH=&!#*PR"#V(KS&Y^#26>H37?A7Q-J7A_P XY>&$EX_H &4X]B32 YWXD>$-
M+^'EK:^*O"MQ+I5^ERL8MUE9DF!R2,$YQQR.F,\5M?$BX8^-_AG<S1M'OO6W
M+_=9F@X/XG]*TM'^$L$6LP:MXDUZ_P#$5W;G="+K(B0]CM);ICIG'M71^,_!
M=AXUTJ.SO));>:"02V]S"</$_J/4>U%@(?B1/';_  W\0/*P539.@)]6&T#\
MR*\S\4?\FT:/](/_ $(UUES\+-1UBPFM/$7C*_U6,1.MM&T(CCC<J0LCJ&S(
M5)R,D<BK^J?#C^TOAI9^#O[5\O[,(Q]K^SYW;3G[F[C/UH ZS1 !H.G # %K
M%@#_ '17E>GZI'\-?'7C'3YP%L+FU;6+)3P"PSN0?4DC_@ KUNRM_L=A;VV_
M?Y,2Q[L8S@8SBN-^(/PUM?'LNG2O?-92VA96=8MYEC;!*]1CIP>>IXIL"E\+
M='ET_P"'<VI7F3?ZP9;Z=SU.X';^G/\ P(U2^ \:3?#.:*50\;WLRLIZ$%5!
M%>F_98UL?LD($<0B\I !PHQ@5SO@'P=_P@_AQM(^W_;<SM-YOD^7]X 8QN/I
MZT6"YY?IWB*7X?>$_''A>20BZTR8C3B?O,D_"D?3(?\ X%7;Z:8_A;\&TN9;
M?S)[2W$TT><;IY&'!/H&8#/H*E\3_"^R\3>-M-\1RWAA%KY?GVPAW"XV-N7+
M;ACT/!X KK=;T:S\0:+=:3J$9>UN4V. <$=P0?4$ CW%*P[GGFCZ?\2/%NE6
MFJW/BVUT>UO8UGCM[.R61EC897YFY!P1W.,U0^$D(MOB%XW@_M";4#%)$C74
MS9>5@7!)/UR/PK8L/ACKNGVHTR+Q_JB:,H*I;1P*LJI_=$N21^ %:GA'X<VO
M@SQ)J.H:9>'[!>01QBR:,DHR@?-YF[YLG<?N_P 7MR!<Q?@I_P >/B?_ +#4
MW\A7J(KEO!/@[_A#H-4B^W_:_MUZ]WGR?+V;@/E^\<].O'TKJJ:%<**** %H
MHI*!BTZF4\4 %)0:* "EI** %I:2B@!:,TE% A:2BBF 4444 %%)12$+124N
M:!A1110 4M)0* '4E%% !1112&%%%%,!:2BB@04E+24 %)2TE "44&B@!#11
M10 444E "T4E+0 M%)2T --%!I*0"T444P"BBB@ I1244"%I:2B@!P-+312Y
MH 6ES244 +FBDHH&&:*3-% @HHI*8!24M!H ;2XHHH$%+24M !2TE&: %HI,
MT4 +1FFYHH 7-%)10 M)110,*6DI10 O:DI:0T --<_XJ.+:(_7^8KH#7/>*
M^;6/\?YBG'XD#V9RXD%.W9JN,TX$@UZ%SDL6@<BE(S42MFI!1<+!MI=N:<".
M]/ %%P.<\5KC2XC_ --A_P"@M14GBX8TJ+_KN/\ T%J*X,1\9U4OA'@TI-,S
M2YKT#SAV>*!29XH%,!:6BB@05I^'_P#D+1_4?^A"LRM30/\ D*Q_4?\ H0K.
MM\#-*7QH]"HHHK@.\**2B@!:*** "EI**0QU+2"E%(8M%<YXQ\86O@_38)Y;
M::\N[J86]I9P??FD/0#T'O[CUK-\.^/Y=1\0#P_KVA7&A:O)$9K>&642I.@S
MG:X Y&"<8[&D!VU+7/\ C'Q5!X/\/OJ4L#7,S.L-O:HV&GE8X"C@^YZ'@5M6
MDD\MG!)=0+!<.@:2)7WA&(Y7=@9QZX%(":BBB@8E%+12 2DI:2F AI#2FDH
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M?58,3Q1VS7" ' <!=PY[9JIX8U[_ (231QJ'V;[/F1DV>9OZ=\X% &S1113
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MU4M6_P"0;+^'\Q28'!8I M/Q28YKU#B$ I<4NW-&,4 -(Q1BE-)0 E=]I/\
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M10 4449H *2BB@ I*6B@!*2EHH 2DIU)0 VBEHH 04M%% !2T4M ##1BE-%
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MP?JVKG5M0T.VEO,[GD)95<^K*"%;\0:YGPT1XP\;:AXP:,-H^C*]CH\8X5V
M_>2CZ] ?0_[-(=SI/#,&@>!-$T_PU+JUA#>A SI+<*DD\K<LP5CDY/3VP*ZV
MO$/A]X2T?QGX U;7-=M$O-5U*>=GNI!EXB!QL/\ #@\_IT%=E\'=6NM7^&FF
MRWDC22PEX/,<Y+*K$+S[# _"A SO<TE%%,0N*2BB@ I*6DH **** #-)110
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MWMY=:G+;[I<DPHJJ0$/\.-^,CT%=!\$]0N;WP&]M<R/+_9][+9QN_4HH5A^
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MTO#XKNU$T:2F,RR'&0#C[U)L=CT>BO/_ (EZA?6DFD6]A>3VSS/(&,,I3/W
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MP;X5MO!OABUT:VD,OEY:68C!D<G);';T ] *WZ,46'<**6DH$%%%% !2444
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M_A9_@W_H-Q?]^W_PH_X6?X-_Z#<7_?M_\*+H+,Z^BN0_X6AX-_Z#<7_?M_\
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M;G\MOD^7]WVSRV>E1-Q2U\OS-\-"I*;5/>TM^UG?\+V\^QZ!17(?\+1\&?\
M0<B_[]O_ (5LZ'XFT?Q(DSZ1>I=+"0)"JD;2>G4>U7<YS5HI:2F 4&BB@ HH
MHH ****0!5+5_P#D&2_\!_F*NU2U?_D&2_\  ?YBA@<3@8I!2TAKTCD$-(1B
MBC-(!N*:U.S2$4AC"*[[2?\ D&1?C_,UP1%=[I/_ "#(OQ_F:Y\1T-:74N4=
MZ**YS4****  4M%%,1QOC+5_&]E<BW\+>'[>]C>')NIIU78^2,;21G P?QKD
MO@2]](WBM]38M?F_'V@L029/FW=..N:]@KRGX.?\A?QO_P!A9OYO2ZAT$^*E
MW?ZUXJ\.^!;&[DM8=2)FO)(CAC&">/IA7..YQ6;XV^%>D^%?"\OB#PK)=V&I
MZ8!/Y@N&;S%!^;.>AQSQ@<8Q5_Q+\G[1GA1FX5M/95)[G]]Q7:_$*18_AUXB
M9S@'3YE_$J0/U- S@_&WCK4;OX4:#/ITA@U'7S' 7C."O&'VGMD\?0U8N_@9
MH$/AM_LDMVNN11%TO_/;+2@9^[G !/IS[UQ%^K0?#OX7R2_*BZ@S%CV!ER/T
MKZ-D8+$[,< *2:-PV.'^$?B6[\2^!()M0D,E[:RM:RR-U?;@@GWP1GW%=U7E
M'P$!/A35I1]Q]3DVGU^5:]6IK83%HKPGQTCWWQ:GL#=R1*]LA10Y W! >@(Y
MZU3F\'W&<IJ$^>X,KKC]36%3%X6E)0JU%%]G?\TFC6&&Q%1.5.FY+RM^3:9]
M T5\XS>%]27*I-<-G/S)=-Q^9JE+X<U2+.ZYU/@9RLV[^5;PG0J6]G6@_P#M
MY?K8QG&M3^.E-?\ ;K_2Y]-TM?+_ /86I"/S6N-7\H'!?)Q^>*NPV&D[F%UJ
M/B&+&,;)D;\\@8KJ^I5VKQ5_1I_J<WUNBG:3MZIK]#Z3I*\$M?#WA&X4;O&.
MN0,3C;*O]0"/UK9L_AQX>OY-EKXXOI7_ +HG3)_"L94:L/BBT;1JTI?#)'L=
M%>7#X,6I&1XFU@@_[:_X4O\ PI>U_P"AFUC_ +[7_"LM330]/HKS#_A3%M_T
M,VL?]]K_ (4G_"E[;_H9M8_[[7_"B["R/4**\O\ ^%,6O_0S:Q_WVM'_  I>
MV_Z&;6/^^UHNPLCU#-)7BNI?#2*Q\5Z)I"^(-5:+45N"[EQN0QJ&&/KFMO\
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MC%%V%D>VTE>7_P#"E;;_ *&?6/\ OM:0_!:V_P"AFUC_ +[6C4-#U"DKR_\
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M)<O;2;U ^=>N/EZ<U?\ LWQ>_P"?S1/\_P# :+A8],HKS3[-\7O^?S1/\_\
M :/LWQ>_Y_-$_P _\!HN%CTRDKS3[-\7O^?S1/\ /_ :3[-\7O\ G\T3_/\
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MY_-%_P _\!H^S?%S_G\T7_/_  &@+'IE KS/[-\7?^?S1?\ /_ :7[-\7?\
MG\T7_/\ P&G<+'I@I:\R^S?%W_G\T3_/_ :7[-\7O^?S1/\ /_ :+A8]+-)7
MFAMOB[_S^:)_G_@-)]F^+O\ S^:+_G_@-%PL>F4M>9_9OB[_ ,_FB?Y_X#1]
MF^+O_/YHG^?^ T7"QZ9BEQ7D,NI?%*'Q#;Z(UYI/VNXMWN$PHV[5(!R=O7GI
M6C]F^+W_ #^:)_G_ (#1<+'IE(:\T^S?%[_G\T3_ #_P&C[-\7?^?S1/\_\
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MX?PJ\OG9C6,HR_B45\KHX*.W\#-@/X:LTR.<VB$"K,6F^ )2!_8^F(2<8>T
M_7&*ZJ72["8@R6D)(Z?(!5*7PSI<JD" H3W5CQ1R9E#:4)?)H.; RW4H_-,I
M1^$O!TH!CT72'R,C;"AS4H\$^%2,CP_IA'_7LO\ A4$G@V#(\F\E3UW*&_EB
MH5\/ZQ9AOLE^"N. &*Y_I1];QD/XE"_^%I_Y!]6PTO@K6]4T7O\ A"/"W_0O
M:;_X#+_A1_PA'A;_ *%[3?\ P&7_  JB1XI@VG/F=L?*WYTJZUKMJV+FP\T9
MYPA!_,<4_P"U::_B4Y1]8O\ 0/[.F_@G%_/_ #+O_"$>%O\ H7M-_P# 9?\
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MM_T+VF_^ R_X4?\ "$>%O^A>TW_P&7_"M^B@5S _X0CPM_T+VF?^ R_X4?\
M"$>%O^A>TW_P&7_"M^B@9@?\(1X6_P"A>TS_ ,!E_P */^$(\+?]"]IO_@,O
M^%;])19"/-_B)X5\/V'A*2>TT:Q@F%S H>.!5.#(H(R!W!KJO^$(\+8Q_P (
M]IO_ (#+_A69\3_^1*D_Z^K?_P!&K78TNH[Z&#_PA'A;_H7M-_\  9?\*/\
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M_0O:9_X#+_A1_P (1X6_Z%[3?_ 9?\*WJ*8KF#_PA'A;_H7M-_\  9?\*/\
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M:HYSM**6DQ3$%)2T4P$HI:,4 )12XHI )5+5_P#D&2_\!_F*O51U?_D&2_\
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M44Q'A?BK_DX;2/\ KXM__0:]PDMX9L^;#&^1@[E!R*\/\5?\G"Z1_P!=[?\
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M2EHHH **** $I:** $KC_AW_ ,@G5_\ L-7G_HRNPKD/AU_R"M7_ .PU>?\
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MHIY+0F CR0?O9/?T]*]FIBPQ1L62-%8]2% )HL%S%\&:(WAOP=I>D2$&6W@
MD(Z;SRWZDUN444P/"O G_)>-:^EU_P"C!7N<D:2H4D174\$,,@UX9X$_Y+QK
M/TNO_1@KW6DAR,.[\'^'[TDRZ7 &.260;#S]*YJ^^%%@[L]A?SVY))". X!S
MV/!_G7H5)71#$UH;2?Y_F<\\-2GO%'D\W@/Q5IY065[#<H"Q WXQ]0WK^-46
MNO$&AAAJ^B"XAQG>4*X_X&G'?O7LU(0",$9%*<Z-7^/1A+_MU)_>D$85:?\
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MVM(&%(:6BF(::*4TE !1110 4444Q!1244 +2BD%** .,\7?\COX)_Z_)_\
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M\UH=/7%?#_\ X_/%O_8;F_\ 05KM:XKX?_\ 'YXM_P"PW-_Z"M4<YVE+113
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MZ,$>8V-VX;#CK][%=)I7B5;B7[-?J()P<;CP#['/0UG_ !/_ .1*D_Z^K?\
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M37Q!_P!>A_F*Z*P_Y!UI_P!<$_\ 015=2>A8HI<4E, HHHH **** $Q12TE
M!1112 ***!3 6N/^'7_()U?_ +#5Y_Z,KL*X_P"'7_()UC_L-7G_ *,I#.PH
MHI13$&*0TM(: "BBB@!0:7--HH ?FC--S2YI .S29I,TF: %KBY_^2RVG_8#
M?_T=79YKBYS_ ,7DM?\ L!O_ .CJ&-'9$TTFC-)0 444F: %HHI:!"BEI**8
MAU(>E%!Z4  I*** "N,^)O\ R*<?_80M/_1R5V=<;\3?^12C_P"PA:?^CDI,
M:.Q/4TE*>II* $Q12T4 )2YI**!BT4E+F@8M+24M !1110 "EHH% "T&EHH
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MH_Q(T;51Y5X#8RG@K*=R'_@7^(%;%[X>T[4D\ZW*Q,P^62+!4_ATKR*F7X[
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M^1F\&?\ 84/_ *+:NRKC?&?_ ",W@S_L*'_T6U=G0 4444Q!1110(6DS110
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MZ]B]12T5Z!Q6&FD%*:2@ HS110 M%%%( HHHH **2EH&<A8_\E:UC_L%6_\
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MQ/-(:3%&:  G%:7A[_D,1_A_Z$*S#6IX>_Y"\?X?^A"LJOP,UI?&CT2BBBN
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M$?V>/:&M') VC&?GHZCZ'7T5SGV7QC_T%-&_\ Y/_BZ/LOC'_H*:/_X!R?\
MQ=,1T=':N<^R^,?^@IH__@')_P#%T?9?&/\ T%-'_P# .3_XN@#HZ*YS[+XQ
M_P"@IH__ (!R?_%T?9?&/_04T?\ \ Y/_BZ!'1T5SGV7QC_T%-'_ / .3_XN
MC[+XQ_Z"FC_^ <G_ ,70!T=%<Y]E\8_]!31__ .3_P"+H^R^,?\ H*:/_P"
M<G_Q= '1T5SGV7QC_P!!31__  #D_P#BZ/LOC'_H*:/_ . <G_Q=,#/\9_\
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MJF%EJX;><7M]Q[%2A'$U:=9.RG>_DTFW]]OQ/1:*YS[+XQ_Z"FC_ /@')_\
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MD# P/6L;[+XQ_P"@IHW_ (!R?_%UBZEI?BZ7Q-H=PUSI\KP?:-L\=JXCAW(
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M8VW_ $"-=_\ !;+_ (4?\)C;?] C7?\ P6R_X5T=% '._P#"8VW_ $"-=_\
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MJ'FL)$1>1U8C %6;O4M-U'3;<_V1KB7*PH!*NF2X)"CKQR*U/B7_ ,DUU_\
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M\)C;?] C7?\ P6R_X4I\8VW_ $"-=_\ !;+_ (5T5!Z4Q'.?\)C;?] C7?\
MP6R_X4?\)C;?] C7?_!;+_A71TAH YS_ (3&V_Z!&N_^"V7_  KEOB!XEM[[
MPU'"NG:O$?MUJVZ:PD0<2J<9(ZG' [FO3*XWXF_\BE'_ -A"T_\ 1R4F-'8J
MV]0X!&X9P1@BE-'<TE,!*4UQ7B3Q/J8UZ/P_H,2&](!DE< [<C/&>.G))JWH
ML'C&WU9$U>[M+FQ*DN\:@$'' &%4]?8UT/#24.>32NKVOJ<ZQ"<^6*;Z7Z'4
MT5P-WXDU[7?$,^E>&S#!%;9$EQ(H(.#@GD' SP,#/]&Q^(_$/AS7;:P\1O!<
M6]R0%N(U QSC(P!T/4$5?U*I;=7M>U];$_7(7V=KVOT/0**X'Q[XAUC2-3M(
M-,NO*62!G9?+1LD$\_,#V%='8Z\DO@Z/6I2"5MC(_NZC!'_?0-9RPTU3C4Z2
M+CB(.<J?6)M45YQX+\3ZYJOB06FHW?F0F!I-GE(OH0<@ ]#20:IXLUCQ)J]A
MINJPPK:32!%EB3&T.5 SL)_.M98&<9.,I)62?EK\C..-A**DDW=V^[YGI0I:
MX3P_XLU*^TW6K:^"IJ-A"[K(J@<@$<CID$?2M3P'JU]K6@/=:A/YTPN&0-L5
M> %XP !W-9U,+.FI.71K\=C2GB85'%1ZW_ ZBG"N*^(&NZIHJ::-,NO(:=W5
MSY:MG&W'W@?4U<TO3_&,-Z'U'6K2>WV,"B1*#NVG:<[!T.#26'?LU4<DKWM\
MOD/ZPO:.FHMV_7YG5T&O*_$&I^./#GV7[9K5L_VEBJ>3$AQC'7,8]:Z"9_%>
MB^&=8O-5U.VGG2-#;/"B_(<G=D; #G(]>E:2P;23YT[[;][=C-8M-M<K5M]O
M7N=I17G6B_\ "=:YI$&HP:]:QQ3;MJR0)N&&*]D]JM>--;UJR\1:5INDWJVW
MVP*GS1JPW,^T$Y!-+ZF_:>S4E?7OI;Y#^MKV?M'%VT[:W^9W=+7G5[KOB[PC
M<03:V]OJ-A*VPO$H4J>O8#!QGJ"#7H5O/'<VT5Q"VZ*5 Z-Z@C(-95:$J:4K
MII]4:4J\:C:LTUT8^J&L?\@N;_@/\Q6A5#6?^07-_P !_F*P-CGB*B(J=JA:
MO0.1,B89J%EJ=A4).#2-$0L *@<U8;%0.!0:(2V/^E)^/\J]$'05YW;?\?:?
MC_*O1!T%<U;XBX[!2TE%9@Q:=312B@D6BBB@!*0TO>DH \@^*5PGA7QWX<\9
M2^5<06ZM!):%P)2#GYD!ZXW?F!ZU@>.?'6E?$M](\,:6&MO/NDDDN[U1&L8P
M1@9/)Y_'BMK6Q9']H>S_ .$@\O[%]A'V'[1CR_,Q[\9SN_'%:'QP70?^$$<W
M/D?VCYB?8=F/,W9&<8YQMSG\*DHJ?$*W6]^*_@729R9+1"9-C<[B#W_[X%=S
M\0K.*^^'VNPS*&46<D@R.A4;@?S%>9>+)+O0M:^&_B/5%<10PI!=2./N-@9W
M>^"3^!KT'XD:_8:=\.M6G:ZA/VFU:& !P?,+C V^O7-,1'\)+M[SX8Z,TA):
M.-HLGN%8@?I7;5R'PMTV32_AMHL$RE96A\UE/;<2P_0BNPIH&>!^#;NVLOCG
MK,UW<16\6;E=\KA%SOZ9->T_\)%H?_0:T[_P*3_&O%O!MG;7WQSUF&[MXIXL
MW+;)4#+G?UP:]I_X1S0_^@/I_P#X#)_A20Y!_P )'H?_ $&=._\  I/\:/\
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M]#_Z VG_ /@,G^%&H"?\)'H7_0:T[_P*3_&E'B+0S_S&M._\"D_QI#X;T/\
MZ VG_P#@,G^%'_".:'_T!M/_ / 9/\* .3\"ZSI5HGB 3ZK8Q[]8G=-UP@W*
M<8(R>1[UUG_"1Z'_ -!G3O\ P*3_ !KDO NBZ3<IX@,VEV4GEZQ.B;K=3M4$
M8 XZ5UG_  CFA_\ 0'T__P !D_PI(;#_ (2/0_\ H,Z=_P"!2?XT?\)'H?\
MT&=._P# I/\ &C_A'-#_ .@/I_\ X#)_A1_PCFA_] ?3_P#P&3_"C40?\)'H
M?_09T[_P*3_&D_X2/0_^@SIW_@4G^-+_ ,(YH?\ T!]/_P# 9/\ "D_X1S0_
M^@/I_P#X#)_A0 ?\)'H?_09T[_P*3_&C_A(]#_Z#.G?^!2?XTO\ PCFA_P#0
M'L/_  &3_"D_X1S0_P#H#Z?_ . R?X4 '_"1Z'_T&=._\"D_QH_X2/0_^@SI
MW_@4G^-+_P (YH?_ $!]/_\  9/\*/\ A&]#_P"@/I__ (#)_A0,/^$BT/\
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MX2/0_P#H,Z=_X%)_C7FW_"KM=(R+RS(/^T?\*3_A5^N_\_=G^9_PKW/JU/\
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M-:=_X%)_C7F?_"KM=_Y^[/\ ,_X4?\*NUW_G[L_S/^%'U:G_ ,_5^(?6)_\
M/M_@>EGQ'H?_ $&=._\  I/\:3_A(]#_ .@SIW_@4G^->:_\*NUT?\O=G^9_
MPI/^%7Z[_P _=G^9_P */JU/_GZOQ#ZS/_GV_P #TO\ X2/0_P#H,Z=_X%)_
MC1_PD>A_]!G3O_ I/\:\T_X5?KO_ #]V?YG_  H_X5?KO_/W9_F?\*/JU/\
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M!G3O_ I/\:\T_P"%7Z[_ ,_=G^9_PH_X5?KO_/W9_F?\*/JU/_GZOQ#ZQ/\
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M%:[6N*\ ?\?GBW_L-S?^@K5&!VM)2TE, HHHH$%%%% !1110 52U?_D&2_\
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M*FN2JFVNJ6YZ?3)8HYXFBE0.C##*>A%><?V_\1/^@+%_WY/_ ,51_;_Q$_Z
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M+H?],O\ R!1]4_OQ^\/K7]R7W'I-+7F4>K_$BV+QR::L[!OOM"I_+:0,4_\
MM_XB?] 2+_OR?_BJ/J4OYH_>A?7(_P LON9Z32&O-_[>^(G_ $!8O^_)_P#B
MJ/[>^(G_ $!8O^_)_P#BJ/J4_P":/WH?UR'\LON9Z/25YQ_;WQ#_ .@+%_WY
M/_Q5)_;WQ#_Z L7_ 'Y/_P 51]2G_-'[T'UR/\LON9Z/17G']O?$+_H"Q?\
M?D__ !5']N_$+_H"Q?\ ?D__ !5'U*?\T?O0?7(?RR^YGH]<=-_R6.U_[ ;_
M /HZLG^WOB%_T!8O^_)_^*K%?5/%Q\;0W3::G]KBP:-8/+X,&_);&?[W&<T/
M!3_FC]Z#ZY#^67W,]B%%>;_V]\0_^@+%_P!^3_\ %4?V]\0_^@+%_P!^3_\
M%4?4I_S1^]!]<C_++[F>D45YO_;WQ"_Z L7_ 'Y/_P 51_;WQ"_Z L7_ 'Y/
M_P 51]2G_-'[T+ZW#^67W,](HKS?^WOB%_T!8O\ OR?_ (JC^WOB%_T!8O\
MOR?_ (JCZE/^:/WH/K<?Y9?<STB@5YO_ &]\0O\ H"Q?]^3_ /%4?V]\0_\
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M_LO4P54'".>=OI^%=769KNCIJML"IVW$8)C;U]C6=X<U>5V.FWI83Q\(6X)
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M,NS@*O3;GH/6N?\ %&G>*-*DL=;U:]M;EK:55C: 8*\[AG"+QQ7<>*+J.^\
M7EW$<QS6RR+]"0:524E5IUH2^+1V]?\ *PZ<8NE.E./PZJ_I_F<_X#\(Z?+I
M^FZ^TUS]K#.VP,NS(9EZ;<]!ZTSX>D#Q-X@)( #')/\ OM71?#__ )$?3O\
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M_P#8)G_]#6NUKBM0_P"2Q:+_ -@F?_T-:[6DAL****8!2444 +1112&%%%%
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MTWZR?^AFNNF_U$G^Z?Y5R/PL_P"2>:;]9/\ T,T=1'8TM%%,04444#"BBEH
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M<BA))VV;W0OJZYW.+:OO;9G,^.])OM9\/I:Z?!YTPG5RN]5X ;G)('<5N:7
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M"?\ )>-:^EU_Z,%>ZUX5X$_Y+QK7TNO_ $8*]UI(J0444M,D2EHHH ***3-
M"YI*** %%+2"EH 0TE*:2@#C_A__ *OQ%_V&KC^8KL*X_P"'_P#J_$7_ &&K
MC^8KL*2&PHHHIB"BBB@ I1244#%IPIM+FD,=124M Q:7--I<T@..\+?\CYXS
M_P"NUM_Z*KLJXSPO_P CYXS_ .NUM_Z*KLLT( HI,TM,!#3:4TE BO?6<=]9
MR6TH^5QU]#V-<UX=NI--U*;2;G(RWR^S8_D176US7BO3B\2ZA",2Q8WD=<=C
M^%>7F-*4''%TE[T-_./5?J>A@:D9WPU3X9;>3Z,Z2BL_1=1&I:>DI(\U?ED
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MPV,;F7&&^I!&??-=K0(\)\5?\G#:1_U\6_\ Z#7NM>%^*O\ DX;2/^OBV_\
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M*X_X<_\ ()UC_L-7G_HRD,["EHHIB"@T4&@84444 %)0:*0PHHI:0Q**6DH
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ME-)0!Q_P_P#]7XB_[#5Q_,5V%<?\/_\ 5^(O^PU<?S%=A20V%%%%,04E+24
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M();,Y?-.5JBP6-2I&:]%1.%R'J3FI4YI% !I<^E6D0Y$JD**4/S46#U)IIE
MXI@C%\9G.D1?]? _]!:BH_%TF_28A_TW'_H+45YN*_B'=0^ CH%&*4#FNPXA
M:7%&*6J  *7%)S3AF@D::U?#O_(7C_#_ -"%99K4\._\A>/\/_0A6=;X&:4O
MC1Z+1117 =P4AI:2@ HHHH ****!BTM-I: .&^,.J2Z5\-=2>%BLD^RW!!YP
MQP?TS7,Z'\0_"WA7P]!H^G:3?W]K:Q!+NYM;7=$7Q\Y+=^<UN_&VSEO/AE>F
M)23!+',P']T-@_SKH/ D6FQ^ M'73EB^R-:(3M P6(^;/OG.:0SCM/;P[I/P
MN\3:WX.NYF@NHY)3&[?ZB0C! 7^$\C\A6O\ !W2+;3OAMILL<:^=>JT\SXY8
MECC/T  KSW0K);JW^*=IHJ[M,*GR GW2PW' _ &O1O@_J4&H?#/25B8%[96@
ME4'E6#'^8(/XT@.=\*1QZ%\>_$>DVJ".UO+07'E)PJO\K9Q_P)OSKUVO(_#;
M+JW[0?B&_MV#06=F(6=>07^1<?HWY5ZWF@#QO]H+_D$Z-_UTF_DM>K:'_P B
M_IO_ %ZQ_P#H(KRG]H D:7HQ'423?R6NRTCP'X8FT6PEDTB)G>WC9B7?DE1D
M]:!]#LJ*YK_A7_A3_H#0_P#?;_XTG_"O_"O_ $!H?^^W_P :8CI:*YK_ (5_
MX5_Z T/_ 'V_^-'_  K_ ,*_] :'_OM__BJ .D-)7-_\(!X5_P"@-#_WV_\
MC1_P@'A7_H#0_P#?;_XT".DHKF_^$ \*_P#0&A_[[?\ QH_X0#PK_P! :'_O
MM_\ &@#I:*YK_A7_ (5_Z T/_?;_ .-'_"O_  K_ - :'_OM_P#&F!TU%<U_
MPK_PK_T!H?\ OM_\:/\ A7_A7_H#0_\ ?;_XT"*7C/\ Y&;P9_V$V_\ 1;5V
M=>8^*?!WAZSUSPM!;Z7$B76HF.4!FPR;&.#SZX-=3_PK_P *_P#0&A_[[?\
MQH Z6BN:_P"%?^%?^@-#_P!]O_C1_P *_P#"O_0&A_[[?_&@#I:*YK_A7_A7
M_H#0_P#?;_XT?\*_\*_] :'_ +[?_P"*H Z6BN:_X5_X5_Z T/\ WV_^-'_"
MO_"O_0&A_P"^W_QH Z6BN:_X5_X5_P"@-#_WV_\ C1_PK_PK_P! :'_OM_\
M&@#I:*YK_A7_ (5_Z T/_?;_ .-'_"O_  K_ - :'_OM_P#&@#I:*YK_ (5_
MX5_Z T/_ 'V_^-'_  K_ ,*_] :'_OM_\: *GQ.&?!<G_7U;_P#HU:["O,OB
M!X-\/:;X4>YL],BBF%S H8,QX,B@CD^AKIQ\/O"@Z:-#_P!]O_C1U#H=-17-
M?\*_\*_] :'_ +[?_&C_ (5_X5_Z T/_ 'V__P 50!TM%<U_PK_PK_T!H?\
MOM__ (JC_A7_ (4_Z T/_?;_ /Q5 '2D!@01D'@@URWA1S#>7UJVW(.??()%
M2_\ "OO"G_0&A_[[?_XJL5?#^E2^(VTF[M$ELUSY41+87Y<CG.>!7EX^\,10
MJ?WFOO1Z&#M*C6I^5_N9WU%<U_PK_P *_P#0&A_[[?\ ^*H_X5_X5_Z T/\
MWV_^->J>>=+17-?\*_\ "O\ T!H?^^W_ ,:/^%?^%?\ H#0_]]O_ (T@.DI*
MYS_A7_A7_H#0_P#?;_XTG_"O_"O_ $!H?^^W_P : +'C3_D1]<_Z\I?_ $$U
M;\/_ /(MZ7_UZ1?^@BN4\6>!_#5GX1U>YM]*BCFBM)'1P[95@IP>M6M%\">&
M+C0=.FETB)I)+:-F)=^25!/>D4=G2US7_"O_  K_ - :'_OM_P#&C_A7WA7_
M * T/_?;_P"- RUX0U6YUSPM9ZC=[//FW[M@P.'91Q] *W:Y&Q^&WAJUM(X9
M[$7<BYS-*S!FY)YP0..GX59_X5]X4_Z T/\ WV__ ,56<%)02EN=&*E3E7G*
MBO=;=O2^ATM%<U_PK[PI_P! :'_OM_\ XJC_ (5]X4_Z T/_ 'V__P 55F!T
MU!KF?^%?>%/^@-#_ -]O_P#%4?\ "OO"G_0&A_[[?_XJ@1TM%<U_PK[PI_T!
MH?\ OM__ (JD_P"%?>%/^@-#_P!]O_\ %4P.EHKFO^%?>%/^@-#_ -]O_P#%
M4?\ "OO"G_0&A_[[?_XJ@1T4W^I?_=/\JY'X6_\ )/--^LG_ *&:LR_#_P *
MB%R-&AR%./G?_&N9^'G@[P]J?@>PN[S2XI;AR^YR[ G#D=C3 ].HKF?^%?>%
M/^@-#_WV_P#C2_\ "OO"G_0&A_[[?_XJ@1TU%<S_ ,*^\*?] :'_ +[?_P"*
MI?\ A7WA3_H#0_\ ?;__ !5 '345S/\ PKWPI_T!H?\ OM__ (JC_A7OA3_H
M#0_]]O\ _%4#.GHKF?\ A7OA/_H#0_\ ?;__ !5'_"O?"G_0&A_[[?\ ^*I
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M_B:Z3%% '.9\;?\ //P]_P!_)_\ XFC/C;_GGX>_[^3_ /Q-=)10!S6?&O\
MSS\/?]_)_P#XFC/C7_GGX>_[^3__ !-=(:*!G-Y\:_W/#W_?R;_XFC/C;_GG
MX>_[^3__ !-=)10!YCK8\4?\+!\,-*NC?:_+NA!M>79C8-V_C/3IC\:ZK/C7
M^YX>_P"_D_\ \36?K_\ R5'PA_URO/\ T6*[.D@.<SXU_P">?A[_ +^3?_$T
M9\:_\\_#W_?R;_XFNCHIB.<SXU_YY^'O^_D__P 31GQK_<\/?]_)_P#XFNCH
MH YS/C7^YX>_[^3_ /Q-&?&O]SP]_P!_)_\ XFNCHH YS/C7_GGX?_[^3?\
MQ-&?&O\ SS\/?]_)_P#XFNCHH YW/C;_ )Y^'O\ OY/_ /$T9\;?\\_#W_?R
M?_XFNCI:!'-Y\;?\\_#W_?R?_P")HSXV_P">?A[_ +^3_P#Q-=)13 \X\?MX
MK_X0+6OMR:+]E^SGS?(>4OC(Z9&,_6MZS/C7[#;[4\/[?*3;EYLXP,?PTGQ+
M_P"2:^(/^O0_S%='8?\ (-M/^N*?^@BEU#H8>?&W_//P]_W\G_\ B:7/C?\
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M.4O_  E=W_T*6O\ _?F+_P".5T@I: .9/BN[_P"A3U__ +\Q?_'*3_A*;O\
MZ%/7_P#OS%_\<KIC24"/,?!6OW5HFN!?#FL3^9JL\A\J-#L)(^5LN.174?\
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M5=_]"GK_ /WYB_\ CE=)12&>87OB"Y?XHZ5=_P#".ZNKQZ;,GV=HT\Q@7'S
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MO7\:\C -X:M+!2V6L?1]/D>GC$J]*.*CN])>O?YFC7'_  Y_Y!.L?]AJ\_\
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M12T !-)F@TE '(?#[_5^(_\ L-7'\Q78UQOP^_U?B+_L-7'\Q799H0V%%%%
MA"*2G4E "44N*2@ HHHH **** "BBB@#D/"__(]>,O\ KM;?^BJ["N/\+_\
M(]>,O^NUM_Z*KL*2&Q110*6F(::2E-)0 M%)2T %(\:R1LCC*L""#W!I12TF
MKZ,:T.1\.N^G:W<Z;*<!L[1GN/\ $5UU<CXEB:PUBUU).A(SCU'_ -:NLBD6
M:))$Y5U##Z&O*RQ^R=3"O[#T]'JCTL>O:*&(7VEKZK1CJ6C%+7JGG''6/_)6
M]9_[!5O_ .AM785Q]C_R5O6?^P5;_P#H;5V%" *2EHIB$HHHH$+VI*7M2"@!
M:**6@!IIM.-)B@!**7%% '%:A_R6+1?^P3<?^AK7:UQ6H?\ )8M%_P"P3/\
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MO6/_ -!%+J4]BXPXJ(U8-0,.:8D-HI<4F*!A1110(*6DI: "EI*6F 4M)2T
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MO_0:]VKPGQ5_R</I'_7Q;?\ H->[5**84E+24Q!2T44P"BE%'>D,2@TII#0
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M44 >$^*O^3A](_Z^+;_T&O=J\)\5?\G#Z1_UWMO_ $&O=JE%,****8@HHHH
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MBBB@ I:** %I:2B@!:*2EH ,4F*6B@#C?"__ "/?C+_KM;?^BJ[&N/\ "_\
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M9ETZ=HY!R$<\?@>HJO!K^I:1.+?5H7D3'#?Q?4'H:2S"K0?+C(<O]Y:Q_P"
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M/_P9-_A6=K__ "5'PA_URO/_ $6*[2A(#F_^$03_ *&'Q'_X,F_PH_X1!/\
MH8?$?_@R;_"NDI*=@.<_X1!/^AA\1_\ @R;_  H_X1!/^A@\1_\ @R;_  KH
MZ*+"N<Y_PB"?]##XC_\ !DW^%'_"()_T,/B/_P &3?X5TE%%@N<W_P (@G_0
MP^(__!DW^%+_ ,(>G_0P^(__  9-_A71T46"YSG_  B"?]##XC_\&3?X4?\
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MCQ2XHL!S?_"'I_T,/B/_ ,&3?X4?\(@G_0P^(_\ P9-_A71TM%@.<_X0]/\
MH8?$?_@R;_"E_P"$/3_H8?$?_@R;_"NC%%%@.<_X0]/^AA\1_P#@R;_"C_A#
MT_Z&'Q'_ .#)O\*Z2BBPSF_^$/3_ *&'Q'_X,F_PKE_ GAE+S3=4;^VM<@\O
M5KJ/$%\4#;7QN/'+'N>]>F5Q_P ./^03K'_8:O/_ $92L!=_X0Y/^AA\1_\
M@R;_  H_X0Y/^AB\1_\ @R;_  KI**=A'.?\(<G_ $,7B/\ \&3?X5%-X'MK
MA D^N:_*H.=LFH%A^1%=32&DXQDK-:#4FG=,Y:?P7;^4!:74JN!C][AMWU(Q
M7/ZGI^MVLR/=7VJQP)\O^BWC(C#\.E>DTA 8$, 0>H->94RJFI<^';IR\MOF
MMCOAF-2W)72G'SW^3.%TZQT[4,)_PDOB.&7^Y)J3#/T..:U_^$/3_H8O$?\
MX,F_PJ74?"UG>%I(/]'E/]T?*3]/\*RA+K^@C:ZF>W7@9^9<?7J*CZWB<-IB
MH77\T?U70OZM0Q&N'E9_RR_1]2__ ,(>G_0P^(__  9-_A1_PAZ?]##XC_\
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M[-\8_P#0QZ?_ ."W_P"SKIJ*+ >9>'K'Q,_C#Q2D&N64<Z30>=(UCN$A\OC
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MA/BK_DX?2/\ KO;?^@U[M4HIA124M,D2BBBF,6BDI: "BBB@ I*** "BDHH
MXS7_ /DJ/A#_ *Y7G_HL5VF:XK7_ /DJ/A#_ *Y7G_HL5VE( HHHI@%%%% "
MT444 %%%+2 *6DI:!A12TE '*?$S_DFOB#_KT/\ ,5T=A_R#;3_K@G_H(KG/
MB9_R37Q!_P!>A_F*Z.P_Y!MI_P!<$_\ 012Z@611110,*2EHIB$I*6B@!**4
MTE @HHHH&+0*04X4 %<?\./^03K'_8;O/_1E=A7'_#C_ )!.L?\ 8;O/_1E(
M#L:**,TQ!2&BBF 4444 )12TE A*2EHH 2BBB@#/O]%L=1YFBP__ #T3AO\
MZ_XUQ4]G-IGC!-+TYW>\:R-TLF OR!]I7/?GGTKT2N-F_P"2RVO_ & W_P#1
MU<&(R[#UGSM6EW6C_ [*&.K4ERIWCV>J+%IXIFMI#;ZK;LK+P75<$?45TEK=
MV]Y$)+>59%/H>GU':FWEA:W\>RYA5QV)ZCZ&N<N?#-W8R_:-)N&R/X"<-^?0
MUS7QV$W_ 'L/NDO\S>V$Q.W[N7_DO_ .LI:Y.S\536TGV?5;=E8'!=5P1]17
M1VM_:7R[K:=)/8'G\NM=F&Q]#$:0EKV>C^XY:^#K4-9K3NM5]Y9I*4TE=ARA
M110: "EI.U':@ HH%% !7&?$[_D4H_\ L(6G_H]*[.N-^)W_ "*4?_80M/\
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M-X+_ .PH?_1;5V=<9XT_Y&;P7_V%#_Z+:NSH ****8!1110(2BE-)0 E%%%
M!112&@04444P..^)O_(ER?\ 7U;_ /HU:[ UQ_Q-_P"1+D_Z^K?_ -&K77GK
M2&% HI: "BBB@04M)2TP"DI:2@ HI:* $I:** ,+QK_R)&N?]>4O_H)JWX>_
MY%K2_P#KTB_]!%5/&O\ R(^N?]>4O_H)JWX>_P"1:TO_ *](O_012ZAT-*EI
M*6F 4"BE%  *6BB@!:*04M "BBBB@ HI:2@!DW^HD_W3_*N0^%?_ "3O3?K)
M_P"AFNOF_P!1)_NG^5<A\*_^2=Z;]9/_ $,TNH=#LJ2EHI@)12TE !28I:*
M$HHHH **** "BBC- !7%^ /^/SQ9_P!AN;_T%:[.N+\ ?\?GBS_L-S?^@K2
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MZ/3_ /D&VG_7!/\ T$4NH%BBEH- Q**6DH$%)2TE,!#12TE !1113$+0***
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M8*]VKPGP'_R7G6OI=?\ HP5[M20V%)1FBF2)12TE, HHHH$%+12T )3J2EH
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M4Q"TE%% @HHHH ,T444 <;XM_P"1V\$_]?D__HHUVE<7XM_Y';P3_P!?D_\
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M6DH$)12FDH *2EI* "DI:2@1Q_Q-_P"1+D_Z^K?_ -&K77GK7(?$W_D2Y/\
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M-C_^*H_X2[PU_P!#%I/_ (&Q_P#Q5,1LT5C?\)=X:_Z&+2?_  -C_P#BJ/\
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MZ&'2?_ V/_XJ@1L45C?\)=X:_P"AATG_ ,#8_P#XJC_A+O#7_0PZ3_X&Q_\
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M_P!=K;_T5788KD/"X_XKOQE_UVMO_15=A0AL*#0*#0,;2T4M(84444 %%%%
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M_09T7_P!D_\ BZ/L?C;_ *#.B_\ @%)_\773T4 <Q]B\;?\ 09T7_P  I/\
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M $&-%_\  *3_ .+KIJ6@1S'V+QK_ -!C1?\ P"D_^+H^Q>-?^@QHO_@%)_\
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MB\;_ /09T7_P!D_^+KIZ7-%@.8^Q^-_^@SHG_@#)_P#%T?8_&_\ T&=$_P#
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M)!J\@<Q(5!? R1DG@\8%=_BN*\ _\?GBS_L-S?\ H*T#.QHIU)BF(*2C%%(
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MEZ=_T#[3_OPO^%']F:=_T#[3_OPO^%6J*!E3^S-/_P"@?:?]^%_PI/[,T_\
MZ!]I_P!^%_PJW10!4_LS3_\ GPM/^_"_X4?V9I__ #X6G_?A?\*M48IB*O\
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M:^EU_P"C!7NM)#9R_P#PKOPK_P! L_\ @1+_ /%4O_"N_"O_ $"S_P"!$O\
M\573T4[$G+_\*[\+?] L_P#@1+_\51_PKOPM_P! L_\ @1+_ /%5U%+18+G+
M_P#"N_"O_0+/_@1+_P#%4?\ "N_"O_0+/_@1+_\ %5U%%%@N<Q_PKOPK_P!
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M*KL:20-G+_\ "N_"O_0+/_@1+_\ %4'X=^%?^@6?_ B7_P"*KJ*#18=SEO\
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M_P"1+D_Z^K?_ -&K77GK7(?$W_D2Y/\ KZM__1JUU](84HI*6F(*,4H%. H
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MK4R "O6/.!4P:E Q0,4CMBF(4L!2!Q4+N32 TKCL7(&S*!7H%>=VI_?+^/\
M*O0ZXL3\?R.N@O=%HI*7-<YL+FDHS10 4M-I: "BDHH 6E-)1F@ I***0PHI
M*6F(\)\"?\EYUKZ77_HP5[K7A7@/_DO.M?2Z_P#1@KW6DAR"BDH[TR1:***
M%I1244 +2TE+0 M+24M "4444 <=\/?N>(_^PW<?S%=C7&_#W[GB/_L-W'\Q
M794D-B4E+24Q!2444 %%%% !1110 4444 %%%% ''^%_^1[\9?\ 7:V_]%5V
M&*X_PO\ \CWXR_Z[6W_HJNQH0V&***6@!E+BEHH'<3%&*=BBD%QM%+24 )24
MZDI@)1FEI*!'(6/_ "5G6/\ L%V__H;5T]U96][&4N(5<'U'(_&N8L?^2M:Q
M_P!@NW_]#:NOJ)1C-.,E=#4G%IQ=F<G>>'+FQE^U:5*Q*G.S/S#_ !J;3O%
MWBWU%/*D'!DQ@9]QVKI:H:EI%KJ<6)5VR#[LBCD?XUY<\OJ4&ZF"E;O%_"_\
MCT8XV%9*&+5_[RW7^9>!#*&4@@C(([TX5QG_ !,_#$X))GM&X[[?_K&NFT[4
M[;4X?,MWY'WD/!6NC"X^-:7LIKEFNC_3N8XC!RI1]I!\T'U7Z]B[1117><1!
M?_\ (.NO^N3_ ,C6%I%DFH>%WMVZEV*GT;L:Z445R5L'&M5526W*XV]3II8E
MTZ;A'>Z=_0XC17E/B*TCF!#PAHSGKPK?_JJ_>K/HNO-J"Q-);39W;>V>H_,9
MKJ**XJ64^SH\BG[RES)VVTM\]#JGF//4YN31JS7?K\M3DM1U%_$'E6=C;R[=
M^YF<=.W..@YKJ8(A!;QPJ<B- H_ 8J2BNS#825*I*K4ES2E;6UM%T2.:OB%4
MA&G"/+%>=]7YG-2?\CS#_N?^R&JUU?1:=XOGN)E=D"@80 GE!ZUUU%<T\MDT
M^2=GS\^U^EK;F\<=%-<T;KEY=_QV.5<S>(]3MW2!X[.$Y+/WYY_$X%/U=$D\
M5V"2*KHR*"K#(/S-73T4WEG-!J<[RE)2;MO;I;L)8_EDG&-DDTE?OUOW.:\4
M6=K;Z9&\-M#&QF )1 IQAO2M^T_X\H/^N:_RJ:BNFEA(TZ\ZT?M)*UK;7,*F
M(<Z,:;Z-N]^YS7A7_CYU+_?7^;5TM%%5@\-]6HJE>]K_ (MO]18FM[>JZEK7
MM^"L%%%%=)SA1110 M%%% '&>+?^1W\$?]?D_P#Z*-=I7%^+?^1W\$?]?D__
M **-=I0AC6I,TIIM A:**6@ I***!A2444@"BBC% PHI:* "BBB@ HHHH 6B
MBB@0#K3J:.M.[4P U@>)O]7#_P "_I6\:YWQ4VVVC/IG^8IQ^)"E\+.<,H08
M%1"3(J!6+MDU*%S7HIG%84G-1E,T\H12A30T"97D7 J#/-79(\BH##4-&B9B
M:_\ \>"?]=1_(T4_Q$NW3X_^NH_D:*XJ_P 9TTOA.@91CI4#P!@:E60,*7M7
MI[GF;%!H2*8"T9K1*BHG@!I.(U((9U(P>M3\$50:,J>*?%.5.&H3&T/F@!'
MJYX<C9-9CR../_0A4:,&&1S6CHZ?\3.%L8RRC_QX5E67N-FU%VDCN*6G!*<
M!7G6.X:%IP6C(I-U #N!3JC!R:D[4P&]::5HSS3@: &45)@&F%: $I*6DH$%
M%%+3$%%%%(#QK]H+_D%:-_UTF_DM>K:'_P B_IO_ %ZQ_P#H(KRG]H+_ )!6
MC?\ 72;^2UZMH?\ R+^F_P#7K'_Z"*74KH7Z6DHIB%I***!A1112 **** "B
MBB@!:*** .,\:?\ (S>"_P#L*'_T6U=G7&>-/^1F\&?]A0_^BVKLZ "BBB@
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MC9O^2RVG_8#?_P!'4@.SI:2ES3 **3-+F@ HHHH ****8A:*2E/2@0E% HH
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M)@=G1113 **** "BBB@ S2TE% A:#11VIB 44"B@!*XSXG?\BC'_ -A"T_\
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MNQS20V+13<TN:8@I,4N:* $Q28IU+0 S%%/HH 913L48H ;2TN** ..\+_\
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MO17#_P#"W?!6?^0L?^_$G^%'_"W?!7_07/\ WXD_^)H"QW-%</\ \+=\%?\
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M;:;5&$L-O&CCR)."% /:BX[,]$I:X?\ X6YX*_Z"S?\ @/)_\32_\+=\%?\
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M$C-RL2K#ZT_RP*:)A3'D!Z&G8GF8DLFP<5V^D'_B6P_\"_F:X)CNZUWND?\
M(-A_X%_Z$:YL1T-Z;N7J3-*:8:YBQ<T9IN:2@!]%-S1FF(7%&*!2T -Q2TZC
M% AM+2XI,4 )1124 >&>*\_\-!:7CJ98 /KLKW3O7D?C+P1XHOOB+'XDT6&U
M80>6\1FE !95QR*T//\ B[G_ (]M%Q]1_P#%5**9Z925YIY_Q<_Y]=%_,?\
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M_B?_ ,BE'_V$+3_T<E8WG?%[_GVT7\Q_\56=K.F_%/7;%;2\MM(\I9HYAL8
M[D8,O?ID"AL:1Z[WHJ.+S#"AEQYFT;\=,]ZDIB%%**2G"D,6EI*6@8444M(!
M*::=2&F TTE+1B@0VC%+0:8A!3NU(*6@0E%%% !2&E-)0,;5+5O^0;+^'\Q5
MZJ6K?\@V7\/YBDQHX +FGA0*7&*6O51P!GM2]*04$YIL0[=BD+#%1D[N!4T<
M?K2 =; _:%/U_E7H>*X.)0'%=[FN+$_'\CIH?"%%)FBL#8,TE+24 %**2E%
M :*4TE "4E+10 W%+112&%%%+3$>$^!>?CMK(Y/-Q_Z'7NN*\%M;'Q7X9^)>
MK:]9^%[R_CEEF1%*LJLK-G<" :ZK_A8'CO/_ "3VXQ_UT?\ ^(J4-JYZCBDK
MS#_A8'CK_HGMQ_W\?_XBC_A8'CG_ *)[<?\ ?Q__ (BG<5CT_-+FO+_^$_\
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MZ_Z)]/\ ]_'_ /B*/^$_\=?]$^G_ ._C_P#Q%%PL>I9I:\M_X6!XZ_Z)]/\
M]_'_ /B*!\0/'7_1/;C_ +^/_P#$47"QT=A_R5O6/^P5;_\ H;5V&:\7@\2>
M-X/%-WKH\"7+27-M';F+<^%"$G.=O?/I6M_PL'QW_P!$]G_[^/\ _$4)CL>I
MT5Y;_P + \=_]$]G_P"_C_\ Q%'_  L#QY_T3VX_[^/_ /$47%8]2HQ7EO\
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MMQ_W\?\ ^(H_X3_QW_T3V?\ [^/_ /$47"QZA17E_P#PG_CO_HGL_P#W\?\
M^(H_X3_QW_T3V?\ [^/_ /$47"QZA17E_P#PL#QW_P!$]G_[^/\ _$4?\+ \
M=_\ 1/9_^_C_ /Q%%PL;OBW_ )'?P3_U^3_^BC7:UY%_;/B_7_%WARYO?!MS
M90V-TS,^6(PZ["22HQC.:]>H0,::2E-)3$.HHS10 444&@!*,TE% PHHI0*
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MGFFD4#&TM)10 4444"$-%+24Q *7-%5[Z\AT^PN+VX;;#;QM+(?15&3_ "H
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M8Q"&R6YF:ZCW $G&,_B*T=!M?B5'K5NVNZAHTNF@GSDMXR'/'&./7% '1_\
M"*>'/^A?TK_P#C_PH_X13PY_T+^E?^ <?^%;%% &/_PBGAS_ *%_2O\ P#C_
M ,*7_A%/#G_0OZ5_X!Q_X5L48I 8_P#PB?AS_H7]*_\  ./_  I/^$3\.?\
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M/3/' \'^,OLLES<1>99WMNNU9>O&./0]AR*]-H R1X4\.?\ 0OZ5_P" <?\
MA3QX4\.?]"_I7_@''_A6I2YH$9@\*>&_^A?TK_P"C_PI?^$3\-_]"_I7_@%'
M_A6F#2YHL!E_\(GX;_Z%_2?_  "C_P */^$3\-_]"_I/_@%'_A6KNHW46 R?
M^$3\-_\ 0OZ5_P" 4?\ A2'PIX;_ .A?TK_P"C_PK6W4TM18#(/A7PY_T+^E
M?^ <?^%-_P"$4\.?] #2O_ ./_"MCK6'XE\7:+X2MHI]9N_(64D1@(6+$=0
M* )/^$4\.?\ 0 TK_P  X_\ "E_X13PY_P! #2O_  #C_P *X;X??$:[\;^/
M-9@B8IHT%N'M8FC ;.X#<3UYYXS72_$CQ+<^$_!5WJ=D5%YO2.#<NX;F8=N_
M&:- U-7_ (13PY_T -*_\ X_\*/^$4\.?] #2O\ P#C_ ,*XA+3XPO&K'4]
M4L =IB.1[=*]"TE;]-(M%U1XGOQ$HN&B&$+XY(]LT 4_^$4\.?\ 0 TK_P
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MHHIB%I:2E[4" 4AXZTHZ5P'Q<&O7/A.+3- M[F2:_N5AG>W0L8XL'<3CH"<
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MGX_RKT.N'$_'\CJH?"%+24M8&H4444 %***!0 48I:2@!#24ZB@!N**=28H
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MCUZC%>'^)_#+?".]TKQ!X;O[P6#W2P7MI/+O5E;O^0/TXKV^-UDC5UZ, 10
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M]A70Y"J6)P!R37SK;^+_  WXD\8WNM>-9+R6UMY2FFZ>(&>)4_O,!U/3CUH
MZS1A>_$OXF6?BN.UFM?#VD*4M))5P;A^>0/J?PP.]3Z]X7\9ZK\5[G5=*DCT
MRTCLUMHK^4+)E>"VU>N<DC)':NAT/XI^$M6U&TT?36N5EF/EPQ_9&1!QTZ8
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MK_D'1?C_ #-<]?H;T>I?SQ3:=VI#6!L-I:3O10 M&:** #-&:;10,=FBDHH
M6BDHH$+7DWQQ/DQ^%+I^(8=54NWIT/\ 0UZQFN=\;>$[?QIX9GTF>0PNQ$D,
MP&?+D'0X[CJ#[&DQHZ-G54+$@*!DDUY1\ _G\.:Y<+_JY=4<H?4;5_QJ%]"^
M+<VB_P#".OJ&C"T*>0VH!F\TQ]/3KCOC/O7H'@[PQ;>#_#-KH]LYD\H%I)2,
M&1SR6QV_P H Z"BFYI<TQ"TM-S2@T .I*6B@!IHI310 E)3J2@!M!8*I9C@
M9)/:G8I" 1@]#0!P/AGP!X&>:\UBR2VUM[N9V>XN&2X56)R548VCK]:Y/5M'
ML_ GQJ\-2Z GV6WUC=#<VD9^3&0,@=AR#CU6M&#P/XU\$:I>MX(O-/N-)NY3
M+]AOLCRF/H1^6<C@#(XK3\-> ]<G\7+XN\:7]O<ZE"FRTM;4'RK<<C//U/YY
MR:0ST>EHQ1BF 4444#%HI** "BBB@ I:2B@!:Y/XF_\ )-/$/_7F]=96)XQT
M>XU_PAJFDVKQI/=V[1(TA(4$^N*0&?\ #3_DFOA[_KR2N-^#K"#Q/X[LWXF7
M4]Y!ZX+2?Y_&O0?"&D7&@>$-*TFZ:-I[2W6)VC)*DCTS7%Z_X%\1Z9XTG\6>
M";RT2XNTVWEE=Y$<IXY&/7 /;GOS0,I?'(B9?"EFI_?3:HNP#KV'\V%>MUY=
MI/@;Q/KOC.S\3>-[NR_XE_-G8V>2BMU!)/OSW)('85ZC0A"44M(33 *2C-)0
M M%%% A:2BB@ H-%!H \J^(7_)6?A_\ ]=Y?YI7=>++?2[OPQ>VFLWPLK"X0
M12SF41[02.-QX&>E8GBKPC?ZWXX\+ZU;2P+;:5([3JY(9@=N-O'M6]XF\/VO
MBCP]>:->%EAN4QO7JC Y5A]" :0S&TKX;>#+30TLH=&L[J"1 3/,@DDD!_BW
M]?RQ7(_"9'T+QQXN\)P3O+IMG*);=7.?+R<$?D1G_=J73]%^+/A_3TT6POM%
MO+.)?+M[NXW>9&@Z<>P]0:ZGX?\ @;_A#[2\GO+S[=J^H2>;>76.&/)P,\XR
M2<]\T@.SHHHJA!1110 F**4TV@84M)10 444R3S/*?RL>9M.W=TSVS2&<%XJ
M^(D]MK#>&?"FGMJWB#'S@?ZJV]W/MGID#U/:G>"? %SI.K3^)O$E]_:/B*Y7
M!D'W(%/\*?AQGCC@>_+>'? GQ+\,->OIVH:#YU[,9IYIE9W=C[[>G4X]S76Z
M':?$R/6K9M;U#1)--#'STMXV#D8.,<>N*0'/^!_W/QS\;02<22(LBCU&5/\
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M10Q!-)FI*,S7?^/%/^N@_D:*37/^/)/^N@_D:*XZ_P 9U4OA.J"G%-P34N&
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MQG'E&]C#9^F<U;U+5+32]+FOKJ[M[>!$R)II B9/W>2<<G% &D#2YKS'X/\
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M)IFKV%ZR\LMM<I(1]=I-<1\7]4O],LO#C6%]<VAEU>*.0P2M&70@Y4X/(]J
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MM4@6ZGN+O,C?O!N &3Q@$<]2?TI^$[9O!_Q5U+P5 [R:!>V9O+>WD;=Y)/4
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MV%;'A;38/"OQUU71=)W0:9<Z:+EK4$E%?*\C/U;_ +Z(JW\ O^2<O_U_2_\
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MV)-+H/J<1XKUGX2W?AZ8^'B=.UFV7S;&>UMI8F\Q>0"V.<XQD],YS7>><_Q
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MP=+H-JE@+_S8KB*#Y4=0 /N]._Z UH>'/^3A_&'_ %X0?^@0TOC[_DKGP_\
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M_P#06HZ#ZG2S^&_#OP_\-WNM:3I%NE[IUA*4FVY>0A<_,>^2!D_6O)?!VO\
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M5&U2I'4X ]CU!.:ZGP3XIU[Q7?ZA>7.CC3] 7 L6G1EGF/J<G&.#T'< $X-
M'GGPK\(:5XCU?Q)>:S +V&UU&18+64DQ*[$[G*]"2 HY]/I6NFCV?A#X_:+:
M:%']CLM5L93<VT9.PE5D(P.W**?S]:L?!+_F;?\ L*M_6I_$?_)PW@__ *\9
M_P#T":@#$\1^'M&E_:*T&RDTRU:UO;&2XN83$-LTA%P2[#N<J#GV%>U00QVT
M$<$*+'%&H1$48"J!@ 5Y%X_NX?#7QD\,>*M1CG32XK.2WEN$C+JK8E ''?\
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M3UOPW/::-JDNF:B")(+B-V4;A_"Q'.T]._K@XK<6G9J6RTCS5=9^+/V06/\
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MIM/!H(S0 RDI:2@!0<4\-D<TRDH >5]*93@V*<0&'% $=+1C%% !FDI<48H
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M.E(:4=*0US&XVEHHH **** $HHH- PS29HHH **6B@!**.** "BBBD 4444
M+FBDIU,!RTIIJTM A#UI*#10 AHH-)0,,T444 %%%% !112T  HHHH 4444E
M A:!110 M*#3<THH >*#24IH 0TTTXTTT )2TE*#0 M!HHH 2DI:* "EI**
M%S2YIM)F@!V:0BDS2YH ;2TM)B@ I:2EH 44M(*6@ H-%)0 4E+10 E&*6B@
M I:2B@!:*3-)F@!V:2DHH&%%%)0 4444 %%)10(44_M3!3QTH 4=*::<.E,-
M "4M)10 4M)10 4444 &:,4N*7% " 4X"BE I7&D)1BG8I:5QV&XHQ3L48HN
M%AF*0BGXI,55Q6&8YIV*,4H% A*,4M% #:3-*33: #-4M6_Y!LOX?S%7:I:M
M_P @V7\/YBA[#1Y\IYJ88Q58'FIH\FO6/+N2J,FI M(HP*>M [CE&!S3@.*3
M%.'2D4F.C^^*[RN#C/[P5W=<.)^/Y'90^$6BDS2U@:A1110 4M)2B@ I#2TA
MH 0T4&BD 444"@ I:*,TP$)IN:4TE(84444 %%%% !112@4 *!FG'@4G04TG
M-,04=Z*.] #FZ4VG-T%-H 3I2@YI#24 .(IE/#4%<T ,HHHI %%%% !2TE%,
M HHHH 4&G!J92T /ZT$4T'%.!S0 HI:**R9:"EI*6A +244E,!:*04M #&%1
M]ZE:H^]4B6%%%%4(6BBB@04E+24 %%%**!A1110(!3NU-[T[M0 C=*:*<W2F
MB@8ZBBDH$%%%% !1110 4E+0:!B444E "T9HHH 2EI*44 +1244 %/[4RGCI
M0 A--S2M30: 'T4F:6@04AI<TV@8M%)2YH **,T4 %%%% !3@:;10"8ZBDS1
MFE8JXM%&:2BP7#-**0TJB@5Q#7/^)U!@B!]_YBNB(KG?%+!;>(GL#_,5</B7
MJ1/X6<ZFU%J.6;/ JKY^_@&E0^M>H>8.)SUJ)\ 5(>M0R$"A@AN>**9N%(7%
M1<NQG>(3_P 2^/\ ZZC^1HJ+7F!L4'_30?R-%>?B?XAW8?X#M=NWFF'GFI6Y
MIC+Z5W,Q3(S2XR*,4 T "]:E!P*C')P!S5F*V9N7.!2 B"ESP*OV,!CO+9B>
MLJC]:C:6* ;5Y-/LY"]];DGCS5_G657X&:0^)'8T4E+7"= 444E PHHHH **
M** "@T44 --(:4TAJD2Q,TN:;13$.HIN:6@0&D-+10 VDIU(10, <4X'-,HS
MB@"2FD4H:EH 9WIW:C%*1Q0%Q#]RH\U+CY*BI#"EH%% @%%***8!1110 4X&
MFT4 /(S3,8-.!I2,T ,I*4C%)0 4H)%%% #P0>M(5Q24X-ZT -HIY7/2FXQ0
M(2EHHH **** "DHI<4 )2XHQ2T -Q12FDH *6DHH 6BEHH ***3- "TA-)FD
MH *<*;WI] !FE#4TTT&D,ES1FH]U+F@!^:0FF9I": '$TPFC-)0 4444#"BB
MB@!12TVEH$+0:** $I*6C% "BE%-IPI@.IAI],/6@!****0!1113 *2EI*0!
M112XH&-JIJ@_XETOX?S%7L53U;_D&R_A_,4 ><Q0A1TJ5F5!UJ&2X51@51>=
MF/6O4;2/-47(MRW0Z"JCR%^]1YSUIZBLW)LT45$%%24W%.%%A-DD0KT[2O\
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MI*6N)G0)1112 ****8!1112 ***2@!#333C3#5(3"DHHJB0HS110 N:*2C-
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MHS0 W!I,5)1Q0!'BC%/XHH ;2TN*,4 )2TN*,4 )12TE !112T -I*?BFD4
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M !1113 ****!#S]VFTX_=IM "&FTZFT %%%% !2@XI** ).&%,(Q0#BG\,*
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MBB@048R:4*32DA1Q3 <5^6F$$4[)VYI WK0 TTVI"H/2F$$4 )1112 ****
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MN+.Y R II-C2,@,#]:T='E$=Z,GK2OIL<@W1N*K?9)[602 < U+6A1=^(/\
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M*3@=\5WNM>!?"^G^$=62VT6U54MI9E#*6VN(R PR3@UD_"U<^+/B!_V&'_\
M0Y:[[Q#"TOAG588D+RR6<R(HZDE" *!'GWPH\(^']0^'NCZE=Z/937C-*QGD
MA!<E9G .?8 ?E7J)8+TKS;X/:WIO_"M;"U:^@CFM'E29'D"E2TK,,@GH0PYK
MT>A >2?%(PIXW\/7'B2.XE\)K&PE$88HL_S8+A>WW/? ;KR*W[+P9\.O$<$-
MWIEAITZ1,KJ]H^,$'(# '\PPKJ+[5]$CO3I&H7MFEQ+$)/LUPZCS$)(SAN",
MJ?RKR;XD:1H'A/[+K7A2Z73M>-PB):V4N1,#U_=CH.GL>F.: -CXZ>?_ &#H
MGV8D3_VFOED#.&VMC]:Z2Q^%_A6'3_)O=,CU"ZD&;B[N69I97/WFW9R,GTQ6
M!\8"[:7X7:10KG5H2P'8[3FO413 \N^%43Z+XH\7>&(IY)-.L+A'MED.3'NW
M9'Y!?RSWJG;V,?Q,^*&N1:PSS:+H#B"*R#E4:7+ LV#SRC_H.E:'@3_DJ_CS
M_KI#_P"S52\/7D'@?XM>);#5G6VM]<D6[M+F4[4<[F.W/3K(P_X#[BD!?\:_
M#71+7PS=ZOX?M/[+U;38VN8)K1F4G:,E2,\Y ..^?Q%8WB^\G\8_!#3O$P&V
M_LW2X9D&,,KF-R!V&?F_"NN^(?C+2M(\&:C$E]!+?7EN\%M!$X=V9UV[L#L
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M:SJ?]L3F&X>Y:ZD\U!)(N%#$Y "X!&>N?6D![%IYNSIMJ;\1B\,*>>(_NB3
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MZK)I&CZ00E[>P#,TLIS\BG^'!##C^Z2<\"@#U"E KQ_Q OB7X5-9ZW'XCO\
M6]#:=8;VUU!O,D0'^)7//8^G..N>-;XR^(+S1/!^D:KI5Y-$?[4A8F"4IYL?
MER-M)'53@<'BBX'I=%>:CP5XM\16T>HZMXUU+3+J91(MEIW[J*WR,A#@@N1W
M)I?AQKNO2:SX@\(^(+P7EYI++Y5Z  SHW3/O]T\\\\]*+@=D_B2Q3Q;%X:Q*
M;^2T-YD ;%0-MY.<Y)]NU;&:\#_X0ZYG^-MSI+>*==67^S?/-_'<[)SR/DR
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MK^I/\A0!P>BZAXF^)FLZO+!KLNAZ'87)MHXK-%\^4CNS'E>,'\<8XS6)X_\
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ME_-MWQS@9Z?4Y/N*ZGX>^*I?&7@ZUU>X@2&X9FCE5/NEE.,CV-<_+\./%%[
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M]H!\,> /#>H6*[I_#5Q"Y8?Q*2 _YOM)_&I="F3Q5\;=1U>,^99Z181PP/\
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MA^9'T)I ;I4'I7D7PPN8KSXD^.[BW</$]R"KCHPWOR/:M6W^'&NK"ME=>/\
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M-!UV>355*D27$PVNS9)##'0C/&/2BP'-CX46; %?%WBP@C((U(<_^.5M>$?
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M/^'NG:[X.TG48/%?B9!+;('C@U *D;@89%&W@!@0!Z"O3-$T#3?#^A0Z-80
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M6GH'_(7B^H_]"%9G>M/0?^0O%]1_Z$*QK?PV:T?XB/0<TM-I17G'H"T49HH
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M%Y*J=K''+9(P.>V:W*\S^+G_ !_>#O\ L,1_S%>F4 )12T4P"BBB@ JGJO\
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MT49/)]JM;C0,DQ2;::&I<T"%Q1BDYI.: '8HQ3,FC)H&/P*,"F9I<T .P*7
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M_G5_XD?\DBU/_KUB_P#0DH L?#+1+72/ FER11C[1>VT=S/,>6D+J&&3Z $
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M1Y)&"/J<>W7!%("S\684T;Q#X5\46BB.]COUMY70<RH>=I]> P_X%2_M _\
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MPDO[06J:5//,FG26$4E[%$Q7SXU5,(2.0"Q7-%PL>NV?B30]0NS:V6M:=<W
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M "%&E?\ )Q&N?]@=?YPTACYOA_XMTY#<:+\0-4DN5Y6+4&,L;GTY) _(UJ^
M/'5WK]S?:%KUJEIK^G'$T:\+*HXW@?7'3CD$=:[6O*-1"V?[2.DF#:#>Z<QN
M,=R$EQG_ +]I3 UO%6HWUO\ %[PA907MS':7$<IF@25ECDP&QN4'!_&O0SD5
MY%\2+C4K3XI^$I](LDO;](93#;O($#GG/S$@#C)_"MC_ (2;XHG_ )D2R_\
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MMU,1FKKFD/IO]HIJMBUCDC[2+A#%D=1NSC]:=I^K:;JR,^FZC:7JK]YK:=9
M/KM)KQ;X.>$+'Q-X>EO->5[VSM+EH;.TD8B)&*AG? ^\3N Y]#6C\1?#-GX
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MR.5(/4>M788TM[>."-=L4:!%7.< # '- '#?"K7-,N/AMHT:7UN)((A!*C2
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MVUEKZK<6EW*=J%P<E23P.68?@OK7IEMX;TFT\17FOP6FS5+R-8YY_,<[U4*
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MH+97:,C !.:XO7KN'P=\>;37-3/DZ9JUC]F^TO\ <C<8')[?=3/INS7=:%X
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M=:7";)8]Q7</3(((_ T#,7X>?\DZ\/?]>$7_ *"*Y/Q%_P G"^#_ /KQG_\
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M\'_)Q]S_ -@4?^A+7JA0=JR1X:TI/$C>(5M/^)JT/V<S^8W,?'&W.WL.<9H
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M& )/N.: ..\!R?\ "5_%_P 2^++12VEPPBRMYL8$C?(,CUX0GZ,*R["Q\/\
MAKXO>([#QAI]A);:Q)]LL+O4($>,$LS,H9AA<ER#[H/:O:-/L;+2;&.RTZUB
MM;6(82*)0JC\!576M!TGQ%:"UU?3X+R%3E1*N2I]5/4'W%%@.?O+#X8Z?;&X
MN[#PI%$/XF@M^?IQS^%8OQQ2.'X6RPPQK'%'<0*B(,*H!P  .@K8L_A-X&L9
MQ-#X>@9P<XFDDE7_ +Y=B/TKH==\/Z9XFTQM.U>U^TVC,',?F,G(Z<J0?UH
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M@^);QH="CM1+#;M(8XYY#G[QX[Y'7^''<UV-G\+O!=A>I>6^A1"9&WJ7ED<
MYSG:S$?I6SKWA;1/$\*1:SIT5VL>=A;*LN>N&4@C\Z8'G?Q%LO VA^#[ZTL-
M+THZK-%MMX[>!'F7')?(!90%!)/M6_IL,EQ\"%AA0O+)H#HBCJQ,) %;&F>
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MI<4M,! *6BB@ HHQ2XH$)3AQ1TII:@!^12$TS- - Q2*;3Z,9H 93UII%*M
M$IZ5$W6I&Z5&W6@0E%%% PJEJO\ R#9?P_F*NU2U7_D&R_A_,4F"/-!3J;2Y
MKU3RQ::PI:* &&F&I*8U0RTRWIA_T^+\?Y&O40Q%>6:9_P A&+\?Y&O4JY*_
MQG71^$>&I>#4=+FL38>5II% :G9H 92KUIV,T!>: 'CI32<"G]!434 -)S2
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M%;I)2Q6#[5''G^[C=Q^+&D^'-W-8?L]W5[;G;/;VM]+&?1EWD?J*5RDC9O\
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MH&B7>JW:2O!:QF1UB +$>P) _6@#0W&EW50T?5(-;T:SU2V21(+N)9460 ,
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MDVWVD74MC$!U!D; (^C&0_A5C6=#;P)X<\ ZX$*RZ5.L=\1UVS?-)GZ$LO\
MP*K6N_#K6K_XH/-#; ^&KZ[M[V\?S$ W1JV5*YW')+=OX_:O1/&VAGQ)X-U3
M2D4---"3"#Q^\7YDY[?,!18#C9B/$?Q]@53OMM!L/,..5\UQQ^CJ?^ U?U_P
M/K-OXEN/$_@_5H[+4+E0+JUN5W0W&!^.#QZ?B.:B^%/A;6M#AU74/$5OY.J7
MLL:8,BN3'&F <J2.23W[?2KFJ:C\1--UFZ%AH>G:OIC/FWVW(AE1<=&+$ _@
M*8BOH?Q!U&+Q#;^'/%^C'3-2N"1;SQ-N@G/L>V?J>HSBO0:\SM_#WBSQ9XOT
MC6_$]I9Z59Z0S26]I!*)9'<X^\PR,95?RQCG->FA:$)G&^,?!$^OZE9:YH^I
MOIFNV*E(9]NY74Y^5AZ<GUZG(-80\>^)?"%S!;^.]&C^QRL(UU6P.Z//^TO;
MOZ'C@&NC\3W?C>PU:*?PYI^GZEIQ@"R6TTOERB3<V2K$@8(*]<]#7*ZYI/CS
MXAP0Z3J^DV6@Z3YRR3N+E9Y7 [+MR._?'U]0 ^.9@ET'01(08&U--Y'(*E6S
M^E>IXP !P!T KRKXW6:3Z!X?LLE8Y-3CBR.H!5A5_P"U_$_1K8:;#HVFZSY8
M\N+4?M(C)4<!I$9@2WKBCJ!1T,"+]HW7EMN$?3E:<#INQ#S]>GYFL'PVOBZX
M^)'CF3P]-I*3K?%)CJ0?)3?($V;0>,#G/^S7>?#[P9>Z#<:AK.N7276NZFVZ
M=T^[&N<[1_G'  Z<T_$G@_7=.\8/XM\'36_VRX39>V-R<1S@ <@]CP.XYYSR
M12&9?B3PK\2_%6BRZ5J-YX8%O(RL3$9E8%3D8)0U5^+%M+:>%O!VFWCK)&EW
M#%<G)*,RIM)R>WWNM;7]K_%6^!@C\-:3IK'C[1/="15]P%8G]*Z7QKX3M_&?
MAN;2IW\J3<)()MN?+D'0X].2#[$TP.A    & .@%</\ &'_DE>M?]L/_ $?'
M6597OQ7T>UCTZ30=-U8Q*$6^%VJ;@. 6!8$G\!FM/Q;I'B3Q#\)[K3;BVMY=
M>N%C+PV[A8\B96P"QQPH[GMWH$;-E_R3>W_[!"_^B17-_ __ ))M!_U\R_SK
MK;6QN8_!,.G/'BZ73E@,>X??$>W&>G7OTK$^%>@ZGX;\$1:=JUM]GNUGD<Q^
M8K\$\<J2* ,;2O\ DXG7?^P.O\X:K^&\3?M!>*7N.9HK)!%NZJN(N@_+GW]Z
MV]/\/:I!\9]6U^2UVZ7/IJP1S^8IW.#%QMSN'W6Y(QQ5?QAX,UB3Q/;>+O"=
MQ!#J\,?E3P3\)<ITY/KCCG'0<@BD,]"I,UP&GZO\2[S4K2&[\-Z9I]IYR?:9
MVNA(3'D;M@5C@XSC([UWV:8K'EWQ9A2Y\1>!8)!F.7551AZ@O&#7J.:X7Q[X
M?U36O$'A"ZT^U\Z'3]26>Z;S%7RT#H<X)!/"G@9/%=Q0,\S^%O'BKQ^!T_MA
M_P#T.6E\"?\ )5_'?_72'_V:M+P%X>U31?$'B^ZU"U\F'4-2:>U;S%;S$+N<
MX!)'##@X/-'A3P_J>E^/_%NJWML(K&^>-K>4R*=X&<\ Y'7N!2 Y>*\NOAU\
M4=;C73KC5K;7C]L$5@/,N(\,Q.8^N,NX[ \<]15ZYM-9^(7C?P_J3Z'>Z/I&
MBS&X\R_41RRON5@ G4<HOZ\]!62EWXBU7X@ZKXK\ V:7]I-&MI++?@)"S*%'
M[OYPQ'R@YXYS6I?^-?B/X9M3J?B'PSICZ9&RB9K24AU!.,_?;N1VH F^-L*7
M&D^'X)!E)-5C1A[%6!KU     8 Z 5Y[X]TR^\9Z'X:O-"MC<Q?;(;TY=4*Q
M%<Y.XCU' YKT*@#S+P'_ ,E7\=_]=8O_ &:G:#_R7_Q=_P!>,'_H$-:7A+P]
MJFF?$+Q9JEY:^79W[QFVD\Q3Y@&<\ Y'7N!3M)\.ZK:?&#Q%KT]KLTR\M8HX
M)_,4[V5(P1M!W#E6ZCM0!DP?\G$7/_8''\UJIXQ-UX-^*-CXKM[?[?%J47V.
M2SB;]^6 '*+U;HO\CC(-;\7A[5%^,T^OFUQI;::(!/YB\OD<;<[NW7&*YKQ9
M<ZEKOQ*L[OP7"U]J>@H\-UYRJ+:,L&&TL6&6Y8$#TZ\&@"3Q9)KGQ.M;30[#
MPUJFEV0N5EN;S5(O)V  CY5S\W7MZ?ET'Q<C$7PFU>-<[46W49]!-'61<^)/
MBQIEM+>WOAG1I;6!3)*L$AW[1R<?O#V]C5[7KJ?XE?!RXET2T9KJ^$>VW9U4
MADF7>-S$#C:3GO0!U?A&".V\&Z)#&,(EA ![_(.:XJ?_ ).(MO\ L#G^;5W^
MA6TMGX?TVUN$V30VL4<BY!PP0 C(XZBN4F\/:HWQF@U\6N=+733 9_,7A\GC
M;G=WZXQ0!E^+O^2T^"_^N<W_ *"U=YKNC6GB'0[O2;T-]GN4V,5/(YR"/<$
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MFW N;<2?=<]QGMT!_#\10BO_ (G:I$+&30]-T9F&V74&N5FVCNT<:D\^F>*
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M<M$PCD(2($*V,$\'IZ&O1VZTE(9S_CJWGN_ >NV]M#)-/+92K'%&I9G)4X
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M$^](C;?N_P#?)'&3\P..*WM"UV7QM8ZA9:EX7U32K5X/*<:A'Y?FAP0RJ.N
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M2V>WIWJ;Q!\1M#\/ZJVE/#J%[J**&:VLK4R, 1D'G [CH:ZR***&)8HD6.-
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M+3L4 <TK .%(W2E%!JA$6*4+2XI:+ )BBBC- A:,TS=1F@0I-)FDHH ****
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M><H4G8V.H..AS0!Z/M-. KS>7P1XNU:W%_>^.=1LM3D7>+>SREO"QY";01N
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MNV\2:%:ZQ9I+';W*ED68 . "1R 2.WK7(^*Q+XN^%+:S'J%YIRG2Y+R2"V<
M2GRMVQSC)7((XQD&L+X;>"+B\\)Z)JR^*M?@0_O?L45V5@^60_+M_NG'(]S3
M$;&IZC?)\>-%TY+VY6QDTII'MA*PB9LS?,5S@G@<^PKT<_=KQGQW-JL/QST.
M/1!$-1GTL0Q/*,K'N>8,Y'?:N3CVK9U7P!XHMM.GU"R\?:S+J<2&0)*^()"!
MG;L!PN<>_P!*9+/2L4F*XKPEXRNM9^&#^(KB 27MM!,9(T&!*\8)X'O@<>]<
MQX5T;7/'^@)K][XZU.WEN&?%MIDOE)!AB I /)XSSV(Y/6@1ZW1FL'PMHFKZ
M);W,&JZ_-K 9P8'FB"M&N.03R2<^I[#IS6]3 X[Q#XMOX/&.E>%M"AMI;ZX_
M?7<EPK,EO .^%(^8X.,GT]:V?$WB;3?">C2:GJ<A6)3M1$&7D8]%4=S7"_##
M_B=>,/&'B>4AVDN_LD#9SB-3T_(1_E4'CJ(:[\9/"7A^Z&^R2)KMHV^ZY&\X
M([\1 ?B:FXRW:^*_B5KT0O-'\*Z=9V+C,9U&5B[CL<!E/Z58L?B3J>DZS;Z3
MXXT,:3)<D+!>0OO@<],$Y..W.3C/..M>C5QOQ5TJ#5?AUJHF52]M']IB8]59
M.>/J,C\:8'2ZUK%IH&BW>JWS%;:VC+O@9)[ #W)( ^M>>VGB[XC^(K8:EH/A
MG3;?39 6@-_*2\J]B,,N,_3'OWJQ#97OCOX$P6:R#[;<V2*K.?OO$XQD_P"U
MY?7WJIX1^)^G:786?AWQ3!/HVIV4*6Y-Q$1&X4;0V1TR!WX]#0(ZSPEK/BC4
MI[NW\1^'DTQH I2:.8.DN2> .>F/7N*ZBHK:Y@O+=+BUGCGA<922)PRL/8C@
MU-3 Y[Q;XDN?#EC ]EHUWJMW<R^3##;C@-C/SMSM'7MV[5R=SXA^*5A;/J-Q
MX8TB2TC7>]M#,QG"CKSN()^@->FUF^(-<L_#FAW>JWT@2&WC+8)Y=NRCW)XI
M#15\)>*+/Q?X>@U>R5D5R4DB8Y:-QU4_H?H16S//%;023S2+'%$I=W8X"J!D
MD^V*\_\ @QH]UI/@%9+N/RWO[E[Q8\8VJP55X]PN?H14/BVZN/&_B0>!]+F>
M.Q@VRZU=1_PIU$(/J>__ -8BE<8GA'XEW_BGQ]-IB64$.C/;27%I*R,)I55@
MFXG=C!(;C%;7C#Q=?^$=7TFXN(;9_#MU)]GNIMK"6WD.<-G.-OX9X/M7.:=;
M0V7Q]-G;1+%;6^AK'%&HP$4%< 5UWQ#TE-9\ :U:,@9A;--'_OI\ZX_%<?C0
M!U"X(!!!!Z$4I%<A\,M6?6/AUHUU*Q:58?(<GJ3&Q3)^H4'\:K_%6'53X&N;
M[1K^[L[NP9;G=;3,A=!PX.#R,'=@_P!VG<#M<4<5D^&=:C\1>&=.U:/&+J!7
M8#^%NC#\&!'X5PF@:QJ/B#XG>)-4BN[QM%T:(VT5I'*PCFE ()VYPQRK]NZ^
MU*X'J6:3->.>$K/7?B5I<VN7OC34+'=,R)9:7)Y0@ Z!L')]>>W>N^\*^']8
MT%KN/4O$ESK$#[?LXN(P&BZYRW);/'?MTIW Z2EQ29HS0(**2BF(*HZM_P @
MV7\/YBKI-4=6/_$NE_#^8H>P(\Y:3--!R:8*<&Q7JW/+L2BE4;C3,Y%68%XR
M:9))&N*M1#BHE Q4JL *L1+QBNNTC_D%P_\  O\ T(UQK/78Z3_R#(?^!?\
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M/!Y_P ZCQJ-=?PG>Q>&XO,U211'%\ZH5!(#$%B "!G'-<Q_P@7C/_HI5Y_X
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M!OI!M6VNY"$20-A@S 9.!DC YXZ9KK" 1@]*\L^ 7_).7_Z_I?\ T%* .7\
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M_$6:&\^%6M75M(LD$UCYD;KT93@@C\#3_B4D,GPW\0+. 4%F[#/]X<K_ ./
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MM=3UQT$DHD?;%;J1G+GCM@]1U'<XJCX<\&>+HOB0?%?B&ZT=BUJ;=TL&D!/
MQPRCT]>PJE\/1YGQ>\>S3#,ZRJB,PY";CP/;"K^0H A\7>(O&6G^#M5M_%NB
MV*6=W:20K>Z9(S+%(R_(KHQ)P3\N>@-=7\)_^27Z%_UQ?_T8U7/B,B2?#GQ
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MW&[?D#FMJ,FO/M:^$/A#5-,EM[?2HK&Y*GRKBW)5D;L2,X(]C3/@EK]]X@\
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M-:N2%!;<I4LHY!YZ=:R8;7XC> +58;06WBC1;90L<1S'=1QCH!ZX''\1]A3
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M1FGU"X%NYM(;@YCM<)_".F<\CT^O-97P*_Y)\_\ U_2?^@K7?ZS_ ,@/4/\
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M5'QR2Q!X!/ '2N:\/^(YO#7P?\3Z7/)MOM)NI;&(#J#(V 1]&,A_"I]9T-O
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M?5+AMT@SC=M3D#/_ -8FL7PY_;?_  O>X_M_^S_M_P#91S]@W^5MRN/O\YH
MZ'5?&VNWGBJ\\.^$=)MKNXL5!N[J]D*Q1DC@8!!/Y^O'&:M:)JGC\:W!9Z]H
M6F?8I-V^]LIR%CP"1E6))SP.W6J>O>!]9M_$MQXF\'ZK'9:A<J!=6MRNZ&XP
M/QP>/3\1S1H?Q!U&+Q#;^'/%VC'3-2N"1;SQ-N@G/L>V?J>HSB@9J>,O&O\
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MT'\C11K/_'FG_70?R-%<E?XSIH_"=N5J%U'6K1'!J!AUKL3"2*<BBJSC%7)
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M#A)!C(/?!('T(![8K$_M?XL_9_L7_",Z3]IQM_M#[6OE?[WE[MW^>G:O2J*
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MK5M\-9M)U2X^W:Q):W"O)YI;>[ERHW-CIN ]!CTKC/@YX)\0^%=6U.?6M/\
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MZS<^-O$%HTEQ(BQ0WCE0!CU;ZU[+?123:?<Q0D"5XF5">@8@XKRCPMIOQ/\
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M&TFG:A:7B+PS6\RR ?4J37C7PE\-V_C+0VO_ !(TFI6^GN;*QMIG.R( !V.
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M(6+9SVZUS41 _:'NB3@#1QDGZK6EX \*>'_^$2T#5/['LOM_V6*7[1Y(W[\
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M:;10 [-**KW9*V4[*2&$;$$=N*\_^"&IW^K> GN=2OKF\G^VR+YMS*TC8 7
MRQ)QS2 ])%**2G4""EH%+0 8HQ2T4 )24II#0 AIIIQIIH 2DI:0T#&FFFGF
MJU[=16-E<7EPVV&"-I9&]%49)_(4ADU%9^A:Q;^(-#L]6M$E2WNHQ(BR@!@#
MZ@$C]:T*!A1110 445D:UXCLM"NM+MKH2M+J=T+6!8P#AB,[FR1\HXZ9/(XH
M UZ*** "BBB@ HJ&[8K93LI(81L01VXKS[X)ZG?ZKX#>YU&^N;R?[9(OFW$K
M2-@!<#+$G% 'H]%%?/-KXCUUOC^VFMK6HFP_M22/[*;I_*VC/R[,XQ[8H ^A
MJ**CN&E6VE:!5>8(3&K' +8X!_&@"2BO*_AGK/Q%U'Q'?P^++.>/3TB8J\]H
ML(63<,!" -XQN]>@Y]?5* "BBN%^+]_>:9\.+^ZL+N>TN%DA"RP2&-QF10<$
M'- '=4H8BO,/@7JNHZOX)O;C4[^ZO9EU%T62YF:1@OEQG +$G&2>/<UZ=0!(
M'!ZB@H#T-1TH)% @(([4E2!P>M!0'I0,8"13P_K3"I%)0(EP&IA0BD!(IX?U
MI@1T5*5!Z4PJ12L%QM%%% PHHHH *EBJ*N.^)>H>+--\+I/X0MY);W[0HE,,
M FD2/!Y5"#GG:.AZ_C0)G9O]ZFUS?@2\\0WWA"SN/$\#0ZHV[>'C$;%<G:64
M?=)'; ^@KI*!A1110 4444 %%?._P2\2:[JWCR2WU'6M1O(!92-Y5S=/(N0R
M8.&)&>37T12 ****8#@Y%+O!ZBF4H4F@0_8IZ&FE2*4(:Y;_ (6)HP^(">#%
MCNI-28',BHIA4B,R8)W9S@>G4T =/@TH2I-ZT'GH:8#=@%+E13&W4W- $A>E
M1LM45/C^]1<+"R\-3*?+]ZF4@$HHHH **** "BBEP: $HIVTTOEF@!E%/V#N
M:7"T 1TN">U/RH[4F_T% "!">U+Y9I/,-(6)[T#'[!W-&%%1T4 2;EH5N:CI
M4^\*!$DI/%15)+VJ.@$%%%% PJIJG_(.E_#^8JZJD_2JNK$#395'M_,4 <*B
MP:=$,X,E0O<O<MDG"^E9X=YGW.<DU;BQD"MZCT,*<=2[$-N*E8X%11\TYSQB
MO-F]3O@B)VS3*5NM)47-R6U_X^4_'^5>C#I7G-I_Q\I^/\J]&'2MZ>QA6^(*
M44E%69#A3J8*=5(EB&FFG&FFJ)$I*6D-,!*2EI*!!125F>(CJR^'[TZ$L;:H
M(_\ 1Q)C!;/OQTSUXS0,TZ*SM!;5&T&R.MK&NIF(?:!'C:&_#C\N*T: "BBL
MKP_XALO$EK<W-B)?*M[J2U+2 #<R'DC!/RG/'0^U &K2BBDH 6EI*!0 ZE%)
M13$+1110 4444 --(:=24@$Q24M&*!A124M !1110 E%+24@"BBEH ***2F
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M?)\QA\BXP-P.>P[U;LK.WTZPM[&UC\NVMHEAB3).U%  &3R> .M KGG&K?\
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M C]*]>^'WBRY\7?#X:G=86]C$D,S(-H9U&0P';((/US5+XV@'X7:AQTEA_\
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M2><=\<^U;OQ$\6ZCHS:9H>@HC:WJ\GEP.^"L*Y +D?CWXX)[8K+\=_\ )5O
M?_767_V6J_CF1=/^,O@S4;IO+M'5H!(>@<EAS_WVM %T?#CQ.T7GM\1=8%^1
MDX)\G/ILW8Q_G%:GCSQ1?^%M&TW3]-Q=:YJ4BVEJ\@'+<!I".G4CCIEO05VM
M>0?&6S23Q)X/N;NXGM=/-RT$UU ^QH=S)\P;L<9.?]DTP-=_A[XJ6R-TGC_5
MFU@+N +?Z,6_N[.F,\9Q^':MCX;^+;CQ9X<>34$6/4[.9K:[51@%AT;';/\
M,&L\?"BT(R/%OBS'_81'_P 16[X0\%:?X+M[N'3[F\G%U*)9&NG5FW8QU"B@
M#HZ2FQ313J6AD2102I*," 1U'%/- A**** $Q12T4#&TN:*3% "TE%% !2T4
M4 (:*6D[T **6D%+0(**** "BBDH ":*#29I#%I:3-%,!:***!!1110 4444
M %%%% "44M% !2TE**  4\=*93E-*2*3%HI:2H+"BBB@84444@"HF.34C' J
M.J2(;$HI:2J$%%%% A:2BBF HI:;3J %%% H%,0N*2EH- #324ZFFD,2BBBD
M,***4"@!*7%. I<4AC,4N*?BC% 6(\44_%)B@5AM%*124Q :2EI*8"BEI!2T
M %%%% A*#12&@85S7C/_ )!@_P _Q+72US/C3C2Q_G^):([H3V9P.:*0&BNM
M,Y["T444Q#UIU-%.JD0S.UG_ (\T_P"N@_D:*-9_X\T_ZZ#^1HKDK_&=5'X3
MK&-0.<<T]FJ)V&#7=8QE,@:3YJ3=DTQN6IHXIF#=R7-%1[J<#3N18<>E:GAW
M_D*QGW'_ *$*RLUK>'58ZK&V/ER!G_@0J*K]QFE+XT>AT\* ,FCA?K322:X#
MN%+9X%-HHH 2BEHP32 $ZTYQS0J\T\XI@1A2:<%HW4TL: 'Y I"U,HH 7-%&
M:* $HHHH **** "BBB@!11110 4E&:* "FFG&FFD #K4AZ4P=:D[4 1XHQ2]
MZ* $Q1BEHQ3 3%&*6B@!**6B@!**6DI %)2T4 %%%+B@!**7%+BF VE[4N*3
M% "=ZD'2F8YIXZ4 ,;K12GK0%H 2C&:>%HSB@! *7%-S2B@!:*** "BBEH$)
M11BB@ Q3<4ZD- "4F*6B@!,4444#"GCI3*>.E "-3:<U-H *#110 E)2FDI
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M9_)W>;N!'WMPVXSZ&NHS1FD!@>+?!^E>,M+6RU)9%:)O,@N(6VR0OZJ?Z?\
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MWKBNWTNR_LW2;*P\SS/LT"0[]N-VU0,X[=*MT4 >>^/OA-IGCB]341>2:?J
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MX']X9&>I[CJ:J?\ "M;C4XI5\3^)KW6CY;I#&\8BAC9E(#^6"0S#/!)KOJ*
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M)Y@]*/,]J &8/I1M/I3_ #/:D\SVH ;M/I2[#Z4OF&DWF@ V'THV&C>:-YH
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M !2BE"T[ IB$"TN*,XI-U #LTFZFYI* '9S24E% "TE)FBD =ZD[5'WJ3M3
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 2*:D!J '%/#5#0R6BF@TN:FPQ:*3-
M(32L N::QI"U,+9JDA"$TE%%6A!1113 **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JGJG_ "#I?P_F*N53U3_D'2_A_,4 >24445TF(4'D444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 NZEW4VBE8!^ZD+4VBBP"YI***8!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 53U3_D'2_A_,5<JAK$JQ:;(6.!Q^G/\ 2@#R
M>BBBNDP"BBB@ [4 X-':D/2DALT](.=2A_X%_P"@FO5AT%>1Z5((]2@+' SC
M\QBO689!+ DBGAE!K.IN5#8DI:2BH*%HI** %HI**  T444 )1110,****
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M &K9_P#/7_QT_P"%']JV?_/7_P =/^%>5"EH]AYC]MY'JG]JV?\ SU_\=/\
MA3QJUEC_ %W_ (Z?\*\G3_6"MB,_N*J.&OU(EB+=#OO[6LO^>W_CI_PI?[6L
MO^>W_CI_PKS9N&HS5?5?,CZSY'I']JV7_/;_ ,=/^%+_ &M9?\]O_'3_ (5Y
MOFG"A87S#ZUY'HW]K67_ #V_\=/^%']K67_/;_QT_P"%>=YI":?U7S%]:_N_
MB>B_VM9?\]O_ !T_X4?VM9?\]O\ QT_X5YP33=U+ZKYE+%>1Z3_:UE_SV_\
M'3_A2?VK9?\ /;_QT_X5YJ6II-3]6\REB/(],_M6S_YZ_P#CI_PI/[5L_P#G
MK_XZ?\*\P8TRE]7\Q^W\CU/^U;/_ )Z_^.G_  H_M6S_ .>O_CI_PKRT4M'U
M=]P]OY'J/]JV?_/7_P =/^%']JV?_/7_ ,=/^%>7]:GBASUI_5GW%]878])_
MM6R_Y[?^.G_"E_M:R_Y[?^.G_"O/E4*,"AF"#FJ>%MU)^L^1Z#_:UE_SV_\
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M_P#/;_QP_P"%<CC%,+A33^J?WOP#ZTNQV7]L6/\ SV_\</\ A1_;%C_SV_\
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M44>S\PYSUO\ M2S_ .>O_CI_PH_M2S_YZ_\ CI_PKR2BCV?F'.>M_P!J6?\
MSU_\=/\ A1_:EG_SU_\ '3_A7DE+1[/S#G/6O[4L_P#GK_XZ?\*/[4L_^>O_
M (Z?\*\DHH]GYASGK?\ :EG_ ,]?_'3_ (4?VI9_\]?_ !T_X5Y+24>S\PYS
MUO\ M2S_ .>O_CI_PH_M2S_YZ_\ CI_PKR2BCV?F'.>M_P!J6?\ SU_\=/\
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M_A1_:EG_ ,]?_'3_ (5Y)11[/S#G/6_[4L_^>O\ XZ?\*/[4L_\ GK_XZ?\
M"O)**/9^8<YZW_:EG_SU_P#'3_A1_:EG_P ]?_'3_A7DE%'L_,.<];_M2S_Y
MZ_\ CI_PH_M2S_YZ_P#CI_PKR2BCV?F'.>M_VI9_\]?_ !T_X4?VI9_\]?\
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M.<]8EUBRB0L9<@>V/YUQGB+Q%]OS! ?W?0D=,5S5%-0MN)RN%%%%:$A1112
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M_CI_PKRT"GJ<&G]7\Q.OY'J']JV7_/;_ ,=/^%+_ &M9?\]O_'3_ (5YFM2
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MU2P_F)U_(]-_M:R_Y[?^.G_"C^UK+_GM_P".G_"O.5%*"<T_JWF+ZQY'HO\
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MTN:;10 I-&:2@GBBX6#-,8T$TPU#9:04445#-+!1110 4444 %%%% !1110
M4444 %+244 %%% H **7%&*!"44N*,4#$HI<48H 2BEQ10(2BBEH 2BEQ1B@
M8E%%% !2FDHH *6DI: "D[T4=Z %-)2T8H 2BEQ1B@!*6BB@0E**2B@8M)2T
ME !2XI** "@44M !2=J4TE  *6D%+0(2BBB@!:,4E% !12T4#$HHHH ****
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M (]$_P!\?R-%+J__ !Z)_OC^1HKFK?$;TOA-;FF-G-6-F*84YKT&CA3&+FI
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M;4(K6X_XFVF/$R%&6$1[W4\8P%S5$ZMJ)_YB%U_W^;_&H_[6U/=_R$;O_O\
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MZ_\  +UG=&73([>&Y@AFB=CB8+AE/N0>:(KJ1-:M/M=Y;ND:MAHRH5<@\9
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M'L:=H.GVE_>G[==PV]O$-S"20(9/]D$_SJ#^W-7_ .@I>_\ @0_^-']N:O\
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MB44M% "44M% "44M% "44M% @Q24M%  *2EHH 2BBB@84444 %%%% !1110
M4M)2T )1110 4444 %%%+0 E&:** #-*:.**!"44M)0,**** "BBB@ HHHH
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MB@!<T4E% !1110 49HHH **** "BBB@ HHHH **** "BBB@ S1110 HHHHH
M#2444 %%%% !1110 444M "44M)0 444M "4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 444M "44M)0 4444 %%%% !112T )2T44 )2T
ME+0 4E+24 %%%% !1110 4444 %*:2B@ HHHH **** "BBB@ HHHQ0 4444
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M;K2=JS;-D@I:2@4ABT44E !1110 4444 %%%% !1110 4444 %%%% !1110
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EJ04T2S-UG_CS3_KH/Y&BEUK_ (\T_P"N@_D:*Y:_QG31^ __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "G 9D# 2(  A$! Q$!_\0
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M_6_QK6HH R?^$;TW^Y+_ -_6_P :/^$;TW^Y+_W];_&M:B@#)_X1O3?[DO\
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MF4^:W4#ZUR_VVZ_Y^9O^^S7=ZO\ \@>]_P"N#_R->>T =QX;_P"0,G_71_\
MT(UK5D^&_P#D#)_UT?\ ]"-:U !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 <3XA\,^(H_%8\3>$[S3DO9;46ES;:DCF&1
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MV5PHHHJ2@HHHH **** "BBB@ HHHH **** *>K_\@>]_ZX/_ "->>UZ%J_\
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M$6L!;*Q#&0&("&0@G<X^\55 NQ0 4444 %%%% !1110 4444 %%%% !1110
M4444 4]7_P"0/>_]<'_D:\]KT+5_^0/>_P#7!_Y&O/: .X\-_P#(&3_KH_\
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M4 %%%% %/5_^0/>_]<'_ )&O/:]"U?\ Y ][_P!<'_D:\]H [CPW_P @9/\
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M"^W/ZT+57_K>P/1V.LHHHH **** "BBB@"GJ_P#R![W_ *X/_(UY[7H6K_\
M('O?^N#_ ,C7GM '<>&_^0,G_71__0C6M63X;_Y R?\ 71__ $(UK4 %%%%
M!1110 5A^+()KG1[=((I)7&IV#E44L0JW<+,>.P4$D]@":Y;Q["=>\;>%_"E
MW/-'I-ZMQ<7<44AC-QY:C;&2"#MYR1_D9OC_ $J'P=X7\-6FAP7,L,/B&V>"
MT-P6)^\?*5F/ )'<]Z%T;ZNWXV'ULNU_P;_0]7HKS#PCK&H:E\5M>N-2TJYT
MMTTJ#_1)9!*V [?,-N<Y]!S7:>'/$]IXEANFM[6_M);6;R9K>^MS#*IP&!VG
ML001['M0ME_75H75_P!=+FW1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<_XEL-L3:M#:?:FAB9+VS6/>;^UVMNAV\AF!;<
M@(Y.4RHD<UT%% '-VFO:1H>EV%C=:]'J%P;=7MO*)GNKN'D)((TW/*=HRSJ,
M$AFPHX$G]K:[J/&F:)]EA/2ZU641_*?NND*;G; Y*2&%N@X).W8M;"SL?/\
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M/EQE,YS\V<YZ"NEHI6TM\OD.^M_Z[GGFL>%-1T[X6P>$]..I7TB6S0&:P>"
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M?^1KSV@#H=-\16FEVAM)XIS(DCYV*I'WC[U<_P"$RT[_ )XW7_?*_P#Q5%%
M!_PF6G?\\;K_ +Y7_P"*H_X3+3O^>-U_WRO_ ,5110 ?\)EIW_/&Z_[Y7_XJ
MC_A,M._YXW7_ 'RO_P 5110 ?\)EIW_/&Z_[Y7_XJC_A,M._YXW7_?*__%44
M4 '_  F6G?\ /&Z_[Y7_ .*H_P"$RT[_ )XW7_?*_P#Q5%% !_PF6G?\\;K_
M +Y7_P"*H_X3+3O^>-U_WRO_ ,5110 ?\)EIW_/&Z_[Y7_XJC_A,M._YXW7_
M 'RO_P 5110 ?\)EIW_/&Z_[Y7_XJC_A,M._YXW7_?*__%444 '_  F6G?\
M/&Z_[Y7_ .*H_P"$RT[_ )XW7_?*_P#Q5%% !_PF6G?\\;K_ +Y7_P"*H_X3
M+3O^>-U_WRO_ ,5110 ?\)EIW_/&Z_[Y7_XJC_A,M._YXW7_ 'RO_P 5110
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MYXW7_?*__%444 '_  F6G?\ /&Z_[Y7_ .*H_P"$RT[_ )XW7_?*_P#Q5%%
M!_PF6G?\\;K_ +Y7_P"*H_X3+3O^>-U_WRO_ ,5110 ?\)EIW_/&Z_[Y7_XJ
MC_A,M._YXW7_ 'RO_P 5110 ?\)EIW_/&Z_[Y7_XJC_A,M._YXW7_?*__%44
M4 '_  F6G?\ /&Z_[Y7_ .*H_P"$RT[_ )XW7_?*_P#Q5%% %>^\5V-U87$"
;17(>2-D!95QDCZUA_8+K_GE_X\/\:** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !^ 40# 2(  A$! Q$!_\0
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MTD7EX)Y)WEDW-Y[#.&(]:U?^$,T;_GE/_P"!#_XT>#/^1<C_ .NLO_H9KH*
M.?\ ^$,T;_GE/_X$/_C1_P (9HW_ #RG_P# A_\ &N@HH Y__A#-&_YY3_\
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M^-'_  AFC?\ /*?_ ,"'_P :Z"B@#G_^$,T;_GE/_P"!#_XT?\(9HW_/*?\
M\"'_ ,:Z"B@#G_\ A#-&_P">4_\ X$/_ (T?\(9HW_/*?_P(?_&N@HH Y_\
MX0S1O^>4_P#X$/\ XT?\(9HW_/*?_P "'_QKH** .?\ ^$,T;_GE/_X$/_C1
M_P (9HW_ #RG_P# A_\ &N@HH Y__A#-&_YY3_\ @0_^-'_"&:-_SRG_ / A
M_P#&N@HH Y__ (0S1O\ GE/_ .!#_P"-'_"&:-_SRG_\"'_QKH** .?_ .$,
MT;_GE/\ ^!#_ .-'_"&:-_SRG_\  A_\:Z"B@#G_ /A#-&_YY3_^!#_XT?\
M"&:-_P \I_\ P(?_ !KH** /)]9,ND:W>65E<7$4$;KM42MW12>]%'BO_D:=
M0_WU_P#0%HH [CP9_P BY'_UUE_]#-=!7/\ @S_D7(_^NLO_ *&:Z"@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *Y34--U/2]=GU+0YK$O?J!/:7CE
M [*.'4C)SCJ,&NKKF_$4 ;7M G8M@321$#_;0KGI0 GA;1Y89[S6[Z\M[O4-
M0(#26_\ JD1> B\\@'/-=+7/^"=J^%;:)2"(GEC!!SG$C5T% !1110 4444
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M"H@P /I6?JWA_3]95#=0D3QG,5Q$Q26,^JL.10!J45RXN]<\.#%^CZOIR_\
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M !1110 4444 >3^*_P#D:=0_WU_] 6BCQ7_R-.H?[Z_^@+10!W'@S_D7(_\
MKK+_ .AFN@KG_!G_ "+D?_767_T,UT% !1110 4444 <PG_)3I/^P5_[4%=/
M7,HK#XF2,0=ITK@_]M!734 %%%% '/:U/<IKMI"KXMGM9RZ@GE@O''3%'@;_
M )$O3/\ KF?_ $(TW6T7^W[&3:-_V:X7/?&RG^!_^1+TS_KF?_0C0!T%%%%
M"$!@01D'@BN.AT#Q'H:3V&@7>GC3I9&DC-U&QDMRQR0,$!ADY&:[*B@#-T'1
MX]#TB*Q21I64EY)6ZR.3EF/U-:5%% !7/ZYIT][XAT"9(?,MX))C.>,*&C(&
M?J:Z"H[C(MI<$@[#@CMQ0!P&B>&-8T;XCA\"308K61;5^"8M[!C&<G. 1QCU
MKT.LOPY))+X?LWED:20H=SL<D\FM2@ ZUQ\('@[73"2XT74I<QD_=MIR>GLK
M?SKL*Y[QG>6D.@R6EQ"+B:]_<6]OWDD/3'ICKGMB@#H:*YO3=%U^WTRVAN?$
M<K3)&JN1;QD9QZE<GZFK7]CZJW+>);T'T2" #]8S0!K7%Q%:VTEQ,X2*-2S,
M>P%>=J;K6YC$-Z7.N-O<D<VUDO0>Q;^M;&N>&-4FTBY$?B#4+I@N[[/*L027
M!SM.U >>G!K4\.QV%W$VN6@<R7R*'#GF/;QY8'8 YXH V(((K:WC@A0)%&H1
M%'0 < 5)110!G:YI2:SI,UFQVNPW1/W1QRK?@:XRQU=[2^AUR53&Q<:?K,70
M1R#A9<>GOZ&O1*Y+Q39VEE#?3PPB:^U:-;-;<_<E?LQ'L.] '6@@C(.0:*Y/
M3O!U[:6EO%+XJUF0QQJC+YB!20,<?+G'XUH:;H%S87?GRZ]J=XNTCRKAT*<]
M^%!H HS^-@UW=1:9HNHZG#:,4N+BW"!%8=57<P+$>U6I_&.F1:!;ZO$)[B.Y
M81P01)^]D?.-FTXP0>N>E8/AKQ#I/AC3+C2-9N(]/O;:XE8QR\&=6<LK)_>R
M#CC)XK)6UN+"RT77;B&>"PBU:6ZEC,9W1Q2#"LR]0.YXXS0!V%AXO2>_.G:A
MIEYIM\86GCBGVL)4'7:RDC(]*MCQ';'PHWB#RI/LZPM,8^-V!G_"LY_%VGZK
M?'3](4:BIMY'FNX&S' -IP"V,$D]@:XT^&+MOA7+<C7]84"TD<6H==G4_+C;
MG'XT >J:?>1ZCIUM>Q!ECN(EE4-U 89Y_.K%<)'XCO?#_A[0=UE";1[>VBW2
M2E7=F49"C'&/>N[H \G\5_\ (TZA_OK_ .@+11XK_P"1IU#_ 'U_] 6B@#N/
M!G_(N1_]=9?_ $,UN7#2I;R-!&LDH4E$9MH8^A.#BL/P9_R+D?\ UUE_]#-=
M!0!BZ?XDMKFZ%C>Q2:?J)X%O<<;S_P!,VZ./IS[5M53U+2K'5[4VU];I-&3D
M;ARI[$'J#[BL"X?6O"L#3*SZQI42Y9)' N85'<,>''L<'W- '5UEZWXCT?PY
M:&YU?4(+6/L';YF^B]3^%>&>(OC7XJUG4!H_AC1)[&:;B,R1EIV!Z$ C _7Z
MUUO@?X2/%=)K_C.Y;5-7;#K%*Q=(C[YZG]!0!K67B&ZO/$#>*H-"U Z*UK]F
M60J!*1N#>8(^I7CZ^U=QINJ6.KV@NM/N8[B$G&Y#T/H1U!]C5L  8  'I6#J
M7A:"XNCJ&FSR:9J7>>WZ2>TB]''UYH WZ*Y5?$]YH[>1XDT^2,CA+RSC:6*4
M^FT LA]CQ[T__B>>(^OF:-IC=O\ EZE'OVC'YGZ4 )KNIV/]HI!:QS7^K1QN
MB6UOR$W#&7;HH^IK2\,Z?/I7ANQL;G;Y\4>'V'(!))Z_C5G3-)L='M?L]C;K
M$F<L1R6/J3U)]S5V@ HHHH **** "BBL75_$MOI5W%9):7=_?2*9!;6B!G"#
M^(EB !]30!M5SNK>(6:>72]&@%[?A2)6W;8K<$=7;U_V1S5*ZUM/$&G74*7%
M_H[VOS7MN\'^D>61QLVD]?5<_A4.F:#+J]K%%-;/INA)S'8=);CWF/7G^[^9
M[4 1^%_&>EP:%#!J+RVC0$Q/<2PD0.P8Y*R#*X_&NU@N(+J%9K>:.:)N5>-@
MRGZ$4BV\*0+ L2")1M"!1@#TQ6)/X-THRM/8";3+ECN,MC(8LGU91\K?B#0!
MM7=U!8VDMU<R+'!$I=W;H *YWP_;2ZQ?-XDOXMOF+ML(6'^IB_O<]&;K],43
M>&]4U"XMH=5U=+S387\QHO(V23,.@<J=I ZXVC-=0    , =J "BBB@ KE[8
MCP]XIDLV^6PU5C+ >T<_\2_\"'/U%=169KVDKK.EO;!_+F4B2"4=8Y!RI_.@
M#3HKSJ_\,ZQJUP+G4_"GAN\NMH5II+R3+8]O+X^E5?\ A!KC_H1_"_\ X&2?
M_&J /3B0 23@#J:YG1@=>UN779!FU@W06"GZX>3ZD\#VS7*WNE:SX?T2[%KX
M>T?3+2<JMW-87+O(L>?F(4H,\>]>DV$-M;Z?;Q6846R1J(@O3;CB@"Q1110!
M');PS,K20H[+T+*"13R 1@@$'L:6FR2)%&TDC!4499F. !0 D<,4*E8HT0'L
MJXIVT;=N!CTKFK?QSI<RF66WO[>U.?+NI+9C"X!QN#+G ]VQ6[8ZC9:G )[&
M[@N8CT>&0./TH RM9\-'69\2:E<QV;A1-:#:4<*<C&1E3ZD$5O 8  Z"BB@#
MR?Q7_P C3J'^^O\ Z M%'BO_ )&G4/\ ?7_T!:* .X\&?\BY'_UUE_\ 0S70
M5S_@S_D7(_\ KK+_ .AFN@H *RO$L8F\,ZE&2 &MWZMM[>M:M9/BB)IO"^IQ
MK]YK=\?E0!SN@11GQC:L47<-"BP<<CE:[BN-T&/;XJLWR?FT*(?DRUV5 !11
M10 A /49I:** "BBB@ HHHH **** "N-N=0M/#_CV[O=6E2TM+RSC2&YE.V/
M<I.5+= >>_6NRIDD4<J[9$5QZ,,T <?HU[!KWCR[U33F$VGP60MC<H/DE<L&
M^4]&P!U'K79TU(TC7;&BJH[*,"G4 %%%% !1110 4444 %%%% !1110 R6))
MHGBD4,C@JRGH0:YOPY.^EZC<^&KE\F >=9,?XX">G_ 3Q],5T]<KXAU"^G\0
MV'A_2[I+*YN(GGENO+#ND:]E!XR3W- '545R-M=:MH'B:STJ_OY-2L+Z-_)G
MF11+'(HR5.P $$>V:LR>.M&CD9&CU3*D@XTNX(_/90!TM<GK,[>(M8/ARUD8
M6L0$FI2KV7M$#ZMW]JKZI\0;-;(QZ;;WS7LS"*$W%C-#&K,< L[J  /K70Z#
MHZ:-IJP%_-N)"9+B<]99#U;_  ]J -!(8XH5A1%6)5"J@'  [5BWO@_1;R<W
M*6IM+LG/VFS<PR9_WEP3^-;M% ')78USPX]O*NKK?V,EPD317D(\U0QQ\KIC
M_P >!^M=;6'XI8)ID+'.!=1=!G^*MR@#R?Q7_P C3J'^^O\ Z M%'BO_ )&G
M4/\ ?7_T!:* .X\&?\BY'_UUE_\ 0S705S_@S_D7(_\ KK+_ .AFN@H *JZG
M;M=Z9=6Z*C-+&R .<#)'>K5% '/:9HMU9Z]!=R>488],2U)4\EP1G\.*Z&BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M45Y__P +-_ZA'_DS_P#84?\ "S?^H1_Y,_\ V% 'H%%>?_\ "S?^H1_Y,_\
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M'_DS_P#84 >@45Y__P +-_ZA'_DS_P#84?\ "S?^H1_Y,_\ V% 'H%%>?_\
M"S?^H1_Y,_\ V%'_  LW_J$?^3/_ -A0!Z!17G__  LW_J$?^3/_ -A1_P +
M-_ZA'_DS_P#84 >@45Y__P +-_ZA'_DS_P#84?\ "S?^H1_Y,_\ V% '?"-%
M8LJ*">I IU>?_P#"S?\ J$?^3/\ ]A1_PLW_ *A'_DS_ /84 >@45Y__ ,+-
M_P"H1_Y,_P#V%'_"S?\ J$?^3/\ ]A0!C^*_^1IU#_?7_P! 6BF3>=XDOKK4
1XTC@$D@'ELY.,*HZXHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !D -\# 2(  A$! Q$!_\0
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MTD7EX)Y)WEDW-Y[#.&(]:U?^$,T;_GE/_P"!#_XT>#/^1<C_ .NLO_H9KH*
M.?\ ^$,T;_GE/_X$/_C1_P (9HW_ #RG_P# A_\ &N@HH Y__A#-&_YY3_\
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M?^01:?\ 7R/_ $!J +W@S_D7(_\ KK+_ .AFN@KG_!G_ "+D?_767_T,UT%
M!1110 4444 %8'CC_D0]?_[!\_\ Z :WZYSQ]/#;^ ->>>5(U:QE0%SC+,I
M'U)( ^M '01?ZE/]T4^F1?ZE/]T4^@ HHHH **** "BBB@ KGO$7_(<\+?\
M82?_ -)IZZ&N:\4SPVVL>%9)Y4B0ZH4W.<#<UO, ,^I) 'N: )/!?_(#N/\
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M1_\ 767_ -#-=!7/^#/^1<C_ .NLO_H9KH* "BBB@ KGK/\ Y*%K'_8-L_\
MT9<5T-<]9_\ )0M8_P"P;9_^C+B@#H:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH Y[QI_R!+;_ +"=C_Z4QT>'/^0WXI_[":?^DT%'C/\
MY EM_P!A*Q_]*8Z/#G_(;\4_]A)/_2:"@#H:Y'X@_P#((M/^OD?^@-775R/Q
M!_Y!%I_U\C_T!J .,_X235]'FGL;*\,=O%,X53&C?Q'N12_\)OXB_P"@A_Y!
MC_\ B:** #_A-_$7_00_\@Q__$T?\)OXB_Z"'_D&/_XFBB@ _P"$W\1?]!#_
M ,@Q_P#Q-'_";>(<Y_M#_P @1_\ Q-%% !_PF_B+_H(?^08__B:/^$W\1?\
M00_\@Q__ !-%% !_PF_B+_H(?^08_P#XFC_A-_$7_00_\@Q__$T44 '_  F_
MB+_H(?\ D&/_ .)H_P"$W\1?]!#_ ,@Q_P#Q-%% !_PF_B+_ *"'_D&/_P")
MH_X3?Q%_T$/_ "#'_P#$T44 '_";^(O^@A_Y!C_^)H_X3?Q%_P!!#_R#'_\
M$T44 '_";^(O^@A_Y!C_ /B:/^$W\1?]!#_R#'_\3110 ?\ ";^(O^@A_P"0
M8_\ XFC_ (3?Q%_T$/\ R#'_ /$T44 '_";^(O\ H(?^08__ (FC_A-_$7_0
M0_\ (,?_ ,3110 ?\)OXB_Z"'_D&/_XFC_A-_$7_ $$/_(,?_P 3110 ?\)M
MXA/74/\ R!'_ /$T?\)MXA_Z"'_D"/\ ^)HHH /^$W\1?]!#_P @Q_\ Q-":
9UJ7B"[M[/4;LRP[BX"QHI!"GN!110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "+ 0P# 2(  A$! Q$!_\0
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MTD7EX)Y)WEDW-Y[#.&(]:U?^$,T;_GE/_P"!#_XT>#/^1<C_ .NLO_H9KH*
M.?\ ^$,T;_GE/_X$/_C1_P (9HW_ #RG_P# A_\ &N@HH Y__A#-&_YY3_\
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M (T?\(9HW_/*?_P(?_&N@HI#.?\ ^$,T;_GE/_X$/_C1_P (9HW_ #RG_P#
MA_\ &N@HH Y__A#-&_YY3_\ @0_^-'_"&:-_SRG_ / A_P#&N@HH Y__ (0S
M1O\ GE/_ .!#_P"-'_"&:-_SRG_\"'_QKH** .?_ .$,T;_GE/\ ^!#_ .-<
M/K)ETC6[RRLKBXB@C==JB5NZ*3WKUBO)_%?_ "-.H?[Z_P#H"T =QX,_Y%R/
M_KK+_P"AFN@KG_!G_(N1_P#767_T,UT% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7&_$?1M3U+2M-OM'MQ=WND:A%?K:E]GGA,@H#T
MS@\?2NRK'\67UQIG@W7+^SD\NZM=/N)H7V@[76-BIP>#@@=:/0#@]4U'6/B+
M?Z+IEMX5UC2;.TU"*]O;O5(O("B,YV1C)+D],_IW'JE8]S?7$?C+3+!9,6LV
MGW<TB;1\SI);!3GKP)'_ #]A6Q1TL'4**** "BBB@ HHHH **** "O)_%?\
MR-.H?[Z_^@+7K%>3^*_^1IU#_?7_ - 6@#N/!G_(N1_]=9?_ $,UT%<_X,_Y
M%R/_ *ZR_P#H9KH* "BBB@ HHHH **** "BBB@ HHK#G\2PR7$MGHUO)JUY&
MYCD$! @@<'!$LQ^52IQN0;I #D(10!N45S_]MWFC?N_$,.81S_:EI 1;8//[
MQ-SO#@;LLV8P%!+@MM'04 %%%% !16'/XEADN);/1K>35KR-S'(("!! X.")
M9C\JE3C<@W2 '(0BH_[5UC2OGUFP^TV\GS^=I4+R_9O^F;QY,DG. )$7G)+)
M&%R0#H**C@GANK>*XMY8YH)4#QR1L&5U(R""."".<U1N_$.B:?>I97NL:?;7
M;XVP37*([9Z84G)H TJY_P =_P#)//$O_8*NO_135T%<GJVJP^*M&OM)T2VD
MU2"]MY+>2]CE$-JBNI4D3E6#G&X?NUDPPP^V@"Y>?\E#T;_L%7__ *-M*Z"N
M3DTKQ'::S;:Y)<VFKR06\T#6D<7V3"R-&S&(EG!.($ 1R,L[DR*NU5W-,UO3
MM8\U;*XW30X\ZWD1HIH<YV^9$X#ID D;@,CD9% &A115/4M5L=(MUGO[F.!'
M<1QAN6E<@D(BCEW.#A5!)[ T 7**Y_S=9U[FU:?1+#M++ C7<XZAD5BRQ+TX
MD0N<L"D94$G]L7^B\>(D@:U_AU*RBD\L'J?.C.XP*!_&79,*Q9DRJD Z"BHX
M)X;JWBN+>6.:"5 \<D;!E=2,@@C@@CG-24 %%%% !7D_BO\ Y&G4/]]?_0%K
MUBO)_%?_ "-.H?[Z_P#H"T =QX,_Y%R/_KK+_P"AFN@KG_!G_(N1_P#767_T
M,UT% !1110 4444 %%%% !6?JVL6^CQ0&9)Y9KF7R+:""(N\TNUF"CLO",=S
M%5&,D@<UH5S_ (A_Y#GA/_L*R?\ I%=4 'V#5-=^?5)9],L_X;&RNMLD@Z@S
M3( R,./DB; (;+R*V!N000VMO%;V\4<,$2!(XXU"JB@8  '  '&*DHH *Y__
M (1Y]'_>^&6@LE_CT^4-]DD YPB@X@8G/SH"/F8LCG&.@HH Y_\ X2VW3]Q/
MIFJPZD?NZ>UJ6D<]MKH3$5Y7+A]B%U#LA.*/[-U36OWFJ7D]A9ORNG64GE2
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M6D:)+I[:I&5$,\I-L $PQ+<0L21E0?EW%@P'<4 %%%% !1110 4444 %%%%
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M;/-:9^SR-$I:'(P=AQE<CCBB.EK]+?A?^OO[C;WMUO\ C_7]6/(K&'Q'X?\
MC%<F_P!17Q)J(T#<DCQ1V*JAG4?,1D!5Y8G!..@->H^&M;'B+0+?5%@\D3%Q
MM#[U.UBNY6P-RG&0<#((.!3M3T"SU)VG&^SU HJ+J%IM2X10P8*'(.5R.5.5
M/<&GZ+HUOH6GFTMWEEW2O-)+,07DD=BS,<  9)Z  >@IIZ6?]:O_ #$][K^M
M#1HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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G_P#;VL?]!:^_\"'_ ,:UM'@34K:6YO2\\YE(,DDC%CA1U.: /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &V 9$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HI&8*,L0!ZFHA>6I;:+B+/INH
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M0 4444 %%%% !1110 4A&Y2#T(Q2T4 9RZ6R'Y;@XPHP1Z?XTATIB<_;)/\
M6!__ *WTK2HH SUTV15*BZ;G=G(]?QH3371\_:W(VJN"/2M"B@"E:V#VTL;F
MX+[ P((^]DY_2HQI;[L_:Y#\^[!^G2M&B@#/_LV0NK-=-PFW@8SSGUI!I;J^
MX7DG^LW\C/X5HT4 5K>VDAA:$R[D(;!QR"35<:6PE9_M3G<%&TC(X_QK1HH
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M RDCJ >13L$]* $HHHH ** 01D$$>HHH **** "BBB@ HHHH **** "BBB@
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M/8W&%[PR'^$^A]*XR:&2VF:*92KKU!KBE&VQ[%.?-N-HHHJ#4**** "BBB@
MHHHH 2M[PE.T>K&(?=E0Y'TK!KJ/!UH&DGO&_A^1?ZU<%[QE6:4'<W-1M]A^
MTKZ@./7T-5*UKU0UE,"<#83^58\;AXU<'(89%;RW.*#NAU26_P#Q]0_]=%_F
M*CJ2W_X^H?\ KHO\Q0BFM#UBBBBO0/ *U%%% %#7--_MG0-0TSS3%]KMWA$@
M_AR,9KSAOA?K-_87<%_>Z9 \FG0V47V-& S$VX,^1WQS7JCNL:,[L%11EB>P
MK(A\6^'KBRNKR+6;1K:UQY\F_ CSTSGUI:#U..L/AQ?PSV%U(]C!/#>-<3B.
M623S 8]@Y8=?Z5"WPJO'TW0K;^T+=&MD-OJ6P-BY@\SS HXZY'?UKHM-^(N@
M7POY9[VWM;6VN?L\4\DGRS_*&ROX'I6E;^,?#U\SQV&KV=U.(6G6*.4990,Y
MIWMK\_U%:^GR.4C^&UQ!XRFU(/:SZ?+>B]022NLD+ 8P% VGV)[51UOPL?#G
MPR73!'YVMF],]G-8P%B9RY9<G&1P<$FNQB\<^'UT^TN=0U2SLI+F)91%).&(
M4G .1U''6II/%VF6E]J$-[<V]M!9K$3.\RD-Y@R!M'(]O6DUIR_UIJ">M_Z[
M%7PEI]_H$-GH9LU%E!9B6:[+<R7+,2X _7-<_<?#W5G\03SPW6FG3Y=7CU3?
M(C?: 5ZQYQC'I74GQMX=&J6.G#4XFGOHS)!C.UAG'7U)_E4T?BWP]*+HIK-F
M5M?]>?,X3G&2?3/&:IO7F_K?]-!+16_K^GJ<F_PZOHO#9M;6>P&IIK!U-)60
MA'&\L$<XST.*Y?Q+X9UG2D@^U31?:KS4KB^>\M8Y#'$'0*8N 2"W3I7J3^,?
M#<<,$SZW9B*=BL3^9PY!P<>V>_2J?B/QYI'AZ6*V^T0W-_)-%']D20;PKG ;
MZ<YJ;=/ZZ?\  _JY5]WZ_K_P3*CT&]\1_">QTE;2/2;@K%MAF+$(J."/?D#/
MXU)H?@_4]*\<7.L+-:6VGS!O-MK=W;SW.,.5880\<X/-=?<:C96MW#:W%U%'
M<3JS11LV&<*,L0/:L]O%OAU6M =9M,W8S;@/GS!G&1CMGBJO[UUU_P"&)M[M
MOZ[FS17-P^-]$6R-SJ-]:V \Z6)!).&W[#@D8_EVJS=^,/#EA!;S76MV<45P
MGF0N9.'3^\/;WI#-NBF12I/"DL3!XW4,K#H0>AI] &=JL;M$KJNX(<D55C<I
M&-T+C'M6G?'%J^?;^=5FGC\LC?SC%=E*3Y$K'GUM)F2\B%R2C<G^[44VWCY"
M/^ U>+#*\]ZNSNI@;!!^E=+G:VAE<71P5L1D$9)/-:%-C&(U'M3J\V;YI-GI
M4U:*"BBBH+"BBB@""ZMA<Q8!Q(IRC>A_PKB?&6BMJ^E"[B3%W:YW+Z@=17>U
MG.,7EPI'!P<?A6%>-XW-Z%1TYJ2/+OA[D^)3CIY+9K3NF:XOYV'WI)B!^>*N
M:1I:Z3XZOHD&(YK<R0_0]12:1:27&L1AD8+$Y=R1TQ7'%:6/4G.+DYKLC?AL
MDTWR[=/NNO)]6[UROCRWN)UM#!$[^4&=BH^[[UT^KW,BS(J\!,/]35:\<2/;
MS*<JZD&NCFYJ;1Y].3A54V<38:A%?6_DS$"0## ]_>JMQ*B$PW2&:W!X8??3
MZ&L[4(#9ZI<PJ2-DAQ]*=&\UT0HVENG+8KB<NA[ZBMULQM]9-9NA#B2&4;HY
M!_$/\:K5I:DRP6=I8B19'BRSLIR 3VK-I26I<6VM0HHHI%!1110 4444 %;.
M@:VNE,\4REH)#DD=5-8U%-.SNB914E9G?:WJD%MI3%7W/.F(QW(/>LC19_.T
M]5)RT9VFN99F;&YB<# R:U?#\FVYDBSPRY_*M.=N1A[)0AH=%4EO_P ?4/\
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2"BBNB/0X9[L\7HHHKTSYL__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %M ; # 2(  A$! Q$!_\0
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M7L?G&+RR7F VX&> ,<TV/Q)#Y4*2/<2*FC"R*-RIE#AO7IQUK&4Z+_SPU/\
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MW9A[%6]XN"\C RKMGTI8[Z.7Y7R#ZCK4-MI<V_Y\;<\$<[OI5IX+*!OG^_\
MW5Y/X^E="<6<%2"6P%IE( 'FQMQP,_I3)((XP95)+#DPQG^M3QL9%\N,!(FX
M*KW^IJCY30SB/=@YQ51W."HK%BWU<L#&0%C(P4']:Y;Q+X>U"*)]0T:^O'@'
MS26_GL6C'JO/(K;_ '=X7&1%<1G!;LU6H&N;/$APR?WE.0*NRB^:.C[=SEE>
M:Y9ZKNNAY"=3U'_H(7?_ '_;_&FG5-2_Z"%W_P!_V_QKM_&'A>.:)]9TN(
M;KF!!T_VU'\Q7 D5W4I0J1ND>16C4HRY6_1DQU34?^@A=_\ ?]O\:8=4U+_H
M(7?_ '_;_&HB*816O)'L9JI+N3'5-2_Z"-W_ -_V_P ::=4U+_H(WG_?]O\
M&H"*:12Y8]BU4EW)CJNI_P#01O/^_P"W^--.K:G_ -!&\_[_ +?XU 13"*7+
M'L:*I+N23:A?3QF.:]N9(SU1YF8'\":ID5,13"*+);%<S>Y]3WETME93W3_=
MB0O]<5\^3W5W<:B]W(Y\VXD+'&&#9/3->J?%'4?L?A06ZN4:[F6/*]=HY/\
M*O'(FFBB62)VV#C*GE3GN*^ Q4M5$_:^'<-:C*L]V[?)?\$L;9$G$4T?ER9X
MS_GI5ZVM7\TI(1@^O&#2O&[6 E:4R7'F?>S_  8ZXI$*%O-9][8Y(XXKE/H&
M[HU;2.,QAG9G*OL( P!^=:$#1MDQHNSIR<<^U9-J5G7AF!;D ^O:MG2B ^)"
M61U/R=B16D3SJ[LFSH-!1Y;A5)) Y&?2NQ*D2?9U *D9.:QO#EMY:>85((4
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M+9(ZGH*F*'6J*QO6%K]H=0!^\5<$GO786Z+8VQD(_>%?E']:S-(L]B1,P 4
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M+-(2(P%)^[_6FB*CU-*WDM#M.)1GJ/4?C6E#<6ZD+"C$G QTK%CB)E103_=
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MJB+];@>6H:+'51@[A3HKLH,1Q-@=V  KSYTE+1['JTZO*[K?IY'1V,WV2/*
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M;W&N,BJ4\>15XX(ZU"R9IB/G_P")$6/&MR/^F4?_ *#7*K%7:?$U,>.;D?\
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M4F:,T +FDS3<T9H =FC--S1F@!V:3/O244 +FC\:2DS0 M%)FC- 'A?Q./\
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MU&ZO@S]9'49INZDS0 _-&:9FC- #\T9IF:0F@!^:-U,W4;J '[J3=3"11N%
M#LTN:CR:-U #R:3--W4F: /%OB2?^*VN?^N47_H-<H#74?$@_P#%;7/_ %RB
M_P#0:Y4&OIL/_"CZ'@UU^\EZD@-/!J,&E!K<YVB4&G U&#3@<4$-$J99@J@L
MQ.  ,DFO:?!/@.W\/P1ZOK<:R:DPW16[<K /4^K?RK)^&'A*.&!?$VIQ@_\
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EC.<55E8U4(:DU*NA%-+UYJG)-BEG<C-9\TA%>A3IW/&KUK'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %V ;,# 2(  A$! Q$!_\0
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M$D<2!5.T*0<#C/)Y]ZU*SKG_ )&'2?\ =G_]!6@:-FJFIO(E@_E.49BJ;AU
M9@"1[X-6ZIZI_P >)_ZZ1_\ H:TBB :98J,?9D;W;+$_4GDTO]FV/_/K%_WS
M5H]:*9!5_LVQ_P"?6+_OFC^S;'_GUB_[YJU10!5_LVQ_Y]8O^^:/[-L?^?6+
M_OFK5% %7^S;'_GUB_[YH_LVQ_Y]8O\ OFK5% %7^S;'_GUB_P"^:/[-L?\
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MB?\ KI'_ .AK5RJ>J?\ 'B?^ND?_ *&M(HD/6B@]:*9 4444 %%%% !1110
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M^'/^1?M/]T_S-:E<4_B9Z=/X$%9US_R,.D_[L_\ Z"M:-9US_P C#I/^[/\
M^@K4FB-FJ>J?\>)_ZZ1_^AK5RJ>J?\>)_P"ND?\ Z&M(HD/6B@]:*9 4444
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MG_7>7_T-JT*S[/\ U4G_ %WE_P#0VIB98HHHH)"BBB@ HHHH **** "BBB@
MHHHH *X+Q;_R'6_ZY+7>UP7BW_D.M_UR6MZ'Q'+BOX9A444^*&2>01Q(78]A
M78>:E<91706OAY/+)NG)<C@(>%_QK.OM)N+++@>9%_?4=/J*S52+=DS:5"I&
M/,T4****T,3T;PY_R+]I_NG^9K4K+\.?\B_:?[I_F:U*\Z?Q,]FG\""LZY_Y
M&'2?]V?_ -!6M&LZY_Y&'2?]V?\ ]!6I-$;-4]4_X\3_ -=(_P#T-:N53U3_
M (\3_P!=(_\ T-:11(>M%!ZT4R HHHH **** "BBB@ HHHH **** "L3Q?\
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MUHUG7/\ R,.D_P"[/_Z"M T;-4]4_P"/$_\ 72/_ -#6KE4]4_X\3_UTC_\
M0UI%$AZT4'K13("BBB@ HHHH **** "BBB@ HHHH *H:S;QW>ER6\P)CD(#
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M_P#LU=Q793^%'RF8?[S+Y?D%%%%:'"5=$_X\9O\ K[N/_1SUI5FZ)_QXS?\
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M^\R^7Y!1116APE71/^/&;_K[N/\ T<]:59NB?\>,W_7W<?\ HYZTJ184444
M%9]G_JI/^N\O_H;5H5GV?^JD_P"N\O\ Z&U,3+%%%%!)E^(_^1?N_P#='\Q7
MG->C>(_^1?N_]T?S%><UV4/A/.Q?QKT"BBBMSD"BBB@ K9\+?\C!!_NM_*L:
MMGPM_P C!!_NM_*HG\+-*7QKU/0:***\\]@*X+Q;_P AUO\ KDM=[7!>+?\
MD.M_UR6MZ'Q'+BOX9A4445V'FA1110 4444 >C>'/^1?M/\ =/\ ,UJ5E^'/
M^1?M/]T_S-:E>=/XF>S3^!!6=<_\C#I/^[/_ .@K6C6=<_\ (PZ3_NS_ /H*
MU)HC9JGJG_'B?^ND?_H:U<JGJG_'B?\ KI'_ .AK2*)#UHH/6BF0%>??$+_D
M)6?_ %Q/\Z]!KS[XA?\ (2L_^N)_G6=7X3T,M_WA?/\ (X^BBBN,^I"BBB@
MHHHH ]:\+?\ (KZ?_P!<OZFM>LCPM_R*^G_]<OZFM>NZ.R/C*_\ %EZO\PK$
M\7_\BM>_1?\ T(5MUB>+_P#D5KWZ+_Z$*)?"QX?^-#U7YGE-%%%<)]D%%%%
M!1110!W/P[Z:C_VS_P#9J[BN'^'?34?^V?\ [-7<5V4_A1\IF'^\R^7Y!111
M6APE71/^/&;_ *^[C_T<]:59NB?\>,W_ %]W'_HYZTJ184444 %9]G_JI/\
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MW6)XO_Y%:]^B_P#H0HE\+'A_XT/5?F>4T445PGV04444 %%%% '<_#OIJ/\
MVS_]FKN*X?X=]-1_[9_^S5W%=E/X4?*9A_O,OE^04445H<)5T3_CQF_Z^[C_
M -'/6E6;HG_'C-_U]W'_ *.>M*D6%%%% !6?9_ZJ3_KO+_Z&U:%9]G_JI/\
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M?_T%:T:SKG_D8=)_W9__ $%:12-FJ>J?\>)_ZZ1_^AK5RJ>J?\>)_P"ND?\
MZ&M(HD/6B@]:*9 5S/B?PU<ZY=P303Q1B-"I#YYYSVKIJ*32:LS6E5E2ESPW
M//?^%?7_ /S^6WY-_A1_PKZ__P"?RV_)O\*]"KG=9\96&A:G'9WEGJ7ELT:2
M7B6Q-O$9#A S^YXXSCOBL_91.S^TL1W7W'/_ /"OK_\ Y_+;\F_PH_X5]?\
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M.:],HH'<YSP3I=YHV@_8[W3X+.82L[&.[-PT[-RTCN57YB<]JZ.BB@04444
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M@"2">@P ::-7TXE M[ YD *A'!)!. >.V:K_ /"/VALWM7>1HFD:3;P N1C
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-0/SJY112&%%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &% ,\# 2(  A$! Q$!_\0
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M * VG?\ @*G^%:-% &=_PCVB?] ;3O\ P%3_  H_X1[1/^@-IW_@*G^%:-%
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M7:6]I<P["K01A,Y<*<XZ\$]:Z:N<\>_\B3J/TC_]&I0!I>'O^19TG_KRA_\
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MBB@ HHHH *YSQ[_R).H_2/\ ]&I71USGCW_D2=1^D?\ Z-2@#2\/?\BSI/\
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M49C>6,J'^A/6O0C<O??#U8;K4H;,Q1+';"SN@5N3@8CDCZAL]?SJ'7=*UM-
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M "+.D_\ 7E#_ .@"M&L[P]_R+.D_]>4/_H K1H **** "BBB@ HHHH ****
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M](__ $:E='7.>/?^1)U'Z1_^C4H TO#W_(LZ3_UY0_\ H K1K.\/?\BSI/\
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MI0!I>'O^19TG_KRA_P#0!6C6=X>_Y%G2?^O*'_T 5HT %%%% !1110 4444
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M***\D[ KG/'O_(DZC](__1J5T=<YX]_Y$G4?I'_Z-2@#2\/?\BSI/_7E#_Z
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MG_D48?\ K\3_ -!>O$Z]+#?PSEJ_$%%%%=)D%%%% !7H'PB_Y&BZ_P"O-O\
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M_0'N?^^:/^$&\3?] >Y_[YKWHZOIBZ:NI'4+46# %;GSE\LY.!\V<=>*N Y
M(Z&CZU+L'L4?/L/@CQ*LR,='N<!@?NU]!'K116-2JZEKEQ@H[!111619R'Q(
MTN]U;PU%;6%M)<3"Z5RB#) VMS^HKRC_ (0;Q-_T![G_ +YKZ&HKHIUY0CRI
M&<J:D[GSS_P@WB;_ * ]S_WS1_P@WB;_ * ]S_WS7OE_J5CI=M]IU"\M[2#.
M/,GD"+GTR:BGUS2;6*VEGU2RBCNB!;N\Z@2_[ISS5_6I=B?8H\(_X0;Q-_T!
M[G_OFC_A!O$W_0'N?^^:]YN-8TRUOXK"XU&TAO)O]7!),JN_T4G-+'JVG3:C
M)IT5_:O?1#,ELLJF11[KG-'UJ78/8H\%_P"$&\3?] >Y_P"^:[3X:>'=7T?Q
M#<3ZA836\36K('<8&[<IQ^AKU*BIGB)2BXM#5))W"BBBN8U"N<\>_P#(DZC]
M(_\ T:E='7.>/?\ D2=1^D?_ *-2@#2\/?\ (LZ3_P!>4/\ Z *T:SO#W_(L
MZ3_UY0_^@"M&@ HHHH *AO)88;&XEN1FW2)FE&W=E0.>!UX[5-10!\^7GV'Q
M-IWB"^T6R^QW'V6."#1[6T>-C9QS*TC2':%9V'103@<<UO0ZMHVEV'BG7!H/
MVO1KO48#I5J]FRQO,L6"^PK\J@CEL=CU->S9/J:,GU- 'A^H:!H]S\%;R>T=
MM1N[:X>XW10RQ1I/+(A<1Q,!\H!P./4]S7MD/^HC_P!Q?Y4_)]:* "BBB@ H
MHHH **** .,^)&MZ=HFC6\EWI<.H7DDI2R6>W,L<+D8,CX!PH!YP,GH*\NN]
M-TS3M.1$2XU;3KCP[/8Z=.+.0@WQE+,JH5S&22-O3@=:^A,D=#2Y/J: /%O$
MEWHTU]I/A[5;9;.ZBAM)-5U1K-WE9HPI6*-E4G<3U;. ,]33=)T2Y3XBV-EI
M[07D=CJ]Q>W%ZEK(DR(X;*32, K<D !2<]>,5[7D^II,GUH **** "BBB@ K
MG/'O_(DZC](__1J5T=<YX]_Y$G4?I'_Z-2@#2\/?\BSI/_7E#_Z *MRW*13Q
MPE6+."<C& !W.353P]_R+.D_]>4/_H JU<6J76T2,VP=4&,'Z]_RH $O+:1=
MR3H1UZ^^/YD?G3?[0L\9^TQXP3GV%1?V5!G=OE+<!FW#+ 8P#QT&!3GTV"2/
MRR7"; I4$8..AZ=10!-]J@,7FK(&3(&5YZ]*C&I6FW<9E5=JG+'CYN@^O%/%
MI'Y A)8H"".@QCZ"H7TNUD"94C8% . >@(Z$8Z$T .DU*TB8AI1A20Q )VGW
M_.B+4K26,OYH7#;2#USG _E3$TJW1F96D#'^+(R/3M4GV"(;"KR*Z=&#<]23
MV[Y- #OMUIG'VA 02IR>XZT-?6RI"_FADF?8A7G)_I42Z5:JDB$,RR*4;<>H
M/_ZJ5M,MGC2.12X0$+T&,G.>,#- $@O[0@D7"8#!"?0GI2?;[98A))*J \88
M\Y]/U%1/I-M(5+&3Y5"_>Z@9Z\>]']FQF24EBJLBH,8)P.<\C&>GY4 2_;X&
M0F(M*0_E[$7DMZ<XIIU*T2-6>79G^$J<CG'('O3OL,8CV+)*,/O5MW*G&.#C
M^>::-/B481Y4! SAAR0<ACD=<T *^I6B,H\Y2"Q0L.@.,\T[[=:>88_M$>\,
M%V@\Y]*A&E0  !Y1MX4AAPO(V].G)_.GP:=;V\PEC4@@D@8'&?PR>O<T +)?
MI$[HT4V]<84*,L.>1S['K2_;4RP6*5L()%P!\ZGN.?YXIIT]#YF9YR7;=G<,
MJ>G''IQ33IL9611<7"K)@%0PX Z <=/:@"W&ZR1K(OW6 (SZ4ZD5=J*N2V!C
M)ZFEH **** "BBB@ KG/'O\ R).H_2/_ -&I71USGCW_ )$G4?I'_P"C4H Q
MM1\;CPK<+HPTW[2MJBQI()]F5 P.-I[8[U3_ .%L#_H"'_P+_P#L***0P_X6
MP/\ H"'_ ,"__L*/^%L#_H"'_P "_P#["BB@ _X6P/\ H"'_ ,"__L*/^%L#
M_H"'_P "_P#["BB@ _X6P/\ H"'_ ,"__L*/^%L#_H"'_P "_P#["BB@ _X6
MP/\ H"'_ ,"__L*/^%L#_H"'_P "_P#["BB@ _X6P/\ H"'_ ,"__L*/^%L#
M_H"'_P "_P#["BB@ _X6P/\ H"'_ ,"__L*/^%L#_H"'_P "_P#["BB@ _X6
MP/\ H"'_ ,"__L*/^%L#_H"'_P "_P#["BB@ _X6P/\ H"'_ ,"__L*/^%L#
M_H"'_P "_P#["BB@ _X6P/\ H"'_ ,"__L*/^%L#_H"'_P "_P#["BB@ _X6
MP/\ H"'_ ,"__L*/^%L#_H"'_P "_P#["BB@ _X6P/\ H"'_ ,"__L*/^%L#
M_H"'_P "_P#["BB@ _X6P/\ H"'_ ,"__L*O:?XBC\>K/HTMC]DA=0TC"7S"
,0#D <#'(%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *$ =P# 2(  A$! Q$!_\0
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M[_H Z7_X!Q_X4?\ "+>'O^@#I?\ X!Q_X5K44 9/_"+>'O\ H Z7_P" <?\
MA1_PBWA[_H Z7_X!Q_X5K44 9/\ PBWA[_H Z7_X!Q_X4?\ "+>'O^@#I?\
MX!Q_X5K44 9/_"+>'O\ H Z7_P" <?\ A1_PBWA[_H Z7_X!Q_X5K44 9/\
MPBWA[_H Z7_X!Q_X4?\ "+>'O^@#I?\ X!Q_X5K44 9/_"+>'O\ H Z7_P"
M<?\ A1_PBWA[_H Z7_X!Q_X5K44 9/\ PBWA[_H Z7_X!Q_X4?\ "+>'O^@#
MI?\ X!Q_X5K44 9/_"+>'O\ H Z7_P" <?\ A1_PBWA[_H Z7_X!Q_X5K44
M9/\ PBWA[_H Z7_X!Q_X4?\ "+>'O^@#I?\ X!Q_X5K44 9/_"+>'O\ H Z7
M_P" <?\ A1_PBWA[_H Z7_X!Q_X5K44 9/\ PBWA[_H Z7_X!Q_X4?\ "+>'
MO^@#I?\ X!Q_X5K44 9/_"+>'O\ H Z7_P" <?\ A1_PBWA[_H Z7_X!Q_X5
MK44 9/\ PBWA[_H Z7_X!Q_X4?\ "+>'O^@#I?\ X!Q_X5K44 9/_"+>'O\
MH Z7_P" <?\ A1_PBWA[_H Z7_X!Q_X5K44 9/\ PBWA[_H Z7_X!Q_X4?\
M"+>'O^@#I?\ X!Q_X5K44 9/_"+>'O\ H Z7_P" <?\ A1_PBWA[_H Z7_X!
MQ_X5K44 9/\ PBWA[_H Z7_X!Q_X4?\ "+>'O^@#I?\ X!Q_X5K44 9/_"+>
M'O\ H Z7_P" <?\ A1_PBWA[_H Z7_X!Q_X5K44 9/\ PBWA[_H Z7_X!Q_X
M4?\ "+>'O^@#I?\ X!Q_X5K44 9/_"+>'O\ H Z7_P" <?\ A1_PBWA[_H Z
M7_X!Q_X5K44 9/\ PBWA[_H Z7_X!Q_X4?\ "+>'O^@#I?\ X!Q_X5K44 9/
M_"+>'O\ H Z7_P" <?\ A1_PBWA[_H Z7_X!Q_X5K44 9/\ PBWA[_H Z7_X
M!Q_X4?\ "+>'O^@#I?\ X!Q_X5K44 9/_"+>'O\ H Z7_P" <?\ A1_PBWA[
M_H Z7_X!Q_X5K44 9/\ PBWA[_H Z7_X!Q_X4?\ "+>'O^@#I?\ X!Q_X5K4
M4 9/_"+>'O\ H Z7_P" <?\ A1_PBWA[_H Z7_X!Q_X5K44 9(\+^'QR-"TP
M'U%I&#_*N2\3>-9? ^J+I<</VF&2(3Q>:Q)C4DKLSU(!4D9]<=J]#KQ#XQ_\
MC=:?]>"?^C)* /6?"W_(HZ+_ ->$'_HM:UJR?"W_ "*.B_\ 7A!_Z+6M:@ K
M,C\1:/+KLFB)J5LVJ1KN:T#_ +P# /3Z$&M.OG_Q)I%]<?$OQCK^C[O[7T!K
M.\@4=)$\O]XA'?*C],=Z /<X]8TZ74;K3X[R%KRT17N(0WS1J1D$CMD5D6/C
M_P ):E?0V5EX@L)[F9MD<22Y9CZ"N$\$:[:>)?B!XMUBQ;,%UI5JX&>5.PAE
M/N""/PK/^"<.L-H.F.OAW2I-,$\Q.I/(/M"_,W08SUXZ]* /5-5\8^&]#O!:
M:IK=C:7! /E2S ,![CM^-;$,T5S"DT$J2Q.-R.C!E8>H(ZBO(?A)HVC:[HOB
M&]UNRM;W5)M2GCO6ND#LJ\87GH.O^14GPDT]=;^'VNZ++/<C2O[2F@M9(9BK
M"'Y3A6].OYF@#T[3=<TO6);J+3K^WNWM'\N<0N&\MN>#CZ'\JK6/BK0-3U23
M3+'6;*XOH\[H(I@S#'7COCVKR[PA9QZ):?%2STB+R4M'=+9$).W;$^,=\UB6
M]C9:?X3^%5_IEO#'J,NI(K2QJ \@8GS 2.2.W- 'MFH>*M TK4HM.U#6+*VO
M)<;(99@K'/3CMGWK8KP.[T^PO]/^+MYJ5O#+>P7+"*2507C50?+VD\CH.G7%
M>N^!IKBX\!Z#-=EC.]A"7+=2=@Y- %S2?$6CZZ]PFE:E;7;VS;9EA<$QGGK^
M1_*I].U6PU>&6;3KN*YCBE:%VC;(5UZJ?<5\^>%#-X.\CQU;AS8/JEQI^L("
M2!$9/DDQ_LD_R]:VM%\5W/A7X0>(]9TL1RSMKDZ02$;E&]E ?WXZ?A0![K17
MD/A7Q/XJL=:8ZT=:FT'["\]S>ZGIBV_V:15+94ID%2!T-9.G>-_$UOXD\.7/
M]IZK?:3K%Y]G+7]A#!%(A(PT05BXQGOC\: /=*S]7US2] LQ=ZM?0V=NSB,2
M3-M!8Y('UX->=:7?^,/$7Q#\1:7:Z\EEI6E7\3L#;J\CH1_JE/93@Y/)Y%==
MI7B;1O&%Y<Z;_9EXWV;YV%_8E8S@X^4L,$T 3:;XZ\+:Q?QV&G:]8W-W+G9%
M')EFP,G ^@-=#7D_P8MK.#PAJNH&RA:>#4KK;((AO  ' .,BN7T?Q[X]UF&W
MU^PAUB[,MW@V$6F*UEY ;!42@[MP]?6@#Z HKRK3M0\8>(OB-XCTFTUY++2]
M+O87;-NKR,A&?*4]@<').3TK$O=?\:7L7CR]L_$IL[7P_>R-!$+5':0#/R%B
M.% ''&<GF@#W"BO&;/Q+XPL]5\#ZIJ&N1W-KXD<)-IZ6JI'""%QM/WB><]>O
MM7J?B+6(?#_AS4=7G(V6D#2X/<@<#\3@?C0 6/B'1]3U.ZTVRU*VN+VT)$\$
M;Y:/!P<CZ\5=N[J&QLY[NX?9!!&TDC8)VJHR3@>PKYO\&:U:Z#X@\):IY5]'
M>7LDT&L33VK1QR^>^Y"'/#8)'Y5V>J:GXH\5ZUXW@L]<BT_3-#A: 69MU<7&
M4;=O)Y .#R#QD>E 'JVD:M9:[I5OJ>G3>=9W"[HI-I7<,XZ$ CD5!9^(M+O]
M<O\ 1;:YWZA8!6N8MC#8&&1R1@_@:\@TS7=9M/A]\._#^B7RZ?<:R[QO>&,.
M8T5CG:#QDYJQX>75-&\;_$<W.I+=ZC;:5&XO$B"%F$1*L5Z!NF>V10![717C
M^B^(_&%I\-KCQUJNK17:#3<6U@D  WAPHED8<DGDD# YJ+P9XD\;SZ_HKW*:
MW?Z=J"9OFO-,6&&#<N5:)UZKSW[4 >RT5XWIGB/Q1:>/8K/Q;K5_I33WQ2VM
M_L$;65U'T5%E'(8^I]11;>(_%%CX^6U\5:U?:1'-?^79Q+81O97,6?E02_>#
M'U/2@#T67QMX=AL]7NWU)3#I$@BOF6-CY+$XQ@#)YXXS6U;7$5W:PW,#;HID
M61&QC*D9!_*O$=?U>^U+P9\4X+N821V=^L4 $:KM7S!P2 ">@Y.36EI.L>)_
M#?B+P5;7FN1:EIVO6P0V@MU06^(U*E".2!D<D\X/X 'IVC^(=+UY[Y--N?/:
MQN&MK@;&79(.HY S]1Q6G7A_A[Q!<>%O"GQ*UBUC62XM]:F\L,,J&9@H)]AG
M/X5?\%^(O&TWB725NX];O]+OXB;R6^TQ8([=RNY6B=>JD\<]J /3]9\0Z1X>
MABFUC4;>RCE;8C3/M#'K@4_4]:TS1M/_ +0U*^@M;3( FE;"DGIS[UYU\:-+
M36V\*:7)]V[U,PY]"R$ _G7#:[J\OC'P'I>C3.6FT33+J[U-,_=D@!AC#>Y/
MS4 ?0]I=V]]9PW=K,DUO,@DCD0Y#J1D$5-7EEQK[:1\*O"5K;:E>V>HW]O;Q
M6ZV5HMQ--\@RJJQ"CJ.2:YN+QWXKM_"OCJUNKZZ6^T40-;7%S#$DZ!W (<)E
M#Q]>M 'LNNZ]IOAK2GU/5KC[/9HRJTFQFP6.!PH)ZUHHRNBNIRK#(/M7B/CZ
M+Q"WP=U'5/$6K17;7[V<T5M!"$2U4L"5!ZMG(R3Z5T/@/Q3J'C'7]2OI+R6Q
MT_2T6&+1B@$KY7(EER,\]@./Z@'IU)N&[;D9/.,\U\_V/C[Q[K,3:[ID.L7+
M?;"J:=!IBO9F$'!4RYW;\=ZW=1L=:U/X^BW@\0W-B1I GC*0(WE1EQF+!]2,
MENM 'KE[>VNFV4U[>SI!;0KODE<X51ZFH+#6M,U32_[3L;Z"XL<,?M$;Y3"_
M>Y]L&L+XF_\ ),O$7_7D]>2:5?S:'X0U?P1!)LNM7-FVFJ#R4NT428]EPWYT
M >[:/KVE>(;5[G2+^"]@1_+9X6W -@''Y$5HUX'X<UR;P#\,?&5SI<:-+::Y
M):V^\95.40,?7'7ZUU&GZOXG\+^//#VB:OKRZY:ZY [,3;K&UNZKG*[>J_7W
MH ]&UC6+'0-)GU34I_(L[< R2;2VT$@= ">I%6;:XBO+2&Z@;?#,BR1MC&5(
MR#^1KP'7-3\4>,/A[XN\03:Y%%I<-P]JNE?9UV^6KK@[_O!N1ZYP?6MWQ#XN
MUNTN?"GAK27U"WBFTB.ZGETZS6XN'^7 55;C QR?>@#U37=?TWPUIAU'5KG[
M/:AU0OL9OF8X PH)K1!#*&'0C(KP?Q7JGB+4_@O>#Q+:7,-U;ZI#%%+<V_D/
M<1;@5=DZ \D'''%>TZCJD.BZ')J-Q'/)%!&K,D$9D<YP.%')ZT :%4K'6-.U
M.XN[>RO(;B:SD\JX2-LF)^>&]#P:@T#7K7Q'I@O[2&ZAB+E-MU"8GR/]D]JX
M;X8LJ>,?B$C, PU7<03R!\W/TH ] TO6-.UJW>XTR\ANH4D,3/$V0''4?7FJ
MVL>*-"\/-$NKZM:63R\HLTH4L/7'I[UQ/P0(_P"$,U"3(V-JUP5;L1\O2J?C
MGP[JFF>+[KQM8Z9IVO68LQ#>Z?=@%XD49+1DY'09]>O!S0!ZG:W5O>VL=S:S
MQSP2C<DL3!E8>H(ZU+6)X1U/3=7\)Z9?:3;"UL9H 8;<*%\L#@K@<<$$<5MT
M %>(?&/_ )&ZT_Z\$_\ 1DE>WUXA\8_^1NM/^O!/_1DE 'K/A;_D4=%_Z\(/
M_1:UK5D^%O\ D4=%_P"O"#_T6M:U !618^&]/T_Q!JFMP++]LU,1K<;GRI"#
M"X';BM>B@#EO#WP]T#PM?:E=Z5#-$VH@B9#)E0,DX4=NIJAH?PJT#P[?6UUI
M]UJR?9Y/,2%KUC$3[KT-=Q10!Q6M?"KPMKFJ3ZC-;W-M<7/_ !\_9+AHEG_W
MP.#74:3I%AH6F0Z=IEK';6D(PD2=!ZGW)]35VB@#&TGPQINC7^KWEJDAEU:;
MSKH2/N4MST'8<FL;2/A?X6T37(]6L[.7SH69[>*29FBMRW4HAX%=E10!Q^N_
M#'PQXBUE]4OK6;SY=OVA(9V1+C;]WS%'WL8KKHHT@B2*)%2-%"JJC 4#@ 4/
M(D94.ZJ6.U<G&3Z"G4 <]8^"M%L/#=]H"0R2:?>O(\R2ON),GWL'M[>E0:3\
M/_#VD>%;CPU':O/I=P[/+%<.7))QWXQ]T8QTKJ** .1TGX;Z#I+3[6U"ZCEM
MWM?*N[QY46)N&55)P. !52Q^$OA:PEL98DOGDL+A9[5I;MW\K:<A%!X"YZC'
M.!7<T4 8^E>&=.T?6=6U6T$HN=4D62YWOE25! P.W6MBBB@#&\-^&-.\*Z?-
M9::LHAFG>X<2ON.]L9_#BL5?A=X;BU,WELM];(TPG:T@O)$MV?.<E <=0..E
M=G10!CZ7X9T[1];U75[42BZU1T>Y+OE25! P.W6J2^!=%2TU^U"W'EZ[(TE[
M^]Y);.=OIUKI:* .;D\#:-+%X>C9;C;H#*UE^]Z$  ;O[WW15WQ+X;L/%>BR
M:3J1F^R2,K.L,FPMM.0"?3-:]% &+X@\*Z7XET%=&OTD%HK(R>2^QD*?=P>U
M9.I?#+PSJVL2:I=07)N)HA'<A+ET6Y & 9 "-QZ?7'-=A10!R5U\./#MYX7T
M_P /S03FUT]MUK()BLL39)R''U_SBG:9\._#^D-J;6<5RK:G:_9;IGG9RZX(
M+9.3N.3DUU=% &1IWAK2]-\,1^'8X/-TQ(3#Y4YW[D.<@^O4UDZ'\.=#\/ZE
M#>V,FH_Z/GR+>6]D>&+((^5"<=">N:ZVB@#CK3X9>'K75X-1/V^X:VF\^W@N
M;QY(H7SD,J$X!':DA^&/AV/5XM1D^WW)@G^T0V]Q>/)#%)G(94)P,'I7944
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MX(^RB+^T?MX\S;CS,[9//W=^N<Y[XKTN@ HHHH **** "BBB@ HHHH ****
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MG63S&9K2!I3*LQ<QC.]1M#9]0.,^E5M;UW3_  ]8B\U&4QQ-(L2A5+,S,<
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MXW=?:@#MZ*YOPVS'7?%(9F(74$ !.<#R(^E8FFZO?:7XMU.>]NY9M&O-3:R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML(, CU[T =^LD;2/&KJ73&Y0>5STR.U.KE?#<HG\6>))]NWS!9OCTS#FNJH
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M63X6_P"11T7_ *\(/_1:UK4 %55TZV759-2$9^UR0K S[CRBDL!CIU8U:HH
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M'<@[3"\ZAP?3!.:LW%W;6@C-S<10B1PB&1PN]CT SU-'LXASL[?_ (2'3O\
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MU'LT'.SL?^$AT[_GH_\ WP:/^$AT[_GH_P#WP:XZBCV:#G9V/_"0Z=_ST?\
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M3[.OV[RO)\[)SLSG;Z4TK6^8F]RW1115$A1110 4444 %%%% !1110 4444
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MJ^G1:>(KQ6)&H:@MN%*G!4$!MQR",CCC-._F*QT/]G67_/I#_P!\T?V=9?\
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M$._*Q1D8')^9OHH]:-1:'86UE:Q3J\=O&CCHP7D<5?JO%_K!5BD,*\0^,?\
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MID1AA@&W[2>N"5X]ZWZ* .-U/X9^';W1[FS@LQ!<2PB(7)DD8@A0H9@& 8X
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M\+?\BCHO_7A!_P"BUK6K)\+?\BCHO_7A!_Z+6M:@!DOW*KU8E^Y5>@ HHHH
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M=<:M917KD!;=YU#DGH,9ZFM$\9SQCKGM0 451&LZ6=*;51J-J=.4$M="4>6
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M@#/%7Z**T2L0%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8'AV%YKW4=9NI(!?:AY>ZWBE5_L\2 A%8@\MR23TR<#I6_3Z""BBB@ HHHH
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M_P">U7ZH6W_'PO\ GM5^LY[FD-@KQ#XQ_P#(W6G_ %X)_P"C)*]OKQ#XQ_\
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MSD]Z[:L:R\+:1I^N2ZM:6-M!.\*PA8K=$"8+'<N!D$[L'V K9JEL2]PHHHH
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M3OM=O_SV3\Z/M=O_ ,]D_.CVGF*T1OV-/[QH^QI_>-.^UV__ #V3\Z/M=O\
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MMX#+M%K=["PD.65N,$>E=Y]GA_N"C[/#_<%.TNX69@Z1I-EH6E6^F:?$8[6
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MW(EN%%%%02%%%% !1110 5RNI>)Y] U#4[?4464-$L^E*B[3.3A##[N'*_\
M 6SVKJJQM:TF74M4T&YC6(II]Z;B3?UV^6R_+QUR1^5'49"=;N=,BLM/O+:X
MU36FM_.N(M/B7"CH6Y8 #/ YR<5,?$23:9::AINFZAJ4%RI=?LT:@H!UW;V7
M!SD8ZY!K)\1>%7O_ ! FL0Z?9:ENMA;26UU.\.W:Q975U!]2""/2J\WA6]2>
MQ\G2=+EL8[3RAISW+B&TE+EFD4;?WF0>X!XXZTPT-23QIIY_LY;2UOKV74;9
MKFVAMXAN95(# [B I&><\<=:V[J2[%BSV5O')=$#RXIWV*"?[Q&>G?'I7,^'
M?"]_I%WH;W#P,EAI<UG*8R>7:16!48Z84_2NO!PP/O0[= ,/PCJ5[JWAN"[U
M!XGNC)+'(T2;%.R1E&!VX%;=8_AC2[C1]"CLKHQF59IG/EMD8>1F'Z$5L4F(
M**** "BBB@ HHHH **** "N=O-4U>W\9Z58E+:/2[KSE'5I9"D>[=GH@!XQR
M3715D:CID]WXAT2_C*>38M.90QP?G3:,#OS0MPZ%+Q-/KFFV5]JUKJEE;VEG
M"94MI;7>9B!]UGW#&3P-H[CK5W6=2OK/PK-J5I9[KU8%E$#*6V$XW9 Y.T$G
M Z[:R=8L_$EWXA68:9I][I5J5>T@DOC%NE_YZ2+L.2#]T=!UZ])-3AUGQ%9Z
MKIK6\-HL7V<QL[,5N'X>2,GC,?1<@=S]*?0KJ1>']?OM1NK^.SO[/Q!:PVRR
M17D$8@3SR3^Y)!(Z8;/49P:+'Q-?6GA?7-4UG[/+/IMW-#MMQL0[=H503[MC
M)^M6M(TK4%\1RZO=V5EIJ&U%O]ELY3()3N!#N=JC@<#C.">>U1-X6FN_#_B#
M3+B6*,ZC>RW,,@&\("59"P^J\BA_U]_^0B3PUK#ZE=3)-K]I>S"(.;6"T,(C
MYZJS<NO;-=+7/6=CK5[XAM=5UB&RM?L=M)!%':S-+YK.5W,25&U1M&%YZ^U=
M#0Q!1112 **** "BBB@ HHHH Y?QUXAN_#VCI):>1"\_F)]KN,F.W(C+ G'<
MD87/&>OI6KH$U_<:+;3ZC/9SS2(&$EH"$8$#U)YZYP<5%XGMM6O-#N;;2/L1
MEFADC=+L-A@5(PI!X.?7BJ_A#P_+X?TR6.=K=9;AUE>"UC*0PD(JE4&3UVY)
M[DFFMF-[(Z"JNI:C;Z5I\U[=%O*B'W5&6=CP%4=V)P /4U:K*UO08=<^R&6\
MO;9K27SHFM)0AWXQDY!!P"<>F:0D<M)XHUJ'P[J$]_<6>GWL>L1V0D,8>.VC
M?8?FR<,5#$$\<UT&EW=]<:-//9:Q8:_.S[89$588E/ (;86Z=?7M6=I7A[5_
M#_\ :T]M.VJ275YYL<%_=X4Q[5&XD)Q)D>F, 5HZ!I5Y:ZOJ>KW\5K;37WE+
M]EM6+J@C! 9FP-S'/7 X '-5H,?X1U&\U;PS;7FH/&]TSRI(T2;%)61EX';@
M5!KFJ:O8Z]HT,"6R:;<WB6\KMEI9"RL< =% VCGDG-0V<&J>&/!'D0VT=WJ4
M<K^5$I+(QDF)&2.< -D^F#6CK>F7&H7.C20F/%E?K<R[CC*A6!QZG+"EU%W^
M9A:KKUPOBV\TL>*-/T6*"& QI<VZ.TSR;B2"S#C@"K-WJ.MWFJZQ;Z;?V5HF
MD11EA<0;_M+LF_+'<-B8XR.^?2K>N0:U>K=V-MI6DSVMQ$8A<7,Y!4,,'='L
M.[&<C!Y]JS-1\)S2VEC8V^F:;=26]FEJNJWDA\Q,#&?+ ^?'4 G&32Z%:7-V
MRU*;6O"MKJ=DT-K+=VRS(9P72/(R<X(R!SWKG;7Q7=VPUJ4:C:>(+/3[ W1N
MK2(1A)1G]R2I(.0-W'('7M6M9C4M/CN-(TRQA>TTVUMX;5[IV3[0^/G!8 C
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M:HUI.BNN&&13/LT7]T_G6<HMLEJY0HJ_]FB_NG\Z/LT7]T_G2Y&+E90HJ_\
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M._\ 0?TK_P #(_\ &G?\(OX?_P"@%IG_ ("1_P"%'_"+^'_^@%IG_@)'_A0
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MX2OP[_T']*_\#(_\:/\ A*_#O_0?TK_P,C_QIW_"+^'_ /H!:9_X"1_X4?\
M"+^'_P#H!:9_X"1_X4 -_P"$K\._]!_2O_ R/_&C_A*_#O\ T']*_P# R/\
MQIW_  B_A_\ Z 6F?^ D?^%'_"+^'_\ H!:9_P" D?\ A0 W_A*_#O\ T']*
M_P# R/\ QH_X2OP[_P!!_2O_  ,C_P :=_PB_A__ * 6F?\ @)'_ (4?\(OX
M?_Z 6F?^ D?^% #?^$K\._\ 0?TK_P #(_\ &C_A*_#O_0?TK_P,C_QIW_"+
M^'_^@%IG_@)'_A1_PB_A_P#Z 6F?^ D?^% #?^$K\._]!_2O_ R/_&C_ (2O
MP[_T']*_\#(_\:=_PB_A_P#Z 6F?^ D?^%'_  B_A_\ Z 6F?^ D?^% #?\
MA*_#O_0?TK_P,C_QH_X2OP[_ -!_2O\ P,C_ ,:=_P (OX?_ .@%IG_@)'_A
M1_PB_A__ * 6F?\ @)'_ (4 -_X2OP[_ -!_2O\ P,C_ ,:/^$K\._\ 0?TK
M_P #(_\ &G?\(OX?_P"@%IG_ ("1_P"%'_"+^'_^@%IG_@)'_A0 W_A*_#O_
M $']*_\  R/_ !H_X2OP[_T']*_\#(_\:=_PB_A__H!:9_X"1_X4?\(OX?\
M^@%IG_@)'_A0 W_A*_#O_0?TK_P,C_QH_P"$K\._]!_2O_ R/_&G?\(OX?\
M^@%IG_@)'_A1_P (OX?_ .@%IG_@)'_A0 W_ (2OP[_T']*_\#(_\:/^$K\.
M_P#0?TK_ ,#(_P#&G?\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%
M #?^$K\._P#0?TK_ ,#(_P#&C_A*_#O_ $']*_\  R/_ !IW_"+^'_\ H!:9
M_P" D?\ A1_PB_A__H!:9_X"1_X4 26OB#1;ZX6WM-7T^XG?.V.*Y1V.!DX
M.>E:-9]MH.CV5PMQ:Z38P3+G;)%;(K#/'! S6A0 5XA\8_\ D;K3_KP3_P!&
M25[?7B'QC_Y&ZT_Z\$_]&24 >L^%O^11T7_KP@_]%K6M63X6_P"11T7_ *\(
M/_1:UK4 %%%% !6%K_BBVT*>UM%M;B]U"ZSY%I;+EV ZDYX ]ZW:X7Q-'>:-
MXZTWQ,EA<WUBMJUK.MLF^2(DDAMO<<_SK.HVE='7A*<*E3EGV=E>UW;17\SH
M]-UU;K3);W4;.;2%B<HZWQ5,8[@YP1SUJXNJZ<]B;Y;^U-F.LXF4QCG'WLXK
MA/%-Q-XBLM&U5=%U&72[._+7=G-;XDD3 P_E]P.>*PKC2KR?PSXSNK'2;JTT
MZ^> V5F8"KDJPW,(QT!_STK-U6M%K_PQVQP-.:4I/E;=K:-+5*V][V=^UNIZ
MI_;FD#S_ /B:V7^C_P"N_P!(3]W_ +W/'XUF^(O%4.BZ1::C:I%?0W-S' K)
M,-N&S\P(!SC%<E'X3L!X[T!/[#B^P_V63,#;_NS)@XW\8+?7FL232+[_ (5L
MMDNEW4C+KQ*VPB8,8^>@[#WZ4G4G9Z?UI_F73P6'YHOF;3:NG9:/F71_W;^C
M1ZI=:W;'2+V\TVYLKM[93D?:55 P[,_1?QJ2'6+5;&VEOKJSMIIH!,4^T*5Q
M@;BK?Q*,]>E>82Z?)>R^++[2="N]/TZ32Q;K;O;>499@0?E0>@ST_K5]M$:^
MUKP'%>::\UK%8,)UDA)1&"# ?(P.1T-"JR?3^KV)E@:,59R\^E_@YK;VWT_J
MQZ.FIV$EB;Y+ZV:T R9Q*IC'_ LXI;74+*]MC<VMY;SVXSF6*0,HQUY'%>.W
M7A[4SI&KP6EA=)96_B SM;Q09+0@8RB-PX'''0UI0Z!+=>$O%#:0=4>YNXXU
M,=S9+:ARIR=B #)*Y!XH5:5]OZU'++J*C?VG5+II?EWU\_33[NU/B^UE\4Z=
MH]D8+N&\BD<W4,X8(4'W<#.?SKI*\JT"V@E\:^&[K3O#MYIL$5G+%<226IB5
MI G?U/N>N:[V_L=;GU>WGLM:CM;%-OFVK6JN9,'GYR<C(XJZ<VTVSFQ6'ITY
MQA%VTUOWN^U_(36?$46AZAID%U;2?9[Z7R!<@C9$Y^Z&^M1V'BBUU#4M6@2,
MQVNF.(Y;V1U$9?NH^G<TGC73TU+P=JD#0M*X@:2)4!+>8HRI&.<Y%</J'AR^
M;X3:/!96EQYBS1W5] J;I9,Y+$JWWB"1P?2E.4XMVVW+P]##U::YG:3?+Y=[
M_=I;:[N>EV^J:?=VC7=M?6TULF=TT<JLBXZY(.!26FK:=J$4DEGJ%K<QQ_?:
M&97"_4@\5YC:VLUCH?B#4M'L[^^GFCBBEM[W3%AC<9Y*Q*!O(&<\?G1X9L+I
M/%.HW*6MVMK/H[JKOIXM5=P0,!%&/IGDTE5=TK&DLOIJ,Y*>VVWE=-?/3N>H
M0:E874JQ6][;32/'YJI'*K$ITW  ]/>L'7O&$FA7$^_0-2GL[90TUY&JB, ]
MQD\X[U1^&6A6^F^%+2[DT_R-2E5EFDD0B0C<< YY P!Q67\0)QJ4L]E'9^(C
M>PJ$@A@A+6EP<@@N.C#L<^E.4Y>SYMF32PU+ZVZ7Q16EWIUWT?\ 6[/1+2YB
MO;."Z@):*:-9$)&,J1D5-5/2/M?]CV7VZ*.*[\A/.CC^ZK8&0/:KE;+8\N:2
MDT@HHHIDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 9^M:U9:!I
MKW]_(RPJ0H"J69F/10!U)K%T;QW8:EIES?7EK=Z;';(7E>ZB*IMW$#:W\1XQ
MCKGBK_BRWCNM EAFT>758G90]O$X5P/[RDXY'L:Y+X:VVLF*YBO(;C^P2A$$
M-\%9A)O.0O?:/?O6,I24TEL>G1H4986527Q)][:=DN_JOR.I\+>*[;Q7;WD]
MK;3P);3F'$P +< YQVZ]*K:MXPDL/$#:-9Z)>:C<I L[^0R@*I.._P#GFL3P
MS?+X9L_%FIZI!<0VXU9W7,1RX8@ J#C.2:J^-K;2KO4+F4Z'KSZQ);*MM<6B
M/L)(RO(.!@GG([5#G+DO?7_AS>.%I?6G'EO#IKUM%[W5[7U.UUCQ%;:%X>_M
M;4(Y(OD4BWX+ER.$'J?\#6.WCZ![72C9Z5>7=YJ4!N(K6(KE4'4DDX[5@:MX
M;\77>CV=[<7-G.]II;(UO<*[N)2AWL-O!DQP#6"-+U%](\.0Z_8WPTR&UDV2
MZ9;,;B-SD!'R,CC\#4RJ3OM8UH8+#.-W)-W>S\G9):-[7WU[]_6M!UVT\0Z+
M#JEH)$ADR"L@PR$'!!^A%8%C\1=/O=0MXC8W<-C=3-!;7\@ BE=>W7([XJMX
M2U&6VT/3?#NI6LMM>W<4PMD6$(5A7H\@'W6.?Q-<O8:=J=WI_ASPK)I%Y%<:
M9J)FNIY(B(?+#$Y#]#D-5.I*RM_3T,X8.CSU%/9/379>]KYZI([&R^(MC>7E
ML#IU[#I]W.;>VOW4>5))G '7(R0<5-'XTGNM:N["R\/WUU':7/V:6YC=-BGN
M>3GWKBHO#KWVJ6&DZ0-=_LVTOQ<,M]%Y<%NJL2=IZN2<@?7WI^NV$-QJ\I\.
M:/KUIX@>^WM<,'6#[WS,3G;M(YJ/:3MK_7H;O!X7GM%;KJ]M=&]4]M]_2QZ3
MXAUZU\.:6;ZZ220%UCCBB&6D<]%%84GQ#M;?3-3GO-,O+6\TX1M-9RX#E7("
ME3T(YIOB&\TGQ)H&HPRKJ)_LR[6-I;.'<ZSJ>J 9SC//UKEK313<KK&LZ[8:
MW?:=<I#;JLJ8NI<,"9-BXVJ"  /2KG.7-[NQSX;"T'2O63NG]^JLEK;5-^>Q
MW$/BJY72-1U+4-!O;"*SA\X"9E)E&"<#!Z\=_6I?#WB2[UUE:30;VQMGA$L<
M\S*5<'& ,'/(.:XK0[':OB)UTO6CX7EME1;*<-YTCY&XHI.>!GO5KP;8M%XR
M,VAV6K66A+:E9TU#< \N?EVAB3P,?K1&<KK^OTV'5PM%0J66JU79:+3XG[U_
M5'I=%%%=)X@5XA\8_P#D;K3_ *\$_P#1DE>WUXA\8_\ D;K3_KP3_P!&24 >
ML^%O^11T7_KP@_\ 1:UK5D^%O^11T7_KP@_]%K6M0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!#=6EM>Q"*Z@CGC#!]DBAAD'(.#
MZ&IJ**!W=K!1110(A-I;&\%X8(S=!/+$VT;PF<[<]<9[5-110-MO<****!$-
MM:6UDCI:P1PJ[F1A&H4,QY)..Y]:FHHH&VV[L****!!1110 5XA\8_\ D;K3
M_KP3_P!&25[?7B'QC_Y&ZT_Z\$_]&24 >L^%O^11T7_KP@_]%K6M63X6_P"1
M1T7_ *\(/_1:UK4 07EY!I]G+=W+E(8E+.0I8X]@.33;:^M[N22.%R7C"LP(
M(X894_0_T/I2WY@_L^X%S.D$+1E7E=@H4$8SD\=ZHZ5:QK>SW4=S#-&8(8(S
M&V[Y5!.3CN=_Y8]: )GUJTCN[B"3S8UMQ^]G>,K$IP#@N>,X(_.F1>(=)GED
MCAOX)6B95DV."$RNX$GTP.M9USH-O/J>HW*WEF'N-J2"2!6>-L+M&[<".@('
M!R013CX4WP2P3:C-*DFUF+H"Q<1&,DGN""./;J: -.'6]*N"PAU*TD*H9"$F
M4X4=3UZ"F+K^D/,T2ZE;%U@^T-B08$>2-V>F,@UGZEHUHB32MJ8L7W/-YN57
M9NC6/.>..!S^&:I6_AFQET^2./6!-#/%N9U8'++*90X8-G 8D'D_6@#>EUW3
M8I;6(7D,DETRB%(W#%@>C 9Z>]22:SI<+2K)J-JAB<)(&F4;&/0'G@\&L2S\
M,V\-W;B#4DPC1W4L*("9&7=AP2Q(!R?7)[]:G?PS)Y?EQ:@8UC>0P PAMBR9
MW@\_-G/!XQ[T :%UK^D6<PAN-1MDE,BQ[#(,AFZ CMFG7FM:=8+<FXO(5>VB
M,TL>\;U0=\=:RAX6$,Z^1J!A"-$\,83(S'CE@3\S$<$C'7G-3W'AI;B[GD:[
MD$,K22"((,K(\?EEMWIM_A]: +<>NV#P12-,D<DL2S"!G4R;3T. 3Q]*M+?6
MCQO(EU R(@=V$@(53T)/8<'FL?4=&@EF>^EU%+:V6()(0 H8J1@NQ.#@CTR/
M6JUOIVCI8W.G)K-O(=3;SU >/+R$Y+*!U!('R]."* -Z+5+"> 3Q7UL\1) =
M9002!DC/L.?I4$?B#2Y2Y%[ (PRJLK2 (Y;. ISR>#6*=(CU*^FEO+V%HKJW
M$,,D;*!<28R9%7)Y"@+C)R >U3WWA$:E(MQ=7I>YZ,P0JC+C:1M5@>1CO0!M
M?VII_EW$GVZWV6YQ,WFC$9]&/:JO_"06+7YLX&:YE%M]J/D;7^0],#.23VP#
M59/#;)#<1K>E-TZ3P*D>(X64Y&$R<Y/7&,^QYJWI>CIIC;Q.TKM'M<E0 6+L
MY(';)<\=J ([#Q+IVHRV\49GC>X#F$3PM'O"8W8R.V?T/I3(O%&G3QV<L NI
M8+N3RXI4MW*EMQ7!...0?PYZ5!+X3ADLK>W%Y.C0*RI(H 8;GW'\QE?H:=!X
M<EM+VUEMKY5@MB^R%[<,%WN6;:<C!P=N>>![F@"]!KVESI<,+V!/L[%9EDD4
M&/#%?FYX!(XJ0ZSIBK*S:C:@18\PF91LSTSSQFLU?"ZFY#S7;2Q1RF2&,Q*-
MNZ42L"?XN5 'I[TV+PL!K#ZC/J$T[F4.BN,A0&+ <D],XX X [\T :,VN:=%
M-:P_:XGENBODI&X)8-G# 9^[QUJO=>)M/LY)8IQ<)(C*H0P,"^20"OJ/E//M
M56'PJMO=6[QWK"&*1)FC,2DNZ@@'=V&#T]OK3V\/WDAO#+J,$S7+@[IK)7VJ
M,X7!;! !XX]3SDT 7!X@T[[1)#),8?+!W/,I1,C&1N/&1D9'O3UUW27AEF74
M[-HH@ID<3KA0W3)SQFLNW\(06[0(+R5[>WD$L,;J"5?*EB6[YV_AD^U5]8\,
M7'V2,Z;(_GHYY1@CJ#(9"RGIG)QSV)[T =1!/#=0)/;RI+#(NY)$8,K#U!'4
M5)532X);72K2WF2-)(HE0K%G:,#&!FK= !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7B'QC_
M .1NM/\ KP3_ -&25[?7B'QC_P"1NM/^O!/_ $9)0!ZSX6_Y%'1?^O"#_P!%
MK6M63X7&/"6C ]18P _]^UK6H IZHMX^GR+IZ0-='&SSVPHYZ]#R.HXZUG:#
MIDUA=3[K?[/$+>&$*)-X=EWDMG S]X#.!T/& *W:* .<N_#US)JDE];311M+
M=Q22@Y^>)-N.WW@5)'L2*K6OA:ZW*EVT1M]Z&:-9G(N"H?=(W PS%ERO(^7K
MTKK** .:ET&^-E;J'AFFAMHXL2.P#LLBO][!.,+C.*@D\+7EW+=7$EW]C>YC
MES%:2852P0 $E?F'RY)P.37644 8EOHCV\GFIY*R-IZVK.HP2XZ'..E9?_"'
M31PL+>X6*5E"^8)7.,PLC_FY#>^,]:Z^B@#DSH&IS:E%J<T5D;J/S!$K3.ZQ
M9B10<[1GYD)(P.&ZU!9^$;];5DN9H=Z;VMU21L0N2A!& HXVMV[_ %KLZ* .
M8A\/7%II\<5O!:"2#4)+I4,C;)PQ;&[Y?E8!N.#@J*I?\(WKLUQ')<7,;DE-
MQ>X+!0DK,H9?+&\@$ '*\^M=I10!QMOX0NX6M \T+0V>[[.B.RE-\;"3#8X)
M8C![#-;WA^PGTS24M9UB5U9B!$<@ GC)P,GU.!6I10 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5XA\8_P#D;K3_ *\$_P#1DE>W
MUXE\88WD\76I1"P%B@.!_P!-)* .H\:>*;_P/=10:6D$D%P#)Y=PI81DDY"[
M2"!GG!S[5RO_  N/Q#_SY:7_ -^I/_BZ** #_A<?B'_GRTO_ +]2?_%T?\+C
M\0_\^6E_]^I/_BZ** #_ (7'XA_Y\M+_ ._4G_Q='_"X_$/_ #Y:7_WZD_\
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M7_WZD_\ BZ** #_A<?B'_GRTO_OU)_\ %T?\+C\0_P#/EI?_ 'ZD_P#BZ**
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'_K110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "$ .8# 2(  A$! Q$!_\0
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M/^ASUS_OS9?_ "/7044 <_\ \(]JG_0YZY_WYLO_ )'H_P"$>U3_ *'/7/\
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M (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\
M]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@Q
MA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .
M@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A
M._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ #P;_R [G_ +"NI?\
MI;-14?@:>&Z\-R7%O+'-!+J>H/')&P974WDQ!!'!!'.:* .DHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #N O0# 2(  A$! Q$!_\0
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MB(0'!^7+X;^!6IO_ #_K]/4%_D>A0N988Y&C>)F4,8WQN4D=#@D9'L33ZS=
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M ,_TW_@._P#A0!V]%065Y#J%A;WMNQ:"XB66,D8RK#(X^AJ>@ HHHH ****
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M\A\(:]KGA;13IY\(ZE<DRM)O".G4 8QL/I0!Z]17 ?\ "P=;_P"A'U/\W_\
MC=9FL^.?%URMB-,\*:E:F.\BDN"4+^; #\\?,?&1W'(H ]2HK@/^%@ZW_P!"
M/J?YO_\ &Z/^%@ZW_P!"/J?YO_\ &Z ._HK@/^%@ZW_T(^I_F_\ \;H_X6#K
M?_0CZG^;_P#QN@#OZ*X#_A8.M_\ 0CZG^;__ !NC_A8.M_\ 0CZG^;__ !N@
M#OZ*Y[PGXG?Q-!>/)I[V4EK-Y+QN^XYQSG@8(Z8KH: "BBB@ HK/AU>WFUVY
MTE3^_@B60]>_4=,< H>O\7L:T* "BBB@ HHHH **** "BBB@ HHHH **** "
MBBJ>JZA'I6EW%]*,K"F0O]X] .AQDD#/O0!<HJGI6HQZKI=O?1#"S)DK_=/0
MCH,X((S[5<H **** "BBB@ HHHH **** "BBB@##\4>'O^$DL;2V^U?9OL]]
M!=[O+W[O+;=MQD8STSV]*Y_QE\-CXKUAKZ#7+C38[JT6RU"&*(-]IA602#!R
M-K=1N(;@XQC(/>44 >>ZY\+8M8\175['K$EMI>HM;'4M-%NK+<_9_P#5J'R"
MBX R,'_#T*BJ6I:QIFC0)/JFHVEC$[;%DNIUB5FQG +$9/!H Y/X/_\ )+]+
M_P"NMU_Z4RUW-<+\'6#?"[2F4@@R71!'?_2):[J@#!\2Z[+HAL/*ACD^T3A'
MWYX7OCWYZ_I6]7+^,=+O-2.E_9(#+Y5QE\$?*..?TKJ*8!1112 **** "BBB
M@ KDOB;_ ,D[U?\ W8__ $8M=;7)?$W_ ))WJ_\ NQ_^C%H U/"/_(EZ%_V#
M[?\ ]%K6S6-X1_Y$O0O^P?;_ /HM:V: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH X%?#FBZ!\3M _LC2[2Q\[3[[S/L\03?AH,9QUQD_G7?5RFJ_\E/\ #7_8
M/O\ _P!"MZZN@ HHHH **** "BBB@ HHHH **** .+\!_P#(3\5_]A:7_P!"
M-=I7%^ _^0GXK_["TO\ Z$:[2@ HHHH XVQ\%W5IXA74SJK/*LGFN_V90)-Q
M.]?O<<9[<;ACV[*JZ1L-1FE(^1HHU!V+U!?//4]1P>!VZFK% !1110 45FWF
MO:=874]K<3N)X+4WCQI"[D0@X+ *#GGL.?:M%&#HK#.&&1D$'\CTH 6BBB@
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M#D8+11*I(].!4)T+2"23I5B2>I-NG^%&@#)/$&EQ:3'JCW0%G(=J/M/S')&
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MST&30!/1110 4444 %%%% !1110 4444 %%%<Y?>/?#&FZA'8W>JHEP]T;,
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MD'H36U10!PGP;18_A9I*(,*LER /;[1)7=UPWP?_ .27Z7_UUNO_ $IEKN:
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M*^&_^?S5?^_L?_Q%>CT4 ><?\*5\-_\ /YJO_?V/_P"(H_X4KX;_ .?S5?\
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M/,\O9P>=V#MQZX.*L57OY%ATZYE<X1(F9CO9> #W7)'U'/I0!8HHHH ****
M"BBB@ HHHH **** .0^)=QCP1J-G!JEE8WL\6Z(75XMN)45T\Q Q(QN!V9R
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M+=R++N&-TG&6')X/'I]*UJYGP8"+;5@1@C4Y@0?HM '34444 %%%% !1110
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MW-:%9^E7,MS]M\UL^7=R1K^]1\*,8^X!M_W6RP[FM"@ KE/B3_R(&I_]LO\
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MF6UCY^GWWF^2FW?M:#&?ID_G7H- !1110 4444 %%%% !1110 4444 %%%%
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MW_\ Z%;UU=>>P^'X="^)V@^5J&J7?G:?>Y^WWLEQMPT'W=Y.WKSCK@>E>A4
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M)?I?_76Z_P#2F6NYKA/@XBQ_"S244859+D >@^T2UW= !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<=\2?^1<@_Z^U_\ 0'KL:R/$=R;73XY!
MHYU4^<!Y(3=MX)W?=/3&.G>F@-?M17,6GBF^N+R&"3PWJ,*2.$,C(V$R<9/R
M]!4VJ>([S3]0DMH= O[M$ _?1(=K9&>, ^N*+ =#16-I>MW&H6UU+-H][:M
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M7_0ZV'_@D'_QZC^P_'7_ $.MA_X)!_\ 'J .PHKC_P"P_'7_ $.MA_X)!_\
M'J/[#\=?]#K8?^"0?_'J .PHKS?Q4?'7AGPOJ&M?\);87'V.+S/)_L<)OY'&
M?-..OI7I Z"@ HHHH **** "BBB@ HHHH **** "BBB@"MJ&G6>K6$UAJ%M%
M<VDR[9(I5W*PZ]/K@U!HFAZ9X<TN/3=(LTM;2,DK&A)Y)R22<DGW)K0HH R;
MO1?M7B?3-9^T;?L5O<0>3LSO\TQG.<\8\OT.<]L5K5\]^(+:.X\/>._&L@<^
M(](\1_9[&[WL##'%+"B*%SMQM9NHYSS7T)0 4444 %%%% !63X9T7_A'/#.G
M:-]H^T?8X%A\[9LWX[XR<?F:Q/BGIU]K'P\U'2]-V?;+MH8H]\RQ _O4)&6(
M'0'CJ?>N;^$EA'X>U[Q-X?N-#L--U*W\B222PN)I(KB(A]AQ*S%2,GN,[N@Q
M0!ZK1110 4444 %9%[HGVSQ/I.L_:-G]GPW$7D[,^9YOE\YSQCR_0YSVQ2^(
M=,U'5].6TT[6IM)=I!YT\,2O(T6"&12WW&.>'&2"*\:L9I1^SKX;LA(Z6VH:
MF+.[=6((A>ZDW<CIG !]B1WH ][HKS;X=Z?;:%X^\=:#IJ-!I5F]C);VP=F6
M-I("7(R2<D@9^@KTF@ HHHH ***\B\8:==VWQJ\$7MSJD]TEU<W(@MF4+';1
MK&G"@=6)9B6/)&T?PT >B^%="_X1GPOIVB_:?M/V.$1>=LV;_?;DX_.MBOG?
MXC:7J$WB3Q'XKUO0]*U/1M.>WMTAEU"19A%N*?)Y+_*2S9/F#C/ X->_:;>0
MZCI=I?6V[R+F%)H]PP=K*",_@: +5%%% !117,^/-+T;5/#,@\0ZE<V.DVTB
MW%R8)_*$RJ"/+? )96S]T<D@8YQ0 MWX2^U?$*P\5_;=OV2R>T^R^5G?N).[
M?GCKTQ72U\Z1V-[;>#M4NK>SN-(\,>)-9LH+6S:5@8[0LV^3!)V"3Y?J..5Q
MGT+X=Z?;:%X^\=:#IJ-!I5H]C);VP=F6-I(27(R2<D@9^@H ])HHHH ****
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MDX% !12*P90RD%2,@CH:6@ K,U#P_I>J:KINIWEKYMYIC.UI)YC+Y9< -P"
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MCDCM]Y?SK1H YS6/ /A77]7BU75=$MKJ]C  D<'YL=-Z@X?_ ($#71
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M$C@T <M\%]?U/Q'X0OKS5;^6^F74I8TEE4*=@5"!@<#J>/>O*]#L-2\,^$M
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:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #^ A4# 2(  A$! Q$!_\0
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M .2*Z"B@#G_^$AU3_H3-<_[_ %E_\D4?\)#JG_0F:Y_W^LO_ )(KH** .?\
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M5/\ H3-<_P"_UE_\D4?\)#JG_0F:Y_W^LO\ Y(KH** .?_X2'5/^A,US_O\
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M6PUT%<_XR_Y =M_V%=-_]+8:Z"@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *KV]];W<]W#!)ODM)1#.-I&
MQRBR <]?E=3QZ^N:L5CZ--;R:KXA2"U\F2+4$2=_,+><_P!E@(?!^[\I5<#^
MYGJ30!L4444 %5[^^M],TZYO[R3R[6UB>:9]I.U%!+' Y. #TJQ6/XLFM[?P
M;KDUY:_:[6/3[AYK?S#'YJ"-BR;ARN1D9'3- &Q1110 4444 %%%% !1110
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M!-"X="]S,X##H2K.0?Q%=S13#<**** "BBB@ HHHH Y_P;_R [G_ +"NI?\
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MS_V%=2_]+9J*/!O_ " [G_L*ZE_Z6S44 'C+_D!VW_85TW_TMAKH*Y_QE_R
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M ZSPIX T+P?+<75C'/<:E=9^TZA>2F6>;+%CEN@R3S@#. 3DC-=110 4444
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MGV!J*Y&@VWB"TEN4T^/6;E&BMI)%03R*!EE4GYB!GH*U:J[Y4F39<S://_\
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MM_Y)#KO_ &[_ /I1'0!Z!1110 4444 %%%% 'S_HO_)(?A;_ -C7!_Z43U]
M5\_Z+_R2'X6_]C7!_P"E$]?0% !1110 4444 %%%% !67!'8CQ5J$L<TAU!K
M*V6>(CY5B#S^6PXZEC*#R?NC@=]2LN"\A?Q5J%DMI&L\-E;2O<C&Z17><*AX
MSA3&Q')^^>!W -2BBB@ HHHH R_#4=C#X5TB+2YI)]/2RA6UED&&>((-C'@<
ME<'H/H*XCXWO)'X.T]X8O-E75K8I'NV[SEL#/;/K7=Z%+YWA[3)?[._LW?:1
M-]AV[?LV4'[O&!C;]W&!TZ"LSQIX4_X2_2[2R^V_9/L][%=;_*\S=L).W&1C
M.>M)[KU7YH.C]'^3/.+S6O$&K_%OP.==\+MH9C>Z\H&]2X\W,?/W0,8P/SKV
MJN;UKPG_ &QXN\/:]]M\G^QS,?(\K=YWF*%^]D;<8]#7252^%+U_,'\5_)?J
M%%%%( HHHH \STD'PA\:=0T=9)%TOQ-;MJ-NC)(5%XI/FJC9*Y*AG;I_ .,#
M/IE>?_&#1I;WP6VLV"8U?094U&SF 3*;""^=XY4*"Q7N47KC!Z >--"7P7#X
MMFN_)TB2))3*5,ACW$+M8)N^8,=I S@@^E '045AZ!XQ\.>*45M%UBTNW*%_
M)5]LJJ&VDM&V'49QR0.H]16Y0 4444 %<7\3_%.J^$?"T5_HT$$][+=QVZ1S
M(6!W9Z $<Y KM*\]^+W_ " -$_[#EG_Z$:EZV2[K\T-:7?D_R97M_B5<ZEI'
M@F_LHK=3K-^+.^C=2?*8 APO/'(R,YXQ7I5?/NM:/=^&/C1HNDP18T;4-8CU
M2V '"2$;95'XX..PQ7T%5IIQYN[?Z:??<FUI./:WZ_\  "BBBD,**** "BBB
M@ HHHH **** "BBB@ HHHH Y_P &_P#(#N?^PKJ7_I;-11X-_P"0'<_]A74O
M_2V:B@ \9?\ (#MO^PKIO_I;#705S_C+_D!VW_85TW_TMAKH* "FJZ.6"LI*
MG# 'H?>G5X?H/C)/#/BOQU;OH.NZCY^J.PDTVS\Y$X(PQW#!J6[.WDW]P[:7
M\U^I[>KJZAD8,I[@Y%+7FGP9O+:Q^$%C=WEQ%;6\<D[22S.$5!YK<DG@4WXJ
MZ\M]X/TJST74HVM]=U**P-Y:3!@(R3NVLIYY7!_$5<DT^5;Z?B)-6N_/\+_Y
M'I,<\4V[RI4?:<':P.#4E<IX;^'/AOPCJ(OM$M);68P&"0>>[K*"0<L&)^8$
M=1CJ:ZNAB"BBBD,***KWU_9Z99R7E_=P6EK'C?-/((T7) &6/ R2!^- %BO-
M_CG?V=O\+=4LYKN".ZNO*^SPO( \NV>,MM4\M@<G'2L/4OB]J7BKQ OAKX;V
M4=U/*@+:K=*RQPJ0=SA" 0%)7YFSD@J$;*Y[SPIX._X1^6XU'4M3GUK7;K*S
M:C<K@B/<6$4:9(CC!.=J\$^P4  T/#WBK0O%=F;K0]3@O8U^^$)#QY) W(<,
MN=IQD#.,CBMBN#\4?#:&_O7U[PQ>2:!XD5&*W%KA(KEBX?%P@'S@L.3WS\P<
M "J=C\2KS0M6CT7XB:?!HMU-G[+J,#E[.[_>%>#R8\ J?G/0Y;9D @'I%%%%
M !14<\\-K;RW%Q+'#!$A>221@JHH&223P !SFO-[_P ;ZOXQU3^POA^LD<4=
MP4O?$<L >UA5-I80YR)'.[&#VY'!WJ <W=Z2_AC0?AMX(N;F"ZUVW\017KP6
M>Z3]P)96:3[H(4!^I ^ZV,A21[A7)^#/A_I'@U'N(?,O-8N4Q>ZG<,6EN&+%
MF/).T%CG ZX7<6(S764 %%%% !1110 4444 %4XX[X:S<RR31G3VMX5@B ^9
M90TGF,>.A4Q <G[IX'>Y67!'8CQ5J$L<TAU!K*V6>(CY5B#S^6PXZEC*#R?N
MC@=P#4HHHH **** *>DQWT.C6,6J31SZ@EO&MU+&,*\H4;V' X+9/0?05<K+
M\-1V,/A72(M+FDGT]+*%;66089X@@V,>!R5P>@^@K4H **** "BBB@ HHJ.>
M>&UMY;BXECA@B0O))(P544#)))X  YS0!S_C'6[O3K*WTS1_+;7M6=[;3U>1
M%$;!"S3-NSE(U&XX5LG:N/FKET^#5CI")+X2\0:SH%XJ1!GBG\V*=T;.^:(X
M#D@D;<A>?NXR#N>#89=9O+OQK>VWDR:I%''IT3E&>"Q4;DR5'#2,S2,NYL90
M9RM=A0!X'XE\ >(T2>36O"&C>*$"7+_VAI#_ -GWQ9F#"615&R1\9P@1^1U.
M3OCT?Q7>6EX\6@?$?RY(Y7:?1_&\1C>+ V,'N.[!@&$:D8R<\AL_0%9>M^&]
M%\1V_D:SI=I?($=$,T09HPPPVQNJ$X'*D'@>E '-^&_&'B6YUBVT;Q-X+OM-
MNI8@PO;9UN+0D*Q8NZ\19*X"Y8_,,]B>DU_Q'I'A;2VU+6KZ.TM X3>P+%F/
M0*J@ECU. #P">@->=Z[\.?\ A"]%U/7/!?B+5=$^Q12WIL/,^T6C[83N'EO_
M !-M'S,6QV' Q<\"^ K&_M](\:^(;N[US7KJWBO(YKQ\QVI<&0+%&. !YG&<
M@%<J%Z4 5QJ_C?XE!SX?\SPKX;=% O[RW)O;D-&23$N<!/F7# @_Q*Y.5'>>
M&/#.G>$=#ATC2Q.+6+D>=,TA+'[QY.%R<DA0%R20!FMBB@ KS?XJ^(?[*_LJ
MSGU'5= MY)?/CUZUC\V&.9.1#+&IW.K+N.#@9"\, ^WTBHYX(;JWEM[B*.:"
M5"DD<BAE=2,$$'@@CC% 'G?A7Q_JD.HZ=X=\86&R_O(@=/U2P_TBVU, XWKY
M8.SY=KG/ !+$(, S:)\4H=4^).H>#[C3OLK0/)';W/G;A.T?)&-HP<9/4]*T
MO"W@"W\&:Y>S:)?SP:)=1#=I#YD2.<8'FJ[$L,J,$=\]<!0/+[[1[BY3QGX@
MTU2=5T#Q&U];[>K*%7S$/L5&??;BE=*6NUG^GY7N.UXZ;Z?K^=K'KW@WQ.WB
MO3;V[:T%L;:_FM-HDW[@AQNZ#&<]*Z*O-/@?=C4/!5]>JA07&K7,H4G.-VTX
M_6O2ZIIJR?9?DB4[Z^;_ #84444AA1110 4444 %%%% !1110!S_ (-_Y =S
M_P!A74O_ $MFHH\&_P#(#N?^PKJ7_I;-10 >,O\ D!VW_85TW_TMAKH*Y_QE
M_P @.V_["NF_^EL-=!0 5R'A7PK?:'JGBJZN9;=TU>^:Y@$3,2JD$8;(&#],
MUU]%)J_W6^\=SS.QTVR^''P?-GXMM['48K9W9H OFQ2N\A,:_.H'4CDC Z]J
MSM.\ 6'B3X6-I>G:OIWV[[>VH)/ITBRP6ER3N\L;#T52%_(XZ5Z[13>K;?6W
MX?\ #"[?/\;_ .9Q_A:V\?KJ D\57^C&TBA,:Q:=&Y:9\CYW9@,8 /"X!STX
M%9_Q6M=4U'0UL+;PS/KNF213/=QVM_\ 9IHG7:8V7KYG\9V;&RRH<< 'T"BF
MW<5CY\TWQ=J6DZLUEI?CJ[LYQ<'=H_CNU9&"F$'<URN2!G!5<I^.?G[=/BAJ
M^@(B^.?!FI:6@2+S-0LL75JNYMK,[*?W8W8PN7;!^F[O-9T/2_$.G/8:O807
MMJV3LF3.TD$;E/56P3AA@C/!KA_^%3?V-/Y_@OQ1JOA[,OF&UW?:K3E-C?NG
M/+' .YBV,<#IA#,/Q7^T+H&G6YB\-PR:M=NF5ED1H8(R0W7< [$$*=H !!^\
M#7FFDZ#XU^.&N3ZC>7OEV$,OS33%O(M]VW,<$?=@H!QQG W-E@3L:-\(7N?B
MTFB^)WL4C_L\:I+#I6Y8Y@'$>WD+Y>YLL0HP!D+M&-OT?8V%GIEG'9V%I!:6
ML>=D,$8C1<DDX4<#))/XT 9_ACPQI?A'0X=(TB#RK>/EF;EY7/5W/=C@?D
M  !L444 %4]5TJQUS2[C3-3MH[FSN$V2Q/T8?S!!P01R" 1@BKE% 'E<_A7Q
M-\-S+?\ @B:35=#5"\^@7TK.T8\S<?LI'0[6;@Y)QD^8Q &A_P +L\%QZ7<W
M5U=7=G=VSM'+IMQ;,MTL@W_)MY&?D/.["DJ&*DXKT2J[V%G)>+>/:0-=)C;,
M8P77 <##=>!)(!_OMZF@#S.+PWXC^)MQ]M\91W>A^'U2/[/H-O<_-<<JY:X8
M '&0 %(5E_V""7],L;"STRSCL["T@M+6/.R&",1HN22<*.!DDG\:L44 %%%%
M !1110 4444 %%%% !6?#+GQ#>Q?V=Y>VT@;[=M_UV7F_=YQSLQNQDX\WH,\
MZ%9\/]H_\)#>^;_R#/LD'V?[O^NWS>;_ +7W?)Z\>G>@#0HHHH **** ,OPT
M\TGA72'N+*.QG:RA,EI'$8E@;8,H$/*A3QCMC%:E4])COH=&L8M4FCGU!+>-
M;J6,85Y0HWL.!P6R>@^@JY0 4444 %%%% 'E>A_$_4;GXK7_ (7U2VMH].-Q
M-:V5Q&C*QECP=K$L0<J>P')%=-X)UR?QCH&JMJUO:R(E_<V)B6/Y'B4XPP8G
M.02#V->;3^'I]<L?'MUIZ_\ $WTKQ"U_8L!SO102!ZY /'KBNJ^!=S)?>!+J
M]E38]SJEQ,5'0%MI./QS2IZQUWLOQ>_YH)Z2TVN_P7_#,]-HHHI@%%%% '/^
M._\ DGGB7_L%77_HIJ/ G_)//#7_ &"K7_T4M'CO_DGGB7_L%77_ **:CP)_
MR3SPU_V"K7_T4M '04444 %%%% !7/>(=3T7P/X>U/7I]. M]ZR72VD">9,S
MLJ;CD@,<L,DGI70UY_\ &W_DD.N_]N__ *41T =M8:;8:5:BVTZRMK.W#%O*
MMXEC3)ZG"@#-6J** "BBB@ HHHH **** "BBB@ HHHH Y_P;_P @.Y_["NI?
M^ELU%'@W_D!W/_85U+_TMFHH /&7_(#MO^PKIO\ Z6PUT%<_XR_Y =M_V%=-
M_P#2V&N@H **** "BBB@ HHHH **** //_\ FX7_ +E3_P!NZ] KS_\ YN%_
M[E3_ -NZ] H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/ATS
MRO$-[JWG9^TVD%MY6W[OE/,V[.><^=C&.-O?/&A10 4444 %%%% %/2=-AT;
M1K'2[=I&@LK>.WC:0@L510H)P ,X'H*N444 %%%% !1110 5GZUK-GH&F'4;
M]_+M5EBB>0D )YDBQAF)( 4%P2>P!K0J.>"&ZMY;>XBCF@E0I)'(H974C!!!
MX((XQ0!CZ;X@:Y\2ZEH-]:QVEY:HMQ;[;A9!=6S$J) ,!@0RE64C"G;@D,#6
MY7D[6NHZ-YFE6MQ/<:WX3B2ZT@*ZQOJ.EMM#P.B;M[?NFCSL!W+"PP6.?3-*
MU6QUS2[?4],N8[FSN$WQ2IT8?S!!R"#R""#@B@"Y116'J/C'PYI6J6^EWFL6
MB:A/<1VR6BOOE\R3[@9%R5!R/F( Y'/(H \[\7^/;M/B%=^"M2@A7PW?1)87
M%U&I$T1N(R =Q)4<YZKT%=5X"U*?[?KGAD[#8^'FM[&S<C]XT8B RYZ$_+V
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MNH:YJ.CVTY>^TX1FYC*, F\97DC!X]*\V\:G7E^-.B?\(TNG'4!I$NT:AO\
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M,O\ D!VW_85TW_TMAKH*Y_QE_P @.V_["NF_^EL-=!0 4444 %%%% !1110
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ME>I(T#.C_NY7B8,CAU(9"&!#*#D$=*R_^$-TO_GZUS_P>WO_ ,>H Z"BN?\
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M Z"BN?\ ^$-TO_GZUS_P>WO_ ,>H_P"$-TO_ )^M<_\ ![>__'J .@HKG_\
MA#=+_P"?K7/_  >WO_QZC_A#=+_Y^M<_\'M[_P#'J .@HKG_ /A#=+_Y^M<_
M\'M[_P#'J/\ A#=+_P"?K7/_  >WO_QZ@#H**Y__ (0W2_\ GZUS_P 'M[_\
M>H_X0W2_^?K7/_![>_\ QZ@#H**Y_P#X0W2_^?K7/_![>_\ QZC_ (0W2_\
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M>WO_ ,>H Z"BN?\ ^$-TO_GZUS_P>WO_ ,>H_P"$-TO_ )^M<_\ ![>__'J
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M_'J .@HKG_\ A#=+_P"?K7/_  >WO_QZC_A#=+_Y^M<_\'M[_P#'J #P;_R
M[G_L*ZE_Z6S45J:7I=IHU@ME9)(L"N[_ +R5Y6+.Y=B6<EB2S$Y)/6B@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %' GP# 2(  A$! Q$!_\0
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M#\CMQTP3P0QI#/6O^&CO!_\ T#=<_P"_$/\ \=H/[17AJ<&*PT77+F]?Y;>
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M'CYCZFO0/!W@#0O W]H_V+'.OV^422>=*7VJ,[47_97<V,Y;GDGC'#_LX_\
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M,@L2<DDXR0, D5Q?A[_DZ'Q9_P!@I/\ T&UKV"O'_#W_ "=#XL_[!2?^@VM
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MFM#PMX@'B#1+&_,8B:YMXYC'NW;-R@XSQG&>N*TJX3X7L?\ A%])'_3E#_Z
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M7^'7B&X\5?#_ $?6+Q<74T128Y'SNC-&S\  ;BI; '&<=JZB@ HHHH ****
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MHHHH **** "BBB@#Q_X0?\E#^)W_ &%1_P"C;BO8*\?^$'_)0_B=_P!A4?\
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ME))VLF=N_GD$'M2>XT-\(?$+5]3\5)H$GV#7K4%EDUC2XIDCAPF1YN5*98C
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M4.W_ ,:YN3X=3>'K:_\ $2>,I++Q"T[W!U1B+:"0NR-Y<R9*E"X/ME^5; %
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MGCZ2\%SS77@3P]<7$LDT\NFVSR22,69V,2DDD\DD]Z -RBBB@ HHHH ****
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M:G8FYY_X2_Y*]\1?^X9_Z3M7H%>?^$O^2O?$7_N&?^D[5Z!2&%%%% !1110
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MZKV"O'_$7_)T/A/_ +!4G_H-U0![!1110 4444 %%%% !1110 4444 %%%%
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MMDCCC4*J*)XP  .  .U='X#_ .2>>&O^P5:_^BEK ^-G_)(==_[8?^CXZW_
M?_)//#7_ &"K7_T4M '04444 %%%% !1110 4444 %%%% !7FGQ#3X:2ZY;K
MXRNVCOTA5HD\ZX4!,M@@)QG.[GK7I=<SXA\6V6AWZ6MSHVL7KM&'$EGI[3H
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M@VM 'L%%%% !1110 4444 %>/^(O^3H?"?\ V"I/_0;JO8*\?\1?\G0^$_\
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M_)T/BS_L%)_Z#:U[!7C_ (>_Y.A\6?\ 8*3_ -!M: /8**** "BBB@ HHHH
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M2_\ 8*NO_134 <]\$O\ DD.A_P#;Q_Z/DKT"O/\ X)?\DAT/_MX_]'R5Z!0
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M,J!XY(V#*ZD9!!'!!'>HH=.L;:\N+R"SMXKJYQY\T<2J\N.FY@,MCWH6CO\
MUIL#U5OZ\SS/2=*NM;U?QK;S76BI/)?R1745_IK3S?9]J^4=PF3";0".."">
MM-3PYIUSXQ\%Z9J,EMKMK;:+,8YI$#1S8*!7VY8$8/')'?TKT34/#FA:O<"X
MU+1=.O9@NP27-JDC!?3+ G')JS'IMA%-!-'96R2V\7DPNL2@Q1\?*IQPO X'
M'%"TMY?HFOU_,):W\_\ @?Y'E.J6EMIOAOXH6%C!';6<11HX(E"HA:!"V%'
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M"KK_ -%-0!SWP2_Y)#H?_;Q_Z/DKT"O/_@E_R2'0_P#MX_\ 1\E>@4 %%%%
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MOB+_ -PS_P!)VKT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** (YX(;JWEM[B*.:"5"DD<BAE=2,$$'@@CC%<G_P *K\#?
MVQ_:G_",V/VC^YM/D_=V_P"ISY?3_9Z\]>:["B@#C[KX5^!KS48+Z7PS8K-#
MMVK"IBC.#D;HT(1N3SN!R.#D<5Q'[0-A9Z9\,-,L["T@M+6/54V0P1B-%S',
M3A1P,DD_C7L]>0?M'?\ )/+#_L*Q_P#HJ6@#U^BBB@ HHHH *X__ (5CX6_X
M3G_A+OL/_$P^_P"5D>3YV<^=LQ_K/?.,_-C=\U=A10!Q^O?#'PMXD\46?B#4
MK'S+NW_UB @1W6!\OFKCYMO;ID8#;@ *N>,_ VB^.M+2QU>*0&)]\-Q 0LL)
MXSM)!&"!@@@@\'J 1TE% ''Z]\,?"VO^%[/P_+8_9;2Q_P"/1[4A9(.?FVL0
M<[OXMV=QY/(!&Q_PBNA?\(O_ ,(U_9D']C>5Y/V7!V[<YSGKNS\V[.[=\V<\
MUL44 8>@>$=%\-^&ET"PLHS8%"LRS*'-P6&&:3C#%AP>,8P    (_"G@O0O!
M=G<6VB6GDK<2F65W8N[<G:I8\[5!P!^/)))Z"B@#D]#^&WA3P[X@N=<TW2HX
MKZ9V9&))6 , &6->B X/09&Y@"%^4<7X>_Y.A\6?]@I/_0;6O8*\?\/?\G0^
M+/\ L%)_Z#:T >P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5E^(M L?%'A^\T74ED-I=(%?RVVLI!#*P/J& /.1QR".*U** ,/PEX4TW
MP7X?BT;2Q(8$=G:27;YDC,<Y<J "<8 ..B@=J\[_ &<?^2?:A_V%9/\ T5%7
ML%>/_LX_\D^U#_L*R?\ HJ*@#V"BBB@ HHHH **** "BBB@ HHHH **** "N
M2^)=[=67@._-G*T,]PT5JLJYR@DD5"1CH<,>:ZVL7Q9H"^*/#%]I!F\AIU'E
MS;<^6ZD,K8[X(%)^?]:J_P"%QK<X_P 0^&](\'WWA+4- T^VL)H]3AL97MXP
MK3PRJ58.0/GY"G+9.1G->E5Q(T'Q+KVH:(_B7^RH;;2Y!=LMA-)(;FX4$*3O
M1=B#)./F.<<UK>)_!/AWQC]E_M_3_MGV7?Y/[Z2/;NQN^XPSG:O7TJNFO=_I
M_P $E?H<_P"$O^2O?$7_ +AG_I.U>@5\P> /!/AW6_C)XHT#4=/\[3+'[7]G
M@\Z1=FRX5%^8,&.%)')->O\ _"DOAY_T+W_D[<?_ !RD,] HKS__ (4E\//^
MA>_\G;C_ ..4?\*2^'G_ $+W_D[<?_'* /0**\__ .%)?#S_ *%[_P G;C_X
MY1_PI+X>?]"]_P"3MQ_\<H ] HKS_P#X4E\//^A>_P#)VX_^.4?\*2^'G_0O
M?^3MQ_\ '* /0**\_P#^%)?#S_H7O_)VX_\ CE'_  I+X>?]"]_Y.W'_ ,<H
M ] HKS__ (4E\//^A>_\G;C_ ..5Y!\=/!/AWP=_8/\ 8&G_ &/[5]H\[]])
M)NV^7M^^QQC<W3UH ^GZ*\__ .%)?#S_ *%[_P G;C_XY1_PI+X>?]"]_P"3
MMQ_\<H ] HKS_P#X4E\//^A>_P#)VX_^.4?\*2^'G_0O?^3MQ_\ '* /0**\
M_P#^%)?#S_H7O_)VX_\ CE'_  I+X>?]"]_Y.W'_ ,<H ] HKS__ (4E\//^
MA>_\G;C_ ..4?\*2^'G_ $+W_D[<?_'* /0**\__ .%)?#S_ *%[_P G;C_X
MY1_PI+X>?]"]_P"3MQ_\<H ] HKS_P#X4E\//^A>_P#)VX_^.5Y!\#/!/AWQ
MC_;W]O:?]L^R_9_)_?21[=WF;ON,,YVKU]* /I^BO/\ _A27P\_Z%[_R=N/_
M (Y1_P *2^'G_0O?^3MQ_P#'* /0*\!^,/B9O'2R^$?#6D:A?SZ3?-+>W*1'
MRT:.-UV#N227'.,E,+NR*[[_ (4E\//^A>_\G;C_ ..5Y9X*\2P?"Q-8\,^*
MK6ZM9XIY+FWF6%RMT!B/$8(!P3'E6.%/.2N.0#V;P+X^L/'-K=B"TNK&_L&6
M.]L[E,-$Y!Z'N,JXYP?E.5&176U\[>!M&G^)WQ \1>*8+W6-#TS8D"36-R89
MI&P@"[@I4C:FYESP63KUKTG_ (59_P!3[XY_\''_ -A0!Z!17G__  JS_J??
M'/\ X./_ +"C_A5G_4^^.?\ P<?_ &% 'H%%>?\ _"K/^I]\<_\ @X_^PH_X
M59_U/OCG_P ''_V% 'H%%?.'C2SUCPY\4_#WA>S\:>*WL=2^S>=)-JCF1?,G
M:-MI& . ,9!YKT__ (59_P!3[XY_\''_ -A0!Z!17G__  JS_J??'/\ X./_
M +"C_A5G_4^^.?\ P<?_ &% 'H%%>?\ _"K/^I]\<_\ @X_^PH_X59_U/OCG
M_P ''_V% '::KJMCHFEW&IZG<QVUG;IOEE<\*/YDDX  Y)( Y-?-EG\1[BQ^
M*.H?$2+0YSH5]BSE5B/,$0$:[UYQNS&IYRN25W9^:N\\<?!B^U3PU(FF>*O$
M&I7D+B:*TU>_\Z*4@$8' "O@G#'CL< Y'F!UO5KL0^%K3PY<Q>(9@MO]BE@V
M*@*YSL;H-N#A@% .22!R ?4VE:K8ZYI=OJ>F7,=S9W";XI4Z,/Y@@Y!!Y!!!
MY%7*\G\,?!3^Q=#AMI/&'B.TNF_>7*:5?>1 9#UVKMR<  ;CR<9P.@V/^%6?
M]3[XY_\ !Q_]A0!Z!17G_P#PJS_J??'/_@X_^PKF/B)X/O/"7@34M<L/''C*
M2ZM?*V)/JQ*'=*B'("@]&/>@#V>BO%_AWX/O/%W@33=<O_''C*.ZN?-WI!JQ
M"#;*Z# *D]%'>NH_X59_U/OCG_P<?_84 >@45Y__ ,*L_P"I]\<_^#C_ .PH
M_P"%6?\ 4^^.?_!Q_P#84 >@45Y__P *L_ZGWQS_ .#C_P"PH_X59_U/OCG_
M ,''_P!A0!Z!17G_ /PJS_J??'/_ (./_L*/^%6?]3[XY_\ !Q_]A0!Z!17G
M_P#PJS_J??'/_@X_^PH_X59_U/OCG_P<?_84 >@45Y__ ,*L_P"I]\<_^#C_
M .PKS V>L?\ "]?^$'_X33Q7_9G_ #U_M1_._P"/;S>OW?O<?=Z?G0!]'T5Y
M_P#\*L_ZGWQS_P"#C_["C_A5G_4^^.?_  <?_84 >@45Y_\ \*L_ZGWQS_X.
M/_L*/^%6?]3[XY_\''_V% ''^-?BQXW\/?$&X\-V6CZ/L9E-F;D29F1ER#O+
MHI).1@#A@5!8C)X/0O&/C7X2Z"UA_96EK;75TTRFZ;S)"Y50<!)1\H"CMP3U
MY%=W\2OA/-;^%)]<L?$WB+4;_20;F-=2O1,%C&#(4)"E&  ;()SLQ@DC',^"
M/#^I?%_Q"-9U"YN-+TW241$>R9E=I_O9B8@JK @,3R0-@YSN !]%Z1)?3:-8
MRZI#'!J#V\;7449RJ2E1O4<G@'(ZGZFKE>?_ /"K/^I]\<_^#C_["C_A5G_4
M^^.?_!Q_]A0!Z!17G_\ PJS_ *GWQS_X./\ ["C_ (59_P!3[XY_\''_ -A0
M!Z!17@GQ9T'4O GA6VU32_&WBZ:>6]2W9;K569=I1VR-H4YRH[^M>O\ @N>:
MZ\">'KBXEDFGETVV>221BS.QC4DDGDDGO0!N4444 %%%% !1110 4444 %,E
MEC@A>:5PD:*69F. H'))I]8'CF.67P#X@C@!,K:=.% &2?D-3-VBV5%7DD<[
MIWB?PW:S6_B&#PA<Z=;ZK/Y(UK[';QB4R/PSE7\T*[ '<RX)*D]:]!KS/Q?+
M;3_ NV%MAEGMK)+55Y)<O'M YZY_E7I:YVC/7'-:25FUV=C-.Z3[J_\ 7]=!
M:***DH**** "BBB@ HHHH J:GJ=GH^GR7U]-Y5O'@%@I8DD@ !0"222   22
M:Y_2KKP[\1M,^W7GA\2"TN)+80ZO91F2)QC>-IW;>V>AXYZ5U=<3X #&P\4A
M/OG7K[;]=PI7M?R5Q]O4DG^(ME%97NHQZ-J]QI%E,T,VHPQQ&(;6"NP!D$C(
MISE@IZ'TKL(Y$FB26-P\;J&5E.00>A%>8>'IK2+]GB7S@%CCTRZCF4\$.-X8
M'WW5W/A*.:+P;HD<X(F6P@#@C!!V#-5:UUVM^*)[?/\ !FQ1112&%%%% !11
M10 4444 <MK7C7^Q(]0N)O#>NS6-@V)KN&&+81@$LJM('91NY8*1P?0UEZ;:
M^#OAW96]QX<TJX=]>>)((+25I9+G 9E(\U\* K,220 #SVJ;QO?3:Z9/!&BD
M-?WL>+^?JEC;-PS-_ML,A5[\G@"H-4LX-+^(?@2U52MI!:W=M;Y[.(TP,^NU
M31'6WK^CO^*M]_8'I]W^5O\ ,Z+1O$\&KZI>Z7)8WNG:C9JCR6UX(]S(_P!U
MU*.RLN01P>",&MRN)3$GQLE,(SY6@*LY'8F<E ?? :NVHZ)_UNU^@=6OZV05
M3U+2=-UFW6WU33[2^@5PZQW4*RJ&P1D!@1G!(S[FKE% !1110 4444 %4M5U
M!M,LOM"6%Y?.75%@M$#.Q8X_B(4 =220 *NU5U&&[N=-N(+&\%G=R1E8KDQ"
M7RF/1MI(#8]#28T<Q!J/A[6_$TZ:OX;%GK6F6Z72RZG;0/(D08D.DB,X 5LG
MJ,$T0_$6SDM+'4)=&U>VTF^G6&#49DB$1+$A&8"0NJL<88J!R.F:X74[35]&
MU3Q1I>L7QUS5M2\.S2V^I)"(6CBC# Q&)3@ DYR#R>M;_BZ6VF^!=M]FPRS6
MUDEJJ\DN7CV@<]<_RIK6S]/Q;7]>8NMO7\K_ /!]#TRBD7(49ZXYI: 04444
M %5_L%G_ &C_ &A]D@^W>5Y'VGRQYGEYW;-W7;GG'3-6** "BBB@ KE?'GB7
M0?#^BJFOZ>^I6]R3_H20),75!O9RCD#:N 23T.*ZJO!O&'B6ZN+;Q?<:GX5\
M2I/+ ]A97!T\_9K>W!^\7)'WV&XD#H%'.*3>I21ZE-KFE^&VTS1-)T6:66ZC
M>:WT_38HHQ'&/F9R&9$49;UY)[U?T#Q';>($O%BM[FTN;*<V]S:W2J)(G !&
M=K,""""""017&^&-274_B7#>R6=Y9M<^'8Q!#>PF*50D[!P5)_W3]"#WK4\+
M;7^)'C>6$?N=]G&Q'0R"+YOQ *U=M;>OX,S3NK^GXK^ON.VHHHJ2@HHHH **
M** "BBB@ KSKR/#\WQ%U'6[#P=JU_KVG2K#/?07$2H&,(4 +)<*#^[8#[OZ\
MUZ+7%:WX9OM,37-<T'Q)=:==7!^V3130PRV[%$ P0R;P"J8R'XZTF[:O;^O^
M"-*^BW_K_@&UK7B:#0[>P,]G=S7E_*L-O8P!&F9R,D<L% 49R=V!CK2:-XG@
MU?5+W2Y+&]T[4;-4>2VO!'N9'^ZZE'967((X/!&#7&V^L2:YXG^'&M7L*Q&]
ML+I@J@[5F:-#@9/<!L5L)MD^-DIB&?*T%5G([$SDH#[X#55K.S\_P_K\2;Z7
M7E^)VU%%%(853TW2=-T:W:WTO3[2Q@9R[1VL*Q*6P!DA0!G '/L*N44 %%%%
M !1110!B^*VT&'0)KOQ'9VMU86Q$OEW$"S#?T7:K Y8[L#OSCO3=!U.6YB@M
MT\,:CI-FD(\DW MT1%  5 D<K,O';:,8QQ6#\5%G?0=)2"=;<MK-H#,Z;UCR
M_P K%<C(#;3C--DNM=T+QQI6CRZY/JUIJMI<?)<6\*2021@'>&B5/E.0,$<>
MM*^[_K:XWT_KK8M3_$6RBL[W48]&U>XTFRF:&;484B,0VD*S &02,JG.2%/0
M^E=A%(DT22Q.'C=0RLIR"#T(KS'P[-:1?L]3>< L<>FW4<RG@AQO# ^^ZNW\
M(QRQ>#=$CG!$RV$ <$8(.P9JK6NNUOQ1/;Y_@S9HHHI#"BBB@ HHHH *1E#*
M58 J1@@]#2T4 <U8> ?#6FW5O<6NG,OV:5IK>%KF5X87;.62)F*(>3T48[8K
MI:** "BBB@ HHHH **** "BBB@"O?646H6CVTSSI&^,FWN'A?@YX="&'X&LO
M1_".D:#<R7&G+?1O([22+)J-Q*CNWWF9'<J6/J1FMRB@#FG^'_AB2\FN6TUO
MWUP+J6 7,HMY)1CYVA#>63P#RM=+111TL'6X4444 %%%9"^(K1O%S^&Q%-]K
M6R%Z9,#R]A?9C.<YS[4>0>9KT444 %%%% '%:G\)? ^LZG<:EJ&B&:[N7,DL
MANYUW,>^ X _"MBY\':#=Z%9:+/8E[&Q*&U7SY \)3[I20-O!'3(/3CI6[10
MM%9!N[F9H_A_3-!6X_L^W9'N9/,GEEF>:65L8!9W)9L#ID\5IUS.A>,8_$6I
MW$-CI-^=/AED@_M)P@A>1#@A1NW$=<-C%;]G?6FHVXN+&Z@N8"2HD@D#J2#@
MC(XX(Q1NKAL3T444 %%%5[:^M+QYTM;J"=H)#%,(I QC<=5;'0^QH L4444
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M.:\Z^&FCZBGB'Q/,WB&]>*VUJ5)H3%#MN6V+\SG9D'D?=P.*]5KB]$\/^(-
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M;.G!:-<*&7 /WLY..V:T/$6N:[>^(?"EAH&H16,6L6L\LKRQ++L4*C!@".6
M)QSC)YSTJ"]\.>/->T!/#6JW>BV^GN%ANK^U:1IYHACA490JLV.3D@9.!707
MOAF>7QAX;U2U:%++2H+B%XV8[SO157:,8.,<Y(J]+^5_PL_UL9INWG;\;K_@
MF9X=O-;TKQ_>^%]3U>35K9M/2_MIYXD22/YRC(=@ 89YSBNZKG/[ NO^%CGQ
M%YD/V/\ LH66S<?,W^:7SC&,8]\^U='2Z+^NK_2Q3W?]= HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K7&G65W<VUS<VD$T
M]JQ:"21 S1$C!*D]#CTHHH LT444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 5Y+&TFO8+R6VA>ZMPRPS,@+QAOO!3U&<#-6*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img_018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )$ @<# 2(  A$! Q$!_\0
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M6ZO'@4B,R.V<*#SM VJ,\X6O,M0TG3=&_:6\*6^EZ?:6,+:;*[1VL*Q*6V7
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M44 9UWHFFWTYGNK.*64@+O8<X%0_\(QHG_0-A_(UC>(;JXBU=DCGD1=B\*Q
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MK;5+QW?R[!+B9@,LV(PS'Z]:YZ+XJZ#*+9A::PL=Y'NL7-@^+QN,I%CDMSW
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M U>*2?1KV&)2TCP.JJ.Y(.*\F'A/7@/^09-^G^-<&*E537)<[,/&FT^<VO\
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M_P##_P!]4?\ "0:3_P _\/\ WU42I*7Q1O\ (B4*<OB2?W$O]D:=_P ^-O\
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M^/\ P D]_P /Z^\]#HHHI %%4]5U6QT/2[C4]2N4MK.W7?+*^<*.G0<DY(
MY)-5?$'B;1O"M@M[K5\EI [A%)5G9F] J@D_@* -:BL'4O&OAS2-"M]:O-6@
M33KG @F3,GFY_NA02?? XQS3]0\7^']+\/1:]=ZI"NES;1%<)F02%N@4*"2>
MO '&#Z&@#;KR'Q%_R<[X1_[!<G_H-S7J>F:G9:SIL&HZ=<QW-I.NZ.6,Y##.
M/Y@C'8BO+/$7_)SOA'_L%R?^@W- 'KU%%% !1110 51NU4ZI8$@9R_;_ &:O
M5RU]XA\O5%_T7/V:1U_UGWNWIQ710IRG)\O8\C-L90PM*+K.UY*VE]FF_P #
MQ_Q)_P C3J__ %^S?^AFOH2U_P"/2'_KFO\ *OG?6YOM&OZC-MV^9=2OC.<9
M8FOHBU_X](?^N:_RKY[+E:K53[_JS](XADIX7#2CLU?[XP):***]D^."BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BLG3?$NE:M=O:V5Q)),B[F4P2)M'N64 5K5,91DKQ=S2
MI2G2ERU$T_,****HS"BBB@ HHHH **** "BBB@ HHHH ***SM<U=-"TJ74)+
M.]NUC*@PV4)EE;) X4=>O- %3Q!XQ\/>%?*&MZK!9M-_JT?+,P]=J@G'OTJA
MI'Q*\'Z]JD.F:7K45S>39\N)8I 6P"3R5 Z UP[>,XH_B,OB)?!_B>>";3Q:
M.7TEA);LKE@4]0VX@],;1UKM=&\?V^M:M#I\?A[Q':M+G$UYIS11+@$_,Q/'
M3'UQ3BKB;.NHHHI#.#^+F@Z9JG@34M0O;437.G6DTEJS.V(V9<$[0<$\<$@X
M[8JYK3VR?%+PF+DKO>RU!;4$<^;^X)Q_P /^M=7<VMO>VLEM=P13V\JE9(I4
M#(X]"#P14&IZ5I^LV9L]3LK>\MB0QBGC#KD=#@]Z /+?!\VG/XD\*R(\9LYY
M->_LH*.,?:5(Q_P /U[56\./:2^*/ MQ;@-8/?:^;!D'RA#(2OYJ'QFO6+[1
M=+U+35TZ]TZUN+)=NVWDB5D7'3"XP,4Z\TC3=0TPZ;>6%M/8D!?LTD0,>!T&
MWIQ@8],4 8'@1UET[6;BU(>REU>Z>T93\K+NPQ7V,@DKRG3+KQ9=_M#>&'\8
M6%I97XLIA'':L"IB\N?!.&;G.[OV%>^VUM!9VT=O;0QP01KM2.)0JJ/0 < 5
MY-XB_P"3G?"/_8+D_P#0;F@#UZBBB@ HHJO<7UI:,JW-U!"6&0)) N?SI2DH
MJ\G8F4HQ5Y.R+%>>:E_R%+O_ *[/_P"A&O04=)(UDC961@"K*<@@]P:\^U+_
M )"EW_UV?_T(UZF6_%+T/B>,7?#T?\3_ /23S#4O^0K>?]=W_P#0C7T;:_\
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MR#&, <=/PKA=2_Y"EW_UV?\ ]"-=9X8_Y%NQ_P!P_P S7)ZE_P A2[_Z[/\
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MW6OG\J_@OU_1'Z9Q5_OD?\*_-A1117JGRH4444 %%%% !1110 4444 %%%%
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ML$9T&03^'VUZWWJ9;)51F*@YW!7(#$8''4UMT4GJ!Y%'K?P;63R+_1=.TR[
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M%>+W/_'W-_OM_.O:*\7N?^/N;_?;^=?,<0_#3^?Z'QO%/PTOG^@6/_(0MO\
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M5>'_ /D"_P#;P_\ Z"E?0<.?\C"/H_R./&_P7\CO?#'_ "#9/^NQ_D*ZQ?\
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M_016S;_\>T7^X/Y5][@O]PH?X8_^DHCCC_D0Y=\O_3://M2_Y"MY_P!=W_\
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M ,+_ "9[W'?_ "-<M_Q?^WTSG?A[_P CUIO_ &U_]%/7NM>%?#W_ )'K3?\
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M5/#.0>">U:75[_TO(SL[?UJ=A1114E!1110 4444 %>0^(O^3G?"/_8+D_\
M0;FO7J\A\1?\G.^$?^P7)_Z#<T <[^TU_P RM_V]_P#M&O*O#_\ R!?^WA__
M $%*]5_::_YE;_M[_P#:->5>'_\ D"_]O#_^@I7T'#G_ ",(^C_(X\;_  7\
MCO?#'_(-D_Z['^0KK%_X];;_ '#_ .A-7)^&/^0;)_UV/\A76+_QZVW^X?\
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MKL;#[._@_7V/FL^1I\O<*/[OM7LY'B*6'QD:E5V5G^1S8J$ITW&*U.O\,?\
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M9'+!^%_W?^^:[3S#Z-L[D7MC;W2QRQ+-&L@CF0HZ@C.&4\@C/([5-7S VO\
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M2,!EM4;<%EFYRD9*,-^, CG%6M;UBUT#2)]2O!*T,.T;(4+N[,P5551U)9@
M/4UP%WKT]QJ!GUKP]!I6IPI(MS!>[95OM*)S*J,N5=T&&*<XY[.: #4/$EEX
MCCWW%II^M#3-4NHKC18F2:5X49XTF6)C\[C (&.0YQSBG>']DVH76CPV5S:^
M&]8$\0TB]B\JXMAL^:6.//R6S?,NT@8=EP &Q6MX<^'OAW3II;BWL=)O].E<
M7>GRR6D<DL!<ERJ2XYC&5*=QD\GBC7;S3M%U>2V\.:19'Q-?Y62:"W0.H;YB
M78#DG[V"<<;CQC-TZ<JDN6),I**NQVH:S-X>TS3O"^DR/J&MK;QVXD;YBNU
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M3'-9-CX':WT^X\,W3>=X?CQ-IERLK"\M)=Q9LOZAFRC#D $-GN <Y=:?J?\
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M/U1["P>6T\+VT@^T7.,-<L.<#/X$ ].&;G:M>C6%A:Z98PV5E L%M"NU(UZ
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MWX<FMDN9U5RRVMY(6+P6V!A8D&T;#RNX=\BO1GBCD9&>-69#E21DJ?4>E/
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M-T<^;G<P;GK6Y?\ AO4_$K75QJ<\>GW%K<E]$>W =[1DW 3,>-^_()C/R[0
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M?X;+0****V/."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME]J!\.>'#OOFR+BY!PMNO?GL1W/;H/F/&WX>\/6?AW3Q;6PWRM@S3D8:1OZ
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MAD-F-+\'63G[)8PH(A.P/)PO [Y(Z<JO.YJ]2BBC@A2&&-8XHU"HB#"J!P
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M>A&3@T 9^D:5?V^H7.HZK>6US>31) /LML88UC1G(X+L227.<G'H!R3LT44
M%%%% !1110 4444 %%%% !1110 4444 %<;\0=8\6:#IT&H^'+73KBVC)%Z+
MJ&61XU) #JL9R5');@D#D \U0\0>-](O-6O_  =J/AWQ)*VP&22ULC(NS.5E
M0QL7QD## <$=B*D\(^-87UD>%=2U 75^$+6=RZ&.2YC49(EC8!DE '.0 P&1
MW  ,B_3Q1&\7B;3=!T^^N;B-5O$TF^6:UU. \?.KJAW*I^5UW]P<@\=7IOAS
MP]X(@O-5#RQ0JO#W4QD%K%G/DQ9^ZFX_='4D=>,6K/3-)\%V>HW274EKI3-Y
MWV9V'D6OJ(E RH9CG:,_,> ,XKD+:VOOBAJBW]^DMIX6M9#]GM\X:Y8<9./Q
M!(Z<JO.YJQJ5.7W8ZR?]7?D>C@\&JR=6J^6G'=_^VQ[R?X;O0+:VOOBAJBW]
M^DMIX6M9#]GM\X:Y8<9./Q!(Z<JO.YJ]+BBC@A2&&-8XHU"HB#"J!P  .@HB
MBC@A2&&-8XHU"HB#"J!P  .@I].G3Y-7JWNR<9C'B&H07+3C\,>WF^[?5_H%
M%%%:G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1161?QQ^)O#T
MT>E:V]NMPI6._P!/D1RI!QPW(ZC!QSUY!YH R/'-R+NS'AO[9=Z5/J:8M=27
M*PF56!$+.K!E+ 8QQN!(!)XKG-*\0>1?33ZX5T1= VP6V@::S!IWD3;S&!B5
M2W^J"<#G//2*TMO$FKZ9>>$]7U2QN-7CC GM-9L_,BN5SD2V\D9C9E''.TLC
M  X(!/3>#_#6J6UC8S^,!INHZYI^Z*UU"$,\@B('WF90=W49QT]R<@%G0_"^
ME&"#4[WPMI%AJC.TQ2&!&,)+$J=V/O[<9([YP2*Z>BB@ HHHH **** "BBB@
M HHHH **** "BBB@ KGX]0TWQ2=:T"Z1 8G:WEMC-B8QX'SE1R@))VGN,,.N
M!;\0:E<:9IH>RB@EO9Y4M[=;B0I%YCG +L 2!]!D\ <FN(%CXC'B!W:+3;'Q
M;Y3744UM)(MAJD8VQLLZXWYC4KM&3@N".K"@!T^FWZ:E9:%JUW.NIPEF\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 <#JNC6^M_%>WMM3>6YM+?3/MD5LY'EJ_F;,8QR#P3GJ0 3@8KOJ
M**QI)7D_-_H>GCZDG&C%O10C9>O-?[^H4445L>8%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img_019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &J DT# 2(  A$! Q$!_\0
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M44 %%%% !1110 445S/C/P]K7B&RMH=%\2SZ')%(7DDABW^:,8 /((Q]?Z4
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MK=31:.TA9F:W\Y1!@GYB-W"YYQBO9X]PB3?]_:-WUH$.HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***9+-%"H:61$!. 68"C<3:
M2NQ]%<WXK\;Z1X0T-M6O3)<0K(L92T*.^6Z<%@,?C6Y]OM/^?J#_ +^"JY9=
MB/;4[7YE]Z_S+%4=5T;3-<M/LFJV%M>V^[<([B,. W3(ST/)Y]ZNJP90P(((
MR"*YN_UF]@^(FC:/'(HLKJQN9I4VC)9"@4YZC[QJ30T+'PSH>FZ7/IEEI-E;
MV-P"LT$<*A901@[A_%QQSVJV=-L6>S<VD!>RS]F.P9ARNT[?3Y>..U<'_P )
MSJ'_  LO[+F ^&#=_P!C"4?>^W>6)>O7KF/'3-;OQ&UN^\.> -5U;39$CO+=
M$,;.H8 F15/!XZ$T :EKX9T.RNC<VND64,_G&X\R.%5/F$%2_ ZD$C/N:CU7
MPGX>UR\CN]5T2PO;B,!5DG@5VP.@)(Y'7@\<UR&I^/[Z3X3:AKMHJ6>N6$J6
MMY;N@;R+@2HDBXYR"&)'/0CO2RW_ (JUGQWXETS3_$UII-GI;6RQI+IZ3%_,
MA#GDLO?/KUH Z_5/"?A[6[J&YU31;"]GA79&\\"N0N20O(Y&2>#QR:=-X7T&
M>VBMI='L7@BG-Q'&8%VI(3DL!C@D^E<UJ6L>(?#FC6-@-1L]<\0:K??9K*4V
M_D11KMRS.JL<J@5B<')R.*JZA?\ BWP*MOJVMZY;:WHKSI#>_P"A+;/:*[!1
M(A4G<H8C(//] #K#X1\.G6O[8.B:?_:6[?\ :?LZ[]W7=G'WO?K1J/A'P[J]
M_P#;M1T/3[NZV[#+-;J[%<8P21SQZ]*YOQ5XQUC3O%>C:58:7-%8RZI!:7>H
M3H DGF*6\N('EN <L.%(QU-3:EJGB+6_%VI:)X<U&TTY-(MX9+B6XMO.,TTH
M9DCQD;4VKDL.>1@4 =I%%'!"D,*+'%&H5$48"@<  >E8C^"O"\FJ_P!J/X?T
MUK[?YAF-LNXOG.X\?>SSGKFN2L?&NL^,8= T_1)K?2K^]LIKV_N)8/.^SB*3
MRBJ(2 =TF1R> .YKIO!6NWVLZ=?0:HL0U+3+Z6PN7A7:DI3!5U!)(#*RG'KF
M@#0U?PSH>OO$^KZ197SP_P"K:XA5ROL">WMTJVFF6,<]O/'9P)+;1&&!UC ,
M49QE5]!\HX'H*Y<^+T@UCQ#J-]>"V\.:(([.1A'O\RY;:SL=H+ ('C4 =V8G
MH,7+#X@>&]2EN(X+V4-!:M>'S;66/S(!UD3<HWK[KF@#1N?#.A7EG<6ESI%E
M+;W,YN9HW@4K)*>LA&.6XZ]:M6NE:?907$-K96\,5Q(TLR1Q@+([?>9AW)[Y
MZUS%K\5?!=[=P6MOK#/-/(L4:_8YQN9B !DI@<D=:YZY\9>(-0OKFZTK6M#M
MBEV]OIVAW102ZDD<AC9O,+@J697VX&/E .>30!W6G>$?#ND&Y.G:'I]J;E2D
MWE6ZKO4]5.!]WVZ5J6UM!9VL5K;1)#!"@CCCC7"HH&  .P K @U>]M?'L^BW
MK[[6]M!>6#%5'EE"$EB)'WNJ.#U^9AG %=)0!S7AOPJFBVIL+B*UGL[*]DGT
MEMI+V\;Y.TY'!4NZ@@G*XZ=*W(=/L[>]N;V&UACNKK8)YE0!Y=HPNX]3@$@9
MJS10 5D6/A70--U.74['1K"VOI<[YXH%5SGKR!QGOCKWK7HH P?#FASZ;=:O
MJ5^T+ZEJEV996AR52)1LAC!(!.U ,G'WF:MZBB@ HHHH **XK6_BAHFA:Q<:
M9=6FI/- 0&:* %3D \$L">OI7+Q_&I/^$MECDTVY_L#[+F-Q;_O_ #\C@_/M
MVXW>_2N]9;BY14E3=GM_5S/VL-KGKM%<9H'Q+T;Q%K,.EVEKJ,<\H8JTT("C
M:"3DACC@5V=<]?#U:$N2K&S\RHR4E=,:D:1)LC147GA1@41QI$@2-%1%X"J,
M 5Y%INL7&G? T):R#^T=1O;C3K,N^W][-=2(#GL0"6_X#71_#64:9_;/A!K@
MS_V+=9MI"=Q:UF'F1_-W()93Z8 K H[J2-)4*2(KH>JL,@T&-&=79%+KG:Q'
M(SUQ7D7B&_U/0/BMJOB6U:273].L[--2M%!):VD,FZ11ZQE5;Z;N0,UE^.;Q
M;BV^)D\%P9+=X-%>-XW)#*SYRI'J/3K0![8UE:-<-<-:PF=EV-(8QN*^A/7'
MM2/8VDLD,DEK [P?ZIFC!,?^Z>WX5YCX>T?X>_\ "16)TWPWKMO?)*'AEN(+
MU(T9>027.WMWXJ;0/"VF_$2/4/$/BB.74!->SPV-NTSI':01N4 558?.2I);
MKTQCN >F-!"TRS-$AE0$*Y4;@#U -1QZ?90QF.*TMT0EB56, $GKQCOWK@?#
M<FNVZ^*O".FZDDMWI%S"MC>:@&D\N"95<*V.79%W 9/)V@\5AVMSJ>C_  E\
M010:G.^H'6YK$7S<2$O=+$TG!X;#$C'0XH ]:2QM(W#QVL"..0RQ@$4J65K'
M(\B6T*N[[W98P"S>I/<^]>5Z]#'\,M3D_P"$=::"WO=$OI3!)*TJ"X@562;#
MD_-\Q!['O5JVT&'P7JG@[4+">Z,^IS"RU0R7#R"\9X6<2.&)^8.N01CAB.E
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MV&(P<[0..^S7FVHZ[XIN];\&XTR"QDFO+E)K:2^;9*5ADP=RH=R;1O4D=<#
M^]6I<>/)(?A]<^)QIZ,\5XUL+?S2 0+KR,[L?\"Z>U ':T5POB7Q;XF\/WMO
M;QZ+I-W)?71M["WCU"3SYQG[Q7R<*%7YF);"^O3-[_A,9/[$\6Z@;%-V@2SQ
MJGFG$WEPK)DG'&=V._2@#K**\[G\>Z_<7>H0:1X?LYET_3H-0FEGO2@(DC+^
M6H"'+'! )P.#G'%6-(\=:M?:CH+7>AQ6VEZ]'(]DZ7/F3ILC,@,B[0/F4$@*
M3CO0!WE%>=_\+!UBSU+1_P"U]&L;.UU:[2UBM?MV;Z N2$>2(J!CID DC=6/
MH7BC6_#N@ZMJ1T6*?0;+6+S[3,;DBX9#<-N>--N"JYY!8$X/2@#URBN<\<ZY
M/H'@?4]4LN;I8@EL0 <22,$0\]<,P/X5A#5-3\.:UI_@3PWI-K=O%I2W?VN\
MNC$J@.59G"HQ8LV#QR2Q)Z4 >@45P]KXS\0:GX>L-1TOPO#<SRO-%=V\NI+#
M]GDC?80"5.\$AN1TXJS%9W/C33YK3Q=X>6P@@D26%;?5F<NV&!):+81C/0Y!
MS[4 =?17E'@7P;I.MZ?KVK117$.DZLLEE80M<RRXMU./.^=B0[.NX?W0JXZF
MNS\ ZQ=:YX)TZ\OO^/T*T%R3CYI8W,;-QZE2?QH Z2BBB@ HHHH **** "BB
MB@ JK>Z?:Z@JK<Q;PARO)&/RKBOBQXRU3P7HFFW>E"W,MS?+;OYZ%AM*L>,$
M<\"N_IIN+NB*E.%2+A-)I]'J8T_A/0[J(Q7&GQS1DYV2$L,_0FI/^$;TK_GU
M_P#(C?XUJT5I[:I_,_O.3^SL':WLH_\ @*&11)!$D4:[410JCT KA?%DMWIO
MCO3M9AL+FZCLM'OFVPQ,VY\QE4R!U8C %=[161VI)*R/'#\-_$+_  WQ_P )
M#?#4=G]J?8OLL/%[_K<;]N_=OXSN_3BM[QY/>>)?@A>7$.G70O;RUA=K,0N9
M$?S$++MQNX(/;H,UZ+10,\?^+WAC5(8+W5M M);F+5DAM=5M84+,2CJT4ZJ!
MDD;=A]F''4B/4;'0$^)GBVX\3^%[[4HIWM/L<T>F2W"X$"A\,H(ZX'X>U>R4
M4 >7W5I;G2-%U[P?X?NXH_#^H22/IKVC6\DL4D>V7RT<#<V'!'J00.>*7Q3K
M'_"Q=*C\*Z-IFJ;+V:+^T+NZLY(([.%'5VR7 W2': %&>_/%>GT4 <;\0+6X
MNIO"1M[>680^(;:63RT+;$"299L= ,CD\<UGSWP\&?$'Q#J5]9:A/9:S;VTE
MO+9VCS@S1*R&$[0<,PVD9P#SSQ7H5% 'COAS3;[P'<>&];UFRNC#+I=S:7QM
MH&F-G))<?:$WJ@+8^9DR <$>]=E\/K6[%IK6JW=K+:_VMJLUY!#,A218<*B;
MU/W6(3./<5V%% 'BVJV5U)\.OB7I,5O+-J']N2RB")"\C)*\4B-M'."I_0^E
M=MXAL;RX^(7A][02PJNGW\?VI(MZP,PBV$Y&W.02 >N*Z*/1;:'Q%-K4321W
M%Q;K;SHI&R4*Q*,PQG<N6 .>C$'.!C1H X^U\->+H;N"6?Q]<7$*2*TD)TNV
M42*#DKD+D9'&1ZUYW<:-9Z7X7\3^%)O#%W<>(+V]F:QECLV<7 =LPS"8#:@0
M$$Y88VMZFO=** ."U.&:;XH^"K;SQ+<:?I][/=D=2K+'&&_%_P"5=[6=:Z+;
M6NM7^KAI9+N]6.-FD;(CC0':B#'"Y+,>Y+'GH!HT %%%% !1110 4444 %%%
M% !1110 4444 >9:7\-KQX_#^GZZ+"YTG37O;F:VR9%GFED8QY5E PJ,3GU/
M3O6S!X&BT/QQIVL^&[2PL+(VTMKJ5O&OE^8IPT;*JC!8,.2<<5VE% '.VGA^
M9/&6N:I<B"2QU"TM[=8C\Q.SS-P8$8P=X[GO7 -\)-7L]#\8:38W]M+!J368
MTPW,KYBBAE+^7(<$X .U2,Y '3I7L-% '(V<WQ#-];B]LO#*VAD7SFANIRX3
M/S;04 )QG&>]4H]"\5^&-1U$>&O[+O=*OIWNEMK^5XGM9GY<*55@T9.3C@C.
M/<]W10!S?A'PY<Z'!?7>J7:7FLZG/]IO9HU*H#@*L: \[% P,\]?H,E_ UW=
M>"]?T2>ZBAGO]2N+ZVFB)81DS>;$3D#H0N1]:[JB@#@7\)ZYXHO[BY\5?8+5
M!I<VG00V$C2X:8 2S995QPH"KSWR?5=*\.>*+K4?#_\ PD+Z<+/0E9D:UD=V
MO)MAC1V!4; %8G )^;VKO:* *^H6<>HZ;=6,S.L5S"\+E#A@&!!Q[\U'I.G0
MZ/H]CIENSM#9V\=O&TA!8JBA03@ 9P/2KE% '.Z9H-W9>.=?UJ1X3:ZA!:QP
MJK'>#&'#;AC ^\,<FL;PCX%N?#WBC4+ZXG@?3XDD@TB"(D?9XI96FD# C&=Q
M5003PM=W10 5YO'X!U9/@Q_PAYFL_P"T?,+>9O;RL?:O.Z[<_=]NOYUZ110!
MP/BSPAJ&J^,+;68],T?6;2.P-HMEJLC+'!*7+>:HV.IR, \ _*,&LRS\#^)=
M.T&"PD@\/ZK;)?W,USIUS'M@N$D;<CH3&QB=3GY0",'KP*]1HH \OTOP#K^A
M:?H\VGMIK7=CJMQ>_87FD%O!%-&R&*-]I;Y=V>0.2?QCO_!/B^;P]>^%[9]'
M_LJ34&NX[J263S6C,_G>65"X#!OXLD8&,<Y'JE% 'G,6@^-[;QCJFO\ V70;
MZ>9C#9O<7DJ?9K8'Y451$<$]6.>3Z5%J?A/Q>;?Q1INF'1_L7B M,T\\LF^!
MWB5)$VA<,#MX.1C.2#TKTNB@#B-*\(:C8S^('EDMB-0TNTLX=KL</%$Z,6XX
M&6&.M,3P;J:Z9X+MENH(9=%MGAN)8V)(8VK0AH^.<,0><<5W5% 'C]A\,]:A
MA\/P_P!E^'+.32KZ"ZN;^%WDN+_RW!)+% 5R"6();+8^Z*TI/!WC";0]4\,M
M/I::5J5]/,]VLKF:""25G9 A3#,0>N0!N(YP#7IU% '+?$'1[G5OA_J=CIRD
MW21I-;HHR6>)UD50/4[,?C4.E63:QXUM/&MG-"^E76A);Q@D^9N:7S 2,8 P
M<=<Y[5U]16]M!:0B&VACAB!)"1J%4$G)X'J23^- '':9\/-,GT5+/Q)IUEJ$
ML-Y=SPDY8(LTS/QG'.-N?<5=E\%Z=I?AK6['PM86NFW>H6CQ!TR@W[&"$D9/
M!8FNIHH QK..U\(^#8([EU2UTJQ42..FV-.3[]*S_AUIMWI?@73H[]=EY/ON
MID((*-*[2;2#T(W8/N*Z2XMH+N!H+F&.:%L;HY%#*<'(R#[@&I: "BBB@ HH
MH/ H **\\T+QIKNM?$B/3;G29M)TF32Y+J""[51<2D2(H=P"?+ZL O7J3U&)
MIM4\3>)O%.LZ=X?U.TTJRT9HX6FEM/M#7,[+N93DC:JY XYSGGT .]HKS&+X
MA:OK&B^'["QAM;3Q'JMY-93EU+Q6Q@SY\BKG+8 !52?XL$\<[?A_6-;L?&=Q
MX3U^[@U"0V(U"TOH8/)+IOV,CIDC<"1C':@#D_VA?^16T/\ ["J?^@/7K]>.
M?M!S1/X9T5$D1F75DRH8$CY'KV S1@X,B9_WA0 ^BF>=%_ST3_OH4>=%_P ]
M$_[Z% #Z*9YT7_/1/^^A1YT7_/1/^^A0 ^BF>=%_ST3_ +Z%'G1?\]$_[Z%
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M7=M')V (2 ,C)XX-=5HCR>)?B?+XEMK2[BTBTTK[##-=6[PFXE:0.S(K@,5
M&,D#FN_HH ^>/C9X T+0K:WUNRCG%[J>JG[07E)4[P[M@=N:[/\ X9\\$?\
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M* "BBB@ HHHH **** ,_7/\ D"W?_7,UY!\7/^0%X&_["2_TKU_7/^0+=_\
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M_:%_Y%;0_P#L*I_Z ]>OT %%%% !1110 4444 %%%% !1110 4444 9^N?\
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M@_4&J?\ 8>D_] NR_P# =/\ "O2HXF@L/["M%OWN;1I=+=4S*4)<W-%G,_\
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M6\.I-&#<1VQ)C5O1<Y/ZG\:OU3TF^DU/2[>\ELKBR>5=QMKD 21\]& )JY0
M4444 %%%% 'D'[0O_(K:'_V%4_\ 0'KU^O(/VA?^16T/_L*I_P"@/7K] !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 >/\ QS_X^O!?_85'\UKV
M"O'_ (Y_\?7@O_L*C^:U[!0!D^)_^1:O_P#KD:3PO_R+-A_UR_J:7Q/_ ,BU
M?_\ 7(TGA?\ Y%FP_P"N7]379_S"?]O?H=__ #!?]O\ _MIKT445QG %%%%
M!1110 5YK\(ON^)/^PDW]:]*KS7X1?=\2?\ 82;^M>IAO]RK_P#;G_I3,9_Q
M(_,]*HHHKRS8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*XUW_H?]9_[Z;_XNO1**O^U,3W7_ (##_P"1(]C#^F_\SSO_ (5QKO\ T/\
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M "*VA_\ 853_ - >O7Z\@_:%_P"16T/_ +"J?^@/7K] !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<^?^1U7_ *X?T-=!7/G_ )'5?^N']#71
M0^UZ/]#R<S_Y<_\ 7R/ZE'XH_P#),/$7_7FW]*9\*?\ DEOA[_KU_P#9C3_B
ME_R3#Q#_ ->;?S%4/AW<W=I\/M%@LK!KZV2WQ'<K(L8D&3R%;D?C7)*:CO\
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M;Z6]Q'@'S!,B\^F"<TW-)7?Y$Q@Y.R_-%^BLZVO;^6X5)M)>",YS(9T8+QZ
MYJXDLC32HT)5%QL?<#OR.>.V/>B,U+5!*#CH_P T2T54>YNEL5F6Q9ISC-OY
MB@CU^;I53^T=5_Z 4O\ X$Q_XTG4BM[_ '/_ "&J4GM;[U_F:U%5_.G\B!_L
MK>8Y421[Q^[!ZG/?'M3_ #)/M)C\D^7L#>;N&"<],=??-7S(CE92^TS?\)(;
M3?\ N/L@DV8'WMY&<]>E:59%M%=R^(9KR:U\B%8/(0F0,7^<G( Z#'K6O6=)
MMIM]V:54DTEV04445J9!1110 5D'_D;U_P"O _\ HP5KU4,%O_:XN/-_TGR"
MGE[A]S=G..O7O6=2-[>J_4TIR2OZ/]"W1116AF%%%% !1110 4444 %%%% '
M.>/+'3-0\%:E#J]__9]FJ"4W@/,#(P9&'J=P' Y/0=:\IEN/&%E9S>,)/$NE
M)IFJV\-H^K0Z=<-<)$A?$ODA<*3EB3TZ8QQ7IGQ+TW^U? =_;B[M+5U:*6-[
MUPD+.LBLJ.3QAB O/<BLB7QQXMFM7LX_ASJ/]I,I7;+<1FU!]Y,X*_SH ZKP
MCIFFZ/X2TNPTB<3V$5NODS!L^:#\V_(]22?QK:KG_ _A^;PKX*TK1;B99I[6
M'$CKG;N)+$#/8$D#V':N@H **** "BBB@#R#]H7_ )%;0_\ L*I_Z ]>OUY!
M^T+_ ,BMH?\ V%4_] >O7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *Y\_\ (ZK_ -</Z&N@KGS_ ,CJO_7#^AKHH?:]'^AY.9_\N?\ KY']
M2C\4?^28>(O^O-OZ4SX4_P#)+?#W_7K_ .S&G_%'_DF'B+_KS;^E,^%/_)+?
M#W_7K_[,:YSUB0?\E,/_ %Z_TKK:Y(?\E+/_ %Z_TKK:[,7]C_"OU._&_P#+
MO_!']0HHHKC. **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ J#(^V@?9VSY>?/P,=?NYZ^_I4]9YNY?^
M$@6RRODFU,O3G=N Z_2HDTK7[EPBW>W8T****L@**** "BBB@ HHHH ****
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ME., CW]ZN&&IU'RQJ:^C]2Z>$HU)<L*MWK]E]$W^AW]%%%<)YP4444 %%%%
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M )</^N_^%=!7/^)_^7#_ *[_ .%=&&_BKY_DSRLX_P!RG\O_ $J)P'_-T/\
MW"O_ &6O7Z\@_P";H?\ N%?^RUZ_7.>J%%%% !7)>,_^/O1/^OH?S6NMKDO&
M?_'WHG_7T/YK79@OXZ^?Y,[\N_WF/H__ $EG6T445QG %%%% !1110 4444
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MZ,C*PZAE8 J?8CTJS5F,HN+Y9*S"BBB@D**** "BBB@ HHHH$%<_XG_Y</\
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MG_/'_P "7^1U-%<MY_C/_GTT[\S_ /%4>?XS_P"?33OS/_Q5'U5_SQ_\"_X
M?4G_ #Q_\"7^1U-%<MY_C/\ Y]-._,__ !5'G^,_^?33OS/_ ,51]5?\\?\
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MF\L>6I Q@'N3ZUO5A5IRIS<);HYJU*5&HZ<]T%%%%9F04444 %%%% !1110
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M-M3D$PC)*'-NH"HO]U\Y^Z<[C7H5%0J+LE<ZO[1A?F]GTMT_RV_(\]L7CM_
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M[&C- "T4FX>HHS0 M%)N'>C- "T&DR.]&0: .4\!?\@^_P#^OH_^@BNLKDO
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MY0PU2479J+L_DSR#XDHNF:?X/^Q#ROM]_&MSCGS &1AUZ<^F*]E73+-#$5A
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M#7_0$\1?^ L?_P <IDG[0_A>,J'T?7UW' W6\0S_ .1* /7**\F_X:"\-?\
M0$\1?^ L?_QRC_AH+PU_T!/$7_@+'_\ '* /6:#7DW_#07AK_H">(O\ P%C_
M /CE'_#07AK_ * GB+_P%C_^.4 =;X"_Y!]__P!?1_\ 01765XU8?%/1O!T;
MVM[8:I<O=$7*-:0HZA2, '+CGBKG_#07AK_H">(O_ 6/_P".5UXUWQ$_7]$=
M^8N^*FUW_1'K-%>3?\-!>&O^@)XB_P# 6/\ ^.4?\-!>&O\ H">(O_ 6/_XY
M7(<!ZS17DW_#07AK_H">(O\ P%C_ /CE'_#07AK_ * GB+_P%C_^.4 >LT5Y
M-_PT%X:_Z GB+_P%C_\ CE'_  T%X:_Z GB+_P !8_\ XY0!ZS17DW_#07AK
M_H">(O\ P%C_ /CE'_#07AK_ * GB+_P%C_^.4 >LT5Y&_[0_A>,J&T?7U+'
M W6\0S]/WE/_ .&@O#7_ $!/$7_@+'_\<H ]9HKR;_AH+PU_T!/$7_@+'_\
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MRQ<[8MK$L7('8;??K7I]% PHHHH$%%%% !1110,**** "BBB@ HHHH ****
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MZ*CRH_[L:* J#//USZG.GX5\.V_A/PU9Z':S2S06H8+)+C<=S%N< #JU;%%
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L;NF<YXZUM44 %%%% !1110 4444 %%%% !1110,**** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img_020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &5 I0# 2(  A$! Q$!_\0
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M\]/P.FHKY0^''P?_ .%@>'KC5O[=^P>3=M;>5]D\W.$1MV=Z_P!_&,=JZ_\
MX9E_ZF[_ ,IO_P!MI ?0%%?/_P#PS+_U-W_E-_\ MM'_  S+_P!3=_Y3?_MM
M 'T!17S_ /\ #,O_ %-W_E-_^VT?\,R_]3=_Y3?_ +;0!] 45\__ /#,O_4W
M?^4W_P"VUSOC#X'_ /"*:7)>_P#"1?:MD$LNS[%LSL7.,^8>M14J1IQYI;?Y
MZ&56K"C'GF[+3\79?BSZBHKYL^$/@)O%OA&YO6U4VPAO7@6,P>9P$1L@[ACE
MCQ5_PEX&_P"$S-X?[1^QFTV?\L/,W[MW^T,8V_K5X>4)8A4JSY8N^N^R['MR
MP%.6!EBJ-3FE&UXVM:[MOL?0E%>0_P#"C?\ J8O_ "2_^V4?\*-_ZF+_ ,DO
M_ME>W]3R_P#Z"?\ R1G@^TJ_R?B>O45Y#_PHW_J8O_)+_P"V4?\ "C?^IB_\
MDO\ [91]3R__ *"?_)&'M*O\GXGKU%>0_P#"C?\ J8O_ "2_^V4?\*-_ZF+_
M ,DO_ME'U/+_ /H)_P#)&'M*O\GXGKU%>0_\*-_ZF+_R2_\ ME'_  HW_J8O
M_)+_ .V4?4\O_P"@G_R1A[2K_)^)Z]17D/\ PHW_ *F+_P DO_ME'_"C?^IB
M_P#)+_[91]3R_P#Z"?\ R1A[2K_)^)Z]17D/_"C?^IB_\DO_ +91_P *-_ZF
M+_R2_P#ME'U/+_\ H)_\D8>TJ_R?B>O45Y#_ ,*-_P"IB_\ )+_[91_PHW_J
M8O\ R2_^V4?4\O\ ^@G_ ,D8>TJ_R?B>O45Y#_PHW_J8O_)+_P"V4?\ "C?^
MIB_\DO\ [91]3R__ *"?_)&'M*O\GXGKU%>0_P#"C?\ J8O_ "2_^V4?\*-_
MZF+_ ,DO_ME'U/+_ /H)_P#)&'M*O\GXGKU%>0_\*-_ZF+_R2_\ ME'_  HW
M_J8O_)+_ .V4?4\O_P"@G_R1A[2K_)^)Z]17D/\ PHW_ *F+_P DO_ME'_"C
M?^IB_P#)+_[91]3R_P#Z"?\ R1A[2K_)^)Z]17D/_"C?^IB_\DO_ +91_P *
M-_ZF+_R2_P#ME'U/+_\ H)_\D8>TJ_R?B>O45Y#_ ,*-_P"IB_\ )+_[91_P
MHW_J8O\ R2_^V4?4\O\ ^@G_ ,D8>TJ_R?B>O45Y#_PHW_J8O_)+_P"V4?\
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M^V4?\*-_ZF+_ ,DO_ME'U/+_ /H)_P#)&'M*O\GXGKU%>0_\*-_ZF+_R2_\
MME'_  HW_J8O_)+_ .V4?4\O_P"@G_R1A[2K_)^)Z]17D/\ PHW_ *F+_P D
MO_ME'_"C?^IB_P#)+_[91]3R_P#Z"?\ R1A[2K_)^)Z]17D/_"C?^IB_\DO_
M +91_P *-_ZF+_R2_P#ME'U/+_\ H)_\D8>TJ_R?B>O45Y#_ ,*-_P"IB_\
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MOOLOVFZ0NXM5947YB,88DY&,'GJ#CBNBJY*SL2G=7"BBBI&%%%% 'C_[./\
MR3S4/^PK)_Z*BKV"O'_V<?\ DGFH?]A63_T5%7L% !1110 4444 %>=?&#_D
M5I_^O*Z_] %>BU7O+*VU"W,%U$)(\@X/&#Z@CD5SXFDZM)PCOI^#3_0X\;0E
M7HNG%ZZ/[FG^AX!\%/B)X5\(^#;RPUS5?LEU)J#S*GV>63*&., Y12.JG\JZ
M?X(ZI971U80W",9?*V#D$[=^1SWY!QZ<UT<OP6^'LLKR-X=4,[%B%NYU&3Z
M/@#V%>+_  *_Y#5U_P!?%I_Z$]9XJ7LXJKU37XM+]3MJYG/!X*K!134W!/R]
MY?YL^I:***[!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"$;#>2RV$ZD<M&\9D /T:,'\3ZT+97W_ ,T$M&^W^3.QHHHH **** "BBB@
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M/X>V2:ZF36+"'49K!Y\74-M]KD38WRQ9(W9QCJIXZ\=*XW_A=OP\_P"AA_\
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M=_[8?^CXZ[\=*X#XV?\ )(==_P"V'_H^.N_'2@ HHHH **** "BBB@ HHHH
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M/_)/-0_["LG_ **BKV"O'_V<?^2>:A_V%9/_ $5%7L% !1110 4444 %%%%
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M^1V&D>/KU]26S\3>&Y_#_GV\EQ:RRW*3)*B#<P.T#8P7G:>P-0Z3\1KZ]O\
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MQ"1H4D((P67*MQSC\ZZRBCK</(****  @$$$9![5GV&A:/I7G?V=I5C9^?\
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MU]%=-/%XBE'EIS:79-HAPC)W:.0_X5?X-_Z _P#Y,S?_ !=;&A^%]&\-^?\
MV39_9OM&WS?WKONVYQ]XG'WCTK7HIU,9B*D>2=1M=FV"IP3ND<WX^TJ]UOP3
MJ.G:?#YUU,$$<>X+G#J3R2!T!K%UGP-#XU\832^)]-,NBV%JD-A']H*^;*QW
M22?NV!&,*N#COQ7?45R6_KY6+_K\;G$>$O"<G@SQ/J=CI5F8_#-W#'<0_O\
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M5-G1Q'4E..78F]I2<H2LW9J*LKKNNYV-%%%>X<X4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 0RVMO.P::WBD8# +H"?UIG]G6/\ SYV__?I?
M\*LT4 -CCCA0)&BH@Z*HP!3J** "BBB@ HHHH \?_9Q_Y)YJ'_85D_\ 145>
MP5X_^SC_ ,D\U#_L*R?^BHJ]@H **** "BBB@ HHHH *\_\ C;_R2'7?^W?_
M -*(Z] KS_XV_P#)(==_[=__ $HCH \K@_Y)#X'_ .W_ /\ 2BO8_#__ ".F
MJ_\ ;;_T8*\<@_Y)#X'_ .W_ /\ 2BO8_#__ ".FJ_\ ;;_T8*\3$?[W3_Q+
M_P!)9IQ!_NN5_P".H=C1117MF84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 8?B[Q-:^$/#%[K=VAD2
MW7Y(@<&1R<*N>V21SV&37!^!?%_AG7/$\=W=>(DU/Q3>1-%!!':S1P6L8!<Q
MQ;D'IR['+8'TKUBBA;Z@]58\#U27P;=:%/X?TWPK)I_C=[C]U;"WDDN(9O,R
M)?M!7)C_ (LYQCMBO5O&/AK5/$V@V]AIWB.ZT2YCG65[NU#;I %8%/E=3@E@
M>O\ ".*Z:BA:*W];6!ZN_P#6]SQ_]G'_ ))YJ'_85D_]%15[!7C_ .SC_P D
M\U#_ +"LG_HJ*O8* "BBB@ HHHH **** "O/_C;_ ,DAUW_MW_\ 2B.O0*\_
M^-O_ "2'7?\ MW_]*(Z /*X/^20^!_\ M_\ _2BO8_#_ /R.FJ_]MO\ T8*\
M<@_Y)#X'_P"W_P#]**]C\/\ _(Z:K_VV_P#1@KQ,1_O=/_$O_26:<0?[KE?^
M.H=C1117MF84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'C_ .SC_P D\U#_ +"LG_HJ*O8*\?\ V<?^2>:A_P!A
M63_T5%7L% !1110 4444 %%%% !6'XP\-0^,/"=_H,]Q);I=HH$R $HRL'4X
M/4;E&1QD9Y'6MRB@#Y@\;? O_A#O"%]K_P#PD?VS[+Y?[C[#Y>[=(J?>\PXQ
MNST[5T/PX^&K>)/ .EZJVLF$S"0>6;??M"R.@YWCLOI7??&W_DD.N_\ ;O\
M^E$='P2_Y)#H7_;Q_P"E$E9SIQJ*TD=F$QM?!S<Z$K-JW]7,O_A3/_4?_P#)
M/_[.N?\ %_P__P"$4TF*^_M/[5YDXAV>1LQE6.<[C_=_6O=*X#XO?\BG:_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /'_V<?\ DGFH?]A63_T5%7L%
M>/\ [./_ "3S4/\ L*R?^BHJ]@H **** "BBB@ HHHH **** //_ (V_\DAU
MW_MW_P#2B.CX)?\ )(="_P"WC_THDH^-O_)(==_[=_\ THCH^"7_ "2'0O\
MMX_]*)* /0*X#XO?\BG:_P#7\G_HN2N_K@/B]_R*=K_U_)_Z+DK#$?PI'KY)
M_P C&C_B_1G5>&/^13T;_KQ@_P#1:UJUE>&/^13T;_KQ@_\ 1:UJUK#X4<&)
M_CS_ ,3_ #9S7C?_ ) L/_7PO_H+5LZ1_P @6P_Z]X__ $$5C>-_^0+#_P!?
M"_\ H+5LZ1_R!;#_ *]X_P#T$5Y]/_?JG^&/YL^=H_\ (TJ_X(_FRY1117I'
MM!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >/\ [./_
M "3S4/\ L*R?^BHJ]@KQ_P#9Q_Y)YJ'_ &%9/_145>P4 %%%% !1110 4444
M %%%% 'G_P ;?^20Z[_V[_\ I1'1\$O^20Z%_P!O'_I1)1\;?^20Z[_V[_\
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MM]::=%?01/NN9EB3>R;MH+$<\'CVH6JOZ?CL#T=OZT//OV<?^2>:A_V%9/\
MT5%7L%>%_ +Q+H.C>!;ZWU36]-L9VU.1UCNKI(F*^5$,@,0<9!&?8UZI_P )
MWX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\
MZ&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_
M /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/
M_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5
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M5D8( 006R"#QBM'_ (3OP?\ ]#7H?_@QA_\ BJUA\*.#$_QY_P")_FR+QO\
M\@6'_KX7_P!!:MG2/^0+8?\ 7O'_ .@BN2\2^)=!UG38[?2];TV^G68.T=K=
M)*P7!&2%).,D#/N*T=/\:>%;73;6WN/$NC0SQ0HDD<E_$K(P !!!;((/&*\^
MG_OU3_#'\V?.T?\ D:5?\$?S9U%%<_\ \)WX/_Z&O0__  8P_P#Q5'_"=^#_
M /H:]#_\&,/_ ,57I'M'045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT
M/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\
MQ5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S
M_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@_
M_H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\
M!C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4
M?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\
M^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8
MP_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '
M045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#P
MG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]
M#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_
M /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)W
MX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT
M/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\
MQ5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S
M_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@_
M_H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\
M!C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4
M?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\
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M ).W'_QRC_A27P\_Z%[_ ,G;C_XY7H%% SS_ /X4E\//^A>_\G;C_P".4?\
M"DOAY_T+W_D[<?\ QRO0** //_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^
M3MQ_\<KT"FR2)%&TDCJD: LS,<!0.I)H X'_ (4E\//^A>_\G;C_ ..5S?AS
MX#:/;:SKLOB"QM+O3IKC=I<4-W.&@BW/\K_=R=IC'5NAY]?2-#\6Z1XATJ\U
M2QG)L+2:2)[AP K; "S Y^[SUK%TCXHZ+J^JVED+#6+.*];;97MY9&*WNCU
MC?/.1R,@4=;!?2Y5_P"%)?#S_H7O_)VX_P#CE'_"DOAY_P!"]_Y.W'_QRKVL
M_$6VTG6[G2X?#GB/59;7:)I=,L1/&C,H8*3N&#@@XQWKKK>7S[>*;RY(_,0-
MLD7#+D9P1V-"U5P>CL<'_P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\
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MVB]O+2S,L%ID9_>.#QP0> :.WF!VE%-BE2:))8G#QNH964Y!!Z$44 .HHHH
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ML Y'3>H(5_\ @0-2T[Z#35M3GO#&IS:AX]TV_P!4V0WE_P"&()(XSQEO,+2
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M4TJ@8PS*">.W6LS5OAUX1US6EU?4M#MKB^!!,A+ .1TWJ"%?_@0-=.JA5"J
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M7CV4OFJ!N=0"2N"<CYAUP?:ISJ6-<72_L5X=UN9_M8B_<##!=A?/W^<XQTH
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M:I]O\[_\ SAF"47S+WFDKZ.]N;?;1W7W+316OT445N>2%%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img_021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %Y K4# 2(  A$! Q$!_\0
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M >P45X__ ,(]\<_^AST/_ORO_P CUD^'?^%T>)M/DO;+Q=I,<:2F(B:WC!R
M#V@/'S"ES).QHJ4Y0=1+16N^U]OOL>[45\_:]JOQ>\+:_P"'M,U+Q5ITKZS=
M"WA,%O&54[D4[B800/W@Z9[UW']B_%C_ *&?2?\ OVO_ ,9KMP^&C63;J1C;
M^9O]$S"4W'HV>DT5YM_8OQ8_Z&?2?^_:_P#QFC^Q?BQ_T,^D_P#?M?\ XS73
M_9]/_H(A]\O_ )$CVK_E?]?,])HKS;^Q?BQ_T,^D_P#?M?\ XS1_8OQ8_P"A
MGTG_ +]K_P#&:/[/I_\ 01#[Y?\ R(>U?\K_ *^9Z317FW]B_%C_ *&?2?\
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M_P#?M?\ XS1_9]/_ *"(??+_ .1#VK_E?]?,])HKS;^Q?BQ_T,^D_P#?M?\
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MX8_]A4_^C;>O8*W/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q_P"$'_)0
M_B=_V%1_Z-N*]@KQ_P"$'_)0_B=_V%1_Z-N*]@H **** "N#^$O_ "*MU_U^
MO_Z E=Y7!_"7_D5;K_K]?_T!*PG_ !8_/]#UL/\ \B^O_BA^<CF_B_\ \E#^
M&/\ V%3_ .C;>O8*\?\ B_\ \E#^&/\ V%3_ .C;>O8*W/)"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#Q_X0?\ )0_B=_V%1_Z-N*]@KQ_X0?\ )0_B=_V%
M1_Z-N*]@H **** "N#^$O_(JW7_7Z_\ Z E=Y7!_"7_D5;K_ *_7_P#0$K"?
M\6/S_0];#_\ (OK_ .*'YR.;^+__ "4/X8_]A4_^C;>O8*\?^+__ "4/X8_]
MA4_^C;>O8*W/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!&W%>P4 %%%% !1110!Y+\9='OM5UGP<^DW4=MJD%VYM))1E%<O#@MP>A
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH CG@ANH'@N(HYH9!M>.10RL/0@]:Y.3X6>"))6<^'K9=S
M;C&C.D9/^X&"_ABM#Q9H7A_5-.:^\06AG@T^*2;(D=-BXRWW6&>%'6O$I-4\
M.?9KVZM_A==R6UI;1WDC'6&#""091RH8G!')QG'>E?4JSL?0EAIUEI=HEII]
MI!:6R?=B@C"*/P'%6:S?#QB;PUI;00);PFUB*0I-YJQKM&%#_P 0'KWK2JI)
MIM,B+NKA1112&%%%% 'C_P (/^2A_$[_ +"H_P#1MQ7L%>/_  @_Y*'\3O\
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M%W';VYG2,/L$@QD?-@XSZXKDKCQ[XSTVT>_U3X;S0:="OF7$T.L0S.D8Y+!
M 6P.<5AQW=VOP1\2^']4=#JFA0R6,^QR0R@ QL,\[2I&"?2H?%W@5] TZUU6
M\\1>*-:\/Q.HU6PNM3=LQ$@;QM RJ]UZD=QBJ>^FVEOF"V5]];_(]<EO)'T=
M[[3X/M<C0&:WAWB/SCMRJ[C]W/ R>F:\_/Q"\;#61I'_  K;_3S;_:1%_;D/
M^KW;=V=N.O&,YKT:U-NUG"UH8S;&-3$8\;2F.,8[8Q7)M_R66/\ [ +?^CQ0
MU[UO7]1)^Y?T_0Z:WO9!H\=]J<"V$@@$MS$TH<0';E@6'!QSR/2N;U+QI>6W
MAW3-1L-":]O=5G$=E8FY$32(0SJS,RX4[%W$'IG&:D^)CR)\.-;,9QF#:_./
MD+ -_P".DUE^/;?PI<3>';;Q//=6NGL\@AECF$-L6,>-DK@AE!4G&" ><FI>
MOWK]7_P"EI]S-G3=>\23:'J%]JOA(Z?=6PW0VBZA'.;A0,G#*, ]@#U/I6_8
M7MOJ6GV]]:2"2WN(UEC<=U(R*X#X:KI]MKGB.P\-WC7/ABW: 6O[YI8XIBI,
MB1N2<K]TGD\FM7X8D_\ "(,BDF"/4+Q(#G_EF)WQ5;_<G^A/^=OPN=E1112&
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+6;<76
MB7]N;4W8EMY$-NKA#+E2-@8\#/3)]:\3:RL[1(=-N_$M[X9NY-.?1YQK>F*$
MGM@Q*;)0WE;E5MN[<<]<"O8-?U^TT: Q27<5O>SP326OG1.Z$QIN);8,X Y(
MR">W->:/K7A364(\5^.[_5(FR&LK>UFL[4@GH41=[ ?[3FIW;'?0]5T.RMM-
MT'3[&RE\ZUM[:.*&3<&WHJ@ Y'!R!5^J6D&Q.C61TM573_(3[,%4J!'@;< \
MCC'6KM:2=Y-D1V04445)04444 >/_"#_ )*'\3O^PJ/_ $;<5[!7C_P@_P"2
MA_$[_L*C_P!&W%>P4 %%%% !1110!P?CS_D:O!W_ %^G_P!#BKF_V<?^2>:A
M_P!A63_T5%6_\29_L.J^&=2DBD:VM;IGD9%ST:-L>F2%; SV->=_!+QQIGAG
MP9>65[!=R2/J#R@PHI&#'&.[#GY37-&<83FY.VWY'NU<-6Q&&PT:,>9VGMY2
MN_S1]"T5EZ!K]EXDTW[=8^8(PYC9)5PRL,'!ZCH0>">M:E=":DKH\:I3G2FX
M35FMT%%%%,S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DL4<\+PS1I)
M%(I5T<95@>""#U%)#!%;P1P01)%#&H1(T4*JJ.  !T%250L-;T[4](&K6ER'
ML<.WG%6484D,<$ \$'\J3MJ!8L[*UT^U2ULK:&VMTSLBAC"(N3DX X')J/4=
M*T[5[<6^IV%K>P!MPCN85D4'UPP(S2:5JMEK>EV^IZ=.)[.X3?%* 1N'T(!'
MT-0:]XATGPQIC:CK-[':6JL%WN"26/0  $D\'@#L:;TW!:[#AH&C+#+"-(L!
M%,B1R(+9-KJGW5(QR!V!Z5;DM+:6XAN)+>)YH-WE2,@+1Y&#M/49'!Q5'0/$
M6D>*--&H:+?1WEJ6*%T!!5AV((!!Y'!'>L_Q!X_\+>%KV*RUG6(;6YE *Q;6
M=@#T+;0=H]SBA]F!J6N@Z/8M$UII-C;F%VDC,5NB;&888C X)'!/>M @$$$9
M![5BW_BW0M-CMY+C4%,=Q%YZ/"C3+Y7'[UB@(6/D?.V%]ZORZG9PWMI9O,/M
M%X&,"*"V\*,L>.@&1R>.0.I% %>R\.:'IMXUY8Z-IUK=/G=-!:HCG/7+ 9IN
MH>%_#^K77VK4M"TR]N-H7S;FTCD? Z#+ G%/N=?TNSUNST:XNUCU"]1GMX64
M_O O7!QC/MG-3SZG9VVIVFG2S;;N[61X(]I.\)C=SC QN'7UH[ 26=E::?:I
M:V5K#;6Z<)%#&$1?H!P*GKA+GXR^ ;.ZFMI]>V30NT<B_8YSA@<$9"8ZUNMX
MT\.IX9B\12:K#%I,PS'<2ADW\D8"D!B>#QC/%%[KFZ!L[&O;6-I9V:V=K:P0
M6J@JL,485 #U 4<=S4&FZ+I6C+(NEZ996*R'+BU@6(,?4[0,UF>'/'7AGQ:\
MD>AZO#=2QC+1;6C<#UVN 2/?%:FH:O8:7):1WMTD+WDZV]NIR3)(>@ '\^@I
MZ_>*Z)Y;2VFN8+B6WADG@W>3*Z M'D8.T]1D<'%12Z7I\XNA-8VL@NP%N0\*
MGS@!@!\CY@!QS61XC\=^&?"5Q!;ZYJT5I-.-T<91W8C.,D*#@9SR<#@^E6M5
M\5:'HFA)K>H:G!#IL@4QS@EQ)N&5VA<ELCGC/%3I:Y6MRQ'H.C10&"/2;!(3
M ;?RUMD"^43DQXQ]TDYV]*L?V?9&:VF^R0>;:J5MW\L9A! !"''R@@ <>E4]
M \1:1XHTT:AHM]'>6I8H70$%6'8@@$'D<$=ZU*K816&G60BN8A9VXCN6+3IY
M2XE)&"6&/F) P<U2@\+^'[6)8K?0M,BC4L56.TC4 LNUL #NI(/J#BM:L63Q
M;H<4;R/>[4COQISL8GPMP<80G;P.0-WW>>M+R T3IUD8+> V=N8K9E:",Q+M
MB*\*5&/E([8Z59(!!!&0>U4M6U:QT/3)M1U&;R;2'&]]C-C)"CA02<D@<"KH
M.1FC<-C,LO#FAZ;>->6.C:=:W3YW306J(YSURP&:N6ME:V2R+:6T-NLLC2R"
M*,('=NK''4GN:GHH IRZ1IL[7;3:=:2&\54N2\*GSU'0/D?,!DX!JS+#%- \
M$L:21.I1HV4%64\$$=Q6;=>)=(LK+4+N>]58-.E$-TX1F\IR%., $G[Z],]:
MU0<C(HW0=2*UM;>RM8[:T@BM[>)=L<42!$0>@ X I/LEM]M%[]GA^U"/RO/V
M#?LSG;NZXSSBN7U+XH>"M)U4Z9>^(+9+M6V,JJ[JC9P0S*"JD=\D8K1\0>,_
M#_A;3[:_UC45@M;IML,JQO*'.,\; >,<YHOU"W0U;^R@U+3[FQNDWV]Q$T4B
M^JL,$?D:SM.T4GPU#H^N1VVHI$ODL94$BS(IPC.K#&X@ D<C.>35/PY\0/"O
MBVYDMM$UB*YN(UW&(H\;D>H#@$CZ=*Z6BWXA<S)].:RT&:Q\/P6=C)Y96W58
MPD43'^+:H[=<=ZET?2[?1-'M--M0?)MHPBD]6]6/N3DGW-%MK.G7E]?6=O=Q
MR3V!472C_ED6&0">F<#\.]8VC_$3PEK^L/I.EZY;W%\N<1 ,N_'78Q #\9/R
MD\<T+5^H'3T53U75;+1=-FU#4)O)M80#))M+8R0!P 3U(JX#D9% !1110 44
M44 %%%% !17(ZE\4/!6DZJ=,O?$%LEVK;&55=U1LX(9E!52.^2,5U!NK<69N
M_.0VPC\WS0V5V8SNSZ8YI75K] ZVZDU%4-/UK3M4T6+6+*Y$VGRQF5)@I&5'
M4X(SV/&,UQZ_&OX>,P4>(1DG'-G.!^>RGUL'2YW]%16US!>6L5U;2I-!,@>.
M1&RKJ1D$'N,5RNN?%#P;X;U:;2]6UC[/>PA3)%]FF?&0&'*H1T([T/1V8+75
M'7T5S_AGQOX=\8FY&@ZC]K-MM\[]S)'MW9Q]]1G[IZ5KM?VRZC'8&3_2GC:4
M1A2<(" 22!@<GC/7G&<&BP%FBBB@ HKGO$?CKPSX2FAAUS5HK26892/8SL1T
MR0H) X/)XXK1CUS3)DT^2*\C>/4?^/21<E9?EW8#=,X!.#UP?2A:AL:%%%%
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MMQ7L% !1110 4444 %>/_LX_\D\U#_L*R?\ HJ*O8*\?_9Q_Y)YJ'_85D_\
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M1110 4444 %%%% '@WP'\5Z)H7@>]M=2O?(F?4GD5?*=LJ8XAG*@CJ#7J/\
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M_P "C_D9?_"Q?"G_ $%?_)>7_P")H_X6+X4_Z"O_ )+R_P#Q-:G_  C6@_\
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M_D9?_"Q?"G_05_\ )>7_ .)H_P"%B^%/^@K_ .2\O_Q-:G_"-:#_ - 33?\
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M_P 31_PL7PI_T%?_ "7E_P#B:U/^$:T'_H":;_X")_A1_P (UH/_ $!--_\
M 1/\*+5NZ^YASY9_)4_\"C_D9?\ PL7PI_T%?_)>7_XFC_A8OA3_ *"O_DO+
M_P#$UJ?\(UH/_0$TW_P$3_"C_A&M!_Z FF_^ B?X46K=U]S#GRS^2I_X%'_(
MR_\ A8OA3_H*_P#DO+_\31_PL7PI_P!!7_R7E_\ B:U/^$:T'_H":;_X")_A
M1_PC6@_] 33?_ 1/\*+5NZ^YASY9_)4_\"C_ )&7_P +%\*?]!7_ ,EY?_B:
M/^%B^%/^@K_Y+R__ !-:G_"-:#_T!--_\!$_PH_X1K0?^@)IO_@(G^%%JW=?
M<PY\L_DJ?^!1_P C+_X6+X4_Z"O_ )+R_P#Q-'_"Q?"G_05_\EY?_B:U/^$:
MT'_H":;_ . B?X4?\(UH/_0$TW_P$3_"BU;NON8<^6?R5/\ P*/^1E_\+%\*
M?]!7_P EY?\ XFC_ (6+X4_Z"O\ Y+R__$UJ?\(UH/\ T!--_P# 1/\ "C_A
M&M!_Z FF_P#@(G^%%JW=?<PY\L_DJ?\ @4?\C+_X6+X4_P"@K_Y+R_\ Q-'_
M  L7PI_T%?\ R7E_^)K4_P"$:T'_ * FF_\ @(G^%'_"-:#_ - 33?\ P$3_
M  HM6[K[F'/EG\E3_P "C_D<KXE^+7A_1/#]UJ-C)_:-S#LV6NV2'S,L%/SE
M"!@$G\,5UV@ZI_;?AW3-6\GR?MUK%<^5NW;-Z!MN<#.,XS@5'_PC6@_] 33?
M_ 1/\*T8HHX(DBB18XT4*B(,!0.@ ["M(<_VK'%B'AVU[!22_O6?Y6'T4459
MS!1110!0UN(SZ#J,*W0M&DMI%%PS;1%E2-Y/;'7/M7EUK:>(9?A>G@^#P1%.
MLEK]G2]34(&M'STN0<[C\W[S&W.:]3UBWCN]$O[>:6.**6WD1Y)4#*@*D$D'
MJ!Z5X?HWB74=,M7T^P\6:V-,LM/^V6[R:%"RM:K((]T>Y_,*#.?FYVJ?;*LF
MVGY%:JS71_Y?U_PY[?HUE-INAV%C<7!N)K:WCB>8]9&50"WXXJ]532I#+I%G
M(UXMZ7A1OM2H$$V0/G ' SUQ[U;JY7<G<SC:RL%%%%24%%%% 'C_ ,(/^2A_
M$[_L*C_T;<5[!7C_ ,(/^2A_$[_L*C_T;<5[!0 4444 %%%% !1110!X_P#L
MX_\ )/-0_P"PK)_Z*BKV"O'_ -G'_DGFH?\ 85D_]%15[!0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &9XA&G
M/X?OX-6O(K.QN('@EFEE6,*K@J?F;@'FO)+'P/XKU!HWT[5O#MWIAT4Z%'J$
M$KOFWW_?V $%]ORXW8SSFND^(\^G)XY\#1:W-:II/GW<LPO'58=RQ#86W<<$
M\9[FL_P?XF\*Z/X^\900:WHUGH\CVLMJJW<20LYC/F%.<$Y SCO2BKZOS_#3
M7[RFVEIY?C_PR/3M(TV+1M&LM,@9FALX$@1GZD*H )]^*N5';W$-W;QW%O-'
M-!*H>.2-@RNIY!!'!!]:DJFVW=D))*R"BBBD,**** /'_A!_R4/XG?\ 85'_
M *-N*]@KQ_X0?\E#^)W_ &%1_P"C;BO8* "BBB@ HHHH **** /'_P!G'_DG
MFH?]A63_ -%15[!7C_[./_)/-0_["LG_ **BKV"@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *UWIUCJ&S[;96
M]SLSM\Z)7VYZXR..@JK_ ,(YH7_0%T[_ ,!4_P *TZ* &Q11PQ)%$BQQH JH
MHP% Z #L*=110 4444 %%%% 'C_P@_Y*'\3O^PJ/_1MQ7L%>/_"#_DH?Q._[
M"H_]&W%>P4 %%%% !1110 4444 ?/@TWQ1\(O&N@:!INNQOX;UO6%*0F%&E*
M[H4<2$IP=K*N5/.,X4G%?0=>/_%__DH?PQ_["I_]&V]>P4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 >/_"#_DH?Q._["H_]&W%>P5X_\(/^2A_$[_L*C_T;<5[!
M0 4444 %%%% !1110!X_\7_^2A_#'_L*G_T;;U[!7C_Q?_Y*'\,?^PJ?_1MO
M7L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'C_P@_Y*'\3O^PJ/_1MQ7L%>/_"#
M_DH?Q._["H_]&W%>P4 %%%% !1110 4444 >/_%__DH?PQ_["I_]&V]>P5X_
M\7_^2A_#'_L*G_T;;U[!0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X_\(/^2A_$
M[_L*C_T;<5[!7C_P@_Y*'\3O^PJ/_1MQ7L% !1110 4444 %%%% 'C_Q?_Y*
M'\,?^PJ?_1MO7L%>/_%__DH?PQ_["I_]&V]>P4 %%%% !1110 4444 %%%%
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MRF_^/T >P45X_P#\*@\8?]%9US\IO_C]'_"H/&'_ $5G7/RF_P#C] !\7_\
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MA_T5G7/RF_\ C] 'L%%>/_\ "H/&'_16=<_*;_X_1_PJ#QA_T5G7/RF_^/T
M>P45X_\ \*@\8?\ 16=<_*;_ ./T?\*@\8?]%9US\IO_ (_0![!17C__  J#
MQA_T5G7/RF_^/U0UWX9^,-$\/:GJO_"T]<F^Q6DMSY69EW[$+;<^<<9QC.#0
M![?17S_X(\#^,/&/A"QU[_A9VN6?VKS/W&^:3;MD9/O><,YVYZ=ZZ#_A4'C#
M_HK.N?E-_P#'Z /8**\?_P"%0>,/^BLZY^4W_P ?H_X5!XP_Z*SKGY3?_'Z
M/8**\?\ ^%0>,/\ HK.N?E-_\?H_X5!XP_Z*SKGY3?\ Q^@#V"BO'_\ A4'C
M#_HK.N?E-_\ 'Z/^%0>,/^BLZY^4W_Q^@#V"BO'_ /A4'C#_ **SKGY3?_'Z
M/^%0>,/^BLZY^4W_ ,?H ]@HKQ__ (5!XP_Z*SKGY3?_ !^C_A4'C#_HK.N?
ME-_\?H ]@HKYPT_PUXPO_BAJW@O_ (61KB?V?:+<_;/-F/F9$1V[/-X_UO7<
M?N^_'7_\*@\8?]%9US\IO_C] 'L%%>/_ /"H/&'_ $5G7/RF_P#C]'_"H/&'
M_16=<_*;_P"/T >P45X__P *@\8?]%9US\IO_C]'_"H/&'_16=<_*;_X_0![
M!17C_P#PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C] 'L%%>/_\ "H/&
M'_16=<_*;_X_1_PJ#QA_T5G7/RF_^/T >P45X_\ \*@\8?\ 16=<_*;_ ./T
M?\*@\8?]%9US\IO_ (_0![!17@GB_P &>,O WABZ\2I\3-9O7L&B=;>02;7)
MD5>=TK CYLX*D'&#UKV/PE?7.I^#=#O[R3S;JZT^":9]H7<[1J6.!P.2>E &
MQ1110 4444 %%%% !1110 4444 %-DD2&)Y975(T!9F8X"@=23V%.KE_'Y)\
M,I&W^HEO[.*X]#$UQ&&!]B#@^QH\@-W3M5T[6+8W.F7]K>P!BAEMIED4,.V5
M)&>15NN5LAY7Q0U=(0!')I5K)/M[R"255)]]HQ] *ZJCHG_7]:!UL%%%9?B.
MSO=1\.W]CI[0+<W,)A4W!(0!N&SCG.TG'OBDW97+IQ4YJ+=DVM>WG\CA?!WC
M:75OB)JMK+=;[&\W?8EP^!Y?W=H)^7<FYFR!DCMTKTZOG[PMX-UF[\1W?V":
MP%UHEVF_SV?8[J[8QA<D90^E?0-<F#G.4'S]SZ+B/#X:CB(?5VOA5TNEDK/;
MJK,****[#YH**** "HYYXK:"2>XE2*&)2\DDC!510,DDG@ #O4E9?B&#29]$
MG.N;/[-AVSS>8Y51L8."<'D9 X[],&@:)+77M'OM/FU"TU:PN+*#/FW,5RCQ
MQX&3N8' P"#S2Z9KFD:T)#I6JV-^(L"0VMPDNS/3.TG'0UQ%_IVH:W8Z[JI%
MMI(U@6ME;1:@QCWQ*^-T@'(=PY54ZXV@X)P.GTC4M277KO1-4>UN)H;:.Z2Y
MM;=H4*NSKL*,[G(*$YW<@]!CEH7H;]%%%( HHHH **** "BBB@ HHHH RY?$
MFA0:H-+EUK3H]0+!!:/=()2QZ#9G.3D8&.]376LZ78WMO97>I6=O=W!Q!!-.
MJ/+SCY5)R>>.*X^"YU?P]%?ZT;W2;W3[K5SO@M8W>0AY5@&)=^T,@VY78>5(
MR,Y%35DBGT?XFR784RIE5+'E42U1XL>F&+$>YS2OI?\ KI_F4HW=O.WXV/2:
M*KV#ROIUJ\^?.:%#)G^]@9_6K%4U9V(3NDPHHHI#"BBB@ HHHH **** *6I:
MQIFC0I-JFHVEC$[;%>ZG6)6;&< L1D\&JT7BCP_-I\VH1:[IDEE P66Y2[C,
M<9/0,V< \CKZU-KNJ)HF@7^J2*66U@>7:/XB!D#\3@5R4GAR^MO#NAV$6H:?
M%JD^H)>WDU[EOM$P#2-M0$%R&"X7</E3J,4+_+^ONNP?]?U]QV6G:KIVL6QN
M=,O[6]@#%#+;3+(H;TRI(SR*MUB:!JEY>7&J:?J'DO=:=.L+SP1F..4-&L@(
M0LQ7 ?!&X],]\#;I@%%%%( HHHH **** "BBB@!DTT5M!)//*D4,:EWDD8*J
MJ!DDD] *CN;VTLK-[RZN88+5%W/-+(%11ZECP!7,?$S3(M2\ ZMY\UPJ6]K+
M/Y<4I19&5&VA\<LH.#CH2!G-)K_S7/@R&3_CV?4%,@/0LMO(R9_X$ ?J!0M?
MO2!Z:^OX'0KK.EOI1U5=2LSIP4M]K$Z^3@'&=^<8SQUJ>ROK34;2.[L;J"ZM
MI,[)H) Z-SCAAP>:\TDX\>R68 &FMXEC=E'W3+]A+_GO"M]>>#74^%QY?B7Q
M=#$ +9=0C=0O02-;QE_QS@GW-"U5_P"NG^8/33^NIU-%%% !1110 4444 %%
M%% !48N(#<M;":,SJ@D:(,-P4D@$CK@D$9]C4E<3H>E0Z?\ $KQ J37,S7-A
M;S2R3S,[$M)-P/[H P !@  ?6CK;U#I<Z:UUW1[W49M.M-5L9[Z#/FVT5PC2
M1X.#N4'(P3@YJ.7Q)H4&J#3)M:TZ/4"P06KW2"4L>@V$YR<C''>N9TZQM-0U
MC1[70+00:%X>DDQ=C.)9=K1F*,GE@"Q+OR"P R3G$<%QJ_AZ+4-:-[I-[I]U
MJWSP6L;O(0\JP#][OVAD&W*[#RI&1G(:U:_KJDOO!]?Z[_Y'?4444@"BBB@
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MY.4G=L****9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
,% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img_022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %' U # 2(  A$! Q$!_\0
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MR\.?]!FS_P"_@H_X3+PY_P!!FS_[^"CVM/\ F7WA]4Q'_/N7W/\ R-RBL/\
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M_09L_P#OX*/^$R\.?]!FS_[^"CVM/^9?>'U3$?\ /N7W/_(W**P_^$R\.?\
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M_ 5/\*U:*.2/8/K-;^=_>_\ ,RO^$9T+_H"Z=_X"I_A1_P (SH7_ $!=._\
M 5/\*U:*.2/8/K-;^=_>_P#,RO\ A&="_P"@+IW_ ("I_A1_PC.A?] 73O\
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MG?WO_,RO^$9T+_H"Z=_X"I_A1_PC.A?] 73O_ 5/\*U:*.2/8/K-;^=_>_\
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M_ 5/\*U:*.2/8/K-;^=_>_\ ,RO^$9T+_H"Z=_X"I_A1_P (SH7_ $!=._\
M 5/\*U:*.2/8/K-;^=_>_P#,RO\ A&="_P"@+IW_ ("I_A1_PC.A?] 73O\
MP%3_  K5HHY(]@^LUOYW][_S,K_A&="_Z NG?^ J?X4?\(SH7_0%T[_P%3_"
MM6BCDCV#ZS6_G?WO_,RO^$9T+_H"Z=_X"I_A5NSTVQT\.+*SM[8/RPAB";OK
M@5:HH48K9$RK59*TI-KU?^844451D%%%% !1110 4444#"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*Y;XE?\ )-/$?_7A+_Z#74URWQ*_Y)IXC_Z\)?\ T&@1S7P$_P"26VO_ %\S
M?^A5Z=7F/P$_Y);:_P#7S-_Z%7IU !1110 5XQ\5_P#DIO@[_KI'_P"CUKV>
MO&/BO_R4WP=_UTC_ /1ZUZF5?[P_\,O_ $EF-;X?FCV<44"BO+-@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH&%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 55O]3L-*MC<ZC>VUG #@RW$J
MQKGZL0*M5YWJWP<T#Q#XJN]=UVZU"^:9ALM3-LBC4 #:,?-CKT(Z]*6MQ]"Y
M=_&'P#92>7+XC@9O6&*64?FBD59T[XI>!]4<+;^);%6/07#&#_T8%IMK\*O
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M+_T(T )_PF6G?\\;K_OE?_BJ/^$RT[_GC=?]\K_\56I10,R_^$RT[_GC=?\
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M_P#A,M._YXW7_?*__%4?\)EIW_/&Z_[Y7_XJM2B@#+_X3+3O^>-U_P!\K_\
M%4?\)EIW_/&Z_P"^5_\ BJU** ,O_A,M._YXW7_?*_\ Q5'_  F6G?\ /&Z_
M[Y7_ .*K4HH R_\ A,M._P">-U_WRO\ \51_PF6G?\\;K_OE?_BJU** ,O\
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MK4)U33P<&^ML_P#79?\ &FDWL@N&QO[I_*C8W]T_E1_:FG_\_P#:_P#?Y?\
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MLIZ!B 26/7 [>O.)?#7B^_O=?NO#GB#3$T_6((A<)Y,OF17$1.-Z'J.>Q_\
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M>9:S_>C8%@1[].#W&#78^+O%H\,PV-O;63ZAJVH2^396:-MWMW9CV4<9/O\
M4@Z._>WX(75>E_Q9TU%<$GC+Q%HFL:=:>+=%L[:UU*4007EC<&18Y3T1PP!Y
M]1Q]>W>T=+AY&)KWB:VT&[TJSDAEN+G4[D6\,41&[IEG.2/E48S]:VZ\W\S^
MV/CYY3D-%HFE%HU_NRR$9/UVMBKWBSX@S^&O%ECH<&C2ZE->VQD@2!\.TF2
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M2/4:***0!1110 4444 %%%% !7+?$K_DFGB/_KPE_P#0:ZFN6^)7_)-/$?\
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MO_7S-_Z%7IU>8_ /_DEMM_U\S?\ H5>G4""BBB@ IDO$;_[II],D&Y&7U!%
M'CG[/CH^DZUM=6Q+#G!S_":]E'2O'O!WPS\9>![>ZATC7=,"W3*TOF0LW*@@
M8X]S72_V;\2_^@_HW_@,W^%>IB5]9JRK2G%.72[_ ,C*'NJUF=[17EOB2[^(
MGAKP_=ZO<:UI4L5L%+)';'<<L%XS]:ZOX?ZU>^(?!&G:KJ#HUU/YN\HNT';*
MZCCZ**YZN$E"E[923C>VG>U^R*4TWRG3T445QEA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 5-4_P"01>_]<'_]!-97
MA[_D!V__  +_ -"-:NJ?\@B]_P"N#_\ H)K*\/?\@.W_ .!?^A&@9IT444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5B:U_R%M&_Z[_^S+6W6)K7_(6T;_KO_P"S+0!U%%%<;J-K
MXY?XCV$]C?6R>%5B'VF!@NYFYS_#NS]W&#CC\SJD#VN<5J'Q'\?^(+NYT_PO
MX$/DI(\)N+Y2R2 $C(+;$!]B6K-\/?!3Q%<>*;'Q#XAOM*LFMIX[@6VGVRKN
M*MNVD(J*#Q]X;C6Q?:1\<&U"Y-GXBTM;4RL808XN$R=O6(GICO4FDZ5\:X]9
MLGU/Q!ILE@LZ&Y18XLM'N&X#$0/3/0BBGT?4)ZW70]=HHHH **** *&J:'I.
MN1)%JVF6=]&AW(MS"L@4^HR.*ET_3+#2;1;33;*WL[922(K>(1J">IP!C-6J
M* ,IO#&@OJPU5]%T]M1#;OM1MD,F[UW8SGWK5HHH *Y;XE?\DT\1_P#7A+_Z
M#74URWQ*_P"2:>(_^O"7_P!!H$<U\!/^26VO_7S-_P"A5Z=7F/P$_P"26VO_
M %\S?^A5Z=0 5SOA[7KK5M7UNTGCA6.PG\J(Q@@D;G'S9)Y^4=,5T5<3X*_Y
M&7Q9_P!?G_L\M1)ZHXZ\Y1K4HIZ-N_\ X"=M1115G89/B;5)]%\/76H6R1M+
M%LVB0$J<N%YP1V-6]*NGOM(LKN4*))X(Y6"] 64$X]N:QO'O_(E:A_VS_P#1
MBUI>'O\ D6M*_P"O.'_T 5%_>L<:G+ZVX7TY4_G=G/?%?_DF>M?[L7_HU*C^
M$?\ R2_1_K/_ .CY*D^*_P#R3/6O]R+_ -&I4?PC_P"27Z/]9_\ T?)7L?\
M,M_[?_\ ;3;_ )??+]3MQ10**\HV*FJW3V.D7MW$%,D$$DJANA*J2,^W%5/#
M.J3ZUX>M=0N5C667?N$8(48<KQDGL*D\0_\ (M:K_P!><W_H!K-\!?\ (E:?
M_P!M/_1C5%_>L<;G+ZVH7TY6_G='244459V!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% %35/^01>_]<'_ /0365X>_P"0';_\"_\
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M6\"VMC?#%W,S7$Z?W&?^'\!@'WS61\1P%\9?#\   :F0 /\ @-7))5$O-?\
M!(3?(WY/_@'H-]<M9:?<W2P2W#0Q-((85R\A SM4=R>@KS?4_&?Q$TK2Y->N
MO"&GQ:7%^\EM3=EKE(^Y)''Z9'<5ZA7"?%37OL/AB31+-/M&L:R#:6MJO+,&
MX9L=@ >I[_C6;NMMS16>C.JT'6K;Q%H5EJ]GN$%U$)%#CE?4'W!R/PJ'Q1K<
M?AOPOJ.KR8(M8&=5)QN?HH_%B!^-,\(Z&?#7A+3-':02/:P!78="W5L>V2:Y
M'XV.S>"K2S'W+S4X('YQP23_ #45517?+'J[?>TB:;T3EZ_<F_T.J\%C5/\
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M>-S.3T!]<9]17I-%*VEGL'6_4Y+X?^%9/!GA$6ES(;B_E=KJ[9.=TK=0/7
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M8GL*!G0T5F?\)!I?_/U_Y#;_  H_X2#2_P#GZ_\ (;?X4 :=%9G_  D&E_\
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M#;_"C_A(-+_Y^O\ R&W^% &G169_PD&E_P#/U_Y#;_"C_A(-+_Y^O_(;?X4
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M5S]U3P#P.QZ$M7/[+W_(^:EE=\?S6]SXO^!]_P"!TE%%%=!]*%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 (Z+(C(ZAE88*D9!%5?[
M*T[_ )\+7_ORO^%6Z* *G]E:=_SX6O\ WY7_  H_LK3O^?"U_P"_*_X5;HH
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MJ5[+7C7B3_DXC1?^N$7_ +4KU<L^.I_@E^1C5V7JCV6BBBO*-@HHHH ****
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M@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5S_X#M_A77_V98?\^5M_WZ7_  H_LRP_Y\K;_OTO^% '(?\ "W/"?_/U<_\
M@.W^%'_"W/"?_/U<_P#@.W^%=?\ V98?\^5M_P!^E_PH_LRP_P"?*V_[]+_A
M0!R'_"W/"?\ S]7/_@.W^%-?XO>$8T+M=W 51DDV[ "NQ_LRP_Y\K;_OTO\
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M_/U<_P#@.W^%=?\ V98?\^5M_P!^E_PH_LRP_P"?*V_[]+_A0!R'_"W/"?\
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M+_A0!R'_  MSPG_S]7/_ (#M_A1_PMSPG_S]7/\ X#M_A77_ -F6'_/E;?\
M?I?\*/[,L/\ GRMO^_2_X4 <A_PMSPG_ ,_5S_X#M_A1_P +<\)_\_5S_P"
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MZE'I]S87JW:3/%YF"H...G4CK7,^#_$WBW3/B9<>"O%5_!JF^U^T6]W%"L9
M S@A0.,!NHSGO1#>SWU_+_APEM=;:?G_ ,,3:_\ $KQ$WB35-(\'^&DU5='
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M8*@XXZ=2.M'V8OSU^\/M27E^@OA#Q#XLUB^N(O$'A3^QH$BW1R_:1)O;(&W
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MRI1UBEW:5_N3?WCD[2;[)MK[VC6T/XE^(HO%FFZ'XQ\-1Z4-6!-C-%,'^BL
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M8\#>"K7P1HLEG%<R7EU<2F>ZNY1AII#WQDX'MD]_6NGHHIMW ****0!1110
M4444 %%%% 'D6H_!G5[CQAJ7B2P\<W.GW5[([9BLSN1">$W"49   Z#I76V/
M@_68/!%WH5WXNOKG4)G+1ZKL*RQ<@@ ;R>,?WAUKL**25H\O0;=WS'F%G\*-
M2N]?T_4_%OB^ZUR/3W$EM;& 1('!!!/S'/09XR<#)[5L^./A\WBK4=-U?3M7
MFTC6=/R(;J--X*GL5R/?\SG-=M13["74X[P/X"'A*74+^\U.75M8U%PUS>RI
MLR!T4#)P.?7TZ8%=C113N 4444@"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .*^+.K7^B
M?#;5+_3+I[:[C\H)+']Y<R*#C\":\TTO2OBW+X3M?%&E^+OM?FVXN!92G<S+
MC. &4J6]N/K7??&[_DDVK_6'_P!&K6K\-G6/X7^'W=@J+8(68G  Q4K:;[6_
M)E2^RO7]"I\+?'A\>>&&NKF)(=1M9/)ND3[I.,A@.P([>H-7M5^)/@[1+]K'
M4/$%I%<H=KQJ2Y0],-M!VGV-><_L^XGU#QA>P#;9S74?E#/ YD/\B*I:IJ_@
MB\.O67A[X>7>NL7F:[U*.VW^7(V2661MS#G)&-O3@4YRV=NE[?(48ZM7ZV/9
MKWQ1H>G:''K5UJELFF2;=ET&W(V>F",YJQ<ZUIMGHIUFXO(H].$0E^T$_+L.
M,'\<C\Z\9^'6B/XK_9ZU31VR[M+.+8'^%UVN@'_ OYFN2NO%D^M_!#0O"T,@
M;4I]2%@4)P3&A#+GVR\8_"JDFFXK?2WS)B[I2>VM_D?15QXJT*U\/QZ[<:I;
M1Z7(H:.Y9L*^>@'<G@\#FF^'_%V@>*HYGT34X;P0D"14R&3/3*D XZ\UYW\5
M/!&IR>$?#::%9#48M!=?,L-N?/1549V_Q?=P0.<,:TOA=XI\+^(;Z_73O#T>
M@Z[%&JWMJL03<JDCC &<$X.0",T*S<DNGY=P=TD^_P#5CTRN:N?B!X3L[2ZN
M;C7;2.*UN#;3$DY64=5"XR3] >AKI:^>OAEX/T/Q/\0O&MSK-DMY]CO76**3
ME,O))DD=S\O'U/MB5=NR[7_(IZ1OYGNNBZ[I?B+3EO\ 2+Z&\M6)7S(CT([$
M=0?8UFZ]X\\+^&;I;76-:MK6X89\HY=P.Q*J"1^->8?!2)=(\>>.-#M"QT^V
MG/E*6)"[9'4?CCO[54^#?A[2O&EWXF\0>(K*WU*[EO-@6Y4.$SEB0#QSD 'M
MMXQ3WMR]KBVO?O;]3V_2M7T[7=/CO]+O(;NUD^[+$V1GN#Z'V/-8FH?$;P?I
M6K'2[WQ!9PWBMM>,L2$/HS 84_4C%>=_!F'^QO'WC?P]:,W]G6UQF)=VX(0[
M*.?7& ?]VN5M5@^&VKZIIOCSP<FIZ9?W;,FKF 2,0<XPQ&/]K *L.3S1=-JV
MS5_^ .SU75.W_!/4_BM\16\#Z';OILMG)JEQ(IC@G5G#1<[F&TCOCOWKI?"G
MBS2_%FEK<Z=?07,L:)]I6+($;E<D8/X_E7FGQZL-)O/AWIVM6T,4DBRQ1VUP
MN<^2RDX'L>#S7HO@GPYI&@>'[8Z5816INH(I)RF?WC;!R<_4TX[2OT?]?\'S
M)D_AMU7]?\#R*OQ'\9)X*\)7%_'-;KJ##;9Q3J6$KY&1@$'@9/6H_A[X]L?&
M>B6I-Y:OK @$EY;0!AY9SCH<\=.YZUG_ !ITNQOOAIJ=S=6R2SV:"2W<]8V+
M*"1^!IOP>\.:1I_@?2M7M+"*+4+RT N)USND^8GG\A2AKS7\OU_I_(<_LV\_
MT_I'8Z5XATC6[B]M]-OHKF6RD\JY5,YC;)&#^1_*C2?$6D:Y->1:9?PW4EG)
MY5PL9YC;G@_D?RKR_P""I'_"5^/UR,_VGG'_  .6H_@9_P A_P =?]A ?^A2
MT1UM_AO^7^8I.U_\5OS/0KKX@^$[.UN;FXUVUCBM;@VTI).5E'5<8R3P>F:)
M_B#X2MM#M]9EUVT6PN&*12AB2[#J H&[([C''>O'?AKX,T+Q5X_\;S:U9B[%
MK>.D43L0@WR29; [C;QZ9/?&(/@]X!\/>(+CQ,-6M&NTLYC;0)(YP@;=EAC'
MS?*.:E-\MWVYBG9-^MCZ"TK5K#7--AU'3+N.ZM)AE)8SD'U^A'H>15#Q!XP\
M/>%A&=;U6WLVEY1')+L/4*,G'OBO-/V<W<>%=9@+L8X]0.T$],HN?Y5F^%-(
ML?&OQP\87.OV\5\FGLT,%O.-R !]@.WH<!3^+9Z\U;7O)+M<6R;?1V_&Q[)H
M7B31O$UFUWHNHP7L*G:QC;E3Z,#R/Q%1:AXLT'2;^2QO]4M[:YCMS=/'(V"(
MA_%7D_A*P@\+_M&:QHVDH(=.N+/S&MT/RH2J/T[8).!V#54\?Z#:>)OVA]%T
M>_+_ &.XLD,RHV"ZKYC[<^A*@4E[W+;K?\+_ .0;<U^EOQM_F>VZ-K6G>(-+
MBU+2KI;FSE)"2J" <$@\$ ]0:X?X@:=%=^-/"DTOB_\ L=TG'E67S?Z4P=>!
M@@9.0O/K7;:)H>F^'-+CTW2;86UG&S,D0=F +$D\L2>I->4?%_\ Y*;\._\
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MMZHZC[SLVWE^  ,8Y/3H>O\ BIX$O?&^C6*Z7=0VVHV%QYT+S$A3QR,@$@\
MCCM7?44WK]]_F)*WW6^1P\/A[Q9J/PSU31?$6J6=YK=Y#-$DZ+LB4,,*#M0=
M.YV]^]9=I\+I;CX.0^"M5NH%O(B\B7%OET1_,9U(W $C!P>G4UZ910];^=OP
M!:6\OU/"6^&'Q,UC2;3PQK?B73E\/VY13Y(W.R+]T#Y 6Q_M$?CBO4]9\,B?
MX?7GAC2C'$&L#9VYF)"K\FT;B ?QP*Z.BB6J:?4%HTUT/.]+\!:I9?!>;P;+
M<69U%[>:(2J[>5EW9ASMSC!':M_P!X>N_"O@C3=%OI()+FV5P[0,2ARY;@D
M]#Z5TM%-MMM][?@*VR[7_$****0PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img_023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &T!#P# 2(  A$! Q$!_\0
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M JU10!5_LVQ_Y](?^^!1_9MC_P ^D/\ WP*M44 5?[-L?^?2'_O@4?V;8_\
M/I#_ -\"K5% %7^S;'_GTA_[X%']FV/_ #Z0_P#? JU10!5_LVQ_Y](?^^!1
M_9MC_P ^D/\ WP*M44 5?[-L?^?2'_O@4?V;8_\ /I#_ -\"K5% %7^S;'_G
MTA_[X%']FV/_ #Z0_P#? JU10!5_LVQ_Y](?^^!1_9MC_P ^D/\ WP*M44 5
M?[-L?^?2'_O@4?V;8_\ /I#_ -\"K5% %7^S;'_GTA_[X%']FV/_ #Z0_P#?
M JU10!5_LVQ_Y](?^^!1_9MC_P ^D/\ WP*M44 5?[-L?^?2'_O@4?V;8_\
M/I#_ -\"K5% %7^S;'_GTA_[X%']FV/_ #Z0_P#? JU10!5_LVQ_Y](?^^!1
M_9MC_P ^D/\ WP*M44 5?[-L?^?2'_O@4?V;8_\ /I#_ -\"K5% %7^S;'_G
MTA_[X%']FV/_ #Z0_P#? JU10!5_LVQ_Y](?^^!1_9MC_P ^D/\ WP*M44 5
M?[-L?^?2'_O@4?V;8_\ /I#_ -\"K5% %7^S;'_GTA_[X%']FV/_ #Z0_P#?
M JU10!5_LVQ_Y](?^^!1_9MC_P ^D/\ WP*M44 5?[-L?^?2'_O@4?V;8_\
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M-ZE_X%/_ (T?\)+KW_0;U+_P*?\ QK+HHY5V"[-3_A)=>_Z#>I?^!3_XT?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<LFZ4V_$B1+N8'&[:!W."./>N=O+=]-U>74-2BGN+5[I?)NX;I@;<$@*C1Y
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M=1UK3TC3=/U[7/$,&C0^7H%U9+%E8RD9GXP5![@@UZ2  ,  #T H  &  !Z
M4^8#R_PR=0\1:E"9HV2;P_8/;)N[W)W*I_(#\JQX$L&T32K"QM)4\71WP,Q\
MIA*OS')9O[N"*]H  S@ 9ZX%'&<X&3WQS3Y@/,YYM"L_&FOGQ;;>:\SI]B:6
M%I%:/'1,?A5N75+70?B%K4M\LL:WMC&+4)$6,I"@;1@=>U>@D XR <=,CI1U
M() R.A]*7,!X[#;"X\ ^%K:4.JR:RT;@$J0"Q!'M6UXTTN'2M3T)8(;>TT2
MR;O,MS/!'*>[IGG/')KT?:O]U?7I2]00>0>H-/F Y/P%;6]OIU\UIJ,5Y;RW
M1=?)MVBCC.!D(&[=.G%=E:_\?47^]4(  P  /05-:_\ 'U%_O5+=P,^BBBD
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M#KL7HOT%4[O1XKB."WBV0VJW/VF>-5_UK [@/;+8)^E:5% !U-%%% !6@O\
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MP?\ 0RC_ , 6_P#BJ/\ A3<'_0RC_P  6_\ BJ])HH^NUN_X!]2H]OQ/-O\
MA3<'_0RC_P  6_\ BJ/^%-P?]#*/_ %O_BJ])HH^NUN_X!]2H]OQ/-O^%-P?
M]#*/_ %O_BJ/^%-P?]#*/_ %O_BJ])HH^NUN_P" ?4J/;\3S;_A3<'_0RC_P
M!;_XJC_A3<'_ $,H_P# %O\ XJO2:*/KM;O^ ?4J/;\3S;_A3<'_ $,H_P#
M%O\ XJC_ (4W!_T,H_\  %O_ (JO2:*/KM;O^ ?4J/;\3S;_ (4W!_T,H_\
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M_P"O1_9J?\_/_D/_ .O5NB@"I_9J?\_/_D/_ .O1_9J?\_/_ )#_ /KU;HH
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M*30&UMOCG)_PD%O9PWZZ'@_8W+1NN\889Y'<8]J+A8]5HHHIB"BBB@ HHHH
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MMG:ZL=.>X6W!^6X7S5#QD>I4G!]0* .S[9HKD8M;M)/$4^M12/)8#0!<C'7
ME8D8[,,8/O4Z:UK5I%IM_J<5C]BOY8HC% '$EL9/N98G#\X!P!UH Z>BBB@
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M!*5 PNY\X...BC.*AAT*]EUFSU'4]3BNGL@X@$5H(6.X;3O;<<C'88&:W:*
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MM>VEJ+0R/#YB2QC'#)D=QD$'C)ZU<TC2UTJWF4SO<7%Q,T]Q.ZA3(YQS@<
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MHR/6M+[;<?WU_P"^%_PH^VW']]?^^%_PHL',^QFY'K1D>M:7VVX_OK_WPO\
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M9BNX!6!)'K]/>@!U%,2:*169)HW"?>*N"%^N.E(9X BN9X@CG"L9!AC['/-
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M_/>O4DBCB!$<:("<D*H&3Z\4W[/ 9O.,$7F_\]-@W?GUK/V>B.WZW[TG;?\
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M/NY_AW;L>W3BMZ:VM[B$0SV\,L0QB.2,,O'3@\5( %4*H 4#  & !0 M%%%
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MM #:*=A/^>B_K1A/^>B_K0 VBG83_GHOZT83_GHOZT -HIV$_P">B_K1A/\
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M .>J_D: "BC='_SU7\C1NC_YZK^1H **-T?_ #U7\C1NC_YZK^1H **-T?\
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M4 %%%% &[I7_ "#?^VI_D*MU4TK_ )!O_;4_R%6ZVCL>?4^-A1113,PHHHH
M**** "BBB@ HHHH *EA^Y+]!_.HJEA^Y+]!_.@ HHHH **** "BBB@ HHHH
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M 9DZ@5J:+HS:;87=K<2)*+B9Y#LR/E88QSWK/T_PS=Z<\4,<NG2VD<FX/+:
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MX:XN)$7:NX@ !1V   H TZ*** "BBB@"8?ZA/J:2E'^H3ZFDH **** "N/\
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M;_\ 83_OFC?_ +"?]\TVJM[J%OI\8>=N3]U%Y9J&TM6.,93?+%79<W_["?\
M?-&__83_ +YK$&HZM<#=;Z:%C/0RM@G^5']LW-JP_M&P:)#_ ,M(SD"H]I$Z
M/JE396;[75S;W_["?]\T;_\ 83_OFHHI8YXEEB<.C#(84^M#F::=F.W_ .PG
M_?-&_P#V$_[YIM% AV__ &$_[YHW_P"PG_?--HH =O\ ]A/^^:-_^PG_ 'S3
M:* ';_\ 83_OFC?_ +"?]\TVB@!V_P#V$_[YHW_["?\ ?--HH =O_P!A/^^:
M-_\ L)_WS3:* ';_ /83_OFC?_L)_P!\TVB@!V__ &$_[YHW_P"PG_?--HH
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M1TZ/_6+]: $R/[B?]\T9'_/-/^^:2B@!<C_GFG_?-&1_SS3_ +YI** %R/\
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MT =L5(Z@CZTE<QX96WL=2O-+;2QI^H)"DTJPW+30RH20&4DY!R#P0#]:Z>@
MHHHH *>OW'^@_G3*>OW'^@_G0 RBBB@ HHHH J:CJ5MI5I]JO'9(-ZQLX7(4
ML< GT&2,GM2SZA;VVH6MA(S&YN@YC15S\JC+,?0<@9]2*DNK2"_LYK.YC$D$
MZ&.1#W4C!KB]!2_@T+7M7>8WFJ6D<VGVKE>0EN"%X[LS?,?4XH [LJ0,D$"@
MJP&2#CZ5P7A[2;\OH^K6T]C%%*FZYN([Z65[M60YW*R[2P;#>V"*L:'9KH6M
M6-KJ-JLM]=K(L.JPW3.+HA=Q\Q"?E..>X]".* .THHHH **** 'Q_P"L'XTR
MGQ_ZP?C3* "BBB@ HHHH JWFHVUA-:17+LANYO(B;;E=^"0">V<''J:/[0MS
MJQTP,S72P^>RA<A$)P,GL2<X'?!J/6=,BUC2+FQE8IYBY21?O1NO*N/<$ UQ
M<=U?Q?#.^\1"8?VKJ82>XN%RHC0L$^7J554SSVR30!Z&5(Z@B@J1U!'UKB;3
MP]J-O+<&UNK'2[2YLI(R;:\DGRYQLF&\#D<Y8'G-6O#<,.E:Q)I<^F+::BUM
MYQE@NFFBN$# %L,<JV2.H_$T =71110 4444 %2'_4)_O&HZD/\ J$_WC0!'
M1110 4444 48-8L;BTO+I9BD5E))'<^8NTQ,G+9!]N1Z@BK-G<+?V4-W"D@C
MF02*'0JV",C([5R/B#2O.\76%HDNRRUK/]H0@?ZW[. RX]-P(5O4 5#JMM=Z
MWXRU&P>&TGBM;:%K:"XNY8-H8'=(@0')SQGM@4 =T%)Z GZ"DKAKO0]3:SL+
MC4C;ZX+2RV7%L+MHB2"3YR-P&8K@?-CIP:ZW2;FWO='LKJSWBVF@1XA)G<%(
MXSGG- %RBBB@ IT?^L7ZTVG1_P"L7ZT -HHHH **** &R2+%$\K_ '44LV/0
M#)K/L=?TW4=!.MVDYDL1&\A<*=P"YW KUR,=*M:A_P @R\_ZX2?^@FO/67_A
M'?"<-^ORZ7JVDI%> #B"X,&$E^C<*WOM- 'HUM,EY;0W$&YHYHUD0D8)4C(X
M^AJ3I7$P6\6J:EH6E:D6:Q&B1SQ6^\HLTWRALX(W%5QQ[YK5\)2L8=5MDF>>
MSM-0D@M)'<N?+ 4E=QZA6++^&.U '0T444 %%%% #C_JT^IIM./^K3ZFFT %
M%%% !U-9\.MV$VG7=^)BEO9M(EP9%*F(Q_>!'Z^^16A7&:WI7G>-+*S67;8:
MN#/?08_UK6^"O_?65#>H44 =?:S"\M8KF)) DJ!U#H58 C(R.Q]JE"D] 3]*
MX34K6\UWQ?J]F\5I,MI%#]FCN+R6 QJRDF1 @.3NR-W;:!2W^C:A]FM+W5/L
M^N):V*I<P+=M$59<DS1G@,2,?>QTX- '<T56TVX@N]+M+FUW_9Y84>+?G=M(
M&,YYSBK- !1110 ^+_6K]:Y/Q5_R%D_ZXK_,UUD7^M7ZUR?BK_D+)_UQ7^9I
MB.CL?^0-:?\ 7)?Y4^F6/_(&M/\ KDO\J?5K8EC9$66-HW&58%2/:L73;DZ9
M.VF7C;0#F"0]&![5N5!=V<%[%Y=Q&&'8]Q]#4R3W6YO2J12<)_"_P?<P]>T"
M^U2\6:.>(QJNU8WR-OK]:C31;O3+/[4;R,7,/*GH"O\ =)/6KPT:Z@^6TU2:
M./LK#.*<NA"5P]]=RW./X2<+4RO)6L;TO9TI<ZJ:=K/7RMM^)!8--K.H1WTL
M?EP0+A%[%^YK>IJ(L:!$4*JC 4# %.JXQLCFK554EHK):)!52'2M/M[N[NX;
M*".XO<?:I50;IL# W>O!-6Z*HQ,5_"'AJ2PAL9-!T][2%R\4+0 JC'J0.V>]
M78]&TN&"[@CTZU2&\):YB6(!93C'S#H> !5VB@#+LO#.A:;)#)8Z/8VTD <1
M/%"%*!OO8(]>](WAC07TE=*;1K%M.5S(MJ808PW7('8UJT4 4;+1M+TUW>QT
MZUMF>-8G,,07<B_=4X["JL/A/PY;VMW;0Z'I\<%YC[3&D "RX.1N'?!YK8HH
M S]0T'1]6M(;74=+M+NWAQY4<T08)@8X].*6;1-*N+&"QFTVU>TMV5X8#$-D
M;#H5'0$9J_10!5.F6)U7^U39P_VAY7D_:=O[S9UVY]*6;3K*XOK:^FM(9+NV
M#""9ER\0;AMI[9JS10!0?1-*DUA-7?3K9M3C7:EV8QY@&",;OH2*CN/#>A7F
MIKJ=SHUA-?K@BXD@4OQTY[UIT4 9^J:#H^N&(ZKI=I?&$DQFXB#E<]<9JQ>6
M%IJ-E)97MM%<6L@"O#(N58#D C\!5BB@"C<:+I=W]C^T:?;R_82&M=R9,!&,
M;/3H/RJO<^%_#][J0U&ZT33YKX,&^T/;J7R.A)[FM:B@#$U_PSIFM0W,\FFV
M4VIFVDBM[F:(%D)4@?-C/!/X5G^'/!UM;^ ]*\/^(;*ROVM$(967S$#;B<J2
M >AKJZ* ,Q/#>AQPW4,>D6217<:Q7")" LJ*,*K =0!TJ9=&TQ+BSN%L+<3V
M4?E6L@3F%,8VJ>PQ5VB@#/U30=(UQ(UU;2[2^$?*?:(@^WZ'M3;CP]HMWI<6
MEW&DV4NGPD&*V:$>6F/0=JTJ* *5CI&FZ9)-)8:?;6KSA1*8(PF\*,+G'H.!
M5VBB@ HHHH *.U%':@#&U+_D(S?A_(55JUJ7_(1F_#^0JK7.]ST8_"@HHHI%
M!1110 4444 0VUI;6:,EM!'"K,78(,98]3]:@_L?3/MGVS^S[;[3NW>;Y8W9
M]?K5VBE9%<TM[E)='TQ+S[6NGVPN=V[S1&-V?7/K5VBBG83DWNPHHHH$%%%%
M !1110!M:5_QXG_KH?Y"KE4]*_X\3_UT/\A5RK6QQS^)A1113("FNBR(R.H9
M&!5E/0@]13J* (4M+:.S6S2",6JIY8AVC8$QC;CTQVJE;^'=%M()X+?2K.**
MX7;,BQ#$@]#[5IT4 4]/TG3M)C>/3K&"U5SEA$@&X^_K5RBB@ HHHH *>OW'
M^@_G3*>OW'^@_G0 RBBB@ HHHH *BM[6"T5UMX4B5Y&E8(,;G8Y+'W)J6B@#
M.M] T>UO6O;?2[2*Z;.94B ;GK^=+8Z#I&F7#7%AIEK;3,,&2*, X],]JT**
M "BBB@ HHHH ?'_K!^-,I\?^L'XTR@ HHHH **** "H8+2VM;1+2""..V1=B
MQ*ORA?3'I4U% &;;>'=%LA,+72;.$3J4E"1 !U/53[>U2:?HVF:3O_LZPM[7
MS,;S$@!;ZFKU% !1110 4444 %2'_4)_O&HZD/\ J$_WC0!'1110 4444 12
M6L$MQ#<20HTT&[RI".4W#!P>V15?4-'TS5O+_M'3[>Z\O[AEC!*_0U=HH S;
MKP[HM[Y/VK2;.;R$"1;XA\BCHH]O:M%55%"JH55&  , #T%+10 4444 %.C_
M -8OUIM.C_UB_6@!M%%% !1110 CJKHR.H96!# ]"#U%0/86<FGG3WM8FLC'
MY7D%?DV8QMQZ58HH I7>D:;?VD=I>6-O/;Q8\N.1 0F!@8]..*LV]O!:6Z6]
MM#'##&,)'&H55'L!4E% !1110 4444 ./^K3ZFFTX_ZM/J:;0 4444 %1/:P
M27,5R\*-/"&6.0CYD#?> /O@?E4M% %'4-%TO5C&=1T^VNC']PRQ@E?H:CNO
M#NBWSQ-=:59S-"@2/?$#M4=%'L/2M*B@!  H"J  !@ #  I:** "BBB@!\7^
MM7ZUR?BK_D+)_P!<5_F:ZR+_ %J_6N3\5?\ (63_ *XK_,TQ'26 SH]H,@?N
MEZGVJ7R_]M/^^J@L_P#D"VG_ %R7^5+5Q6A#9-Y?^VG_ 'U1Y?\ MI_WU4-'
M JK"N3>7_MI_WU1Y?^VG_?55O.CSPX/TYI5D1^%8$^E%@N6/+_VT_P"^J/+_
M -M/^^JAHHL%R;R_]M/^^J/+_P!M/^^JAHHL%R;R_P#;3_OJCR_]M/\ OJH:
M*+!<F\O_ &T_[ZH\O_;3_OJH:*+!<F\O_;3_ +ZH\O\ VT_[ZJ&BBP7)O+_V
MT_[ZH\O_ &T_[ZJ&BBP7)O+_ -M/^^J/+_VT_P"^JAHHL%R;R_\ ;3_OJCR_
M]M/^^JAHHL%R;R_]M/\ OJCR_P#;3_OJH:*+!<F\O_;3_OJCR_\ ;3_OJH:*
M+!<F\O\ VT_[ZH\O_;3_ +ZJ&BBP7)O+_P!M/^^J/+_VT_[ZJ&BBP7)O+_VT
M_P"^J/+_ -M/^^JAHHL%R;R_]M/^^J/+_P!M/^^JAHHL%R;R_P#;3_OJCR_]
MM/\ OJH:*+!<F\O_ &T_[ZH\O_;3_OJH:*+!<S]0@#7\I^T6ZYQPTF#T%5OL
MP_Y^;;_OZ*BU;_D*3_4?R%4JY6]3TX1?*M32^S#_ )^;;_OZ*/LP_P"?FV_[
M^BLVBE<KE?<TOLP_Y^;;_OZ*/LP_Y^;;_OZ*S:*+ARON:7V8?\_-M_W]%'V8
M?\_-M_W]%9M%%PY7W-+[,/\ GYMO^_HH^S#_ )^;;_OZ*S:*+ARON:7V8?\
M/S;?]_11]F'_ #\VW_?T5FT47#E?<TOLP_Y^;;_OZ*/LP_Y^;;_OZ*S:*+AR
MON:7V8?\_-M_W]%'V8?\_-M_W]%9M%%PY7W-+[,/^?FV_P"_HH^S#_GYMO\
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M4 6L+_ST3_OJC"_\]$_[ZJK10!:PO_/1/^^J,+_ST3_OJJM% %K"_P#/1/\
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MH L1J!(IWH>>QKDO%7_(63_KBO\ ,UU$/^N3ZUR_BK_D+)_UQ7^9H Z*S_Y
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MO_/)/UHW+_SR3]:+A8BHJ7<O_/)/UHW+_P \D_6BX6(J*EW+_P \D_6C<O\
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ME'IMM;^+;'7M/EF\375VS6#F!G>13C88V X IV"Q[?@YQWKE=-\=V6I^+I]
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M**** "BBB@ HHHH V=*_X\V_ZZ'^0J[5+2O^/-O^NA_D*NU:V..?Q,****9
M445#=W<%A93WEU*(K>"-I)9#T50,D_E0!-15%M9TU-$_MHWD7]F>3Y_VD$E?
M+QG=Q5X<@$<@C(H **** "BBB@ IP^ZU-IP^ZU #:*** "BBB@ HJM?:A::9
M D][.L$3RI$'?.-['"@GMDD#GBB>_M;6]M;.:=4N;LL((L$E]HRV,=@.YH L
MT444 %%%% !1110 Y/O"FTY/O"FT %%%% !1110 44R65((9)I6"QQJ7=CV
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M6&!OO2*O4CMQ0!<HJN+^U.I'3A.OVP0BX,/.?++;=WIC(Q5B@ HHHH ****
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M\#T'Y48'H/RHHI"# ]!^5&!Z"BB@ Z9P ,]:.^>_K110 =R>YZFC '0 444
M%%%% !1110 4444 %%%% !1VHH[4 9VH_P#'])^'\A56K6H_\?TGX?R%5:YW
MN>C'X4%%%%(H**** "J>JZ9#K&EW&GW _=SIMS_=/8_@:N4=#0--IW1P7@R.
MZN$OM<OY!<W=E$UC /01CD_4\52T6\\2ZA#9:M;F_F>2X_?E[F/[,8]V"HCS
ME2!^-=_I^F6>EQ2164/E))(TK#<3ECU/-4E\*Z&FH"^33XUG#^8"K,%W]=VW
M.,Y]JRY'9';]8@Y2;6^VGX',W5QJ.F^)C+K-[J26<UV%M+BTF4P;<\1NF.#Z
M]Z[X]:QU\+:(NH?;_L"&X\SS<EF*[^N[;G&<^U;%7%-;F%:I&=K= HHHJC *
M*** "BBB@#9TK_CS;_KH?Y"KM4M*_P"/-O\ KH?Y"KM6MCCG\3"BBBF0%8?C
M0X\"^(".O]G3_P#H!K<J"]LX-1L;BRNH_,M[B-HI4R1N5A@C(YZ4 >6>(5/A
M7PGJ^C'":-J^GO/IY/W;>XV!I(/8-RZCUW#TKJI(Y_$'C.[TFXU"^M+.PL+>
M6*&SG:!I7D+Y=F7DA=@ &<<G-;^JZ%IFN:.VDZE:+<6)"CRF)&-OW2"#D$8Z
MTS5/#FE:S)#+>V[F:%2B30S/#($/5=R$$KQT/% %'P5J%WJ&A2B\G-S):WMQ
M:+<L #.D<A57..,X&"1W!KHJ@LK*UTVRALK*WCM[:%=L<48PJCVJ>@ HHHH
M*</NM3:</NM0 VBBB@ HHHH J:IIEMK6E76F7B;K>ZC,3CN >X]P<$>XK@]
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M4D2X PKJ0P!  //..:MZ=IMEI-BEE86Z6]NA)")ZDY))/))/))Y- %JBBB@
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M_P#OD_XT44 '_"4WW_/.W_[Y/^-'_"4WW_/.W_[Y/^-%% !_PE-]_P \[?\
M[Y/^-'_"4WW_ #SM_P#OD_XT44 '_"4WW_/.W_[Y/^-'_"4WW_/.W_[Y/^-%
M% !_PE-]_P \[?\ [Y/^-'_"4WW_ #SM_P#OD_XT44 '_"4WW_/.W_[Y/^-'
M_"4WW_/.W_[Y/^-%% !_PE-]_P \[?\ [Y/^-'_"4WW_ #SM_P#OD_XT44 '
M_"4WW_/.W_[Y/^-'_"4WW_/.W_[Y/^-%% !_PE-]_P \[?\ [Y/^-'_"4WW_
M #SM_P#OD_XT44 '_"4WW_/.W_[Y/^-'_"4WW_/.W_[Y/^-%% !_PE%]_P \
M[?\ [Y/^-'_"4WW_ #SM_P#OD_XT44 '_"4WW_/.W_[Y/^-'_"4WW_/.W_[Y
M/^-%% !_PE-]_P \[?\ [Y/^-'_"4WW_ #SM_P#OD_XT44 '_"4WW_/.W_[Y
M/^-'_"4WW_/.W_[Y/^-%% !_PE-]_P \[?\ [Y/^-'_"4WW_ #SM_P#OD_XT
M44 '_"4WW_/.W_[Y/^-'_"4WW_/.W_[Y/^-%% !_PE-]_P \[?\ [Y/^-'_"
M4WW_ #SM_P#OD_XT44 '_"4WW_/.W_[Y/^-'_"4WW_/.W_[Y/^-%% !_PE-]
M_P \[?\ [Y/^-'_"4WW_ #SM_P#OD_XT44 '_"47W_/.W_[Y/^-'_"4WW_/.
MW_[Y/^-%% !_PE-]_P \[?\ [Y/^-'_"4WW_ #SM_P#OD_XT44 '_"4WW_/.
MW_[Y/^-'_"4WW_/.W_[Y/^-%% !_PE-]_P \[?\ [Y/^-'_"4WW_ #SM_P#O
MD_XT44 '_"4WW_/.W_[Y/^-'_"4WW_/.W_[Y/^-%% !_PE-]_P \[?\ [Y/^
M-'_"4WW_ #SM_P#OD_XT44 '_"4WW_/.W_[Y/^-'_"47W_/.W_[Y/^-%% !_
MPE-]_P \[?\ [Y/^-'_"4WW_ #SM_P#OD_XT44 '_"4WW_/.W_[Y/^-'_"4W
MW_/.W_[Y/^-%% !_PE-]_P \[?\ [Y/^-'_"4WW_ #SM_P#OD_XT44 '_"4W
MW_/.W_[Y/^-'_"4WW_/.W_[Y/^-%% !_PE-]_P \[?\ [Y/^-'_"4WW_ #SM
M_P#OD_XT44 '_"4WW_/.W_[Y/^-'_"4WW_/.W_[Y/^-%% !_PE%]_P \[?\
M[Y/^-'_"4WW_ #SM_P#OD_XT44 '_"4WW_/.W_[Y/^-'_"4WW_/.W_[Y/^-%
M% !_PE-]_P \[?\ [Y/^-'_"4WW_ #SM_P#OD_XT44 '_"4WW_/.W_[Y/^-'
M_"4WW_/.W_[Y/^-%% !_PE-]_P \[?\ [Y/^-'_"4WW_ #SM_P#OD_XT44 '
M_"4WW_/.W_[Y/^-'_"4WW_/.W_[Y/^-%% !_PE-]_P \[?\ [Y/^-'_"4WW_
M #SM_P#OD_XT44 '_"4WW_/.W_[Y/^-'_"47W_/.W_[Y/^-%% !_PE-]_P \
M[?\ [Y/^-'_"4WW_ #SM_P#OD_XT44 '_"4WW_/.W_[Y/^-'_"4WW_/.W_[Y
M/^-%% !_PE-]_P \[?\ [Y/^-'_"4WW_ #SM_P#OD_XT44 '_"4WW_/.W_[Y
M/^-'_"4WW_/.W_[Y/^-%% !_PE-]_P \[?\ [Y/^-'_"4WW_ #SM_P#OD_XT
M44 '_"4WW_/.W_[Y/^-'_"4WW_/.W_[Y/^-%% !_PE-]_P \[?\ [Y/^-'_"
M4WW_ #SM_P#OD_XT44 '_"4WW_/.W_[Y/^-'_"4WW_/.W_[Y/^-%% !_PE-]
M_P \[?\ [Y/^-'_"4WW_ #SM_P#OD_XT44 '_"4WW_/.W_[Y/^-'_"4WW_/.
MW_[Y/^-%% !_PE-]_P \[?\ [Y/^-'_"4WW_ #SM_P#OD_XT44 '_"4WW_/.
MW_[Y/^-'_"4WW_/.W_[Y/^-%% !_PE%]_P \[?\ [Y/^-'_"4WW_ #SM_P#O
MD_XT44 '_"4WW_/.W_[Y/^-'_"4WW_/.W_[Y/^-%% !_PE-]_P \[?\ [Y/^
M-'_"4WW_ #SM_P#OD_XT44 '_"4WW_/.W_[Y/^-'_"4WW_/.W_[Y/^-%% !_
MPE-]_P \[?\ [Y/^-'_"4WW_ #SM_P#OD_XT44 '_"4WW_/.W_[Y/^-'_"4W
LW_/.W_[Y/^-%%  /$]\Q"[(!DXR$/^-==:6D44&2/,>0[W=^2Q(HHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img_024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *9!#T# 2(  A$! Q$!_\0
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MLPD*G(4LRX!/K\I-<?X>G:SMO#MY>W"S:6[2Q1-@ 6L[.P4L1U##*@GH3[T
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M&HOX*BT?3M(AMUC>W6:X=X5<W!)P02>W7\ZO?V9::;\6=*:SB6&.ZMVG:)>
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M_E]W_!/+6^'7B!L;A"V.F9LT#X=>(!C A&.F)>E>I44?4J7G]X?VIB/+[O\
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MK;74-G#-%&$,5D"(4 X 3/.,8H O4444#"BBB@ HHHH **** "BBB@ HHHH
M**** *VG_P#+W_U]/_2J&O>(CHMWI]I%IMS?W-^TBQ10.BGY%W')8@=/Y5?T
M_P#Y>_\ KZ?^E9'B31]5OM5T74M)DLEGTYYFV7A?:V]-O\(SQS0(FMO%^CS:
M/_:4\[6:+.;:2*=#YB3#K'M&26^F>*DN/%N@6L-G-+JL 2\&;<KEO,&<9P 2
M!GC)[USD_@&\;3[>5-1C?5EU&349GR\,<CR#:RJ4.Y !C!'I[U)8>$-5T/4+
M34-'?3(IOLK6US!.TLD:@RF3<C'YB<DYSUH$=)_PD>C_ -K-I?\ :$/VU208
MN>H&2N<8W <XSGVK/_X3_P )[&?^W+8A4#G ;D'N..??'3O65;^!9[;7YK@R
M07%B][)?1F6>97BD8'I&#Y9()^\><4[2_!-W8PZ,DD]JQL-,N+-]H/S/(>&'
M'3KGZT :-]XYTC3=8M[2[GBCL[BQ%Y'>[R58%MH  ![<YK2F\2:+;ZA#8RZE
M MS,$*)DD'=]W)' W=LD9[5R3^"-;AMK-+.[TW?'HG]DS>>KD')^9EP/3IGK
M0OPYEMM07RIX;JPD6U$T=Q/-&0855<A4.U\[01NZ&@#K[#Q!I.IWTUE97\4]
MS"&,L:YRF&VG/''-4]$\40:_>S1V5I-]DC!*W;R(!)@XX3.\ \X) !Q3_#6A
MR:+87UO.\3M<WL]P6B_NR-D Y'4"N6TOP;J?A:9-0MXK*\.FVLT-I%:H4FO"
M[ CSF/''MF@#M]4OI=/L_.@T^ZOY2X18+8+N.>Y+$ #WKG'^(5E]@M[B#3+^
MXFD2:26V0+O@2$XD9B3@X/3'6M;Q'::Y?Z']ET>YMK2\EP)I9&8;4Q\P0@$@
M]LXZ>]<Y)X-UD6MHUDVD65Q%9S:>\*"5H?)DP=P)^8N#DG/7- &V?&>FMK&D
MZ=;QW$[:DH>.94Q&@9"ZY)ZD@=!T[TS3_&MGJ.OC2H[.Z3?)-%%.Q7#M%]\%
M0=RCT+ 9I7\,/&WA6.VG0P:(V'\S.Z1?*V#&.^>:S-&\&:CIOBE=4EO+4J)9
MGFN(]_GWBO\ =20'Y0%XQC^Z.E ';T444#"BBB@ HHHH **** "BBB@ HHHH
M *K6O_(3O_I%_P"@FK-5K7_D)W_TB_\ 030)EQCM4L>P)KC8?B3I<W@^Y\1?
M9KE8X)A"UL<>86.,8YQR#GZ UV3C<C*.X(KS:#X:7\=I%;M?6WE#3VCDC&[:
MUV$>-).GW0K_ %R*"3L)/%>C6RV(O+Q;62\B26-) > _3+ 8'/')J4^)-%&J
M2:8=1@%['N\R$D@IM4,2>P 4YSTKD=<\#:_JMH+)=6@^QBTMX4B>255C>/&X
MA5X8,1U;./2MH^$GF/BM)YXU37,*CQC+QKY6SG/OSB@!+WQ_HL%C!>VDZ7=L
M][':32@E%BW@G?R/F  [=:V;77M+OM)DU6UO$FLHPQ>1%)V[>H*XSD>F,USS
M>&]>O=+T>SU&?2_^)9?6TR&W5P'BB!!SG^(\8'2MGP]H\VCMJQFDC<7NHRWB
M>7GY5?& <]^* ,D_$&R/AV364L+L(M_]@6"4K&Y?(P3N.%'/<\5TFF7KZCIL
M-W);-;-*"?*:17(&>/F4E3GKP:YN+PSJ5II&HVT<>D7DEUJDMZ([Z-GB\MSP
M#QPP^A%3>%]*U#PW':Z-Y$<UNXGN;BYCRD4+LX*Q1KUQR?P'O0!9OO%2Z=K4
M%C=:5?1VT]PEJE\0OE-*PR !G<1VSBJNF^/-.U"X96MKNVMGAEGMKF505N(X
MCARH4D\=<$9(J*[T3Q%=>,4U.5]*N-/@8+:PRO(&@4\.X &#(1GD].U1>&_!
ME_I&JZ?)=WEM+9:3#-#8B)6$CB1LDR9XR ,<4 3P^/K*XT87\.GWS227YT^"
MT*JLLLO7H3A>,GD\8K<T368-=T[[7!'+$5D>&6&4 /%(IPRG'&0:YQ_!UR=#
MU&S=+&ZGN-6DU" RR2QB(,<@[DPP<>U;7A;0!X;T1;'S1+*TKSRNH(4NQR<
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MTDL<D1NF-Y 4. 9(RN #C.0:+!<[2BN#\._$&YUJ'69)]-CMA!9OJ&G?,?\
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M7GYID(P <<<]Z L>H45Q5AXWNKOX77GBUK.!;BWBN'%N&.P^6[*.>O.*Q?\
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MN[BY$WE'$/FD':1GG&.N15.X^'$L6G:OIFC:I#IVG:M;Q)<0+;9"2+@.Z8(
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M2W,UVCI'+]FM9)4A9ONAV4$*34%]\0_#6G:E/97%Y+FWD$5Q<);N\$#G^%Y
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M/M4AMB_AJU2ZELYP1B#SP"T..N RDCV:O0WO[.*X2WDNH$FDC,J1M( S(.K
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M.IZM8V4DHS&ES<+&7&<< GFIO[2L/M\=A]MMOMDD?FI;^:OF.G]X+G)'!YH
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MNW8XVXZUZ9<^+?#5E=/:W7B#2X+B,A7BENT5E/H03D5.GB#19-4.F)J]@VH
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MBLCPZMMIND>!-2\0V4DFA06=W$V^V:5(+AI3M9T /5> <5[MDXQGBER<YR:
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M_<.,=*WM&\7:/9?$S7[Z^FEMH]7M-/:TW02-OS'T^53@C<!S7JA=0%)=0"<
MD]?I2EP&"E@&;H">3]* /,O$4VEZ1\4)=2\5V9FTJ;3$AL9I+1KB*.0.3(F
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M&: L>0ZG)<Z+\1?%GBNV\R2+3YK:WU*!#D/:R0+EP/5& ;Z9KN/A@ /AEX?
M.1]EZ_\  FKJ/L\!,I,$7[X8E^0?O.,?-Z\<<TL44<$2Q0QI'&HPJ(H50/8#
MI0%A]%%% RMI_P#R]_\ 7T_]*IZ]XHTCPTMO_:=PZ/<$B&**%Y9'P,L0J@G
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M![B_G(_ULDZY8_0 @#V%=2;.U(F!MH<3_P"N'EC]YQCYO7\:E5510J*%51@
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M@9P?YUV-9NB>']*\.636FDVBVT+N9'^9G9VZ99F)).!CDUI4#"BBB@ HHHH
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M(2\=E?>3>RWZM;;E8A=D?WU88Z].#ZUZ?H7@/PQX;NQ=:5I20W"J521Y'E9
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M3>6&R$++(2!0%CJZ*X37/$.N6MAK4<TT6GW<<,SVD9M6.]%88=)=VUSM()&
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MXLU9EN#Y-MIEBD&HQF$*7ORQ#8/8 +G _O47 ]$HHHI@%%%% !1110 4444
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M:1=:RD$0M/LMU)L<18@:,-L PQ=CE<,& Z]J!W.L7P[HJ/<NFE6BM= K/B,
M2 G)!'3D\U9NM,L+X3"[LX9A/&L<OF+G>JDD _0DD>]<CJ.MZ_I4<L;7MI<S
MRVMO<0NUML6)GG2-EP#\RX;C//'6K.H:CK-K<ZC:C5[:-M+L5NWEFM5_TLL7
M.,9&U!L"Y'.3UH%=&_%HVD6]\+R*RMDNEPHEP-PXP/QP,>N*LO8VDEXMX]M$
MURL30B4J"PC)R5SZ$@<5PB3F[U=;EHS$TVO6,AC/52UHIQ^&<4Z#Q7XA;2;C
M7?LD;V2P7,AA?RP(63.P#:Q=N1A@P'?IBBP7.T@TO3K58(H+.WC6WA:&%%0
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M,*\R#H_3[WOUK$L/$\E_'92/9RV0GU&2S E17\P+Y@X(;Y3^[Y)!],'K3?\
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M+#%.8S+$DAC<2(67.UN1N'H>3S[U'/8VEU+#+<6T,LD!+1.Z F,GK@]JGHH
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M:?Q!J$D$VI74<EN[Z'%<&UBF= C-.1D$C(.,<XHL%ST*BN:N?$MY%/>W4=E
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MTDAU(75SHMJ+)(H9&.\0E7 *C"L&Z]#7IOS9[Y-4H=7LYYY(8Y7WI))&V48
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M1/&8I42X=5E0LS8< _-@NQ&>F:R(+_4-0TCPGJLM_.CS7<<4T46$CN,[P78
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MA,DS/LC8J2HR>GRKCTQ6E12*L065G!IUE#9VJ%((5VHI).!]34]%% !1110
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M;YL* Q[FF-XXT5/-9WF6!8Y9(YM@*S"+[^P YXYZ@9QD4!H:2:#I<>JG4UM
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M$FG6Z"^N?LMG&C22-D%PSN%4G&$) 7)J6#Q'K5[<6EE;:5;Q7DT<[LUVTD:
M1.BAE!7<58/D9 (H UIO#VGSQ2H1,C279O1+'*5>.8C!96'3CC'3!-.L] T^
MQFMIH4E,UOYN)'D+,[2X+LY/WF.T<UF:5XCU#7IH$TZQM8U6WAGNS<RME3(6
M^5-HYP%)R<#D>]-TKQ7<ZKJD21:;(=/FFEB2812YCV;@'=BH3:Q4C@Y&1[X
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M))'+YT,I1T=%*J5(Z<,0?4&K&F:7:Z1;R06OF[9)FG=I9"[,[<L23SS5VB@
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M)($JD\?0&KS?\AO_ +=?_9ZM4B6<$^C:E8>(6T^&UEFTJ'3[PV4ZC*QB39B
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MK=5('EV\EF[^<V0"&E!"Q#D<GIUH#0M:?X;%EJ=MJ,EZ\]RDD\LS>6%$KRA
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M&(U9_O-CN?<FK=% PHHHH 5?OCZU2TK_ )!D/_ O_0C5U?OCZU2TK_D&0_\
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MFNZN;2WO+62TNH(YK>1=KQ2+E6'H14"Z1IR030"R@$4R+'*FSAU48 /J .*
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MW]SJ%O;B]>/2!/&,.@8SL#CGWR/2KESXKU2U^UV@$<U]I2W=Q>J$QYD2+F'
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MW1TTNWN+F73[&TDN'E4?9W$."QSR0/O#;SD?C7H+:OI\=Q;6LU[;Q75PJM'
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M**RU\1:2^JV^FI?1/<W$ N(0K AT)P"".N?Z59L]4T_4))8[*^M[AX3B18I
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M.27:A#! "Q[8P3COCWIFC:?>PZ'?6US9M#=SAV>:2Y65KB1EP78J %[ #H
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MCY01@?A4C6UNR2HT$3+,,2J4!#C&,-Z\<<T!8XTZMJ\NI1:1;ZNCK_:1M3J
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MWM)59O-BMI'"*IPQ?"_)@]=V,8/I39_%.CV]Q=PR73%K.,RW+)"[)"NP/EF
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MHXS-*\$A:1WZ!6''4J ,$L2<5;?Q9HT=J+B2YE0&?[-Y3V\@E$NW<$\O&[)
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MLUZT\RM=QF&,1JX4;1Y:C"\8//)SFM5]+T^2.&-["U9(!B%6A4B/_=&./PH
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M+!;N(Y"6!WRIOP6 !&1@Y8DGM0!TM%%% !1110 4444 %%%% !5:U_Y"=_\
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MP2K#(R.W!J>@ HHHH 5?OCZU2TK_ )!D/_ O_0C5U?OCZU2TK_D&0_\  O\
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M+Y+6OR=1]PKM\S<6YS^%9EM>&YU&ZD_M"X%S&NH+&YFG/VU_F\O8N/+&U0<
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M)=,2Y1KZ&)9G@!^948X!/U(H PK2YN--\!RW(DFU=DCD:/8LD;LA8X4;LO\
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MK]+G_A(@%"R.$,+.BM\GW2I4DDD>^>*R;B6_UHZ@L%I>1+>Z;>B>U#W#E90
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MPF4!CQP 6XSFO8-R[RFY=X&2N><>N*IZEJ2:=8/=+!->%2O[FUVM(V6"Y )
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M*/3'U!S(+9(3.Q*$$(!N/RGG..W6FR:A;11VKR2[1=.J0 @Y=F&0 /H"?;%
M'%74=O'?:7=:;;W=T@CA6/3Y(;B/9\YW.C\!6&26#]0HZ=Y_$QM'\7O#J"ZC
M+;#22\<=GYI_>^:P!Q'SN[ GBNBTSQ/I.L3K!97C/)(ADC5XGC\Q1P63<!N
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MGG1LK1[0^PKD'[V:+A9'FUGX O;/X:Z+&NBO)J*W4,VLV)E DO(49\19)Q@
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M9<-]X,=V6!QT/%:D<:0Q)%$BI&BA551@*!P *=10 4444 %5K7_D)W_TB_\
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ML8+::*_%S<;KZ2Z:0+"\:G<XZ@MP/2FIX7GC\0W,TMM'>65Q?K?"1[^6,PN
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %;3_^7O\
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M>1?/93&_  ' 7OD<FMN[^)][IMM=VU_I%O'J\&IIIP2.=W@RZ>8'+!-V N>
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MFX#E>F[#8!/3-:6#G'.?2@+'FT%UJ%U91+I>JZC/J#:=)-J*S.W[BX0*RC!
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M()4=<.Y8YV[A@  8%6M1T2&WTRV-R)[N&UTM].>"W@+R3;P@W #I]S\,]>*
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M<44LT4T$YEMRX*/*\BE?F&&7>PYR#Z5III+P^&(-(C>VE:*WC@+7,'F1R!0
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M3D$Y!6'S!ZCY,]*](CC2*-(XQA$4*H] .!5<Z;9MJ:ZDT :\6,QK*S$[5/7
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MVJ?F .<5B?#_ ,;ZK'IOAZSUNU>:VU.2ZBAU26[WR,\;NWSJ1PN 0#G^'TH
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M:>T/G862::&(PQCR]H>)L[T9>!M P>>!G-.\&Z'+IL\<ES9W]M=0V8MI#+Y
MAE.025,8#.<@D,W.">YKL:9%-%.F^&1)$R5W(P(R#@CCN#Q1<+'%W7AZXG\6
M7<UY;W\T-Q=PSV]Q;" K$J!?D9G'F* 5;(7@ACZFJLWA76+BPU.Q$8CCL8&M
M-);S!^]B>0.W/.WY L7/H>U>@T47"QPD'AD7$ME(=,O5A;4XY[FWOD@50J0R
M*&"1?+C+*#ZX'I4EMH$UAK]I=#1Q)9PWUX$2-4_=1R^64< D84%6Z<C/2NTD
MFBA"F65$#,$7<P&6/0#W/I3Z+A8XWP_9WNB7,ZVNBW!L-J(@G2%+@$R<C>K?
MO(P"6RWS<=R:[*BBD J_?'UJEI7_ "#(?^!?^A&KJ_?'UJEI7_(,A_X%_P"A
M&KB)F1JOB*XTKQ5:VLT<7]DO;JUQ-T>%WD*(Q/39D 'TW ],UF7WBK4(DLQY
M]O:>=J-W:O*;-[C:D6[;A%.<G:,FNFN-'MKO4)[FY'FQSV?V.2!E^5DW%C_/
M%8MMX.FL++38K+6YUN+"XGF2XF@61G\W((89&< ]?:J))8]2U;4KY;#3KNSC
M\BTCGN+R:T<^8TF[:JQ;@5&%).3GH*@N?$>K#PW->PP627=E>&UO0Y9DRLBJ
M3&/]H,",GC/>M&?0[UKI+^VUA[?4&@6"YE%LKI.%)*DH3\I!)P0>_>E/AN#_
M (1Z72!<S'SY/.FN7 +R2%P[,>@Y(Z#@#Z4 5]:U758=0U"'3/LBQZ;9B[F$
MZ,QG)+D1@@C;PA^;GDCBJ<_B;4&CN]5M1;#2K%X$DA="991(J,S!\X7:)!@8
M.<'UK3UCP^^J74T\&HS67VJW^RW:QQJWFQ9. "?NL-S#</7IP*BN?"L<UQ(L
M5[+!IT[1/<V2QJ1(8PH7#'E00B COCMDT 7;_64LM233X;*[O;IH_-:.V"_N
MX\[=S%F Y.<#J<'CBFW.O0V>KPZ?<6MQ'Y[&.&<E-CMM+8QNW#@'DC&11?Z/
M//JZ:I8Z@UE=>4()OW*RK+&&+ $'H02<$>IXK-3P9$NKB_-ZQ"WCWBJ;=-Y9
M@P*M)]YE&XX'&, <XH M:3XIMM7FM$2ROK>.]@,]K+<1JJS* "V,,2",@\@9
M[55\1>*6L+74H["VN9)[,1K+<K&K10NY4A3DY/!!. 0,C-7[+P_%9)HBK<R/
M_95N\"94#S RA<GT^[574O"K7\NHB'59[6VU%DDN84B5LNH495CR,A5!'/3M
M0 LOC#3?[2DL(R^[SI+5)LIL,ZJ3LQNW=B,[<9&,U5TWQ419V,NH.SF6PLYI
MC'" $>9BF\G/W=V,C''7GM<M_# M-2N)[>[5;6>229K=K5&97?.[;)]X#))Q
M^&<4V#PE:Q6<EK)<22QOI<6FG*@':F[#C_:^;/X"@!UWXNT^TN9+8132SK.\
M"HK(@D9%5G(9V PNX#DCG@9IUAXKLM5O(+?3[:[N1+!'<F9$ CCC?< 6)/7*
MD8&358^#HUL--CBOV^VV0D!NYX$E\\R'=(70\9+ '@C&/2M2PT@6-_/>&<R2
M36\,# 1A%_=[OF '3.\\=L4 8NN>*+VTB\2Q6UD\;:5:I+'=':REF4MRN<GI
MQQZYJW+XF4OY#6MW87(GME*7,*L7CEDV C#X&2"#DY7T-/U+PR-0FU5A?20P
MZG;+!<1B(-@J"%=3GC@].]2ZCX>BU'4A>/<R(P^S?(%!'[F4R#\R<&@"32]=
MBUB>=;:TN!!"[QFX?9M+(VTK@-N4Y!QD#(&:+O78;#5;>QN;:XC6XD$4=P2F
MPN02!C=NQP1G;C-1VN@&'Q ^L3W@EF*/&HCMUBRK$'YR/OXP ,].?6L^X\'C
M^TY-3ANM\JWGV^.)X4#-(!PAE^]L]!V]\4 /C\;Z>RF6:TO+>U-FU\EQ*J;7
MA!"[@ Q;))& 1GD4J^-M/92HM;MKH3QV_P!FC\N1RTBLR'*L5P=K#KP1S7/:
M#X6O9()-.O;26.SN[5TO7FMHXY(WW;E$3JQW -D\C;P#[5U$'AR0+:_:K])7
MMKM+I6BLTAW;59=I"]<[B<T!J0+XM,VI:?9V^E79>>:>&X20HKP-&H)!^;!X
M8'()XZ<U?O=8EM/$5AI:6,DR74,LKSJZ@1A"H[D<?-D_I5=_#6-274+>_>*X
M6\DNLF(,N)$5&3'T08/45=OM*-WJMCJ$5R89+99(V4QAUEC?:64YZ'Y1R/>@
M"KIWB>UU&YMXTM;R&*[#-9W$R 1W(49.W!)''(W 9'(J;5==AT::$75M<?9Y
M&13<*4V(6;:,@L&/)&< XS573?#'V"XL2^HS7%KIP9;&W:-5\H,"OS,.7PI*
MCIQUR:@U7P;#JNIW-V]ZR+<-"[*8$=U,9! 1SRJG:,@=\\\T =,1@X-%*3DD
M^M)0,K:?_P O?_7T_P#2LS6;!Y/$FA:B-/\ M<5L9HY=JJ6CWA=K_,1P"ISC
MD9Z5IZ?_ ,O?_7T_]*N4"."M?"=U!H^DBVLX[34UFN_/N5"AT$B3!69AR1EH
MSCGMZ5>\&Z(^G3>=/9:A:W$=HEM()O($3D'.5\K!<YSAFYP?>NOHH \YLM-D
MOM0U!;71_P#2E\1/.-3R@$:(ZE@6SOR0"NT#!W?6HI/#VN:HUT]QI:P37&F7
MEO,/*ACB,S[2@7:2SKD$AF/OQDUZ1'#%#O\ *C1-[%VVJ!N8]2?4GUI] CA-
M2T/4M4@NVL=/DL?.TB*W6)RB'>LQ9X^"0-RY&>GS<TEOX86XGL9#IEZ(#J:3
MW,%\D"JJK ZA@D7RXR5!]2!Z5WE% SA[3P_/I^O6ES_8XDM(;R]5$C5/W4<I
MC,;@$C"Y5NG(STJ;P]9WVB7$Z6VBW!L,1QQ^>D*7"DO@_.K?O(U!+9;YOJ37
M944 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56M?^0G?_ $B_
M]!-6:K6O_(3O_I%_Z":!,;JNC66M1VJ7J,ZVMU'=Q;7*XD0Y4G'4>U9LG@C0
M9-7U;5/LC+=:M:M:WC)(0)$8 'CH"<#D5%XW\6_\(EIMG+';+/<WMTMK"'W;
M%8@DLVT%B  > "37/1?$76KM-$MK30(1J.I7-U:[+F62&,-$H82*63<4(.>5
M![4$F_:?#[0+71KK2'CN[O3[E41H+N[DE5 GW=F3\F/]G'0>E6]!\'Z/X<N)
MKJRBGDNYU"/<W4[S2E!T4,Q)"^PKDIOB?<_\(G9ZG%:Z;#?R&X$UG<3R$GR6
M*L8PB,2"1U. .YK*E\:ZU)XGEUS2+19[5O"\.I265S=LB1KO8L5 !!? QG _
MI0!Z&_A#19;36+6:T,L&L2F:\1W)#O@#(_NXVC&.A%5%^'_AY=$ETHVT[Q2W
M NGG>Y<SF9?NOYF=P8 8'-<<_CTZ;JOB3Q&5N)[(:1IUQ;632$!6FR!QR%Y8
M9(':KI^).M#0;VZ7PZ9KBTNHHGFC2?[.(G4DRX:,2$*058!>N#TH [S1=%L?
M#^F)IVFQ&*W4LQW.69F8Y9F8\DD]S6#IOPU\+Z7<13064S^5')'''-<R2(GF
M AR%)P&8$@D4^]\6R6OPVF\51I9W4D=KY^RWF+0N0<8#$ X^H!!XK G^)FI:
M6FIIJVAP)=06MO=6L5O=%UD$[^6BNQ4;2"1DC(ZT ;MG\./#U@H^SK?JZVK6
MB2?;I2\<18-M0YRH!48QC'/K4B_#[P^NGM:^3=&1KK[8;LW<GVGSL8W^;G=G
M''TK!O?B-JNDV.L0ZAHMJ=8TNXM(Y(8+DF*5+@@*58J"#UX(JKJ/C2^F=]-U
M;3$@OK#7;&U?[%?.$99OF5MP )QW4C!H ZN[\":'?P6$=TM[*]CO$4[7LOG,
MKG+J[[MS*>X)J=_!VC2>%8/#302?V9 4,<?FG<-C;U^;KU%<LWQ&U9-3F+Z+
M:?V5!KIT62<7)\TN6 5PFW&!D9Y^E6='^(5QJ6IZ?I,MC;PZ@)KM-47S3LM(
MX#C?D]=V5QGU- &WK7@7P_K^I&_U"UD:9U5)UCG>-+A5.5$BJ0' ]ZO1>&]-
MAO=7NXXG$NK(D=W\YPRHA10!_#\I[5Q-E\3[^ZO]0LH=*M=1GCT^2^LQITTC
M";:X79ET7<3D'*9';K38?&LNM6_AN>XCMS<3:V+4I97<R"%O+)Q*C*IR#D%&
M&.AH ZZV\&:+9M8-#!*#8V3V$&92<0MC(/J>.M5)OAUX;GM--MFMKA4T^ V\
M)CNI$8Q'JC%2"RGT-8NG_$N>[EM+6;38TO(5O9-7B20M]D2W./E]2QVXSZU/
MX)^(-WXJU)+>?2?(@N+7[5!/")2J#('ER%T4%L$'*DCK0!JCX>^&Q;FW-G(\
M)TT:7L:9B/LX?>!UZ[N<]::GP[\.BSO[:2"YF6_@CM[EI[J21W6,Y0[B<@@X
MP1Z"NJHI@8$7@S18YHY9(I[ETL7T\FYG:7? [;F5MQ^;)[FJ=K\.?#=G97]J
MEM<.E[;_ &25YKIY'6#M&C,254>@KJZ* ,JU\.Z=9:PNJP1N+M;)+ ,9"1Y*
MG(&/7/>M6BB@ HHHH **** *3?\ (;_[=?\ V>K#R)$C2.ZHB LS,<!0.I)[
M57;_ )#?_;K_ .SUF^,+2:]\,7,,%N]R0\4DEN@RTT:R*SH!W)4$8[].](ED
MD?BW09;2XNH]8MFM[?;YL@?A=QPOUR>!5BUU[2;RRGO;;4K9[:#/G2"0 1X_
MO9Z?C7/^(==T_5/#S26+SR):WEG)*/LLJE%$Z$\%0> #D#IBL_76&N3ZMJ>G
M65Q+9_V<MK)-Y+H97,RL'5<!G\I=S<#G.!WH"QVVGZI9:K"T]A=QW"*VQF0\
MJWH1U!JWD^IK@]+M]1OM/\1BTOGN9Y]NW4Y+3RS=?NBOEA#M V\#<..?7-:U
MW!K=EX#FBBG>;5$M5"&&,*ZX #!1DY8#=@]SB@+'3<Y[YJA>ZUI^GR31W=T(
MVAA6>0%2=J,VT'@?WABN-U.6W&FZ?_8UQ>?V,;I_MTL_VIV#;/D#<B0+GK@X
MSC/>J-]:7C:;>!II]09M&@5+CR'4R?Z4Q PWS9"XZ\G&3UH"QW%]X;LKZ\GN
MI&NXGN(Q%<""X:-9E&<!@.O!(XP<&K]I);E'M;5E"VI$+1H,"/"@A?R(KEK1
MVA\>S();B_\ .EDRY:9#9C;G:RG]VR<  CG+#KR:@O([Z[U26V>6_2W?Q J-
MY3NG[C[+D@$=$+>G?WH [C!)[YJ*"YBN6E$,@=HI#')C^%@ 2/U%>=:@L]G!
M(KW-[+%9WES';6$LEP#<)\A7;*GS;ADA=V0=Q],BS/-=O*S:DVHQ:0=8E^TA
M#(&1/(4QJ2GS!-_7;QG\: L=E EEJ&H+J<+-)/:B6TW D!?F&]2.YR@Y]JNL
MZH 7<*,@ DXY)P/Q)KRP"\BM8$>>\M=(>>^82SQW!<R&;]V7\LA_N9*EN#]<
M5TWB2S:;P=I?VV6:\^SW-G+<SQHZ,ZJZ[Y"J_,.,DCJ/PH ZB"]@NI[J&*7?
M):N(YEP?D8J& _)@?QJ?GKS7GMQI[*WB+5;1K])HKVU:S,<D@!3RX03MZ/D9
M!R#TJ31CJ,OBT_;=1D@O4NYS+;&&<B6#+!%!)\H+MV,"!G(QU)H"QWGF*9/+
MWC>1NVYYQZX]*=S[UQ^L6:?\)PEPR3B6;2I(;61&<*9@Q(7C@'!SS_2L&^U:
M^O=%M(K%]36YM]!G6X812(4N (@ 21S(#N]>_K0%CT[GW]:#DC)S7GVJ:/+;
M3>(!;7&K[;6RANK/%W,V+@[]S#GYB=JY7D>W-/FDN_[:GW2:C_;G]J1BVC4R
M^0;/<N>!^[V;-^2>=WOB@+'??-[T<@^E>>K8R#PG]NN=3OH+J6]DWFX>=D=%
MED"1%4.40C'S#!X&<CBNG\.:BEUIUM;FUN;6=+=9&BF\Q]JEF4?O'&6SMS@_
M-@C(%,#:S1110(**** "BBB@".O+O%?V<ZOXL6;4-/B9H;<K9S0*TUS^Z^[&
MV=RD_=! ."<UZC2;$W!]B[AT; R/QK)'2U<X.Z\13MXFM$M9[BW(OXK.>UFN
M5;Y2OS'R0N<<CYRPR1QP:HG7M1M=/N(4U5KR</!]IU&.[$END+.0S@A"86Z
M@@[0<CIFO2L#=NVC=ZXYH"JH(55 /4 8S1<5C@H=2NA/IT&H>)$CTN:2X9;V
MTN@^2NS9"\Q4 D9D/09P!S@U>T2ZO+;X5B[T\-/>1VT\D),?+MO<@[?7OC\*
MZ_8FW;L7;_=VC'Y4M%QV/.[K5[J*WNH]&\0W-_;&&U=KQF61H)7N$0J#C W(
M6.P],=LUU&B?:+;6M8TV6]N+N&V,#Q/<L&==ZDL-P R,CCTS6V%4 @*H!.2
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M7+ZS\1W-HMI#)8V^F&]=_-VOD,PX&/\ 9QU[Y]J9J7BZ/3K&"Z:QEE$NFMJ
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MEE;SW445M-YJE9,%_F+%6..5)8Y'TK1H&%%%% !1110 4444 %%%% !1110
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MJRVH<12"1-RY#'/'0^M>?2:QXCU3X5V&IWU[;SW,VNPBW"AD88N&&UVR?EX
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M(O\ #C+<#'(!YK+U?Q)K&NZIIDQ%E;Z5;>+([&*-'<7+-&6!+\[2IYX[<=:
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MZRR)*N 7)XW XX''U- &A>_$/3-'\8ZEHNM7%O8VUO#;O#.VXEVDSD-@$ #
MYX'-;-UXNT"RU>/2KG5(4O7**(\,0"_W S ;5+=@2,URWB?P+KFKZSKUQI^H
MZ;!:ZS:PV<ZW$+O(B(#N92.-W/ Z?3%0W7PPE_X2*:ZAFM;K3KJ2WDFANY;A
M60Q!5R%C<*^0H(W#@T =:/&'AYM8N-)&JPF]MU=IDPVV/8,MN?&T$#J,Y%0V
M?COPO?V-[>VNL0R6]BGF7#;'!1/[VTC)7W (K#A\#ZQ'9Z[H)U*R_P"$?U62
MYF+B%OM2--SC.=I /?J1Q5.3X>:YJ-GJ;:IJ6G&\ET8:/:BUA=(Q&&#;Y,Y)
M;(' X% &\?B;X+5)&/B"VQ&P5OD?OT;[O*_[73WK1U'Q?X>TF\AM+[58(9I5
M5U&&8!6.%9F (4$]"Q&:YS4/ %Y>/K+)=6J_;]"BTJ/*M\CKG+'C[O3IS5#5
M/A?=7>I&YCN+.XANK*WM;R"YEN(US$H7<OE,N\$#[K=^: .YUGQ%I/A]86U2
M\6 S;O+4(SL^T98A5!. .2<8%9\GC[PK%#:S2:S$L=TGFQ,8W^YNVAV^7Y5)
MX#-@&N4^*,$TNJZ#% TMBD,,_P#Q,!#-(N&4)Y.806!(Y]#CUK/M?A]J>N:?
M8:H;.SL#<Z='97.EW4MS&D:1DA"/+8$@K@E']>N: .]O?'?A?3M3?3KS68(;
MN.18GC96^1F *Y(& "".2<59?Q9H,>NC16U.$:@7$7E8;&\C(0MC:&(YVYS[
M5RNJ?#N[O+'Q?;6]W:QC6VM/L^X,?*6%5&&_[YXQFFQ_#::#Q=-J'FVESIT^
MI+J12>6X62*08.%16$;'(X9AD=.: .D@\<^&;D7?D:M%)]CC:2XV(Y\I0VPY
MXZ[N,=>^,51O_'MDT6C3:+)#?17NL1:9/O#HT!8$G*D AA@<$=ZJ0>"]9L?
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MIUR;FU9TDC$A<,@# AOFQ@\5:@\"ZE#%K>C_ -KVY\/:M)<321?9S]I1YAR
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M2;[080F%$F -X]#@#D8J/QAKK:'I4)@NHX+VZN$M[8/:O<&1CR55%(). >I
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M6U/F0L\8"OL5%) Y&0IQOJ[IB1ZKKNLZI':O_9]Q;P1*9X"GVB6/>3(%89P
M54$CG''2NH^8D'DGM2$,>2#]: L<5:EM-TCP;?W<,XM[. K<;86=H6>':K%0
M"W7(Z<;JJ::QT:6#4=0LKI;.YMKQ(8UMF=H_,N#(J%5!*EE(Z^F#7H'S9SSF
MCYE/<&BX6.'O(]7T+P=X>N+>&>2^LXEMY;:/+9\R,H,@==C[#GL :S'M_$-M
M::EI\,NH2-H\*VZ7#;V:Y26579UP0798@5X.02<<UZ6 W4 U4;4[19[.$3!V
MO&=(-GS!BH+-R.F #^5 6.(M+&2\?38(]2O)],GU%_,2!+B 1H+=LH6<E]I8
M ]>IP*DAAOO^$P>.XOYK6:*^'V9/(G<26H480,&\O:1G)(R&R3VKO_F)/4GO
M2?-M[XHN%CB/$UE=75]X@G234%-KI44MD()9$43@RG<H7AFX7CGMQ4.H65WI
MT]U!:OJ7]G2+937FV661]A=Q,4.2P) 7<%YQG KL/[6LQ=SVOFOYT$D<3@1L
M<-(,KR!W'?H.]7<,!G!Q0%CS^*TFOKZTM8)-370I-3819DE1FA^S$LI8_.(S
M)TR?IQBG0PWW_"8/'<7\UK-%?#[,GD3N)+4*,(&#>7M(SDD9!R3VKOL-WSS^
MM'S#CD>U%PL)14-]=PZ=937EVQC@A0N[;2<#V Y)]J6VG%U;1SK'+&'&0DT9
M1Q]5/(I#):*** %7[X^M4M*_Y!D/_ O_ $(U=7[X^M4M*_Y!D/\ P+_T(U<2
M65]1\/:%J]XD^I:78W=TD917FC#.$/4?3DTK>'=%>.[C;2[4I=Q)#<*4XE1!
MA%;U ' KCO%6N3Z1XUU.6U@M!<6OA6>[BG>'=(&63A2V?N=\>M9-S\0/$^BV
MES-?_P!GWKS: FKVRP6[1B!F=4VMR=ZC?N)XZ51)Z#=^&/#=W>F]O-(TZ6Z5
M$4S2QKN"J1MR>V,#!]JLZMH.DZ\D2:OIMM?+$Q:,3INVD]<?6O&]6U"[@7QQ
M>7MUI.LW":;IVYT@S ^9>C)N(R,^OH:[JW\3ZC>>--5M6U;3-.TS1YHXI+6:
M+=/<J8]Q8,6&WVP#TH Z*Z\)^';Z8376A:?-((1 &>!21&. OT';TJVNEZ;%
M-=N+.V62_ 6YRHS/M7: P/WL+Q]*\MB^(.MWTVIVUM>QS6\^C75_9W)L1 R&
M/.W:/,8L".[8.><5=TO4[O[+\.6O+NUU::Z:1C.T0,D.+8-M# GY^Q8\G/2@
M+GH6DZ#I&@I*FD:;;6*RL&D$$87<1TS]*:/#^CB-8QIEML6[^VJNS@7'7S?]
M[WKS[P]X_P!;U"^T66ZN=,G@UI+HK96\1$NGF($C>=QW#C!R!R:BT7QQXMFA
MT"YNYM)F&MZ?=RPQ&(PK#+"I*EGW<AB.>@% 7/0K3PMH%A>"\L]%L8+D.T@E
MCA 8,P(8Y]P2/QJ,>$/#:Z=/IZZ%8"SGD$LL A&QG'1L>M8?@/Q-J.L6FJ1:
MS,)-5L-AGM$M1$8B5+ !E9E<''!&/<5A^'O'6O:K>:.)K[2Y4UVWNGCM[:']
MYIK1J2I<[OG'8YQS0!WMKX>T&U:+[)I=C$;:8SQB) /*E*[2P Z'  _"G7?A
MS1+_ %2'4[S2;.>_A*F.XDB!=<'(Y[X[9Z5P_P *X[?0?A8VO7D\*B>.2[GN
M!!\P"EN7(),AZG/!YQ60GQ0URSM-<>3R;XV]A!>6LTMH+<+YL@3+(KME &#<
MD'CF@#U/3=$L-*L)K*U@S!/++-,)#O,C2$ERQ/7.?RXJE;^$/#%O#-;VVAZ=
M&CQM!*D<0&48@E6]B0#@^E<7KFH^(8;[PK;GQCIK_:-0E6:\M;95B $.Y5<;
M\'J>"1G*GM2W'B2_T?4?%.HVD-FEMI^LVJZ@R0?/-;,BAW)_O#<"#Z T!<[Z
M?0]&FDD:XT^T=[BW%H_F(#YD0Y$?/4#KBETS0M)T0.-+TVVLA(JJ_D1A=P7.
MW..N,G\ZX&W\1ZAK%[X5U&Z@LWM]0UNX6P+P?-%;JC!&!S]X[2<^A%4M$\1>
M);3P-J6O-K$-_+9ZG(]S:- "Z6ZS$28.XD<<@8X"XYH"YZ2OA_1EO[N^&E6?
MVJ\0QW,OE#=,IZAO4<#\J@MO"7AVSM&MK;1+&&W:59RB1  R)]UOJ.WI5'P?
MXAGUZPNM5NYH([&ZOI(M*4@(SPJ=H//+%B&/T%8;WVJ2_$WQ)92ZPD=A!ID3
M1V31C]Z&1S\N6X8'DD#D8'&* .ON/#VAW\-XEQI=G<1WSK)<AD#"9EX5CZD=
MC4,_A#PW=2+)/H.GR.L(MU9H 2(QP%^@'2O,/"GBG7O#'AKP['+]DO;"YT6Z
MN;>VCA*R1M NX OD[MW?@8KJ_A_XH\1:]='^U88Y+*>R2ZBN%B2+8Y.#&%61
MBRX/#'!X.: .JG\-Z)<WT][/I-I)=7$)MYIFB&Z2,C!5CW!''TJ9M%TMWT]V
MT^W+:<,69*#-N, ?)Z< ?E5ZB@9EW7AO0[[5(M4NM)LYK^(@I<O$"X(Z<^W;
MTK4HHH **** *VG_ /+W_P!?3_TJY5/3_P#E[_Z^G_I5R@04444 '2BBB@ H
MHHH **** "BBB@ HHHH **** "CI110 4444 %%%% !1110 4444 %5K7_D)
MW_TB_P#035FJUK_R$[_Z1?\ H)H$PU31]-UNU%KJEC!>0!@XCF0, PZ$>AKD
M]?\ AU8WMW;7-D=,M+:%)%:RN[$36Q:0@F4)N4"3@#//':K7Q#\37_AG2M/;
M3HP9[Z^CM/-,8?R0P)+!2R@MQ@ D#)KA=:?7/%K>#[+7%MX/,U:X@DCDMU=)
MPB$K(T8<@'&05R<'F@D[VQ\!^&;/1-,TR_M+346TZ+9%/>(I?!;=^"Y/ Z#B
MMFX\/:-=1WJ7&F6LB7SH]T&0$3,F-I;UQ@8^E>+WML]C9_$#7+F/3K^>#5H[
M)%N;,, OF0X&=WW0,87U&:[R'Q+JFJ>+-;M?[2TRRL-+G-K_ &?-%NGNOW>[
M=N+# )/& <@&@#KH=%TA-7DUJ"PM1J$R;'NT0;W7C@L.O0?E23^']'NM4&J3
MZ9:R7XB,/VAHQOV$$%<^F"1^->36?CC7;?P_X8TW1;.VMI+G2I+W]Q:JR,RN
M5$:JTBA5[L02>>E:>K>-/%^[4Y+5]/L?[.T2#5)H)8/..]@Q:,,& P<=>>@H
M ]$_X1S1!%;H=+M/+MH&MH5,8(2)AAD'^R1U%0VGA/PW:VTL-IHNGI!/#Y$B
MI"NV2/).T^HR:X?3];U75O&FN?:-6CAL?[&MYH]/* [_ #(78A23P03DD#D8
M!QBL;3?&6J>#_ WATJB2V=]H92P7RLL+\, JDCJ&#9Q[&@#UVVT;3+32/[)M
M["WCT[:4^RB,>65/)&WISDU7MO"^@V>DSZ5;:/91:?<9\ZW6$!)/]X=ZY[Q/
MKVMZ-!X9TH7ME;:CJCF&YU&XBS#$RQ[FPN0,L> ":JVNO^);KQA)I,&HZ;<6
M5EI]O>W$\5OEKG.X,L>&P V.N3C'>@#K;;PWHMGY7V;2[6+RK=K5-D8&V%CD
MH/\ 9)YQ4%UX.\-WMO:076AV$T5FNRW5X0?*7^Z/;VZ5P6@?$'7[ZYTJ2:ZT
M>Z36K6ZGCM(E*'3VB4E1(^XY4]"2!@U'9>-O%UQH&I0K+:R>(;6: 36CVR)Y
M,;ABQB;S"DQ('RC(/!H ]2MM-LK2[NKJVM8HKB[*F>1%P92HPN?7 XJE'X9\
M/P1VMO'I-DBVTYNK>,1@>7+W=1Z^]<?J_B:\U#X'WVNZ;JF^[^S/FZ2V,+ A
M]K )N.QAR,@GD9%9FHC6I_&'A'[#K=G-J)TJ\)OWM]R8^4\(K8)Z#KZGVH ]
M#O/"V@ZC'<I>:1:3K<S+/,'C!WR 8#GW XS27?A+P]?V-M8W6B6$UK:C%O$T
M VQ#N%]!_.O,/^%G>*-2L]&33K:&.[N-*:_D*P+(LTBR,FSYY%")\N2021N'
M%;?Q/N+F]\">'I9H%AFN]2L_.MVN3$F75MT;2+T7G&X?6@#O=0T+2M5L([#4
M--MKFTC*F."6(%4QP,#M@<56G\)>'KG3!IDVB6+V0D,PMS"-BN3DL!V)SVKQ
M*YFE_P"$%U#3?.)\CQ/!"+87[O;QQL/]6MQG=L/.3QC/2EN9I4\#:WIHEQY'
MB&UC6V6_>2WBC?'R)<$[MIYR>,>E 'M]]X8T+4M/M]/O='LIK2W_ -1"\(VQ
M=OE';\*C;PEX=>^MKUM$L3<VJ*D$AA&8U7A0/IV]*XOX87\.GMXBL;N[BMX[
M?4(XX8/MIGMXMZ#:D4KG+$G.1Q@]J]-H JRZ;93W\=]+:Q/=QQM$DS+EE1OO
M*#Z&LZ?P=X:N;2SM9]"L)8+/_CVC> $1#.2![9[5MT4P,^YT+2;S4;34+G3K
M:6\L^+>=HQOB_P!T]JT*** "BBB@"DW_ "&_^W7_ -GK'\>:%=^)O!6I:-8M
M$MS<J@0S,0O#JQR0#V!K8;_D-_\ ;K_[/53Q'K]GX7T"[UB_W?9[9=Q5!\SG
MH%'N32$SE/%W@2\U/5[#4=(\D1P6+V$MD+I[12C'.59%/'8KCD8KE[WPKJL_
MBC5/#VD6VFA3X<M;&1KMG80H2P)C;!+$>^,\>E>CR>.O#,%I:W-SJ\,"749D
MA$JLI<!@IP",D[CC']*LIXKT*376T1=3A_M($K]G.02P&2 2,$@<X!S0+4Y_
M2? DEEK6NS7$L3P7NF6UA;7 YF3RXC&['(XSP>#SBL'2/AIJ-EIL]KJ%G87[
MQ:<UA TVI3%)D+J<%-O[H<9X)PV,5VMAXZ\+:I=BULM=LYIC$TH4,1\JC+')
M&. "2.HJM<>.M)N-*>\T;4;"Y\NXAA=IVDC0"1L#!VY)/.,<'UH#4Y5OAYXF
MFT?3O.U-'N].U![BUMS>R#9"R!?+^T!=Q88R&*^U:6D^ ;BQU3P]<M;VB6]A
M;WBSPF=IR)9CD%6906[Y/'4UU;>*="771HAU2W&I%M@@R<[L9VYZ;L<[<Y]J
MK6OCKPM?:BFGVVN6DEV^_;$"<G;G<.1U&#QUH#4Y3P]X&\0^'9O"MS"VFS2Z
M=:365XCRN $DEW[HR%Y('8XK1\)>%-9T/Q/=W;&TLM'E1S]@MKEYD>5GSYBA
MU'E<=5!()-;GA;Q?I?C"RFNM,>0K%(R.KH01AB <]"#MR,>O.*GU;Q1H>A7,
M=MJFIP6L\J!XXY"<N-P7@ <\G&* NSC+[P5XJU+Q;;ZA>ZE;365IK,=];KY[
M+B!?X/*"[0X&?F))/M3M-^'^HV5OX?#?8A-8:Y-J-PZ,<M$Y? !V\M@KP?3K
M76GQAX=74Y]-_M>W-Y KF2($DC8-S@$#!8#DJ,D>E3)XFT23['LU* B\MVNH
M#D@/"HRSY[ #UQ0&I@^)/"FH:OXDN=1MGMUADT"YTU0[D-YLARIZ?=]3^E9,
M/P\O8Y+5C'I^(O"QT@X_Y^#_ !?=^[UYZ^U=5;^-_#%U87-]#K5LUK:E!/)R
M F\X4G(S@D\'I[U&WC[PHJ6[_P!N6I6X+"(KN;=M;:3P.%W<9/'O0&IRT/P\
MU01QB<V,C)X3_L4%F+8N/[PROW??K[4O_"M[Z98;=IK6VA/A;^QI7BR2)]P.
M[&!E>#SG-:FL^/3HT<\TB6$D,6MQ:;(R3-^YC899Y,J,,.N!D8[U:N_'=@XT
M&;1I8-1M=3U,:>\JL1Y1VDDXQG(QT/K0/4Y,?#'5KC0+^WN?LD>HF&VBAF>^
MEN8YA"X<*RLHV(<< 9QDU:N? GB'4(];FN1I4%SJ5]878BMI&\M!!C>,E<D\
M=<<GTKN+7Q5H-[K,FD6NJV\M_&6!A5CDE?O 'H2.X!)%)J/BK0M(U*'3M0U.
M&VNYMI2.3/\ $<+DXP,G@9(H%=G':AX+\5:GXNAU&\U&WFL;36H[^W4SLN(%
M/^K\H+M#@9^8DD^U13?#_7;GPMK7AY[BPB@EU$ZA8W"2/N=C+YFR08^4=L@G
MGGM77R^-_#$&K#2I=:M4OS/]G\AB0PDX^4\8!.>,]>U9VL?$'2[+7M/T6PN+
M:\OYM2CLKJ$.0T 8'+=,$@@ CMGF@-2#PYH^M>'95QID33ZG?!]0F.H/<^7$
ML?WRSA27) 4 #TS7;UDZSXGT3P\\*:MJ,5J\P)C5@26 ZG !P!ZGBF7'BO0;
M368M(N-4@BOYBH2)LC)8949QC)[#.33 V:*X71OB/;:GJ^O_ &AK*ST?29&B
M:YEE<2.00-V"NT*22 ,YZ<<UUFDZSIVNV9N]+NX[J .49DR"K#JI!P0?8B@5
MB]1110 4444 1UQ.J6-[=ZO>1,E[]EDUBSSY;.H,/D@/@CHN>#BNVJE?:M9Z
M=:7=Q/-\EH%,ZH-S)NZ<>^:Q.EG&7&G-:79M;NUU"3PY#?S9AB\V3 ,49C.%
M^=H]YDZ9 )'I5F>UN1JUU)9VUTEN]YI1C(1P3$OWLYYP!][/3O7<$,#CG-&&
M]#3N%C@[;2+J$6VI11W@U-M:G0N[N0+<O+@%2<>7C:>F.AK*L[#5_P"Q;MHK
MC4AJHL]E];+:2Q-*V]2["1G*L^!(%*8R&^E>HX/7FC#=\T7"QRGA>UM(]?U=
M[&SO(--E@MEB^TQR(&(\S<%#\@<C/O6!INFQV>AZ/:7.GWR6$%Q,NJP1Q2Y,
MG/E,0O+I[KD9*DUZ2<]Z,GUHN%CC9OMMO\+]8,IN8G6WNVM1*Q$T<.6\H$GD
M,%QUY'&:RWMY5,UQHUIJJ6,4=I+=I(DN^299U9R@;EF$8;=MX/ YKT"[M8+Z
MTFM+F,203(8Y$/1E/!%3 ;0 .@&!1<+' W,-QKOB"5O(U---GU2WSE9(?,A%
MM(&XX(0M@'IS]:2^TV6'6;Z#3;>XNY9X9HD:2.:-K/\ <$+LD)\MX\@ #J"V
M<G%=_D^M&:+A8\[U"XU?4X4_LJVU.-XM%$4K20/&=_FQ>8B@XR^P/T//8UT7
MA"V2WM[QX;B=[:252D,EG);K"0H!VK(2V#U/;.:Z+)]:,YH"QP<=I<G6E+V^
MH'6SJI,DY$GDFRWGC=]S9Y>!MZ[NV>:J:/X?@>T\.:?+IUS&+:\N1?(4D09\
MN0+ENZG*\@X/%>CYHS1<+'FEU8:@JV]M=F]CTF+[7# ?LTUP8W\X^62$8-_J
M\;&.171:#I,@U_4+R_>[N)8!;I;33ED5OW"AW"9QDG.>O-=3D^M%%PL<;>VU
M\/$=]+##<".35-.;>BL T:J YR.JCOV]:JVND7D$5EJ,$=V-4?5KE'DD=R!"
M6FVAE)P(_N$<>E=YFBBX6/--,TR>72KC[9J&JVMR;-4OHUTZ?+2[U)9CN(DY
M# [,95CT&,=!8KJ3^!=0BT^S^Q7P6=;79O42'^&1%D^9,]@>A]JZO)]:*+A8
M\TU'2DO=,U&#2M.U$::UI#YL-RDH9[D3*<@/R6";MQ''3K7I,<4<$:PPJ%C0
M;54=@.E.R?6B@$@HHHI#%7[X^M4M*_Y!D/\ P+_T(U=7[X^M4M*_Y!D/_ O_
M $(U<265=4_X1Z&Z1]7.FQW%Y$;-#=% \\9/,0W<L"3TI]I::'J$$5[9P6%S
M";<VL<T2JZF$'!C!'&W(Z=.*X_6].^V?&O16>ZE"Q:3+.L>U"H*R#CE3P>YZ
M\<$5S_A[6=?U>R\$V$&N26 U*TOY+F6W@BRQCD.W:-NT'C' ]?K5$W/3/^$<
M\.VEA/"-'TV&S:,+,@MT5"BDL-W&, Y//2FK#X9U/6;>[6+2KO5!;B>"8*CS
M>2> ZGKM[9Z5Y-_PFFLZMH>EQZKKYTRWN=&NI#.D"'[?<+(T?EG(/\(!PN"<
M\5/8:YJ.FZ+&MG<B'[-X#2[A*QJ624-@-N(S^&<>U 7/6;3P]HEA)OL]'L+=
M\,-T5NJG#8W#@=\#/TI;7P_HUB(!::396XMY&EA$4"KY;L,,RX'!(X)KRV^\
M3^*='@OT.OFZDE\.PZLLD\"+Y#M(JL(PHZ;2<;L\XS55O%FL2>';K4;3QFOD
M_P!H;8X;F\MEN3;JF2H<(460G)YZ@ 4!<]?M]$TFTO;B]MM+LH;JY!$\T<"J
M\@/7<0,FF_V#HXAMX?[*LO*MHWB@3R%VQHXPRJ,< C@CO7(ZYKNH/\,--U33
M-8%A<W A/VC4BD$DJG)9=Q4HCMC@XQ^=8UCX]>*7PW>7FK7<.EWFFW9=[Y$#
M2SH^$Y1<,?3;]X8XYH ]+TW2=-T:!H-+T^ULH6;<4MXA&"?4XIMKHNE65Y<7
MEIIEG;W5S_KIHH%5Y/\ >(&37C1\;ZRUCHYO_%LNEK<>'7O6G\J-C+<K*P4<
MKP2!C ZXQU-3ZMXXUV-\WOB)]$G_ .$=@OX[=8$/G79W?)A@2-W'R]?RH"Y[
M);Z?96E@+"WM((K-5*"W2,",*>HV],')JK:^'=$LHWBM-'L((WC,++';JH9"
M<E2,<@GG%>6:]XV\16\]Y)/JKZ1?VUE936&E"W5AJ$DB@R*006;#$KA2,5T-
MO>>(M8\5^+8%UNXL[72HXC%9PQ(27DMMV"Q!. W('K0%SKO^$6\/#3AIW]A:
M;]A63S1;_9D\L/\ WMN,9]ZDN;71;598KJ&QA&J2"&5)%51=N5P%(/WS@8QZ
M"N1^&DPN?A=&MIK<]W=K;$.2RLUI+L^X..W7#9/-</8/]N\!>!8;;7IIKTZ]
M;I([[7:QD*O\H&.O?#9YH"Y[:-+T\)9H+&W"V/\ QZ@1C$'&/D_N\<<5E:MX
M5@N["^@TEX-&N-0.+VZMK1&DG0@AE.>YR?F[5YO>>,/$UG9-8/JDCPP:_<Z?
M/JC-%!((T16C5G92B$DGDCMBNCOO$&NVWP2NM;DOX&U>*$E+RU975P)0H;(&
MTDKUP,9S0!U]OX:TJV@T:%+<E-&7%D"Q^0[-FXCH3C/)[DU:FTC3+G4(]0GT
MZUEO8T*)</$ID52"" W7&"?SKR=O&NN0Z?XB;3=>;5K.W%FPU0VRG[&96Q,
M% !VCG!'R]ZKZWKFHZCX,UZ)?$%Q?:58ZI9K#JZ(BF:-F4R L%P0C8Y ^O%
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M7PVTAUE:0W,0F.Y5&WJ,#:!D<=\GGK7;4#*VG_\ +W_U]/\ TJY5/3_^7O\
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M&XN;P(S.$!"C"J%  )Z#O7G6B:WXACD\/:K<Z[?W4=[K%S8S6<BJ8_)0R8P
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MDTL84V-V%_U:G:-N?F&SG@9KT#X<62V7P[T)1++)YMG'*?-(RI91\HP!P.U
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M*** "BBB@"MI_P#R]_\ 7T_]*N53T_\ Y>_^OI_Z5<H$%%%% !1110 4444
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MQG)[TD\^OOX2TS29[#6)YA)>K#=M)<AE*N5B1A%@LQ&"K.=M 7/<!NQ@9Q2
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1PLB+RF]11Y3>HJ6BBX61_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img_025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '& VP# 2(  A$! Q$!_\0
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M_P !8_\ "C_A']$_Z VG?^ L?^%:-% &=_PC^B?] ;3O_ 6/_"C_ (1_1/\
MH#:=_P" L?\ A6C10!G?\(_HG_0&T[_P%C_PH_X1_1/^@-IW_@+'_A6C10!G
M?\(_HG_0&T[_ ,!8_P#"C_A']$_Z VG?^ L?^%:-% &=_P (_HG_ $!M._\
M 6/_  H_X1_1/^@-IW_@+'_A6C10!G?\(_HG_0&T[_P%C_PH_P"$?T3_ * V
MG?\ @+'_ (4R77K1+B6""&[NWA.V4VL!D6,^A/3/L,FK=C?VVI6PN+2421Y*
MG@@JPZJP/((]#0.S17_X1_1/^@-IW_@+'_A1_P (_HG_ $!M._\  6/_  K1
MHH$9W_"/Z)_T!M._\!8_\*/^$?T3_H#:=_X"Q_X5HT4 9W_"/Z)_T!M._P#
M6/\ PH_X1_1/^@-IW_@+'_A6C10!G?\ "/Z)_P! ;3O_  %C_P */^$?T3_H
M#:=_X"Q_X5HT4 9W_"/Z)_T!M._\!8_\*/\ A']$_P"@-IW_ ("Q_P"%:-%
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M']$_Z VG?^ L?^%:-% &=_PC^B?] ;3O_ 6/_"C_ (1_1/\ H#:=_P" L?\
MA6C10!G?\(_HG_0&T[_P%C_PH_X1_1/^@-IW_@+'_A6C10!G?\(_HG_0&T[_
M ,!8_P#"C_A']$_Z VG?^ L?^%:-% &=_P (_HG_ $!M._\  6/_  H_X1_1
M/^@-IW_@+'_A6C10!G?\(_HG_0&T[_P%C_PH_P"$?T3_ * VG?\ @+'_ (5H
MT4 9W_"/Z)_T!M._\!8_\*/^$?T3_H#:=_X"Q_X5HT4 9W_"/Z)_T!M._P#
M6/\ PH_X1_1/^@-IW_@+'_A6C10!G?\ "/Z)_P! ;3O_  %C_P */^$?T3_H
M#:=_X"Q_X5HT4 9W_"/Z)_T!M._\!8_\*/\ A']$_P"@-IW_ ("Q_P"%:-%
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M "BBB@ JC?:O9Z=+'%,[M/(-R00QF21@.^U><>_2K<TL=O#)-,X2*-2[L>@
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M;0/-,X2-!EF/85S45K=LDVI7'R32A)Q(_6-%))11] ./>JBK[F<YN.B+\OB
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M2UMXH$)R5B0*"?PHL-SM=$JJJ(J(H55& H& !Z4M%%48A1110 4444 %%%%
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M(Z/IQU*>.:X"G.Y692<XP,9H"QWE%%% @K(\4_\ (K:E_P!<3_,5KUD>*?\
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M:!!1110 4444 %%%% "K]X?6LSPI_P B[#_UUF_]&O6FOWA]:S/"G_(NP_\
M76;_ -&O04BSK_\ R+FJ?]>DO_H!IUE_R#[7_KBG_H(INO\ _(N:I_UZ2_\
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M<FWTX[K2=9ML\+9SN#@#GGT]*(?A_ID>@:GH\U_J]Y%J2A)YKN\,LN!T"DC
M_*NJ#*V=K*<=<'.*YGQ9X]T3P7<6$.KFX4WI81-%&& P0"6.1CJ*!F]IUC#I
M>F6FGVY<PVL*PQESEMJC R?7BN9USX<:1XAU"XNKV_U@17+*T]E%?,EO+C'5
M/P'3%7O%WC71_!6FP7VK/,8KB3RXU@0.S'&<XR.,#K[BMJUNXKRP@O(R5AGC
M65"_!PPR,^_- B2&&.W@C@A0)%&H1%'15 P!3Z0D  E@ >ASQ6!XL\66OA&S
ML[FYMY;@75XEH%A895GS@G/;B@#H**0E0^TL-WIGFC(+%01N'49Y% "T50BU
MO3I]:NM'CN5:_M8TDFBP1M5_N\],G'2K] !1110 J_>'UK,\*?\ (NP_]=9O
M_1KUIK]X?6LSPI_R+L/_ %UF_P#1KT%(LZ__ ,BYJG_7I+_Z :=9?\@^U_ZX
MI_Z"*;K_ /R+FJ?]>DO_ * :=9?\@^U_ZXI_Z"*0,GHHHIDF%K'@SPWX@O%O
M-7T:UO+A4$8DE4DA1D@=?<USGB7X?IJ&K^$(M.T^R71-*EF-S;.?E\M\<!3G
M=GFO0** ,>T\*Z!8:/<:1::3:PZ?<@B>!$PLF>#N[FI/^$;T7=IC?V;!G2QB
MQ./^/<8 ^7\A^5:E% &'JW@SPUKMX+S5-#LKNY  \V2/YB/<]_QKG]?\"_VW
M\0M&U">QLY]!M=/DM9X),=3NV@)CH,K]*[RB@#&_X1+P\="&B?V-9_V6&W_9
M?+&S=_>^OOUK/O=#N/#GA^2V\":-I4%U,^&6;,: $'YB1RQ!QP?>NIK"\8^(
M_P#A$_"E[K8M?M7V8+^YW[-VY@O7!QU]*!E7P#X27P7X5ATLRI-<L[37,R+@
M/(W7'L!@#Z5LZKH^G:[9&RU2SBN[8L'\J49&X=#7-Z=\0K2]^&UQXPEM3 +=
M)/-M"^2LBG:$W8[G';O3_!GCN#Q1X3N-?O[>/28;>=XI1+/E4V@9)8@8ZT =
M#?Z+INJ/:/?645PUG*)K<N,^4XZ,/?@4JZ/IR:Q+JZV<0U":(0R7&/F9!_"?
M;@56TCQ/H6O"8Z3JUI>>2,R"&0$J/4CKCWJA>>-]#&E33Z;JMC=W1LIKNVA6
M7/FB-6).!SC*G\C0!/:>"?"]CJPU2TT&PAO@Q=9DB *L>X'0'Z5HV&CZ=I=Q
M>3V-G%;RWDOG7+H.97_O'WY-8.@>-K*]\(:)K.M7%K83ZH-L<6XX=]Q&U0<D
M]OSK4U3Q5X?T2\CM-4UFRL[F3E8II@K8]<=A]: *A\ ^$FDNI#X=T[?=',Q\
MD?-\V[\.0#QBL&Z\ +JWQ,U'5]8L+.\T6XT^."..4[F$JD<[>W0\YK7\2?$#
M0?"VH:99ZA=QA[YOO"08ACP3YC?[)Z#UKI+6Z@OK2&[M94FMYD$D<B'(=2,@
MCVH JG0]);1AHYTVU.FA-@M3$#&%],57T;PKH/AY9QI&DVEGYXVRF-.7'H2>
MHYZ5KT4".=A\ ^$K8L8?#NGQEI5F)6+!WJ<J0>V#V'%6[WPOH6HZQ!J]YI-K
M/J,!4QW+I\ZE3E3GV/2M>B@#.M=!TFR6^6WTZW1;^1I+M=F1.QZE@>N<FJ-G
MX'\+:?#=PVF@V,4=VGEW"K%Q(N<[3[9[5OT4 9&B^%M!\.F5M'TFULFEX=HD
MPS#TSUQ[5KT44 %%%% &9IO_ "-&L_\ 7*V_D];=8FF_\C1K/_7*V_D];=(L
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'O?\ D:=-_P"O.Z_]
M#@K0K/O?^1ITW_KSNO\ T."M"F2PHHHH$%%%% !1110!0UO_ )%_4_\ KTE_
M] ->$Z-XQT6/X"KX8BF-YKEW'+;QV$,;.^YY&*D\8& 0:^A" RE6 ((P01D&
MH(-/LK63S+:SMH7QC='$JG\P*!W/%O$7AL?;/A5X=UD,Q\J2"Z19""1M3<F0
M<X['%:7B#^QO!'Q=\*7$J1Z;HD.FS0QR;3Y:,2YQGGNP_.O6W@AEDCDDAC>2
M/E'9 2GT/:DGMH+E0MQ!%,H.0)$# 'UYH"Y\YSR0:GX,^(M]#+*D#:U#<H#$
M<2*7.T.."%.0<UVWPVM]%O?'&I:Y%>>'5O);5(X=/TDEA$HP&DRRJ<G&#@=^
M:[+QGX/_ .$GL+=;2YAL[JVNTNU+P"2*9EZ+*O\ $*HZ#X%N[;Q7'XDUF]L9
M;R"!H+>#3K/[/$@;JQY)8]>M &'\4=.AUCQMX+TN<CRKS[9 WT:,#/ZUY_+=
M7?BCPGJ<FH1MGPIHC6#;^]RTFPL/^V: ?6OH]X(9)(Y)(8WDCY1V4$K]#VIO
MV.UV2I]E@VS',J^6,.?5N.?QH"YXYXLUFV2U\$:+?P:/#9S:<DYU+5;8SQQ$
M1@%53(!)P.OJ*X^-C'\$O&L*R$Q1ZU'Y0$9B4*70@JA^X#UQVKZ3EL[6>-(Y
MK:&1(^45XP0OT!'%#V=K*DB26T#K*VZ16C!#GU/')XH"YXU\1/#NG>&OAKI"
MZ+:1Q3W&IVDLCR.6,TNQB&<DY/)/YU<\%&ZL=5\7:;JR ^/9(Y)H[EFR+B,K
M\GDD@84'' ]O3CUN6W@G14F@BD12"JN@8 CH0#2-;0-<+<-!$TZ#"RE 64>@
M/44!<^:/"UA:W=IH<3ZUH6EZS;ZBKMNMIAJ+2[R-CMGY@<CMC]:[6Q@\+Z/\
M==?BUBULK=Y_L\FFB:'K,V,LG'#%CU]:]@-G:FY^TFU@^T?\]?+7?_WUC-.D
MM;>:9)I;>%Y8_N.Z LOT)Y% 7)3UHHHH$%%%% !1110 5D>*?^16U+_KB?YB
MM>LCQ3_R*VI?]<3_ #% (WZQ?$'^NT;_ +"*?^@/6U6+X@_UVC?]A%/_ $!Z
M19I4444R KSCXZ'_ (M7>\_\O$'_ *&*]'JKJ&FV.K6;6>I6<%W;,06AG0.I
M(Z'!H \Q^+\/VO1?!=NTDD8EU6WC+QMAE!3&0>QYZUF#3SX+^(GBG3/"RSPQ
MGPZ]W%;B5I,SCHPW$DM7K]YI6G:@MNM[8V]PMM()8!+&&\IQT9<]"/6G#3;$
M:HVJ"S@&H-'Y1N=@\PI_=W=<>U [GS[X*TZ>Y?PQJVF7VAV>H&Z4W=PVL.UU
M> MAXWB(^\>P_P#UUU7A;PQ8^(OB5XQN-2ENI(M-U99[>V24K&)>3O*CJ?E
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M4H &, #' P.E+10 U41 0J*H)R0% R?6@1HJ% B!3G*A1@_A3J* $"*H 5%
M'0 #BH;*S@T^U6VM4V1*68#))R223D^I)-3T4 -5$0$(BJ"<D*H&:18HU0HL
M2!#U4* #^%/HH :B)&NU$5%]%&!2&*-G#F)"XZ,5&1^-/HH 3:,YVC/7I0%
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M $:]!2+.O_\ (N:I_P!>DO\ Z :=9?\ (/M?^N*?^@BFZ_\ \BYJG_7I+_Z
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M?]<3_,4 C?K%\0?Z[1O^PBG_ * ];58OB#_7:-_V$4_] >D6:5%%%,@****
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M@#'O?^1ITW_KSNO_ $."M"L^]_Y&G3?^O.Z_]#@K0IDL****!!1110 4444
M%%%% !1110 4444 %%%% !7COC'_ )&[4?\ ?7_T!:]BKQWQC_R-VH_[Z_\
MH"UC6V/7RG^,_3]3#HJ2"WFNIEA@B:21NBJ,FNPTGP<D>V;4R)&ZB%3\H^I[
MUA&+EL>W7Q-.BKS?RZG-Z9HM[JS_ .CQXB!^:5^%'^-7M5\*WNGH983]IA ^
M8H/F7ZCTKT!$6-%1%"HHP%48 IU;^R5CQ99I5Y[I:=O^">/T5Z)JWABSU+=+
M%BWN3_&H^5OJ/ZUQ&HZ5>:7+LNHBH/W9!RK?0UC*#B>MA\93KZ+1]BBWW3]*
M][M_^/6'_KFO\J\$;[I^E>]V_P#QZP_]<U_E6E'J>?F^T/G^A)11170>"%9'
MBG_D5M2_ZXG^8K7K(\4_\BMJ7_7$_P Q0"-^L7Q!_KM&_P"PBG_H#UM5B^(/
M]=HW_813_P! >D6:5%%%,@**** "BBB@ HHHH **** "BBB@ HHHH *:\@B0
MNW1>>*=4-U_QZR?2@#EK72K:WF>9AYDK,6RPX7)["K^[WJ)F(#8&3S@$XS7G
M&AZQXID^*B:=KEQ'#%-8/<"P@;,</S87)_B; R3[T/4:26QZ9NHW5XS/X[;5
M=4OI[SQ+J.CZ?!=&"&+3K3>%4'&^:0]-W8?I7K%T9[C391I]S'%/)%^XG9-Z
MJ2.&([BD,O;J-U>7Q7?B30/'6FZ0?$,NNO<VLLU[;R1 "#"DJPQ]T$XP/\:Q
MO#GQ U"S>6ZO]6DU59---Q);,H!@NS*42%<#C/''XT >T-M="C@,IZ@C(-9D
M>B1IJMK<6K;0LRLT9Z8SVK#\%>(;2^LQILVN+J.M1*9;L<_*Q/*IP 54_+QF
MNPMC_I47^^/YU2=B6D]SH****0!1110 J_>'UK,\*?\ (NP_]=9O_1KUIK]X
M?6LSPI_R+L/_ %UF_P#1KT%(LZ__ ,BYJG_7I+_Z :=9?\@^U_ZXI_Z"*;K_
M /R+FJ?]>DO_ * :=9?\@^U_ZXI_Z"*0,GHHHIDA1110 455FU*QMY3%-=PQ
MR+U5FP13/[8TW_G_ +?_ +[I\K[$\T>Y=HJE_;&F_P#/_;_]]T?VQIO_ #_V
M_P#WW1ROL'/'N7:*I?VQIO\ S_V__?=']L:;_P _]O\ ]]T<K[!SQ[EVBJ7]
ML:;_ ,_]O_WW1_;&F?\ /_;_ /?='*^P<\>Y=HI 0RA@<@C(([BEI%!6+K,$
M4U[;F5 VR-BH/3.16U61JQQ=P_\ 7)OYBFB6D]RMFLRY\2:'9WHLKK6;"&Z)
MP(9+A0V?IFK^:\T^)>B2KIFIW=MX<TI[&6-9;S4< W2$-\Q0' R !W[FD7<]
M.+@*6)& ,Y]JR+3Q;X=O[N.TM-=T^>YD.U(HYU9F/H!3-'>WO/!]D-.E<P2V
M"K;O-][!3 +>_K7F^EV&I?#;4/#MMJNG:%=VUU<_9TNK> _:HW8\-O(R<9_*
M@+GJ]OK&FWE]/8VVH6LUW!_K8(Y0SI]0.E2VU]:WC3+;7,4Q@D,4HC8-L<=5
M/H?:O&/[)U_PCJMI,NFQ)=12W5M9W*R*3?RW#?)P.<(/F.>F*W? _B273KG3
M] .G1"PN;BYMX[T2EI9KB/YI'<=,,2<?A0!ZCFM'2@J6[(BA4#9  ]>M96:U
M=+_U,GU% B_1110 4444 9FF_P#(T:S_ -<K;^3UMUB:;_R-&L_]<K;^3UMT
MBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,>]_Y&G3?^O.Z_\
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M]=HW_813_P! >D6:5%%%,@**** "BBB@ HHHH **** "BBB@ HHHH *BN?\
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M\*?\B[#_ -=9O_1KT%(LZ_\ \BYJG_7I+_Z :=9?\@^U_P"N*?\ H(INO_\
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M4%EJ%X=3A5)$22Y_T<2@@MA<<=\&M74- UU=:C\0:;]A>]N;1;?4;*Z.8I>
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M!6A6?>_\C3IO_7G=?^AP5H4R6%%%% @H['Z44'H?I0!Y"WC7Q"&8?V@>"?\
MEDG^%)_PFOB'_H(G_OTG^%8+??;ZG^==78>%+,Z"-3U34&MTFCWQ&.,L(QN
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M/M?^N*?^@BD#)Z***9(4444 <!XD_P"0_<_\!_\ 01656KXD_P"0_<_\!_\
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MZ_\ ,5I2^-&.(_ALY>BBBNT\L**** "BBB@ KO/#'_(!A_WW_G7!UWGAC_D
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M0!0UO_D!7_\ UP:O,*]/UO\ Y 5__P!<&KS"M8;&%7<****LR"BBB@ HHHH
MZ'P9_P AQO\ K@W\Q7>UP7@S_D.-_P!<&_F*[VLI[G13^$*4?>'UI*4?>'UJ
M#0\EN?\ C[G_ .NC?S-15+<_\?<__71OYFHJZ#C"BBB@ HHHH *N:3_R&;+_
M *[I_.J=7-)_Y#-E_P!=T_G0-;GJ7>BCO17.=84444 *OWA]:S/"G_(NP_\
M76;_ -&O6FOWA]:S/"G_ "+L/_76;_T:]!2+.O\ _(N:I_UZ2_\ H!IUE_R#
M[7_KBG_H(INO_P#(N:I_UZ2_^@&G67_(/M?^N*?^@BD#)Z***9(4444 <!XD
M_P"0_<_\!_\ 01656KXD_P"0_<_\!_\ 01657H0^%'CU/C?J%%%%40%%%% !
M0>AHH/0T >GVW_'I!_US7^0J6HK;_CT@_P"N:_R%2UYSW/:6P5R?C+_6V?\
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M%_YZWO\ W\'_ ,31_P *ZT7_ )ZWO_?P?_$T>RD']J8?S^X\M;[I^E>]V_\
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MZ_\ \BYJG_7I+_Z :=9?\@^U_P"N*?\ H(INO_\ (N:I_P!>DO\ Z :=9?\
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MUUI6OF2XFO;C5;6!?.E++#&,Y5%[9(!/O0%CV*BE;[QI*!!1110 4444 !(
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ME73 )R>^<<"HK'78?#7Q&BUWQ-;II<&I>&XO*4H0D;J%W1 =C\IX^E 6/6M
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MQM[A-0<;F]3ZFNHUWPKIGB.QLK/4%F:*RF2>+9(5.]!@9/>MJB@+@>31110
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MURN,5!'HNDQ2+)'I=BCJ<JRVR @^QQ5ZB@#/_L'1B<_V1I^?^O5/\*T
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MHP('(JUX?^'V@^'-1_M&TCNI[Q8_*CFO+AIFB3^ZF>@KJ:* N%%%% !1110
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M6T:UCD2]<,"0H#C]UPP* BJD_A+5Y4")'8JF%5DDN6D5@(]F2IBP6[@GH2:
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M'_"T=#_Y]M1_[])_\7110%@_X6CH?_/MJ/\ WZ3_ .+H_P"%HZ'_ ,^VH_\
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M1_PM'0_^?;4?^_2?_%T44!8/^%HZ'_S[:C_WZ3_XNC_A:.A_\^VH_P#?I/\
MXNBB@+!_PM'0_P#GVU'_ +])_P#%T?\ "T=#_P"?;4?^_2?_ !=%% 6#_A:.
MA_\ /MJ/_?I/_BZ/^%HZ'_S[:C_WZ3_XNBB@+!_PM'0_^?;4?^_2?_%T?\+1
MT/\ Y]M1_P"_2?\ Q=%% 6#_ (6CH?\ S[:C_P!^D_\ BZ/^%HZ'_P ^VH_]
M^D_^+HHH"P?\+1T/_GVU'_OTG_Q='_"T=#_Y]M1_[])_\7110%@_X6CH?_/M
MJ/\ WZ3_ .+H_P"%HZ'_ ,^VH_\ ?I/_ (NBB@+!_P +1T/_ )]M1_[])_\
M%T?\+1T/_GVU'_OTG_Q=%% 6#_A:.A_\^VH_]^D_^+H_X6CH?_/MJ/\ WZ3_
M .+HHH"P?\+1T/\ Y]M1_P"_2?\ Q='_  M#0_\ GVU'_OTG_P 7110%CHO#
MQ^VBXUK&Q;\)Y<><E40$#/N22?RK;HHH*"BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
